% $ biblatex auxiliary file $
% $ biblatex bbl format version 2.4 $
% Do not modify the above lines!
%
% This is an auxiliary file used by the 'biblatex' package.
% This file may safely be deleted. It will be recreated by
% biber as required.
%
\begingroup
\makeatletter
\@ifundefined{ver@biblatex.sty}
  {\@latex@error
     {Missing 'biblatex' package}
     {The bibliography requires the 'biblatex' package.}
      \aftergroup\endinput}
  {}
\endgroup


\refsection{0}
  \sortlist{}{}
    \entry{kessel2010}{book}{}
      \name{labelname}{2}{}{%
        {{hash=09d96aa5b560f746a81c4f0086d6aeb4}{Kessel}{K\bibinitperiod}{A}{A\bibinitperiod}{}{}{}{}}%
        {{hash=adc989901810b45b4084e719b53e6668}{Ben-Tal}{B\bibinithyphendelim T\bibinitperiod}{N}{N\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=09d96aa5b560f746a81c4f0086d6aeb4}{Kessel}{K\bibinitperiod}{A}{A\bibinitperiod}{}{}{}{}}%
        {{hash=adc989901810b45b4084e719b53e6668}{Ben-Tal}{B\bibinithyphendelim T\bibinitperiod}{N}{N\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {CRC Press}%
      }
      \strng{namehash}{f607c969a2c8cea129a86878a4c3fb63}
      \strng{fullhash}{f607c969a2c8cea129a86878a4c3fb63}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Introduction to Proteins: Structure, Function, and Motion}}
      \field{isbn}{9781439810729}
      \field{series}{Chapman {\&} Hall/CRC Mathematical and Computational Biology}
      \field{title}{{Introduction to Proteins: Structure, Function, and Motion}}
      \field{year}{2010}
      \verb{url}
      \verb https://books.google.es/books?id=cMMgypIrxocC
      \endverb
    \endentry
    \entry{thecell2008}{book}{}
      \name{labelname}{1}{}{%
        {{hash=f351b421c470c2f155156f0ed44b791f}{Alberts}{A\bibinitperiod}{B.}{B\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=f351b421c470c2f155156f0ed44b791f}{Alberts}{A\bibinitperiod}{B.}{B\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Garland Science}%
      }
      \strng{namehash}{f351b421c470c2f155156f0ed44b791f}
      \strng{fullhash}{f351b421c470c2f155156f0ed44b791f}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{Molecular Biology of the Cell: Reference edition}
      \field{isbn}{9780815341116}
      \field{number}{v. 1}
      \field{series}{Molecular Biology of the Cell: Reference Edition}
      \field{title}{Molecular Biology of the Cell: Reference edition}
      \field{year}{2008}
      \verb{url}
      \verb https://books.google.es/books?id=iepqmRfP3ZoC
      \endverb
    \endentry
    \entry{DSSP}{article}{}
      \name{labelname}{2}{}{%
        {{hash=7f410e758870d5022f40f18e19d55197}{Kabsch}{K\bibinitperiod}{Wolfgang}{W\bibinitperiod}{}{}{}{}}%
        {{hash=fe52d1a32f8a4d5b93db74a3f31bdb50}{Sander}{S\bibinitperiod}{Christian}{C\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=7f410e758870d5022f40f18e19d55197}{Kabsch}{K\bibinitperiod}{Wolfgang}{W\bibinitperiod}{}{}{}{}}%
        {{hash=fe52d1a32f8a4d5b93db74a3f31bdb50}{Sander}{S\bibinitperiod}{Christian}{C\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Wiley Subscription Services, Inc., A Wiley Company}%
      }
      \strng{namehash}{5ce8be718914c8a388f5d1b1455152fc}
      \strng{fullhash}{5ce8be718914c8a388f5d1b1455152fc}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Dictionary of protein secondary structure: Pattern recognition of hydrogen-bonded and geometrical features}}
      \field{issn}{1097-0282}
      \field{journaltitle}{Biopolymers}
      \field{number}{12}
      \field{title}{{Dictionary of protein secondary structure: Pattern recognition of hydrogen-bonded and geometrical features}}
      \field{volume}{22}
      \field{year}{1983}
      \field{pages}{2577\bibrangedash 2637}
      \verb{doi}
      \verb 10.1002/bip.360221211
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1002/bip.360221211
      \endverb
    \endentry
    \entry{Dill1990}{article}{}
      \name{labelname}{1}{}{%
        {{hash=9a39ef1b41588121d5d2cefe3071d1b6}{Dill}{D\bibinitperiod}{K\bibnamedelima A}{K\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=9a39ef1b41588121d5d2cefe3071d1b6}{Dill}{D\bibinitperiod}{K\bibnamedelima A}{K\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{9a39ef1b41588121d5d2cefe3071d1b6}
      \strng{fullhash}{9a39ef1b41588121d5d2cefe3071d1b6}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Dominant forces in protein folding.}}
      \field{abstract}{PMID: 2207096}
      \field{isbn}{0006-2960}
      \field{issn}{0006-2960}
      \field{journaltitle}{Biochemistry}
      \field{number}{31}
      \field{title}{{Dominant forces in protein folding.}}
      \field{volume}{29}
      \field{year}{1990}
      \field{pages}{7133\bibrangedash 7155}
      \verb{doi}
      \verb 10.1021/bi00483a001
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/bi00483a001.pdf:pdf
      \endverb
    \endentry
    \entry{StructureSequence}{article}{}
      \name{labelname}{2}{}{%
        {{hash=76acb31aa7f188100748edec31345f05}{Chothial}{C\bibinitperiod}{Cyrus}{C\bibinitperiod}{}{}{}{}}%
        {{hash=80caa77742ed8b6aef79492d161c7bb3}{Lesk}{L\bibinitperiod}{Arthur\bibnamedelima M}{A\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=76acb31aa7f188100748edec31345f05}{Chothial}{C\bibinitperiod}{Cyrus}{C\bibinitperiod}{}{}{}{}}%
        {{hash=80caa77742ed8b6aef79492d161c7bb3}{Lesk}{L\bibinitperiod}{Arthur\bibnamedelima M}{A\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{dc0fd253e013d7e6a32a8dc8c6b770ee}
      \strng{fullhash}{dc0fd253e013d7e6a32a8dc8c6b770ee}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{proteins}
      \field{number}{4}
      \field{title}{proteins}
      \field{volume}{5}
      \field{year}{1986}
      \field{pages}{823\bibrangedash 826}
      \verb{file}
      \verb :home/fran/Downloads/emboj00167-0187.pdf:pdf
      \endverb
    \endentry
    \entry{conservPPI}{article}{}
      \name{labelname}{4}{}{%
        {{hash=cdbd829290aac4452bad6ad432b8f3b7}{Ma}{M\bibinitperiod}{Buyong}{B\bibinitperiod}{}{}{}{}}%
        {{hash=30f8080ada0f81c014ad52a0e4ae30c8}{Elkayam}{E\bibinitperiod}{Tal}{T\bibinitperiod}{}{}{}{}}%
        {{hash=c7dad2d76c9f649d2d5e2eda8598c14f}{Wolfson}{W\bibinitperiod}{Haim}{H\bibinitperiod}{}{}{}{}}%
        {{hash=5df4f003753b6d9cfad61f047a6dab01}{Nussinov}{N\bibinitperiod}{Ruth}{R\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=cdbd829290aac4452bad6ad432b8f3b7}{Ma}{M\bibinitperiod}{Buyong}{B\bibinitperiod}{}{}{}{}}%
        {{hash=30f8080ada0f81c014ad52a0e4ae30c8}{Elkayam}{E\bibinitperiod}{Tal}{T\bibinitperiod}{}{}{}{}}%
        {{hash=c7dad2d76c9f649d2d5e2eda8598c14f}{Wolfson}{W\bibinitperiod}{Haim}{H\bibinitperiod}{}{}{}{}}%
        {{hash=5df4f003753b6d9cfad61f047a6dab01}{Nussinov}{N\bibinitperiod}{Ruth}{R\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{305706773835f47aca04bcfde0824ada}
      \strng{fullhash}{811e01ddc6d2e367c99bb2fa8c0aeda8}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Protein -- protein interactions : Structurally conserved residues distinguish between binding sites and exposed protein surfaces}}
      \field{number}{Track II}
      \field{title}{{Protein -- protein interactions : Structurally conserved residues distinguish between binding sites and exposed protein surfaces}}
      \field{year}{2003}
      \verb{file}
      \verb :home/fran/Downloads/PNAS-2003-Ma-5772-7.pdf:pdf
      \endverb
    \endentry
    \entry{Raj2007}{article}{}
      \name{labelname}{2}{}{%
        {{hash=e1f7f25c7909b5dd589dbb0dcfc6c78a}{Sasidharan}{S\bibinitperiod}{Rajkumar}{R\bibinitperiod}{}{}{}{}}%
        {{hash=e7519839a5afb3dc61bb297b7fb4f313}{Chothia}{C\bibinitperiod}{Cyrus}{C\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=e1f7f25c7909b5dd589dbb0dcfc6c78a}{Sasidharan}{S\bibinitperiod}{Rajkumar}{R\bibinitperiod}{}{}{}{}}%
        {{hash=e7519839a5afb3dc61bb297b7fb4f313}{Chothia}{C\bibinitperiod}{Cyrus}{C\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{7aeadfdcc51d156d5f4e5e485d5a4b53}
      \strng{fullhash}{7aeadfdcc51d156d5f4e5e485d5a4b53}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{The selection of acceptable protein mutations}}
      \field{isbn}{0703737104}
      \field{title}{{The selection of acceptable protein mutations}}
      \field{volume}{2007}
      \field{year}{2007}
      \verb{file}
      \verb :home/fran/Downloads/zpq10080.pdf:pdf
      \endverb
    \endentry
    \entry{Todd2001}{article}{}
      \name{labelname}{3}{}{%
        {{hash=84dbfdfd9d845898fa36a2b8db9952d4}{Todd}{T\bibinitperiod}{Annabel\bibnamedelima E}{A\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=299543f55499c67e26036baabc306fe2}{Orengo}{O\bibinitperiod}{Christine\bibnamedelima A}{C\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=57d4b2a8608ed46ecd78623269176506}{Thornton}{T\bibinitperiod}{Janet\bibnamedelima M}{J\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=84dbfdfd9d845898fa36a2b8db9952d4}{Todd}{T\bibinitperiod}{Annabel\bibnamedelima E}{A\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=299543f55499c67e26036baabc306fe2}{Orengo}{O\bibinitperiod}{Christine\bibnamedelima A}{C\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=57d4b2a8608ed46ecd78623269176506}{Thornton}{T\bibinitperiod}{Janet\bibnamedelima M}{J\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{9d2da1dcd3a2355eb7347cd582d14844}
      \strng{fullhash}{9d2da1dcd3a2355eb7347cd582d14844}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Evolution of Function in Protein Superfamilies , from a Structural Perspective}}
      \field{title}{{Evolution of Function in Protein Superfamilies , from a Structural Perspective}}
      \field{year}{2001}
      \verb{doi}
      \verb 10.1006/jmbi.2001.4513
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/1-s2.0-S0022283601945139-main.pdf:pdf
      \endverb
    \endentry
    \entry{KENDREW1960}{article}{}
      \name{labelname}{7}{}{%
        {{hash=d97ded3f06f615e6609b1bf284577c25}{KENDREW}{K\bibinitperiod}{J\bibnamedelima C}{J\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=b7c2e0891cd46c21469e5e30a355155a}{DICKERSON}{D\bibinitperiod}{R\bibnamedelima E}{R\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=7511ac0193595ce2c4ea22730cdb7cb9}{STRANDBERG}{S\bibinitperiod}{B\bibnamedelima E}{B\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=526f673eaa0c43849ccaa2f3dce8992d}{HART}{H\bibinitperiod}{R\bibnamedelima G}{R\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=55a9b522b46075bf8bf2975b7a1b6f9a}{DAVIES}{D\bibinitperiod}{D\bibnamedelima R}{D\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=308e6c65fb56dea4b04a8b9b95a73ce8}{PHILLIPS}{P\bibinitperiod}{D\bibnamedelima C}{D\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=93c04c434b431a5d51578d3211ea0e79}{SHORE}{S\bibinitperiod}{V\bibnamedelima C}{V\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{7}{}{%
        {{hash=d97ded3f06f615e6609b1bf284577c25}{KENDREW}{K\bibinitperiod}{J\bibnamedelima C}{J\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=b7c2e0891cd46c21469e5e30a355155a}{DICKERSON}{D\bibinitperiod}{R\bibnamedelima E}{R\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=7511ac0193595ce2c4ea22730cdb7cb9}{STRANDBERG}{S\bibinitperiod}{B\bibnamedelima E}{B\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=526f673eaa0c43849ccaa2f3dce8992d}{HART}{H\bibinitperiod}{R\bibnamedelima G}{R\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=55a9b522b46075bf8bf2975b7a1b6f9a}{DAVIES}{D\bibinitperiod}{D\bibnamedelima R}{D\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=308e6c65fb56dea4b04a8b9b95a73ce8}{PHILLIPS}{P\bibinitperiod}{D\bibnamedelima C}{D\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=93c04c434b431a5d51578d3211ea0e79}{SHORE}{S\bibinitperiod}{V\bibnamedelima C}{V\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{8287f11a7247c594a2dcc77e4400b2f4}
      \strng{fullhash}{b8a00f7a56e6a4af8a30f421c882006d}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Structure of Myoglobin: A Three-Dimensional Fourier Synthesis at 2 [angst]. Resolution}}
      \field{annotation}{10.1038/185422a0}
      \field{journaltitle}{Nature}
      \field{month}{02}
      \field{number}{4711}
      \field{title}{{Structure of Myoglobin: A Three-Dimensional Fourier Synthesis at 2 [angst]. Resolution}}
      \field{volume}{185}
      \field{year}{1960}
      \field{pages}{422\bibrangedash 427}
      \verb{url}
      \verb http://dx.doi.org/10.1038/185422a0
      \endverb
    \endentry
    \entry{Berman2000}{article}{}
      \name{labelname}{8}{}{%
        {{hash=0363d036b24e1191b76fc6f4bb86cd79}{Berman}{B\bibinitperiod}{Helen\bibnamedelima M}{H\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=cafb3691e83b5fe5369b6ddfbd7c7fec}{Westbrook}{W\bibinitperiod}{John}{J\bibinitperiod}{}{}{}{}}%
        {{hash=3468c1fce34977da673dea11e3fc64b0}{Feng}{F\bibinitperiod}{Zukang}{Z\bibinitperiod}{}{}{}{}}%
        {{hash=ef13e40589ce50a74a82205ece5f053d}{Gilliland}{G\bibinitperiod}{Gary}{G\bibinitperiod}{}{}{}{}}%
        {{hash=0febc6fc4d8962b7459c9ea72d71fd2e}{Bhat}{B\bibinitperiod}{T\bibnamedelima N}{T\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
        {{hash=f6cfd7bb473bc51e886cbc11b1c76cb8}{Weissig}{W\bibinitperiod}{Helge}{H\bibinitperiod}{}{}{}{}}%
        {{hash=50ae25b4d890af1d9462cb8025df09c6}{Shindyalov}{S\bibinitperiod}{Ilya\bibnamedelima N}{I\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
        {{hash=7c11f3af2e76014f9f3869e767aba8c4}{Bourne}{B\bibinitperiod}{Philip\bibnamedelima E}{P\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{8}{}{%
        {{hash=0363d036b24e1191b76fc6f4bb86cd79}{Berman}{B\bibinitperiod}{Helen\bibnamedelima M}{H\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=cafb3691e83b5fe5369b6ddfbd7c7fec}{Westbrook}{W\bibinitperiod}{John}{J\bibinitperiod}{}{}{}{}}%
        {{hash=3468c1fce34977da673dea11e3fc64b0}{Feng}{F\bibinitperiod}{Zukang}{Z\bibinitperiod}{}{}{}{}}%
        {{hash=ef13e40589ce50a74a82205ece5f053d}{Gilliland}{G\bibinitperiod}{Gary}{G\bibinitperiod}{}{}{}{}}%
        {{hash=0febc6fc4d8962b7459c9ea72d71fd2e}{Bhat}{B\bibinitperiod}{T\bibnamedelima N}{T\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
        {{hash=f6cfd7bb473bc51e886cbc11b1c76cb8}{Weissig}{W\bibinitperiod}{Helge}{H\bibinitperiod}{}{}{}{}}%
        {{hash=50ae25b4d890af1d9462cb8025df09c6}{Shindyalov}{S\bibinitperiod}{Ilya\bibnamedelima N}{I\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
        {{hash=7c11f3af2e76014f9f3869e767aba8c4}{Bourne}{B\bibinitperiod}{Philip\bibnamedelima E}{P\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{a85430ce9df4b0d45d7353531c90d416}
      \strng{fullhash}{c3cdddbde2be0f288eb6b69c4dad7edc}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{The Protein Data Bank}}
      \field{abstract}{The Protein Data Bank (PDB; http://www.rcsb.org/pdb/ ) is the single worldwide archive of structural data of biological macromolecules. This paper describes the goals of the PDB, the systems in place for data deposition and access, how to obtain further information, and near-term plans for the future development of the resource.}
      \field{annotation}{10.1093/nar/28.1.235}
      \field{journaltitle}{Nucleic Acids Research}
      \field{month}{01}
      \field{number}{1}
      \field{title}{{The Protein Data Bank}}
      \field{volume}{28}
      \field{year}{2000}
      \field{pages}{235\bibrangedash 242}
      \verb{doi}
      \verb 10.1093/nar/28.1.235
      \endverb
      \verb{url}
      \verb http://nar.oxfordjournals.org/content/28/1/235.abstract
      \endverb
    \endentry
    \entry{Norvell2007}{article}{}
      \name{labelname}{2}{}{%
        {{hash=f0595b02cbe9d16d4e5c13037b5806b5}{Norvell}{N\bibinitperiod}{John\bibnamedelima C}{J\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=8029c37c392881fde147ecc3e41a40f9}{Berg}{B\bibinitperiod}{Jeremy\bibnamedelima M}{J\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=f0595b02cbe9d16d4e5c13037b5806b5}{Norvell}{N\bibinitperiod}{John\bibnamedelima C}{J\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=8029c37c392881fde147ecc3e41a40f9}{Berg}{B\bibinitperiod}{Jeremy\bibnamedelima M}{J\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{29a1cccbf417eed7e7c20b8c2f1e7d0e}
      \strng{fullhash}{29a1cccbf417eed7e7c20b8c2f1e7d0e}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Update on the Protein Structure Initiative}}
      \field{issn}{0969-2126}
      \field{journaltitle}{Structure}
      \field{month}{12}
      \field{number}{12}
      \field{title}{{Update on the Protein Structure Initiative}}
      \field{volume}{15}
      \field{year}{2007}
      \field{pages}{1519\bibrangedash 1522}
      \verb{doi}
      \verb http://dx.doi.org/10.1016/j.str.2007.11.004
      \endverb
      \verb{url}
      \verb http://www.sciencedirect.com/science/article/pii/S0969212607004248
      \endverb
    \endentry
    \entry{GIleadi2007}{article}{}
      \name{labelname}{7}{}{%
        {{hash=5b90178f5994899b8224fe4dd3effa66}{Gileadi}{G\bibinitperiod}{Opher}{O\bibinitperiod}{}{}{}{}}%
        {{hash=6068b3859996527329cb4fd5aa5d1064}{Knapp}{K\bibinitperiod}{{{\AE}}\bibnamedelima Stefan}{{\AE}\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=27612d4b580cb4cd938ad1009d4ee213}{Hwa}{H\bibinitperiod}{{{\AE}}\bibnamedelima Wen}{{\AE}\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=4628a07a56b645837725e1a38b0fe75a}{Brian}{B\bibinitperiod}{Lee\bibnamedelima {{\AE}}}{L\bibinitperiod\bibinitdelim {\AE}\bibinitperiod}{}{}{}{}}%
        {{hash=6aeabe2d7df1947b6032b00243a31779}{Frank}{F\bibinitperiod}{{{\AE}}}{{\AE}\bibinitperiod}{}{}{}{}}%
        {{hash=5a9cbf8143dba13439402928b7c6158b}{Kathryn}{K\bibinitperiod}{H\bibnamedelima Niesen\bibnamedelima {{\AE}}}{H\bibinitperiod\bibinitdelim N\bibinitperiod\bibinitdelim {\AE}\bibinitperiod}{}{}{}{}}%
        {{hash=861cc6383aea70c7af97a60eeaaa0f3d}{Linda}{L\bibinitperiod}{L\bibnamedelima Kavanagh\bibnamedelima {{\AE}}}{L\bibinitperiod\bibinitdelim K\bibinitperiod\bibinitdelim {\AE}\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{7}{}{%
        {{hash=5b90178f5994899b8224fe4dd3effa66}{Gileadi}{G\bibinitperiod}{Opher}{O\bibinitperiod}{}{}{}{}}%
        {{hash=6068b3859996527329cb4fd5aa5d1064}{Knapp}{K\bibinitperiod}{{{\AE}}\bibnamedelima Stefan}{{\AE}\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=27612d4b580cb4cd938ad1009d4ee213}{Hwa}{H\bibinitperiod}{{{\AE}}\bibnamedelima Wen}{{\AE}\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=4628a07a56b645837725e1a38b0fe75a}{Brian}{B\bibinitperiod}{Lee\bibnamedelima {{\AE}}}{L\bibinitperiod\bibinitdelim {\AE}\bibinitperiod}{}{}{}{}}%
        {{hash=6aeabe2d7df1947b6032b00243a31779}{Frank}{F\bibinitperiod}{{{\AE}}}{{\AE}\bibinitperiod}{}{}{}{}}%
        {{hash=5a9cbf8143dba13439402928b7c6158b}{Kathryn}{K\bibinitperiod}{H\bibnamedelima Niesen\bibnamedelima {{\AE}}}{H\bibinitperiod\bibinitdelim N\bibinitperiod\bibinitdelim {\AE}\bibinitperiod}{}{}{}{}}%
        {{hash=861cc6383aea70c7af97a60eeaaa0f3d}{Linda}{L\bibinitperiod}{L\bibnamedelima Kavanagh\bibnamedelima {{\AE}}}{L\bibinitperiod\bibinitdelim K\bibinitperiod\bibinitdelim {\AE}\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{10a02661ba9d1113255cc71153ab4c82}
      \strng{fullhash}{16e89ad6bdd930aa18cadb60d2f1f79c}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{The scientific impact of the Structural Genomics Consortium : a protein family and ligand-centered approach to medically-relevant human proteins}}
      \field{title}{{The scientific impact of the Structural Genomics Consortium : a protein family and ligand-centered approach to medically-relevant human proteins}}
      \field{year}{2007}
      \field{pages}{107\bibrangedash 119}
      \verb{doi}
      \verb 10.1007/s10969-007-9027-2
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/art{\%}3A10.1007{\%}2Fs10969-007-9027-2.pdf:pdf
      \endverb
    \endentry
    \entry{Smyth2000}{article}{}
      \name{labelname}{2}{}{%
        {{hash=52c300e5d6fb78024ef538c5d298915a}{Smyth}{S\bibinitperiod}{M\bibnamedelima S}{M\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=bfaa7649e6d28f67106ac1fbaa12b55b}{Martin}{M\bibinitperiod}{J\bibnamedelima H\bibnamedelima J}{J\bibinitperiod\bibinitdelim H\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=52c300e5d6fb78024ef538c5d298915a}{Smyth}{S\bibinitperiod}{M\bibnamedelima S}{M\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=bfaa7649e6d28f67106ac1fbaa12b55b}{Martin}{M\bibinitperiod}{J\bibnamedelima H\bibnamedelima J}{J\bibinitperiod\bibinitdelim H\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{e5f299614d3278c44659ca169ec477ed}
      \strng{fullhash}{e5f299614d3278c44659ca169ec477ed}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{x Ray crystallography}}
      \field{abstract}{x Ray crystallography is currently the most favoured technique for structure determination of proteins and biological macromolecules. Increasingly, those interested in all branches of the biological sciences require structural information to shed light on previously unanswered questions. Furthermore, the availability of a protein structure can provide a more detailed focus for future research. The extension of the technique to systems such as viruses, immune complexes, and protein--nucleic acid complexes serves only to widen the appeal of crystallography. Structure based drug design, site directed mutagenesis, elucidation of enzyme mechanisms, and specificity of protein--ligand interactions are just a few of the areas in which x ray crystallography has provided clarification.}
      \field{annotation}{10.1136/mp.53.1.8}
      \field{journaltitle}{Molecular Pathology}
      \field{month}{02}
      \field{number}{1}
      \field{title}{{x Ray crystallography}}
      \field{volume}{53}
      \field{year}{2000}
      \field{pages}{8\bibrangedash 14}
      \verb{doi}
      \verb 10.1136/mp.53.1.8
      \endverb
      \verb{url}
      \verb http://mp.bmj.com/content/53/1/8.abstract
      \endverb
    \endentry
    \entry{Bill2011}{article}{}
      \name{labelname}{10}{}{%
        {{hash=06a311949828d59b7e4b3b1a9efd3125}{Bill}{B\bibinitperiod}{Roslyn\bibnamedelima M}{R\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=503311d75248be397b1b4d4509d184f3}{Henderson}{H\bibinitperiod}{Peter\bibnamedelimb J\bibnamedelima F}{P\bibinitperiod\bibinitdelim J\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{hash=ebe4aed96b9022ddfb50caed802e3801}{Iwata}{I\bibinitperiod}{So}{S\bibinitperiod}{}{}{}{}}%
        {{hash=4503b328233c1043ca7a2b5960dea646}{Kunji}{K\bibinitperiod}{Edmund\bibnamedelimb R\bibnamedelima S}{E\bibinitperiod\bibinitdelim R\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=64b31a537509f887e6991ce1e6955272}{Michel}{M\bibinitperiod}{Hartmut}{H\bibinitperiod}{}{}{}{}}%
        {{hash=8050fec8b521b49653b69709bdf45d26}{Neutze}{N\bibinitperiod}{Richard}{R\bibinitperiod}{}{}{}{}}%
        {{hash=834ea5365b8a63582d9ddfad8736b1e8}{Newstead}{N\bibinitperiod}{Simon}{S\bibinitperiod}{}{}{}{}}%
        {{hash=c5b90a84288d961f7e7e5b88c0d01f9d}{Poolman}{P\bibinitperiod}{Bert}{B\bibinitperiod}{}{}{}{}}%
        {{hash=7d0a773ead80f40a3aa3630081b806bc}{Tate}{T\bibinitperiod}{Christopher\bibnamedelima G}{C\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=3e03ba5604e981fd33254810cf11ad35}{Vogel}{V\bibinitperiod}{Horst}{H\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{10}{}{%
        {{hash=06a311949828d59b7e4b3b1a9efd3125}{Bill}{B\bibinitperiod}{Roslyn\bibnamedelima M}{R\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=503311d75248be397b1b4d4509d184f3}{Henderson}{H\bibinitperiod}{Peter\bibnamedelimb J\bibnamedelima F}{P\bibinitperiod\bibinitdelim J\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{hash=ebe4aed96b9022ddfb50caed802e3801}{Iwata}{I\bibinitperiod}{So}{S\bibinitperiod}{}{}{}{}}%
        {{hash=4503b328233c1043ca7a2b5960dea646}{Kunji}{K\bibinitperiod}{Edmund\bibnamedelimb R\bibnamedelima S}{E\bibinitperiod\bibinitdelim R\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=64b31a537509f887e6991ce1e6955272}{Michel}{M\bibinitperiod}{Hartmut}{H\bibinitperiod}{}{}{}{}}%
        {{hash=8050fec8b521b49653b69709bdf45d26}{Neutze}{N\bibinitperiod}{Richard}{R\bibinitperiod}{}{}{}{}}%
        {{hash=834ea5365b8a63582d9ddfad8736b1e8}{Newstead}{N\bibinitperiod}{Simon}{S\bibinitperiod}{}{}{}{}}%
        {{hash=c5b90a84288d961f7e7e5b88c0d01f9d}{Poolman}{P\bibinitperiod}{Bert}{B\bibinitperiod}{}{}{}{}}%
        {{hash=7d0a773ead80f40a3aa3630081b806bc}{Tate}{T\bibinitperiod}{Christopher\bibnamedelima G}{C\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=3e03ba5604e981fd33254810cf11ad35}{Vogel}{V\bibinitperiod}{Horst}{H\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group}%
      }
      \strng{namehash}{7ca5bd6a5c186afc9d0627a4a279195e}
      \strng{fullhash}{5cc7eef09f59e4a5d25c41ae1013ae0b}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{perspective Overcoming barriers to membrane protein structure determination}}
      \field{issn}{1087-0156}
      \field{journaltitle}{Nature Biotechnology}
      \field{number}{4}
      \field{title}{{perspective Overcoming barriers to membrane protein structure determination}}
      \field{volume}{29}
      \field{year}{2011}
      \field{pages}{335\bibrangedash 340}
      \verb{doi}
      \verb 10.1038/nbt.1833
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/nbt.1833.pdf:pdf
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1038/nbt.1833
      \endverb
    \endentry
    \entry{Yaffe2005}{article}{}
      \name{labelname}{1}{}{%
        {{hash=784e1463079a6f278a7dd8546a176806}{Yaffe}{Y\bibinitperiod}{Michael\bibnamedelima B}{M\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=784e1463079a6f278a7dd8546a176806}{Yaffe}{Y\bibinitperiod}{Michael\bibnamedelima B}{M\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{784e1463079a6f278a7dd8546a176806}
      \strng{fullhash}{784e1463079a6f278a7dd8546a176806}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{X-ray crystallography and structural biology}}
      \field{issn}{0090-3493}
      \field{journaltitle}{Critical Care Medicine}
      \field{number}{12}
      \field{title}{{X-ray crystallography and structural biology}}
      \field{volume}{33}
      \field{year}{2005}
      \verb{url}
      \verb http://journals.lww.com/ccmjournal/Fulltext/2005/12001/X%7B%5C_%7Dray%7B%5C_%7Dcrystallography%7B%5C_%7Dand%7B%5C_%7Dstructural%7B%5C_%7Dbiology.13.aspx
      \endverb
    \endentry
    \entry{Morris1992}{article}{}
      \name{labelname}{4}{}{%
        {{hash=ca545d3f9551f8f6ce94efdbbc4a346c}{Morris}{M\bibinitperiod}{A\bibnamedelima L}{A\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=5c4eb1cd238e391dc3c289863ad4ac4a}{MacArthur}{M\bibinitperiod}{M\bibnamedelima W}{M\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=9992b643c702bf350318bbcf30cb5d11}{Hutchinson}{H\bibinitperiod}{E\bibnamedelima G}{E\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=4e0a85c4306de0b0c0b90e73ab079396}{Thornton}{T\bibinitperiod}{J\bibnamedelima M}{J\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=ca545d3f9551f8f6ce94efdbbc4a346c}{Morris}{M\bibinitperiod}{A\bibnamedelima L}{A\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=5c4eb1cd238e391dc3c289863ad4ac4a}{MacArthur}{M\bibinitperiod}{M\bibnamedelima W}{M\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=9992b643c702bf350318bbcf30cb5d11}{Hutchinson}{H\bibinitperiod}{E\bibnamedelima G}{E\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=4e0a85c4306de0b0c0b90e73ab079396}{Thornton}{T\bibinitperiod}{J\bibnamedelima M}{J\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{a62f2c8f696c5112bc444536a3637d4d}
      \strng{fullhash}{7c4392cedd5e2971f3b15807f2e9aa91}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Stereochemical quality of protein structure coordinates.}}
      \field{abstract}{Methods have been developed to assess the stereochemical quality of any protein structure both globally and locally using various criteria. Several parameters can be derived from the coordinates of a given structure. Global parameters include the distribution of phi, psi and chi 1 torsion angles, and hydrogen bond energies. There are clear correlations between these parameters and resolution; as the resolution improves, the distribution of the parameters becomes more clustered. These features show a broad distribution about ideal values derived from high-resolution structures. Some structures have tightly clustered distributions even at relatively low resolutions, while others show abnormal scatter though the data go to high resolution. Additional indicators of local irregularity include proline phi angles, peptide bond planarities, disulfide bond lengths, and their chi 3 torsion angles. These stereochemical parameters have been used to generate measures of stereochemical quality which provide a simple guide as to the reliability of a structure, in addition to the most important measures, resolution and R-factor. The parameters used in this evaluation are not novel, and are easily calculated from structure coordinates. A program suite is currently being developed which will quickly check a given structure, highlighting unusual stereochemistry and possible errors.}
      \field{issn}{0887-3585}
      \field{journaltitle}{Proteins}
      \field{month}{04}
      \field{number}{4}
      \field{title}{{Stereochemical quality of protein structure coordinates.}}
      \field{volume}{12}
      \field{year}{1992}
      \field{pages}{345\bibrangedash 64}
      \verb{doi}
      \verb 10.1002/prot.340120407
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/1579569
      \endverb
    \endentry
    \entry{Wider2000}{article}{}
      \name{labelname}{1}{}{%
        {{hash=8ff508576e15ddc36a991d63efec7a65}{Wider}{W\bibinitperiod}{Gerhard}{G\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=8ff508576e15ddc36a991d63efec7a65}{Wider}{W\bibinitperiod}{Gerhard}{G\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{8ff508576e15ddc36a991d63efec7a65}
      \strng{fullhash}{8ff508576e15ddc36a991d63efec7a65}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Structure Determination of Biological Macromolecules in Solution Using NMR spectroscopy}}
      \field{title}{{Structure Determination of Biological Macromolecules in Solution Using NMR spectroscopy}}
      \field{volume}{1294}
      \field{year}{2000}
      \field{pages}{1278\bibrangedash 1294}
      \verb{file}
      \verb :home/fran/Downloads/Guide-1997-Wider.pdf:pdf
      \endverb
    \endentry
    \entry{Gadian1993}{inbook}{}
      \name{labelname}{4}{}{%
        {{hash=ea789d788f1dbb6421322e0b21f5892c}{Gadian}{G\bibinitperiod}{David\bibnamedelima G}{D\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=55ef8ad51e26dc13ed256093d4dbb331}{Williams}{W\bibinitperiod}{S\bibnamedelima R}{S\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=c46b279e69384c924ebbee8dc9bec2b4}{Bates}{B\bibinitperiod}{T\bibnamedelima E}{T\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=cc834580c06e9234687d5bac41c708ba}{Kauppinen}{K\bibinitperiod}{R\bibnamedelima A}{R\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=ea789d788f1dbb6421322e0b21f5892c}{Gadian}{G\bibinitperiod}{David\bibnamedelima G}{D\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=55ef8ad51e26dc13ed256093d4dbb331}{Williams}{W\bibinitperiod}{S\bibnamedelima R}{S\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=c46b279e69384c924ebbee8dc9bec2b4}{Bates}{B\bibinitperiod}{T\bibnamedelima E}{T\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=cc834580c06e9234687d5bac41c708ba}{Kauppinen}{K\bibinitperiod}{R\bibnamedelima A}{R\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \name{editor}{3}{}{%
        {{hash=b883c437ea4b18bb330c9f183700926d}{Baethmann}{B\bibinitperiod}{Alexander}{A\bibinitperiod}{}{}{}{}}%
        {{hash=42cf7795e55b1bbb8433ec56e271ea90}{Kempski}{K\bibinitperiod}{Oliver}{O\bibinitperiod}{}{}{}{}}%
        {{hash=6d5b254ce5ca2b62a527c52392e63f66}{Sch{\"{u}}rer}{S\bibinitperiod}{Ludwig}{L\bibinitperiod}{}{}{}{}}%
      }
      \list{location}{1}{%
        {Vienna}%
      }
      \list{publisher}{1}{%
        {Springer Vienna}%
      }
      \strng{namehash}{cf3674bd64b3eb0f6d286a9085ce672b}
      \strng{fullhash}{6161b0c0af55feabf8f34f4305d690c5}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Mechanisms of Secondary Brain Damage: Current State}}
      \field{chapter}{NMR Spectr}
      \field{isbn}{978-3-7091-9266-5}
      \field{title}{{Mechanisms of Secondary Brain Damage: Current State}}
      \field{year}{1993}
      \field{pages}{1\bibrangedash 8}
      \verb{doi}
      \verb 10.1007/978-3-7091-9266-5_1
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1007/978-3-7091-9266-5%7B%5C_%7D1
      \endverb
    \endentry
    \entry{CryoEM}{article}{}
      \name{labelname}{4}{}{%
        {{hash=c9d0a219c4a539032eb0d79df4277ea3}{Up}{U\bibinitperiod}{Kicking}{K\bibinitperiod}{}{}{}{}}%
        {{hash=d250e4bf2382052ed37179e39ab71c4e}{In}{I\bibinitperiod}{A\bibnamedelima Storm}{A\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=37c7ce0c1e3d1f0f8cb1c3955b956511}{By}{B\bibinitperiod}{Biology}{B\bibinitperiod}{}{}{}{}}%
        {{hash=78ec7ea12d0fab6eff5bad8482c174d9}{The}{T\bibinitperiod}{Revealing}{R\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=c9d0a219c4a539032eb0d79df4277ea3}{Up}{U\bibinitperiod}{Kicking}{K\bibinitperiod}{}{}{}{}}%
        {{hash=d250e4bf2382052ed37179e39ab71c4e}{In}{I\bibinitperiod}{A\bibnamedelima Storm}{A\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=37c7ce0c1e3d1f0f8cb1c3955b956511}{By}{B\bibinitperiod}{Biology}{B\bibinitperiod}{}{}{}{}}%
        {{hash=78ec7ea12d0fab6eff5bad8482c174d9}{The}{T\bibinitperiod}{Revealing}{R\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{805315148e84bccbed827e82f5ef10eb}
      \strng{fullhash}{1e07bca05729a3ceb20708c44d371aa3}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{THE REVOLUTION WILL NOT BE CRYSTALLIZED}}
      \field{title}{{THE REVOLUTION WILL NOT BE CRYSTALLIZED}}
      \field{year}{2015}
      \field{pages}{7\bibrangedash 9}
      \verb{file}
      \verb :home/fran/Downloads/525172a.pdf:pdf
      \endverb
    \endentry
    \entry{Khatter2015}{article}{}
      \name{labelname}{4}{}{%
        {{hash=1237b30a79f31cc24e88f9fb5b2a979c}{Khatter}{K\bibinitperiod}{Heena}{H\bibinitperiod}{}{}{}{}}%
        {{hash=ab22a119ed136babaf1d53f74bcecc46}{Myasnikov}{M\bibinitperiod}{Alexander\bibnamedelima G}{A\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=7c017909f5c7c1d9050f654cdd840e71}{Natchiar}{N\bibinitperiod}{S\bibnamedelima Kundhavai}{S\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=7f33303a33f9674830d02e59631ee840}{Klaholz}{K\bibinitperiod}{Bruno\bibnamedelima P}{B\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=1237b30a79f31cc24e88f9fb5b2a979c}{Khatter}{K\bibinitperiod}{Heena}{H\bibinitperiod}{}{}{}{}}%
        {{hash=ab22a119ed136babaf1d53f74bcecc46}{Myasnikov}{M\bibinitperiod}{Alexander\bibnamedelima G}{A\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=7c017909f5c7c1d9050f654cdd840e71}{Natchiar}{N\bibinitperiod}{S\bibnamedelima Kundhavai}{S\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=7f33303a33f9674830d02e59631ee840}{Klaholz}{K\bibinitperiod}{Bruno\bibnamedelima P}{B\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.}%
      }
      \strng{namehash}{ad25b6b27717e671bc5d8c3638b26d0a}
      \strng{fullhash}{51acb4591ac4e0e4974e151566d9aa00}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Structure of the human 80S ribosome}}
      \field{abstract}{Ribosomes are translational machineries that catalyse protein synthesis. Ribosome structures from various species are known at the atomic level, but obtaining the structure of the human ribosome has remained a challenge; efforts to address this would be highly relevant with regard to human diseases. Here we report the near-atomic structure of the human ribosome derived from high-resolution single-particle cryo-electron microscopy and atomic model building. The structure has an average resolution of 3.6 A, reaching 2.9 A resolution in the most stable regions. It provides unprecedented insights into ribosomal RNA entities and amino acid side chains, notably of the transfer RNA binding sites and specific molecular interactions with the exit site tRNA. It reveals atomic details of the subunit interface, which is seen to remodel strongly upon rotational movements of the ribosomal subunits. Furthermore, the structure paves the way for analysing antibiotic side effects and diseases associated with deregulated protein synthesis.}
      \field{issn}{0028-0836}
      \field{journaltitle}{Nature}
      \field{month}{04}
      \field{number}{7549}
      \field{title}{{Structure of the human 80S ribosome}}
      \field{volume}{520}
      \field{year}{2015}
      \field{pages}{640\bibrangedash 645}
      \verb{url}
      \verb http://dx.doi.org/10.1038/nature14427%2010.1038/nature14427
      \endverb
    \endentry
    \entry{Zhao2015}{article}{}
      \name{labelname}{3}{}{%
        {{hash=69572537c7bd6eb7c3adb629938f30c0}{Zhao}{Z\bibinitperiod}{Jianhua}{J\bibinitperiod}{}{}{}{}}%
        {{hash=9e0844847d80f069f7d6f12741860d10}{Benlekbir}{B\bibinitperiod}{Samir}{S\bibinitperiod}{}{}{}{}}%
        {{hash=1b76f2f19d82e39b7328494a644bba77}{Rubinstein}{R\bibinitperiod}{John\bibnamedelima L}{J\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=69572537c7bd6eb7c3adb629938f30c0}{Zhao}{Z\bibinitperiod}{Jianhua}{J\bibinitperiod}{}{}{}{}}%
        {{hash=9e0844847d80f069f7d6f12741860d10}{Benlekbir}{B\bibinitperiod}{Samir}{S\bibinitperiod}{}{}{}{}}%
        {{hash=1b76f2f19d82e39b7328494a644bba77}{Rubinstein}{R\bibinitperiod}{John\bibnamedelima L}{J\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.}%
      }
      \strng{namehash}{71082dd705473c5fc1d8a14571322223}
      \strng{fullhash}{71082dd705473c5fc1d8a14571322223}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Electron cryomicroscopy observation of rotational states in a eukaryotic V-ATPase}}
      \field{issn}{0028-0836}
      \field{journaltitle}{Nature}
      \field{month}{05}
      \field{number}{7551}
      \field{title}{{Electron cryomicroscopy observation of rotational states in a eukaryotic V-ATPase}}
      \field{volume}{521}
      \field{year}{2015}
      \field{pages}{241\bibrangedash 245}
      \verb{url}
      \verb http://dx.doi.org/10.1038/nature14365%2010.1038/nature14365%20http://www.nature.com/nature/journal/v521/n7551/abs/nature14365.html%7B%5C#%7Dsupplementary-information
      \endverb
    \endentry
    \entry{Liao2013}{article}{}
      \name{labelname}{4}{}{%
        {{hash=89839d096b28899d33ce9b0189dc510c}{Liao}{L\bibinitperiod}{Maofu}{M\bibinitperiod}{}{}{}{}}%
        {{hash=7043918d8850265dec994752bffd5273}{Cao}{C\bibinitperiod}{Erhu}{E\bibinitperiod}{}{}{}{}}%
        {{hash=40a54a2081cceaeb2d7b4dbbe61aae12}{Julius}{J\bibinitperiod}{David}{D\bibinitperiod}{}{}{}{}}%
        {{hash=e02c0c0762e7a0f83481d4d0fd26fc71}{Cheng}{C\bibinitperiod}{Yifan}{Y\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=89839d096b28899d33ce9b0189dc510c}{Liao}{L\bibinitperiod}{Maofu}{M\bibinitperiod}{}{}{}{}}%
        {{hash=7043918d8850265dec994752bffd5273}{Cao}{C\bibinitperiod}{Erhu}{E\bibinitperiod}{}{}{}{}}%
        {{hash=40a54a2081cceaeb2d7b4dbbe61aae12}{Julius}{J\bibinitperiod}{David}{D\bibinitperiod}{}{}{}{}}%
        {{hash=e02c0c0762e7a0f83481d4d0fd26fc71}{Cheng}{C\bibinitperiod}{Yifan}{Y\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.}%
      }
      \strng{namehash}{bb30bf2bd4392e52357379a16d5fe8aa}
      \strng{fullhash}{4ec89c1c903023c6b4bd70aa24e7454a}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Structure of the TRPV1 ion channel determined by electron cryo-microscopy}}
      \field{abstract}{Transient receptor potential (TRP) channels are sensors for a wide range of cellular and environmental signals, but elucidating how these channels respond to physical and chemical stimuli has been hampered by a lack of detailed structural information. Here we exploit advances in electron cryo-microscopy to determine the structure of a mammalian TRP channel, TRPV1, at 3.4[thinsp]A resolution, breaking the side-chain resolution barrier for membrane proteins without crystallization. Like voltage-gated channels, TRPV1 exhibits four-fold symmetry around a central ion pathway formed by transmembrane segments 5-6 (S5-S6) and the intervening pore loop, which is flanked by S1-S4 voltage-sensor-like domains. TRPV1 has a wide extracellular /`mouth/' with a short selectivity filter. The conserved /`TRP domain/' interacts with the S4-S5 linker, consistent with its contribution to allosteric modulation. Subunit organization is facilitated by interactions among cytoplasmic domains, including amino-terminal ankyrin repeats. These observations provide a structural blueprint for understanding unique aspects of TRP channel function.}
      \field{issn}{0028-0836}
      \field{journaltitle}{Nature}
      \field{month}{12}
      \field{number}{7478}
      \field{title}{{Structure of the TRPV1 ion channel determined by electron cryo-microscopy}}
      \field{volume}{504}
      \field{year}{2013}
      \field{pages}{107\bibrangedash 112}
      \verb{url}
      \verb http://dx.doi.org/10.1038/nature12822%2010.1038/nature12822
      \endverb
    \endentry
    \entry{Bai2015}{article}{}
      \name{labelname}{9}{}{%
        {{hash=618573f5c4d28040ba3d1987d367698d}{Bai}{B\bibinitperiod}{Xiao-chen}{X\bibinithyphendelim c\bibinitperiod}{}{}{}{}}%
        {{hash=a2499a066e63e3b7cb4dec037bb0ad0b}{Yan}{Y\bibinitperiod}{Chuangye}{C\bibinitperiod}{}{}{}{}}%
        {{hash=a086c2fb30943a9ec11a79d3c7bb1cc6}{Yang}{Y\bibinitperiod}{Guanghui}{G\bibinitperiod}{}{}{}{}}%
        {{hash=480d6622a7b9e66fbafc3caca77c1649}{Lu}{L\bibinitperiod}{Peilong}{P\bibinitperiod}{}{}{}{}}%
        {{hash=943e61c0dd3e3cb0a693aed25ec1c0ce}{Ma}{M\bibinitperiod}{Dan}{D\bibinitperiod}{}{}{}{}}%
        {{hash=a6dcdd240f56bc8f342b864416f1e18a}{Sun}{S\bibinitperiod}{Linfeng}{L\bibinitperiod}{}{}{}{}}%
        {{hash=cdb7d456d9550085d585ecff364a3de5}{Zhou}{Z\bibinitperiod}{Rui}{R\bibinitperiod}{}{}{}{}}%
        {{hash=3e32b03d218a1690fd03a982dee8338e}{Scheres}{S\bibinitperiod}{Sjors\bibnamedelimb H\bibnamedelima W}{S\bibinitperiod\bibinitdelim H\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=14866a4828424fc08a8278c4dc04e309}{Shi}{S\bibinitperiod}{Yigong}{Y\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{9}{}{%
        {{hash=618573f5c4d28040ba3d1987d367698d}{Bai}{B\bibinitperiod}{Xiao-chen}{X\bibinithyphendelim c\bibinitperiod}{}{}{}{}}%
        {{hash=a2499a066e63e3b7cb4dec037bb0ad0b}{Yan}{Y\bibinitperiod}{Chuangye}{C\bibinitperiod}{}{}{}{}}%
        {{hash=a086c2fb30943a9ec11a79d3c7bb1cc6}{Yang}{Y\bibinitperiod}{Guanghui}{G\bibinitperiod}{}{}{}{}}%
        {{hash=480d6622a7b9e66fbafc3caca77c1649}{Lu}{L\bibinitperiod}{Peilong}{P\bibinitperiod}{}{}{}{}}%
        {{hash=943e61c0dd3e3cb0a693aed25ec1c0ce}{Ma}{M\bibinitperiod}{Dan}{D\bibinitperiod}{}{}{}{}}%
        {{hash=a6dcdd240f56bc8f342b864416f1e18a}{Sun}{S\bibinitperiod}{Linfeng}{L\bibinitperiod}{}{}{}{}}%
        {{hash=cdb7d456d9550085d585ecff364a3de5}{Zhou}{Z\bibinitperiod}{Rui}{R\bibinitperiod}{}{}{}{}}%
        {{hash=3e32b03d218a1690fd03a982dee8338e}{Scheres}{S\bibinitperiod}{Sjors\bibnamedelimb H\bibnamedelima W}{S\bibinitperiod\bibinitdelim H\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=14866a4828424fc08a8278c4dc04e309}{Shi}{S\bibinitperiod}{Yigong}{Y\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.}%
      }
      \strng{namehash}{34b482037e84f119ac569db9dfa544c1}
      \strng{fullhash}{a473d7a9e4782bd0cc5bbebd22c09d17}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{An atomic structure of human [ggr]-secretase}}
      \field{abstract}{Dysfunction of the intramembrane protease [ggr]-secretase is thought to cause Alzheimer/'s disease, with most mutations derived from Alzheimer/'s disease mapping to the catalytic subunit presenilin 1 (PS1). Here we report an atomic structure of human [ggr]-secretase at 3.4 A resolution, determined by single-particle cryo-electron microscopy. Mutations derived from Alzheimer/'s disease affect residues at two hotspots in PS1, each located at the centre of a distinct four transmembrane segment (TM) bundle. TM2 and, to a lesser extent, TM6 exhibit considerable flexibility, yielding a plastic active site and adaptable surrounding elements. The active site of PS1 is accessible from the convex side of the TM horseshoe, suggesting considerable conformational changes in nicastrin extracellular domain after substrate recruitment. Component protein APH-1 serves as a scaffold, anchoring the lone transmembrane helix from nicastrin and supporting the flexible conformation of PS1. Ordered phospholipids stabilize the complex inside the membrane. Our structure serves as a molecular basis for mechanistic understanding of [ggr]-secretase function.}
      \field{issn}{0028-0836}
      \field{journaltitle}{Nature}
      \field{month}{09}
      \field{number}{7568}
      \field{title}{{An atomic structure of human [ggr]-secretase}}
      \field{volume}{525}
      \field{year}{2015}
      \field{pages}{212\bibrangedash 217}
      \verb{url}
      \verb http://dx.doi.org/10.1038/nature14892%2010.1038/nature14892
      \endverb
    \endentry
    \entry{Jones1992}{article}{}
      \name{labelname}{3}{}{%
        {{hash=af16bd4867635ba09445f9fff6c0335a}{Jones}{J\bibinitperiod}{D\bibnamedelima T}{D\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=4d2e06bbca95a0136a88c069edaf5605}{Taylort}{T\bibinitperiod}{W\bibnamedelima R}{W\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=4e0a85c4306de0b0c0b90e73ab079396}{Thornton}{T\bibinitperiod}{J\bibnamedelima M}{J\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=af16bd4867635ba09445f9fff6c0335a}{Jones}{J\bibinitperiod}{D\bibnamedelima T}{D\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=4d2e06bbca95a0136a88c069edaf5605}{Taylort}{T\bibinitperiod}{W\bibnamedelima R}{W\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=4e0a85c4306de0b0c0b90e73ab079396}{Thornton}{T\bibinitperiod}{J\bibnamedelima M}{J\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{9efd91eb936bd31081c84ffa45dba8ba}
      \strng{fullhash}{9efd91eb936bd31081c84ffa45dba8ba}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{A new approach to protein fold recognition}}
      \field{annotation}{10.1038/358086a0}
      \field{journaltitle}{Nature}
      \field{month}{07}
      \field{number}{6381}
      \field{title}{{A new approach to protein fold recognition}}
      \field{volume}{358}
      \field{year}{1992}
      \field{pages}{86\bibrangedash 89}
      \verb{url}
      \verb http://dx.doi.org/10.1038/358086a0
      \endverb
    \endentry
    \entry{Bowie1991}{article}{}
      \name{labelname}{3}{}{%
        {{hash=d4bd76546b4d6b82d6d0c044b5b616d5}{Bowie}{B\bibinitperiod}{J\bibnamedelima U}{J\bibinitperiod\bibinitdelim U\bibinitperiod}{}{}{}{}}%
        {{hash=fa8afe37484dda68472af72f14bedb31}{Luthy}{L\bibinitperiod}{R}{R\bibinitperiod}{}{}{}{}}%
        {{hash=5011b825249e7610f91f155dda93271e}{Eisenberg}{E\bibinitperiod}{D}{D\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=d4bd76546b4d6b82d6d0c044b5b616d5}{Bowie}{B\bibinitperiod}{J\bibnamedelima U}{J\bibinitperiod\bibinitdelim U\bibinitperiod}{}{}{}{}}%
        {{hash=fa8afe37484dda68472af72f14bedb31}{Luthy}{L\bibinitperiod}{R}{R\bibinitperiod}{}{}{}{}}%
        {{hash=5011b825249e7610f91f155dda93271e}{Eisenberg}{E\bibinitperiod}{D}{D\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{661ebff2c790fa080dede730f9e75a72}
      \strng{fullhash}{661ebff2c790fa080dede730f9e75a72}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{A method to identify protein sequences that fold into a known three-dimensional structure}}
      \field{abstract}{The inverse protein folding problem, the problem of finding which amino acid sequences fold into a known three-dimensional (3D) structure, can be effectively attacked by finding sequences that are most compatible with the environments of the residues in the 3D structure. The environments are described by: (i) the area of the residue buried in the protein and inaccessible to solvent; (ii) the fraction of side-chain area that is covered by polar atoms (O and N); and (iii) the local secondary structure. Examples of this 3D profile method are presented for four families of proteins: the globins, cyclic AMP (adenosine 3',5'-monophosphate) receptor-like proteins, the periplasmic binding proteins, and the actins. This method is able to detect the structural similarity of the actins and 70- kilodalton heat shock proteins, even though these protein families share no detectable sequence similarity.}
      \field{journaltitle}{Science}
      \field{month}{07}
      \field{number}{5016}
      \field{title}{{A method to identify protein sequences that fold into a known three-dimensional structure}}
      \field{volume}{253}
      \field{year}{1991}
      \field{pages}{164\bibrangedash 170}
      \verb{url}
      \verb http://science.sciencemag.org/content/253/5016/164.abstract
      \endverb
    \endentry
    \entry{Lee2009}{inbook}{}
      \name{labelname}{3}{}{%
        {{hash=5b2f0d528aea9e816f7016945db7adf6}{Lee}{L\bibinitperiod}{Jooyoung}{J\bibinitperiod}{}{}{}{}}%
        {{hash=8f4ebdd0f614f53d548b9dd8d0f9159c}{Wu}{W\bibinitperiod}{Sitao}{S\bibinitperiod}{}{}{}{}}%
        {{hash=e760d38078aff4a5b24c867aa5178c26}{Zhang}{Z\bibinitperiod}{Yang}{Y\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=5b2f0d528aea9e816f7016945db7adf6}{Lee}{L\bibinitperiod}{Jooyoung}{J\bibinitperiod}{}{}{}{}}%
        {{hash=8f4ebdd0f614f53d548b9dd8d0f9159c}{Wu}{W\bibinitperiod}{Sitao}{S\bibinitperiod}{}{}{}{}}%
        {{hash=e760d38078aff4a5b24c867aa5178c26}{Zhang}{Z\bibinitperiod}{Yang}{Y\bibinitperiod}{}{}{}{}}%
      }
      \name{editor}{1}{}{%
        {{hash=a072ee8766bfb7d578e1e2752d5a1260}{Rigden}{R\bibinitperiod}{Daniel\bibnamedelima John}{D\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \list{location}{1}{%
        {Dordrecht}%
      }
      \list{publisher}{1}{%
        {Springer Netherlands}%
      }
      \strng{namehash}{db657250955c52e88732249c8c7c252e}
      \strng{fullhash}{db657250955c52e88732249c8c7c252e}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{From Protein Structure to Function with Bioinformatics}}
      \field{chapter}{Ab Initio}
      \field{isbn}{978-1-4020-9058-5}
      \field{title}{{From Protein Structure to Function with Bioinformatics}}
      \field{year}{2009}
      \field{pages}{3\bibrangedash 25}
      \verb{doi}
      \verb 10.1007/978-1-4020-9058-5_1
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1007/978-1-4020-9058-5%7B%5C_%7D1
      \endverb
    \endentry
    \entry{Russel2012}{article}{}
      \name{labelname}{8}{}{%
        {{hash=f03be77275b8afe021f4c417188f9554}{Russel}{R\bibinitperiod}{Daniel}{D\bibinitperiod}{}{}{}{}}%
        {{hash=f89fb0914c74069d2ac17a2c57dff5fc}{Lasker}{L\bibinitperiod}{Keren}{K\bibinitperiod}{}{}{}{}}%
        {{hash=f6202d41c7a5dbee0cec6179ce443b0e}{Webb}{W\bibinitperiod}{Ben}{B\bibinitperiod}{}{}{}{}}%
        {{hash=3cc9460302d940cf170600a38d4053d9}{Vel{\'{a}}zquez-Muriel}{V\bibinithyphendelim M\bibinitperiod}{Javier}{J\bibinitperiod}{}{}{}{}}%
        {{hash=8b7ff375921119bc24ba872b664b0f66}{Tjioe}{T\bibinitperiod}{Elina}{E\bibinitperiod}{}{}{}{}}%
        {{hash=1e1d535f241b3723b64dee3eb90da671}{Schneidman-Duhovny}{S\bibinithyphendelim D\bibinitperiod}{Dina}{D\bibinitperiod}{}{}{}{}}%
        {{hash=3402d6e6862fca8a38f6ce7b41f181b6}{Peterson}{P\bibinitperiod}{Bret}{B\bibinitperiod}{}{}{}{}}%
        {{hash=f3bdee19cfffe5535eb11a4f1ee54225}{Sali}{S\bibinitperiod}{Andrej}{A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{8}{}{%
        {{hash=f03be77275b8afe021f4c417188f9554}{Russel}{R\bibinitperiod}{Daniel}{D\bibinitperiod}{}{}{}{}}%
        {{hash=f89fb0914c74069d2ac17a2c57dff5fc}{Lasker}{L\bibinitperiod}{Keren}{K\bibinitperiod}{}{}{}{}}%
        {{hash=f6202d41c7a5dbee0cec6179ce443b0e}{Webb}{W\bibinitperiod}{Ben}{B\bibinitperiod}{}{}{}{}}%
        {{hash=3cc9460302d940cf170600a38d4053d9}{Vel{\'{a}}zquez-Muriel}{V\bibinithyphendelim M\bibinitperiod}{Javier}{J\bibinitperiod}{}{}{}{}}%
        {{hash=8b7ff375921119bc24ba872b664b0f66}{Tjioe}{T\bibinitperiod}{Elina}{E\bibinitperiod}{}{}{}{}}%
        {{hash=1e1d535f241b3723b64dee3eb90da671}{Schneidman-Duhovny}{S\bibinithyphendelim D\bibinitperiod}{Dina}{D\bibinitperiod}{}{}{}{}}%
        {{hash=3402d6e6862fca8a38f6ce7b41f181b6}{Peterson}{P\bibinitperiod}{Bret}{B\bibinitperiod}{}{}{}{}}%
        {{hash=f3bdee19cfffe5535eb11a4f1ee54225}{Sali}{S\bibinitperiod}{Andrej}{A\bibinitperiod}{}{}{}{}}%
      }
      \list{location}{1}{%
        {San Francisco, USA}%
      }
      \list{publisher}{1}{%
        {Public Library of Science}%
      }
      \strng{namehash}{5507ec60e7c19a3fb2f0f99ecc5b6b00}
      \strng{fullhash}{f5716bdb278d1800851f7a5fc72bed65}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Putting the Pieces Together: Integrative Modeling Platform Software for Structure Determination of Macromolecular Assemblies}}
      \field{abstract}{A set of software tools for building and distributing models of macromolecular assemblies uses an integrative structure modeling approach, which casts the building of models as a computational optimization problem where information is encoded into a scoring function used to evaluate candidate models.}
      \field{issn}{1544-9173}
      \field{journaltitle}{PLoS Biology}
      \field{month}{01}
      \field{number}{1}
      \field{title}{{Putting the Pieces Together: Integrative Modeling Platform Software for Structure Determination of Macromolecular Assemblies}}
      \field{volume}{10}
      \field{year}{2012}
      \field{pages}{e1001244}
      \verb{doi}
      \verb 10.1371/journal.pbio.1001244
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3260315/
      \endverb
    \endentry
    \entry{Eswar2007}{article}{}
      \name{labelname}{8}{}{%
        {{hash=40e29ff69658648458afc77145a5471a}{Eswar}{E\bibinitperiod}{Narayanan}{N\bibinitperiod}{}{}{}{}}%
        {{hash=f6202d41c7a5dbee0cec6179ce443b0e}{Webb}{W\bibinitperiod}{Ben}{B\bibinitperiod}{}{}{}{}}%
        {{hash=24f88df3c6af6a41f2b4b5d26f2b5d94}{Marti-Renom}{M\bibinithyphendelim R\bibinitperiod}{Marc\bibnamedelima A}{M\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=8fbaaf817a730509f1555c4a4cd49933}{Madhusudhan}{M\bibinitperiod}{M\bibnamedelima S}{M\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=0bd28561b7fb607311714f5d813b411a}{Eramian}{E\bibinitperiod}{David}{D\bibinitperiod}{}{}{}{}}%
        {{hash=01c11c5217d66a703779cd4b09590db5}{Shen}{S\bibinitperiod}{Min-Yi}{M\bibinithyphendelim Y\bibinitperiod}{}{}{}{}}%
        {{hash=ed697f1b151831b61b4a519f41fdb295}{Pieper}{P\bibinitperiod}{Ursula}{U\bibinitperiod}{}{}{}{}}%
        {{hash=f3bdee19cfffe5535eb11a4f1ee54225}{Sali}{S\bibinitperiod}{Andrej}{A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{8}{}{%
        {{hash=40e29ff69658648458afc77145a5471a}{Eswar}{E\bibinitperiod}{Narayanan}{N\bibinitperiod}{}{}{}{}}%
        {{hash=f6202d41c7a5dbee0cec6179ce443b0e}{Webb}{W\bibinitperiod}{Ben}{B\bibinitperiod}{}{}{}{}}%
        {{hash=24f88df3c6af6a41f2b4b5d26f2b5d94}{Marti-Renom}{M\bibinithyphendelim R\bibinitperiod}{Marc\bibnamedelima A}{M\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=8fbaaf817a730509f1555c4a4cd49933}{Madhusudhan}{M\bibinitperiod}{M\bibnamedelima S}{M\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=0bd28561b7fb607311714f5d813b411a}{Eramian}{E\bibinitperiod}{David}{D\bibinitperiod}{}{}{}{}}%
        {{hash=01c11c5217d66a703779cd4b09590db5}{Shen}{S\bibinitperiod}{Min-Yi}{M\bibinithyphendelim Y\bibinitperiod}{}{}{}{}}%
        {{hash=ed697f1b151831b61b4a519f41fdb295}{Pieper}{P\bibinitperiod}{Ursula}{U\bibinitperiod}{}{}{}{}}%
        {{hash=f3bdee19cfffe5535eb11a4f1ee54225}{Sali}{S\bibinitperiod}{Andrej}{A\bibinitperiod}{}{}{}{}}%
      }
      \list{language}{1}{%
        {en}%
      }
      \list{publisher}{1}{%
        {John Wiley {\&} Sons, Inc.}%
      }
      \strng{namehash}{c175c9991d3fff01a7ea1bd6a1acf03c}
      \strng{fullhash}{7a068769b56299e2a5067882575d7f68}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Comparative protein structure modeling using MODELLER.}}
      \field{abstract}{Functional characterization of a protein sequence is a common goal in biology, and is usually facilitated by having an accurate three-dimensional (3-D) structure of the studied protein. In the absence of an experimentally determined structure, comparative or homology modeling can sometimes provide a useful 3-D model for a protein that is related to at least one known protein structure. Comparative modeling predicts the 3-D structure of a given protein sequence (target) based primarily on its alignment to one or more proteins of known structure (templates). The prediction process consists of fold assignment, target-template alignment, model building, and model evaluation. This unit describes how to calculate comparative models using the program MODELLER and discusses all four steps of comparative modeling, frequently observed errors, and some applications. Modeling lactate dehydrogenase from Trichomonas vaginalis (TvLDH) is described as an example. The download and installation of the MODELLER software is also described.}
      \field{isbn}{9780471140863}
      \field{issn}{1934-3663}
      \field{journaltitle}{Current protocols in protein science / editorial board, John E. Coligan ... [et al.]}
      \field{month}{12}
      \field{title}{{Comparative protein structure modeling using MODELLER.}}
      \field{volume}{Chapter 2}
      \field{year}{2007}
      \field{pages}{Unit 2.9}
      \verb{doi}
      \verb 10.1002/0471140864.ps0209s50
      \endverb
      \verb{url}
      \verb http://onlinelibrary.wiley.com/doi/10.1002/0471140864.ps0209s50/full
      \endverb
    \endentry
    \entry{Baker2001}{article}{}
      \name{labelname}{1}{}{%
        {{hash=a4ae2debe1c7f5174d0b3d98accdb733}{Baker}{B\bibinitperiod}{D}{D\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=a4ae2debe1c7f5174d0b3d98accdb733}{Baker}{B\bibinitperiod}{D}{D\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{a4ae2debe1c7f5174d0b3d98accdb733}
      \strng{fullhash}{a4ae2debe1c7f5174d0b3d98accdb733}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Protein structure prediction and structural genomics}}
      \field{abstract}{Genome sequencing projects are producing linear amino acid sequences, but full understanding of the biological role of these proteins will require knowledge of their structure and function. Although experimental structure determination methods are providing high-resolution structure information about a subset of the proteins, computational structure prediction methods will provide valuable information for the large fraction of sequences whose structures will not be determined experimentally. The first class of protein structure prediction methods, including threading and comparative modeling, rely on detectable similarity spanning most of the modeled sequence and at least one known structure. The second class of methods, de novo or ab initio methods, predict the structure from sequence alone, without relying on similarity at the fold level between the modeled sequence and any of the known structures. In this Viewpoint, we begin by describing the essential features of the methods, the accuracy of the models, and their application to the prediction and understanding of protein function, both for single proteins and on the scale of whole genomes. We then discuss the important role that protein structure prediction methods play in the growing worldwide effort in structural genomics.}
      \field{isbn}{0036-8075 (Print)$\backslash$n0036-8075 (Linking)}
      \field{issn}{00368075}
      \field{journaltitle}{Science}
      \field{title}{{Protein structure prediction and structural genomics}}
      \field{volume}{294}
      \field{year}{2001}
      \field{pages}{93\bibrangedash 96}
      \verb{doi}
      \verb 10.1126/science.1065659
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/93.full.pdf:pdf
      \endverb
    \endentry
    \entry{twilight1996}{article}{}
      \name{labelname}{2}{}{%
        {{hash=33b59b34f9681453b77f82a576780fe1}{Chung}{C\bibinitperiod}{Su\bibnamedelima Yun}{S\bibinitperiod\bibinitdelim Y\bibinitperiod}{}{}{}{}}%
        {{hash=56286ad2cb905e2bba8546f13b6487aa}{Subbiah}{S\bibinitperiod}{S}{S\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=33b59b34f9681453b77f82a576780fe1}{Chung}{C\bibinitperiod}{Su\bibnamedelima Yun}{S\bibinitperiod\bibinitdelim Y\bibinitperiod}{}{}{}{}}%
        {{hash=56286ad2cb905e2bba8546f13b6487aa}{Subbiah}{S\bibinitperiod}{S}{S\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{fa4026a43546ea25682396e3985f69cf}
      \strng{fullhash}{fa4026a43546ea25682396e3985f69cf}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{A structural explanation for the twilight zone of protein sequence homology}}
      \field{abstract}{Homology modeling of protein structures as a function of sequence breaks down at the twilight zone limit of sequence identity between the template and target proteins. Our results suggest that protein sequences that have diverged from a common ancestor beyond the twilight zone may adopt side-chain interactions that are very different from those endowed by the ancestral sequence.}
      \field{issn}{09692126}
      \field{journaltitle}{Structure}
      \field{month}{10}
      \field{number}{10}
      \field{title}{{A structural explanation for the twilight zone of protein sequence homology}}
      \field{volume}{4}
      \field{year}{1996}
      \field{pages}{1123\bibrangedash 1127}
      \verb{doi}
      \verb 10.1016/S0969-2126(96)00119-0
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Chung, Subbiah - 1996 - A structural explanation for the twilight zone of protein sequence homology.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.sciencedirect.com/science/article/pii/S0969212696001190
      \endverb
    \endentry
    \entry{Sander1991}{article}{}
      \name{labelname}{2}{}{%
        {{hash=31a874f827fdd07d0136f7e2a1beb6a1}{Sander}{S\bibinitperiod}{C}{C\bibinitperiod}{}{}{}{}}%
        {{hash=a00cee35baadb952574e0c6f19b304c0}{Schneider}{S\bibinitperiod}{R}{R\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=31a874f827fdd07d0136f7e2a1beb6a1}{Sander}{S\bibinitperiod}{C}{C\bibinitperiod}{}{}{}{}}%
        {{hash=a00cee35baadb952574e0c6f19b304c0}{Schneider}{S\bibinitperiod}{R}{R\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{d628a87baec1b75e4e30b019f12c7a26}
      \strng{fullhash}{d628a87baec1b75e4e30b019f12c7a26}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Database of homology-derived protein structures and the structural meaning of sequence alignment.}}
      \field{abstract}{The database of known protein three-dimensional structures can be significantly increased by the use of sequence homology, based on the following observations. (1) The database of known sequences, currently at more than 12,000 proteins, is two orders of magnitude larger than the database of known structures. (2) The currently most powerful method of predicting protein structures is model building by homology. (3) Structural homology can be inferred from the level of sequence similarity. (4) The threshold of sequence similarity sufficient for structural homology depends strongly on the length of the alignment. Here, we first quantify the relation between sequence similarity, structure similarity, and alignment length by an exhaustive survey of alignments between proteins of known structure and report a homology threshold curve as a function of alignment length. We then produce a database of homology-derived secondary structure of proteins (HSSP) by aligning to each protein of known structure all sequences deemed homologous on the basis of the threshold curve. For each known protein structure, the derived database contains the aligned sequences, secondary structure, sequence variability, and sequence profile. Tertiary structures of the aligned sequences are implied, but not modeled explicitly. The database effectively increases the number of known protein structures by a factor of five to more than 1800. The results may be useful in assessing the structural significance of matches in sequence database searches, in deriving preferences and patterns for structure prediction, in elucidating the structural role of conserved residues, and in modeling three-dimensional detail by homology.}
      \field{issn}{0887-3585}
      \field{journaltitle}{Proteins}
      \field{month}{01}
      \field{number}{1}
      \field{title}{{Database of homology-derived protein structures and the structural meaning of sequence alignment.}}
      \field{volume}{9}
      \field{year}{1991}
      \field{pages}{56\bibrangedash 68}
      \verb{doi}
      \verb 10.1002/prot.340090107
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/2017436
      \endverb
    \endentry
    \entry{PRO1410}{article}{}
      \name{labelname}{2}{}{%
        {{hash=ed874de6afebf6119f7e51dd153e71cd}{Ferrada}{F\bibinitperiod}{Evandro}{E\bibinitperiod}{}{}{}{}}%
        {{hash=021094801a7b30af836225098951e626}{Melo}{M\bibinitperiod}{Francisco}{F\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=ed874de6afebf6119f7e51dd153e71cd}{Ferrada}{F\bibinitperiod}{Evandro}{E\bibinitperiod}{}{}{}{}}%
        {{hash=021094801a7b30af836225098951e626}{Melo}{M\bibinitperiod}{Francisco}{F\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Cold Spring Harbor Laboratory Press}%
      }
      \strng{namehash}{0f90a37fb41046e4f0175876923e05c9}
      \strng{fullhash}{0f90a37fb41046e4f0175876923e05c9}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Nonbonded terms extrapolated from nonlocal knowledge-based energy functions improve error detection in near-native protein structure models}}
      \field{issn}{1469-896X}
      \field{journaltitle}{Protein Science}
      \field{number}{7}
      \field{title}{{Nonbonded terms extrapolated from nonlocal knowledge-based energy functions improve error detection in near-native protein structure models}}
      \field{volume}{16}
      \field{year}{2007}
      \field{pages}{1410\bibrangedash 1421}
      \verb{doi}
      \verb 10.1110/ps.062735907
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1110/ps.062735907
      \endverb
    \endentry
    \entry{Fiser2000}{article}{}
      \name{labelname}{3}{}{%
        {{hash=e517b392b84f852e678aa3386139ef84}{Fiser}{F\bibinitperiod}{A}{A\bibinitperiod}{}{}{}{}}%
        {{hash=62cbc31614526d6298eb31e942719390}{Do}{D\bibinitperiod}{R\bibnamedelima K}{R\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=a62b855d7bfef6fb576bae4790097131}{Sali}{S\bibinitperiod}{A}{A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=e517b392b84f852e678aa3386139ef84}{Fiser}{F\bibinitperiod}{A}{A\bibinitperiod}{}{}{}{}}%
        {{hash=62cbc31614526d6298eb31e942719390}{Do}{D\bibinitperiod}{R\bibnamedelima K}{R\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=a62b855d7bfef6fb576bae4790097131}{Sali}{S\bibinitperiod}{A}{A\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{8353bfb31ac3e76ac7c791a114f69de7}
      \strng{fullhash}{8353bfb31ac3e76ac7c791a114f69de7}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Modeling of loops in protein structures.}}
      \field{abstract}{Comparative protein structure prediction is limited mostly by the errors in alignment and loop modeling. We describe here a new automated modeling technique that significantly improves the accuracy of loop predictions in protein structures. The positions of all nonhydrogen atoms of the loop are optimized in a fixed environment with respect to a pseudo energy function. The energy is a sum of many spatial restraints that include the bond length, bond angle, and improper dihedral angle terms from the CHARMM-22 force field, statistical preferences for the main-chain and side-chain dihedral angles, and statistical preferences for nonbonded atomic contacts that depend on the two atom types, their distance through space, and separation in sequence. The energy function is optimized with the method of conjugate gradients combined with molecular dynamics and simulated annealing. Typically, the predicted loop conformation corresponds to the lowest energy conformation among 500 independent optimizations. Predictions were made for 40 loops of known structure at each length from 1 to 14 residues. The accuracy of loop predictions is evaluated as a function of thoroughness of conformational sampling, loop length, and structural properties of native loops. When accuracy is measured by local superposition of the model on the native loop, 100, 90, and 30{\%} of 4-, 8-, and 12-residue loop predictions, respectively, had {<}2 A RMSD error for the mainchain N, C(alpha), C, and O atoms; the average accuracies were 0.59 +/- 0.05, 1.16 +/- 0.10, and 2.61 +/- 0.16 A, respectively. To simulate real comparative modeling problems, the method was also evaluated by predicting loops of known structure in only approximately correct environments with errors typical of comparative modeling without misalignment. When the RMSD distortion of the main-chain stem atoms is 2.5 A, the average loop prediction error increased by 180, 25, and 3{\%} for 4-, 8-, and 12-residue loops, respectively. The accuracy of the lowest energy prediction for a given loop can be estimated from the structural variability among a number of low energy predictions. The relative value of the present method is gauged by (1) comparing it with one of the most successful previously described methods, and (2) describing its accuracy in recent blind predictions of protein structure. Finally, it is shown that the average accuracy of prediction is limited primarily by the accuracy of the energy function rather than by the extent of conformational sampling.}
      \field{issn}{0961-8368}
      \field{journaltitle}{Protein science : a publication of the Protein Society}
      \field{month}{09}
      \field{number}{9}
      \field{title}{{Modeling of loops in protein structures.}}
      \field{volume}{9}
      \field{year}{2000}
      \field{pages}{1753\bibrangedash 73}
      \verb{doi}
      \verb 10.1110/ps.9.9.1753
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Fiser, Do, Sali - 2000 - Modeling of loops in protein structures.pdf:pdf
      \endverb
      \verb{url}
      \verb http://doi.wiley.com/10.1110/ps.9.9.1753
      \endverb
    \endentry
    \entry{Kidera1995}{article}{}
      \name{labelname}{1}{}{%
        {{hash=c8282476e68c4b209aeb46e585725654}{Kidera}{K\bibinitperiod}{A}{A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=c8282476e68c4b209aeb46e585725654}{Kidera}{K\bibinitperiod}{A}{A\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{c8282476e68c4b209aeb46e585725654}
      \strng{fullhash}{c8282476e68c4b209aeb46e585725654}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Enhanced conformational sampling in Monte Carlo simulations of proteins: application to a constrained peptide.}}
      \field{abstract}{A Monte Carlo simulation method for globular proteins, called extended-scaled-collective-variable (ESCV) Monte Carlo, is proposed. This method combines two Monte Carlo algorithms known as entropy-sampling and scaled-collective-variable algorithms. Entropy-sampling Monte Carlo is able to sample a large configurational space even in a disordered system that has a large number of potential barriers. In contrast, scaled-collective-variable Monte Carlo provides an efficient sampling for a system whose dynamics is highly cooperative. Because a globular protein is a disordered system whose dynamics is characterized by collective motions, a combination of these two algorithms could provide an optimal Monte Carlo simulation for a globular protein. As a test case, we have carried out an ESCV Monte Carlo simulation for a cell adhesive Arg-Gly-Asp-containing peptide, Lys-Arg-Cys-Arg-Gly-Asp-Cys-Met-Asp, and determined the conformational distribution at 300 K. The peptide contains a disulfide bridge between the two cysteine residues. This bond mimics the strong geometrical constraints that result from a protein's globular nature and give rise to highly cooperative dynamics. Computation results show that the ESCV Monte Carlo was not trapped at any local minimum and that the canonical distribution was correctly determined.}
      \field{issn}{0027-8424}
      \field{journaltitle}{Proceedings of the National Academy of Sciences of the United States of America}
      \field{month}{10}
      \field{number}{21}
      \field{title}{{Enhanced conformational sampling in Monte Carlo simulations of proteins: application to a constrained peptide.}}
      \field{volume}{92}
      \field{year}{1995}
      \field{pages}{9886\bibrangedash 9889}
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC40907/
      \endverb
    \endentry
    \entry{McGarrah1993}{article}{}
      \name{labelname}{2}{}{%
        {{hash=afa2565c534a053018d91d67a2814411}{McGarrah}{M\bibinitperiod}{D.B.}{D\bibinitperiod}{}{}{}{}}%
        {{hash=7bf5a3f7da10e7f2d2b6890edcb1a7e7}{Judson}{J\bibinitperiod}{R.S.}{R\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=afa2565c534a053018d91d67a2814411}{McGarrah}{M\bibinitperiod}{D.B.}{D\bibinitperiod}{}{}{}{}}%
        {{hash=7bf5a3f7da10e7f2d2b6890edcb1a7e7}{Judson}{J\bibinitperiod}{R.S.}{R\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{b557d80f46ce10a1e6cf0a02d5e9542e}
      \strng{fullhash}{b557d80f46ce10a1e6cf0a02d5e9542e}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Analysis of the genetic algorithm method of molecular conformation determination}}
      \field{issn}{0192-8651}
      \field{journaltitle}{Journal of Computational Chemistry}
      \field{month}{11}
      \field{number}{11}
      \field{title}{{Analysis of the genetic algorithm method of molecular conformation determination}}
      \field{volume}{14}
      \field{year}{1993}
      \field{pages}{1385\bibrangedash 1395}
      \verb{doi}
      \verb 10.1002/jcc.540141115
      \endverb
      \verb{url}
      \verb http://doi.wiley.com/10.1002/jcc.540141115
      \endverb
    \endentry
    \entry{PROT21669}{article}{}
      \name{labelname}{4}{}{%
        {{hash=12359cfa1c314fa9ffa69f64abcf8575}{Cozzetto}{C\bibinitperiod}{Domenico}{D\bibinitperiod}{}{}{}{}}%
        {{hash=ba6a5be81953dca645cba617720be57e}{Kryshtafovych}{K\bibinitperiod}{Andriy}{A\bibinitperiod}{}{}{}{}}%
        {{hash=27c340ebfd002c512570fec269643a08}{Ceriani}{C\bibinitperiod}{Michele}{M\bibinitperiod}{}{}{}{}}%
        {{hash=5d268ce86b3c3897806533826d1f6dbf}{Tramontano}{T\bibinitperiod}{Anna}{A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=12359cfa1c314fa9ffa69f64abcf8575}{Cozzetto}{C\bibinitperiod}{Domenico}{D\bibinitperiod}{}{}{}{}}%
        {{hash=ba6a5be81953dca645cba617720be57e}{Kryshtafovych}{K\bibinitperiod}{Andriy}{A\bibinitperiod}{}{}{}{}}%
        {{hash=27c340ebfd002c512570fec269643a08}{Ceriani}{C\bibinitperiod}{Michele}{M\bibinitperiod}{}{}{}{}}%
        {{hash=5d268ce86b3c3897806533826d1f6dbf}{Tramontano}{T\bibinitperiod}{Anna}{A\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Wiley Subscription Services, Inc., A Wiley Company}%
      }
      \strng{namehash}{b427c3b1eca69ff97cfa451eb3b896bf}
      \strng{fullhash}{873712a7e5f4ae4075b44fd1321b4c3e}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Assessment of predictions in the model quality assessment category}}
      \field{issn}{1097-0134}
      \field{journaltitle}{Proteins: Structure, Function, and Bioinformatics}
      \field{number}{S8}
      \field{title}{{Assessment of predictions in the model quality assessment category}}
      \field{volume}{69}
      \field{year}{2007}
      \field{pages}{175\bibrangedash 183}
      \verb{doi}
      \verb 10.1002/prot.21669
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1002/prot.21669
      \endverb
    \endentry
    \entry{Melo2002}{article}{}
      \name{labelname}{3}{}{%
        {{hash=021094801a7b30af836225098951e626}{Melo}{M\bibinitperiod}{Francisco}{F\bibinitperiod}{}{}{}{}}%
        {{hash=9c025a3feb761e31b3dadda76221a12e}{S{\'{a}}nchez}{S\bibinitperiod}{Roberto}{R\bibinitperiod}{}{}{}{}}%
        {{hash=f3bdee19cfffe5535eb11a4f1ee54225}{Sali}{S\bibinitperiod}{Andrej}{A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=021094801a7b30af836225098951e626}{Melo}{M\bibinitperiod}{Francisco}{F\bibinitperiod}{}{}{}{}}%
        {{hash=9c025a3feb761e31b3dadda76221a12e}{S{\'{a}}nchez}{S\bibinitperiod}{Roberto}{R\bibinitperiod}{}{}{}{}}%
        {{hash=f3bdee19cfffe5535eb11a4f1ee54225}{Sali}{S\bibinitperiod}{Andrej}{A\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{cb2016e390357806a2ae00bb310baf4f}
      \strng{fullhash}{cb2016e390357806a2ae00bb310baf4f}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Statistical potentials for fold assessment.}}
      \field{abstract}{A protein structure model generally needs to be evaluated to assess whether or not it has the correct fold. To improve fold assessment, four types of a residue-level statistical potential were optimized, including distance-dependent, contact, Phi/Psi dihedral angle, and accessible surface statistical potentials. Approximately 10,000 test models with the correct and incorrect folds were built by automated comparative modeling of protein sequences of known structure. The criterion used to discriminate between the correct and incorrect models was the Z-score of the model energy. The performance of a Z-score was determined as a function of many variables in the derivation and use of the corresponding statistical potential. The performance was measured by the fractions of the correctly and incorrectly assessed test models. The most discriminating combination of any one of the four tested potentials is the sum of the normalized distance-dependent and accessible surface potentials. The distance-dependent potential that is optimal for assessing models of all sizes uses both C(alpha) and C(beta) atoms as interaction centers, distinguishes between all 20 standard residue types, has the distance range of 30 A, and is derived and used by taking into account the sequence separation of the interacting atom pairs. The terms for the sequentially local interactions are significantly less informative than those for the sequentially nonlocal interactions. The accessible surface potential that is optimal for assessing models of all sizes uses C(beta) atoms as interaction centers and distinguishes between all 20 standard residue types. The performance of the tested statistical potentials is not likely to improve significantly with an increase in the number of known protein structures used in their derivation. The parameters of fold assessment whose optimal values vary significantly with model size include the size of the known protein structures used to derive the potential and the distance range of the accessible surface potential. Fold assessment by statistical potentials is most difficult for the very small models. This difficulty presents a challenge to fold assessment in large-scale comparative modeling, which produces many small and incomplete models. The results described in this study provide a basis for an optimal use of statistical potentials in fold assessment.}
      \field{issn}{0961-8368}
      \field{journaltitle}{Protein science : a publication of the Protein Society}
      \field{month}{03}
      \field{number}{2}
      \field{title}{{Statistical potentials for fold assessment.}}
      \field{volume}{11}
      \field{year}{2002}
      \field{pages}{430\bibrangedash 48}
      \verb{doi}
      \verb 10.1002/pro.110430
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Melo, S{\'{a}}nchez, Sali - 2002 - Statistical potentials for fold assessment.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2373452%7B%5C&%7Dtool=pmcentrez%7B%5C&%7Drendertype=abstract
      \endverb
    \endentry
    \entry{Samudrala1998}{article}{}
      \name{labelname}{2}{}{%
        {{hash=4686b65e891cc32a515a532dc45bdd4d}{Samudrala}{S\bibinitperiod}{R}{R\bibinitperiod}{}{}{}{}}%
        {{hash=5a9caa6978492f08cfed191ff7c57cc8}{Moult}{M\bibinitperiod}{J}{J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=4686b65e891cc32a515a532dc45bdd4d}{Samudrala}{S\bibinitperiod}{R}{R\bibinitperiod}{}{}{}{}}%
        {{hash=5a9caa6978492f08cfed191ff7c57cc8}{Moult}{M\bibinitperiod}{J}{J\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{0b201f2a39a0643ac8358aefca502064}
      \strng{fullhash}{0b201f2a39a0643ac8358aefca502064}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{An all-atom distance-dependent conditional probability discriminatory function for protein structure prediction.}}
      \field{abstract}{We present a formalism to compute the probability of an amino acid sequence conformation being native-like, given a set of pairwise atom-atom distances. The formalism is used to derive three discriminatory functions with different types of representations for the atom-atom contacts observed in a database of protein structures. These functions include two virtual atom representations and one all-heavy atom representation. When applied to six different decoy sets containing a range of correct and incorrect conformations of amino acid sequences, the all-atom distance-dependent discriminatory function is able to identify correct from incorrect more often than the discriminatory functions using approximate representations. We illustrate the importance of using a detailed atomic description for obtaining the most accurate discrimination, and the necessity for testing discriminatory functions against a wide variety of decoys. The discriminatory function is also shown to be capable of capturing the fine details of atom-atom preferences. These results suggest that the all-atom distance-dependent discriminatory function will be useful for protein structure prediction and model refinement.}
      \field{issn}{0022-2836}
      \field{journaltitle}{Journal of molecular biology}
      \field{month}{02}
      \field{number}{5}
      \field{title}{{An all-atom distance-dependent conditional probability discriminatory function for protein structure prediction.}}
      \field{volume}{275}
      \field{year}{1998}
      \field{pages}{895\bibrangedash 916}
      \verb{doi}
      \verb 10.1006/jmbi.1997.1479
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Samudrala, Moult - 1998 - An all-atom distance-dependent conditional probability discriminatory function for protein structure predictio.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.sciencedirect.com/science/article/pii/S0022283697914790
      \endverb
    \endentry
    \entry{CASE2005}{article}{}
      \name{labelname}{10}{}{%
        {{hash=afbf75d7017415fc860e6a64510eabb9}{CASE}{C\bibinitperiod}{DAVID\bibnamedelima A}{D\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=2a3b350b0d9f9a1caeee0850b8f68133}{CHEATHAM}{C\bibinitperiod}{THOMAS\bibnamedelima E}{T\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=520a880201c03cb5ffb801d8f0b42aaf}{DARDEN}{D\bibinitperiod}{T\bibnamedelima O\bibnamedelima M}{T\bibinitperiod\bibinitdelim O\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=cf891775c1d840e5e86598f49a71c507}{GOHLKE}{G\bibinitperiod}{HOLGER}{H\bibinitperiod}{}{}{}{}}%
        {{hash=054487ae1fa27aa51403cd95b63e5353}{LUO}{L\bibinitperiod}{R\bibnamedelima A\bibnamedelima Y}{R\bibinitperiod\bibinitdelim A\bibinitperiod\bibinitdelim Y\bibinitperiod}{}{}{}{}}%
        {{hash=73373d35a0232230946c0e7be8c66e9d}{MERZ}{M\bibinitperiod}{KENNETH\bibnamedelima M}{K\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=dfc15a926f24420e0d9e9d7f1f5f40a8}{ONUFRIEV}{O\bibinitperiod}{ALEXEY}{A\bibinitperiod}{}{}{}{}}%
        {{hash=1a2b5ec1ebee175aa142c3339abd5ea0}{SIMMERLING}{S\bibinitperiod}{CARLOS}{C\bibinitperiod}{}{}{}{}}%
        {{hash=27e5b55bf04eafe15cfcbd85e82afa2a}{WANG}{W\bibinitperiod}{BING}{B\bibinitperiod}{}{}{}{}}%
        {{hash=d8b8461422b971d2decef4f1c5c50780}{WOODS}{W\bibinitperiod}{ROBERT\bibnamedelima J}{R\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{10}{}{%
        {{hash=afbf75d7017415fc860e6a64510eabb9}{CASE}{C\bibinitperiod}{DAVID\bibnamedelima A}{D\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=2a3b350b0d9f9a1caeee0850b8f68133}{CHEATHAM}{C\bibinitperiod}{THOMAS\bibnamedelima E}{T\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=520a880201c03cb5ffb801d8f0b42aaf}{DARDEN}{D\bibinitperiod}{T\bibnamedelima O\bibnamedelima M}{T\bibinitperiod\bibinitdelim O\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=cf891775c1d840e5e86598f49a71c507}{GOHLKE}{G\bibinitperiod}{HOLGER}{H\bibinitperiod}{}{}{}{}}%
        {{hash=054487ae1fa27aa51403cd95b63e5353}{LUO}{L\bibinitperiod}{R\bibnamedelima A\bibnamedelima Y}{R\bibinitperiod\bibinitdelim A\bibinitperiod\bibinitdelim Y\bibinitperiod}{}{}{}{}}%
        {{hash=73373d35a0232230946c0e7be8c66e9d}{MERZ}{M\bibinitperiod}{KENNETH\bibnamedelima M}{K\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=dfc15a926f24420e0d9e9d7f1f5f40a8}{ONUFRIEV}{O\bibinitperiod}{ALEXEY}{A\bibinitperiod}{}{}{}{}}%
        {{hash=1a2b5ec1ebee175aa142c3339abd5ea0}{SIMMERLING}{S\bibinitperiod}{CARLOS}{C\bibinitperiod}{}{}{}{}}%
        {{hash=27e5b55bf04eafe15cfcbd85e82afa2a}{WANG}{W\bibinitperiod}{BING}{B\bibinitperiod}{}{}{}{}}%
        {{hash=d8b8461422b971d2decef4f1c5c50780}{WOODS}{W\bibinitperiod}{ROBERT\bibnamedelima J}{R\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{d6ab83104171a1ae7f329995dbd3efa5}
      \strng{fullhash}{8fac7a6e9fe4cd0745d478213ab1aadf}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{The Amber Biomolecular Simulation Programs}}
      \field{abstract}{We describe the development, current features, and some directions for future development of the Amber package of computer programs. This package evolved from a program that was constructed in the late 1970s to do Assisted Model Building with Energy Refinement, and now contains a group of programs embodying a number of powerful tools of modern computational chemistry, focused on molecular dynamics and free energy calculations of proteins, nucleic acids, and carbohydrates.}
      \field{issn}{0192-8651}
      \field{journaltitle}{Journal of computational chemistry}
      \field{month}{12}
      \field{number}{16}
      \field{title}{{The Amber Biomolecular Simulation Programs}}
      \field{volume}{26}
      \field{year}{2005}
      \field{pages}{1668\bibrangedash 1688}
      \verb{doi}
      \verb 10.1002/jcc.20290
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1989667/
      \endverb
    \endentry
    \entry{Brooks1983}{article}{}
      \name{labelname}{6}{}{%
        {{hash=1389ef60927aa2662a371d4342c55037}{Brooks}{B\bibinitperiod}{Bernard\bibnamedelima R.}{B\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=2417da553beb849755a5b169592d1baf}{Bruccoleri}{B\bibinitperiod}{Robert\bibnamedelima E.}{R\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=d2dab0cdd0820888b399d5fdc25a32af}{Olafson}{O\bibinitperiod}{Barry\bibnamedelima D.}{B\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=d44b9be3654b44a716d9118bdfbe8708}{States}{S\bibinitperiod}{David\bibnamedelima J.}{D\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=f73c3ad8bb4bba4c8dbd40ecf5a28662}{Swaminathan}{S\bibinitperiod}{S.}{S\bibinitperiod}{}{}{}{}}%
        {{hash=5743d79be0ffa377a441f1fe37a0d8cd}{Karplus}{K\bibinitperiod}{Martin}{M\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{6}{}{%
        {{hash=1389ef60927aa2662a371d4342c55037}{Brooks}{B\bibinitperiod}{Bernard\bibnamedelima R.}{B\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=2417da553beb849755a5b169592d1baf}{Bruccoleri}{B\bibinitperiod}{Robert\bibnamedelima E.}{R\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=d2dab0cdd0820888b399d5fdc25a32af}{Olafson}{O\bibinitperiod}{Barry\bibnamedelima D.}{B\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=d44b9be3654b44a716d9118bdfbe8708}{States}{S\bibinitperiod}{David\bibnamedelima J.}{D\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=f73c3ad8bb4bba4c8dbd40ecf5a28662}{Swaminathan}{S\bibinitperiod}{S.}{S\bibinitperiod}{}{}{}{}}%
        {{hash=5743d79be0ffa377a441f1fe37a0d8cd}{Karplus}{K\bibinitperiod}{Martin}{M\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{8b84e15f99b2ac77e2514f794aaa3250}
      \strng{fullhash}{03869cc9823daab579933399e29b261e}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{CHARMM: A program for macromolecular energy, minimization, and dynamics calculations}}
      \field{issn}{0192-8651}
      \field{journaltitle}{Journal of Computational Chemistry}
      \field{number}{2}
      \field{title}{{CHARMM: A program for macromolecular energy, minimization, and dynamics calculations}}
      \field{volume}{4}
      \field{year}{1983}
      \field{pages}{187\bibrangedash 217}
      \verb{doi}
      \verb 10.1002/jcc.540040211
      \endverb
      \verb{url}
      \verb http://doi.wiley.com/10.1002/jcc.540040211
      \endverb
    \endentry
    \entry{Fogolari2003}{article}{}
      \name{labelname}{3}{}{%
        {{hash=b0a19adab2b43ba18a8d19175bf30eec}{Fogolari}{F\bibinitperiod}{Federico}{F\bibinitperiod}{}{}{}{}}%
        {{hash=3fc9fe51666c0f664516555fa88b7f00}{Brigo}{B\bibinitperiod}{Alessandro}{A\bibinitperiod}{}{}{}{}}%
        {{hash=dcdabdb877b70c13a41d1aec410043b9}{Molinari}{M\bibinitperiod}{Henriette}{H\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=b0a19adab2b43ba18a8d19175bf30eec}{Fogolari}{F\bibinitperiod}{Federico}{F\bibinitperiod}{}{}{}{}}%
        {{hash=3fc9fe51666c0f664516555fa88b7f00}{Brigo}{B\bibinitperiod}{Alessandro}{A\bibinitperiod}{}{}{}{}}%
        {{hash=dcdabdb877b70c13a41d1aec410043b9}{Molinari}{M\bibinitperiod}{Henriette}{H\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{e30fd074a9b6ff83afefc3e237d489e2}
      \strng{fullhash}{e30fd074a9b6ff83afefc3e237d489e2}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Protocol for MM/PBSA molecular dynamics simulations of proteins.}}
      \field{abstract}{Continuum solvent models have been employed in past years for understanding processes such as protein folding or biomolecular association. In the last decade, several attempts have been made to merge atomic detail molecular dynamics simulations with solvent continuum models. Among continuum models, the Poisson-Boltzmann solvent accessible surface area model is one of the oldest and most fundamental. Notwithstanding its wide usage for simulation of biomolecular electrostatic potential, the Poisson-Boltzmann equation has been very seldom used to obtain solvation forces for molecular dynamics simulation. We propose here a fast and reliable methodology to implement continuum forces in standard molecular mechanics and dynamics algorithms. Results for a totally unrestrained 1 ns molecular dynamics simulation of a small protein are quantitatively similar to results obtained by explicit solvent molecular dynamics simulations.}
      \field{issn}{0006-3495}
      \field{journaltitle}{Biophysical journal}
      \field{month}{07}
      \field{number}{1}
      \field{title}{{Protocol for MM/PBSA molecular dynamics simulations of proteins.}}
      \field{volume}{85}
      \field{year}{2003}
      \field{pages}{159\bibrangedash 66}
      \verb{doi}
      \verb 10.1016/S0006-3495(03)74462-2
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Fogolari, Brigo, Molinari - 2003 - Protocol for MMPBSA molecular dynamics simulations of proteins.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.sciencedirect.com/science/article/pii/S0006349503744622
      \endverb
    \endentry
    \entry{Thomas1996}{article}{}
      \name{labelname}{2}{}{%
        {{hash=1113f5f32914572528c35375f4f2235e}{Thomas}{T\bibinitperiod}{P\bibnamedelima D}{P\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=9a39ef1b41588121d5d2cefe3071d1b6}{Dill}{D\bibinitperiod}{K\bibnamedelima A}{K\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=1113f5f32914572528c35375f4f2235e}{Thomas}{T\bibinitperiod}{P\bibnamedelima D}{P\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=9a39ef1b41588121d5d2cefe3071d1b6}{Dill}{D\bibinitperiod}{K\bibnamedelima A}{K\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{3d422cf20eb10f05439de205b25a7a2d}
      \strng{fullhash}{3d422cf20eb10f05439de205b25a7a2d}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Statistical potentials extracted from protein structures: how accurate are they?}}
      \field{abstract}{"Statistical potentials" are energies widely used in computer algorithms to fold, dock, or recognize protein structures. They are derived from: (1) observed pairing frequencies of the 20 amino acids in databases of known protein structures, and (2) approximations and assumptions about the physical process that these quantities measure. Using exact lattice models, we construct a rigorous test of those assumptions and approximations. We find that statistical potentials often correctly rank-order the relative strengths of interresidue interactions, but they do not reflect the true underlying energies because of systematic errors arising from the neglect of excluded volume in proteins. We find that complex residue-residue distance dependences observed in statistical potentials, even those among charged groups, can be largely explained as an indirect consequence of the burial of non-polar groups. Our results suggest that current statistical potentials may have limited value in protein folding algorithms and wherever they are used to provide energy-like quantities.}
      \field{issn}{0022-2836}
      \field{journaltitle}{Journal of molecular biology}
      \field{month}{03}
      \field{number}{2}
      \field{title}{{Statistical potentials extracted from protein structures: how accurate are they?}}
      \field{volume}{257}
      \field{year}{1996}
      \field{pages}{457\bibrangedash 69}
      \verb{doi}
      \verb 10.1006/jmbi.1996.0175
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Thomas, Dill - 1996 - Statistical potentials extracted from protein structures how accurate are they.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.sciencedirect.com/science/article/pii/S0022283696901758
      \endverb
    \endentry
    \entry{Shen2006}{article}{}
      \name{labelname}{2}{}{%
        {{hash=6529665068922e70b8d60070c8f3c1bc}{Shen}{S\bibinitperiod}{Min-yi}{M\bibinithyphendelim y\bibinitperiod}{}{}{}{}}%
        {{hash=f3bdee19cfffe5535eb11a4f1ee54225}{Sali}{S\bibinitperiod}{Andrej}{A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=6529665068922e70b8d60070c8f3c1bc}{Shen}{S\bibinitperiod}{Min-yi}{M\bibinithyphendelim y\bibinitperiod}{}{}{}{}}%
        {{hash=f3bdee19cfffe5535eb11a4f1ee54225}{Sali}{S\bibinitperiod}{Andrej}{A\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Blackwell Publishing}%
      }
      \strng{namehash}{d980f1da7c156433669b8b153bf33028}
      \strng{fullhash}{d980f1da7c156433669b8b153bf33028}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Statistical potential for assessment and prediction of protein structures}}
      \field{abstract}{Protein structures in the Protein Data Bank provide a wealth of data about the interactions that determine the native states of proteins. Using the probability theory, we derive an atomic distance-dependent statistical potential from a sample of native structures that does not depend on any adjustable parameters (Discrete Optimized Protein Energy, or DOPE). DOPE is based on an improved reference state that corresponds to noninteracting atoms in a homogeneous sphere with the radius dependent on a sample native structure; it thus accounts for the finite and spherical shape of the native structures. The DOPE potential was extracted from a nonredundant set of 1472 crystallographic structures. We tested DOPE and five other scoring functions by the detection of the native state among six multiple target decoy sets, the correlation between the score and model error, and the identification of the most accurate non-native structure in the decoy set. For all decoy sets, DOPE is the best performing function in terms of all criteria, except for a tie in one criterion for one decoy set. To facilitate its use in various applications, such as model assessment, loop modeling, and fitting into cryo-electron microscopy mass density maps combined with comparative protein structure modeling, DOPE was incorporated into the modeling package MODELLER-8.}
      \field{issn}{0961-8368}
      \field{journaltitle}{Protein Science : A Publication of the Protein Society}
      \field{month}{11}
      \field{number}{11}
      \field{title}{{Statistical potential for assessment and prediction of protein structures}}
      \field{volume}{15}
      \field{year}{2006}
      \field{pages}{2507\bibrangedash 2524}
      \verb{doi}
      \verb 10.1110/ps.062416606
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2242414/
      \endverb
    \endentry
    \entry{Zhou2002}{article}{}
      \name{labelname}{2}{}{%
        {{hash=df8e91a61dfc6515a464839aaba565ce}{Zhou}{Z\bibinitperiod}{Hongyi}{H\bibinitperiod}{}{}{}{}}%
        {{hash=ce7558f60198035c0f0a04b2acfdca0f}{Zhou}{Z\bibinitperiod}{Yaoqi}{Y\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=df8e91a61dfc6515a464839aaba565ce}{Zhou}{Z\bibinitperiod}{Hongyi}{H\bibinitperiod}{}{}{}{}}%
        {{hash=ce7558f60198035c0f0a04b2acfdca0f}{Zhou}{Z\bibinitperiod}{Yaoqi}{Y\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{45802cd4f4878477bd12b4fe648e19ae}
      \strng{fullhash}{45802cd4f4878477bd12b4fe648e19ae}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Distance-scaled, finite ideal-gas reference state improves structure-derived potentials of mean force for structure selection and stability prediction.}}
      \field{abstract}{The distance-dependent structure-derived potentials developed so far all employed a reference state that can be characterized as a residue (atom)-averaged state. Here, we establish a new reference state called the distance-scaled, finite ideal-gas reference (DFIRE) state. The reference state is used to construct a residue-specific all-atom potential of mean force from a database of 1011 nonhomologous (less than 30{\%} homology) protein structures with resolution less than 2 A. The new all-atom potential recognizes more native proteins from 32 multiple decoy sets, and raises an average Z-score by 1.4 units more than two previously developed, residue-specific, all-atom knowledge-based potentials. When only backbone and C(beta) atoms are used in scoring, the performance of the DFIRE-based potential, although is worse than that of the all-atom version, is comparable to those of the previously developed potentials on the all-atom level. In addition, the DFIRE-based all-atom potential provides the most accurate prediction of the stabilities of 895 mutants among three knowledge-based all-atom potentials. Comparison with several physical-based potentials is made.}
      \field{issn}{0961-8368}
      \field{journaltitle}{Protein science : a publication of the Protein Society}
      \field{month}{12}
      \field{number}{11}
      \field{title}{{Distance-scaled, finite ideal-gas reference state improves structure-derived potentials of mean force for structure selection and stability prediction.}}
      \field{volume}{11}
      \field{year}{2002}
      \field{pages}{2714\bibrangedash 26}
      \verb{doi}
      \verb 10.1110/ps.0217002
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Zhou, Zhou - 2002 - Distance-scaled, finite ideal-gas reference state improves structure-derived potentials of mean force for structure.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2373736%7B%5C&%7Dtool=pmcentrez%7B%5C&%7Drendertype=abstract
      \endverb
    \endentry
    \entry{Sippl1995}{article}{}
      \name{labelname}{1}{}{%
        {{hash=8e55892f5d151274795af5e5648e0d79}{Sippl}{S\bibinitperiod}{Manfred\bibnamedelima J}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=8e55892f5d151274795af5e5648e0d79}{Sippl}{S\bibinitperiod}{Manfred\bibnamedelima J}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{8e55892f5d151274795af5e5648e0d79}
      \strng{fullhash}{8e55892f5d151274795af5e5648e0d79}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Knowledge-based potentials for proteins}}
      \field{abstract}{Knowledge based potentials and energy functions are extracted from a number of databases of known protein structures. Recent developments have shown that this type of potential is successful in many areas of protein structure research. Among these are quality assessment and error recognition of folds and the prediction of unknown structures by fold-recognition techniques.}
      \field{issn}{0959440X}
      \field{journaltitle}{Current Opinion in Structural Biology}
      \field{month}{04}
      \field{number}{2}
      \field{title}{{Knowledge-based potentials for proteins}}
      \field{volume}{5}
      \field{year}{1995}
      \field{pages}{229\bibrangedash 235}
      \verb{doi}
      \verb 10.1016/0959-440X(95)80081-6
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Sippl - 1995 - Knowledge-based potentials for proteins.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.sciencedirect.com/science/article/pii/0959440X95800816
      \endverb
    \endentry
    \entry{Du2012}{article}{}
      \name{labelname}{2}{}{%
        {{hash=2736bf88ecd6e7286f45cd9d073cbc29}{Du}{D\bibinitperiod}{Changsheng}{C\bibinitperiod}{}{}{}{}}%
        {{hash=575a5ee21fb18fa9d777a9a1a1c55273}{Xie}{X\bibinitperiod}{Xin}{X\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=2736bf88ecd6e7286f45cd9d073cbc29}{Du}{D\bibinitperiod}{Changsheng}{C\bibinitperiod}{}{}{}{}}%
        {{hash=575a5ee21fb18fa9d777a9a1a1c55273}{Xie}{X\bibinitperiod}{Xin}{X\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences}%
      }
      \strng{namehash}{5cb5b09bb0795e7d48f5943207b56549}
      \strng{fullhash}{5cb5b09bb0795e7d48f5943207b56549}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{G protein-coupled receptors as therapeutic targets for multiple sclerosis}}
      \field{issn}{1001-0602}
      \field{journaltitle}{Cell Res}
      \field{month}{06}
      \field{number}{7}
      \field{title}{{G protein-coupled receptors as therapeutic targets for multiple sclerosis}}
      \field{volume}{22}
      \field{year}{2012}
      \field{pages}{1108\bibrangedash 1128}
      \verb{url}
      \verb http://dx.doi.org/10.1038/cr.2012.87
      \endverb
    \endentry
    \entry{Kampen2011}{article}{}
      \name{labelname}{1}{}{%
        {{hash=6faf1f529ac51f2ada4a7ef12dc34733}{Kampen}{K\bibinitperiod}{Kim\bibnamedelima R}{K\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=6faf1f529ac51f2ada4a7ef12dc34733}{Kampen}{K\bibinitperiod}{Kim\bibnamedelima R}{K\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{6faf1f529ac51f2ada4a7ef12dc34733}
      \strng{fullhash}{6faf1f529ac51f2ada4a7ef12dc34733}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Membrane Proteins: The Key Players of a Cancer Cell}}
      \field{abstract}{Membrane proteins are involved in the prognosis of the most common forms of cancer. Membrane proteins are the hallmark of a cancer cell. The overexpressed membrane receptors are becoming increasingly important in cancer cell therapy. Current renewing therapy approaches based on receptor overexpression include; antibody therapy, nanocarrier drug delivery, and fluorescent tumor imaging in surgery. Gene profiling reveals cancer specific signatures and may identify membrane proteins that are related to cancer progression and lead to the development of improved therapy strategies in the future.}
      \field{issn}{1432-1424}
      \field{journaltitle}{The Journal of Membrane Biology}
      \field{number}{2}
      \field{title}{{Membrane Proteins: The Key Players of a Cancer Cell}}
      \field{volume}{242}
      \field{year}{2011}
      \field{pages}{69\bibrangedash 74}
      \verb{doi}
      \verb 10.1007/s00232-011-9381-7
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1007/s00232-011-9381-7
      \endverb
    \endentry
    \entry{Leman2015}{article}{}
      \name{labelname}{3}{}{%
        {{hash=04b64b548d25da9e9da8769cb47701f6}{Leman}{L\bibinitperiod}{Julia\bibnamedelima Koehler}{J\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=13a6189e01d1f11e15d62379f62fb5f4}{Ulmschneider}{U\bibinitperiod}{Martin\bibnamedelima B}{M\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=d068a2b0cc92b1384f4242acfcd42f18}{Gray}{G\bibinitperiod}{Jeffrey\bibnamedelima J}{J\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=04b64b548d25da9e9da8769cb47701f6}{Leman}{L\bibinitperiod}{Julia\bibnamedelima Koehler}{J\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=13a6189e01d1f11e15d62379f62fb5f4}{Ulmschneider}{U\bibinitperiod}{Martin\bibnamedelima B}{M\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=d068a2b0cc92b1384f4242acfcd42f18}{Gray}{G\bibinitperiod}{Jeffrey\bibnamedelima J}{J\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{49252d59e07f87e1e3962d9a136638b9}
      \strng{fullhash}{49252d59e07f87e1e3962d9a136638b9}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Computational modeling of membrane proteins}}
      \field{abstract}{The determination of membrane protein (MP) structures has always trailed that of soluble proteins due to difficulties in their overexpression, reconstitution into membrane mimetics, and subsequent structure determination. The percentage of MP structures in the protein databank (PDB) has been at a constant 1-2{\%} for the last decade. In contrast, over half of all drugs target MPs, only highlighting how little we understand about drug-specific effects in the human body. To reduce this gap, researchers have attempted to predict structural features of MPs even before the first structure was experimentally elucidated. In this review, we present current computational methods to predict MP structure, starting with secondary structure prediction, prediction of trans-membrane spans, and topology. Even though these methods generate reliable predictions, challenges such as predicting kinks or precise beginnings and ends of secondary structure elements are still waiting to be addressed. We describe recent developments in the prediction of 3D structures of both $\alpha$-helical MPs as well as $\beta$-barrels using comparative modeling techniques, de novo methods, and molecular dynamics (MD) simulations. The increase of MP structures has (1) facilitated comparative modeling due to availability of more and better templates, and (2) improved the statistics for knowledge-based scoring functions. Moreover, de novo methods have benefitted from the use of correlated mutations as restraints. Finally, we outline current advances that will likely shape the field in the forthcoming decade.}
      \field{issn}{0887-3585}
      \field{journaltitle}{Proteins}
      \field{month}{01}
      \field{number}{1}
      \field{title}{{Computational modeling of membrane proteins}}
      \field{volume}{83}
      \field{year}{2015}
      \field{pages}{1\bibrangedash 24}
      \verb{doi}
      \verb 10.1002/prot.24703
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4270820/
      \endverb
    \endentry
    \entry{Marti-Renom2000}{article}{}
      \name{labelname}{6}{}{%
        {{hash=5461b6b5d70b5f6a29c839ffa86a0f19}{Mart{\'{\i}}-Renom}{M\bibinithyphendelim R\bibinitperiod}{Marc\bibnamedelima A}{M\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=35af4cbf9d6f921414f47c2a8ed0bba3}{Stuart}{S\bibinitperiod}{Ashley\bibnamedelima C}{A\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=99fdd219dd063e730ce1c4561adc7bce}{Fiser}{F\bibinitperiod}{Andr{\'{a}}s}{A\bibinitperiod}{}{}{}{}}%
        {{hash=9c025a3feb761e31b3dadda76221a12e}{S{\'{a}}nchez}{S\bibinitperiod}{Roberto}{R\bibinitperiod}{}{}{}{}}%
        {{hash=021094801a7b30af836225098951e626}{Melo}{M\bibinitperiod}{Francisco}{F\bibinitperiod}{}{}{}{}}%
        {{hash=e3a033f64b8a1952a2f23a82a0e89b0d}{{\v{S}}ali}{\v{S}\bibinitperiod}{Andrej}{A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{6}{}{%
        {{hash=5461b6b5d70b5f6a29c839ffa86a0f19}{Mart{\'{\i}}-Renom}{M\bibinithyphendelim R\bibinitperiod}{Marc\bibnamedelima A}{M\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=35af4cbf9d6f921414f47c2a8ed0bba3}{Stuart}{S\bibinitperiod}{Ashley\bibnamedelima C}{A\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=99fdd219dd063e730ce1c4561adc7bce}{Fiser}{F\bibinitperiod}{Andr{\'{a}}s}{A\bibinitperiod}{}{}{}{}}%
        {{hash=9c025a3feb761e31b3dadda76221a12e}{S{\'{a}}nchez}{S\bibinitperiod}{Roberto}{R\bibinitperiod}{}{}{}{}}%
        {{hash=021094801a7b30af836225098951e626}{Melo}{M\bibinitperiod}{Francisco}{F\bibinitperiod}{}{}{}{}}%
        {{hash=e3a033f64b8a1952a2f23a82a0e89b0d}{{\v{S}}ali}{\v{S}\bibinitperiod}{Andrej}{A\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Annual Reviews}%
      }
      \strng{namehash}{f41a3e5a842bfad97bea612d8fb25b3a}
      \strng{fullhash}{fbf17a2a63c3d668cc93a16c3e4bf91a}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Comparative Protein Structure Modeling of Genes and Genomes}}
      \field{annotation}{doi: 10.1146/annurev.biophys.29.1.291}
      \field{issn}{1056-8700}
      \field{journaltitle}{Annual Review of Biophysics and Biomolecular Structure}
      \field{month}{06}
      \field{number}{1}
      \field{title}{{Comparative Protein Structure Modeling of Genes and Genomes}}
      \field{volume}{29}
      \field{year}{2000}
      \field{pages}{291\bibrangedash 325}
      \verb{doi}
      \verb 10.1146/annurev.biophys.29.1.291
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1146/annurev.biophys.29.1.291
      \endverb
    \endentry
    \entry{Malmstrom2010}{article}{}
      \name{labelname}{2}{}{%
        {{hash=50909ec1aeaa7f40002966c164db28a1}{Malmstr{\"{o}}m}{M\bibinitperiod}{Lars}{L\bibinitperiod}{}{}{}{}}%
        {{hash=b7abecd7ba3e2d20a76b6aa99be8a0c7}{Goodlett}{G\bibinitperiod}{David\bibnamedelima R}{D\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=50909ec1aeaa7f40002966c164db28a1}{Malmstr{\"{o}}m}{M\bibinitperiod}{Lars}{L\bibinitperiod}{}{}{}{}}%
        {{hash=b7abecd7ba3e2d20a76b6aa99be8a0c7}{Goodlett}{G\bibinitperiod}{David\bibnamedelima R}{D\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{6ac46e7b81e0b55e9135150d2281a4e9}
      \strng{fullhash}{6ac46e7b81e0b55e9135150d2281a4e9}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Protein structure modeling.}}
      \field{abstract}{The tertiary structure of proteins can reveal information that is hard to detect in a linear sequence. Knowing the tertiary structure is valuable when generating hypothesis and interpreting data. Unfortunately, the gap between the number of known protein sequences and their associated structures is widening. One way to bridge this gap is to use computer-generated structure models of proteins. Here we present concepts and online resources that can be used to identify structural domains in proteins and to create structure models of those domains.}
      \field{isbn}{9789812778772}
      \field{issn}{1940-6029}
      \field{journaltitle}{Methods in molecular biology (Clifton, N.J.)}
      \field{title}{{Protein structure modeling.}}
      \field{volume}{673}
      \field{year}{2010}
      \field{pages}{63\bibrangedash 72}
      \verb{doi}
      \verb 10.1007/978-1-60761-842-3_5
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/6659{\_}chap01.pdf:pdf
      \endverb
    \endentry
    \entry{Sali1993}{article}{}
      \name{labelname}{2}{}{%
        {{hash=a62b855d7bfef6fb576bae4790097131}{Sali}{S\bibinitperiod}{A}{A\bibinitperiod}{}{}{}{}}%
        {{hash=22bf569e666f3d049884d611ba3c6232}{Blundell}{B\bibinitperiod}{T\bibnamedelima L}{T\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=a62b855d7bfef6fb576bae4790097131}{Sali}{S\bibinitperiod}{A}{A\bibinitperiod}{}{}{}{}}%
        {{hash=22bf569e666f3d049884d611ba3c6232}{Blundell}{B\bibinitperiod}{T\bibnamedelima L}{T\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{0d8f75433cffdb520aad9363ee32a09d}
      \strng{fullhash}{0d8f75433cffdb520aad9363ee32a09d}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Comparative protein modelling by satisfaction of spatial restraints.}}
      \field{abstract}{We describe a comparative protein modelling method designed to find the most probable structure for a sequence given its alignment with related structures. The three-dimensional (3D) model is obtained by optimally satisfying spatial restraints derived from the alignment and expressed as probability density functions (pdfs) for the features restrained. For example, the probabilities for main-chain conformations of a modelled residue may be restrained by its residue type, main-chain conformation of an equivalent residue in a related protein, and the local similarity between the two sequences. Several such pdfs are obtained from the correlations between structural features in 17 families of homologous proteins which have been aligned on the basis of their 3D structures. The pdfs restrain C alpha-C alpha distances, main-chain N-O distances, main-chain and side-chain dihedral angles. A smoothing procedure is used in the derivation of these relationships to minimize the problem of a sparse database. The 3D model of a protein is obtained by optimization of the molecular pdf such that the model violates the input restraints as little as possible. The molecular pdf is derived as a combination of pdfs restraining individual spatial features of the whole molecule. The optimization procedure is a variable target function method that applies the conjugate gradients algorithm to positions of all non-hydrogen atoms. The method is automated and is illustrated by the modelling of trypsin from two other serine proteinases.}
      \field{issn}{0022-2836}
      \field{journaltitle}{Journal of molecular biology}
      \field{month}{12}
      \field{number}{3}
      \field{title}{{Comparative protein modelling by satisfaction of spatial restraints.}}
      \field{volume}{234}
      \field{year}{1993}
      \field{pages}{779\bibrangedash 815}
      \verb{doi}
      \verb 10.1006/jmbi.1993.1626
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Sali, Blundell - 1993 - Comparative protein modelling by satisfaction of spatial restraints.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.sciencedirect.com/science/article/pii/S0022283683716268
      \endverb
    \endentry
    \entry{Biasini2014}{article}{}
      \name{labelname}{11}{}{%
        {{hash=8c5c2e3281ac90e7e047326cb8521061}{Biasini}{B\bibinitperiod}{Marco}{M\bibinitperiod}{}{}{}{}}%
        {{hash=e17c8faf02e044a87dc3538d9eaa17ad}{Bienert}{B\bibinitperiod}{Stefan}{S\bibinitperiod}{}{}{}{}}%
        {{hash=3f5f2d064275270f946fff614f447695}{Waterhouse}{W\bibinitperiod}{Andrew}{A\bibinitperiod}{}{}{}{}}%
        {{hash=bb290d8c6f623fe5716fac818a936550}{Arnold}{A\bibinitperiod}{Konstantin}{K\bibinitperiod}{}{}{}{}}%
        {{hash=1ced0d8807b5d18b90fa0eff110760ec}{Studer}{S\bibinitperiod}{Gabriel}{G\bibinitperiod}{}{}{}{}}%
        {{hash=b30253c75a6934483ba798b3afe56cd3}{Schmidt}{S\bibinitperiod}{Tobias}{T\bibinitperiod}{}{}{}{}}%
        {{hash=c7f06671679c5a76978a676d7e876574}{Kiefer}{K\bibinitperiod}{Florian}{F\bibinitperiod}{}{}{}{}}%
        {{hash=5f57a74cb6d6e11dd14892836edd8945}{Cassarino}{C\bibinitperiod}{Tiziano\bibnamedelima Gallo}{T\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=576452f85aa87f2c057793940f04cbba}{Bertoni}{B\bibinitperiod}{Martino}{M\bibinitperiod}{}{}{}{}}%
        {{hash=bb7862e6edfdd811260dee5da9e55634}{Bordoli}{B\bibinitperiod}{Lorenza}{L\bibinitperiod}{}{}{}{}}%
        {{hash=ac78e4bbb3a5578563150b327b14e1b8}{Schwede}{S\bibinitperiod}{Torsten}{T\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{11}{}{%
        {{hash=8c5c2e3281ac90e7e047326cb8521061}{Biasini}{B\bibinitperiod}{Marco}{M\bibinitperiod}{}{}{}{}}%
        {{hash=e17c8faf02e044a87dc3538d9eaa17ad}{Bienert}{B\bibinitperiod}{Stefan}{S\bibinitperiod}{}{}{}{}}%
        {{hash=3f5f2d064275270f946fff614f447695}{Waterhouse}{W\bibinitperiod}{Andrew}{A\bibinitperiod}{}{}{}{}}%
        {{hash=bb290d8c6f623fe5716fac818a936550}{Arnold}{A\bibinitperiod}{Konstantin}{K\bibinitperiod}{}{}{}{}}%
        {{hash=1ced0d8807b5d18b90fa0eff110760ec}{Studer}{S\bibinitperiod}{Gabriel}{G\bibinitperiod}{}{}{}{}}%
        {{hash=b30253c75a6934483ba798b3afe56cd3}{Schmidt}{S\bibinitperiod}{Tobias}{T\bibinitperiod}{}{}{}{}}%
        {{hash=c7f06671679c5a76978a676d7e876574}{Kiefer}{K\bibinitperiod}{Florian}{F\bibinitperiod}{}{}{}{}}%
        {{hash=5f57a74cb6d6e11dd14892836edd8945}{Cassarino}{C\bibinitperiod}{Tiziano\bibnamedelima Gallo}{T\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=576452f85aa87f2c057793940f04cbba}{Bertoni}{B\bibinitperiod}{Martino}{M\bibinitperiod}{}{}{}{}}%
        {{hash=bb7862e6edfdd811260dee5da9e55634}{Bordoli}{B\bibinitperiod}{Lorenza}{L\bibinitperiod}{}{}{}{}}%
        {{hash=ac78e4bbb3a5578563150b327b14e1b8}{Schwede}{S\bibinitperiod}{Torsten}{T\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Oxford University Press}%
      }
      \strng{namehash}{fc6df58544ad5fe1e1fcdf8f6d018e7b}
      \strng{fullhash}{2d0b0732151e429a0a1fe908e52e33ef}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information}}
      \field{abstract}{Protein structure homology modelling has become a routine technique to generate 3D models for proteins when experimental structures are not available. Fully automated servers such as SWISS-MODEL with user-friendly web interfaces generate reliable models without the need for complex software packages or downloading large databases. Here, we describe the latest version of the SWISS-MODEL expert system for protein structure modelling. The SWISS-MODEL template library provides annotation of quaternary structure and essential ligands and co-factors to allow for building of complete structural models, including their oligomeric structure. The improved SWISS-MODEL pipeline makes extensive use of model quality estimation for selection of the most suitable templates and provides estimates of the expected accuracy of the resulting models. The accuracy of the models generated by SWISS-MODEL is continuously evaluated by the CAMEO system. The new web site allows users to interactively search for templates, cluster them by sequence similarity, structurally compare alternative templates and select the ones to be used for model building. In cases where multiple alternative template structures are available for a protein of interest, a user-guided template selection step allows building models in different functional states. SWISS-MODEL is available at http://swissmodel.expasy.org/.}
      \field{issn}{0305-1048}
      \field{journaltitle}{Nucleic Acids Research}
      \field{month}{07}
      \field{number}{Web Server issue}
      \field{title}{{SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information}}
      \field{volume}{42}
      \field{year}{2014}
      \field{pages}{W252\bibrangedash W258}
      \verb{doi}
      \verb 10.1093/nar/gku340
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086089/
      \endverb
    \endentry
    \entry{Soding2005}{article}{}
      \name{labelname}{3}{}{%
        {{hash=61f1ee7ce63e60c4b4dae9a4a0cfaef0}{S{\"{o}}ding}{S\bibinitperiod}{Johannes}{J\bibinitperiod}{}{}{}{}}%
        {{hash=6486032f1fd7b53b2499d56d8a872253}{Biegert}{B\bibinitperiod}{Andreas}{A\bibinitperiod}{}{}{}{}}%
        {{hash=8081813a444f5747b912efbb7db96323}{Lupas}{L\bibinitperiod}{Andrei\bibnamedelima N}{A\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=61f1ee7ce63e60c4b4dae9a4a0cfaef0}{S{\"{o}}ding}{S\bibinitperiod}{Johannes}{J\bibinitperiod}{}{}{}{}}%
        {{hash=6486032f1fd7b53b2499d56d8a872253}{Biegert}{B\bibinitperiod}{Andreas}{A\bibinitperiod}{}{}{}{}}%
        {{hash=8081813a444f5747b912efbb7db96323}{Lupas}{L\bibinitperiod}{Andrei\bibnamedelima N}{A\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Oxford University Press}%
      }
      \strng{namehash}{0f06a60cfcf41812e52313df1fdf7c89}
      \strng{fullhash}{0f06a60cfcf41812e52313df1fdf7c89}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{The HHpred interactive server for protein homology detection and structure prediction}}
      \field{abstract}{HHpred is a fast server for remote protein homology detection and structure prediction and is the first to implement pairwise comparison of profile hidden Markov models (HMMs). It allows to search a wide choice of databases, such as the PDB, SCOP, Pfam, SMART, COGs and CDD. It accepts a single query sequence or a multiple alignment as input. Within only a few minutes it returns the search results in a user-friendly format similar to that of PSI-BLAST. Search options include local or global alignment and scoring secondary structure similarity. HHpred can produce pairwise query-template alignments, multiple alignments of the query with a set of templates selected from the search results, as well as 3D structural models that are calculated by the MODELLER software from these alignments. A detailed help facility is available. As a demonstration, we analyze the sequence of SpoVT, a transcriptional regulator from Bacillus subtilis. HHpred can be accessed at .}
      \field{issn}{0305-1048}
      \field{journaltitle}{Nucleic Acids Research}
      \field{month}{07}
      \field{number}{Web Server issue}
      \field{title}{{The HHpred interactive server for protein homology detection and structure prediction}}
      \field{volume}{33}
      \field{year}{2005}
      \field{pages}{W244\bibrangedash W248}
      \verb{doi}
      \verb 10.1093/nar/gki408
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1160169/
      \endverb
    \endentry
    \entry{Yang2015a}{article}{}
      \name{labelname}{6}{}{%
        {{hash=382479cb8879c413d413cc0d65c513e6}{Yang}{Y\bibinitperiod}{Jianyi}{J\bibinitperiod}{}{}{}{}}%
        {{hash=2d6f2067dafb0b13323e1d1b1f3d9de9}{Yan}{Y\bibinitperiod}{Renxiang}{R\bibinitperiod}{}{}{}{}}%
        {{hash=32b724aac9cf1ba7e73e7fbb0fda1b1a}{Roy}{R\bibinitperiod}{Ambrish}{A\bibinitperiod}{}{}{}{}}%
        {{hash=be17c750657847fd489802d414210d61}{Xu}{X\bibinitperiod}{Dong}{D\bibinitperiod}{}{}{}{}}%
        {{hash=69ee6e7891fcac9735315c26f786415d}{Poisson}{P\bibinitperiod}{Jonathan}{J\bibinitperiod}{}{}{}{}}%
        {{hash=e760d38078aff4a5b24c867aa5178c26}{Zhang}{Z\bibinitperiod}{Yang}{Y\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{6}{}{%
        {{hash=382479cb8879c413d413cc0d65c513e6}{Yang}{Y\bibinitperiod}{Jianyi}{J\bibinitperiod}{}{}{}{}}%
        {{hash=2d6f2067dafb0b13323e1d1b1f3d9de9}{Yan}{Y\bibinitperiod}{Renxiang}{R\bibinitperiod}{}{}{}{}}%
        {{hash=32b724aac9cf1ba7e73e7fbb0fda1b1a}{Roy}{R\bibinitperiod}{Ambrish}{A\bibinitperiod}{}{}{}{}}%
        {{hash=be17c750657847fd489802d414210d61}{Xu}{X\bibinitperiod}{Dong}{D\bibinitperiod}{}{}{}{}}%
        {{hash=69ee6e7891fcac9735315c26f786415d}{Poisson}{P\bibinitperiod}{Jonathan}{J\bibinitperiod}{}{}{}{}}%
        {{hash=e760d38078aff4a5b24c867aa5178c26}{Zhang}{Z\bibinitperiod}{Yang}{Y\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.}%
      }
      \strng{namehash}{2a370f297e2c905c67d9f3acea8245a9}
      \strng{fullhash}{6410a1a9ea2bbeb9b8536a073ecb62c9}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{The I-TASSER Suite: protein structure and function prediction}}
      \field{issn}{1548-7091}
      \field{journaltitle}{Nat Meth}
      \field{month}{01}
      \field{number}{1}
      \field{title}{{The I-TASSER Suite: protein structure and function prediction}}
      \field{volume}{12}
      \field{year}{2015}
      \field{pages}{7\bibrangedash 8}
      \verb{url}
      \verb http://dx.doi.org/10.1038/nmeth.3213%2010.1038/nmeth.3213%20http://www.nature.com/nmeth/journal/v12/n1/abs/nmeth.3213.html%7B%5C#%7Dsupplementary-information
      \endverb
    \endentry
    \entry{Roy2010}{article}{}
      \name{labelname}{3}{}{%
        {{hash=32b724aac9cf1ba7e73e7fbb0fda1b1a}{Roy}{R\bibinitperiod}{Ambrish}{A\bibinitperiod}{}{}{}{}}%
        {{hash=4c65e01cb598a5ee95e78fa42f50b50e}{Kucukural}{K\bibinitperiod}{Alper}{A\bibinitperiod}{}{}{}{}}%
        {{hash=e760d38078aff4a5b24c867aa5178c26}{Zhang}{Z\bibinitperiod}{Yang}{Y\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=32b724aac9cf1ba7e73e7fbb0fda1b1a}{Roy}{R\bibinitperiod}{Ambrish}{A\bibinitperiod}{}{}{}{}}%
        {{hash=4c65e01cb598a5ee95e78fa42f50b50e}{Kucukural}{K\bibinitperiod}{Alper}{A\bibinitperiod}{}{}{}{}}%
        {{hash=e760d38078aff4a5b24c867aa5178c26}{Zhang}{Z\bibinitperiod}{Yang}{Y\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{eab520074224de5113b6a930159d48da}
      \strng{fullhash}{eab520074224de5113b6a930159d48da}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{I-TASSER: a unified platform for automated protein structure and function prediction}}
      \field{abstract}{The I-TASSER server is an integrated platform for automated protein structure and function prediction based on the sequence-to-structure-to-function paradigm. Starting from an amino acid sequence, I-TASSER first generates three-dimensional atomic models from multiple threading alignments and iterative structural assembly simulations. The function of the protein is then inferred by structurally matching the 3D models with other known proteins. The output from a typical server run contains full-length secondary and tertiary structure predictions, and functional annotations on ligand-binding sites, Enzyme Commission numbers and Gene Ontology terms. An estimate of accuracy of the predictions is provided based on the confidence score of the modeling. This protocol provides new insights and guidelines for designing of on-line server systems for the state-of-the-art protein structure and function predictions. The server is available at http://zhang.bioinformatics.ku.edu/I-TASSER.}
      \field{issn}{1754-2189}
      \field{journaltitle}{Nature protocols}
      \field{month}{04}
      \field{number}{4}
      \field{title}{{I-TASSER: a unified platform for automated protein structure and function prediction}}
      \field{volume}{5}
      \field{year}{2010}
      \field{pages}{725\bibrangedash 738}
      \verb{doi}
      \verb 10.1038/nprot.2010.5
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2849174/
      \endverb
    \endentry
    \entry{Zhang2008}{article}{}
      \name{labelname}{1}{}{%
        {{hash=e760d38078aff4a5b24c867aa5178c26}{Zhang}{Z\bibinitperiod}{Yang}{Y\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=e760d38078aff4a5b24c867aa5178c26}{Zhang}{Z\bibinitperiod}{Yang}{Y\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {BioMed Central}%
      }
      \strng{namehash}{e760d38078aff4a5b24c867aa5178c26}
      \strng{fullhash}{e760d38078aff4a5b24c867aa5178c26}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{I-TASSER server for protein 3D structure prediction}}
      \field{abstract}{BACKGROUND: Prediction of 3-dimensional protein structures from amino acid sequences represents one of the most important problems in computational structural biology. The community-wide Critical Assessment of Structure Prediction (CASP) experiments have been designed to obtain an objective assessment of the state-of-the-art of the field, where I-TASSER was ranked as the best method in the server section of the recent 7th CASP experiment. Our laboratory has since then received numerous requests about the public availability of the I-TASSER algorithm and the usage of the I-TASSER predictions. RESULTS: An on-line version of I-TASSER is developed at the KU Center for Bioinformatics which has generated protein structure predictions for thousands of modeling requests from more than 35 countries. A scoring function (C-score) based on the relative clustering structural density and the consensus significance score of multiple threading templates is introduced to estimate the accuracy of the I-TASSER predictions. A large-scale benchmark test demonstrates a strong correlation between the C-score and the TM-score (a structural similarity measurement with values in [0, 1]) of the first models with a correlation coefficient of 0.91. Using a C-score cutoff {>} -1.5 for the models of correct topology, both false positive and false negative rates are below 0.1. Combining C-score and protein length, the accuracy of the I-TASSER models can be predicted with an average error of 0.08 for TM-score and 2 {\r{A}} for RMSD. CONCLUSION: The I-TASSER server has been developed to generate automated full-length 3D protein structural predictions where the benchmarked scoring system helps users to obtain quantitative assessments of the I-TASSER models. The output of the I-TASSER server for each query includes up to five full-length models, the confidence score, the estimated TM-score and RMSD, and the standard deviation of the estimations. The I-TASSER server is freely available to the academic community at .}
      \field{issn}{1471-2105}
      \field{journaltitle}{BMC Bioinformatics}
      \field{month}{01}
      \field{title}{{I-TASSER server for protein 3D structure prediction}}
      \field{volume}{9}
      \field{year}{2008}
      \field{pages}{40}
      \verb{doi}
      \verb 10.1186/1471-2105-9-40
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2245901/
      \endverb
    \endentry
    \entry{Kim2004}{article}{}
      \name{labelname}{3}{}{%
        {{hash=339e12ef3231908dc13e1e8d9f327d03}{Kim}{K\bibinitperiod}{David\bibnamedelima E}{D\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=384871ed5ad08f441a9752c0ef6144f0}{Chivian}{C\bibinitperiod}{Dylan}{D\bibinitperiod}{}{}{}{}}%
        {{hash=db711af07f28528a9ee5cf2922c529a3}{Baker}{B\bibinitperiod}{David}{D\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=339e12ef3231908dc13e1e8d9f327d03}{Kim}{K\bibinitperiod}{David\bibnamedelima E}{D\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=384871ed5ad08f441a9752c0ef6144f0}{Chivian}{C\bibinitperiod}{Dylan}{D\bibinitperiod}{}{}{}{}}%
        {{hash=db711af07f28528a9ee5cf2922c529a3}{Baker}{B\bibinitperiod}{David}{D\bibinitperiod}{}{}{}{}}%
      }
      \list{location}{1}{%
        {Oxford, UK}%
      }
      \list{publisher}{1}{%
        {Oxford University Press}%
      }
      \strng{namehash}{69f279c6d47da3b36a34d9bdf2e8d521}
      \strng{fullhash}{69f279c6d47da3b36a34d9bdf2e8d521}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Protein structure prediction and analysis using the Robetta server}}
      \field{abstract}{The Robetta server (http://robetta.bakerlab.org) provides automated tools for protein structure prediction and analysis. For structure prediction, sequences submitted to the server are parsed into putative domains and structural models are generated using either comparative modeling or de novo structure prediction methods. If a confident match to a protein of known structure is found using BLAST, PSI-BLAST, FFAS03 or 3D-Jury, it is used as a template for comparative modeling. If no match is found, structure predictions are made using the de novo Rosetta fragment insertion method. Experimental nuclear magnetic resonance (NMR) constraints data can also be submitted with a query sequence for RosettaNMR de novo structure determination. Other current capabilities include the prediction of the effects of mutations on protein--protein interactions using computational interface alanine scanning. The Rosetta protein design and protein--protein docking methodologies will soon be available through the server as well.}
      \field{issn}{0305-1048}
      \field{journaltitle}{Nucleic Acids Research}
      \field{month}{07}
      \field{number}{Web Server issue}
      \field{title}{{Protein structure prediction and analysis using the Robetta server}}
      \field{volume}{32}
      \field{year}{2004}
      \field{pages}{W526\bibrangedash W531}
      \verb{doi}
      \verb 10.1093/nar/gkh468
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC441606/
      \endverb
    \endentry
    \entry{Kallberg2014}{inbook}{}
      \name{labelname}{5}{}{%
        {{hash=ff40308fdc7de968f78476a252f035f7}{K{\"{a}}llberg}{K\bibinitperiod}{Morten}{M\bibinitperiod}{}{}{}{}}%
        {{hash=4b8c1ea1ad36d2610a71726f6042de8d}{Margaryan}{M\bibinitperiod}{Gohar}{G\bibinitperiod}{}{}{}{}}%
        {{hash=6bf0d8a8573aa1ba9713d0e20811cdb7}{Wang}{W\bibinitperiod}{Sheng}{S\bibinitperiod}{}{}{}{}}%
        {{hash=4110e2c106851274d8af7b534f7a748e}{Ma}{M\bibinitperiod}{Jianzhu}{J\bibinitperiod}{}{}{}{}}%
        {{hash=716306a09f303b9d16a4e7585e74f403}{Xu}{X\bibinitperiod}{Jinbo}{J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{5}{}{%
        {{hash=ff40308fdc7de968f78476a252f035f7}{K{\"{a}}llberg}{K\bibinitperiod}{Morten}{M\bibinitperiod}{}{}{}{}}%
        {{hash=4b8c1ea1ad36d2610a71726f6042de8d}{Margaryan}{M\bibinitperiod}{Gohar}{G\bibinitperiod}{}{}{}{}}%
        {{hash=6bf0d8a8573aa1ba9713d0e20811cdb7}{Wang}{W\bibinitperiod}{Sheng}{S\bibinitperiod}{}{}{}{}}%
        {{hash=4110e2c106851274d8af7b534f7a748e}{Ma}{M\bibinitperiod}{Jianzhu}{J\bibinitperiod}{}{}{}{}}%
        {{hash=716306a09f303b9d16a4e7585e74f403}{Xu}{X\bibinitperiod}{Jinbo}{J\bibinitperiod}{}{}{}{}}%
      }
      \name{editor}{1}{}{%
        {{hash=d34e70d4f763f52fcf8a13a10907d7ae}{Kihara}{K\bibinitperiod}{Daisuke}{D\bibinitperiod}{}{}{}{}}%
      }
      \list{location}{1}{%
        {New York, NY}%
      }
      \list{publisher}{1}{%
        {Springer New York}%
      }
      \strng{namehash}{7bb6df332ee33a3b3bc8e2d81c94d48c}
      \strng{fullhash}{3e3d22eed4312ada18428808833ac5b3}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Protein Structure Prediction}}
      \field{chapter}{RaptorX se}
      \field{isbn}{978-1-4939-0366-5}
      \field{title}{{Protein Structure Prediction}}
      \field{year}{2014}
      \field{pages}{17\bibrangedash 27}
      \verb{doi}
      \verb 10.1007/978-1-4939-0366-5_2
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1007/978-1-4939-0366-5%7B%5C_%7D2
      \endverb
    \endentry
    \entry{Bates2001}{article}{}
      \name{labelname}{4}{}{%
        {{hash=514eeb149ed44638917f125adb1a3e26}{Bates}{B\bibinitperiod}{P\bibnamedelima A}{P\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=63a108e094225e08eb00471327dc1e56}{Kelley}{K\bibinitperiod}{L\bibnamedelima A}{L\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=a48db3f3e2769a224c0eed1abbce2c02}{MacCallum}{M\bibinitperiod}{R\bibnamedelima M}{R\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=060ac14ca776c9fb01d20f6f8bc50aa9}{Sternberg}{S\bibinitperiod}{M\bibnamedelima J}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=514eeb149ed44638917f125adb1a3e26}{Bates}{B\bibinitperiod}{P\bibnamedelima A}{P\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=63a108e094225e08eb00471327dc1e56}{Kelley}{K\bibinitperiod}{L\bibnamedelima A}{L\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=a48db3f3e2769a224c0eed1abbce2c02}{MacCallum}{M\bibinitperiod}{R\bibnamedelima M}{R\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=060ac14ca776c9fb01d20f6f8bc50aa9}{Sternberg}{S\bibinitperiod}{M\bibnamedelima J}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{48d90d351452ad0636a9dfd616cfd232}
      \strng{fullhash}{90e3d3083b08d660b1ac39657cd6f690}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Enhancement of protein modeling by human intervention in applying the automatic programs 3D-JIGSAW and 3D-PSSM.}}
      \field{abstract}{Fourteen models were constructed and analyzed for the comparative modeling section of Critical Assessment of Techniques for Protein Structure Prediction (CASP4). Sequence identity between each target and the best possible parent(s) ranged between 55 and 13{\%}, and the root-mean-square deviation between model and target was from 0.8 to 17.9 A. In the fold recognition section, 10 of the 11 remote homologues were recognized. The modeling protocols are a combination of automated computer algorithms, 3D-JIGSAW (for comparative modeling) and 3D-PSSM (for fold recognition), with human intervention at certain critical stages. In particular, intervention is required to check superfamily assignment, best possible parents from which to model, sequence alignments to those parents and take-off regions for modeling variable regions. There now is a convergence of algorithms for comparative modeling and fold recognition, particularly in the region of remote homology.}
      \field{issn}{0887-3585}
      \field{journaltitle}{Proteins}
      \field{month}{01}
      \field{title}{{Enhancement of protein modeling by human intervention in applying the automatic programs 3D-JIGSAW and 3D-PSSM.}}
      \field{volume}{Suppl 5}
      \field{year}{2001}
      \field{pages}{39\bibrangedash 46}
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/11835480
      \endverb
    \endentry
    \entry{Vriend1990}{article}{}
      \name{labelname}{1}{}{%
        {{hash=6cc0e7fcba697b2730c1dbec3a1726d7}{Vriend}{V\bibinitperiod}{G.}{G\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=6cc0e7fcba697b2730c1dbec3a1726d7}{Vriend}{V\bibinitperiod}{G.}{G\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{6cc0e7fcba697b2730c1dbec3a1726d7}
      \strng{fullhash}{6cc0e7fcba697b2730c1dbec3a1726d7}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{WHAT IF: A molecular modeling and drug design program}}
      \field{abstract}{A FORTRAN 77 computer program has been written to aid with macromolecular modeling and drug design. Called WHAT IF, it provides an intelligent and flexible environment for displaying, manipulating, and analyzing small molecules, proteins, nucleic acids, and their interactions. A relational protein structure database is incorporated to be queried. The program is suitable for most common crystallographic work. The menu-driven operation of WHAT IF, combined with the use of default values wherever user input is required, makes it very easy to use for a novice user while keeping full flexibility for more sophisticated studies. Although there are not too many unique features in WHAT IF, the fact that everything is integrated in one program makes it a unique tool for many purposes.}
      \field{issn}{02637855}
      \field{journaltitle}{Journal of Molecular Graphics}
      \field{month}{03}
      \field{number}{1}
      \field{title}{{WHAT IF: A molecular modeling and drug design program}}
      \field{volume}{8}
      \field{year}{1990}
      \field{pages}{52\bibrangedash 56}
      \verb{doi}
      \verb 10.1016/0263-7855(90)80070-V
      \endverb
      \verb{url}
      \verb http://www.sciencedirect.com/science/article/pii/026378559080070V
      \endverb
    \endentry
    \entry{Richardson1981}{book}{}
      \name{labelname}{1}{}{%
        {{hash=1942b77d65e62ed294185de18324007a}{Richardson}{R\bibinitperiod}{Jane\bibnamedelima S.}{J\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=1942b77d65e62ed294185de18324007a}{Richardson}{R\bibinitperiod}{Jane\bibnamedelima S.}{J\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{1942b77d65e62ed294185de18324007a}
      \strng{fullhash}{1942b77d65e62ed294185de18324007a}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Advances in Protein Chemistry Volume 34}}
      \field{abstract}{This chapter investigates the anatomy and taxonomy of protein structures. A protein is a polypeptide chain made up of amino acid residues linked together in a definite sequence. Amino acids are {$\textquotedblleft$}handed,{$\textquotedblright$} and naturally occurring proteins contain only L-amino acids. A simple mnemonic for that purpose is the {$\textquotedblleft$}corncrib.{$\textquotedblright$} The sequence of side chains determines all that is unique about a particular protein, including its biological function and its specific three-dimensional structure. The major possible routes to knowledge of three-dimensional protein structure are prediction from the amino acid sequence and analysis of spectroscopic measurements such as circular dichroism, laser Raman spectroscopy, and nuclear magnetic resonance. The analysis and discussion of protein structure is based on the results of three-dimensional X-ray crystallography of globular proteins. The basic elements of protein structures are discussed. The most useful level at which protein structures are to be categorized is the domain, as there are many cases of multiple-domain proteins in which each separate domain resembles other entire smaller proteins. The simplest type of stable protein structure consists of polypeptide backbone wrapped more or less uniformly around the outside of a single hydrophobic core. The outline of the taxonomy is also provided in the chapter.}
      \field{booktitle}{Advances in Protein Chemistry}
      \field{isbn}{9780120342341}
      \field{issn}{00653233}
      \field{title}{{Advances in Protein Chemistry Volume 34}}
      \field{volume}{34}
      \field{year}{1981}
      \field{pages}{167\bibrangedash 339}
      \verb{doi}
      \verb 10.1016/S0065-3233(08)60520-3
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/richardson1981.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.sciencedirect.com/science/article/pii/S0065323308605203
      \endverb
    \endentry
    \entry{That1991}{article}{}
      \name{labelname}{2}{}{%
        {{hash=7be716f68dbba1528c49b2b89583be8a}{That}{T\bibinitperiod}{Extracellular\bibnamedelima Proteins}{E\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=064b675fcb4b96f4755f7e10884b94db}{Interactions}{I\bibinitperiod}{Modulate\bibnamedelima Cell-matrix}{M\bibinitperiod\bibinitdelim C\bibinithyphendelim m\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=7be716f68dbba1528c49b2b89583be8a}{That}{T\bibinitperiod}{Extracellular\bibnamedelima Proteins}{E\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=064b675fcb4b96f4755f7e10884b94db}{Interactions}{I\bibinitperiod}{Modulate\bibnamedelima Cell-matrix}{M\bibinitperiod\bibinitdelim C\bibinithyphendelim m\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{5c4382f6ad563e2fbf1264a7315b9096}
      \strng{fullhash}{5c4382f6ad563e2fbf1264a7315b9096}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Extracellular Proteins That}}
      \field{isbn}{0014579391}
      \field{number}{23}
      \field{title}{{Extracellular Proteins That}}
      \field{volume}{266}
      \field{year}{1991}
      \field{pages}{15\bibrangedash 18}
      \verb{file}
      \verb :home/fran/Downloads/feb2001457939180937x.pdf:pdf
      \endverb
    \endentry
    \entry{DomainDef}{article}{}
      \name{labelname}{1}{}{%
        {{hash=b7c7eb2a631e8b995a080136f28071f0}{Wetlaufer}{W\bibinitperiod}{D\bibnamedelima B}{D\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=b7c7eb2a631e8b995a080136f28071f0}{Wetlaufer}{W\bibinitperiod}{D\bibnamedelima B}{D\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{b7c7eb2a631e8b995a080136f28071f0}
      \strng{fullhash}{b7c7eb2a631e8b995a080136f28071f0}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Nucleation, rapid folding, and globular intrachain regions in proteins.}}
      \field{abstract}{Distinct structural regions have been found in several globular proteins composed of single polypeptide chains. The existence of such regions and the continuity of peptide chain within them, coupled with kinetic arguments, suggests that the early stages of three-dimensional structure formation (nucleation) occur independently in separate parts of these molecules. A nucleus can grow rapidly by adding peptide chain segments that are close to the nucleus in aminoacid sequence. Such a process would generate three-dimensional (native) protein structures that contain separate regions of continuous peptide chain. Possible means of testing this hypothesis are discussed.}
      \field{issn}{0027-8424}
      \field{journaltitle}{Proceedings of the National Academy of Sciences of the United States of America}
      \field{number}{3}
      \field{title}{{Nucleation, rapid folding, and globular intrachain regions in proteins.}}
      \field{volume}{70}
      \field{year}{1973}
      \field{pages}{697\bibrangedash 701}
      \verb{doi}
      \verb 10.1073/pnas.70.3.697
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/PNAS-1973-Wetlaufer-697-701.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=433338%7B%5C&%7Dtool=pmcentrez%7B%5C&%7Drendertype=abstract
      \endverb
    \endentry
    \entry{Islam1995}{article}{}
      \name{labelname}{5}{}{%
        {{hash=60ec6bc1b20fb6fea05a648850a77b3a}{Islam}{I\bibinitperiod}{Suhail\bibnamedelima A}{S\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=7669ad50b7c3c5960975148ae5ff650c}{Luo}{L\bibinitperiod}{Jingchu}{J\bibinitperiod}{}{}{}{}}%
        {{hash=ce3ba6c2553ffabc0b04f57ac5aa78c2}{Michael}{M\bibinitperiod}{J\bibnamedelima E\bibnamedelima S}{J\bibinitperiod\bibinitdelim E\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=5a9d607dd3bf84039e2eea05b6fd9db6}{Fields}{F\bibinitperiod}{Inn}{I\bibinitperiod}{}{}{}{}}%
        {{hash=352220d8df95e4341bb6fd1bd7a7824f}{Wca}{W\bibinitperiod}{London}{L\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{5}{}{%
        {{hash=60ec6bc1b20fb6fea05a648850a77b3a}{Islam}{I\bibinitperiod}{Suhail\bibnamedelima A}{S\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=7669ad50b7c3c5960975148ae5ff650c}{Luo}{L\bibinitperiod}{Jingchu}{J\bibinitperiod}{}{}{}{}}%
        {{hash=ce3ba6c2553ffabc0b04f57ac5aa78c2}{Michael}{M\bibinitperiod}{J\bibnamedelima E\bibnamedelima S}{J\bibinitperiod\bibinitdelim E\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=5a9d607dd3bf84039e2eea05b6fd9db6}{Fields}{F\bibinitperiod}{Inn}{I\bibinitperiod}{}{}{}{}}%
        {{hash=352220d8df95e4341bb6fd1bd7a7824f}{Wca}{W\bibinitperiod}{London}{L\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{88a4ab26d2afe794fca9bd47e80f5465}
      \strng{fullhash}{61dd19938af845aba752b158acf1e2f6}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Identification and analysis of domains in proteins presented to identify domains in proteins}}
      \field{number}{6}
      \field{title}{{Identification and analysis of domains in proteins presented to identify domains in proteins}}
      \field{volume}{8}
      \field{year}{1995}
      \field{pages}{513\bibrangedash 525}
      \verb{file}
      \verb :home/fran/Downloads/islam1995.pdf:pdf
      \endverb
    \endentry
    \entry{Han2007}{article}{}
      \name{labelname}{5}{}{%
        {{hash=1a1fc9219f4ad5c54b013e9aedb81b96}{Han}{H\bibinitperiod}{Jung-Hoon}{J\bibinithyphendelim H\bibinitperiod}{}{}{}{}}%
        {{hash=dbfbb4cf0629c9e7fd499ce6fa01d6da}{Batey}{B\bibinitperiod}{Sarah}{S\bibinitperiod}{}{}{}{}}%
        {{hash=80035313591885d16e25f8faafa989ce}{Nickson}{N\bibinitperiod}{Adrian\bibnamedelima a}{A\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
        {{hash=c2f5cd48e8daabc6e9d7f794465a9647}{Teichmann}{T\bibinitperiod}{Sarah\bibnamedelima a}{S\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
        {{hash=1f7cf7004ea1f6288a78d10bcd247212}{Clarke}{C\bibinitperiod}{Jane}{J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{5}{}{%
        {{hash=1a1fc9219f4ad5c54b013e9aedb81b96}{Han}{H\bibinitperiod}{Jung-Hoon}{J\bibinithyphendelim H\bibinitperiod}{}{}{}{}}%
        {{hash=dbfbb4cf0629c9e7fd499ce6fa01d6da}{Batey}{B\bibinitperiod}{Sarah}{S\bibinitperiod}{}{}{}{}}%
        {{hash=80035313591885d16e25f8faafa989ce}{Nickson}{N\bibinitperiod}{Adrian\bibnamedelima a}{A\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
        {{hash=c2f5cd48e8daabc6e9d7f794465a9647}{Teichmann}{T\bibinitperiod}{Sarah\bibnamedelima a}{S\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
        {{hash=1f7cf7004ea1f6288a78d10bcd247212}{Clarke}{C\bibinitperiod}{Jane}{J\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{34c454b290fbed90ebb25b13f611aff2}
      \strng{fullhash}{2c4440340e1ff3b3831064ad7a75fe30}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{The folding and evolution of multidomain proteins.}}
      \field{abstract}{Analyses of genomes show that more than 70{\%} of eukaryotic proteins are composed of multiple domains. However, most studies of protein folding focus on individual domains and do not consider how interactions between domains might affect folding. Here, we address this by analysing the three-dimensional structures of multidomain proteins that have been characterized experimentally and observe that where the interface is small and loosely packed, or unstructured, the folding of the domains is independent. Furthermore, recent studies indicate that multidomain proteins have evolved mechanisms to minimize the problems of interdomain misfolding.}
      \field{issn}{1471-0072}
      \field{journaltitle}{Nature reviews. Molecular cell biology}
      \field{number}{4}
      \field{title}{{The folding and evolution of multidomain proteins.}}
      \field{volume}{8}
      \field{year}{2007}
      \field{pages}{319\bibrangedash 330}
      \verb{doi}
      \verb 10.1038/nrm2144
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/nrm2144.pdf:pdf
      \endverb
    \endentry
    \entry{Chothia2003}{article}{}
      \name{labelname}{4}{}{%
        {{hash=e7519839a5afb3dc61bb297b7fb4f313}{Chothia}{C\bibinitperiod}{Cyrus}{C\bibinitperiod}{}{}{}{}}%
        {{hash=d555f8ccbc9d14ac20a0f70424b46e75}{Gough}{G\bibinitperiod}{Julian}{J\bibinitperiod}{}{}{}{}}%
        {{hash=b631f76e3a5923ac7e82caac9f5d6600}{Vogel}{V\bibinitperiod}{Christine}{C\bibinitperiod}{}{}{}{}}%
        {{hash=c2f5cd48e8daabc6e9d7f794465a9647}{Teichmann}{T\bibinitperiod}{Sarah\bibnamedelima a}{S\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=e7519839a5afb3dc61bb297b7fb4f313}{Chothia}{C\bibinitperiod}{Cyrus}{C\bibinitperiod}{}{}{}{}}%
        {{hash=d555f8ccbc9d14ac20a0f70424b46e75}{Gough}{G\bibinitperiod}{Julian}{J\bibinitperiod}{}{}{}{}}%
        {{hash=b631f76e3a5923ac7e82caac9f5d6600}{Vogel}{V\bibinitperiod}{Christine}{C\bibinitperiod}{}{}{}{}}%
        {{hash=c2f5cd48e8daabc6e9d7f794465a9647}{Teichmann}{T\bibinitperiod}{Sarah\bibnamedelima a}{S\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{6407dacea043bf1cdf1480a479796cc6}
      \strng{fullhash}{9433c49cf099ddc98c2612479ca165cc}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Evolution of the protein repertoire.}}
      \field{issn}{1095-9203}
      \field{journaltitle}{Science (New York, N.Y.)}
      \field{number}{5626}
      \field{title}{{Evolution of the protein repertoire.}}
      \field{volume}{300}
      \field{year}{2003}
      \field{pages}{1701\bibrangedash 3}
      \verb{doi}
      \verb 10.1126/science.1085371
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/1701.full.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/12805536
      \endverb
    \endentry
    \entry{Vogel2004}{article}{}
      \name{labelname}{5}{}{%
        {{hash=b631f76e3a5923ac7e82caac9f5d6600}{Vogel}{V\bibinitperiod}{Christine}{C\bibinitperiod}{}{}{}{}}%
        {{hash=567527bbc47ea3a86d781dbcfbeeecd5}{Bashton}{B\bibinitperiod}{Matthew}{M\bibinitperiod}{}{}{}{}}%
        {{hash=a14d3c6cfa9248bdd6df783471d74676}{Kerrison}{K\bibinitperiod}{Nicola\bibnamedelima D.}{N\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=e7519839a5afb3dc61bb297b7fb4f313}{Chothia}{C\bibinitperiod}{Cyrus}{C\bibinitperiod}{}{}{}{}}%
        {{hash=297bedd4a585ea429676a28716291cc1}{Teichmann}{T\bibinitperiod}{Sarah\bibnamedelima A.}{S\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{5}{}{%
        {{hash=b631f76e3a5923ac7e82caac9f5d6600}{Vogel}{V\bibinitperiod}{Christine}{C\bibinitperiod}{}{}{}{}}%
        {{hash=567527bbc47ea3a86d781dbcfbeeecd5}{Bashton}{B\bibinitperiod}{Matthew}{M\bibinitperiod}{}{}{}{}}%
        {{hash=a14d3c6cfa9248bdd6df783471d74676}{Kerrison}{K\bibinitperiod}{Nicola\bibnamedelima D.}{N\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=e7519839a5afb3dc61bb297b7fb4f313}{Chothia}{C\bibinitperiod}{Cyrus}{C\bibinitperiod}{}{}{}{}}%
        {{hash=297bedd4a585ea429676a28716291cc1}{Teichmann}{T\bibinitperiod}{Sarah\bibnamedelima A.}{S\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{2fec1062bda54de126927ac9a9f99178}
      \strng{fullhash}{39592d1af1fe60179c0e93bc784a8b9f}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Structure, function and evolution of multidomain proteins}}
      \field{abstract}{Proteins are composed of evolutionary units called domains; the majority of proteins consist of at least two domains. These domains and nature of their interactions determine the function of the protein. The roles that combinations of domains play in the formation of the protein repertoire have been found by analysis of domain assignments to genome sequences. Additional findings on the geometry of domains have been gained from examination of three-dimensional protein structures. Future work will require a domain-centric functional classification scheme and efforts to determine structures of domain combinations.}
      \field{issn}{0959440X}
      \field{journaltitle}{Current Opinion in Structural Biology}
      \field{number}{2}
      \field{title}{{Structure, function and evolution of multidomain proteins}}
      \field{volume}{14}
      \field{year}{2004}
      \field{pages}{208\bibrangedash 216}
      \verb{doi}
      \verb 10.1016/j.sbi.2004.03.011
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/160{\_}cosb{\_}14{\_}208{\_}04.pdf:pdf
      \endverb
    \endentry
    \entry{Apic2001}{article}{}
      \name{labelname}{3}{}{%
        {{hash=efcbb06bb1ea6e9715bdd02e9dd88814}{Apic}{A\bibinitperiod}{G}{G\bibinitperiod}{}{}{}{}}%
        {{hash=dd105c1a4f8e69affb33bb12ab748ccf}{Gough}{G\bibinitperiod}{J}{J\bibinitperiod}{}{}{}{}}%
        {{hash=d7ad71301f2645f8897b81854d6ab6cf}{Teichmann}{T\bibinitperiod}{S\bibnamedelima a}{S\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=efcbb06bb1ea6e9715bdd02e9dd88814}{Apic}{A\bibinitperiod}{G}{G\bibinitperiod}{}{}{}{}}%
        {{hash=dd105c1a4f8e69affb33bb12ab748ccf}{Gough}{G\bibinitperiod}{J}{J\bibinitperiod}{}{}{}{}}%
        {{hash=d7ad71301f2645f8897b81854d6ab6cf}{Teichmann}{T\bibinitperiod}{S\bibnamedelima a}{S\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{f431ae4c3e719ffdcaa9e8da5219bbba}
      \strng{fullhash}{f431ae4c3e719ffdcaa9e8da5219bbba}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Domain combinations in archaeal, eubacterial and eukaryotic proteomes.}}
      \field{abstract}{There is a limited repertoire of domain families that are duplicated and combined in different ways to form the set of proteins in a genome. Proteins are gene products, and at the level of genes, duplication, recombination, fusion and fission are the processes that produce new genes. We attempt to gain an overview of these processes by studying the evolutionary units in proteins, domains, in the protein sequences of 40 genomes. The domain and superfamily definitions in the Structural Classification of Proteins Database are used, so that we can view all pairs of adjacent domains in genome sequences in terms of their superfamily combinations. We find 783 out of the 859 superfamilies in SCOP in these genomes, and the 783 families occur in 1307 pairwise combinations. Most families are observed in combination with one or two other families, while a few families are very versatile in their combinatorial behaviour; 209 families do not make combinations with other families. This type of pattern can be described as a scale-free network. We also study the N to C-terminal orientation of domain pairs and domain repeats. The phylogenetic distribution of domain combinations is surveyed, to establish the extent of common and kingdom-specific combinations. Of the kingdom-specific combinations, significantly more combinations consist of families present in all three kingdoms than of families present in one or two kingdoms. Hence, we are led to conclude that recombination between common families, as compared to the invention of new families and recombination among these, has also been a major contribution to the evolution of kingdom-specific and species-specific functions in organisms in all three kingdoms. Finally, we compare the set of the domain combinations in the genomes to those in the RCSB Protein Data Bank, and discuss the implications for structural genomics.}
      \field{issn}{0022-2836}
      \field{journaltitle}{Journal of molecular biology}
      \field{number}{2}
      \field{title}{{Domain combinations in archaeal, eubacterial and eukaryotic proteomes.}}
      \field{volume}{310}
      \field{year}{2001}
      \field{pages}{311\bibrangedash 325}
      \verb{doi}
      \verb 10.1006/jmbi.2001.4776
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/1-s2.0-S002228360194776X-main.pdf:pdf
      \endverb
    \endentry
    \entry{Murzin1995}{article}{}
      \name{labelname}{4}{}{%
        {{hash=42b7f51d15c595136efc59e73a14de59}{Murzin}{M\bibinitperiod}{Alexey\bibnamedelima G.}{A\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=eaa050d847c04a972f7923961fd20e5c}{Brenner}{B\bibinitperiod}{Steven\bibnamedelima E.}{S\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=ea8c6f86565db567f286380a1200bde2}{Hubbard}{H\bibinitperiod}{Tim}{T\bibinitperiod}{}{}{}{}}%
        {{hash=e7519839a5afb3dc61bb297b7fb4f313}{Chothia}{C\bibinitperiod}{Cyrus}{C\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=42b7f51d15c595136efc59e73a14de59}{Murzin}{M\bibinitperiod}{Alexey\bibnamedelima G.}{A\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=eaa050d847c04a972f7923961fd20e5c}{Brenner}{B\bibinitperiod}{Steven\bibnamedelima E.}{S\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=ea8c6f86565db567f286380a1200bde2}{Hubbard}{H\bibinitperiod}{Tim}{T\bibinitperiod}{}{}{}{}}%
        {{hash=e7519839a5afb3dc61bb297b7fb4f313}{Chothia}{C\bibinitperiod}{Cyrus}{C\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{ee746f630cfdbaeb6b971463fe66ae82}
      \strng{fullhash}{7e82c14f0c89c460f251127c1d401a0c}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{SCOP: A structural classification of proteins database for the investigation of sequences and structures}}
      \field{issn}{00222836}
      \field{journaltitle}{Journal of Molecular Biology}
      \field{number}{4}
      \field{title}{{SCOP: A structural classification of proteins database for the investigation of sequences and structures}}
      \field{volume}{247}
      \field{year}{1995}
      \field{pages}{536\bibrangedash 540}
      \verb{doi}
      \verb 10.1016/S0022-2836(05)80134-2
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/murzin1995.pdf:pdf
      \endverb
    \endentry
    \entry{Orengo1997}{article}{}
      \name{labelname}{6}{}{%
        {{hash=919c26011075f6007f9ab8fd83661920}{Orengo}{O\bibinitperiod}{Ca}{C\bibinitperiod}{}{}{}{}}%
        {{hash=70bfe79af73cfaedcd77fd4a0f2f9904}{Michie}{M\bibinitperiod}{Ad}{A\bibinitperiod}{}{}{}{}}%
        {{hash=34ac6afd6fa2a04708410458765f2c91}{Jones}{J\bibinitperiod}{S}{S\bibinitperiod}{}{}{}{}}%
        {{hash=3a16cbc5d72721281ac685fbeeb35975}{Jones}{J\bibinitperiod}{Dt}{D\bibinitperiod}{}{}{}{}}%
        {{hash=884beffdd9846c9fb86206fddfe93a98}{Swindells}{S\bibinitperiod}{Mb}{M\bibinitperiod}{}{}{}{}}%
        {{hash=029dc3641f9bd9ee9f780eff69c66151}{Thornton}{T\bibinitperiod}{Jm}{J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{6}{}{%
        {{hash=919c26011075f6007f9ab8fd83661920}{Orengo}{O\bibinitperiod}{Ca}{C\bibinitperiod}{}{}{}{}}%
        {{hash=70bfe79af73cfaedcd77fd4a0f2f9904}{Michie}{M\bibinitperiod}{Ad}{A\bibinitperiod}{}{}{}{}}%
        {{hash=34ac6afd6fa2a04708410458765f2c91}{Jones}{J\bibinitperiod}{S}{S\bibinitperiod}{}{}{}{}}%
        {{hash=3a16cbc5d72721281ac685fbeeb35975}{Jones}{J\bibinitperiod}{Dt}{D\bibinitperiod}{}{}{}{}}%
        {{hash=884beffdd9846c9fb86206fddfe93a98}{Swindells}{S\bibinitperiod}{Mb}{M\bibinitperiod}{}{}{}{}}%
        {{hash=029dc3641f9bd9ee9f780eff69c66151}{Thornton}{T\bibinitperiod}{Jm}{J\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{062fd1321b616555f7ae3d86dd31d88a}
      \strng{fullhash}{642168b9f8af74b9310a4ec88457999f}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{CATH - a hierarchic classification of protein domain structures}}
      \field{isbn}{0969-2126}
      \field{issn}{09692126}
      \field{journaltitle}{Structure}
      \field{number}{March}
      \field{title}{{CATH - a hierarchic classification of protein domain structures}}
      \field{year}{1997}
      \field{pages}{1093\bibrangedash 1109}
      \verb{doi}
      \verb 10.1016/S0969-2126(97)00260-8
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/1-s2.0-S0969212697002608-main.pdf:pdf
      \endverb
      \verb{url}
      \verb http://discovery.ucl.ac.uk/170914/
      \endverb
    \endentry
    \entry{Bateman2002}{article}{}
      \name{labelname}{14}{}{%
        {{hash=7aa94dfe398db505f1e5cac138d3ffc3}{Bateman}{B\bibinitperiod}{A}{A\bibinitperiod}{}{}{}{}}%
        {{hash=38d9b4f76963eda738134c8361436ae7}{Birney}{B\bibinitperiod}{E}{E\bibinitperiod}{}{}{}{}}%
        {{hash=d0cc3bd390785b9edf80dd933ac556a2}{Durbin}{D\bibinitperiod}{R}{R\bibinitperiod}{}{}{}{}}%
        {{hash=b14e84d528aad327fd0a1a9a76072adb}{Eddy}{E\bibinitperiod}{S\bibnamedelima R}{S\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=9dbdc8511f53f0e6bc96be475c82c48b}{Howe}{H\bibinitperiod}{K\bibnamedelima L}{K\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=b5c7a880e14a298ece95f41d15ffc0c3}{Sonnhammer}{S\bibinitperiod}{E\bibnamedelima L}{E\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=cbaaf82c8572f48c8890546e7ee5c201}{Cerruti}{C\bibinitperiod}{L}{L\bibinitperiod}{}{}{}{}}%
        {{hash=d0cc3bd390785b9edf80dd933ac556a2}{Durbin}{D\bibinitperiod}{R}{R\bibinitperiod}{}{}{}{}}%
        {{hash=58b3b2b8cfe8430a48abcd1e3333ecf6}{Etwiller}{E\bibinitperiod}{L}{L\bibinitperiod}{}{}{}{}}%
        {{hash=b14e84d528aad327fd0a1a9a76072adb}{Eddy}{E\bibinitperiod}{S\bibnamedelima R}{S\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=56e1e30c7e35ef73c9897f8bc5c82d2d}{Griffiths-Jones}{G\bibinithyphendelim J\bibinitperiod}{S}{S\bibinitperiod}{}{}{}{}}%
        {{hash=9dbdc8511f53f0e6bc96be475c82c48b}{Howe}{H\bibinitperiod}{K\bibnamedelima L}{K\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=a2db27cb04781e0fc0e516fdf26b7e7c}{Marshall}{M\bibinitperiod}{M}{M\bibinitperiod}{}{}{}{}}%
        {{hash=b5c7a880e14a298ece95f41d15ffc0c3}{Sonnhammer}{S\bibinitperiod}{E\bibnamedelima L}{E\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{14}{}{%
        {{hash=7aa94dfe398db505f1e5cac138d3ffc3}{Bateman}{B\bibinitperiod}{A}{A\bibinitperiod}{}{}{}{}}%
        {{hash=38d9b4f76963eda738134c8361436ae7}{Birney}{B\bibinitperiod}{E}{E\bibinitperiod}{}{}{}{}}%
        {{hash=d0cc3bd390785b9edf80dd933ac556a2}{Durbin}{D\bibinitperiod}{R}{R\bibinitperiod}{}{}{}{}}%
        {{hash=b14e84d528aad327fd0a1a9a76072adb}{Eddy}{E\bibinitperiod}{S\bibnamedelima R}{S\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=9dbdc8511f53f0e6bc96be475c82c48b}{Howe}{H\bibinitperiod}{K\bibnamedelima L}{K\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=b5c7a880e14a298ece95f41d15ffc0c3}{Sonnhammer}{S\bibinitperiod}{E\bibnamedelima L}{E\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=cbaaf82c8572f48c8890546e7ee5c201}{Cerruti}{C\bibinitperiod}{L}{L\bibinitperiod}{}{}{}{}}%
        {{hash=d0cc3bd390785b9edf80dd933ac556a2}{Durbin}{D\bibinitperiod}{R}{R\bibinitperiod}{}{}{}{}}%
        {{hash=58b3b2b8cfe8430a48abcd1e3333ecf6}{Etwiller}{E\bibinitperiod}{L}{L\bibinitperiod}{}{}{}{}}%
        {{hash=b14e84d528aad327fd0a1a9a76072adb}{Eddy}{E\bibinitperiod}{S\bibnamedelima R}{S\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=56e1e30c7e35ef73c9897f8bc5c82d2d}{Griffiths-Jones}{G\bibinithyphendelim J\bibinitperiod}{S}{S\bibinitperiod}{}{}{}{}}%
        {{hash=9dbdc8511f53f0e6bc96be475c82c48b}{Howe}{H\bibinitperiod}{K\bibnamedelima L}{K\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=a2db27cb04781e0fc0e516fdf26b7e7c}{Marshall}{M\bibinitperiod}{M}{M\bibinitperiod}{}{}{}{}}%
        {{hash=b5c7a880e14a298ece95f41d15ffc0c3}{Sonnhammer}{S\bibinitperiod}{E\bibnamedelima L}{E\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{ac1f75dec5abaa6fae284f3762a05a5a}
      \strng{fullhash}{d1c9970cbfd214b3a3ff79f3f819a5aa}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{The Pfam protein families database}}
      \field{isbn}{1362-4962 (Electronic)}
      \field{issn}{0305-1048 (Print) 0305-1048 (Linking)}
      \field{journaltitle}{Nucleic Acids Research}
      \field{number}{1}
      \field{title}{{The Pfam protein families database}}
      \field{volume}{28}
      \field{year}{2002}
      \field{pages}{276\bibrangedash 280}
      \verb{doi}
      \verb gkd038 [pii]
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/Nucl. Acids Res.-2002-Bateman-276-80.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve%7B%5C&%7Ddb=PubMed%7B%5C&%7Ddopt=Citation%7B%5C&%7Dlist%7B%5C_%7Duids=11752314%20http://www.ncbi.nlm.nih.gov/pubmed/10592242
      \endverb
    \endentry
    \entry{Hunter2009}{article}{}
      \name{labelname}{38}{}{%
        {{hash=4232913ae552b928ff5101e7d581375f}{Hunter}{H\bibinitperiod}{Sarah}{S\bibinitperiod}{}{}{}{}}%
        {{hash=88e451f539cb133a865445c7b4a72945}{Apweiler}{A\bibinitperiod}{Rolf}{R\bibinitperiod}{}{}{}{}}%
        {{hash=0d2826c48375171a50da9d818710ac95}{Attwood}{A\bibinitperiod}{Teresa\bibnamedelima K.}{T\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=b2ebd3ba772b0e00ce7ff11062d7bb7e}{Bairoch}{B\bibinitperiod}{Amos}{A\bibinitperiod}{}{}{}{}}%
        {{hash=1ced5c37e13ed96f4cb024911c267029}{Bateman}{B\bibinitperiod}{Alex}{A\bibinitperiod}{}{}{}{}}%
        {{hash=8ac693a590925614d5eab4124b16d815}{Binns}{B\bibinitperiod}{David}{D\bibinitperiod}{}{}{}{}}%
        {{hash=e661978528e2df38a8c66036d9e7c3a2}{Bork}{B\bibinitperiod}{Peer}{P\bibinitperiod}{}{}{}{}}%
        {{hash=070cb6ad7a7d5d2d766209c073611eb1}{Das}{D\bibinitperiod}{Ujjwal}{U\bibinitperiod}{}{}{}{}}%
        {{hash=3181a4e63e23edf46ad3a0ab584a861d}{Daugherty}{D\bibinitperiod}{Louise}{L\bibinitperiod}{}{}{}{}}%
        {{hash=a0324e3154f8264b92b921f82b7485ac}{Duquenne}{D\bibinitperiod}{Lauranne}{L\bibinitperiod}{}{}{}{}}%
        {{hash=f0db7057368bb4f4edb12e97a28cbf3b}{Finn}{F\bibinitperiod}{Robert\bibnamedelima D.}{R\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=d555f8ccbc9d14ac20a0f70424b46e75}{Gough}{G\bibinitperiod}{Julian}{J\bibinitperiod}{}{}{}{}}%
        {{hash=c23f9faa75b1688ba9504d8cf32b1bfd}{Haft}{H\bibinitperiod}{Daniel}{D\bibinitperiod}{}{}{}{}}%
        {{hash=284b9e8e35db019d7497fde6cb5b9983}{Hulo}{H\bibinitperiod}{Nicolas}{N\bibinitperiod}{}{}{}{}}%
        {{hash=e703131d4a240ed85e6dc263888115bf}{Kahn}{K\bibinitperiod}{Daniel}{D\bibinitperiod}{}{}{}{}}%
        {{hash=f8ed66e6c7d354ed4455da12896952be}{Kelly}{K\bibinitperiod}{Elizabeth}{E\bibinitperiod}{}{}{}{}}%
        {{hash=8492bc72a9da536e7e9f199a0fc1f4c9}{Laugraud}{L\bibinitperiod}{Aur??lie}{A\bibinitperiod}{}{}{}{}}%
        {{hash=90a16251283487ab24f75284582c22c5}{Letunic}{L\bibinitperiod}{Ivica}{I\bibinitperiod}{}{}{}{}}%
        {{hash=a56293848f9dcd3094d2283c3fc99db3}{Lonsdale}{L\bibinitperiod}{David}{D\bibinitperiod}{}{}{}{}}%
        {{hash=17a3cab6e1f118259eff98d86f83696c}{Lopez}{L\bibinitperiod}{Rodrigo}{R\bibinitperiod}{}{}{}{}}%
        {{hash=9a4d3938b52ce74c36efbba638833ed1}{Madera}{M\bibinitperiod}{Martin}{M\bibinitperiod}{}{}{}{}}%
        {{hash=0455dbb54f5f8b6810eacc4653fabbcc}{Maslen}{M\bibinitperiod}{John}{J\bibinitperiod}{}{}{}{}}%
        {{hash=1286b3ab4e9a1d3695545852236fc928}{Mcanulla}{M\bibinitperiod}{Craig}{C\bibinitperiod}{}{}{}{}}%
        {{hash=7954fac33104571b85919358e4bf2ad3}{McDowall}{M\bibinitperiod}{Jennifer}{J\bibinitperiod}{}{}{}{}}%
        {{hash=8ca0b214376f4df31410b35ef1c9fe1d}{Mistry}{M\bibinitperiod}{Jaina}{J\bibinitperiod}{}{}{}{}}%
        {{hash=1f91e7dd8020f782dbfef26202b0be20}{Mitchell}{M\bibinitperiod}{Alex}{A\bibinitperiod}{}{}{}{}}%
        {{hash=b8af15e2018255691770ceb0e69f4993}{Mulder}{M\bibinitperiod}{Nicola}{N\bibinitperiod}{}{}{}{}}%
        {{hash=3c129c48ae7c6572216c11dddccbd601}{Natale}{N\bibinitperiod}{Darren}{D\bibinitperiod}{}{}{}{}}%
        {{hash=bddfe32932b7ca216def972d9c89c31c}{Orengo}{O\bibinitperiod}{Christine}{C\bibinitperiod}{}{}{}{}}%
        {{hash=f1f1b82004db81a90bccbddfa0c38753}{Quinn}{Q\bibinitperiod}{Antony\bibnamedelima F.}{A\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{hash=e2a4bdc6dab085ac91ceff07a8cadc05}{Selengut}{S\bibinitperiod}{Jeremy\bibnamedelima D.}{J\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=fe189056a4a73122866483d01a3cc1d0}{Sigrist}{S\bibinitperiod}{Christian\bibnamedelimb J\bibnamedelima A}{C\bibinitperiod\bibinitdelim J\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=150d07436146618a8d675e6dfd355c06}{Thimma}{T\bibinitperiod}{Manjula}{M\bibinitperiod}{}{}{}{}}%
        {{hash=b059cba4d10ec33a57140580b6c247d0}{Thomas}{T\bibinitperiod}{Paul\bibnamedelima D.}{P\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=4abd71267b7194c5014fc3cef027d93d}{Valentin}{V\bibinitperiod}{Franck}{F\bibinitperiod}{}{}{}{}}%
        {{hash=f7787f6390ae7ef739a0836d9eb8c07a}{Wilson}{W\bibinitperiod}{Derek}{D\bibinitperiod}{}{}{}{}}%
        {{hash=326b210a8fa7b9a4c03903af7b374ee7}{Wu}{W\bibinitperiod}{Cathy\bibnamedelima H.}{C\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=9b8386d82c2d30d29a7c1f6ef50a8373}{Yeats}{Y\bibinitperiod}{Corin}{C\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{38}{}{%
        {{hash=4232913ae552b928ff5101e7d581375f}{Hunter}{H\bibinitperiod}{Sarah}{S\bibinitperiod}{}{}{}{}}%
        {{hash=88e451f539cb133a865445c7b4a72945}{Apweiler}{A\bibinitperiod}{Rolf}{R\bibinitperiod}{}{}{}{}}%
        {{hash=0d2826c48375171a50da9d818710ac95}{Attwood}{A\bibinitperiod}{Teresa\bibnamedelima K.}{T\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=b2ebd3ba772b0e00ce7ff11062d7bb7e}{Bairoch}{B\bibinitperiod}{Amos}{A\bibinitperiod}{}{}{}{}}%
        {{hash=1ced5c37e13ed96f4cb024911c267029}{Bateman}{B\bibinitperiod}{Alex}{A\bibinitperiod}{}{}{}{}}%
        {{hash=8ac693a590925614d5eab4124b16d815}{Binns}{B\bibinitperiod}{David}{D\bibinitperiod}{}{}{}{}}%
        {{hash=e661978528e2df38a8c66036d9e7c3a2}{Bork}{B\bibinitperiod}{Peer}{P\bibinitperiod}{}{}{}{}}%
        {{hash=070cb6ad7a7d5d2d766209c073611eb1}{Das}{D\bibinitperiod}{Ujjwal}{U\bibinitperiod}{}{}{}{}}%
        {{hash=3181a4e63e23edf46ad3a0ab584a861d}{Daugherty}{D\bibinitperiod}{Louise}{L\bibinitperiod}{}{}{}{}}%
        {{hash=a0324e3154f8264b92b921f82b7485ac}{Duquenne}{D\bibinitperiod}{Lauranne}{L\bibinitperiod}{}{}{}{}}%
        {{hash=f0db7057368bb4f4edb12e97a28cbf3b}{Finn}{F\bibinitperiod}{Robert\bibnamedelima D.}{R\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=d555f8ccbc9d14ac20a0f70424b46e75}{Gough}{G\bibinitperiod}{Julian}{J\bibinitperiod}{}{}{}{}}%
        {{hash=c23f9faa75b1688ba9504d8cf32b1bfd}{Haft}{H\bibinitperiod}{Daniel}{D\bibinitperiod}{}{}{}{}}%
        {{hash=284b9e8e35db019d7497fde6cb5b9983}{Hulo}{H\bibinitperiod}{Nicolas}{N\bibinitperiod}{}{}{}{}}%
        {{hash=e703131d4a240ed85e6dc263888115bf}{Kahn}{K\bibinitperiod}{Daniel}{D\bibinitperiod}{}{}{}{}}%
        {{hash=f8ed66e6c7d354ed4455da12896952be}{Kelly}{K\bibinitperiod}{Elizabeth}{E\bibinitperiod}{}{}{}{}}%
        {{hash=8492bc72a9da536e7e9f199a0fc1f4c9}{Laugraud}{L\bibinitperiod}{Aur??lie}{A\bibinitperiod}{}{}{}{}}%
        {{hash=90a16251283487ab24f75284582c22c5}{Letunic}{L\bibinitperiod}{Ivica}{I\bibinitperiod}{}{}{}{}}%
        {{hash=a56293848f9dcd3094d2283c3fc99db3}{Lonsdale}{L\bibinitperiod}{David}{D\bibinitperiod}{}{}{}{}}%
        {{hash=17a3cab6e1f118259eff98d86f83696c}{Lopez}{L\bibinitperiod}{Rodrigo}{R\bibinitperiod}{}{}{}{}}%
        {{hash=9a4d3938b52ce74c36efbba638833ed1}{Madera}{M\bibinitperiod}{Martin}{M\bibinitperiod}{}{}{}{}}%
        {{hash=0455dbb54f5f8b6810eacc4653fabbcc}{Maslen}{M\bibinitperiod}{John}{J\bibinitperiod}{}{}{}{}}%
        {{hash=1286b3ab4e9a1d3695545852236fc928}{Mcanulla}{M\bibinitperiod}{Craig}{C\bibinitperiod}{}{}{}{}}%
        {{hash=7954fac33104571b85919358e4bf2ad3}{McDowall}{M\bibinitperiod}{Jennifer}{J\bibinitperiod}{}{}{}{}}%
        {{hash=8ca0b214376f4df31410b35ef1c9fe1d}{Mistry}{M\bibinitperiod}{Jaina}{J\bibinitperiod}{}{}{}{}}%
        {{hash=1f91e7dd8020f782dbfef26202b0be20}{Mitchell}{M\bibinitperiod}{Alex}{A\bibinitperiod}{}{}{}{}}%
        {{hash=b8af15e2018255691770ceb0e69f4993}{Mulder}{M\bibinitperiod}{Nicola}{N\bibinitperiod}{}{}{}{}}%
        {{hash=3c129c48ae7c6572216c11dddccbd601}{Natale}{N\bibinitperiod}{Darren}{D\bibinitperiod}{}{}{}{}}%
        {{hash=bddfe32932b7ca216def972d9c89c31c}{Orengo}{O\bibinitperiod}{Christine}{C\bibinitperiod}{}{}{}{}}%
        {{hash=f1f1b82004db81a90bccbddfa0c38753}{Quinn}{Q\bibinitperiod}{Antony\bibnamedelima F.}{A\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{hash=e2a4bdc6dab085ac91ceff07a8cadc05}{Selengut}{S\bibinitperiod}{Jeremy\bibnamedelima D.}{J\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=fe189056a4a73122866483d01a3cc1d0}{Sigrist}{S\bibinitperiod}{Christian\bibnamedelimb J\bibnamedelima A}{C\bibinitperiod\bibinitdelim J\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=150d07436146618a8d675e6dfd355c06}{Thimma}{T\bibinitperiod}{Manjula}{M\bibinitperiod}{}{}{}{}}%
        {{hash=b059cba4d10ec33a57140580b6c247d0}{Thomas}{T\bibinitperiod}{Paul\bibnamedelima D.}{P\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=4abd71267b7194c5014fc3cef027d93d}{Valentin}{V\bibinitperiod}{Franck}{F\bibinitperiod}{}{}{}{}}%
        {{hash=f7787f6390ae7ef739a0836d9eb8c07a}{Wilson}{W\bibinitperiod}{Derek}{D\bibinitperiod}{}{}{}{}}%
        {{hash=326b210a8fa7b9a4c03903af7b374ee7}{Wu}{W\bibinitperiod}{Cathy\bibnamedelima H.}{C\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=9b8386d82c2d30d29a7c1f6ef50a8373}{Yeats}{Y\bibinitperiod}{Corin}{C\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{df938e0e62460dd9cefdb865bfd431cb}
      \strng{fullhash}{c8ffd207d43b4a706de7f7ac7aeaf01e}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{InterPro: The integrative protein signature database}}
      \field{isbn}{1362-4962 (Electronic)$\backslash$r0305-1048 (Linking)}
      \field{issn}{03051048}
      \field{journaltitle}{Nucleic Acids Research}
      \field{number}{SUPPL. 1}
      \field{title}{{InterPro: The integrative protein signature database}}
      \field{volume}{37}
      \field{year}{2009}
      \field{pages}{211\bibrangedash 215}
      \verb{doi}
      \verb 10.1093/nar/gkn785
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/gkn785.pdf:pdf
      \endverb
    \endentry
    \entry{Cramer1994}{incollection}{}
      \name{labelname}{1}{}{%
        {{hash=c9fa1cbc09ce354850b917005441be71}{Cramer}{C\bibinitperiod}{Friedrich}{F\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=c9fa1cbc09ce354850b917005441be71}{Cramer}{C\bibinitperiod}{Friedrich}{F\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {John Wiley {\&} Sons, Ltd.}%
      }
      \strng{namehash}{c9fa1cbc09ce354850b917005441be71}
      \strng{fullhash}{c9fa1cbc09ce354850b917005441be71}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Emil Fischer's Lock and Key Hypothesis after 100 years towards a Supracellular Chemistry}}
      \field{booktitle}{Perspectives in Supramolecular Chemistry}
      \field{isbn}{9780470511411}
      \field{title}{{Emil Fischer's Lock and Key Hypothesis after 100 years towards a Supracellular Chemistry}}
      \field{year}{1994}
      \field{pages}{1\bibrangedash 23}
      \verb{doi}
      \verb 10.1002/9780470511411.ch1
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1002/9780470511411.ch1
      \endverb
    \endentry
    \entry{Koshland1959}{article}{}
      \name{labelname}{1}{}{%
        {{hash=f8f7e8410315321d421d14b84914faf4}{Koshland}{K\bibinitperiod}{D\bibnamedelima E}{D\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=f8f7e8410315321d421d14b84914faf4}{Koshland}{K\bibinitperiod}{D\bibnamedelima E}{D\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{2}{%
        {The Wistar Institute of Anatomy}%
        {Biology}%
      }
      \strng{namehash}{f8f7e8410315321d421d14b84914faf4}
      \strng{fullhash}{f8f7e8410315321d421d14b84914faf4}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Enzyme flexibility and enzyme action}}
      \field{issn}{1553-0809}
      \field{journaltitle}{Journal of Cellular and Comparative Physiology}
      \field{month}{12}
      \field{number}{S1}
      \field{title}{{Enzyme flexibility and enzyme action}}
      \field{volume}{54}
      \field{year}{1959}
      \field{pages}{245\bibrangedash 258}
      \verb{doi}
      \verb 10.1002/jcp.1030540420
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1002/jcp.1030540420
      \endverb
    \endentry
    \entry{Monod1965}{article}{}
      \name{labelname}{3}{}{%
        {{hash=2c505e4db5966573609da0412ee1568d}{Monod}{M\bibinitperiod}{Jacque}{J\bibinitperiod}{}{}{}{}}%
        {{hash=4ed7d3878e536a84daaa5e605c7547c3}{Wyman}{W\bibinitperiod}{Jeffries}{J\bibinitperiod}{}{}{}{}}%
        {{hash=d92fb554aa564df22347ceae22fe7221}{Changeux}{C\bibinitperiod}{Jean-Pierre}{J\bibinithyphendelim P\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=2c505e4db5966573609da0412ee1568d}{Monod}{M\bibinitperiod}{Jacque}{J\bibinitperiod}{}{}{}{}}%
        {{hash=4ed7d3878e536a84daaa5e605c7547c3}{Wyman}{W\bibinitperiod}{Jeffries}{J\bibinitperiod}{}{}{}{}}%
        {{hash=d92fb554aa564df22347ceae22fe7221}{Changeux}{C\bibinitperiod}{Jean-Pierre}{J\bibinithyphendelim P\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{ce5ff2a4ea836bfca74c7d4045054c31}
      \strng{fullhash}{ce5ff2a4ea836bfca74c7d4045054c31}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{On the nature of allosteric transitions: A plausible model}}
      \field{issn}{00222836}
      \field{journaltitle}{Journal of Molecular Biology}
      \field{month}{05}
      \field{number}{1}
      \field{title}{{On the nature of allosteric transitions: A plausible model}}
      \field{volume}{12}
      \field{year}{1965}
      \field{pages}{88\bibrangedash 118}
      \verb{doi}
      \verb 10.1016/S0022-2836(65)80285-6
      \endverb
      \verb{url}
      \verb http://www.sciencedirect.com/science/article/pii/S0022283665802856
      \endverb
    \endentry
    \entry{Kitao1998}{article}{}
      \name{labelname}{3}{}{%
        {{hash=4e8a018e6e6fe8c69d308ada76ffd8b7}{Kitao}{K\bibinitperiod}{Akio}{A\bibinitperiod}{}{}{}{}}%
        {{hash=483931f5b0b7f43dab6ab46bfc54189f}{Hayward}{H\bibinitperiod}{Steven}{S\bibinitperiod}{}{}{}{}}%
        {{hash=5fce22464821b5b3e5134afc17d6cd88}{Go}{G\bibinitperiod}{Nobuhiro}{N\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=4e8a018e6e6fe8c69d308ada76ffd8b7}{Kitao}{K\bibinitperiod}{Akio}{A\bibinitperiod}{}{}{}{}}%
        {{hash=483931f5b0b7f43dab6ab46bfc54189f}{Hayward}{H\bibinitperiod}{Steven}{S\bibinitperiod}{}{}{}{}}%
        {{hash=5fce22464821b5b3e5134afc17d6cd88}{Go}{G\bibinitperiod}{Nobuhiro}{N\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Wiley Subscription Services, Inc., A Wiley Company}%
      }
      \strng{namehash}{7e58475201f84e936c0ebed3a041ce3e}
      \strng{fullhash}{7e58475201f84e936c0ebed3a041ce3e}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Energy landscape of a native protein: Jumping among minima model}}
      \field{issn}{1097-0134}
      \field{journaltitle}{Proteins: Structure, Function, and Bioinformatics}
      \field{month}{12}
      \field{number}{4}
      \field{title}{{Energy landscape of a native protein: Jumping among minima model}}
      \field{volume}{33}
      \field{year}{1998}
      \field{pages}{496\bibrangedash 517}
      \verb{doi}
      \verb 10.1002/(SICI)1097-0134(19981201)33:4<496::AID-PROT4>3.0.CO;2-1
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1002/(SICI)1097-0134(19981201)33:4%7B%3C%7D496::AID-PROT4%7B%3E%7D3.0.CO%202-1
      \endverb
    \endentry
    \entry{Petsko1984}{article}{}
      \name{labelname}{2}{}{%
        {{hash=1476d6945186dfdf31bd995b819295a1}{Petsko}{P\bibinitperiod}{G\bibnamedelima A}{G\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=1ec96b11f9665fb1c877ecd5608d8912}{Ringe}{R\bibinitperiod}{D}{D\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=1476d6945186dfdf31bd995b819295a1}{Petsko}{P\bibinitperiod}{G\bibnamedelima A}{G\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=1ec96b11f9665fb1c877ecd5608d8912}{Ringe}{R\bibinitperiod}{D}{D\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Annual Reviews}%
      }
      \strng{namehash}{9b5f7b7d156c9107dfe4f76434f6608f}
      \strng{fullhash}{9b5f7b7d156c9107dfe4f76434f6608f}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Fluctuations in Protein Structure from X-Ray Diffraction}}
      \field{annotation}{doi: 10.1146/annurev.bb.13.060184.001555}
      \field{issn}{0084-6589}
      \field{journaltitle}{Annual Review of Biophysics and Bioengineering}
      \field{month}{06}
      \field{number}{1}
      \field{title}{{Fluctuations in Protein Structure from X-Ray Diffraction}}
      \field{volume}{13}
      \field{year}{1984}
      \field{pages}{331\bibrangedash 371}
      \verb{doi}
      \verb 10.1146/annurev.bb.13.060184.001555
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1146/annurev.bb.13.060184.001555
      \endverb
    \endentry
    \entry{Foote1994}{article}{}
      \name{labelname}{2}{}{%
        {{hash=2b272101783e033fafd5c54f6cd0cd87}{Foote}{F\bibinitperiod}{J}{J\bibinitperiod}{}{}{}{}}%
        {{hash=b0cac038b408d96f8bc86a87be5e1e95}{Milstein}{M\bibinitperiod}{C}{C\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=2b272101783e033fafd5c54f6cd0cd87}{Foote}{F\bibinitperiod}{J}{J\bibinitperiod}{}{}{}{}}%
        {{hash=b0cac038b408d96f8bc86a87be5e1e95}{Milstein}{M\bibinitperiod}{C}{C\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{263aeb0429687da4df891051919f0e95}
      \strng{fullhash}{263aeb0429687da4df891051919f0e95}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Conformational isomerism and the diversity of antibodies.}}
      \field{abstract}{The fact that one cell encodes a single antibody sequence does not necessarily mean that the resulting antibody folds into a single structure, although this is a common assumption. Here we challenge this view and suggest that many antibodies do not have a single conformation at the combining site. The basis for this proposal comes from the kinetic analysis of a set of murine hybridomas derived from defined stages of the immune response to 2-phenyl-5-oxazolone (Ox). Among them we have identified three antibodies that exhibit complex hapten-binding kinetics. We observed biphasic or triphasic reactions in stopped-flow fluorescence experiments, indicating that ligand binding involved isomerization, as well as associative steps. The existence of an equilibrium between at least two antibody conformations, with ligands binding preferentially to one form, was deduced from the variation with hapten concentration of the apparent rate of each phase.}
      \field{issn}{0027-8424}
      \field{journaltitle}{Proceedings of the National Academy of Sciences of the United States of America}
      \field{month}{10}
      \field{number}{22}
      \field{title}{{Conformational isomerism and the diversity of antibodies.}}
      \field{volume}{91}
      \field{year}{1994}
      \field{pages}{10370\bibrangedash 10374}
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC45021/
      \endverb
    \endentry
    \entry{James2003}{article}{}
      \name{labelname}{3}{}{%
        {{hash=3712dfaed00c7d94986d5cf9ac76aa5f}{James}{J\bibinitperiod}{Leo\bibnamedelima C}{L\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=44320ac15125b5ba914c711bfcc388aa}{Roversi}{R\bibinitperiod}{Pietro}{P\bibinitperiod}{}{}{}{}}%
        {{hash=91cd6a4a953369f963f48e0bc013c72d}{Tawfik}{T\bibinitperiod}{Dan\bibnamedelima S}{D\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=3712dfaed00c7d94986d5cf9ac76aa5f}{James}{J\bibinitperiod}{Leo\bibnamedelima C}{L\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=44320ac15125b5ba914c711bfcc388aa}{Roversi}{R\bibinitperiod}{Pietro}{P\bibinitperiod}{}{}{}{}}%
        {{hash=91cd6a4a953369f963f48e0bc013c72d}{Tawfik}{T\bibinitperiod}{Dan\bibnamedelima S}{D\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{2ccea57ab2d9e24bb363b19b680455a8}
      \strng{fullhash}{2ccea57ab2d9e24bb363b19b680455a8}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Antibody Multispecificity Mediated by Conformational Diversity}}
      \field{journaltitle}{Science}
      \field{month}{02}
      \field{number}{5611}
      \field{title}{{Antibody Multispecificity Mediated by Conformational Diversity}}
      \field{volume}{299}
      \field{year}{2003}
      \field{pages}{1362\bibrangedash 1367}
      \verb{url}
      \verb http://science.sciencemag.org/content/299/5611/1362.abstract
      \endverb
    \endentry
    \entry{Dunn2001}{incollection}{}
      \name{labelname}{1}{}{%
        {{hash=46ec57e109a0eb5deef09da9dfe6d092}{Dunn}{D\bibinitperiod}{Michael\bibnamedelima F}{M\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=46ec57e109a0eb5deef09da9dfe6d092}{Dunn}{D\bibinitperiod}{Michael\bibnamedelima F}{M\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {John Wiley {\&} Sons, Ltd}%
      }
      \strng{namehash}{46ec57e109a0eb5deef09da9dfe6d092}
      \strng{fullhash}{46ec57e109a0eb5deef09da9dfe6d092}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Protein-Ligand Interactions: General Description}}
      \field{booktitle}{eLS}
      \field{isbn}{9780470015902}
      \field{title}{{Protein-Ligand Interactions: General Description}}
      \field{year}{2001}
      \verb{doi}
      \verb 10.1038/npg.els.0001340
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1038/npg.els.0001340
      \endverb
    \endentry
    \entry{Michel2009a}{article}{}
      \name{labelname}{3}{}{%
        {{hash=0cfceab6b7b504ed285ed70f6b525631}{Michel}{M\bibinitperiod}{Julien}{J\bibinitperiod}{}{}{}{}}%
        {{hash=fa07f5dac805ae2d3948eb372fed4252}{Tirado-Rives}{T\bibinithyphendelim R\bibinitperiod}{Julian}{J\bibinitperiod}{}{}{}{}}%
        {{hash=c19e67db2cc0994d3900bcf8da4333bc}{Jorgensen}{J\bibinitperiod}{William\bibnamedelima L}{W\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=0cfceab6b7b504ed285ed70f6b525631}{Michel}{M\bibinitperiod}{Julien}{J\bibinitperiod}{}{}{}{}}%
        {{hash=fa07f5dac805ae2d3948eb372fed4252}{Tirado-Rives}{T\bibinithyphendelim R\bibinitperiod}{Julian}{J\bibinitperiod}{}{}{}{}}%
        {{hash=c19e67db2cc0994d3900bcf8da4333bc}{Jorgensen}{J\bibinitperiod}{William\bibnamedelima L}{W\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{c45d5bf953b08e681565b5aed5f55440}
      \strng{fullhash}{c45d5bf953b08e681565b5aed5f55440}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Energetics of Displacing Water Molecules from Protein Binding Sites: Consequences for Ligand Optimization}}
      \field{issn}{0002-7863}
      \field{journaltitle}{Journal of the American Chemical Society}
      \field{month}{10}
      \field{number}{42}
      \field{title}{{Energetics of Displacing Water Molecules from Protein Binding Sites: Consequences for Ligand Optimization}}
      \field{volume}{131}
      \field{year}{2009}
      \field{pages}{15403\bibrangedash 15411}
      \verb{doi}
      \verb 10.1021/ja906058w
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2783447/
      \endverb
    \endentry
    \entry{Ravindranathan2011}{article}{}
      \name{labelname}{4}{}{%
        {{hash=d8e71ece1e236ff5b18f3b2fdb5d3d7b}{Ravindranathan}{R\bibinitperiod}{Krishna}{K\bibinitperiod}{}{}{}{}}%
        {{hash=fa07f5dac805ae2d3948eb372fed4252}{Tirado-Rives}{T\bibinithyphendelim R\bibinitperiod}{Julian}{J\bibinitperiod}{}{}{}{}}%
        {{hash=c19e67db2cc0994d3900bcf8da4333bc}{Jorgensen}{J\bibinitperiod}{William\bibnamedelima L}{W\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=6714b8a850eb66a35c7a0a569b3db536}{Guimar{\~{a}}es}{G\bibinitperiod}{Cristiano\bibnamedelimb R\bibnamedelima W}{C\bibinitperiod\bibinitdelim R\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=d8e71ece1e236ff5b18f3b2fdb5d3d7b}{Ravindranathan}{R\bibinitperiod}{Krishna}{K\bibinitperiod}{}{}{}{}}%
        {{hash=fa07f5dac805ae2d3948eb372fed4252}{Tirado-Rives}{T\bibinithyphendelim R\bibinitperiod}{Julian}{J\bibinitperiod}{}{}{}{}}%
        {{hash=c19e67db2cc0994d3900bcf8da4333bc}{Jorgensen}{J\bibinitperiod}{William\bibnamedelima L}{W\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=6714b8a850eb66a35c7a0a569b3db536}{Guimar{\~{a}}es}{G\bibinitperiod}{Cristiano\bibnamedelimb R\bibnamedelima W}{C\bibinitperiod\bibinitdelim R\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{f1fa3fed6d367a23959254d353414454}
      \strng{fullhash}{808dafe0e66cb9e4321c1114ac7c2e8a}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Improving MM-GB SA Scoring through the Application of the Variable Dielectric Model}}
      \field{abstract}{A variable dielectric model based on residue types for better description of protein-ligand electrostatics in MM-GBSA scoring is reported. The variable dielectric approach provides better correlation with binding data and reduces the score dynamic range, typically observed in the standard MM-GB/SA method. The latter supports the view that exaggerated enthalpic separation between weak and potent compounds due to the lack of shielding effects in the model is greatly responsible for the wide scoring spread.}
      \field{issn}{1549-9618}
      \field{journaltitle}{Journal of chemical theory and computation}
      \field{month}{12}
      \field{number}{12}
      \field{title}{{Improving MM-GB SA Scoring through the Application of the Variable Dielectric Model}}
      \field{volume}{7}
      \field{year}{2011}
      \field{pages}{3859\bibrangedash 3865}
      \verb{doi}
      \verb 10.1021/ct200565u
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3351111/
      \endverb
    \endentry
    \entry{Michel2006}{article}{}
      \name{labelname}{3}{}{%
        {{hash=0cfceab6b7b504ed285ed70f6b525631}{Michel}{M\bibinitperiod}{Julien}{J\bibinitperiod}{}{}{}{}}%
        {{hash=1950e3a3242a1047913c14da60b68015}{Verdonk}{V\bibinitperiod}{Marcel\bibnamedelima L}{M\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=d5933f58df57a2fed80a7bc91e9fdb34}{Essex}{E\bibinitperiod}{Jonathan\bibnamedelima W}{J\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=0cfceab6b7b504ed285ed70f6b525631}{Michel}{M\bibinitperiod}{Julien}{J\bibinitperiod}{}{}{}{}}%
        {{hash=1950e3a3242a1047913c14da60b68015}{Verdonk}{V\bibinitperiod}{Marcel\bibnamedelima L}{M\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=d5933f58df57a2fed80a7bc91e9fdb34}{Essex}{E\bibinitperiod}{Jonathan\bibnamedelima W}{J\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {American Chemical Society}%
      }
      \strng{namehash}{1c60f373ca2302344f96a386c3ea86a1}
      \strng{fullhash}{1c60f373ca2302344f96a386c3ea86a1}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Protein Ligand Binding Affinity Predictions by Implicit Solvent Simulations: A Tool for Lead Optimization}}
      \field{annotation}{doi: 10.1021/jm061021s}
      \field{issn}{0022-2623}
      \field{journaltitle}{Journal of Medicinal Chemistry}
      \field{month}{12}
      \field{number}{25}
      \field{title}{{Protein Ligand Binding Affinity Predictions by Implicit Solvent Simulations: A Tool for Lead Optimization}}
      \field{volume}{49}
      \field{year}{2006}
      \field{pages}{7427\bibrangedash 7439}
      \verb{doi}
      \verb 10.1021/jm061021s
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1021/jm061021s
      \endverb
    \endentry
    \entry{Liu2009}{article}{}
      \name{labelname}{3}{}{%
        {{hash=6aa49f9f28cc919cecad2a76567a5114}{Liu}{L\bibinitperiod}{Hao-Yang}{H\bibinithyphendelim Y\bibinitperiod}{}{}{}{}}%
        {{hash=47adf8eb924c34a05a4f673de9cee38b}{Grinter}{G\bibinitperiod}{Sam\bibnamedelima Z}{S\bibinitperiod\bibinitdelim Z\bibinitperiod}{}{}{}{}}%
        {{hash=d15cbe55cf4442531f4a92a782a22ece}{Zou}{Z\bibinitperiod}{Xiaoqin}{X\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=6aa49f9f28cc919cecad2a76567a5114}{Liu}{L\bibinitperiod}{Hao-Yang}{H\bibinithyphendelim Y\bibinitperiod}{}{}{}{}}%
        {{hash=47adf8eb924c34a05a4f673de9cee38b}{Grinter}{G\bibinitperiod}{Sam\bibnamedelima Z}{S\bibinitperiod\bibinitdelim Z\bibinitperiod}{}{}{}{}}%
        {{hash=d15cbe55cf4442531f4a92a782a22ece}{Zou}{Z\bibinitperiod}{Xiaoqin}{X\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{c9f797fb69980044cd1c83cd47bdfe11}
      \strng{fullhash}{c9f797fb69980044cd1c83cd47bdfe11}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Multiscale generalized Born modeling of ligand binding energies for virtual database screening}}
      \field{issn}{1520-6106}
      \field{journaltitle}{The journal of physical chemistry. B}
      \field{month}{09}
      \field{number}{35}
      \field{title}{{Multiscale generalized Born modeling of ligand binding energies for virtual database screening}}
      \field{volume}{113}
      \field{year}{2009}
      \field{pages}{11793\bibrangedash 11799}
      \verb{doi}
      \verb 10.1021/jp901212t
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2763608/
      \endverb
    \endentry
    \entry{Lu2007}{article}{}
      \name{labelname}{4}{}{%
        {{hash=7af7df921c83cc455a4c4de1e072c4ac}{Lu}{L\bibinitperiod}{Yipin}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=4ab84d11d93fb5236a319ffca24e31ad}{Wang}{W\bibinitperiod}{Renxiao}{R\bibinitperiod}{}{}{}{}}%
        {{hash=bae857a0cb56934c2102ac6ad924f2fb}{Yang}{Y\bibinitperiod}{Chao-Yie}{C\bibinithyphendelim Y\bibinitperiod}{}{}{}{}}%
        {{hash=c5c6a61f0a352dfd208ab4e65ed64df7}{Wang}{W\bibinitperiod}{Shaomeng}{S\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=7af7df921c83cc455a4c4de1e072c4ac}{Lu}{L\bibinitperiod}{Yipin}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=4ab84d11d93fb5236a319ffca24e31ad}{Wang}{W\bibinitperiod}{Renxiao}{R\bibinitperiod}{}{}{}{}}%
        {{hash=bae857a0cb56934c2102ac6ad924f2fb}{Yang}{Y\bibinitperiod}{Chao-Yie}{C\bibinithyphendelim Y\bibinitperiod}{}{}{}{}}%
        {{hash=c5c6a61f0a352dfd208ab4e65ed64df7}{Wang}{W\bibinitperiod}{Shaomeng}{S\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {American Chemical Society}%
      }
      \strng{namehash}{148341607dd551f60a2ae90ae91576c3}
      \strng{fullhash}{f1ceb3a8a3eb0edd73cded4e95e5271a}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Analysis of Ligand-Bound Water Molecules in High-Resolution Crystal Structures of Protein-Ligand Complexes}}
      \field{annotation}{doi: 10.1021/ci6003527}
      \field{issn}{1549-9596}
      \field{journaltitle}{Journal of Chemical Information and Modeling}
      \field{month}{03}
      \field{number}{2}
      \field{title}{{Analysis of Ligand-Bound Water Molecules in High-Resolution Crystal Structures of Protein-Ligand Complexes}}
      \field{volume}{47}
      \field{year}{2007}
      \field{pages}{668\bibrangedash 675}
      \verb{doi}
      \verb 10.1021/ci6003527
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1021/ci6003527
      \endverb
    \endentry
    \entry{Sharp1990}{article}{}
      \name{labelname}{2}{}{%
        {{hash=d45d7d88903e633ac60e4f7ef9ccee81}{Sharp}{S\bibinitperiod}{Kim\bibnamedelima A}{K\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=1d96e1e0a77ad2809933313618d93d17}{Honig}{H\bibinitperiod}{Barry.}{B\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=d45d7d88903e633ac60e4f7ef9ccee81}{Sharp}{S\bibinitperiod}{Kim\bibnamedelima A}{K\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=1d96e1e0a77ad2809933313618d93d17}{Honig}{H\bibinitperiod}{Barry.}{B\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {American Chemical Society}%
      }
      \strng{namehash}{8acd8027f3b2e897de04377c1ec364ce}
      \strng{fullhash}{8acd8027f3b2e897de04377c1ec364ce}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Calculating total electrostatic energies with the nonlinear Poisson-Boltzmann equation}}
      \field{annotation}{doi: 10.1021/j100382a068}
      \field{issn}{0022-3654}
      \field{journaltitle}{The Journal of Physical Chemistry}
      \field{month}{09}
      \field{number}{19}
      \field{title}{{Calculating total electrostatic energies with the nonlinear Poisson-Boltzmann equation}}
      \field{volume}{94}
      \field{year}{1990}
      \field{pages}{7684\bibrangedash 7692}
      \verb{doi}
      \verb 10.1021/j100382a068
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1021/j100382a068
      \endverb
    \endentry
    \entry{Bashford2000}{article}{}
      \name{labelname}{2}{}{%
        {{hash=d5aa9c2314a5d50215a7550ba5dc1fab}{Bashford}{B\bibinitperiod}{Donald}{D\bibinitperiod}{}{}{}{}}%
        {{hash=4d8f9f3e905177579a487e2df19e8b27}{Case}{C\bibinitperiod}{David\bibnamedelima A}{D\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=d5aa9c2314a5d50215a7550ba5dc1fab}{Bashford}{B\bibinitperiod}{Donald}{D\bibinitperiod}{}{}{}{}}%
        {{hash=4d8f9f3e905177579a487e2df19e8b27}{Case}{C\bibinitperiod}{David\bibnamedelima A}{D\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Annual Reviews}%
      }
      \strng{namehash}{250297f747c3e68e467cb6aca100f5be}
      \strng{fullhash}{250297f747c3e68e467cb6aca100f5be}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{GENERALIZED BORN MODELS OF MACROMOLECULAR SOLVATION EFFECTS}}
      \field{annotation}{doi: 10.1146/annurev.physchem.51.1.129}
      \field{issn}{0066-426X}
      \field{journaltitle}{Annual Review of Physical Chemistry}
      \field{month}{10}
      \field{number}{1}
      \field{title}{{GENERALIZED BORN MODELS OF MACROMOLECULAR SOLVATION EFFECTS}}
      \field{volume}{51}
      \field{year}{2000}
      \field{pages}{129\bibrangedash 152}
      \verb{doi}
      \verb 10.1146/annurev.physchem.51.1.129
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1146/annurev.physchem.51.1.129
      \endverb
    \endentry
    \entry{Friesner2004}{article}{}
      \name{labelname}{13}{}{%
        {{hash=d1293cea8ffd0a3608d02a91d7819106}{Friesner}{F\bibinitperiod}{Richard\bibnamedelima A.}{R\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=b7210133fdb29b7248e1b762a3d4e9a6}{Banks}{B\bibinitperiod}{Jay\bibnamedelima L.}{J\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=93227c851ae44852868eb9785c256d4d}{Murphy}{M\bibinitperiod}{Robert\bibnamedelima B.}{R\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=8de40fc87416f72bcef748b942f8e50a}{Halgren}{H\bibinitperiod}{Thomas\bibnamedelima A.}{T\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=fa269921f9343f9b11a9772f83c66efa}{Klicic}{K\bibinitperiod}{Jasna\bibnamedelima J.}{J\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=76bb5d98594a0c8563d7e9aec9c640d6}{Mainz}{M\bibinitperiod}{Daniel\bibnamedelima T.}{D\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=5249e50dc29069a18e2fdb7e293707d0}{Repasky}{R\bibinitperiod}{Matthew\bibnamedelima P.}{M\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=b1b245f78dd9ca0acbfa6f6c82e5db90}{Knoll}{K\bibinitperiod}{Eric\bibnamedelima H.}{E\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=eb40ad6d772a89176a112def5f30c030}{Shelley}{S\bibinitperiod}{Mee}{M\bibinitperiod}{}{}{}{}}%
        {{hash=ae625a89c24572d1d2aa86b4a4ce7c94}{Perry}{P\bibinitperiod}{Jason\bibnamedelima K.}{J\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=d14c2080ec5f9fa3e2c7dad904c9cc89}{Shaw}{S\bibinitperiod}{David\bibnamedelima E.}{D\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=a4a4610ec2e43b70aa3a990de22060ce}{Francis}{F\bibinitperiod}{Perry}{P\bibinitperiod}{}{}{}{}}%
        {{hash=aef3da4748b2d9801d1eff8cc30670c4}{Shenkin}{S\bibinitperiod}{Peter\bibnamedelima S.}{P\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{13}{}{%
        {{hash=d1293cea8ffd0a3608d02a91d7819106}{Friesner}{F\bibinitperiod}{Richard\bibnamedelima A.}{R\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=b7210133fdb29b7248e1b762a3d4e9a6}{Banks}{B\bibinitperiod}{Jay\bibnamedelima L.}{J\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=93227c851ae44852868eb9785c256d4d}{Murphy}{M\bibinitperiod}{Robert\bibnamedelima B.}{R\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=8de40fc87416f72bcef748b942f8e50a}{Halgren}{H\bibinitperiod}{Thomas\bibnamedelima A.}{T\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=fa269921f9343f9b11a9772f83c66efa}{Klicic}{K\bibinitperiod}{Jasna\bibnamedelima J.}{J\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=76bb5d98594a0c8563d7e9aec9c640d6}{Mainz}{M\bibinitperiod}{Daniel\bibnamedelima T.}{D\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=5249e50dc29069a18e2fdb7e293707d0}{Repasky}{R\bibinitperiod}{Matthew\bibnamedelima P.}{M\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=b1b245f78dd9ca0acbfa6f6c82e5db90}{Knoll}{K\bibinitperiod}{Eric\bibnamedelima H.}{E\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=eb40ad6d772a89176a112def5f30c030}{Shelley}{S\bibinitperiod}{Mee}{M\bibinitperiod}{}{}{}{}}%
        {{hash=ae625a89c24572d1d2aa86b4a4ce7c94}{Perry}{P\bibinitperiod}{Jason\bibnamedelima K.}{J\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=d14c2080ec5f9fa3e2c7dad904c9cc89}{Shaw}{S\bibinitperiod}{David\bibnamedelima E.}{D\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=a4a4610ec2e43b70aa3a990de22060ce}{Francis}{F\bibinitperiod}{Perry}{P\bibinitperiod}{}{}{}{}}%
        {{hash=aef3da4748b2d9801d1eff8cc30670c4}{Shenkin}{S\bibinitperiod}{Peter\bibnamedelima S.}{P\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{958b6cb56862ed1d8fb3b4b415e9d4ad}
      \strng{fullhash}{7d4703db8320284ee13fd8f26daedb07}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Glide: A New Approach for Rapid, Accurate Docking and Scoring}}
      \field{abstract}{Unlike other methods for docking ligands to the rigid 3D structure of a known protein receptor, Glide approximates a complete systematic search of the conformational, orientational, and positional space of the docked ligand. In this search, an initial rough positioning and scoring phase that dramatically narrows the search space is followed by torsionally flexible energy optimization on an OPLS-AA nonbonded potential grid for a few hundred surviving candidate poses. The very best candidates are further refined via a Monte Carlo sampling of pose conformation; in some cases, this is crucial to obtaining an accurate docked pose. Selection of the best docked pose uses a model energy function that combines empirical and force-field-based terms. Docking accuracy is assessed by redocking ligands from 282 cocrystallized PDB complexes starting from conformationally optimized ligand geometries that bear no memory of the correctly docked pose. Errors in geometry for the top-ranked pose are less than 1 A in nearly half of the cases and are greater than 2 A in only about one-third of them. Comparisons to published data on rms deviations show that Glide is nearly twice as accurate as GOLD and more than twice as accurate as FlexX for ligands having up to 20 rotatable bonds. Glide is also found to be more accurate than the recently described Surflex method.}
      \field{eprinttype}{arXiv}
      \field{isbn}{0022-2623}
      \field{issn}{00222623}
      \field{journaltitle}{Journal of Medicinal Chemistry}
      \field{number}{7}
      \field{title}{{Glide: A New Approach for Rapid, Accurate Docking and Scoring}}
      \field{volume}{47}
      \field{year}{2004}
      \field{pages}{1739\bibrangedash 1749}
      \verb{doi}
      \verb 10.1021/jm0306430
      \endverb
      \verb{eprint}
      \verb arXiv:1011.1669v3
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/jm0306430.pdf:pdf
      \endverb
    \endentry
    \entry{Steffen2010}{article}{}
      \name{labelname}{6}{}{%
        {{hash=f0200b90cce0c7ed201c36567c484f44}{Steffen}{S\bibinitperiod}{Claudia}{C\bibinitperiod}{}{}{}{}}%
        {{hash=02ba2568b23db03323306bcf110af8f2}{Thomas}{T\bibinitperiod}{Klaus}{K\bibinitperiod}{}{}{}{}}%
        {{hash=e506e505f3239ec54b030e93af7d4dd1}{Huniar}{H\bibinitperiod}{Uwe}{U\bibinitperiod}{}{}{}{}}%
        {{hash=26cb7261125c49065b71e481f2cae976}{Hellweg}{H\bibinitperiod}{Arnim}{A\bibinitperiod}{}{}{}{}}%
        {{hash=bfa810d090d2bb6fc1235b5f7abd5ccc}{Rubner}{R\bibinitperiod}{Oliver}{O\bibinitperiod}{}{}{}{}}%
        {{hash=f31907787de502bf384bbe5b5c8e4d15}{Schroer}{S\bibinitperiod}{Alexander}{A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{6}{}{%
        {{hash=f0200b90cce0c7ed201c36567c484f44}{Steffen}{S\bibinitperiod}{Claudia}{C\bibinitperiod}{}{}{}{}}%
        {{hash=02ba2568b23db03323306bcf110af8f2}{Thomas}{T\bibinitperiod}{Klaus}{K\bibinitperiod}{}{}{}{}}%
        {{hash=e506e505f3239ec54b030e93af7d4dd1}{Huniar}{H\bibinitperiod}{Uwe}{U\bibinitperiod}{}{}{}{}}%
        {{hash=26cb7261125c49065b71e481f2cae976}{Hellweg}{H\bibinitperiod}{Arnim}{A\bibinitperiod}{}{}{}{}}%
        {{hash=bfa810d090d2bb6fc1235b5f7abd5ccc}{Rubner}{R\bibinitperiod}{Oliver}{O\bibinitperiod}{}{}{}{}}%
        {{hash=f31907787de502bf384bbe5b5c8e4d15}{Schroer}{S\bibinitperiod}{Alexander}{A\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{ef5643eef482a6309ddfcbbc92e33e9b}
      \strng{fullhash}{bb15e46f5a2c536a77598498ba074c6a}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{TmoleX a graphical user interface for TURBOMOLE.}}
      \field{abstract}{We herein present the graphical user interface (GUI) TmoleX for the quantum chemical program package TURBOMOLE. TmoleX allows users to execute the complete workflow of a quantum chemical investigation from the initial building of a structure to the visualization of the results in a user friendly graphical front end. The purpose of TmoleX is to make TURBOMOLE easy to use and to provide a high degree of flexibility. Hence, it should be a valuable tool for most users from beginners to experts. The program is developed in Java and runs on Linux, Windows, and Mac platforms. It can be used to run calculations on local desktops as well as on remote computers.}
      \field{eprinttype}{arXiv}
      \field{isbn}{1096-987X}
      \field{issn}{1096-987X}
      \field{journaltitle}{Journal of computational chemistry}
      \field{number}{16}
      \field{title}{{TmoleX a graphical user interface for TURBOMOLE.}}
      \field{volume}{31}
      \field{year}{2010}
      \field{pages}{2967\bibrangedash 2970}
      \verb{doi}
      \verb 10.1002/jcc
      \endverb
      \verb{eprint}
      \verb NIHMS150003
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/277.pdf:pdf
      \endverb
    \endentry
    \entry{Csermely2013}{article}{}
      \name{labelname}{5}{}{%
        {{hash=d54b624e57b038f5da8e8aa7d328d5f1}{Csermely}{C\bibinitperiod}{Peter}{P\bibinitperiod}{}{}{}{}}%
        {{hash=21927bd3d3ef7bd76a9c5c9aed5afe76}{Korcsmros}{K\bibinitperiod}{Tams}{T\bibinitperiod}{}{}{}{}}%
        {{hash=7cf2327f4e582c91594bee4bfa69b341}{Kiss}{K\bibinitperiod}{Huba\bibnamedelimb J\bibnamedelima M}{H\bibinitperiod\bibinitdelim J\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=6557ef9cb3cef4f9d0febc5527188b3f}{London}{L\bibinitperiod}{Gbor}{G\bibinitperiod}{}{}{}{}}%
        {{hash=5df4f003753b6d9cfad61f047a6dab01}{Nussinov}{N\bibinitperiod}{Ruth}{R\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{5}{}{%
        {{hash=d54b624e57b038f5da8e8aa7d328d5f1}{Csermely}{C\bibinitperiod}{Peter}{P\bibinitperiod}{}{}{}{}}%
        {{hash=21927bd3d3ef7bd76a9c5c9aed5afe76}{Korcsmros}{K\bibinitperiod}{Tams}{T\bibinitperiod}{}{}{}{}}%
        {{hash=7cf2327f4e582c91594bee4bfa69b341}{Kiss}{K\bibinitperiod}{Huba\bibnamedelimb J\bibnamedelima M}{H\bibinitperiod\bibinitdelim J\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=6557ef9cb3cef4f9d0febc5527188b3f}{London}{L\bibinitperiod}{Gbor}{G\bibinitperiod}{}{}{}{}}%
        {{hash=5df4f003753b6d9cfad61f047a6dab01}{Nussinov}{N\bibinitperiod}{Ruth}{R\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Elsevier Inc.}%
      }
      \strng{namehash}{129ff8392ff1b456d9c7c15403a12d6f}
      \strng{fullhash}{6fd99be197a52f60871a499b626e7654}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Structure and dynamics of molecular networks: A novel paradigm of drug discovery: A comprehensive review}}
      \field{abstract}{Despite considerable progress in genome- and proteome-based high-throughput screening methods and in rational drug design, the increase in approved drugs in the past decade did not match the increase of drug development costs. Network description and analysis not only give a systems-level understanding of drug action and disease complexity, but can also help to improve the efficiency of drug design. We give a comprehensive assessment of the analytical tools of network topology and dynamics. The state-of-the-art use of chemical similarity, protein structure, protein-protein interaction, signaling, genetic interaction and metabolic networks in the discovery of drug targets is summarized. We propose that network targeting follows two basic strategies. The "central hit strategy" selectively targets central nodes/edges of the flexible networks of infectious agents or cancer cells to kill them. The "network influence strategy" works against other diseases, where an efficient reconfiguration of rigid networks needs to be achieved by targeting the neighbors of central nodes/edges. It is shown how network techniques can help in the identification of single-target, edgetic, multi-target and allo-network drug target candidates. We review the recent boom in network methods helping hit identification, lead selection optimizing drug efficacy, as well as minimizing side-effects and drug toxicity. Successful network-based drug development strategies are shown through the examples of infections, cancer, metabolic diseases, neurodegenerative diseases and aging. Summarizing {>}1200 references we suggest an optimized protocol of network-aided drug development, and provide a list of systems-level hallmarks of drug quality. Finally, we highlight network-related drug development trends helping to achieve these hallmarks by a cohesive, global approach. ?? 2013 Elsevier Inc.}
      \field{eprinttype}{arXiv}
      \field{isbn}{0163-7258}
      \field{issn}{01637258}
      \field{journaltitle}{Pharmacology and Therapeutics}
      \field{number}{3}
      \field{title}{{Structure and dynamics of molecular networks: A novel paradigm of drug discovery: A comprehensive review}}
      \field{volume}{138}
      \field{year}{2013}
      \field{pages}{333\bibrangedash 408}
      \verb{doi}
      \verb 10.1016/j.pharmthera.2013.01.016
      \endverb
      \verb{eprint}
      \verb 1210.0330
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/1-s2.0-S0163725813000284-main.pdf:pdf
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1016/j.pharmthera.2013.01.016
      \endverb
    \endentry
    \entry{prathipati2015}{article}{}
      \name{labelname}{2}{}{%
        {{hash=8700385450dadae64b1eb678712f5dfc}{Prathipati}{P\bibinitperiod}{Philip}{P\bibinitperiod}{}{}{}{}}%
        {{hash=427dd8e854a414f1427f3a59e3dc0bd3}{Mizuguchi}{M\bibinitperiod}{Kenji}{K\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=8700385450dadae64b1eb678712f5dfc}{Prathipati}{P\bibinitperiod}{Philip}{P\bibinitperiod}{}{}{}{}}%
        {{hash=427dd8e854a414f1427f3a59e3dc0bd3}{Mizuguchi}{M\bibinitperiod}{Kenji}{K\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{c4340dbd543cf3ec96416529947c29aa}
      \strng{fullhash}{c4340dbd543cf3ec96416529947c29aa}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Systems Biology Approaches to a Rational Drug Discovery Paradigm}}
      \field{abstract}{Ligand- and structure-based drug design approaches complement phenotypic and target screens, respectively, and are the two major frameworks for guiding early-stage drug discovery efforts. Since the beginning of this century, the advent of the genomic era has presented researchers with a myriad of high throughput biological data (parts lists and their interaction networks) to address efficacy and toxicity, augmenting the traditional ligand- and structure-based approaches. This data rich era has also presented us with challenges related to integrating and analyzing these multi-platform and multi-dimensional datasets and translating them into viable hypotheses. Hence in the present paper, we review these existing approaches to drug discovery research and argue the case for a new systems biology based approach. We present the basic principles and the foundational arguments/underlying assumptions of the systems biology based approaches to drug design. Also discussed are systems biology data types (key entities, their attributes and their relationships with each other, and data models/representations), software and tools used for both retrospective and prospective analysis, and the hypotheses that can be inferred. In addition, we summarize some of the existing resources for a systems biology based drug discovery paradigm (open TG-GATEs, DrugMatrix, CMap and LINCs) in terms of their strengths and limitations.}
      \field{journaltitle}{Current Topics in Medicinal Chemistry}
      \field{number}{9}
      \field{title}{{Systems Biology Approaches to a Rational Drug Discovery Paradigm}}
      \field{volume}{16}
      \field{pages}{1009\bibrangedash 1025}
      \verb{url}
      \verb http://www.ingentaconnect.com/content/ben/ctmc/2016/00000016/00000009/art00012
      \endverb
    \endentry
    \entry{Bento2014}{article}{}
      \name{labelname}{14}{}{%
        {{hash=95ff9989a925f87f836accdd15f930ee}{Bento}{B\bibinitperiod}{A\bibnamedelima Patr{\'{\i}}cia}{A\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=ef090f0c6ff6138278103ca580237c79}{Gaulton}{G\bibinitperiod}{Anna}{A\bibinitperiod}{}{}{}{}}%
        {{hash=26c46675e41f83087572952ccbdfe62c}{Hersey}{H\bibinitperiod}{Anne}{A\bibinitperiod}{}{}{}{}}%
        {{hash=bbdff51456c268530cdc846c556ca68e}{Bellis}{B\bibinitperiod}{Louisa\bibnamedelima J}{L\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=f2013483442290f22126dc84887e4935}{Chambers}{C\bibinitperiod}{Jon}{J\bibinitperiod}{}{}{}{}}%
        {{hash=48f427e0352f9d97eb37585a65f73622}{Davies}{D\bibinitperiod}{Mark}{M\bibinitperiod}{}{}{}{}}%
        {{hash=01c03eabbe420a5ccc38c7cd40b53fc6}{Kr{\"{u}}ger}{K\bibinitperiod}{Felix\bibnamedelima A}{F\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=2f075c18cc8850e81a86667c17e24508}{Light}{L\bibinitperiod}{Yvonne}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=ec7cfcedc898a233332987e1a85bfbcf}{Mak}{M\bibinitperiod}{Lora}{L\bibinitperiod}{}{}{}{}}%
        {{hash=b02717f1abad23d3f3931a27cd38d61d}{McGlinchey}{M\bibinitperiod}{Shaun}{S\bibinitperiod}{}{}{}{}}%
        {{hash=0c091af453037cf6cc5190a176b46209}{Nowotka}{N\bibinitperiod}{Michal}{M\bibinitperiod}{}{}{}{}}%
        {{hash=d0d9d6fafa34670d65fe13aa0977dbe6}{Papadatos}{P\bibinitperiod}{George}{G\bibinitperiod}{}{}{}{}}%
        {{hash=5a34c22daf2cec5307b183940a765c62}{Santos}{S\bibinitperiod}{Rita}{R\bibinitperiod}{}{}{}{}}%
        {{hash=53d44917db2ed8d5ebb266672e3d6189}{Overington}{O\bibinitperiod}{John\bibnamedelima P}{J\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{14}{}{%
        {{hash=95ff9989a925f87f836accdd15f930ee}{Bento}{B\bibinitperiod}{A\bibnamedelima Patr{\'{\i}}cia}{A\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=ef090f0c6ff6138278103ca580237c79}{Gaulton}{G\bibinitperiod}{Anna}{A\bibinitperiod}{}{}{}{}}%
        {{hash=26c46675e41f83087572952ccbdfe62c}{Hersey}{H\bibinitperiod}{Anne}{A\bibinitperiod}{}{}{}{}}%
        {{hash=bbdff51456c268530cdc846c556ca68e}{Bellis}{B\bibinitperiod}{Louisa\bibnamedelima J}{L\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=f2013483442290f22126dc84887e4935}{Chambers}{C\bibinitperiod}{Jon}{J\bibinitperiod}{}{}{}{}}%
        {{hash=48f427e0352f9d97eb37585a65f73622}{Davies}{D\bibinitperiod}{Mark}{M\bibinitperiod}{}{}{}{}}%
        {{hash=01c03eabbe420a5ccc38c7cd40b53fc6}{Kr{\"{u}}ger}{K\bibinitperiod}{Felix\bibnamedelima A}{F\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=2f075c18cc8850e81a86667c17e24508}{Light}{L\bibinitperiod}{Yvonne}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=ec7cfcedc898a233332987e1a85bfbcf}{Mak}{M\bibinitperiod}{Lora}{L\bibinitperiod}{}{}{}{}}%
        {{hash=b02717f1abad23d3f3931a27cd38d61d}{McGlinchey}{M\bibinitperiod}{Shaun}{S\bibinitperiod}{}{}{}{}}%
        {{hash=0c091af453037cf6cc5190a176b46209}{Nowotka}{N\bibinitperiod}{Michal}{M\bibinitperiod}{}{}{}{}}%
        {{hash=d0d9d6fafa34670d65fe13aa0977dbe6}{Papadatos}{P\bibinitperiod}{George}{G\bibinitperiod}{}{}{}{}}%
        {{hash=5a34c22daf2cec5307b183940a765c62}{Santos}{S\bibinitperiod}{Rita}{R\bibinitperiod}{}{}{}{}}%
        {{hash=53d44917db2ed8d5ebb266672e3d6189}{Overington}{O\bibinitperiod}{John\bibnamedelima P}{J\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{52c9e03829d425622c35c53599414b01}
      \strng{fullhash}{e2d1e2fbbd6e1c245c403d434751e5f5}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{The ChEMBL bioactivity database: an update}}
      \field{issn}{0305-1048}
      \field{journaltitle}{Nucleic acids research}
      \field{month}{01}
      \field{number}{Database issue}
      \field{title}{{The ChEMBL bioactivity database: an update}}
      \field{volume}{42}
      \field{year}{2014}
      \field{pages}{D1083\bibrangedash 90}
      \verb{doi}
      \verb 10.1093/nar/gkt1031
      \endverb
      \verb{url}
      \verb http://europepmc.org/articles/PMC3965067
      \endverb
    \endentry
    \entry{Zhu2012a}{article}{}
      \name{labelname}{13}{}{%
        {{hash=c527382ce6a2bdfc4548a1f28e479d85}{Zhu}{Z\bibinitperiod}{Feng}{F\bibinitperiod}{}{}{}{}}%
        {{hash=d7cede02af5ba10feb48d4309c5f06dd}{Shi}{S\bibinitperiod}{Zhe}{Z\bibinitperiod}{}{}{}{}}%
        {{hash=5a9f53dda42b5b759ecf58ae8ca52191}{Qin}{Q\bibinitperiod}{Chu}{C\bibinitperiod}{}{}{}{}}%
        {{hash=c879b58bfbb585f308159c96a3e6c234}{Tao}{T\bibinitperiod}{Lin}{L\bibinitperiod}{}{}{}{}}%
        {{hash=4f1e33032cdd17c1c4c17fe05bd0772d}{Liu}{L\bibinitperiod}{Xin}{X\bibinitperiod}{}{}{}{}}%
        {{hash=7b489e462941f869f448a19abc85df4b}{Xu}{X\bibinitperiod}{Feng}{F\bibinitperiod}{}{}{}{}}%
        {{hash=32a08717e0d6dcde59bc98b96800ed6c}{Zhang}{Z\bibinitperiod}{Li}{L\bibinitperiod}{}{}{}{}}%
        {{hash=7dacbb5a6e92ab16944d46ba03705563}{Song}{S\bibinitperiod}{Yang}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=fb4c22e0b090d2ed34486344670fbcf6}{Liu}{L\bibinitperiod}{Xianghui}{X\bibinitperiod}{}{}{}{}}%
        {{hash=74060cf382134f36b5ad81a18b247ff7}{Zhang}{Z\bibinitperiod}{Jingxian}{J\bibinitperiod}{}{}{}{}}%
        {{hash=9887eb306f0532aca8eee77da4783f20}{Han}{H\bibinitperiod}{Bucong}{B\bibinitperiod}{}{}{}{}}%
        {{hash=f189b293bd3263254702f8c5fe1d714b}{Zhang}{Z\bibinitperiod}{Peng}{P\bibinitperiod}{}{}{}{}}%
        {{hash=5b8d30ffe6c857e26131901598abfc5a}{Chen}{C\bibinitperiod}{Yuzong}{Y\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{13}{}{%
        {{hash=c527382ce6a2bdfc4548a1f28e479d85}{Zhu}{Z\bibinitperiod}{Feng}{F\bibinitperiod}{}{}{}{}}%
        {{hash=d7cede02af5ba10feb48d4309c5f06dd}{Shi}{S\bibinitperiod}{Zhe}{Z\bibinitperiod}{}{}{}{}}%
        {{hash=5a9f53dda42b5b759ecf58ae8ca52191}{Qin}{Q\bibinitperiod}{Chu}{C\bibinitperiod}{}{}{}{}}%
        {{hash=c879b58bfbb585f308159c96a3e6c234}{Tao}{T\bibinitperiod}{Lin}{L\bibinitperiod}{}{}{}{}}%
        {{hash=4f1e33032cdd17c1c4c17fe05bd0772d}{Liu}{L\bibinitperiod}{Xin}{X\bibinitperiod}{}{}{}{}}%
        {{hash=7b489e462941f869f448a19abc85df4b}{Xu}{X\bibinitperiod}{Feng}{F\bibinitperiod}{}{}{}{}}%
        {{hash=32a08717e0d6dcde59bc98b96800ed6c}{Zhang}{Z\bibinitperiod}{Li}{L\bibinitperiod}{}{}{}{}}%
        {{hash=7dacbb5a6e92ab16944d46ba03705563}{Song}{S\bibinitperiod}{Yang}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=fb4c22e0b090d2ed34486344670fbcf6}{Liu}{L\bibinitperiod}{Xianghui}{X\bibinitperiod}{}{}{}{}}%
        {{hash=74060cf382134f36b5ad81a18b247ff7}{Zhang}{Z\bibinitperiod}{Jingxian}{J\bibinitperiod}{}{}{}{}}%
        {{hash=9887eb306f0532aca8eee77da4783f20}{Han}{H\bibinitperiod}{Bucong}{B\bibinitperiod}{}{}{}{}}%
        {{hash=f189b293bd3263254702f8c5fe1d714b}{Zhang}{Z\bibinitperiod}{Peng}{P\bibinitperiod}{}{}{}{}}%
        {{hash=5b8d30ffe6c857e26131901598abfc5a}{Chen}{C\bibinitperiod}{Yuzong}{Y\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Oxford University Press}%
      }
      \strng{namehash}{a01d75b0f79d0fd687dc7c4961e4ff4e}
      \strng{fullhash}{0810e2df3544a4fdfe343f0a738a922c}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery}}
      \field{abstract}{Knowledge and investigation of therapeutic targets (responsible for drug efficacy) and the targeted drugs facilitate target and drug discovery and validation. Therapeutic Target Database (TTD, http://bidd.nus.edu.sg/group/ttd/ttd.asp) has been developed to provide comprehensive information about efficacy targets and the corresponding approved, clinical trial and investigative drugs. Since its last update, major improvements and updates have been made to TTD. In addition to the significant increase of data content (from 1894 targets and 5028 drugs to 2025 targets and 17\x{2009}816 drugs), we added target validation information (drug potency against target, effect against disease models and effect of target knockout, knockdown or genetic variations) for 932 targets, and 841 quantitative structure activity relationship models for active compounds of 228 chemical types against 121 targets. Moreover, we added the data from our previous drug studies including 3681 multi-target agents against 108 target pairs, 116 drug combinations with their synergistic, additive, antagonistic, potentiative or reductive mechanisms, 1427 natural product-derived approved, clinical trial and pre-clinical drugs and cross-links to the clinical trial information page in the ClinicalTrials.gov database for 770 clinical trial drugs. These updates are useful for facilitating target discovery and validation, drug lead discovery and optimization, and the development of multi-target drugs and drug combinations.}
      \field{issn}{0305-1048}
      \field{journaltitle}{Nucleic Acids Research}
      \field{month}{01}
      \field{number}{Database issue}
      \field{title}{{Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery}}
      \field{volume}{40}
      \field{year}{2012}
      \field{pages}{D1128\bibrangedash D1136}
      \verb{doi}
      \verb 10.1093/nar/gkr797
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3245130/
      \endverb
    \endentry
    \entry{Hu2005}{article}{}
      \name{labelname}{5}{}{%
        {{hash=ef9dd8fe86cd22d7d1773bd23067921a}{Hu}{H\bibinitperiod}{Liegi}{L\bibinitperiod}{}{}{}{}}%
        {{hash=d52e68ba646f66e80500383fab929c6c}{Benson}{B\bibinitperiod}{Mark\bibnamedelima L}{M\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=ce98a703a81a0863e1ec0a89210327f2}{Smith}{S\bibinitperiod}{Richard\bibnamedelima D}{R\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=fd6f7744f9ba408fd1be6d9669e3b695}{Lerner}{L\bibinitperiod}{Michael\bibnamedelima G}{M\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=c09e5daf6c7da2989e1eb4f4394d6b1e}{Carlson}{C\bibinitperiod}{Heather\bibnamedelima a}{H\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{5}{}{%
        {{hash=ef9dd8fe86cd22d7d1773bd23067921a}{Hu}{H\bibinitperiod}{Liegi}{L\bibinitperiod}{}{}{}{}}%
        {{hash=d52e68ba646f66e80500383fab929c6c}{Benson}{B\bibinitperiod}{Mark\bibnamedelima L}{M\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=ce98a703a81a0863e1ec0a89210327f2}{Smith}{S\bibinitperiod}{Richard\bibnamedelima D}{R\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=fd6f7744f9ba408fd1be6d9669e3b695}{Lerner}{L\bibinitperiod}{Michael\bibnamedelima G}{M\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=c09e5daf6c7da2989e1eb4f4394d6b1e}{Carlson}{C\bibinitperiod}{Heather\bibnamedelima a}{H\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{a87d083a97f95c4c75dc01f5d9b2fa1a}
      \strng{fullhash}{7914cb502efc76c8aa5f6e2fa2ad3294}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Binding MOAD (Mother Of All Databases).}}
      \field{abstract}{Binding MOAD (Mother of All Databases) is the largest collection of high-quality, protein-ligand complexes available from the Protein Data Bank. At this time, Binding MOAD contains 5331 protein-ligand complexes comprised of 1780 unique protein families and 2630 unique ligands. We have searched the crystallography papers for all 5000+ structures and compiled binding data for 1375 (26{\%}) of the protein-ligand complexes. The binding-affinity data ranges 13 orders of magnitude. This is the largest collection of binding data reported to date in the literature. We have also addressed the issue of redundancy in the data. To create a nonredundant dataset, one protein from each of the 1780 protein families was chosen as a representative. Representatives were chosen by tightest binding, best resolution, etc. For the 1780 "best" complexes that comprise the nonredundant version of Binding MOAD, 475 (27{\%}) have binding data. This significant collection of protein-ligand complexes will be very useful in elucidating the biophysical patterns of molecular recognition and enzymatic regulation. The complexes with binding-affinity data will help in the development of improved scoring functions and structure-based drug discovery techniques. The dataset can be accessed at http://www.BindingMOAD.org.}
      \field{issn}{1097-0134}
      \field{journaltitle}{Proteins}
      \field{month}{08}
      \field{number}{3}
      \field{title}{{Binding MOAD (Mother Of All Databases).}}
      \field{volume}{60}
      \field{year}{2005}
      \field{pages}{333\bibrangedash 40}
      \verb{doi}
      \verb 10.1002/prot.20512
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Hu et al. - 2005 - Binding MOAD (Mother Of All Databases).pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/15971202
      \endverb
    \endentry
    \entry{Liu2007}{article}{}
      \name{labelname}{5}{}{%
        {{hash=7433e3fa80fd3d4838fc6e0b0af5b9cc}{Liu}{L\bibinitperiod}{Tiqing}{T\bibinitperiod}{}{}{}{}}%
        {{hash=a3872d9500c273cabec4a3b50f18dec8}{Lin}{L\bibinitperiod}{Yuhmei}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=9494e496566b0e2237ecf0c82781bae2}{Wen}{W\bibinitperiod}{Xin}{X\bibinitperiod}{}{}{}{}}%
        {{hash=8403fbc76c8802a3fe88cc7c34e86d4f}{Jorissen}{J\bibinitperiod}{Robert\bibnamedelima N}{R\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
        {{hash=850fbb308817a3e08f16b6b51602269c}{Gilson}{G\bibinitperiod}{Michael\bibnamedelima K}{M\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{5}{}{%
        {{hash=7433e3fa80fd3d4838fc6e0b0af5b9cc}{Liu}{L\bibinitperiod}{Tiqing}{T\bibinitperiod}{}{}{}{}}%
        {{hash=a3872d9500c273cabec4a3b50f18dec8}{Lin}{L\bibinitperiod}{Yuhmei}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=9494e496566b0e2237ecf0c82781bae2}{Wen}{W\bibinitperiod}{Xin}{X\bibinitperiod}{}{}{}{}}%
        {{hash=8403fbc76c8802a3fe88cc7c34e86d4f}{Jorissen}{J\bibinitperiod}{Robert\bibnamedelima N}{R\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
        {{hash=850fbb308817a3e08f16b6b51602269c}{Gilson}{G\bibinitperiod}{Michael\bibnamedelima K}{M\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Oxford University Press}%
      }
      \strng{namehash}{1afb7c1714b22c94c9791bdd67ea533b}
      \strng{fullhash}{b2b37650f574e74445de7a7a3613c788}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{BindingDB: a web-accessible database of experimentally determined protein--ligand binding affinities}}
      \field{abstract}{BindingDB () is a publicly accessible database currently containing \x{223c}20\x{2009}000 experimentally determined binding affinities of protein--ligand complexes, for 110 protein targets including isoforms and mutational variants, and \x{223c}11\x{2009}000 small molecule ligands. The data are extracted from the scientific literature, data collection focusing on proteins that are drug-targets or candidate drug-targets and for which structural data are present in the Protein Data Bank. The BindingDB website supports a range of query types, including searches by chemical structure, substructure and similarity; protein sequence; ligand and protein names; affinity ranges and molecular weight. Data sets generated by BindingDB queries can be downloaded in the form of annotated SDfiles for further analysis, or used as the basis for virtual screening of a compound database uploaded by the user. The data in BindingDB are linked both to structural data in the PDB via PDB IDs and chemical and sequence searches, and to the literature in PubMed via PubMed IDs.}
      \field{issn}{0305-1048}
      \field{journaltitle}{Nucleic Acids Research}
      \field{month}{01}
      \field{number}{Database issue}
      \field{title}{{BindingDB: a web-accessible database of experimentally determined protein--ligand binding affinities}}
      \field{volume}{35}
      \field{year}{2007}
      \field{pages}{D198\bibrangedash D201}
      \verb{doi}
      \verb 10.1093/nar/gkl999
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1751547/
      \endverb
    \endentry
    \entry{Kim2016}{article}{}
      \name{labelname}{14}{}{%
        {{hash=03fd2567460f66228ee7a405a947f9b5}{Kim}{K\bibinitperiod}{Sunghwan}{S\bibinitperiod}{}{}{}{}}%
        {{hash=1f5fafc5dbbd3ca99d5f8dc5888d11c6}{Thiessen}{T\bibinitperiod}{Paul\bibnamedelima A}{P\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=3027a54196efa284df3d27b56180e4ef}{Bolton}{B\bibinitperiod}{Evan\bibnamedelima E}{E\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=f12458352bf48d8ebe2ba46b11310c19}{Chen}{C\bibinitperiod}{Jie}{J\bibinitperiod}{}{}{}{}}%
        {{hash=213a62ce5c316d5c0e7389e9440f1c9b}{Fu}{F\bibinitperiod}{Gang}{G\bibinitperiod}{}{}{}{}}%
        {{hash=06d44bae1ca2d0d4da9e5e271fca4dc3}{Gindulyte}{G\bibinitperiod}{Asta}{A\bibinitperiod}{}{}{}{}}%
        {{hash=a15423f068081a7a507e9c3e831edf4a}{Han}{H\bibinitperiod}{Lianyi}{L\bibinitperiod}{}{}{}{}}%
        {{hash=3da461cd3979f8980d1f0705330de22f}{He}{H\bibinitperiod}{Jane}{J\bibinitperiod}{}{}{}{}}%
        {{hash=e0d752ea39e238941a430432bc1fbe0e}{He}{H\bibinitperiod}{Siqian}{S\bibinitperiod}{}{}{}{}}%
        {{hash=697bf0d3621c45b573d759f72b6e28a0}{Shoemaker}{S\bibinitperiod}{Benjamin\bibnamedelima A}{B\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=b6e8cb3a4bf918cb95447db412013a03}{Wang}{W\bibinitperiod}{Jiyao}{J\bibinitperiod}{}{}{}{}}%
        {{hash=acae0d16fe2fdc8a53507106044e646c}{Yu}{Y\bibinitperiod}{Bo}{B\bibinitperiod}{}{}{}{}}%
        {{hash=112faefb37293f52cd92c3bb36fcc08b}{Zhang}{Z\bibinitperiod}{Jian}{J\bibinitperiod}{}{}{}{}}%
        {{hash=16f15656f80743960f12e4414e72d477}{Bryant}{B\bibinitperiod}{Stephen\bibnamedelima H}{S\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{14}{}{%
        {{hash=03fd2567460f66228ee7a405a947f9b5}{Kim}{K\bibinitperiod}{Sunghwan}{S\bibinitperiod}{}{}{}{}}%
        {{hash=1f5fafc5dbbd3ca99d5f8dc5888d11c6}{Thiessen}{T\bibinitperiod}{Paul\bibnamedelima A}{P\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=3027a54196efa284df3d27b56180e4ef}{Bolton}{B\bibinitperiod}{Evan\bibnamedelima E}{E\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=f12458352bf48d8ebe2ba46b11310c19}{Chen}{C\bibinitperiod}{Jie}{J\bibinitperiod}{}{}{}{}}%
        {{hash=213a62ce5c316d5c0e7389e9440f1c9b}{Fu}{F\bibinitperiod}{Gang}{G\bibinitperiod}{}{}{}{}}%
        {{hash=06d44bae1ca2d0d4da9e5e271fca4dc3}{Gindulyte}{G\bibinitperiod}{Asta}{A\bibinitperiod}{}{}{}{}}%
        {{hash=a15423f068081a7a507e9c3e831edf4a}{Han}{H\bibinitperiod}{Lianyi}{L\bibinitperiod}{}{}{}{}}%
        {{hash=3da461cd3979f8980d1f0705330de22f}{He}{H\bibinitperiod}{Jane}{J\bibinitperiod}{}{}{}{}}%
        {{hash=e0d752ea39e238941a430432bc1fbe0e}{He}{H\bibinitperiod}{Siqian}{S\bibinitperiod}{}{}{}{}}%
        {{hash=697bf0d3621c45b573d759f72b6e28a0}{Shoemaker}{S\bibinitperiod}{Benjamin\bibnamedelima A}{B\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=b6e8cb3a4bf918cb95447db412013a03}{Wang}{W\bibinitperiod}{Jiyao}{J\bibinitperiod}{}{}{}{}}%
        {{hash=acae0d16fe2fdc8a53507106044e646c}{Yu}{Y\bibinitperiod}{Bo}{B\bibinitperiod}{}{}{}{}}%
        {{hash=112faefb37293f52cd92c3bb36fcc08b}{Zhang}{Z\bibinitperiod}{Jian}{J\bibinitperiod}{}{}{}{}}%
        {{hash=16f15656f80743960f12e4414e72d477}{Bryant}{B\bibinitperiod}{Stephen\bibnamedelima H}{S\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{abaf1427cf681c4ae7181842fbd523c2}
      \strng{fullhash}{41f2f5838e09d4a8fc45813860ceada8}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{PubChem Substance and Compound databases}}
      \field{abstract}{PubChem (https://pubchem.ncbi.nlm.nih.gov) is a public repository for information on chemical substances and their biological activities, launched in 2004 as a component of the Molecular Libraries Roadmap Initiatives of the US National Institutes of Health (NIH). For the past 11 years, PubChem has grown to a sizable system, serving as a chemical information resource for the scientific research community. PubChem consists of three inter-linked databases, Substance, Compound and BioAssay. The Substance database contains chemical information deposited by individual data contributors to PubChem, and the Compound database stores unique chemical structures extracted from the Substance database. Biological activity data of chemical substances tested in assay experiments are contained in the BioAssay database. This paper provides an overview of the PubChem Substance and Compound databases, including data sources and contents, data organization, data submission using PubChem Upload, chemical structure standardization, web-based interfaces for textual and non-textual searches, and programmatic access. It also gives a brief description of PubChem3D, a resource derived from theoretical three-dimensional structures of compounds in PubChem, as well as PubChemRDF, Resource Description Framework (RDF)-formatted PubChem data for data sharing, analysis and integration with information contained in other databases.}
      \field{annotation}{10.1093/nar/gkv951}
      \field{journaltitle}{Nucleic Acids Research}
      \field{month}{01}
      \field{number}{D1}
      \field{title}{{PubChem Substance and Compound databases}}
      \field{volume}{44}
      \field{year}{2016}
      \field{pages}{D1202\bibrangedash D1213}
      \verb{doi}
      \verb 10.1093/nar/gkv951
      \endverb
      \verb{url}
      \verb http://nar.oxfordjournals.org/content/44/D1/D1202.abstract
      \endverb
    \endentry
    \entry{Wang2014}{article}{}
      \name{labelname}{9}{}{%
        {{hash=51d6921349f3514f95ec5892d20fc20a}{Wang}{W\bibinitperiod}{Yanli}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=2d981543ac40b7dfe8b9fcf6cebc6ce9}{Suzek}{S\bibinitperiod}{Tugba}{T\bibinitperiod}{}{}{}{}}%
        {{hash=112faefb37293f52cd92c3bb36fcc08b}{Zhang}{Z\bibinitperiod}{Jian}{J\bibinitperiod}{}{}{}{}}%
        {{hash=b6e8cb3a4bf918cb95447db412013a03}{Wang}{W\bibinitperiod}{Jiyao}{J\bibinitperiod}{}{}{}{}}%
        {{hash=e0d752ea39e238941a430432bc1fbe0e}{He}{H\bibinitperiod}{Siqian}{S\bibinitperiod}{}{}{}{}}%
        {{hash=6695a445237a5fda0e23ec879f8c15ab}{Cheng}{C\bibinitperiod}{Tiejun}{T\bibinitperiod}{}{}{}{}}%
        {{hash=697bf0d3621c45b573d759f72b6e28a0}{Shoemaker}{S\bibinitperiod}{Benjamin\bibnamedelima A}{B\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=06d44bae1ca2d0d4da9e5e271fca4dc3}{Gindulyte}{G\bibinitperiod}{Asta}{A\bibinitperiod}{}{}{}{}}%
        {{hash=16f15656f80743960f12e4414e72d477}{Bryant}{B\bibinitperiod}{Stephen\bibnamedelima H}{S\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{9}{}{%
        {{hash=51d6921349f3514f95ec5892d20fc20a}{Wang}{W\bibinitperiod}{Yanli}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=2d981543ac40b7dfe8b9fcf6cebc6ce9}{Suzek}{S\bibinitperiod}{Tugba}{T\bibinitperiod}{}{}{}{}}%
        {{hash=112faefb37293f52cd92c3bb36fcc08b}{Zhang}{Z\bibinitperiod}{Jian}{J\bibinitperiod}{}{}{}{}}%
        {{hash=b6e8cb3a4bf918cb95447db412013a03}{Wang}{W\bibinitperiod}{Jiyao}{J\bibinitperiod}{}{}{}{}}%
        {{hash=e0d752ea39e238941a430432bc1fbe0e}{He}{H\bibinitperiod}{Siqian}{S\bibinitperiod}{}{}{}{}}%
        {{hash=6695a445237a5fda0e23ec879f8c15ab}{Cheng}{C\bibinitperiod}{Tiejun}{T\bibinitperiod}{}{}{}{}}%
        {{hash=697bf0d3621c45b573d759f72b6e28a0}{Shoemaker}{S\bibinitperiod}{Benjamin\bibnamedelima A}{B\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=06d44bae1ca2d0d4da9e5e271fca4dc3}{Gindulyte}{G\bibinitperiod}{Asta}{A\bibinitperiod}{}{}{}{}}%
        {{hash=16f15656f80743960f12e4414e72d477}{Bryant}{B\bibinitperiod}{Stephen\bibnamedelima H}{S\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Oxford University Press}%
      }
      \strng{namehash}{370f88cf498160f6ce133b0b20ee3778}
      \strng{fullhash}{032789d7c8490b71f0ab59fdaf37b474}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{PubChem BioAssay: 2014 update}}
      \field{abstract}{PubChem's BioAssay database (http://pubchem.ncbi.nlm.nih.gov) is a public repository for archiving biological tests of small molecules generated through high-throughput screening experiments, medicinal chemistry studies, chemical biology research and drug discovery programs. In addition, the BioAssay database contains data from high-throughput RNA interference screening aimed at identifying critical genes responsible for a biological process or disease condition. The mission of PubChem is to serve the community by providing free and easy access to all deposited data. To this end, PubChem BioAssay is integrated into the National Center for Biotechnology Information retrieval system, making them searchable by Entrez queries and cross-linked to other biomedical information archived at National Center for Biotechnology Information. Moreover, PubChem BioAssay provides web-based and programmatic tools allowing users to search, access and analyze bioassay test results and metadata. In this work, we provide an update for the PubChem BioAssay resource, such as information content growth, new developments supporting data integration and search, and the recently deployed PubChem Upload to streamline chemical structure and bioassay submissions.}
      \field{issn}{0305-1048}
      \field{journaltitle}{Nucleic Acids Research}
      \field{month}{01}
      \field{number}{Database issue}
      \field{title}{{PubChem BioAssay: 2014 update}}
      \field{volume}{42}
      \field{year}{2014}
      \field{pages}{D1075\bibrangedash D1082}
      \verb{doi}
      \verb 10.1093/nar/gkt978
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3965008/
      \endverb
    \endentry
    \entry{Irwin2012}{article}{}
      \name{labelname}{5}{}{%
        {{hash=7b74817dd0fa7af0c4a9b1281fb251c4}{Irwin}{I\bibinitperiod}{John\bibnamedelima J}{J\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=1d62ad764ccb3d47cb78bde11bbf44fc}{Sterling}{S\bibinitperiod}{Teague}{T\bibinitperiod}{}{}{}{}}%
        {{hash=e44925a0755085539287a089d962cf31}{Mysinger}{M\bibinitperiod}{Michael\bibnamedelima M}{M\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=20b1c7f5ec87097efbd4c645a63e035f}{Bolstad}{B\bibinitperiod}{Erin\bibnamedelima S}{E\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=721483d264b0eebd22c8d7754e1bd898}{Coleman}{C\bibinitperiod}{Ryan\bibnamedelima G}{R\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{5}{}{%
        {{hash=7b74817dd0fa7af0c4a9b1281fb251c4}{Irwin}{I\bibinitperiod}{John\bibnamedelima J}{J\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=1d62ad764ccb3d47cb78bde11bbf44fc}{Sterling}{S\bibinitperiod}{Teague}{T\bibinitperiod}{}{}{}{}}%
        {{hash=e44925a0755085539287a089d962cf31}{Mysinger}{M\bibinitperiod}{Michael\bibnamedelima M}{M\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=20b1c7f5ec87097efbd4c645a63e035f}{Bolstad}{B\bibinitperiod}{Erin\bibnamedelima S}{E\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=721483d264b0eebd22c8d7754e1bd898}{Coleman}{C\bibinitperiod}{Ryan\bibnamedelima G}{R\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {American Chemical Society}%
      }
      \strng{namehash}{c8793a7809366b5fb3fc9811e90d3619}
      \strng{fullhash}{4ebf734cdd61a3fbe265c6e7d7052934}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{ZINC: A Free Tool to Discover Chemistry for Biology}}
      \field{annotation}{doi: 10.1021/ci3001277}
      \field{issn}{1549-9596}
      \field{journaltitle}{Journal of Chemical Information and Modeling}
      \field{month}{07}
      \field{number}{7}
      \field{title}{{ZINC: A Free Tool to Discover Chemistry for Biology}}
      \field{volume}{52}
      \field{year}{2012}
      \field{pages}{1757\bibrangedash 1768}
      \verb{doi}
      \verb 10.1021/ci3001277
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1021/ci3001277
      \endverb
    \endentry
    \entry{Alonso2006}{article}{}
      \name{labelname}{3}{}{%
        {{hash=16449e4444ae8019c5981d6bf8b71daf}{Alonso}{A\bibinitperiod}{Hern{\'{a}}n}{H\bibinitperiod}{}{}{}{}}%
        {{hash=5258d97ecb19feb40752e1ad8779abfa}{Bliznyuk}{B\bibinitperiod}{Andrey\bibnamedelima A.}{A\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=b14503906adf5d4bb5c59fc0c85f2f74}{Gready}{G\bibinitperiod}{Jill\bibnamedelima E.}{J\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=16449e4444ae8019c5981d6bf8b71daf}{Alonso}{A\bibinitperiod}{Hern{\'{a}}n}{H\bibinitperiod}{}{}{}{}}%
        {{hash=5258d97ecb19feb40752e1ad8779abfa}{Bliznyuk}{B\bibinitperiod}{Andrey\bibnamedelima A.}{A\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=b14503906adf5d4bb5c59fc0c85f2f74}{Gready}{G\bibinitperiod}{Jill\bibnamedelima E.}{J\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{6454e718290aafe1833903ce9cd08121}
      \strng{fullhash}{6454e718290aafe1833903ce9cd08121}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Combining docking and molecular dynamic simulations in drug design}}
      \field{abstract}{A rational approach is needed to maximize the chances of finding new drugs, and to exploit the opportunities of potential new drug targets emerging from genomic and proteomic initiatives, and from the large libraries of small compounds now readily available through combinatorial chemistry. Despite a shaky early history, computer-aided drug design techniques can now be effective in reducing costs and speeding up drug discovery. This happy outcome results from development of more accurate and reliable algorithms, use of more thoughtfully planned strategies to apply them, and greatly increased computer power to allow studies with the necessary reliability to be performed. Our review focuses on applications and protocols, with the main emphasis on critical analysis of recent studies where docking calculations and molecular dynamics (MD) simulations were combined to dock small molecules into protein receptors. We highlight successes to demonstrate what is possible now, but also point out drawbacks and future directions. The review is structured to lead the reader from the simpler to more compute-intensive methods. Thus, while inexpensive and fast docking algorithms can be used to scan large compound libraries and reduce their size, more accurate but expensive MD simulations can be applied when a few selected ligand candidates remain. MD simulations can be used: during the preparation of the protein receptor before docking, to optimize its structure and account for protein flexibility; for the refinement of docked complexes, to include solvent effects and account for induced fit; to calculate binding free energies, to provide an accurate ranking of the potential ligands; and in the latest developments, during the docking process itself to find the binding site and correctly dock the ligand a priori.}
      \field{isbn}{0198-6325}
      \field{issn}{01986325}
      \field{journaltitle}{Medicinal Research Reviews}
      \field{number}{5}
      \field{title}{{Combining docking and molecular dynamic simulations in drug design}}
      \field{volume}{26}
      \field{year}{2006}
      \field{pages}{531\bibrangedash 568}
      \verb{doi}
      \verb 10.1002/med.20067
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/20067{\_}ftp.pdf:pdf
      \endverb
    \endentry
    \entry{Morris2009}{article}{}
      \name{labelname}{7}{}{%
        {{hash=03875878cdd3ca1814f4d19b2b707378}{Morris}{M\bibinitperiod}{Garrett\bibnamedelima M}{G\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=abfe839ffd42235f7ccf52fd38c70880}{Huey}{H\bibinitperiod}{Ruth}{R\bibinitperiod}{}{}{}{}}%
        {{hash=7ce3f604e3542482b2e574077c087c59}{Lindstrom}{L\bibinitperiod}{William}{W\bibinitperiod}{}{}{}{}}%
        {{hash=3dfc8441c51c12ddc628b0f54cfbae9c}{Sanner}{S\bibinitperiod}{Michel\bibnamedelima F}{M\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{hash=a96e4886230504267de9e02ab5572d86}{Belew}{B\bibinitperiod}{Richard\bibnamedelima K}{R\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=099ad0f327ebce4a161a3ee9fcdaf3ae}{Goodsell}{G\bibinitperiod}{David\bibnamedelima S}{D\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=33425ff8f67a18e0e5fd479e2b7e19ed}{Olson}{O\bibinitperiod}{Arthur\bibnamedelima J}{A\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{7}{}{%
        {{hash=03875878cdd3ca1814f4d19b2b707378}{Morris}{M\bibinitperiod}{Garrett\bibnamedelima M}{G\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=abfe839ffd42235f7ccf52fd38c70880}{Huey}{H\bibinitperiod}{Ruth}{R\bibinitperiod}{}{}{}{}}%
        {{hash=7ce3f604e3542482b2e574077c087c59}{Lindstrom}{L\bibinitperiod}{William}{W\bibinitperiod}{}{}{}{}}%
        {{hash=3dfc8441c51c12ddc628b0f54cfbae9c}{Sanner}{S\bibinitperiod}{Michel\bibnamedelima F}{M\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{hash=a96e4886230504267de9e02ab5572d86}{Belew}{B\bibinitperiod}{Richard\bibnamedelima K}{R\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=099ad0f327ebce4a161a3ee9fcdaf3ae}{Goodsell}{G\bibinitperiod}{David\bibnamedelima S}{D\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=33425ff8f67a18e0e5fd479e2b7e19ed}{Olson}{O\bibinitperiod}{Arthur\bibnamedelima J}{A\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{23b02cde1d1079d91e1b7646f16cabfd}
      \strng{fullhash}{bf3c0b6869056c842e862e3ff241219a}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility}}
      \field{abstract}{We describe the testing and release of AutoDock4 and the accompanying graphical user interface AutoDockTools. AutoDock4 incorporates limited flexibility in the receptor. Several tests are reported here, including a redocking experiment with 188 diverse ligand-protein complexes and a cross-docking experiment using flexible sidechains in 87 HIV protease complexes. We also report its utility in analysis of covalently-bound ligands, using both a grid-based docking method and a modification of the flexible sidechain technique.}
      \field{issn}{0192-8651}
      \field{journaltitle}{Journal of computational chemistry}
      \field{month}{12}
      \field{number}{16}
      \field{title}{{AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility}}
      \field{volume}{30}
      \field{year}{2009}
      \field{pages}{2785\bibrangedash 2791}
      \verb{doi}
      \verb 10.1002/jcc.21256
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2760638/
      \endverb
    \endentry
    \entry{Trott2010}{article}{}
      \name{labelname}{2}{}{%
        {{hash=4a4f9e841fae09e46988ea87c501122e}{Trott}{T\bibinitperiod}{Oleg}{O\bibinitperiod}{}{}{}{}}%
        {{hash=33425ff8f67a18e0e5fd479e2b7e19ed}{Olson}{O\bibinitperiod}{Arthur\bibnamedelima J}{A\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=4a4f9e841fae09e46988ea87c501122e}{Trott}{T\bibinitperiod}{Oleg}{O\bibinitperiod}{}{}{}{}}%
        {{hash=33425ff8f67a18e0e5fd479e2b7e19ed}{Olson}{O\bibinitperiod}{Arthur\bibnamedelima J}{A\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{33edd37cdbf195a31f3e025a1c785fa9}
      \strng{fullhash}{33edd37cdbf195a31f3e025a1c785fa9}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading}}
      \field{abstract}{AutoDock Vina, a new program for molecular docking and virtual screening, is presented. AutoDock Vina achieves an approximately two orders of magnitude speed-up compared to the molecular docking software previously developed in our lab (AutoDock 4), while also significantly improving the accuracy of the binding mode predictions, judging by our tests on the training set used in AutoDock 4 development. Further speed-up is achieved from parallelism, by using multithreading on multi-core machines. AutoDock Vina automatically calculates the grid maps and clusters the results in a way transparent to the user.}
      \field{issn}{0192-8651}
      \field{journaltitle}{Journal of computational chemistry}
      \field{month}{01}
      \field{number}{2}
      \field{title}{{AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading}}
      \field{volume}{31}
      \field{year}{2010}
      \field{pages}{455\bibrangedash 461}
      \verb{doi}
      \verb 10.1002/jcc.21334
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3041641/
      \endverb
    \endentry
    \entry{Ewing1997}{article}{}
      \name{labelname}{2}{}{%
        {{hash=dba045c922a8481d53b876410ad27d10}{Ewing}{E\bibinitperiod}{Todd\bibnamedelimb J\bibnamedelima a.}{T\bibinitperiod\bibinitdelim J\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
        {{hash=66f58288a79e7a0da002535ed008780c}{Kuntz}{K\bibinitperiod}{Irwin\bibnamedelima D}{I\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=dba045c922a8481d53b876410ad27d10}{Ewing}{E\bibinitperiod}{Todd\bibnamedelimb J\bibnamedelima a.}{T\bibinitperiod\bibinitdelim J\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
        {{hash=66f58288a79e7a0da002535ed008780c}{Kuntz}{K\bibinitperiod}{Irwin\bibnamedelima D}{I\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{f786628caf79940a091f9aed5a9ea487}
      \strng{fullhash}{f786628caf79940a091f9aed5a9ea487}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Critical evaluation of search algorithms for automated molecular docking and database screening}}
      \field{abstract}{The DOCK program explores possible orientations of a molecule within a macromolecular active site by superimposing atoms onto precomputed site points. Here we compare a number of different search methods, including an exhaustive matching algorithm based on a single docking graph. We evaluate the performance of each method by screening a small database of molecules to a variety of macromolecular targets. By varying the amount of sampling, we can monitor the time convergence of scores and rankings. We not only show that the site point\x{e05d}directed search is tenfold faster than a random search, but that the single graph matching algorithm boosts the speed of database screening up to 60-fold. The new algorithm, in fact, outperforms the bipartite graph matching algorithm currently used in DOCK. The results indicate that a critical issue for rapid database screening is the extent to which a search method biases run time toward the highest-ranking molecules. The single docking graph matching algorithm will be incorporated into DOCK version 4.0.}
      \field{isbn}{1096-987X}
      \field{issn}{0192-8651}
      \field{journaltitle}{Journal of Computational Chemistry}
      \field{title}{{Critical evaluation of search algorithms for automated molecular docking and database screening}}
      \field{volume}{18}
      \field{year}{1997}
      \field{pages}{1175\bibrangedash 1189}
      \verb{doi}
      \verb 10.1002/(SICI)1096-987X(19970715)18:9<1175::AID-JCC6>3.0.CO;2-O
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/10.1.1.639.8641.pdf:pdf
      \endverb
      \verb{url}
      \verb http://doi.wiley.com/10.1002/(SICI)1096-987X(19970715)18:9%7B%3C%7D1175::AID-JCC6%7B%3E%7D3.0.CO;2-O
      \endverb
    \endentry
    \entry{Rarey1996}{article}{}
      \name{labelname}{4}{}{%
        {{hash=3f75acc2c1dd637578817bce878cfbf9}{Rarey}{R\bibinitperiod}{Matthias}{M\bibinitperiod}{}{}{}{}}%
        {{hash=835ed9811dc9c10081202aa3f000b0aa}{Kramer}{K\bibinitperiod}{Bernd}{B\bibinitperiod}{}{}{}{}}%
        {{hash=523d57c46fd06417e60e5209d0122f34}{Lengauer}{L\bibinitperiod}{Thomas}{T\bibinitperiod}{}{}{}{}}%
        {{hash=93001fe15285ce67c1470749a34acf5c}{Klebe}{K\bibinitperiod}{Gerhard}{G\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=3f75acc2c1dd637578817bce878cfbf9}{Rarey}{R\bibinitperiod}{Matthias}{M\bibinitperiod}{}{}{}{}}%
        {{hash=835ed9811dc9c10081202aa3f000b0aa}{Kramer}{K\bibinitperiod}{Bernd}{B\bibinitperiod}{}{}{}{}}%
        {{hash=523d57c46fd06417e60e5209d0122f34}{Lengauer}{L\bibinitperiod}{Thomas}{T\bibinitperiod}{}{}{}{}}%
        {{hash=93001fe15285ce67c1470749a34acf5c}{Klebe}{K\bibinitperiod}{Gerhard}{G\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{73331c045801d26208890eb0368fd661}
      \strng{fullhash}{a5d7d69f7d4dce46d07e6797d593c3b0}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{A Fast Flexible Docking Method using an Incremental Construction Algorithm}}
      \field{abstract}{We present an automatic method for docking organic ligands into protein binding sites. The method can be used in the design process of specific protein ligands. It combines an appropriate model of the physico-chemical properties of the docked molecules with efficient methods for sampling the conformational space of the ligand. If the ligand is flexible, it can adopt a large variety of different conformations. Each such minimum in conformational space presents a potential candidate for the conformation of the ligand in the complexed state. Our docking method samples the conformation space of the ligand on the basis of a discrete model and uses a tree-search technique for placing the ligand incrementally into the active site. For placing the first fragment of the ligand into the protein, we use hashing techniques adapted from computer vision. The incremental construction algorithm is based on a greedy strategy combined with efficient methods for overlap detection and for the search of new interactions. We present results on 19 complexes of which the binding geometry has been crystallographically determined. All considered ligands are docked in at most three minutes on a current workstation. The experimentally observed binding mode of the ligand is reproduced with 0.5 to 1.2 {\r{A}} rms deviation. It is almost always found among the highest-ranking conformations computed.}
      \field{issn}{0022-2836}
      \field{journaltitle}{Journal of Molecular Biology}
      \field{month}{08}
      \field{number}{3}
      \field{title}{{A Fast Flexible Docking Method using an Incremental Construction Algorithm}}
      \field{volume}{261}
      \field{year}{1996}
      \field{pages}{470\bibrangedash 489}
      \verb{doi}
      \verb http://dx.doi.org/10.1006/jmbi.1996.0477
      \endverb
      \verb{url}
      \verb http://www.sciencedirect.com/science/article/pii/S0022283696904775
      \endverb
    \endentry
    \entry{Jones1997}{article}{}
      \name{labelname}{5}{}{%
        {{hash=f88a014a24f604954783c16ad0524d80}{Jones}{J\bibinitperiod}{G}{G\bibinitperiod}{}{}{}{}}%
        {{hash=bc95329d7c7bb64be647e9af3e6d66c7}{Willett}{W\bibinitperiod}{P}{P\bibinitperiod}{}{}{}{}}%
        {{hash=9642b54c498ba7e775da8d582d81f459}{Glen}{G\bibinitperiod}{R\bibnamedelima C}{R\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=a2ae35575b01b3ae1a6f1b799c6d173b}{Leach}{L\bibinitperiod}{A\bibnamedelima R}{A\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=96687293a6bacd111cb2a3c218f41763}{Taylor}{T\bibinitperiod}{R}{R\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{5}{}{%
        {{hash=f88a014a24f604954783c16ad0524d80}{Jones}{J\bibinitperiod}{G}{G\bibinitperiod}{}{}{}{}}%
        {{hash=bc95329d7c7bb64be647e9af3e6d66c7}{Willett}{W\bibinitperiod}{P}{P\bibinitperiod}{}{}{}{}}%
        {{hash=9642b54c498ba7e775da8d582d81f459}{Glen}{G\bibinitperiod}{R\bibnamedelima C}{R\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=a2ae35575b01b3ae1a6f1b799c6d173b}{Leach}{L\bibinitperiod}{A\bibnamedelima R}{A\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=96687293a6bacd111cb2a3c218f41763}{Taylor}{T\bibinitperiod}{R}{R\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{9d473c267249894dfe464c0b4ec98886}
      \strng{fullhash}{8dd2f51111a00512a78442e2bda72730}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Development and validation of a genetic algorithm for flexible docking.}}
      \field{abstract}{Prediction of small molecule binding modes to macromolecules of known three-dimensional structure is a problem of paramount importance in rational drug design (the "docking" problem). We report the development and validation of the program GOLD (Genetic Optimisation for Ligand Docking). GOLD is an automated ligand docking program that uses a genetic algorithm to explore the full range of ligand conformational flexibility with partial flexibility of the protein, and satisfies the fundamental requirement that the ligand must displace loosely bound water on binding. Numerous enhancements and modifications have been applied to the original technique resulting in a substantial increase in the reliability and the applicability of the algorithm. The advanced algorithm has been tested on a dataset of 100 complexes extracted from the Brookhaven Protein DataBank. When used to dock the ligand back into the binding site, GOLD achieved a 71{\%} success rate in identifying the experimental binding mode.}
      \field{issn}{0022-2836}
      \field{journaltitle}{Journal of molecular biology}
      \field{month}{04}
      \field{number}{3}
      \field{title}{{Development and validation of a genetic algorithm for flexible docking.}}
      \field{volume}{267}
      \field{year}{1997}
      \field{pages}{727\bibrangedash 48}
      \verb{doi}
      \verb 10.1006/jmbi.1996.0897
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Jones et al. - 1997 - Development and validation of a genetic algorithm for flexible docking.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.sciencedirect.com/science/article/pii/S0022283696908979
      \endverb
    \endentry
    \entry{Schames2004}{article}{}
      \name{labelname}{6}{}{%
        {{hash=25e2b872bb563a410ef59ebd2a104348}{Schames}{S\bibinitperiod}{Julie\bibnamedelima R}{J\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=c1b05c08b8caf0ef031dd8a0667848ef}{Henchman}{H\bibinitperiod}{Richard\bibnamedelima H}{R\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=5017cd6da2aab5899f7819c52db8e302}{Siegel}{S\bibinitperiod}{Jay\bibnamedelima S}{J\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=351681bce3e0a85122e52033b32dba26}{Sotriffer}{S\bibinitperiod}{Christoph\bibnamedelima A}{C\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=3c0d462e7ec04da0fb68d0b0f4ea3452}{Ni}{N\bibinitperiod}{Haihong}{H\bibinitperiod}{}{}{}{}}%
        {{hash=ce37dc17080f7261773ea665c47a3b8f}{McCammon}{M\bibinitperiod}{J\bibnamedelima Andrew}{J\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{6}{}{%
        {{hash=25e2b872bb563a410ef59ebd2a104348}{Schames}{S\bibinitperiod}{Julie\bibnamedelima R}{J\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=c1b05c08b8caf0ef031dd8a0667848ef}{Henchman}{H\bibinitperiod}{Richard\bibnamedelima H}{R\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=5017cd6da2aab5899f7819c52db8e302}{Siegel}{S\bibinitperiod}{Jay\bibnamedelima S}{J\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=351681bce3e0a85122e52033b32dba26}{Sotriffer}{S\bibinitperiod}{Christoph\bibnamedelima A}{C\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=3c0d462e7ec04da0fb68d0b0f4ea3452}{Ni}{N\bibinitperiod}{Haihong}{H\bibinitperiod}{}{}{}{}}%
        {{hash=ce37dc17080f7261773ea665c47a3b8f}{McCammon}{M\bibinitperiod}{J\bibnamedelima Andrew}{J\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{fa07db4662657dd6ceeea9e5e3296b4f}
      \strng{fullhash}{4864a1764a1d258f55b948c7e5d4b1be}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Discovery of a novel binding trench in HIV integrase.}}
      \field{abstract}{Docking of the 5CITEP inhibitor to snapshots of a 2 ns HIV-1 integrase MD trajectory indicated a previously uncharacterized trench adjacent to the active site that intermittently opens. Further docking studies of novel ligands with the potential to bind to both regions showed greater selective affinity when able to bind to the trench. Our ranking of ligands is open to experimental testing, and our approach suggests a new target for HIV-1 therapeutics.}
      \field{issn}{0022-2623}
      \field{journaltitle}{Journal of medicinal chemistry}
      \field{month}{04}
      \field{number}{8}
      \field{title}{{Discovery of a novel binding trench in HIV integrase.}}
      \field{volume}{47}
      \field{year}{2004}
      \field{pages}{1879\bibrangedash 81}
      \verb{doi}
      \verb 10.1021/jm0341913
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/15055986
      \endverb
    \endentry
    \entry{Enyedy2001}{article}{}
      \name{labelname}{14}{}{%
        {{hash=cccf019e920cf7f70685b6246efb298d}{Enyedy}{E\bibinitperiod}{Istvan\bibnamedelima J}{I\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=c694d2c3eb473e57844e782b31a92fba}{Ling}{L\bibinitperiod}{Yan}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=fecc59c070cac4d1c4a97a9e61edb558}{Nacro}{N\bibinitperiod}{Kassoum}{K\bibinitperiod}{}{}{}{}}%
        {{hash=edb66759a7b93be5cc4e2c1b5ccdd85b}{Tomita}{T\bibinitperiod}{York}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=be81dcecc1a8eb047716a69c86263cf3}{Wu}{W\bibinitperiod}{Xihan}{X\bibinitperiod}{}{}{}{}}%
        {{hash=99ce062a587c0af7a6385e1f8a7744b4}{Cao}{C\bibinitperiod}{Yeyu}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=fb78758065389ccf8aed41797ee6959d}{Guo}{G\bibinitperiod}{Ribo}{R\bibinitperiod}{}{}{}{}}%
        {{hash=f4ca30a8e501af9789454143e86ff623}{Li}{L\bibinitperiod}{Bihua}{B\bibinitperiod}{}{}{}{}}%
        {{hash=44fa4398633b23ed4ba8cb6975596172}{Zhu}{Z\bibinitperiod}{Xiaofeng}{X\bibinitperiod}{}{}{}{}}%
        {{hash=07da2ad0d080188097acdb1ce63432a9}{Huang}{H\bibinitperiod}{Ying}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=d39fadee94b51b745305d60070ec4ecf}{Long}{L\bibinitperiod}{Ya-Qiu}{Y\bibinithyphendelim Q\bibinitperiod}{}{}{}{}}%
        {{hash=6042de6c9a438a594f3061e7018fd632}{Roller}{R\bibinitperiod}{Peter\bibnamedelima P}{P\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=224bfac0a6322d270dc6a455104fb85f}{Yang}{Y\bibinitperiod}{Dajun}{D\bibinitperiod}{}{}{}{}}%
        {{hash=c5c6a61f0a352dfd208ab4e65ed64df7}{Wang}{W\bibinitperiod}{Shaomeng}{S\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{14}{}{%
        {{hash=cccf019e920cf7f70685b6246efb298d}{Enyedy}{E\bibinitperiod}{Istvan\bibnamedelima J}{I\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=c694d2c3eb473e57844e782b31a92fba}{Ling}{L\bibinitperiod}{Yan}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=fecc59c070cac4d1c4a97a9e61edb558}{Nacro}{N\bibinitperiod}{Kassoum}{K\bibinitperiod}{}{}{}{}}%
        {{hash=edb66759a7b93be5cc4e2c1b5ccdd85b}{Tomita}{T\bibinitperiod}{York}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=be81dcecc1a8eb047716a69c86263cf3}{Wu}{W\bibinitperiod}{Xihan}{X\bibinitperiod}{}{}{}{}}%
        {{hash=99ce062a587c0af7a6385e1f8a7744b4}{Cao}{C\bibinitperiod}{Yeyu}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=fb78758065389ccf8aed41797ee6959d}{Guo}{G\bibinitperiod}{Ribo}{R\bibinitperiod}{}{}{}{}}%
        {{hash=f4ca30a8e501af9789454143e86ff623}{Li}{L\bibinitperiod}{Bihua}{B\bibinitperiod}{}{}{}{}}%
        {{hash=44fa4398633b23ed4ba8cb6975596172}{Zhu}{Z\bibinitperiod}{Xiaofeng}{X\bibinitperiod}{}{}{}{}}%
        {{hash=07da2ad0d080188097acdb1ce63432a9}{Huang}{H\bibinitperiod}{Ying}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=d39fadee94b51b745305d60070ec4ecf}{Long}{L\bibinitperiod}{Ya-Qiu}{Y\bibinithyphendelim Q\bibinitperiod}{}{}{}{}}%
        {{hash=6042de6c9a438a594f3061e7018fd632}{Roller}{R\bibinitperiod}{Peter\bibnamedelima P}{P\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=224bfac0a6322d270dc6a455104fb85f}{Yang}{Y\bibinitperiod}{Dajun}{D\bibinitperiod}{}{}{}{}}%
        {{hash=c5c6a61f0a352dfd208ab4e65ed64df7}{Wang}{W\bibinitperiod}{Shaomeng}{S\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {American Chemical Society}%
      }
      \strng{namehash}{f9da54e365ba9e602528a302353ed4b8}
      \strng{fullhash}{a48895d6899040b4e3f47bedc272c9e3}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Discovery of Small-Molecule Inhibitors of Bcl-2 through Structure-Based Computer Screening}}
      \field{annotation}{doi: 10.1021/jm010016f}
      \field{issn}{0022-2623}
      \field{journaltitle}{Journal of Medicinal Chemistry}
      \field{month}{12}
      \field{number}{25}
      \field{title}{{Discovery of Small-Molecule Inhibitors of Bcl-2 through Structure-Based Computer Screening}}
      \field{volume}{44}
      \field{year}{2001}
      \field{pages}{4313\bibrangedash 4324}
      \verb{doi}
      \verb 10.1021/jm010016f
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1021/jm010016f
      \endverb
    \endentry
    \entry{Vangrevelinghe2003}{article}{}
      \name{labelname}{6}{}{%
        {{hash=416ae76db4e5bfac620e322ce3d2255f}{Vangrevelinghe}{V\bibinitperiod}{Eric}{E\bibinitperiod}{}{}{}{}}%
        {{hash=99329fab5807f1c1cddc960e56e8cf97}{Zimmermann}{Z\bibinitperiod}{Kaspar}{K\bibinitperiod}{}{}{}{}}%
        {{hash=ffa0a96cf758bed67725638480d2c761}{Schoepfer}{S\bibinitperiod}{Joseph}{J\bibinitperiod}{}{}{}{}}%
        {{hash=34d8013be664b59d9d2b15c004928a65}{Portmann}{P\bibinitperiod}{Robert}{R\bibinitperiod}{}{}{}{}}%
        {{hash=5d41ce0abc7c6487d82cac05657b4128}{Fabbro}{F\bibinitperiod}{Doriano}{D\bibinitperiod}{}{}{}{}}%
        {{hash=5d7c345aebbee9f07f5d2f193ce19f2c}{Furet}{F\bibinitperiod}{Pascal}{P\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{6}{}{%
        {{hash=416ae76db4e5bfac620e322ce3d2255f}{Vangrevelinghe}{V\bibinitperiod}{Eric}{E\bibinitperiod}{}{}{}{}}%
        {{hash=99329fab5807f1c1cddc960e56e8cf97}{Zimmermann}{Z\bibinitperiod}{Kaspar}{K\bibinitperiod}{}{}{}{}}%
        {{hash=ffa0a96cf758bed67725638480d2c761}{Schoepfer}{S\bibinitperiod}{Joseph}{J\bibinitperiod}{}{}{}{}}%
        {{hash=34d8013be664b59d9d2b15c004928a65}{Portmann}{P\bibinitperiod}{Robert}{R\bibinitperiod}{}{}{}{}}%
        {{hash=5d41ce0abc7c6487d82cac05657b4128}{Fabbro}{F\bibinitperiod}{Doriano}{D\bibinitperiod}{}{}{}{}}%
        {{hash=5d7c345aebbee9f07f5d2f193ce19f2c}{Furet}{F\bibinitperiod}{Pascal}{P\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {American Chemical Society}%
      }
      \strng{namehash}{d99e57891711703298ad52220db47a3e}
      \strng{fullhash}{8c154f5a3bc93810bccec8ca776853c1}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Discovery of a Potent and Selective Protein Kinase CK2 Inhibitor by High-Throughput Docking}}
      \field{annotation}{doi: 10.1021/jm030827e}
      \field{issn}{0022-2623}
      \field{journaltitle}{Journal of Medicinal Chemistry}
      \field{month}{06}
      \field{number}{13}
      \field{title}{{Discovery of a Potent and Selective Protein Kinase CK2 Inhibitor by High-Throughput Docking}}
      \field{volume}{46}
      \field{year}{2003}
      \field{pages}{2656\bibrangedash 2662}
      \verb{doi}
      \verb 10.1021/jm030827e
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1021/jm030827e
      \endverb
    \endentry
    \entry{Kitchen2004}{article}{}
      \name{labelname}{4}{}{%
        {{hash=fb875aae80088d06b6f38ba9e8b99512}{Kitchen}{K\bibinitperiod}{D}{D\bibinitperiod}{}{}{}{}}%
        {{hash=2a362dc9d3c737b94c4856350d6b11c6}{Decornez}{D\bibinitperiod}{H}{H\bibinitperiod}{}{}{}{}}%
        {{hash=d0d071f4c19665e202a4e902352309c6}{Furr}{F\bibinitperiod}{J}{J\bibinitperiod}{}{}{}{}}%
        {{hash=73602a565d4438564ee5eee7cfb36d57}{Bajorath}{B\bibinitperiod}{J}{J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=fb875aae80088d06b6f38ba9e8b99512}{Kitchen}{K\bibinitperiod}{D}{D\bibinitperiod}{}{}{}{}}%
        {{hash=2a362dc9d3c737b94c4856350d6b11c6}{Decornez}{D\bibinitperiod}{H}{H\bibinitperiod}{}{}{}{}}%
        {{hash=d0d071f4c19665e202a4e902352309c6}{Furr}{F\bibinitperiod}{J}{J\bibinitperiod}{}{}{}{}}%
        {{hash=73602a565d4438564ee5eee7cfb36d57}{Bajorath}{B\bibinitperiod}{J}{J\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{729980ccbae263fe121457afa5d0f544}
      \strng{fullhash}{1d20d8b3ac59460a1c72f90db50effd5}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Docking and scoring in virtual screening for drug discovery: methods and applications}}
      \field{abstract}{Computational approaches that 'dock' small molecules into the structures of macromolecular targets and 'score' their potential complementarity to binding sites are widely used in hit identification and lead optimization. Indeed, there are now a number of drugs whose development was heavily influenced by or based on structure-based design and screening strategies, such as HIV protease inhibitors. Nevertheless, there remain significant challenges in the application of these approaches, in particular in relation to current scoring schemes. Here, we review key concepts and specific features of small-molecule-protein docking methods, highlight selected applications and discuss recent advances that aim to address the acknowledged limitations of established approaches.}
      \field{isbn}{1474-1776}
      \field{issn}{1474-1784}
      \field{journaltitle}{Nature Reviews Drug Discovery}
      \field{number}{11}
      \field{title}{{Docking and scoring in virtual screening for drug discovery: methods and applications}}
      \field{volume}{3}
      \field{year}{2004}
      \field{pages}{935\bibrangedash 949}
      \verb{doi}
      \verb 10.1038/nrd1549
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/nrd1549.pdf:pdf
      \endverb
      \verb{url}
      \verb papers://ae875177-834e-4ba8-8523-120292c79891/Paper/p6840
      \endverb
    \endentry
    \entry{Reardon2013}{article}{}
      \name{labelname}{1}{}{%
        {{hash=31d7884c35df263e6201d4313efff9b8}{Reardon}{R\bibinitperiod}{Sara}{S\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=31d7884c35df263e6201d4313efff9b8}{Reardon}{R\bibinitperiod}{Sara}{S\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{31d7884c35df263e6201d4313efff9b8}
      \strng{fullhash}{31d7884c35df263e6201d4313efff9b8}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Project ranks billions of drug interactions.}}
      \field{abstract}{Drugable.com predicts mechanisms through computation.}
      \field{isbn}{0028-0836, 1476-4687}
      \field{issn}{1476-4687}
      \field{journaltitle}{Nature}
      \field{number}{7477}
      \field{title}{{Project ranks billions of drug interactions.}}
      \field{volume}{503}
      \field{year}{2013}
      \field{pages}{449\bibrangedash 50}
      \verb{doi}
      \verb 10.1038/503449a
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/503449a.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/24284710
      \endverb
    \endentry
    \entry{Drews2000}{article}{}
      \name{labelname}{1}{}{%
        {{hash=7f737abe1c40888301694155f653bf67}{Drews}{D\bibinitperiod}{J}{J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=7f737abe1c40888301694155f653bf67}{Drews}{D\bibinitperiod}{J}{J\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{7f737abe1c40888301694155f653bf67}
      \strng{fullhash}{7f737abe1c40888301694155f653bf67}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Drug discovery: a historical perspective.}}
      \field{abstract}{Driven by chemistry but increasingly guided by pharmacology and the clinical sciences, drug research has contributed more to the progress of medicine during the past century than any other scientific factor. The advent of molecular biology and, in particular, of genomic sciences is having a deep impact on drug discovery. Recombinant proteins and monoclonal antibodies have greatly enriched our therapeutic armamentarium. Genome sciences, combined with bioinformatic tools, allow us to dissect the genetic basis of multifactorial diseases and to determine the most suitable points of attack for future medicines, thereby increasing the number of treatment options. The dramatic increase in the complexity of drug research is enforcing changes in the institutional basis of this interdisciplinary endeavor. The biotech industry is establishing itself as the discovery arm of the pharmaceutical industry. In bridging the gap between academia and large pharmaceutical companies, the biotech firms have been effective instruments of technology transfer.}
      \field{isbn}{0036-8075 (Print)$\backslash$r0036-8075 (Linking)}
      \field{issn}{0036-8075}
      \field{journaltitle}{Science}
      \field{number}{5460}
      \field{title}{{Drug discovery: a historical perspective.}}
      \field{volume}{287}
      \field{year}{2000}
      \field{pages}{1960\bibrangedash 64}
      \verb{doi}
      \verb 10.1126/science.287.5460.1960
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Drews - 2000 - Drug discovery a historical perspective.pdf:pdf
      \endverb
    \endentry
    \entry{Patrick2001}{incollection}{}
      \name{labelname}{1}{}{%
        {{hash=4465ab199916481254817ec67ee5b8cd}{Patrick}{P\bibinitperiod}{Graham\bibnamedelima L}{G\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=4465ab199916481254817ec67ee5b8cd}{Patrick}{P\bibinitperiod}{Graham\bibnamedelima L}{G\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {John Wiley {\&} Sons, Ltd}%
      }
      \strng{namehash}{4465ab199916481254817ec67ee5b8cd}
      \strng{fullhash}{4465ab199916481254817ec67ee5b8cd}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{History of Drug Discovery}}
      \field{booktitle}{eLS}
      \field{isbn}{9780470015902}
      \field{title}{{History of Drug Discovery}}
      \field{year}{2001}
      \verb{doi}
      \verb 10.1002/9780470015902.a0003090.pub2
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1002/9780470015902.a0003090.pub2
      \endverb
    \endentry
    \entry{Hutchinson2011}{article}{}
      \name{labelname}{2}{}{%
        {{hash=7a84fb05e00d19e09c13f2308cea00a9}{Hutchinson}{H\bibinitperiod}{Lisa}{L\bibinitperiod}{}{}{}{}}%
        {{hash=15158fb6261af364cae4159e52b2b4f7}{Kirk}{K\bibinitperiod}{Rebecca}{R\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=7a84fb05e00d19e09c13f2308cea00a9}{Hutchinson}{H\bibinitperiod}{Lisa}{L\bibinitperiod}{}{}{}{}}%
        {{hash=15158fb6261af364cae4159e52b2b4f7}{Kirk}{K\bibinitperiod}{Rebecca}{R\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.}%
      }
      \strng{namehash}{bd3222581da1ea760a8d32c3da4e431a}
      \strng{fullhash}{bd3222581da1ea760a8d32c3da4e431a}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{High drug attrition rates[mdash]where are we going wrong?}}
      \field{annotation}{10.1038/nrclinonc.2011.34}
      \field{issn}{1759-4774}
      \field{journaltitle}{Nat Rev Clin Oncol}
      \field{month}{04}
      \field{number}{4}
      \field{title}{{High drug attrition rates[mdash]where are we going wrong?}}
      \field{volume}{8}
      \field{year}{2011}
      \field{pages}{189\bibrangedash 190}
      \verb{url}
      \verb http://dx.doi.org/10.1038/nrclinonc.2011.34
      \endverb
    \endentry
    \entry{Lindsay2003}{article}{}
      \name{labelname}{1}{}{%
        {{hash=a5155f6dc3e790f98b57e7cb5acff83f}{Lindsay}{L\bibinitperiod}{Mark\bibnamedelima A}{M\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=a5155f6dc3e790f98b57e7cb5acff83f}{Lindsay}{L\bibinitperiod}{Mark\bibnamedelima A}{M\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{a5155f6dc3e790f98b57e7cb5acff83f}
      \strng{fullhash}{a5155f6dc3e790f98b57e7cb5acff83f}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Target discovery}}
      \field{annotation}{10.1038/nrd1202}
      \field{issn}{1474-1776}
      \field{journaltitle}{Nat Rev Drug Discov}
      \field{month}{10}
      \field{number}{10}
      \field{title}{{Target discovery}}
      \field{volume}{2}
      \field{year}{2003}
      \field{pages}{831\bibrangedash 838}
      \verb{url}
      \verb http://dx.doi.org/10.1038/nrd1202
      \endverb
    \endentry
    \entry{Hughes2011}{article}{}
      \name{labelname}{4}{}{%
        {{hash=92719bef4f321d41abd3ecd5f8a324e8}{Hughes}{H\bibinitperiod}{J.\bibnamedelimi P.}{J\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=58af7fb877b52267ca0802270218e792}{Rees}{R\bibinitperiod}{S.\bibnamedelimi S.}{S\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=b87a82c50fd2be81651acc86f9f447ab}{Kalindjian}{K\bibinitperiod}{S.\bibnamedelimi B.}{S\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=756bec188428515abb80c02e107b6d5f}{Philpott}{P\bibinitperiod}{K.\bibnamedelimi L.}{K\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=92719bef4f321d41abd3ecd5f8a324e8}{Hughes}{H\bibinitperiod}{J.\bibnamedelimi P.}{J\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=58af7fb877b52267ca0802270218e792}{Rees}{R\bibinitperiod}{S.\bibnamedelimi S.}{S\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=b87a82c50fd2be81651acc86f9f447ab}{Kalindjian}{K\bibinitperiod}{S.\bibnamedelimi B.}{S\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=756bec188428515abb80c02e107b6d5f}{Philpott}{P\bibinitperiod}{K.\bibnamedelimi L.}{K\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{0d9256a110c28d0a71b5d61772955000}
      \strng{fullhash}{7616c217328de39ddfa3cd656893c4df}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Principles of early drug discovery}}
      \field{abstract}{Developing a new drug from original idea to the launch of a finished product is a complex process which can take 12-15 years and cost in excess of {\$}1 billion. The idea for a target can come from a variety of sources including academic and clinical research and from the commercial sector. It may take many years to build up a body of supporting evidence before selecting a target for a costly drug discovery programme. Once a target has been chosen, the pharmaceutical industry and more recently some academic centres have streamlined a number of early processes to identify molecules which possess suitable characteristics to make acceptable drugs. This review will look at key preclinical stages of the drug discovery process, from initial target identification and validation, through assay development, high throughput screening, hit identification, lead optimization and finally the selection of a candidate molecule for clinical development.}
      \field{isbn}{1476-5381 (Electronic)$\backslash$r0007-1188 (Linking)}
      \field{issn}{00071188}
      \field{journaltitle}{British Journal of Pharmacology}
      \field{number}{6}
      \field{title}{{Principles of early drug discovery}}
      \field{volume}{162}
      \field{year}{2011}
      \field{pages}{1239\bibrangedash 1249}
      \verb{doi}
      \verb 10.1111/j.1476-5381.2010.01127.x
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/bph0162-1239.pdf:pdf
      \endverb
    \endentry
    \entry{Imming2006}{article}{}
      \name{labelname}{3}{}{%
        {{hash=1a19a796268a240beeaedfb8c0675724}{Imming}{I\bibinitperiod}{Peter}{P\bibinitperiod}{}{}{}{}}%
        {{hash=907a669a7856a85ad150b785a05d657d}{Sinning}{S\bibinitperiod}{Christian}{C\bibinitperiod}{}{}{}{}}%
        {{hash=83eb7db208fafcc3e91592718cec9e20}{Meyer}{M\bibinitperiod}{Achim}{A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=1a19a796268a240beeaedfb8c0675724}{Imming}{I\bibinitperiod}{Peter}{P\bibinitperiod}{}{}{}{}}%
        {{hash=907a669a7856a85ad150b785a05d657d}{Sinning}{S\bibinitperiod}{Christian}{C\bibinitperiod}{}{}{}{}}%
        {{hash=83eb7db208fafcc3e91592718cec9e20}{Meyer}{M\bibinitperiod}{Achim}{A\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{db3a3f86fa1154cd45ce750cce8c6cd3}
      \strng{fullhash}{db3a3f86fa1154cd45ce750cce8c6cd3}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Drugs, their targets and the nature and number of drug targets.}}
      \field{abstract}{What is a drug target? And how many such targets are there? Here, we consider the nature of drug targets, and by classifying known drug substances on the basis of the discussed principles we provide an estimation of the total number of current drug targets.}
      \field{isbn}{1474-1776}
      \field{issn}{1474-1776}
      \field{journaltitle}{Nature reviews. Drug discovery}
      \field{number}{10}
      \field{title}{{Drugs, their targets and the nature and number of drug targets.}}
      \field{volume}{5}
      \field{year}{2006}
      \field{pages}{821\bibrangedash 834}
      \verb{doi}
      \verb 10.1038/nrd2132
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/nrd2132.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.nature.com/doifinder/10.1038/nrd2132$%5Cbackslash$nhttp://www.ncbi.nlm.nih.gov/pubmed/17016423
      \endverb
    \endentry
    \entry{Klees1997}{article}{}
      \name{labelname}{2}{}{%
        {{hash=a1ef150710a6594730f2284153694ac5}{Klees}{K\bibinitperiod}{J\bibnamedelima E}{J\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=87a5182bfc881678b1f525597597e1bc}{Joines}{J\bibinitperiod}{R}{R\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=a1ef150710a6594730f2284153694ac5}{Klees}{K\bibinitperiod}{J\bibnamedelima E}{J\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=87a5182bfc881678b1f525597597e1bc}{Joines}{J\bibinitperiod}{R}{R\bibinitperiod}{}{}{}{}}%
      }
      \list{language}{1}{%
        {eng}%
      }
      \list{location}{1}{%
        {BASF Corporation Mount Olive, New Jersey, USA.}%
      }
      \strng{namehash}{b24ddfa983616a7c94b39fb7165d4288}
      \strng{fullhash}{b24ddfa983616a7c94b39fb7165d4288}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Occupational health issues in the pharmaceutical research and development process}}
      \field{issn}{0885-114X}
      \field{journaltitle}{Occupational medicine (Philadelphia, Pa.)}
      \field{number}{1}
      \field{title}{{Occupational health issues in the pharmaceutical research and development process}}
      \field{volume}{12}
      \field{year}{1997}
      \field{pages}{5\bibrangedash 27}
      \verb{url}
      \verb http://europepmc.org/abstract/MED/9153050
      \endverb
    \endentry
    \entry{Paul2010}{article}{}
      \name{labelname}{7}{}{%
        {{hash=b366568bb7c37bec2692f4b4ce012674}{Paul}{P\bibinitperiod}{Steven\bibnamedelima M}{S\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=688f1f09f5e342999801d127e72095a3}{Mytelka}{M\bibinitperiod}{Daniel\bibnamedelima S}{D\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=a3b55c4ad2ad4184c60822cd8551ae05}{Dunwiddie}{D\bibinitperiod}{Christopher\bibnamedelima T}{C\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=351d5da2feb8a3e00527230bb23ac3c6}{Persinger}{P\bibinitperiod}{Charles\bibnamedelima C}{C\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=6cde7adaa226a2ab0c7d0a811628733d}{Munos}{M\bibinitperiod}{Bernard\bibnamedelima H}{B\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=f3097c95f17ec534d356f865a2b8b86a}{Lindborg}{L\bibinitperiod}{Stacy\bibnamedelima R}{S\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=7d4c963a6c590a9ba12f4f19d7f07185}{Schacht}{S\bibinitperiod}{Aaron\bibnamedelima L}{A\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{7}{}{%
        {{hash=b366568bb7c37bec2692f4b4ce012674}{Paul}{P\bibinitperiod}{Steven\bibnamedelima M}{S\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=688f1f09f5e342999801d127e72095a3}{Mytelka}{M\bibinitperiod}{Daniel\bibnamedelima S}{D\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=a3b55c4ad2ad4184c60822cd8551ae05}{Dunwiddie}{D\bibinitperiod}{Christopher\bibnamedelima T}{C\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=351d5da2feb8a3e00527230bb23ac3c6}{Persinger}{P\bibinitperiod}{Charles\bibnamedelima C}{C\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=6cde7adaa226a2ab0c7d0a811628733d}{Munos}{M\bibinitperiod}{Bernard\bibnamedelima H}{B\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=f3097c95f17ec534d356f865a2b8b86a}{Lindborg}{L\bibinitperiod}{Stacy\bibnamedelima R}{S\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=7d4c963a6c590a9ba12f4f19d7f07185}{Schacht}{S\bibinitperiod}{Aaron\bibnamedelima L}{A\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{ec0c820d22c5ffc3bd4acba8e8c8f62b}
      \strng{fullhash}{b4542eeb6d87f80aa6d2ad603c5b0e1e}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{How to improve R{\&}D productivity: the pharmaceutical industry's grand challenge.}}
      \field{abstract}{The pharmaceutical industry is under growing pressure from a range of environmental issues, including major losses of revenue owing to patent expirations, increasingly cost-constrained healthcare systems and more demanding regulatory requirements. In our view, the key to tackling the challenges such issues pose to both the future viability of the pharmaceutical industry and advances in healthcare is to substantially increase the number and quality of innovative, cost-effective new medicines, without incurring unsustainable R{\&}D costs. However, it is widely acknowledged that trends in industry R{\&}D productivity have been moving in the opposite direction for a number of years. Here, we present a detailed analysis based on comprehensive, recent, industry-wide data to identify the relative contributions of each of the steps in the drug discovery and development process to overall R{\&}D productivity. We then propose specific strategies that could have the most substantial impact in improving R{\&}D productivity.}
      \field{isbn}{1474-1776}
      \field{issn}{1474-1776}
      \field{journaltitle}{Nature reviews. Drug discovery}
      \field{number}{3}
      \field{title}{{How to improve R{\&}D productivity: the pharmaceutical industry's grand challenge.}}
      \field{volume}{9}
      \field{year}{2010}
      \field{pages}{203\bibrangedash 214}
      \verb{doi}
      \verb 10.1038/nrd3078
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Paul et al. - 2010 - How to improve R{\&}D productivity the pharmaceutical industry's grand challenge.pdf:pdf
      \endverb
    \endentry
    \entry{Scannell2012}{article}{}
      \name{labelname}{4}{}{%
        {{hash=bbafbad45bc890a624d6cad5d0f09816}{Scannell}{S\bibinitperiod}{Jack\bibnamedelima W}{J\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=a02e1cbb665aa678d8b4e57a143360c6}{Blanckley}{B\bibinitperiod}{Alex}{A\bibinitperiod}{}{}{}{}}%
        {{hash=f42f13c8d7d443a29d13d5b7c2131465}{Boldon}{B\bibinitperiod}{Helen}{H\bibinitperiod}{}{}{}{}}%
        {{hash=5eb39bacb2b338ede1118e9d772cabd3}{Warrington}{W\bibinitperiod}{Brian}{B\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=bbafbad45bc890a624d6cad5d0f09816}{Scannell}{S\bibinitperiod}{Jack\bibnamedelima W}{J\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=a02e1cbb665aa678d8b4e57a143360c6}{Blanckley}{B\bibinitperiod}{Alex}{A\bibinitperiod}{}{}{}{}}%
        {{hash=f42f13c8d7d443a29d13d5b7c2131465}{Boldon}{B\bibinitperiod}{Helen}{H\bibinitperiod}{}{}{}{}}%
        {{hash=5eb39bacb2b338ede1118e9d772cabd3}{Warrington}{W\bibinitperiod}{Brian}{B\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group}%
      }
      \strng{namehash}{37dbe186f18e6efb263daba350860b38}
      \strng{fullhash}{758a96d05a4a23a98d44fbd1b3a74f04}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Diagnosing the decline in pharmaceutical R{\&}D efficiency.}}
      \field{abstract}{The past 60 years have seen huge advances in many of the scientific, technological and managerial factors that should tend to raise the efficiency of commercial drug research and development (RD). Yet the number of new drugs approved per billion US dollars spent on RD has halved roughly every 9 years since 1950, falling around 80-fold in inflation-adjusted terms. There have been many proposed solutions to the problem of declining RD efficiency. However, their apparent lack of impact so far and the contrast between improving inputs and declining output in terms of the number of new drugs make it sensible to ask whether the underlying problems have been correctly diagnosed. Here, we discuss four factors that we consider to be primary causes, which we call the 'better than the Beatles' problem; the 'cautious regulator' problem; the 'throw money at it' tendency; and the 'basic research-brute force' bias. Our aim is to provoke a more systematic analysis of the causes of the decline in RD efficiency.}
      \field{isbn}{1474-1784 (Electronic)$\backslash$r1474-1776 (Linking)}
      \field{issn}{1474-1784}
      \field{journaltitle}{Nature reviews. Drug discovery}
      \field{number}{3}
      \field{title}{{Diagnosing the decline in pharmaceutical R{\&}D efficiency.}}
      \field{volume}{11}
      \field{year}{2012}
      \field{pages}{191\bibrangedash 200}
      \verb{doi}
      \verb 10.1038/nrd3681
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Scannell et al. - 2012 - Diagnosing the decline in pharmaceutical R{\&}D efficiency.pdf:pdf
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1038/nrd3681
      \endverb
    \endentry
    \entry{Sliwoski2014}{article}{}
      \name{labelname}{4}{}{%
        {{hash=4b72c860300008db45ec8dae84b81b6d}{Sliwoski}{S\bibinitperiod}{Gregory}{G\bibinitperiod}{}{}{}{}}%
        {{hash=58f90429c84a9d8496428bfcfed58f15}{Kothiwale}{K\bibinitperiod}{Sandeepkumar}{S\bibinitperiod}{}{}{}{}}%
        {{hash=26b1ee76f095f43650e27a349d54e2dc}{Meiler}{M\bibinitperiod}{Jens}{J\bibinitperiod}{}{}{}{}}%
        {{hash=1894d4b0a31806b728983bf32041617f}{Lowe}{L\bibinitperiod}{Edward\bibnamedelima W}{E\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=4b72c860300008db45ec8dae84b81b6d}{Sliwoski}{S\bibinitperiod}{Gregory}{G\bibinitperiod}{}{}{}{}}%
        {{hash=58f90429c84a9d8496428bfcfed58f15}{Kothiwale}{K\bibinitperiod}{Sandeepkumar}{S\bibinitperiod}{}{}{}{}}%
        {{hash=26b1ee76f095f43650e27a349d54e2dc}{Meiler}{M\bibinitperiod}{Jens}{J\bibinitperiod}{}{}{}{}}%
        {{hash=1894d4b0a31806b728983bf32041617f}{Lowe}{L\bibinitperiod}{Edward\bibnamedelima W}{E\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{8ee8ee539dc8e3ec7eed19c478dd9f0e}
      \strng{fullhash}{27770022ff03415f231ba4291b0f85b5}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Computational Methods in Drug Discovery}}
      \field{number}{January}
      \field{title}{{Computational Methods in Drug Discovery}}
      \field{year}{2014}
      \field{pages}{334\bibrangedash 395}
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Sliwoski et al. - 2014 - Computational Methods in Drug Discovery.pdf:pdf
      \endverb
    \endentry
    \entry{Yang2009}{article}{}
      \name{labelname}{3}{}{%
        {{hash=2d98df2198aa3bf03b8bd576c1004d84}{Yang}{Y\bibinitperiod}{Yongliang}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=f679baa07793b941fa308dc9844d8d6a}{Adelstein}{A\bibinitperiod}{S.\bibnamedelimi James}{S\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=5fa6ef59d0a6bd6225c42d516cbb0747}{Kassis}{K\bibinitperiod}{Amin\bibnamedelima I.}{A\bibinitperiod\bibinitdelim I\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=2d98df2198aa3bf03b8bd576c1004d84}{Yang}{Y\bibinitperiod}{Yongliang}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=f679baa07793b941fa308dc9844d8d6a}{Adelstein}{A\bibinitperiod}{S.\bibnamedelimi James}{S\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=5fa6ef59d0a6bd6225c42d516cbb0747}{Kassis}{K\bibinitperiod}{Amin\bibnamedelima I.}{A\bibinitperiod\bibinitdelim I\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{4a70b9a937ed48a12bb0131e86595b43}
      \strng{fullhash}{4a70b9a937ed48a12bb0131e86595b43}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Target discovery from data mining approaches}}
      \field{abstract}{Data mining of available biomedical data and information has greatly boosted target discovery in the 'omics' era. Target discovery is the key step in the biomarker and drug discovery pipeline to diagnose and fight human diseases. In biomedical science, the 'target' is a broad concept ranging from molecular entities (such as genes, proteins and miRNAs) to biological phenomena (such as molecular functions, pathways and phenotypes). Within the context of biomedical science, data mining refers to a bioinformatics approach that combines biological concepts with computer tools or statistical methods that are mainly used to discover, select and prioritize targets. In response to the huge demand of data mining for target discovery in the 'omics' era, this review explicates various data mining approaches and their applications to target discovery with emphasis on text and microarray data analysis. Two emerging data mining approaches, chemogenomic data mining and proteomic data mining, are briefly introduced. Also discussed are the limitations of various data mining approaches found in the level of database integration, the quality of data annotation, sample heterogeneity and the performance of analytical and mining tools. Tentative strategies of integrating different data sources for target discovery, such as integrated text mining with high-throughput data analysis and integrated mining with pathway databases, are introduced.}
      \field{isbn}{1878-5832 (Electronic)$\backslash$r1359-6446 (Linking)}
      \field{issn}{13596446}
      \field{journaltitle}{Drug Discovery Today}
      \field{number}{3-4}
      \field{title}{{Target discovery from data mining approaches}}
      \field{volume}{14}
      \field{year}{2009}
      \field{pages}{147\bibrangedash 154}
      \verb{doi}
      \verb 10.1016/j.drudis.2008.12.005
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/1-s2.0-S1359644608004133-main.pdf:pdf
      \endverb
    \endentry
    \entry{predict}{misc}{}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{PREDICT: a method for inferring novel drug indications with application to personalized medicine}}
      \field{title}{{PREDICT: a method for inferring novel drug indications with application to personalized medicine}}
    \endentry
    \entry{Zhang2011}{article}{}
      \name{labelname}{5}{}{%
        {{hash=922b74338e14a4c81b03a7487c18522b}{Zhang}{Z\bibinitperiod}{M}{M\bibinitperiod}{}{}{}{}}%
        {{hash=9c4f74447bd064e137b853534877a881}{Zhu}{Z\bibinitperiod}{C}{C\bibinitperiod}{}{}{}{}}%
        {{hash=fd2da39b0bac9019c7c792d123b2a20f}{Jacomy}{J\bibinitperiod}{A}{A\bibinitperiod}{}{}{}{}}%
        {{hash=770b46a0ab1ecc2cd8f72f396a95c6d9}{Lu}{L\bibinitperiod}{L\bibnamedelima J}{L\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=d52cad485c9a2636b603840bbf05271f}{Jegga}{J\bibinitperiod}{A\bibnamedelima G}{A\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{5}{}{%
        {{hash=922b74338e14a4c81b03a7487c18522b}{Zhang}{Z\bibinitperiod}{M}{M\bibinitperiod}{}{}{}{}}%
        {{hash=9c4f74447bd064e137b853534877a881}{Zhu}{Z\bibinitperiod}{C}{C\bibinitperiod}{}{}{}{}}%
        {{hash=fd2da39b0bac9019c7c792d123b2a20f}{Jacomy}{J\bibinitperiod}{A}{A\bibinitperiod}{}{}{}{}}%
        {{hash=770b46a0ab1ecc2cd8f72f396a95c6d9}{Lu}{L\bibinitperiod}{L\bibnamedelima J}{L\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=d52cad485c9a2636b603840bbf05271f}{Jegga}{J\bibinitperiod}{A\bibnamedelima G}{A\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{0ac61aa61d59b1cc2166a7777538626d}
      \strng{fullhash}{7220fbdfab8f0dc92e69d7c2f4f1b63b}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{The orphan disease networks}}
      \field{journaltitle}{Am J Hum Genet}
      \field{title}{{The orphan disease networks}}
      \field{volume}{88}
      \field{year}{2011}
      \verb{doi}
      \verb 10.1016/j.ajhg.2011.05.006
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1016/j.ajhg.2011.05.006
      \endverb
    \endentry
    \entry{YutakaFukuoka2013}{article}{}
      \name{labelname}{2}{}{%
        {{hash=7ff2181b937c079f5f6ae90e299d0484}{{Yutaka\bibnamedelimb Fukuoka}}{Y\bibinitperiod}{D\bibnamedelima T}{D\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=4f445702a463193accf05d949e14c770}{Hisamichi}{H\bibinitperiod}{O\bibnamedelima g.\bibnamedelimi a.\bibnamedelimi w.\bibnamedelimi a.}{O\bibinitperiod\bibinitdelim g\bibinitperiod\bibinitdelim a\bibinitperiod\bibinitdelim w\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=7ff2181b937c079f5f6ae90e299d0484}{{Yutaka\bibnamedelimb Fukuoka}}{Y\bibinitperiod}{D\bibnamedelima T}{D\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=4f445702a463193accf05d949e14c770}{Hisamichi}{H\bibinitperiod}{O\bibnamedelima g.\bibnamedelimi a.\bibnamedelimi w.\bibnamedelimi a.}{O\bibinitperiod\bibinitdelim g\bibinitperiod\bibinitdelim a\bibinitperiod\bibinitdelim w\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{251b2e9209f5e64a31b2ac1c0ce1cc5a}
      \strng{fullhash}{251b2e9209f5e64a31b2ac1c0ce1cc5a}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{A two-step drug repositioning method based on a protein-protein interaction network of genes shared by two diseases and the similarity of drugs}}
      \field{journaltitle}{Bioinformation}
      \field{title}{{A two-step drug repositioning method based on a protein-protein interaction network of genes shared by two diseases and the similarity of drugs}}
      \field{volume}{9}
      \field{year}{2013}
      \verb{doi}
      \verb 10.6026/97320630009089
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.6026/97320630009089
      \endverb
    \endentry
    \entry{Raman2008}{article}{}
      \name{labelname}{2}{}{%
        {{hash=059e831bb53855ce1b1223bae01bbe86}{Raman}{R\bibinitperiod}{K}{K\bibinitperiod}{}{}{}{}}%
        {{hash=3a1567ea429d962cf6a5e13bafa47f4c}{Chandra}{C\bibinitperiod}{N}{N\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=059e831bb53855ce1b1223bae01bbe86}{Raman}{R\bibinitperiod}{K}{K\bibinitperiod}{}{}{}{}}%
        {{hash=3a1567ea429d962cf6a5e13bafa47f4c}{Chandra}{C\bibinitperiod}{N}{N\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{c6910bb9d7b410a664066360979bbcf6}
      \strng{fullhash}{c6910bb9d7b410a664066360979bbcf6}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Mycobacterium tuberculosis interactome analysis unravels potential pathways to drug resistance}}
      \field{journaltitle}{BMC Microbiology}
      \field{title}{{Mycobacterium tuberculosis interactome analysis unravels potential pathways to drug resistance}}
      \field{volume}{8}
      \field{year}{2008}
    \endentry
    \entry{Phaiphinit2016}{article}{}
      \name{labelname}{4}{}{%
        {{hash=e5ed77ddbbf18ff43ab9dc731da8c143}{Phaiphinit}{P\bibinitperiod}{Suthat}{S\bibinitperiod}{}{}{}{}}%
        {{hash=915cbf3f1cfddbc79bc362f13cdf5b16}{Pattaradilokrat}{P\bibinitperiod}{Sittiporn}{S\bibinitperiod}{}{}{}{}}%
        {{hash=8cdca83642a199ccac594a23d984a5f5}{Lursinsap}{L\bibinitperiod}{Chidchanok}{C\bibinitperiod}{}{}{}{}}%
        {{hash=8bf664d45f580dc651a9430da44b9877}{Plaimas}{P\bibinitperiod}{Kitiporn}{K\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=e5ed77ddbbf18ff43ab9dc731da8c143}{Phaiphinit}{P\bibinitperiod}{Suthat}{S\bibinitperiod}{}{}{}{}}%
        {{hash=915cbf3f1cfddbc79bc362f13cdf5b16}{Pattaradilokrat}{P\bibinitperiod}{Sittiporn}{S\bibinitperiod}{}{}{}{}}%
        {{hash=8cdca83642a199ccac594a23d984a5f5}{Lursinsap}{L\bibinitperiod}{Chidchanok}{C\bibinitperiod}{}{}{}{}}%
        {{hash=8bf664d45f580dc651a9430da44b9877}{Plaimas}{P\bibinitperiod}{Kitiporn}{K\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{42361eb902dda635feb087312bffdd95}
      \strng{fullhash}{d43bf1a2d16b52f8b42afb9d63ced04b}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{In silico multiple-targets identification for heme detoxification in the human malaria parasite Plasmodium falciparum}}
      \field{issn}{1567-1348}
      \field{journaltitle}{Infection, Genetics and Evolution}
      \field{month}{01}
      \field{title}{{In silico multiple-targets identification for heme detoxification in the human malaria parasite Plasmodium falciparum}}
      \field{volume}{37}
      \field{year}{2016}
      \field{pages}{237\bibrangedash 244}
      \verb{doi}
      \verb http://dx.doi.org/10.1016/j.meegid.2015.11.025
      \endverb
      \verb{url}
      \verb http://www.sciencedirect.com/science/article/pii/S1567134815300551
      \endverb
    \endentry
    \entry{Jeon2014}{article}{}
      \name{labelname}{8}{}{%
        {{hash=0bbcbd2ef5dd87550374f54bc88ee251}{Jeon}{J\bibinitperiod}{Jouhyun}{J\bibinitperiod}{}{}{}{}}%
        {{hash=fa91ad558556dc32d1088c177961236f}{Nim}{N\bibinitperiod}{Satra}{S\bibinitperiod}{}{}{}{}}%
        {{hash=0ae5567bddd0faad885a9e2c240038be}{Teyra}{T\bibinitperiod}{Joan}{J\bibinitperiod}{}{}{}{}}%
        {{hash=131347f30ebd8eae2646981716c60166}{Datti}{D\bibinitperiod}{Alessandro}{A\bibinitperiod}{}{}{}{}}%
        {{hash=d7a174b422ffe9ba5cb16c66f91b6783}{Wrana}{W\bibinitperiod}{Jeffrey\bibnamedelima L}{J\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=f3ecd7ac05beb6f1477644abc12c9859}{Sidhu}{S\bibinitperiod}{Sachdev\bibnamedelima S}{S\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=37c4fced035824080cfd955b315fcf34}{Moffat}{M\bibinitperiod}{Jason}{J\bibinitperiod}{}{}{}{}}%
        {{hash=9adc2c77fe970ba23f5da498e6a6748c}{Kim}{K\bibinitperiod}{Philip\bibnamedelima M}{P\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{8}{}{%
        {{hash=0bbcbd2ef5dd87550374f54bc88ee251}{Jeon}{J\bibinitperiod}{Jouhyun}{J\bibinitperiod}{}{}{}{}}%
        {{hash=fa91ad558556dc32d1088c177961236f}{Nim}{N\bibinitperiod}{Satra}{S\bibinitperiod}{}{}{}{}}%
        {{hash=0ae5567bddd0faad885a9e2c240038be}{Teyra}{T\bibinitperiod}{Joan}{J\bibinitperiod}{}{}{}{}}%
        {{hash=131347f30ebd8eae2646981716c60166}{Datti}{D\bibinitperiod}{Alessandro}{A\bibinitperiod}{}{}{}{}}%
        {{hash=d7a174b422ffe9ba5cb16c66f91b6783}{Wrana}{W\bibinitperiod}{Jeffrey\bibnamedelima L}{J\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=f3ecd7ac05beb6f1477644abc12c9859}{Sidhu}{S\bibinitperiod}{Sachdev\bibnamedelima S}{S\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=37c4fced035824080cfd955b315fcf34}{Moffat}{M\bibinitperiod}{Jason}{J\bibinitperiod}{}{}{}{}}%
        {{hash=9adc2c77fe970ba23f5da498e6a6748c}{Kim}{K\bibinitperiod}{Philip\bibnamedelima M}{P\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{7c461db0d4499d9c0fbf087d8bbfb76c}
      \strng{fullhash}{5dee8c21e13c0801e4f733a102a0f8fb}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{A systematic approach to identify novel cancer drug targets using machine learning, inhibitor design and high-throughput screening}}
      \field{abstract}{We present an integrated approach that predicts and validates novel anti-cancer drug targets. We first built a classifier that integrates a variety of genomic and systematic datasets to prioritize drug targets specific for breast, pancreatic and ovarian cancer. We then devised strategies to inhibit these anti-cancer drug targets and selected a set of targets that are amenable to inhibition by small molecules, antibodies and synthetic peptides. We validated the predicted drug targets by showing strong anti-proliferative effects of both synthetic peptide and small molecule inhibitors against our predicted targets.}
      \field{issn}{1756-994X}
      \field{journaltitle}{Genome Medicine}
      \field{number}{7}
      \field{title}{{A systematic approach to identify novel cancer drug targets using machine learning, inhibitor design and high-throughput screening}}
      \field{volume}{6}
      \field{year}{2014}
      \field{pages}{1\bibrangedash 18}
      \verb{doi}
      \verb 10.1186/s13073-014-0057-7
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1186/s13073-014-0057-7
      \endverb
    \endentry
    \entry{Augustin2012}{article}{}
      \name{labelname}{8}{}{%
        {{hash=f4c3f007e64456fd3e21baff78f54b45}{Augustin}{A\bibinitperiod}{Regina}{R\bibinitperiod}{}{}{}{}}%
        {{hash=f1d9d1d92014214edb3eb43c9465f889}{Endres}{E\bibinitperiod}{Kristina}{K\bibinitperiod}{}{}{}{}}%
        {{hash=a888634c7e54a5c7dc9e9e9e8d757768}{Reinhardt}{R\bibinitperiod}{Sven}{S\bibinitperiod}{}{}{}{}}%
        {{hash=23f5b35687a70026c45beaeaac63bb12}{Kuhn}{K\bibinitperiod}{Peer-Hendrik}{P\bibinithyphendelim H\bibinitperiod}{}{}{}{}}%
        {{hash=d5b0de48d76049730d1120d8da0901e0}{Lichtenthaler}{L\bibinitperiod}{Stefan\bibnamedelima F}{S\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{hash=2ea2c73d8388a5bf85d22232b986b28b}{Hansen}{H\bibinitperiod}{Jens}{J\bibinitperiod}{}{}{}{}}%
        {{hash=39f0264772b09e386b77fb16f7814c46}{Wurst}{W\bibinitperiod}{Wolfgang}{W\bibinitperiod}{}{}{}{}}%
        {{hash=b7a2bfdc63606d74ab85e02ecc423c2a}{Tr{\"{u}}mbach}{T\bibinitperiod}{Dietrich}{D\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{8}{}{%
        {{hash=f4c3f007e64456fd3e21baff78f54b45}{Augustin}{A\bibinitperiod}{Regina}{R\bibinitperiod}{}{}{}{}}%
        {{hash=f1d9d1d92014214edb3eb43c9465f889}{Endres}{E\bibinitperiod}{Kristina}{K\bibinitperiod}{}{}{}{}}%
        {{hash=a888634c7e54a5c7dc9e9e9e8d757768}{Reinhardt}{R\bibinitperiod}{Sven}{S\bibinitperiod}{}{}{}{}}%
        {{hash=23f5b35687a70026c45beaeaac63bb12}{Kuhn}{K\bibinitperiod}{Peer-Hendrik}{P\bibinithyphendelim H\bibinitperiod}{}{}{}{}}%
        {{hash=d5b0de48d76049730d1120d8da0901e0}{Lichtenthaler}{L\bibinitperiod}{Stefan\bibnamedelima F}{S\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{hash=2ea2c73d8388a5bf85d22232b986b28b}{Hansen}{H\bibinitperiod}{Jens}{J\bibinitperiod}{}{}{}{}}%
        {{hash=39f0264772b09e386b77fb16f7814c46}{Wurst}{W\bibinitperiod}{Wolfgang}{W\bibinitperiod}{}{}{}{}}%
        {{hash=b7a2bfdc63606d74ab85e02ecc423c2a}{Tr{\"{u}}mbach}{T\bibinitperiod}{Dietrich}{D\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{27ab1d2fe1a1f3949c13cfef9478bc6f}
      \strng{fullhash}{1de2a36306ce71a308b45e5c5a1d14fb}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Computational identification and experimental validation of microRNAs binding to the Alzheimer-related gene ADAM10}}
      \field{abstract}{MicroRNAs (miRNAs) are post-transcriptional regulators involved in numerous biological processes including the pathogenesis of Alzheimer's disease (AD). A key gene of AD, ADAM10, controls the proteolytic processing of APP and the formation of the amyloid plaques and is known to be regulated by miRNA in hepatic cancer cell lines. To predict miRNAs regulating ADAM10 expression concerning AD, we developed a computational approach.}
      \field{issn}{1471-2350}
      \field{journaltitle}{BMC Medical Genetics}
      \field{number}{1}
      \field{title}{{Computational identification and experimental validation of microRNAs binding to the Alzheimer-related gene ADAM10}}
      \field{volume}{13}
      \field{year}{2012}
      \field{pages}{1\bibrangedash 12}
      \verb{doi}
      \verb 10.1186/1471-2350-13-35
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1186/1471-2350-13-35
      \endverb
    \endentry
    \entry{Martinez-Jimenez2013}{article}{}
      \name{labelname}{10}{}{%
        {{hash=9f1694dcbbd71d71a2b23228fee9da83}{Mart{\'{\i}}nez-Jim{\'{e}}nez}{M\bibinithyphendelim J\bibinitperiod}{Francisco}{F\bibinitperiod}{}{}{}{}}%
        {{hash=d0d9d6fafa34670d65fe13aa0977dbe6}{Papadatos}{P\bibinitperiod}{George}{G\bibinitperiod}{}{}{}{}}%
        {{hash=8b737472161f9411595cc50369d7322c}{Yang}{Y\bibinitperiod}{Lun}{L\bibinitperiod}{}{}{}{}}%
        {{hash=afeee9102ae93cefcca6135bb08c25c1}{Wallace}{W\bibinitperiod}{Iain\bibnamedelima M.}{I\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=08a43e8ef8e3a2d464e9e8800f2ab3c9}{Kumar}{K\bibinitperiod}{Vinod}{V\bibinitperiod}{}{}{}{}}%
        {{hash=ed697f1b151831b61b4a519f41fdb295}{Pieper}{P\bibinitperiod}{Ursula}{U\bibinitperiod}{}{}{}{}}%
        {{hash=f3bdee19cfffe5535eb11a4f1ee54225}{Sali}{S\bibinitperiod}{Andrej}{A\bibinitperiod}{}{}{}{}}%
        {{hash=7eaedf0fe73ed481fe8ca70fe96db5f9}{Brown}{B\bibinitperiod}{James\bibnamedelima R.}{J\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=e4e933dff0b707e6aa02a1448b3f48af}{Overington}{O\bibinitperiod}{John\bibnamedelima P.}{J\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=a0f6156def7676c24698f54ed6b75e41}{Marti-Renom}{M\bibinithyphendelim R\bibinitperiod}{Marc\bibnamedelima a.}{M\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{10}{}{%
        {{hash=9f1694dcbbd71d71a2b23228fee9da83}{Mart{\'{\i}}nez-Jim{\'{e}}nez}{M\bibinithyphendelim J\bibinitperiod}{Francisco}{F\bibinitperiod}{}{}{}{}}%
        {{hash=d0d9d6fafa34670d65fe13aa0977dbe6}{Papadatos}{P\bibinitperiod}{George}{G\bibinitperiod}{}{}{}{}}%
        {{hash=8b737472161f9411595cc50369d7322c}{Yang}{Y\bibinitperiod}{Lun}{L\bibinitperiod}{}{}{}{}}%
        {{hash=afeee9102ae93cefcca6135bb08c25c1}{Wallace}{W\bibinitperiod}{Iain\bibnamedelima M.}{I\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=08a43e8ef8e3a2d464e9e8800f2ab3c9}{Kumar}{K\bibinitperiod}{Vinod}{V\bibinitperiod}{}{}{}{}}%
        {{hash=ed697f1b151831b61b4a519f41fdb295}{Pieper}{P\bibinitperiod}{Ursula}{U\bibinitperiod}{}{}{}{}}%
        {{hash=f3bdee19cfffe5535eb11a4f1ee54225}{Sali}{S\bibinitperiod}{Andrej}{A\bibinitperiod}{}{}{}{}}%
        {{hash=7eaedf0fe73ed481fe8ca70fe96db5f9}{Brown}{B\bibinitperiod}{James\bibnamedelima R.}{J\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=e4e933dff0b707e6aa02a1448b3f48af}{Overington}{O\bibinitperiod}{John\bibnamedelima P.}{J\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=a0f6156def7676c24698f54ed6b75e41}{Marti-Renom}{M\bibinithyphendelim R\bibinitperiod}{Marc\bibnamedelima a.}{M\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
      }
      \name{editor}{1}{}{%
        {{hash=41e57eef71f3ac9e59df91591a0eef68}{MacKerell}{M\bibinitperiod}{Alexander\bibnamedelima Donald}{A\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{c4595e912fd12973b6d1290fbc255c59}
      \strng{fullhash}{9f652e7aaece5cbb7e9e7eefdc8d6da0}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Target Prediction for an Open Access Set of Compounds Active against Mycobacterium tuberculosis}}
      \field{issn}{1553-7358}
      \field{journaltitle}{PLoS Computational Biology}
      \field{month}{10}
      \field{number}{10}
      \field{title}{{Target Prediction for an Open Access Set of Compounds Active against Mycobacterium tuberculosis}}
      \field{volume}{9}
      \field{year}{2013}
      \field{pages}{e1003253}
      \verb{doi}
      \verb 10.1371/journal.pcbi.1003253
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Mart{\'{\i}}nez-Jim{\'{e}}nez et al. - 2013 - Target Prediction for an Open Access Set of Compounds Active against Mycobacterium tuberculosis.pdf:pdf
      \endverb
      \verb{url}
      \verb http://dx.plos.org/10.1371/journal.pcbi.1003253
      \endverb
    \endentry
    \entry{Perkins2003}{article}{}
      \name{labelname}{4}{}{%
        {{hash=93a6b9064c4ba4ae360171f4dba83592}{Perkins}{P\bibinitperiod}{Roger}{R\bibinitperiod}{}{}{}{}}%
        {{hash=daeda31120dc0a0452eabb3c271893e1}{Fang}{F\bibinitperiod}{Hong}{H\bibinitperiod}{}{}{}{}}%
        {{hash=50b19a795924bc4d7edf515869228fdb}{Tong}{T\bibinitperiod}{Weida}{W\bibinitperiod}{}{}{}{}}%
        {{hash=9d6b5c73cc393314dd90d2c84a91a96f}{Welsh}{W\bibinitperiod}{William\bibnamedelima J}{W\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=93a6b9064c4ba4ae360171f4dba83592}{Perkins}{P\bibinitperiod}{Roger}{R\bibinitperiod}{}{}{}{}}%
        {{hash=daeda31120dc0a0452eabb3c271893e1}{Fang}{F\bibinitperiod}{Hong}{H\bibinitperiod}{}{}{}{}}%
        {{hash=50b19a795924bc4d7edf515869228fdb}{Tong}{T\bibinitperiod}{Weida}{W\bibinitperiod}{}{}{}{}}%
        {{hash=9d6b5c73cc393314dd90d2c84a91a96f}{Welsh}{W\bibinitperiod}{William\bibnamedelima J}{W\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{a3e22706c755f53be5aa3f1fc9f1e301}
      \strng{fullhash}{978f1ced5a8d72c3b27e0b1710978734}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Quantitative structure-activity relationship methods: perspectives on drug discovery and toxicology.}}
      \field{abstract}{Quantitative structure-activity relationships (QSARs) attempt to correlate chemical structure with activity using statistical approaches. The QSAR models are useful for various purposes including the prediction of activities of untested chemicals. Quantitative structure-activity relationships and other related approaches have attracted broad scientific interest, particularly in the pharmaceutical industry for drug discovery and in toxicology and environmental science for risk assessment. An assortment of new QSAR methods have been developed during the past decade, most of them focused on drug discovery. Besides advancing our fundamental knowledge of QSARs, these scientific efforts have stimulated their application in a wider range of disciplines, such as toxicology, where QSARs have not yet gained full appreciation. In this review, we attempt to summarize the status of QSAR with emphasis on illuminating the utility and limitations of QSAR technology. We will first review two-dimensional (2D) QSAR with a discussion of the availability and appropriate selection of molecular descriptors. We will then proceed to describe three-dimensional (3D) QSAR and key issues associated with this technology, then compare the relative suitability of 2D and 3D QSAR for different applications. Given the recent technological advances in biological research for rapid identification of drug targets, we mention several examples in which QSAR approaches are employed in conjunction with improved knowledge of the structure and function of the target receptor. The review will conclude by discussing statistical validation of QSAR models, a topic that has received sparse attention in recent years despite its critical importance.}
      \field{isbn}{0730-7268}
      \field{issn}{1092-874X}
      \field{journaltitle}{Environmental toxicology and chemistry / SETAC}
      \field{number}{8}
      \field{title}{{Quantitative structure-activity relationship methods: perspectives on drug discovery and toxicology.}}
      \field{volume}{22}
      \field{year}{2003}
      \field{pages}{1666\bibrangedash 1679}
      \verb{doi}
      \verb 10.1897/01-171
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/5620220803{\_}ftp.pdf:pdf
      \endverb
    \endentry
    \entry{Penzotti2004}{article}{}
      \name{labelname}{3}{}{%
        {{hash=38f22595d16d6c5cc281e7764b7a8e74}{Penzotti}{P\bibinitperiod}{Julie\bibnamedelima E}{J\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=aa786c6f173bc576888dd16bd420ad27}{Landrum}{L\bibinitperiod}{Gregory\bibnamedelima A}{G\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=90a663a593b89a86a84aecfaa3d93a43}{Putta}{P\bibinitperiod}{Santosh}{S\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=38f22595d16d6c5cc281e7764b7a8e74}{Penzotti}{P\bibinitperiod}{Julie\bibnamedelima E}{J\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=aa786c6f173bc576888dd16bd420ad27}{Landrum}{L\bibinitperiod}{Gregory\bibnamedelima A}{G\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=90a663a593b89a86a84aecfaa3d93a43}{Putta}{P\bibinitperiod}{Santosh}{S\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{3266b94a9237736c603a243f2cdcb61d}
      \strng{fullhash}{3266b94a9237736c603a243f2cdcb61d}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Building predictive ADMET models for early decisions in drug discovery}}
      \field{issn}{1367-6733}
      \field{journaltitle}{Current opinion in drug discovery {\&} development}
      \field{month}{01}
      \field{number}{1}
      \field{title}{{Building predictive ADMET models for early decisions in drug discovery}}
      \field{volume}{7}
      \field{year}{2004}
      \field{pages}{49\bibrangedash 61}
      \verb{url}
      \verb http://europepmc.org/abstract/MED/14982148
      \endverb
    \endentry
    \entry{Obrezanova2007}{article}{}
      \name{labelname}{4}{}{%
        {{hash=456ba92b104ba4d7c7ba0e5e22746ed5}{Obrezanova}{O\bibinitperiod}{Olga}{O\bibinitperiod}{}{}{}{}}%
        {{hash=fc446f82b9fe56cf46041ff1e8828309}{Cs{\'{a}}nyi}{C\bibinitperiod}{G{\'{a}}bor}{G\bibinitperiod}{}{}{}{}}%
        {{hash=b678a582e926cffdfd575b2e798e45db}{Gola}{G\bibinitperiod}{Joelle\bibnamedelimb M\bibnamedelima R}{J\bibinitperiod\bibinitdelim M\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=fbfb1c3587a7bbd308400d55877ec2f1}{Segall}{S\bibinitperiod}{Matthew\bibnamedelima D}{M\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=456ba92b104ba4d7c7ba0e5e22746ed5}{Obrezanova}{O\bibinitperiod}{Olga}{O\bibinitperiod}{}{}{}{}}%
        {{hash=fc446f82b9fe56cf46041ff1e8828309}{Cs{\'{a}}nyi}{C\bibinitperiod}{G{\'{a}}bor}{G\bibinitperiod}{}{}{}{}}%
        {{hash=b678a582e926cffdfd575b2e798e45db}{Gola}{G\bibinitperiod}{Joelle\bibnamedelimb M\bibnamedelima R}{J\bibinitperiod\bibinitdelim M\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=fbfb1c3587a7bbd308400d55877ec2f1}{Segall}{S\bibinitperiod}{Matthew\bibnamedelima D}{M\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {American Chemical Society}%
      }
      \strng{namehash}{d283ac5d758854ffb61c9d3fcf4514b3}
      \strng{fullhash}{f3723e8f8ea576e85c41c473c2ad878b}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Gaussian Processes: A Method for Automatic QSAR Modeling of ADME Properties}}
      \field{annotation}{doi: 10.1021/ci7000633}
      \field{issn}{1549-9596}
      \field{journaltitle}{Journal of Chemical Information and Modeling}
      \field{month}{09}
      \field{number}{5}
      \field{title}{{Gaussian Processes: A Method for Automatic QSAR Modeling of ADME Properties}}
      \field{volume}{47}
      \field{year}{2007}
      \field{pages}{1847\bibrangedash 1857}
      \verb{doi}
      \verb 10.1021/ci7000633
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1021/ci7000633
      \endverb
    \endentry
    \entry{Yoshida2000}{article}{}
      \name{labelname}{2}{}{%
        {{hash=8a8c5fdcb9640b2d39d99f6264bf7403}{Yoshida}{Y\bibinitperiod}{Fumitaka}{F\bibinitperiod}{}{}{}{}}%
        {{hash=5d795b56025859873fe1a139fd0f4d96}{Topliss}{T\bibinitperiod}{John\bibnamedelima G}{J\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=8a8c5fdcb9640b2d39d99f6264bf7403}{Yoshida}{Y\bibinitperiod}{Fumitaka}{F\bibinitperiod}{}{}{}{}}%
        {{hash=5d795b56025859873fe1a139fd0f4d96}{Topliss}{T\bibinitperiod}{John\bibnamedelima G}{J\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {American Chemical Society}%
      }
      \strng{namehash}{f0b9c2ea6c0c4cfdb865df1139ef4d72}
      \strng{fullhash}{f0b9c2ea6c0c4cfdb865df1139ef4d72}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{QSAR Model for Drug Human Oral Bioavailability}}
      \field{annotation}{doi: 10.1021/jm0000564}
      \field{issn}{0022-2623}
      \field{journaltitle}{Journal of Medicinal Chemistry}
      \field{month}{06}
      \field{number}{13}
      \field{title}{{QSAR Model for Drug Human Oral Bioavailability}}
      \field{volume}{43}
      \field{year}{2000}
      \field{pages}{2575\bibrangedash 2585}
      \verb{doi}
      \verb 10.1021/jm0000564
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1021/jm0000564
      \endverb
    \endentry
    \entry{Verma2010}{article}{}
      \name{labelname}{3}{}{%
        {{hash=490d387acf664c6cad74c3b5674d4528}{Verma}{V\bibinitperiod}{Jitender}{J\bibinitperiod}{}{}{}{}}%
        {{hash=6dce28ee747b135ed562325fcb7c9c40}{Khedkar}{K\bibinitperiod}{Vijay\bibnamedelima M.}{V\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=6b264a1bf78d58d121eb4791382d93d1}{Coutinho}{C\bibinitperiod}{Evans\bibnamedelima C.}{E\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=490d387acf664c6cad74c3b5674d4528}{Verma}{V\bibinitperiod}{Jitender}{J\bibinitperiod}{}{}{}{}}%
        {{hash=6dce28ee747b135ed562325fcb7c9c40}{Khedkar}{K\bibinitperiod}{Vijay\bibnamedelima M.}{V\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=6b264a1bf78d58d121eb4791382d93d1}{Coutinho}{C\bibinitperiod}{Evans\bibnamedelima C.}{E\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{1aafa1ec9835a8d2f7b83f3c63ec8e3c}
      \strng{fullhash}{1aafa1ec9835a8d2f7b83f3c63ec8e3c}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{3D-QSAR in Drug Design}}
      \field{abstract}{Quantitative structure-activity relationships (QSAR) have been applied for decades in the development of relationships between physicochemical properties of chemical substances and their biological activities to obtain a reliable statistical model for prediction of the activities of new chemical entities. The fundamental principle underlying the formalism is that the difference in structural properties is responsible for the variations in biological activities of the compounds. In the classical QSAR studies, affinities of ligands to their binding sites, inhibition constants, rate constants, and other biological end points, with atomic, group or molecular properties such as lipophilicity, polarizability, electronic and steric properties (Hansch analysis) or with certain structural features (Free-Wilson analysis) have been correlated. However such an approach has only a limited utility for designing a new molecule due to the lack of consideration of the 3D structure of the molecules. 3D-QSAR has emerged as a natural extension to the classical Hansch and Free-Wilson approaches, which exploits the three-dimensional properties of the ligands to predict their biological activities using robust chemometric techniques such as PLS, G/PLS, ANN etc. It has served as a valuable predictive tool in the design of pharmaceuticals and agrochemicals. Although the trial and error factor involved in the development of a new drug cannot be ignored completely, QSAR certainly decreases the number of compounds to be synthesized by facilitating the selection of the most promising candidates. Several success stories of QSAR have attracted the medicinal chemists to investigate the relationships of structural properties with biological activity. This review seeks to provide a bird's eye view of the different 3D-QSAR approaches employed within the current drug discovery community to construct predictive structure-activity relationships and also discusses the limitations that are fundamental to these approaches, as well as those that might be overcome with the improved strategies. The components involved in building a useful 3D-QSAR model are discussed, including the validation techniques available for this purpose.}
      \field{isbn}{1568-0266}
      \field{issn}{15680266}
      \field{journaltitle}{Current Topics in Medicinal Chemistry}
      \field{number}{1}
      \field{title}{{3D-QSAR in Drug Design}}
      \field{volume}{10}
      \field{year}{2010}
      \field{pages}{95\bibrangedash 115}
      \verb{doi}
      \verb 10.2174/156802610790232260
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/2010{\_}CTMC{\_}3D{\_}QSAR{\_}Review.pdf:pdf
      \endverb
    \endentry
    \entry{Cramer1988}{article}{}
      \name{labelname}{3}{}{%
        {{hash=7c96c92cf1e36e5a905da7a182862f73}{Cramer}{C\bibinitperiod}{R\bibnamedelima D}{R\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=725b72bfc786ce8d4c6aa6d0db2a9eca}{Patterson}{P\bibinitperiod}{D\bibnamedelima E}{D\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=7ff36b92b953e370cb5b8d6d2f6d5ff3}{Bunce}{B\bibinitperiod}{J\bibnamedelima D}{J\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=7c96c92cf1e36e5a905da7a182862f73}{Cramer}{C\bibinitperiod}{R\bibnamedelima D}{R\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=725b72bfc786ce8d4c6aa6d0db2a9eca}{Patterson}{P\bibinitperiod}{D\bibnamedelima E}{D\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=7ff36b92b953e370cb5b8d6d2f6d5ff3}{Bunce}{B\bibinitperiod}{J\bibnamedelima D}{J\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{e1f27be58dce3b83bdbd05d8bf887b94}
      \strng{fullhash}{e1f27be58dce3b83bdbd05d8bf887b94}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Comparative molecular field analysis (CoMFA)}}
      \field{abstract}{Comparative molecular field analysis (CoMFA) is a promising new approach to structure/activity correlation. Its characteristic features are (1) representation of ligand molecules by their steric and electrostatic fields, sampled at the intersections of a three-dimensional lattice, (2) a new "field fit{$\textquotedblright$} technique, allowing optimal mutual alignment within a series, by minimizing the RMS field differences between molecules, (3) data analysis by partial least squares (PLS), using cross-validation to maximize the likelihood that the results have predictive validity, and (4) graphic representation of results, as contoured three-dimensional coefficient plots. CoMFA is exemplified by analyses of the affinities of 21 varied steroids to corticosteroid- and testosterone-binding globulins. Also described are the sensitivities of results to the nature of the field and the definition of the lattice and, for comparison, analyses of the same data using various combinations of other parameters. From these results, a set of ten steroid-binding affinity values unknown to us during the CoMFA analysis were well predicted.}
      \field{isbn}{0002-7863 (Print)$\backslash$n0002-7863 (Linking)}
      \field{issn}{0002-7863}
      \field{journaltitle}{Journal of the American Chemical Society}
      \field{number}{18}
      \field{title}{{Comparative molecular field analysis (CoMFA)}}
      \field{volume}{110}
      \field{year}{1988}
      \field{pages}{5959\bibrangedash 5967}
      \verb{doi}
      \verb 10.1021/ja00226a005
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/ja00226a005.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/22148765
      \endverb
    \endentry
    \entry{Hopfinger1997}{article}{}
      \name{labelname}{7}{}{%
        {{hash=2dda2e0640d5a5cad16afa3e6e7db64d}{Hopfinger}{H\bibinitperiod}{A\bibnamedelima J}{A\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=2f2bb9422125d3f4e6a018760477a75e}{Wang}{W\bibinitperiod}{Shen}{S\bibinitperiod}{}{}{}{}}%
        {{hash=5e31da4d4a0b69c4cfe621baf8a22455}{Tokarski}{T\bibinitperiod}{John\bibnamedelima S}{J\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=e58fb480fe41d902c4833aef64fb209e}{Jin}{J\bibinitperiod}{Baiqiang}{B\bibinitperiod}{}{}{}{}}%
        {{hash=8cf843e5137701c8962e2719f8ffaeaf}{Albuquerque}{A\bibinitperiod}{Magaly}{M\bibinitperiod}{}{}{}{}}%
        {{hash=04337ce14b1653cfa67b4654554c92b2}{Madhav}{M\bibinitperiod}{Prakash\bibnamedelima J}{P\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=6daa0ddf57ef31532bd252cb6847f8bb}{Duraiswami}{D\bibinitperiod}{Chaya}{C\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{7}{}{%
        {{hash=2dda2e0640d5a5cad16afa3e6e7db64d}{Hopfinger}{H\bibinitperiod}{A\bibnamedelima J}{A\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=2f2bb9422125d3f4e6a018760477a75e}{Wang}{W\bibinitperiod}{Shen}{S\bibinitperiod}{}{}{}{}}%
        {{hash=5e31da4d4a0b69c4cfe621baf8a22455}{Tokarski}{T\bibinitperiod}{John\bibnamedelima S}{J\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=e58fb480fe41d902c4833aef64fb209e}{Jin}{J\bibinitperiod}{Baiqiang}{B\bibinitperiod}{}{}{}{}}%
        {{hash=8cf843e5137701c8962e2719f8ffaeaf}{Albuquerque}{A\bibinitperiod}{Magaly}{M\bibinitperiod}{}{}{}{}}%
        {{hash=04337ce14b1653cfa67b4654554c92b2}{Madhav}{M\bibinitperiod}{Prakash\bibnamedelima J}{P\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=6daa0ddf57ef31532bd252cb6847f8bb}{Duraiswami}{D\bibinitperiod}{Chaya}{C\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {American Chemical Society}%
      }
      \strng{namehash}{ec2d004ee532e0a88785ea95607cc964}
      \strng{fullhash}{ed74c6cc2eee5ad2eefd3f983b842d98}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Construction of 3D-QSAR Models Using the 4D-QSAR Analysis Formalism}}
      \field{annotation}{doi: 10.1021/ja9718937}
      \field{issn}{0002-7863}
      \field{journaltitle}{Journal of the American Chemical Society}
      \field{month}{10}
      \field{number}{43}
      \field{title}{{Construction of 3D-QSAR Models Using the 4D-QSAR Analysis Formalism}}
      \field{volume}{119}
      \field{year}{1997}
      \field{pages}{10509\bibrangedash 10524}
      \verb{doi}
      \verb 10.1021/ja9718937
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1021/ja9718937
      \endverb
    \endentry
    \entry{Ekins2000}{article}{}
      \name{labelname}{7}{}{%
        {{hash=5752f3a4325e2b3630c5d6a2fbf20203}{Ekins}{E\bibinitperiod}{Sean}{S\bibinitperiod}{}{}{}{}}%
        {{hash=18ca03abd85f692b5667f4bb09f63418}{Bravi}{B\bibinitperiod}{Gianpaolo}{G\bibinitperiod}{}{}{}{}}%
        {{hash=0a6da73a9b1724f1e7ef2eb7efc1a5b5}{Binkley}{B\bibinitperiod}{Shelly}{S\bibinitperiod}{}{}{}{}}%
        {{hash=d6f3f9848d030b0011df81901208bbd0}{Gillespie}{G\bibinitperiod}{Jennifer\bibnamedelima S}{J\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=50a37297a321d8ce109721c297ef455d}{Ring}{R\bibinitperiod}{Barbara\bibnamedelima J}{B\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=20649076d2d797eef2c9eb0345a6d392}{Wikel}{W\bibinitperiod}{James\bibnamedelima H}{J\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=0b9891ae2d4d3d5e726fddd8d807c66d}{Wrighton}{W\bibinitperiod}{Steven\bibnamedelima A}{S\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{7}{}{%
        {{hash=5752f3a4325e2b3630c5d6a2fbf20203}{Ekins}{E\bibinitperiod}{Sean}{S\bibinitperiod}{}{}{}{}}%
        {{hash=18ca03abd85f692b5667f4bb09f63418}{Bravi}{B\bibinitperiod}{Gianpaolo}{G\bibinitperiod}{}{}{}{}}%
        {{hash=0a6da73a9b1724f1e7ef2eb7efc1a5b5}{Binkley}{B\bibinitperiod}{Shelly}{S\bibinitperiod}{}{}{}{}}%
        {{hash=d6f3f9848d030b0011df81901208bbd0}{Gillespie}{G\bibinitperiod}{Jennifer\bibnamedelima S}{J\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=50a37297a321d8ce109721c297ef455d}{Ring}{R\bibinitperiod}{Barbara\bibnamedelima J}{B\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=20649076d2d797eef2c9eb0345a6d392}{Wikel}{W\bibinitperiod}{James\bibnamedelima H}{J\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=0b9891ae2d4d3d5e726fddd8d807c66d}{Wrighton}{W\bibinitperiod}{Steven\bibnamedelima A}{S\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{0f369f193e1ab7717e2185c2797e8a90}
      \strng{fullhash}{2aba0cf411b7bc672478fb3c45d2cc6f}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Three-and Four-Dimensional Quantitative Structure Activity Relationship (3D/4D-QSAR) Analyses of CYP2C9 Inhibitors}}
      \field{abstract}{The interaction of competitive type inhibitors with the active site of cytochrome P450 (CYP) 2C9 has been predicted using three- and four-dimensional quantitative structure activity relationship (3D-/4D-QSAR) models constructed using previously unreported and literature-derived data. 3D-QSAR pharmacophore models of the common structural features of CYP2C9 inhibitors were built using the program Catalyst and compared with 3D- and 4D-QSAR partial least-squares models, which use molecular surface-weighted holistic invariant molecular descriptors of the size and shape of inhibitors. The Catalyst models generated from multiple conformers of competitive inhibitors of CYP2C9 activities contained at least one hydrophobic and two hydrogen bond acceptor/donor regions. Catalyst model 1 was constructed with Ki(apparent) values for inhibitors of tolbutamide and diclofenac 4\x{2032}-hydroxylation (n = 9). Catalyst model 2 was generated from literature Ki(apparent) values for (S)-warfarin 7-hydroxylation (n = 29), and Catalyst model 3 from literature IC50 values for tolbutamide 4-hydroxylation (n = 13). These three models illustrated correlation values of observed and predicted inhibition for CYP2C9 of r = 0.91, 0.89, and 0.71, respectively. Catalyst pharmacophores generated withKi(apparent) values were validated by predicting the Ki(apparent) value of a test set of CYP2C9 inhibitors also derived from the literature (n = 14). Twelve of fourteen of theseKi(apparent) values were predicted to be within 1 log residual of the observed value using Catalyst model 1, whereas Catalyst model 2 predicted 10 of 14Ki(apparent) values. The corresponding partial least-squares molecular surface-weighted holistic invariant molecular 3D- and 4D-QSAR models for all CYP2C9 data sets yielded predictable models as assessed using cross-validation. These 3D- and 4D-QSAR models of CYP inhibition will aid in future prediction of drug-drug interactions.}
      \field{journaltitle}{Drug Metabolism and Disposition}
      \field{month}{08}
      \field{number}{8}
      \field{title}{{Three-and Four-Dimensional Quantitative Structure Activity Relationship (3D/4D-QSAR) Analyses of CYP2C9 Inhibitors}}
      \field{volume}{28}
      \field{year}{2000}
      \field{pages}{994\bibrangedash 1002}
      \verb{url}
      \verb http://dmd.aspetjournals.org/content/28/8/994.abstract
      \endverb
    \endentry
    \entry{Iyer2007}{article}{}
      \name{labelname}{2}{}{%
        {{hash=ec9c6ac53e43bc585db8f58df037639e}{Iyer}{I\bibinitperiod}{Manisha}{M\bibinitperiod}{}{}{}{}}%
        {{hash=2dda2e0640d5a5cad16afa3e6e7db64d}{Hopfinger}{H\bibinitperiod}{A\bibnamedelima J}{A\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=ec9c6ac53e43bc585db8f58df037639e}{Iyer}{I\bibinitperiod}{Manisha}{M\bibinitperiod}{}{}{}{}}%
        {{hash=2dda2e0640d5a5cad16afa3e6e7db64d}{Hopfinger}{H\bibinitperiod}{A\bibnamedelima J}{A\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {American Chemical Society}%
      }
      \strng{namehash}{44b75f3e30b89f1d268432584bd5433a}
      \strng{fullhash}{44b75f3e30b89f1d268432584bd5433a}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Treating Chemical Diversity in QSAR Analysis Modeling Diverse HIV-1 Integrase Inhibitors Using 4D Fingerprints}}
      \field{annotation}{doi: 10.1021/ci700153g}
      \field{issn}{1549-9596}
      \field{journaltitle}{Journal of Chemical Information and Modeling}
      \field{month}{09}
      \field{number}{5}
      \field{title}{{Treating Chemical Diversity in QSAR Analysis Modeling Diverse HIV-1 Integrase Inhibitors Using 4D Fingerprints}}
      \field{volume}{47}
      \field{year}{2007}
      \field{pages}{1945\bibrangedash 1960}
      \verb{doi}
      \verb 10.1021/ci700153g
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1021/ci700153g
      \endverb
    \endentry
    \entry{Romeiro2010}{article}{}
      \name{labelname}{5}{}{%
        {{hash=21e31c66ecbfd4c0bf13d6e72bfc46a9}{Romeiro}{R\bibinitperiod}{Nelilma\bibnamedelima Correia}{N\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=8d5f0a4dc5ad47de506efacf4b8aff07}{Albuquerque}{A\bibinitperiod}{Magaly\bibnamedelima Gir{\~{a}}o}{M\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=e7e870482fd645741388b25c4d7e055c}{Alencastro}{A\bibinitperiod}{Ricardo\bibnamedelima Bicca}{R\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=a0c51f7d307e44f3129c39b3ea28ffba}{Ravi}{R\bibinitperiod}{Malini}{M\bibinitperiod}{}{}{}{}}%
        {{hash=9a02dcf0a348a631715a06bddb58b441}{Hopfinger}{H\bibinitperiod}{Anton\bibnamedelima J}{A\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{5}{}{%
        {{hash=21e31c66ecbfd4c0bf13d6e72bfc46a9}{Romeiro}{R\bibinitperiod}{Nelilma\bibnamedelima Correia}{N\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=8d5f0a4dc5ad47de506efacf4b8aff07}{Albuquerque}{A\bibinitperiod}{Magaly\bibnamedelima Gir{\~{a}}o}{M\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=e7e870482fd645741388b25c4d7e055c}{Alencastro}{A\bibinitperiod}{Ricardo\bibnamedelima Bicca}{R\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=a0c51f7d307e44f3129c39b3ea28ffba}{Ravi}{R\bibinitperiod}{Malini}{M\bibinitperiod}{}{}{}{}}%
        {{hash=9a02dcf0a348a631715a06bddb58b441}{Hopfinger}{H\bibinitperiod}{Anton\bibnamedelima J}{A\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{201510b9dd8ce89d71e511c817b901e4}
      \strng{fullhash}{43f38db42194bf55fec06621be5d3bfe}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Construction of 4D-QSAR Models for Use in the Design of Novel p38-MAPK Inhibitors}}
      \field{abstract}{The p38-mitogen-activated protein kinase (p38-MAPK) plays a key role in lipopolysaccharide-induced tumor necrosis factor-{\$}\alpha{\$} (TNF-{\$}\alpha{\$}) and interleukin{$\textminus$}1 (IL{$\textminus$}1) release during the inflammatory process, emerging as an attractive target for new anti-inflammatory agents. Four-dimensional quantitative structure-activity relationship (4D-QSAR) analysis [Hopfinger et al., J. Am. Chem. Soc., 119 (1997) 10509] was applied to a series of 33 (a training set of 28 and a test set of 5) pyridinyl-imidazole and pyrimidinyl-imidazole inhibitors of p38-MAPK, with IC50 ranging from 0.11 to 2100 nM [Liverton et al., J. Med. Chem., 42 (1999) 2180]. Five thousand conformations of each analogue were sampled from a molecular dynamics simulation (MDS) during 50 ps at a constant temperature of 303 K. Each conformation was placed in a 2 {\{}{\r{A}}{\}} grid cell lattice for each of three trial alignments. 4D-QSAR models were constructed by genetic algorithm (GA) optimization and partial least squares (PLS) fitting, and evaluated by leave-one-out cross-validation technique. In the best models, with three to six terms, the adjusted cross-validated squared correlation coefficients, Q2adj, ranged from 0.67 to 0.85. Model D (Q2adj = 0.84) was identified as the most robust model from alignment 1, and it is representative of the other best models. This model encompasses new molecular regions as containing pharmacophore sites, such as the amino-benzyl moiety of pyrimidine analogs and the N1-substituent in the imidazole ring. These regions of the ligands should be further explored to identify better anti-inflammatory inhibitors of p38-MAPK.}
      \field{issn}{1573-4951}
      \field{journaltitle}{Journal of Computer-Aided Molecular Design}
      \field{number}{6}
      \field{title}{{Construction of 4D-QSAR Models for Use in the Design of Novel p38-MAPK Inhibitors}}
      \field{volume}{19}
      \field{pages}{385\bibrangedash 400}
      \verb{doi}
      \verb 10.1007/s10822-005-7927-4
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1007/s10822-005-7927-4
      \endverb
    \endentry
    \entry{Andrade2010}{article}{}
      \name{labelname}{4}{}{%
        {{hash=fea9b4c54be4bb2dc9cc223f99083028}{Andrade}{A\bibinitperiod}{Carolina\bibnamedelima H.}{C\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=6ec6e66ae3eddf5b2f1f56df2bce3ec5}{Pasqualoto}{P\bibinitperiod}{Kerly\bibnamedelimb F\bibnamedelima M}{K\bibinitperiod\bibinitdelim F\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=821f8346c9a6a886ab45fb499efaf6e1}{Ferreira}{F\bibinitperiod}{Elizabeth\bibnamedelima I.}{E\bibinitperiod\bibinitdelim I\bibinitperiod}{}{}{}{}}%
        {{hash=7ceabe347b7cab78254b799dcfe4a8c3}{Hopfinger}{H\bibinitperiod}{Anton\bibnamedelima J.}{A\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=fea9b4c54be4bb2dc9cc223f99083028}{Andrade}{A\bibinitperiod}{Carolina\bibnamedelima H.}{C\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=6ec6e66ae3eddf5b2f1f56df2bce3ec5}{Pasqualoto}{P\bibinitperiod}{Kerly\bibnamedelimb F\bibnamedelima M}{K\bibinitperiod\bibinitdelim F\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=821f8346c9a6a886ab45fb499efaf6e1}{Ferreira}{F\bibinitperiod}{Elizabeth\bibnamedelima I.}{E\bibinitperiod\bibinitdelim I\bibinitperiod}{}{}{}{}}%
        {{hash=7ceabe347b7cab78254b799dcfe4a8c3}{Hopfinger}{H\bibinitperiod}{Anton\bibnamedelima J.}{A\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{6e32ec912ceb8e32d326d69253794f1b}
      \strng{fullhash}{5999086021afd434c0ae700d792d84f2}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{4D-QSAR: Perspectives in drug design}}
      \field{abstract}{Drug design is a process driven by innovation and technological breakthroughs involving a combination of advanced experimental and computational methods. A broad variety of medicinal chemistry approaches can be used for the identification of hits, generation of leads, as well as to accelerate the optimization of leads into drug candidates. The quantitative structure-activity relationship (QSAR) formalisms are among the most important strategies that can be applied for the successful design new molecules. This review provides a comprehensive review on the evolution and current status of 4D-QSAR, highlighting present challenges and new opportunities in drug design.}
      \field{isbn}{1420-3049}
      \field{issn}{14203049}
      \field{journaltitle}{Molecules}
      \field{number}{5}
      \field{title}{{4D-QSAR: Perspectives in drug design}}
      \field{volume}{15}
      \field{year}{2010}
      \field{pages}{3281\bibrangedash 3294}
      \verb{doi}
      \verb 10.3390/molecules15053281
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/molecules-15-03281.pdf:pdf
      \endverb
    \endentry
    \entry{Vedani2002}{article}{}
      \name{labelname}{2}{}{%
        {{hash=9da2354f5ea78e4dba1b3a03ec5ea9e7}{Vedani}{V\bibinitperiod}{Angelo}{A\bibinitperiod}{}{}{}{}}%
        {{hash=e30e899a058f5e333f376cd77542eb42}{Dobler}{D\bibinitperiod}{Max}{M\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=9da2354f5ea78e4dba1b3a03ec5ea9e7}{Vedani}{V\bibinitperiod}{Angelo}{A\bibinitperiod}{}{}{}{}}%
        {{hash=e30e899a058f5e333f376cd77542eb42}{Dobler}{D\bibinitperiod}{Max}{M\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {American Chemical Society}%
      }
      \strng{namehash}{6e10480c48847e09fdb06143fdd2894c}
      \strng{fullhash}{6e10480c48847e09fdb06143fdd2894c}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{5D-QSAR: The Key for Simulating Induced Fit}}
      \field{annotation}{doi: 10.1021/jm011005p}
      \field{issn}{0022-2623}
      \field{journaltitle}{Journal of Medicinal Chemistry}
      \field{month}{05}
      \field{number}{11}
      \field{title}{{5D-QSAR: The Key for Simulating Induced Fit}}
      \field{volume}{45}
      \field{year}{2002}
      \field{pages}{2139\bibrangedash 2149}
      \verb{doi}
      \verb 10.1021/jm011005p
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1021/jm011005p
      \endverb
    \endentry
    \entry{Vedani2005}{article}{}
      \name{labelname}{3}{}{%
        {{hash=9da2354f5ea78e4dba1b3a03ec5ea9e7}{Vedani}{V\bibinitperiod}{Angelo}{A\bibinitperiod}{}{}{}{}}%
        {{hash=e30e899a058f5e333f376cd77542eb42}{Dobler}{D\bibinitperiod}{Max}{M\bibinitperiod}{}{}{}{}}%
        {{hash=6a4745ef07a905b67e20d77c91389abb}{Lill}{L\bibinitperiod}{Markus\bibnamedelima A}{M\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=9da2354f5ea78e4dba1b3a03ec5ea9e7}{Vedani}{V\bibinitperiod}{Angelo}{A\bibinitperiod}{}{}{}{}}%
        {{hash=e30e899a058f5e333f376cd77542eb42}{Dobler}{D\bibinitperiod}{Max}{M\bibinitperiod}{}{}{}{}}%
        {{hash=6a4745ef07a905b67e20d77c91389abb}{Lill}{L\bibinitperiod}{Markus\bibnamedelima A}{M\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {American Chemical Society}%
      }
      \strng{namehash}{76727a5529264ad14d8aded49651b207}
      \strng{fullhash}{76727a5529264ad14d8aded49651b207}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Combining Protein Modeling and 6D-QSAR. Simulating the Binding of Structurally Diverse Ligands to the Estrogen Receptor}}
      \field{annotation}{doi: 10.1021/jm050185q}
      \field{issn}{0022-2623}
      \field{journaltitle}{Journal of Medicinal Chemistry}
      \field{month}{06}
      \field{number}{11}
      \field{title}{{Combining Protein Modeling and 6D-QSAR. Simulating the Binding of Structurally Diverse Ligands to the Estrogen Receptor}}
      \field{volume}{48}
      \field{year}{2005}
      \field{pages}{3700\bibrangedash 3703}
      \verb{doi}
      \verb 10.1021/jm050185q
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1021/jm050185q
      \endverb
    \endentry
    \entry{Lipinski2004}{article}{}
      \name{labelname}{1}{}{%
        {{hash=e142db5f9f7ef18bfd0d219865780a4d}{Lipinski}{L\bibinitperiod}{Christopher\bibnamedelima A}{C\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=e142db5f9f7ef18bfd0d219865780a4d}{Lipinski}{L\bibinitperiod}{Christopher\bibnamedelima A}{C\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{e142db5f9f7ef18bfd0d219865780a4d}
      \strng{fullhash}{e142db5f9f7ef18bfd0d219865780a4d}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Lead and drug-like compounds: the rule of five revolution.}}
      \field{abstract}{Citations in CAS SciFinder to the rule-of-five (RO5) publication will exceed 1000 by year-end 2004. Trends in the RO5 literature explosion that can be discerned are the further definitions of drug-like. This topic is explored in terms of drug-like physicochemical features, drug-like structural features, a comparison of drug-like and non-drug-like in drug discovery and a discussion of how drug-like features relate to clinical success. Physicochemical features of CNS drugs and features related to CNS blood-brain transporter affinity are briefly reviewed. Recent literature on features of non-oral drugs is reviewed and how features of lead-like compounds differ from those of drug-like compounds is discussed. Most recently, partly driven by NIH roadmap initiatives, considerations have arisen as to what tool-like means in the search for chemical tools to probe biology space. All these topics frame the scope of this short review/perspective.:}
      \field{issn}{1740-6749}
      \field{journaltitle}{Drug discovery today. Technologies}
      \field{month}{12}
      \field{number}{4}
      \field{title}{{Lead and drug-like compounds: the rule of five revolution.}}
      \field{volume}{1}
      \field{year}{2004}
      \field{pages}{337\bibrangedash 41}
      \verb{doi}
      \verb 10.1016/j.ddtec.2004.11.007
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Lipinski - 2004 - Lead- and drug-like compounds the rule-of-five revolution.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.sciencedirect.com/science/article/pii/S1740674904000551
      \endverb
    \endentry
    \entry{Bickerton2012}{article}{}
      \name{labelname}{5}{}{%
        {{hash=e73d95976fb8fbb4d667630d4cb6e096}{Bickerton}{B\bibinitperiod}{G\bibnamedelima Richard}{G\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=575584f83412d66c419135b776befb96}{Paolini}{P\bibinitperiod}{Gaia\bibnamedelima V}{G\bibinitperiod\bibinitdelim V\bibinitperiod}{}{}{}{}}%
        {{hash=d5006548cd462007283b82e3c471cf8c}{Besnard}{B\bibinitperiod}{J{\'{e}}r{\'{e}}my}{J\bibinitperiod}{}{}{}{}}%
        {{hash=282b768c71f849d8ff9a440e5e1e3933}{Muresan}{M\bibinitperiod}{Sorel}{S\bibinitperiod}{}{}{}{}}%
        {{hash=6242c3a4009e8510e5776bb8a9cbafcf}{Hopkins}{H\bibinitperiod}{Andrew\bibnamedelima L}{A\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{5}{}{%
        {{hash=e73d95976fb8fbb4d667630d4cb6e096}{Bickerton}{B\bibinitperiod}{G\bibnamedelima Richard}{G\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=575584f83412d66c419135b776befb96}{Paolini}{P\bibinitperiod}{Gaia\bibnamedelima V}{G\bibinitperiod\bibinitdelim V\bibinitperiod}{}{}{}{}}%
        {{hash=d5006548cd462007283b82e3c471cf8c}{Besnard}{B\bibinitperiod}{J{\'{e}}r{\'{e}}my}{J\bibinitperiod}{}{}{}{}}%
        {{hash=282b768c71f849d8ff9a440e5e1e3933}{Muresan}{M\bibinitperiod}{Sorel}{S\bibinitperiod}{}{}{}{}}%
        {{hash=6242c3a4009e8510e5776bb8a9cbafcf}{Hopkins}{H\bibinitperiod}{Andrew\bibnamedelima L}{A\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \list{language}{1}{%
        {en}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group}%
      }
      \strng{namehash}{18ea0a3208375660a81fc45cbdfea5dc}
      \strng{fullhash}{2f0b58b1549fd7837e5aeba2ded33d25}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Quantifying the chemical beauty of drugs.}}
      \field{abstract}{Drug-likeness is a key consideration when selecting compounds during the early stages of drug discovery. However, evaluation of drug-likeness in absolute terms does not reflect adequately the whole spectrum of compound quality. More worryingly, widely used rules may inadvertently foster undesirable molecular property inflation as they permit the encroachment of rule-compliant compounds towards their boundaries. We propose a measure of drug-likeness based on the concept of desirability called the quantitative estimate of drug-likeness (QED). The empirical rationale of QED reflects the underlying distribution of molecular properties. QED is intuitive, transparent, straightforward to implement in many practical settings and allows compounds to be ranked by their relative merit. We extended the utility of QED by applying it to the problem of molecular target druggability assessment by prioritizing a large set of published bioactive compounds. The measure may also capture the abstract notion of aesthetics in medicinal chemistry.}
      \field{issn}{1755-4349}
      \field{journaltitle}{Nature chemistry}
      \field{month}{02}
      \field{number}{2}
      \field{title}{{Quantifying the chemical beauty of drugs.}}
      \field{volume}{4}
      \field{year}{2012}
      \field{pages}{90\bibrangedash 8}
      \verb{doi}
      \verb 10.1038/nchem.1243
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Bickerton et al. - 2012 - Quantifying the chemical beauty of drugs.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.nature.com/nchem/journal/v4/n2/full/nchem.1243.html?WT.mc%7B%5C_%7Did=TWT%7B%5C_%7DNatureChemistry
      \endverb
    \endentry
    \entry{Besnard2012b}{article}{}
      \name{labelname}{21}{}{%
        {{hash=d5006548cd462007283b82e3c471cf8c}{Besnard}{B\bibinitperiod}{J{\'{e}}r{\'{e}}my}{J\bibinitperiod}{}{}{}{}}%
        {{hash=08054e5669853818f072a4c1d4f0df86}{Ruda}{R\bibinitperiod}{Gian\bibnamedelima Filippo}{G\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{hash=ee903c7f559bcebca827e0067ec05dca}{Setola}{S\bibinitperiod}{Vincent}{V\bibinitperiod}{}{}{}{}}%
        {{hash=ca07ae4ae926637c055d7be0e01507d4}{Abecassis}{A\bibinitperiod}{Keren}{K\bibinitperiod}{}{}{}{}}%
        {{hash=35718e9506f7b2951182e9538363f836}{Rodriguiz}{R\bibinitperiod}{Ramona\bibnamedelima M.}{R\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=b1fb53b3cf40d964af67dd2479659fa1}{Huang}{H\bibinitperiod}{Xi-Ping}{X\bibinithyphendelim P\bibinitperiod}{}{}{}{}}%
        {{hash=285eca0a185b2ab488c05cc120d48728}{Norval}{N\bibinitperiod}{Suzanne}{S\bibinitperiod}{}{}{}{}}%
        {{hash=67671917b139cb1760f866593e612b9d}{Sassano}{S\bibinitperiod}{Maria\bibnamedelima F.}{M\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{hash=ae9770de6f7a479fe69da708c3b85fba}{Shin}{S\bibinitperiod}{Antony\bibnamedelima I.}{A\bibinitperiod\bibinitdelim I\bibinitperiod}{}{}{}{}}%
        {{hash=9c9ebb2286e075ae496f617263e53496}{Webster}{W\bibinitperiod}{Lauren\bibnamedelima A.}{L\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=d4b977a258dfe2407739581e9d47389c}{Simeons}{S\bibinitperiod}{Frederick\bibnamedelimb R.\bibnamedelimi C.}{F\bibinitperiod\bibinitdelim R\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=54b35da39f8650b65a2d286cb46f2b82}{Stojanovski}{S\bibinitperiod}{Laste}{L\bibinitperiod}{}{}{}{}}%
        {{hash=aa6bfa9790824a126372733b41c0d781}{Prat}{P\bibinitperiod}{Annik}{A\bibinitperiod}{}{}{}{}}%
        {{hash=29f3098b90e8281da191cafe70d4b10c}{Seidah}{S\bibinitperiod}{Nabil\bibnamedelima G.}{N\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=d2c204cf0e3f1548ca344fbe459ebdb7}{Constam}{C\bibinitperiod}{Daniel\bibnamedelima B.}{D\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=fe7e1e4127617490b7e563671953f314}{Bickerton}{B\bibinitperiod}{G.\bibnamedelimi Richard}{G\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=6b4e0c286f037b5402e02ee42c8d04e1}{Read}{R\bibinitperiod}{Kevin\bibnamedelima D.}{K\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=eda0d80a51ce0731e10eb77c78c2b21c}{Wetsel}{W\bibinitperiod}{William\bibnamedelima C.}{W\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=3fa4b087c4607fcfba0059962a4696db}{Gilbert}{G\bibinitperiod}{Ian\bibnamedelima H.}{I\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=a59443df0f459116914d03c622bd8323}{Roth}{R\bibinitperiod}{Bryan\bibnamedelima L.}{B\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=4104a8f39c11c7d7f247db1307dfa8c7}{Hopkins}{H\bibinitperiod}{Andrew\bibnamedelima L.}{A\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{21}{}{%
        {{hash=d5006548cd462007283b82e3c471cf8c}{Besnard}{B\bibinitperiod}{J{\'{e}}r{\'{e}}my}{J\bibinitperiod}{}{}{}{}}%
        {{hash=08054e5669853818f072a4c1d4f0df86}{Ruda}{R\bibinitperiod}{Gian\bibnamedelima Filippo}{G\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{hash=ee903c7f559bcebca827e0067ec05dca}{Setola}{S\bibinitperiod}{Vincent}{V\bibinitperiod}{}{}{}{}}%
        {{hash=ca07ae4ae926637c055d7be0e01507d4}{Abecassis}{A\bibinitperiod}{Keren}{K\bibinitperiod}{}{}{}{}}%
        {{hash=35718e9506f7b2951182e9538363f836}{Rodriguiz}{R\bibinitperiod}{Ramona\bibnamedelima M.}{R\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=b1fb53b3cf40d964af67dd2479659fa1}{Huang}{H\bibinitperiod}{Xi-Ping}{X\bibinithyphendelim P\bibinitperiod}{}{}{}{}}%
        {{hash=285eca0a185b2ab488c05cc120d48728}{Norval}{N\bibinitperiod}{Suzanne}{S\bibinitperiod}{}{}{}{}}%
        {{hash=67671917b139cb1760f866593e612b9d}{Sassano}{S\bibinitperiod}{Maria\bibnamedelima F.}{M\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{hash=ae9770de6f7a479fe69da708c3b85fba}{Shin}{S\bibinitperiod}{Antony\bibnamedelima I.}{A\bibinitperiod\bibinitdelim I\bibinitperiod}{}{}{}{}}%
        {{hash=9c9ebb2286e075ae496f617263e53496}{Webster}{W\bibinitperiod}{Lauren\bibnamedelima A.}{L\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=d4b977a258dfe2407739581e9d47389c}{Simeons}{S\bibinitperiod}{Frederick\bibnamedelimb R.\bibnamedelimi C.}{F\bibinitperiod\bibinitdelim R\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=54b35da39f8650b65a2d286cb46f2b82}{Stojanovski}{S\bibinitperiod}{Laste}{L\bibinitperiod}{}{}{}{}}%
        {{hash=aa6bfa9790824a126372733b41c0d781}{Prat}{P\bibinitperiod}{Annik}{A\bibinitperiod}{}{}{}{}}%
        {{hash=29f3098b90e8281da191cafe70d4b10c}{Seidah}{S\bibinitperiod}{Nabil\bibnamedelima G.}{N\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=d2c204cf0e3f1548ca344fbe459ebdb7}{Constam}{C\bibinitperiod}{Daniel\bibnamedelima B.}{D\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=fe7e1e4127617490b7e563671953f314}{Bickerton}{B\bibinitperiod}{G.\bibnamedelimi Richard}{G\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=6b4e0c286f037b5402e02ee42c8d04e1}{Read}{R\bibinitperiod}{Kevin\bibnamedelima D.}{K\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=eda0d80a51ce0731e10eb77c78c2b21c}{Wetsel}{W\bibinitperiod}{William\bibnamedelima C.}{W\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=3fa4b087c4607fcfba0059962a4696db}{Gilbert}{G\bibinitperiod}{Ian\bibnamedelima H.}{I\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=a59443df0f459116914d03c622bd8323}{Roth}{R\bibinitperiod}{Bryan\bibnamedelima L.}{B\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=4104a8f39c11c7d7f247db1307dfa8c7}{Hopkins}{H\bibinitperiod}{Andrew\bibnamedelima L.}{A\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{4dafac3533ea8726a8c0138e2025cce1}
      \strng{fullhash}{c37ef82aa8ecceb0afeb702fcc72764c}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Automated design of ligands to polypharmacological profiles}}
      \field{abstract}{The clinical efficacy and safety of a drug is determined by its activity profile across many proteins in the proteome. However, designing drugs with a specific multi-target profile is both complex and difficult. Therefore methods to design drugs rationally a priori against profiles of several proteins would have immense value in drug discovery. Here we describe a new approach for the automated design of ligands against profiles of multiple drug targets. The method is demonstrated by the evolution of an approved acetylcholinesterase inhibitor drug into brain-penetrable ligands with either specific polypharmacology or exquisite selectivity profiles for G-protein-coupled receptors. Overall, 800 ligand-target predictions of prospectively designed ligands were tested experimentally, of which 75{\%} were confirmed to be correct. We also demonstrate target engagement in vivo. The approach can be a useful source of drug leads when multi-target profiles are required to achieve either selectivity over other drug targets or a desired polypharmacology.}
      \field{issn}{0028-0836}
      \field{journaltitle}{Nature}
      \field{month}{12}
      \field{number}{7428}
      \field{title}{{Automated design of ligands to polypharmacological profiles}}
      \field{volume}{492}
      \field{year}{2012}
      \field{pages}{215\bibrangedash 220}
      \verb{doi}
      \verb 10.1038/nature11691
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Besnard et al. - 2012 - Automated design of ligands to polypharmacological profiles.pdf:pdf
      \endverb
      \verb{url}
      \verb http://f1000.com/prime/717967952
      \endverb
    \endentry
    \entry{Lewandowski2015}{article}{}
      \name{labelname}{3}{}{%
        {{hash=72484d0fc7af300bc89ff39acc8a72c0}{Lewandowski}{L\bibinitperiod}{Clare\bibnamedelima M.}{C\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=8f76ccd109247a6c6bec053141ee8558}{Co-investigator}{C\bibinithyphendelim i\bibinitperiod}{New}{N\bibinitperiod}{}{}{}{}}%
        {{hash=72484d0fc7af300bc89ff39acc8a72c0}{Lewandowski}{L\bibinitperiod}{Clare\bibnamedelima M.}{C\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=72484d0fc7af300bc89ff39acc8a72c0}{Lewandowski}{L\bibinitperiod}{Clare\bibnamedelima M.}{C\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=8f76ccd109247a6c6bec053141ee8558}{Co-investigator}{C\bibinithyphendelim i\bibinitperiod}{New}{N\bibinitperiod}{}{}{}{}}%
        {{hash=72484d0fc7af300bc89ff39acc8a72c0}{Lewandowski}{L\bibinitperiod}{Clare\bibnamedelima M.}{C\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{cce07b5cd75af09fae07660bc0659e1a}
      \strng{fullhash}{cce07b5cd75af09fae07660bc0659e1a}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{WHO Glocal tuberculosis report 2015}}
      \field{abstract}{Predicting the binding mode of flexible polypeptides to proteins is an important task that falls outside the domain of applicability of most small molecule and protein{$\textminus$}protein docking tools. Here, we test the small molecule flexible ligand docking program Glide on a set of 19 non-$\alpha$-helical peptides and systematically improve pose prediction accuracy by enhancing Glide sampling for flexible polypeptides. In addition, scoring of the poses was improved by post-processing with physics-based implicit solvent MM- GBSA calculations. Using the best RMSD among the top 10 scoring poses as a metric, the success rate (RMSD \x{2264} 2.0 {\r{A}} for the interface backbone atoms) increased from 21{\%} with default Glide SP settings to 58{\%} with the enhanced peptide sampling and scoring protocol in the case of redocking to the native protein structure. This approaches the accuracy of the recently developed Rosetta FlexPepDock method (63{\%} success for these 19 peptides) while being over 100 times faster. Cross-docking was performed for a subset of cases where an unbound receptor structure was available, and in that case, 40{\%} of peptides were docked successfully. We analyze the results and find that the optimized polypeptide protocol is most accurate for extended peptides of limited size and number of formal charges, defining a domain of applicability for this approach.}
      \field{eprinttype}{arXiv}
      \field{isbn}{9788578110796}
      \field{issn}{1098-6596}
      \field{journaltitle}{The effects of brief mindfulness intervention on acute pain experience: An examination of individual difference}
      \field{title}{{WHO Glocal tuberculosis report 2015}}
      \field{volume}{1}
      \field{year}{2015}
      \field{pages}{1689\bibrangedash 1699}
      \verb{doi}
      \verb 10.1017/CBO9781107415324.004
      \endverb
      \verb{eprint}
      \verb arXiv:1011.1669v3
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/9789241565059{\_}eng.pdf:pdf
      \endverb
    \endentry
    \entry{Connell2011}{article}{}
      \name{labelname}{4}{}{%
        {{hash=5c18ef067f87e83c217b92ca8df4cf07}{Connell}{C\bibinitperiod}{D\bibnamedelima W}{D\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=c39b5bef0dadef3d5a4f70afa0a11abe}{Berry}{B\bibinitperiod}{M}{M\bibinitperiod}{}{}{}{}}%
        {{hash=b7e14b84d88f10d6e308a40ce78e9b03}{Cooke}{C\bibinitperiod}{G}{G\bibinitperiod}{}{}{}{}}%
        {{hash=9fc9304114a8019453109d0d8f76caee}{Kon}{K\bibinitperiod}{O\bibnamedelima M}{O\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=5c18ef067f87e83c217b92ca8df4cf07}{Connell}{C\bibinitperiod}{D\bibnamedelima W}{D\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=c39b5bef0dadef3d5a4f70afa0a11abe}{Berry}{B\bibinitperiod}{M}{M\bibinitperiod}{}{}{}{}}%
        {{hash=b7e14b84d88f10d6e308a40ce78e9b03}{Cooke}{C\bibinitperiod}{G}{G\bibinitperiod}{}{}{}{}}%
        {{hash=9fc9304114a8019453109d0d8f76caee}{Kon}{K\bibinitperiod}{O\bibnamedelima M}{O\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{59a0285a7c20865102d657a24581fe04}
      \strng{fullhash}{6d6f70257140b5df15fff96ac7020613}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Update on tuberculosis: TB in the early 21st century}}
      \field{abstract}{Mycobacterium tuberculosis infection remains a major cause of global mortality and morbidity and the resulting disease, tuberculosis (TB), caused an estimated 1.7 million deaths in 2009 [1]. However, the majority of the 2 billion people estimated to be infected with M. tuberculosis have asymptomatic infection, termed latent TB infection (LTBI) [2, 3]. Traditionally, LTBI has been defined by evidence of a cellular immune response to M. tuberculosis-derived antigens, for example by the tuberculin skin test (TST) in asymptomatic individuals who have been potentially exposed to M. tuberculosis. For these individuals, the life time risk of progression from LTBI to active, symptomatic disease is only 10{\%}; however, defects in cellular immunity can increase this risk significantly [4, 5]. Of these, the most important is HIV infection, and the ongoing HIV epidemic has helped to fuel the spread of TB globally over the past 40 yrs with 0.38 million deaths in HIV co-infected individuals in 2009 [1].Despite dramatic falls in the overall prevalence of TB over the past 100 yrs in Europe, TB is no longer a disease of historical interest and the European region defined by the World Health Organization (WHO) saw a 2.7{\%} mean annual increase in cases from 2004--2008 [6]. Of concern, an estimated 3.6{\%} of all new cases globally were multi-drug resistant (MDR) [1, 7].With this in mind, we present an update on a selection of important areas in TB clinical practice and clinical research today, with particular relevance to Europe. We will review some of the important epidemiological features of TB, with a focus on migration and recent work on factors which might influence the burden of TB at a population level, such as cigarette smoking/biomass fuel {\ldots}}
      \field{journaltitle}{European Respiratory Review}
      \field{month}{06}
      \field{number}{120}
      \field{title}{{Update on tuberculosis: TB in the early 21st century}}
      \field{volume}{20}
      \field{year}{2011}
      \field{pages}{71\bibrangedash 84}
      \verb{url}
      \verb http://err.ersjournals.com/content/20/120/71.abstract
      \endverb
    \endentry
    \entry{Berry2009}{article}{}
      \name{labelname}{2}{}{%
        {{hash=c39b5bef0dadef3d5a4f70afa0a11abe}{Berry}{B\bibinitperiod}{M}{M\bibinitperiod}{}{}{}{}}%
        {{hash=9fc9304114a8019453109d0d8f76caee}{Kon}{K\bibinitperiod}{O\bibnamedelima M}{O\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=c39b5bef0dadef3d5a4f70afa0a11abe}{Berry}{B\bibinitperiod}{M}{M\bibinitperiod}{}{}{}{}}%
        {{hash=9fc9304114a8019453109d0d8f76caee}{Kon}{K\bibinitperiod}{O\bibnamedelima M}{O\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{2f5e3885ef2face4232318b0326b2ba5}
      \strng{fullhash}{2f5e3885ef2face4232318b0326b2ba5}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Multidrug- and extensively drug-resistant tuberculosis: an emerging threat}}
      \field{abstract}{Despite dramatic improvements in public health and medical care, Mycobacterium tuberculosis remains as much of a threat in the 21st century as it was when first identified as a pathogen by Koch [1] in 1882. Tuberculosis was reported to be the seventh leading cause of death worldwide by the World Health Organization (WHO) in 2004 [2]. Recent figures show an increase in the total number of cases, with an estimated 9.2 million new cases and 1.7 million deaths attributed to tuberculosis in 2006 [3]. Drug-resistant strains of Mycobacterium tuberculosis represent an emerging problem in the struggle to contain tuberculosis. In this issue of the European Respiratory Review, Sasse and Teichmann [4] describe their experience of managing a patient infected with a strain of Mycobacterium tuberculosis with a wide spectrum of drug resistance. The latest estimates based on survey data report that 11.1{\%} of new tuberculosis cases showed resistance to any drug, which rises to 25.1{\%} in previously treated cases. 1.6{\%} of new cases and 11.7{\%} of previously treated cases met the definition of multidrug-resistant tuberculosis (MDR-TB), this being resistance to rifampicin and isoniazid, the two most potent first-line antituberculosis drugs. Much of this burden is carried by eastern Europe, where 45.5{\%} of previously treated tuberculosis cases meet the definition for MDR-TB. The patient described by Sasse and Teichmann [4] was originally from Burma, where MDR-TB accounts for 4{\%} of new tuberculosis cases [5]. Outcomes in MDR-TB are worse than for non-MDR-TB, with one retrospective study in Estonia finding a cure rate of 83.4{\%} in non-MDR-TB, compared with only 57.4{\%} in MDR-TB [6]. More recently, attention has been drawn to the emergence of a form of MDR-TB that has a more {\ldots}}
      \field{journaltitle}{European Respiratory Review}
      \field{month}{11}
      \field{number}{114}
      \field{title}{{Multidrug- and extensively drug-resistant tuberculosis: an emerging threat}}
      \field{volume}{18}
      \field{year}{2009}
      \field{pages}{195\bibrangedash 197}
      \verb{url}
      \verb http://err.ersjournals.com/content/18/114/195.abstract
      \endverb
    \endentry
    \entry{Trouiller2016}{article}{}
      \name{labelname}{6}{}{%
        {{hash=1422f4f91dc5f13dda8e2b9a037ebfc4}{Trouiller}{T\bibinitperiod}{Patrice}{P\bibinitperiod}{}{}{}{}}%
        {{hash=0cdfde7c9cc5e8b8862878155561437b}{Olliaro}{O\bibinitperiod}{Piero}{P\bibinitperiod}{}{}{}{}}%
        {{hash=d071a3ebb5a009a00717f4e6dfc7e6bc}{Torreele}{T\bibinitperiod}{Els}{E\bibinitperiod}{}{}{}{}}%
        {{hash=1c5ed1178a09ae8098ab692906819f73}{Orbinski}{O\bibinitperiod}{James}{J\bibinitperiod}{}{}{}{}}%
        {{hash=c6fa729d5bd15441c948243b4ce244de}{Laing}{L\bibinitperiod}{Richard}{R\bibinitperiod}{}{}{}{}}%
        {{hash=1d50af60eff1012adc613ec74df429ea}{Ford}{F\bibinitperiod}{Nathan}{N\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{6}{}{%
        {{hash=1422f4f91dc5f13dda8e2b9a037ebfc4}{Trouiller}{T\bibinitperiod}{Patrice}{P\bibinitperiod}{}{}{}{}}%
        {{hash=0cdfde7c9cc5e8b8862878155561437b}{Olliaro}{O\bibinitperiod}{Piero}{P\bibinitperiod}{}{}{}{}}%
        {{hash=d071a3ebb5a009a00717f4e6dfc7e6bc}{Torreele}{T\bibinitperiod}{Els}{E\bibinitperiod}{}{}{}{}}%
        {{hash=1c5ed1178a09ae8098ab692906819f73}{Orbinski}{O\bibinitperiod}{James}{J\bibinitperiod}{}{}{}{}}%
        {{hash=c6fa729d5bd15441c948243b4ce244de}{Laing}{L\bibinitperiod}{Richard}{R\bibinitperiod}{}{}{}{}}%
        {{hash=1d50af60eff1012adc613ec74df429ea}{Ford}{F\bibinitperiod}{Nathan}{N\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Elsevier}%
      }
      \strng{namehash}{828973d64a8acc532e0760c360337f0d}
      \strng{fullhash}{b7c4a0250805db9352931f5b99668f64}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Drug development for neglected diseases: a deficient market and a public-health policy failure}}
      \field{annotation}{doi: 10.1016/S0140-6736(02)09096-7}
      \field{issn}{01406736}
      \field{journaltitle}{The Lancet}
      \field{month}{06}
      \field{number}{9324}
      \field{title}{{Drug development for neglected diseases: a deficient market and a public-health policy failure}}
      \field{volume}{359}
      \field{year}{2002}
      \field{pages}{2188\bibrangedash 2194}
      \verb{doi}
      \verb 10.1016/S0140-6736(02)09096-7
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1016/S0140-6736(02)09096-7%20http://linkinghub.elsevier.com/retrieve/pii/S0140673602090967
      \endverb
    \endentry
    \entry{Lewis2013}{article}{}
      \name{labelname}{1}{}{%
        {{hash=088dcc553932f421594707259a1309e8}{Lewis}{L\bibinitperiod}{Kim}{K\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=088dcc553932f421594707259a1309e8}{Lewis}{L\bibinitperiod}{Kim}{K\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.}%
      }
      \strng{namehash}{088dcc553932f421594707259a1309e8}
      \strng{fullhash}{088dcc553932f421594707259a1309e8}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Platforms for antibiotic discovery}}
      \field{issn}{1474-1776}
      \field{journaltitle}{Nat Rev Drug Discov}
      \field{month}{05}
      \field{number}{5}
      \field{title}{{Platforms for antibiotic discovery}}
      \field{volume}{12}
      \field{year}{2013}
      \field{pages}{371\bibrangedash 387}
      \verb{url}
      \verb http://dx.doi.org/10.1038/nrd3975%20http://10.1038/nrd3975
      \endverb
    \endentry
    \entry{Conly2005}{article}{}
      \name{labelname}{2}{}{%
        {{hash=c40927d8c551299c9d394b5e770407cc}{Conly}{C\bibinitperiod}{J\bibnamedelima M}{J\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=1dbbe9995e9bb5dd0e47aa9cae2258f2}{Johnston}{J\bibinitperiod}{B\bibnamedelima L}{B\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=c40927d8c551299c9d394b5e770407cc}{Conly}{C\bibinitperiod}{J\bibnamedelima M}{J\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=1dbbe9995e9bb5dd0e47aa9cae2258f2}{Johnston}{J\bibinitperiod}{B\bibnamedelima L}{B\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Pulsus Group Inc}%
      }
      \strng{namehash}{e0d192517669ea66a91f9b5d20254f61}
      \strng{fullhash}{e0d192517669ea66a91f9b5d20254f61}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Where are all the new antibiotics? The new antibiotic paradox}}
      \field{issn}{1712-9532}
      \field{journaltitle}{The Canadian Journal of Infectious Diseases {\&} Medical Microbiology}
      \field{month}{03}
      \field{number}{3}
      \field{title}{{Where are all the new antibiotics? The new antibiotic paradox}}
      \field{volume}{16}
      \field{year}{2005}
      \field{pages}{159\bibrangedash 160}
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2095020/
      \endverb
    \endentry
    \entry{Ling2015a}{article}{}
      \name{labelname}{20}{}{%
        {{hash=96171523cc203e5dcc637c8fd70a2610}{Ling}{L\bibinitperiod}{Losee\bibnamedelima L}{L\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=8300572fa7a4e6ca345805ae3f2a27c4}{Schneider}{S\bibinitperiod}{Tanja}{T\bibinitperiod}{}{}{}{}}%
        {{hash=98be8e2ca7eeaa848d4bb7ddca3c4874}{Peoples}{P\bibinitperiod}{Aaron\bibnamedelima J}{A\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=6d7cc6e3d7e2887d60bbf50b1825ed1f}{Spoering}{S\bibinitperiod}{Amy\bibnamedelima L}{A\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=0e55e0555530d1700952c1f4ff29e443}{Engels}{E\bibinitperiod}{Ina}{I\bibinitperiod}{}{}{}{}}%
        {{hash=2a82def793abf5f62edccd035a7e7052}{Conlon}{C\bibinitperiod}{Brian\bibnamedelima P}{B\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=2153258d8d736bf1c8c7434a4c6873a4}{Mueller}{M\bibinitperiod}{Anna}{A\bibinitperiod}{}{}{}{}}%
        {{hash=36c75068299fd777c119d2d736014efb}{Hughes}{H\bibinitperiod}{Dallas\bibnamedelima E}{D\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=57942143f1d62d2ec8607ff56234a4f0}{Epstein}{E\bibinitperiod}{Slava}{S\bibinitperiod}{}{}{}{}}%
        {{hash=5a25bc91f524ca6dfc2ecf9f4a13903c}{Jones}{J\bibinitperiod}{Michael}{M\bibinitperiod}{}{}{}{}}%
        {{hash=8112656e2d7f3a37a8f154a150b8f9ce}{Lazarides}{L\bibinitperiod}{Linos}{L\bibinitperiod}{}{}{}{}}%
        {{hash=a51158fddd717ce5a31702b0871df294}{Steadman}{S\bibinitperiod}{Victoria\bibnamedelima a}{V\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
        {{hash=2cab3283d5958e1b28e6e16dfc792f2e}{Cohen}{C\bibinitperiod}{Douglas\bibnamedelima R}{D\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=e7d3aae82cc0c6d7c7a0c8a607a1721f}{Felix}{F\bibinitperiod}{Cintia\bibnamedelima R}{C\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=c87d008cd794bbfd7af4c3cc1ddd8de2}{Fetterman}{F\bibinitperiod}{K\bibnamedelima Ashley}{K\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=ad69b472a89fcbd0d800e1f5d4188d6c}{Millett}{M\bibinitperiod}{William\bibnamedelima P}{W\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=c7bfe1615207c8075856ec94f5b5df8d}{Nitti}{N\bibinitperiod}{Anthony\bibnamedelima G}{A\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=12fedc32d83672f9af47bb3ba5b89993}{Zullo}{Z\bibinitperiod}{Ashley\bibnamedelima M}{A\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=531c7be3c2524682e36a7baa8d7ab92f}{Chen}{C\bibinitperiod}{Chao}{C\bibinitperiod}{}{}{}{}}%
        {{hash=088dcc553932f421594707259a1309e8}{Lewis}{L\bibinitperiod}{Kim}{K\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{20}{}{%
        {{hash=96171523cc203e5dcc637c8fd70a2610}{Ling}{L\bibinitperiod}{Losee\bibnamedelima L}{L\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=8300572fa7a4e6ca345805ae3f2a27c4}{Schneider}{S\bibinitperiod}{Tanja}{T\bibinitperiod}{}{}{}{}}%
        {{hash=98be8e2ca7eeaa848d4bb7ddca3c4874}{Peoples}{P\bibinitperiod}{Aaron\bibnamedelima J}{A\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=6d7cc6e3d7e2887d60bbf50b1825ed1f}{Spoering}{S\bibinitperiod}{Amy\bibnamedelima L}{A\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=0e55e0555530d1700952c1f4ff29e443}{Engels}{E\bibinitperiod}{Ina}{I\bibinitperiod}{}{}{}{}}%
        {{hash=2a82def793abf5f62edccd035a7e7052}{Conlon}{C\bibinitperiod}{Brian\bibnamedelima P}{B\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=2153258d8d736bf1c8c7434a4c6873a4}{Mueller}{M\bibinitperiod}{Anna}{A\bibinitperiod}{}{}{}{}}%
        {{hash=36c75068299fd777c119d2d736014efb}{Hughes}{H\bibinitperiod}{Dallas\bibnamedelima E}{D\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=57942143f1d62d2ec8607ff56234a4f0}{Epstein}{E\bibinitperiod}{Slava}{S\bibinitperiod}{}{}{}{}}%
        {{hash=5a25bc91f524ca6dfc2ecf9f4a13903c}{Jones}{J\bibinitperiod}{Michael}{M\bibinitperiod}{}{}{}{}}%
        {{hash=8112656e2d7f3a37a8f154a150b8f9ce}{Lazarides}{L\bibinitperiod}{Linos}{L\bibinitperiod}{}{}{}{}}%
        {{hash=a51158fddd717ce5a31702b0871df294}{Steadman}{S\bibinitperiod}{Victoria\bibnamedelima a}{V\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
        {{hash=2cab3283d5958e1b28e6e16dfc792f2e}{Cohen}{C\bibinitperiod}{Douglas\bibnamedelima R}{D\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=e7d3aae82cc0c6d7c7a0c8a607a1721f}{Felix}{F\bibinitperiod}{Cintia\bibnamedelima R}{C\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=c87d008cd794bbfd7af4c3cc1ddd8de2}{Fetterman}{F\bibinitperiod}{K\bibnamedelima Ashley}{K\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=ad69b472a89fcbd0d800e1f5d4188d6c}{Millett}{M\bibinitperiod}{William\bibnamedelima P}{W\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=c7bfe1615207c8075856ec94f5b5df8d}{Nitti}{N\bibinitperiod}{Anthony\bibnamedelima G}{A\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=12fedc32d83672f9af47bb3ba5b89993}{Zullo}{Z\bibinitperiod}{Ashley\bibnamedelima M}{A\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=531c7be3c2524682e36a7baa8d7ab92f}{Chen}{C\bibinitperiod}{Chao}{C\bibinitperiod}{}{}{}{}}%
        {{hash=088dcc553932f421594707259a1309e8}{Lewis}{L\bibinitperiod}{Kim}{K\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{37c3e2e580611af4d73b24c221639f1d}
      \strng{fullhash}{cb47d8917d15735d603b480168a4985b}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{A new antibiotic kills pathogens without detectable resistance}}
      \field{abstract}{Antibiotic resistance is spreading faster than the introduction of new compounds into clinical practice, causing a public health crisis. Most antibiotics were produced by screening soil microorganisms, but this limited resource of cultivable bacteria was overmined by the 1960s. Synthetic approaches to produce antibiotics have been unable to replace this platform. Uncultured bacteria make up approximately 99{\%} of all species in external environments, and are an untapped source of new antibiotics. Wedeveloped several methods to grow uncultured organisms by cultivation in situ or by using specific growth factors. Here we report a new antibiotic that we term teixobactin, discovered in a screen of uncultured bacteria. Teixobactin inhibits cell wall synthesis by binding to a highly conserved motif of lipid II (precursor of peptidoglycan) and lipid III (precursor of cell wall teichoic acid). We did not obtain any mutants of Staphylococcus aureus or Mycobacterium tuberculosis resistant to teixobactin. The properties of this compound suggest a path towards developing antibiotics that are likely to avoid development of resistance.}
      \field{isbn}{1476-4687 (Electronic)$\backslash$r0028-0836 (Linking)}
      \field{issn}{1476-4687}
      \field{journaltitle}{Nature}
      \field{number}{7535}
      \field{title}{{A new antibiotic kills pathogens without detectable resistance}}
      \field{volume}{517}
      \field{year}{2015}
      \field{pages}{455\bibrangedash 459}
      \verb{doi}
      \verb 10.1038/nature14098
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/nature14098.pdf:pdf
      \endverb
    \endentry
    \entry{BroadInstitute}{misc}{}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Philanthropists unite to accelerate global fight against tuberculosis with combined {\$}20 million gift to Broad Institute - https://www.broadinstitute.org/news/6981 -}}
      \field{title}{{Philanthropists unite to accelerate global fight against tuberculosis with combined {\$}20 million gift to Broad Institute - https://www.broadinstitute.org/news/6981 -}}
      \verb{url}
      \verb https://www.broadinstitute.org/news/6981
      \endverb
    \endentry
    \entry{Karki2007}{article}{}
      \name{labelname}{5}{}{%
        {{hash=78218bb7562a9b79c7469e40819eb583}{Karki}{K\bibinitperiod}{Deepak\bibnamedelima K}{D\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=724c78a5b336f2554da7519386581962}{Mirzoev}{M\bibinitperiod}{Tolib\bibnamedelima N}{T\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
        {{hash=c2e8db7da2de663dad83fb3ac1d87c78}{Green}{G\bibinitperiod}{Andrew\bibnamedelima T}{A\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=29569a538f5fc1af33f66eba38916b25}{Newell}{N\bibinitperiod}{James\bibnamedelima N}{J\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
        {{hash=ae45aaef42b7e4471c0664b236ec97f0}{Baral}{B\bibinitperiod}{Sushil\bibnamedelima C}{S\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{5}{}{%
        {{hash=78218bb7562a9b79c7469e40819eb583}{Karki}{K\bibinitperiod}{Deepak\bibnamedelima K}{D\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=724c78a5b336f2554da7519386581962}{Mirzoev}{M\bibinitperiod}{Tolib\bibnamedelima N}{T\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
        {{hash=c2e8db7da2de663dad83fb3ac1d87c78}{Green}{G\bibinitperiod}{Andrew\bibnamedelima T}{A\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=29569a538f5fc1af33f66eba38916b25}{Newell}{N\bibinitperiod}{James\bibnamedelima N}{J\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
        {{hash=ae45aaef42b7e4471c0664b236ec97f0}{Baral}{B\bibinitperiod}{Sushil\bibnamedelima C}{S\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{30149b31413806a1e66bb7c5f80d777a}
      \strng{fullhash}{d1598db3fc4016d7b04a1f513d1edebe}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Costs of a successful public-private partnership for TB control in an urban setting in Nepal}}
      \field{abstract}{In South Asia a large number of patients seek treatment for TB from private practitioners (PPs), and there is increasing international interest in involving PPs in TB control. To evaluate the feasibility, effectiveness and costs of public-private partnerships (PPPs) for TB control, a PPP was developed in Lalitpur municipality, Nepal, where it is estimated that 50{\%} of patients with TB are managed in the private sector. From the clinical perspective the PPP was shown to be effective. The aim of this paper is to assess and report on the costs involved in the PPP scheme.}
      \field{issn}{1471-2458}
      \field{journaltitle}{BMC Public Health}
      \field{number}{1}
      \field{title}{{Costs of a successful public-private partnership for TB control in an urban setting in Nepal}}
      \field{volume}{7}
      \field{year}{2007}
      \field{pages}{1\bibrangedash 12}
      \verb{doi}
      \verb 10.1186/1471-2458-7-84
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1186/1471-2458-7-84
      \endverb
    \endentry
    \entry{Murthy2001}{article}{}
      \name{labelname}{4}{}{%
        {{hash=8af5754bf339a98c52f8164d8ea8a52f}{Murthy}{M\bibinitperiod}{K.\bibnamedelimi J\bibnamedelima R}{K\bibinitperiod\bibinitdelim J\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=8b8bd58537f01d5c0d2cece922b7b68c}{Frieden}{F\bibinitperiod}{T.\bibnamedelimi R.}{T\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=0e1bc3b44a1c003c5b0563892209d5a7}{Yazdani}{Y\bibinitperiod}{A.}{A\bibinitperiod}{}{}{}{}}%
        {{hash=c0cf65429b7c080b192a768cee7a7a46}{Hreshikesh}{H\bibinitperiod}{P.}{P\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=8af5754bf339a98c52f8164d8ea8a52f}{Murthy}{M\bibinitperiod}{K.\bibnamedelimi J\bibnamedelima R}{K\bibinitperiod\bibinitdelim J\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=8b8bd58537f01d5c0d2cece922b7b68c}{Frieden}{F\bibinitperiod}{T.\bibnamedelimi R.}{T\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=0e1bc3b44a1c003c5b0563892209d5a7}{Yazdani}{Y\bibinitperiod}{A.}{A\bibinitperiod}{}{}{}{}}%
        {{hash=c0cf65429b7c080b192a768cee7a7a46}{Hreshikesh}{H\bibinitperiod}{P.}{P\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{5a6507293e9aa14c43142ca79bcac1c7}
      \strng{fullhash}{d950bedbfcafd587ada86718d87ee191}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Public-private partnership in tuberculosis control: Experience in Hyderabad, India}}
      \field{abstract}{SETTING: Hyderabad, India. OBJECTIVE: To determine whether private practitioners and the government can collaborate with a nongovernmental intermediary to implement DOTS effectively. DESIGN: A non-profit hospital provided DOTS services to a population of 100000 for 3 years, then expanded coverage to 500000 in October 1998. A hospital physician visited all private practitioners, encouraged them to refer patients, and gave feedback on each patient referred. After diagnosis, patients received directly observed treatment free of charge at the trust hospital or at 30 conveniently located small hospitals operated by local private practitioners. No financial incentives were used to encourage physicians to refer patients or to provide treatment observation. Diagnosis, treatment, and case and outcome definitions were performed as per DOTS policies; medicines and laboratory reagents were provided by the government. RESULTS: All 244 allopathic and 114 non-allopathic physicians practising in the area agreed to participate; 59{\%} referred at least one patient. Of 2244 persons referred, 969 (43{\%}) had tuberculosis. Physicians had obtained chest radiographs on 80{\%} of patients before referral for sputum microscopy. The detection rate increased from 50 to 200/100000 over the first 2-3 years of the project, and has increased gradually since expansion; 90{\%} of new smear-positive patients and 77{\%} of re-treatment patients were successfully treated. Compared with those treated at a neighbouring government DOTS centre, patients in this project paid less for diagnosis ({\$}5 vs. {\$}20) and treatment ({\$}1 vs. {\$}11), largely due to lower transport costs. CONCLUSIONS: Collaborative efforts between private practitioners and the government can achieve moderate-high rates of case detection and high rates of treatment success. Public-private services appeared to be more convenient to patients, who paid less for care and were less likely to miss work in order to participate in DOTS. Clearly defined roles and expectations and frequent communication are essential to success. An institution such as a non-profit hospital can serve as an effective intermediary between the government DOTS programme and private practitioners.}
      \field{isbn}{1027-3719}
      \field{issn}{10273719}
      \field{journaltitle}{International Journal of Tuberculosis and Lung Disease}
      \field{number}{4}
      \field{title}{{Public-private partnership in tuberculosis control: Experience in Hyderabad, India}}
      \field{volume}{5}
      \field{year}{2001}
      \field{pages}{354\bibrangedash 359}
      \verb{file}
      \verb :home/fran/Downloads/s10.pdf:pdf
      \endverb
    \endentry
    \entry{Lei2015}{article}{}
      \name{labelname}{7}{}{%
        {{hash=185062bab6a304a91919ac0c872b80d4}{Lei}{L\bibinitperiod}{Xun}{X\bibinitperiod}{}{}{}{}}%
        {{hash=e2d6477b8aa1e334fb8a5f13e09aa386}{Liu}{L\bibinitperiod}{Qin}{Q\bibinitperiod}{}{}{}{}}%
        {{hash=0016e634cdee11fbf15990223f3de121}{Escobar}{E\bibinitperiod}{Erin}{E\bibinitperiod}{}{}{}{}}%
        {{hash=15aac5574a434a4812279f669dff432c}{Philogene}{P\bibinitperiod}{Johane}{J\bibinitperiod}{}{}{}{}}%
        {{hash=bec5e6e4ddd93c61bd281e176a4cc608}{Zhu}{Z\bibinitperiod}{Hang}{H\bibinitperiod}{}{}{}{}}%
        {{hash=a84866b4900b3fe9a714de1f78dbf282}{Wang}{W\bibinitperiod}{Yang}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=333300ff1f906993ca996a007d36545c}{Tang}{T\bibinitperiod}{Shenglan}{S\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{7}{}{%
        {{hash=185062bab6a304a91919ac0c872b80d4}{Lei}{L\bibinitperiod}{Xun}{X\bibinitperiod}{}{}{}{}}%
        {{hash=e2d6477b8aa1e334fb8a5f13e09aa386}{Liu}{L\bibinitperiod}{Qin}{Q\bibinitperiod}{}{}{}{}}%
        {{hash=0016e634cdee11fbf15990223f3de121}{Escobar}{E\bibinitperiod}{Erin}{E\bibinitperiod}{}{}{}{}}%
        {{hash=15aac5574a434a4812279f669dff432c}{Philogene}{P\bibinitperiod}{Johane}{J\bibinitperiod}{}{}{}{}}%
        {{hash=bec5e6e4ddd93c61bd281e176a4cc608}{Zhu}{Z\bibinitperiod}{Hang}{H\bibinitperiod}{}{}{}{}}%
        {{hash=a84866b4900b3fe9a714de1f78dbf282}{Wang}{W\bibinitperiod}{Yang}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=333300ff1f906993ca996a007d36545c}{Tang}{T\bibinitperiod}{Shenglan}{S\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{4e90874f440e4bb60b92995fe72c8a97}
      \strng{fullhash}{66d0e285646e64a04d1e980808af6d6e}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Public--private mix for tuberculosis care and control: a systematic review}}
      \field{abstract}{SummaryBackground Public--private mix (PPM), recommended by the World Health Organization (WHO), was introduced to cope with the tuberculosis (TB) epidemic worldwide. In many developing countries, PPM has played a powerful role in TB control, while in others it has failed to meet expectations. Thus we performed a systematic review to determine the mechanisms used by global PPM programs implemented in different countries and to evaluate their performance. Methods A comprehensive search of the current literature for original studies published up to May 2014 was done using electronic databases and online resources; these publications were then screened using rigorous criteria. Descriptive information and evaluative outcomes data were extracted from eligible studies for synthesis and analysis. Results A total of 78 eligible studies were included in the final review. These assessed 48 PPM TB programs worldwide, subsequently categorized into three mechanisms based on collaborative characteristics: support, contract, and multi-partner group. Furthermore, we assessed the effectiveness of PPM programs against six health system themes, including utilization of the directly observed treatment strategy (DOTS), case detection, treatment outcomes, case management, costs, and access and equity, under the different collaborative mechanisms. Analysis of the comparative studies suggested that PPM could improve overall outcomes of a TB service, and multiple collaborative mechanisms may significantly promote case detection, treatment, referral, and service accessibility, especially in resource-limited areas. However, the less positive outcomes of several programs indicated limited funding and poor governance to be the predominant reasons. Conclusions PPM is a promising strategy to strengthen global TB care and control, but is affected by contextual characteristics in different areas. The scaling-up of PPM should contain essential commonalities, particularly substantial financial support and continuous material input. Additionally, it is important to improve program governance and training for the health providers involved, through integrated collaborative mechanisms.}
      \field{issn}{1201-9712}
      \field{journaltitle}{International Journal of Infectious Diseases}
      \field{month}{05}
      \field{title}{{Public--private mix for tuberculosis care and control: a systematic review}}
      \field{volume}{34}
      \field{year}{2015}
      \field{pages}{20\bibrangedash 32}
      \verb{doi}
      \verb http://dx.doi.org/10.1016/j.ijid.2015.02.015
      \endverb
      \verb{url}
      \verb http://www.sciencedirect.com/science/article/pii/S1201971215000521
      \endverb
    \endentry
    \entry{Zuniga2015}{article}{}
      \name{labelname}{3}{}{%
        {{hash=16fd1a328586cd0d43a3fe015d66d3b9}{Zuniga}{Z\bibinitperiod}{Edison\bibnamedelima S}{E\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=d5b7aab61b590c9c104d90acff319162}{Early}{E\bibinitperiod}{Julie}{J\bibinitperiod}{}{}{}{}}%
        {{hash=02eac32a41cfc8d6d68a9f3ce8eb7e5a}{Parish}{P\bibinitperiod}{Tanya}{T\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=16fd1a328586cd0d43a3fe015d66d3b9}{Zuniga}{Z\bibinitperiod}{Edison\bibnamedelima S}{E\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=d5b7aab61b590c9c104d90acff319162}{Early}{E\bibinitperiod}{Julie}{J\bibinitperiod}{}{}{}{}}%
        {{hash=02eac32a41cfc8d6d68a9f3ce8eb7e5a}{Parish}{P\bibinitperiod}{Tanya}{T\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{0e2282e0007fd844be73c30ff232cf9b}
      \strng{fullhash}{0e2282e0007fd844be73c30ff232cf9b}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{The future for early-stage tuberculosis drug discovery}}
      \field{abstract}{There is an urgent need for new and better drugs to treat tuberculosis due to lengthy and complex treatment regimens and a rising problem of drug resistance. Drug discovery efforts have increased over the past few years, with a larger focus on modern high-throughput screening technologies. A combination of target-based approaches, with the traditional empirical means of drug identification, has been complemented by the use of target-based phenotypic screens only recently made possibly with newer genetic tools. Using these approaches, a number of promising compound series have been discovered. However, significant problems remain in developing these into drugs. This review highlights recent advances in TB drug discovery, including an overview of screening campaigns, lessons learned and future directions.}
      \field{issn}{1746-0913}
      \field{journaltitle}{Future Microbiology}
      \field{number}{2}
      \field{title}{{The future for early-stage tuberculosis drug discovery}}
      \field{volume}{10}
      \field{year}{2015}
      \field{pages}{217\bibrangedash 229}
      \verb{doi}
      \verb 10.2217/fmb.14.125
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Zuniga, Early, Parish - 2015 - The future for early-stage tuberculosis drug discovery.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.futuremedicine.com/doi/abs/10.2217/fmb.14.125
      \endverb
    \endentry
    \entry{Brennan2003}{article}{}
      \name{labelname}{1}{}{%
        {{hash=42c77fbe69a810cdf6bcd47e1de3de4e}{Brennan}{B\bibinitperiod}{P\bibnamedelima J}{P\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=42c77fbe69a810cdf6bcd47e1de3de4e}{Brennan}{B\bibinitperiod}{P\bibnamedelima J}{P\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{42c77fbe69a810cdf6bcd47e1de3de4e}
      \strng{fullhash}{42c77fbe69a810cdf6bcd47e1de3de4e}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis}}
      \field{abstract}{Much of the early structural definition of the cell wall of Mycobacterium spp. was initiated in the 1960s and 1970s. There was a long period of inactivity, but more recent developments in NMR and mass spectral analysis and definition of the M. tuberculosis genome have resulted in a thorough understanding, not only of the structure of the mycobacterial cell wall and its lipids but also the basic genetics and biosynthesis. Our understanding nowadays of cell-wall architecture amounts to a massive {$\textquotedblleft$}core{$\textquotedblright$} comprised of peptidoglycan covalently attached via a linker unit (l-Rha--d-GlcNAc-P) to a linear galactofuran, in turn attached to several strands of a highly branched arabinofuran, in turn attached to mycolic acids. The mycolic acids are oriented perpendicular to the plane of the membrane and provide a truly special lipid barrier responsible for many of the physiological and disease-inducing aspects of M. tuberculosis. Intercalated within this lipid environment are the lipids that have intrigued researchers for over five decades: the phthiocerol dimycocerosate, cord factor/dimycolyltrehalose, the sulfolipids, the phosphatidylinositol mannosides, etc. Knowledge of their roles in {$\textquotedblleft$}signaling{$\textquotedblright$} events, in pathogenesis, and in the immune response is now emerging, sometimes piecemeal and sometimes in an organized fashion. Some of the more intriguing observations are those demonstrating that mycolic acids are recognized by CD1-restricted T-cells, that antigen 85, one of the most powerful protective antigens of M. tuberculosis, is a mycolyltransferase, and that lipoarabinomannan (LAM), when {$\textquotedblleft$}capped{$\textquotedblright$} with short mannose oligosaccharides, is involved in phagocytosis of M. tuberculosis. Definition of the genome of M. tuberculosis has greatly aided efforts to define the biosynthetic pathways for all of these exotic molecules: the mycolic acids, the mycocerosates, phthiocerol, LAM, and the polyprenyl phosphates. For example, we know that synthesis of the entire core is initiated on a decaprenyl-P with synthesis of the linker unit, and then there is concomitant extension of the galactan and arabinan chains while this intermediate is transported through the cytoplasmic membrane. The final steps in these events, the attachment of mycolic acids and ligation to peptidoglycan, await definition and will prove to be excellent targets for a new generation of anti-tuberculosis drugs.}
      \field{issn}{1472-9792}
      \field{journaltitle}{Tuberculosis}
      \field{month}{02}
      \field{number}{1--3}
      \field{title}{{Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis}}
      \field{volume}{83}
      \field{year}{2003}
      \field{pages}{91\bibrangedash 97}
      \verb{doi}
      \verb http://dx.doi.org/10.1016/S1472-9792(02)00089-6
      \endverb
      \verb{url}
      \verb http://www.sciencedirect.com/science/article/pii/S1472979202000896
      \endverb
    \endentry
    \entry{Rodrigues2012}{article}{}
      \name{labelname}{5}{}{%
        {{hash=c074f3d972f6f68eac9a32bed4f106df}{Rodrigues}{R\bibinitperiod}{Liliana}{L\bibinitperiod}{}{}{}{}}%
        {{hash=39e8925451501613253c9181da8a4cbb}{Machado}{M\bibinitperiod}{Diana}{D\bibinitperiod}{}{}{}{}}%
        {{hash=1146737ee3f12db6060676fab2893385}{Couto}{C\bibinitperiod}{Isabel}{I\bibinitperiod}{}{}{}{}}%
        {{hash=52f35d1d4eb225a6d06246d3fb9dd3e4}{Amaral}{A\bibinitperiod}{Leonard}{L\bibinitperiod}{}{}{}{}}%
        {{hash=0f76bf06e80070831d3bee09aebbedeb}{Viveiros}{V\bibinitperiod}{Miguel}{M\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{5}{}{%
        {{hash=c074f3d972f6f68eac9a32bed4f106df}{Rodrigues}{R\bibinitperiod}{Liliana}{L\bibinitperiod}{}{}{}{}}%
        {{hash=39e8925451501613253c9181da8a4cbb}{Machado}{M\bibinitperiod}{Diana}{D\bibinitperiod}{}{}{}{}}%
        {{hash=1146737ee3f12db6060676fab2893385}{Couto}{C\bibinitperiod}{Isabel}{I\bibinitperiod}{}{}{}{}}%
        {{hash=52f35d1d4eb225a6d06246d3fb9dd3e4}{Amaral}{A\bibinitperiod}{Leonard}{L\bibinitperiod}{}{}{}{}}%
        {{hash=0f76bf06e80070831d3bee09aebbedeb}{Viveiros}{V\bibinitperiod}{Miguel}{M\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{3798080aec9095fd19060364cc1e91dc}
      \strng{fullhash}{acf04b2740aa2cf98a37508cd3b4e0c2}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Contribution of efflux activity to isoniazid resistance in the Mycobacterium tuberculosis complex}}
      \field{abstract}{Resistance to isoniazid (INH), one of the main drugs used in tuberculosis (TB) therapy, is mostly due to chromosomal mutations in target genes. However, approximately 20--30{\%} of INH resistant Mycobacterium tuberculosis isolates do not have mutations in any of the genes associated with INH resistance. This suggests that other mechanism(s) may be involved, namely efflux pump systems capable of extruding the drug to the exterior of the cell. In a previous work, we have induced clinical INH susceptible M. tuberculosis isolates and the H37Rv reference strain to high-level resistance to INH, by gradual exposure to increasing concentrations of this drug. In the present study, we have characterized these strains and Mycobacterium bovis BCG induced to INH resistance with respect to their efflux activity and its contribution to INH resistance using the following approach: determination of the susceptibility to INH in the presence and absence of the efflux inhibitors (EIs) chlorpromazine, thioridazine and verapamil; evaluation of efflux activity by a semi-automated fluorometric method; and quantification of the expression level of genes coding for efflux pumps by real-time RT-qPCR. The EIs decreased INH resistance in the INH induced strains, in particular verapamil promoted a reversal of resistance in some of the strains tested. The induced strains presented an increased efflux activity that was inhibited by the EIs and showed overexpression of the efflux pump genes efpA, mmpL7, mmr, p55 and the Tap-like gene Rv1258c. Altogether, these results correlate efflux activity with INH resistance and demonstrate that efflux pumps play an important role in acquired INH resistance in M. tuberculosis complex. The development of EIs that can restore the antimicrobial activity of the antibiotic subject to efflux is an approach that can be useful in order to prevent the emergence of this resistance and guide the development of new effective anti-TB therapeutical approaches.}
      \field{issn}{1567-1348}
      \field{journaltitle}{Infection, Genetics and Evolution}
      \field{month}{06}
      \field{number}{4}
      \field{title}{{Contribution of efflux activity to isoniazid resistance in the Mycobacterium tuberculosis complex}}
      \field{volume}{12}
      \field{year}{2012}
      \field{pages}{695\bibrangedash 700}
      \verb{doi}
      \verb http://dx.doi.org/10.1016/j.meegid.2011.08.009
      \endverb
      \verb{url}
      \verb http://www.sciencedirect.com/science/article/pii/S1567134811002887
      \endverb
    \endentry
    \entry{Manjunatha2015}{article}{}
      \name{labelname}{2}{}{%
        {{hash=be8674f6cc03382aa462597d2cc1bc1d}{Manjunatha}{M\bibinitperiod}{Ujjini\bibnamedelima H}{U\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=55cfd356590cd8481821d6ac32a0ce3f}{Smith}{S\bibinitperiod}{Paul\bibnamedelima W}{P\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=be8674f6cc03382aa462597d2cc1bc1d}{Manjunatha}{M\bibinitperiod}{Ujjini\bibnamedelima H}{U\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=55cfd356590cd8481821d6ac32a0ce3f}{Smith}{S\bibinitperiod}{Paul\bibnamedelima W}{P\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{538ab133a8bef52b6b8672fc40fe5585}
      \strng{fullhash}{538ab133a8bef52b6b8672fc40fe5585}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening}}
      \field{abstract}{Abstract Tuberculosis poses a major global health problem and multi-drug resistant strains are increasingly prevalent. Hence there is an urgent need to discover new TB drugs. Cell based phenotypic screening represents a powerful approach to identify anti-mycobacterial compounds and elucidate novel targets. Three high throughput phenotypic screens were performed at NITD against mycobacterium. Hits were identified and chemical series selected for optimisation. This produced compounds with good in vitro anti-mycobacterial activity and pharmacokinetic properties. Some compounds displayed oral activity in mouse efficacy models of TB. Herein, we review the TB discovery efforts at NITD and share experiences in optimisation of phenotypic hits, describing challenges encountered and lessons learned. We also offer perspectives to facilitate future selection and advancement of phenotypic hits.}
      \field{issn}{0968-0896}
      \field{journaltitle}{Bioorganic {\&} Medicinal Chemistry}
      \field{month}{08}
      \field{number}{16}
      \field{title}{{Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening}}
      \field{volume}{23}
      \field{year}{2015}
      \field{pages}{5087\bibrangedash 5097}
      \verb{doi}
      \verb http://dx.doi.org/10.1016/j.bmc.2014.12.031
      \endverb
      \verb{url}
      \verb http://www.sciencedirect.com/science/article/pii/S0968089614008797
      \endverb
    \endentry
    \entry{Ballell2013}{article}{}
      \name{labelname}{24}{}{%
        {{hash=92f9f1ebf3e833237d95513e96fb2683}{Ballell}{B\bibinitperiod}{Llu{\'{\i}}s}{L\bibinitperiod}{}{}{}{}}%
        {{hash=efe2cecb5400eed22762474ccee551df}{Bates}{B\bibinitperiod}{Robert\bibnamedelima H}{R\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=a6a697dfcfe00f4eed02d45342907903}{Young}{Y\bibinitperiod}{Rob\bibnamedelima J}{R\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=d624b2a0fb75d41ac6f14b4ebb6c414e}{Alvarez-Gomez}{A\bibinithyphendelim G\bibinitperiod}{Daniel}{D\bibinitperiod}{}{}{}{}}%
        {{hash=f961b135ebec0ec2ea7cd846a7f18a40}{Alvarez-Ruiz}{A\bibinithyphendelim R\bibinitperiod}{Emilio}{E\bibinitperiod}{}{}{}{}}%
        {{hash=eb94738be4b5124a107198c7e147ee7e}{Barroso}{B\bibinitperiod}{Vanessa}{V\bibinitperiod}{}{}{}{}}%
        {{hash=db388038e9f9f9a2a5173ca4e78d8361}{Blanco}{B\bibinitperiod}{Delia}{D\bibinitperiod}{}{}{}{}}%
        {{hash=153dba706e242d0c063dba7b00df65bd}{Crespo}{C\bibinitperiod}{Benigno}{B\bibinitperiod}{}{}{}{}}%
        {{hash=2e9a080216c809365c08d8c86327aede}{Escribano}{E\bibinitperiod}{Jaime}{J\bibinitperiod}{}{}{}{}}%
        {{hash=47c28321b0d9453b21d5e5e486ca866c}{Gonz{\'{a}}lez}{G\bibinitperiod}{Rub{\'{e}}n}{R\bibinitperiod}{}{}{}{}}%
        {{hash=83234e74f41ee378970e4d4ad091c96f}{Lozano}{L\bibinitperiod}{Sonia}{S\bibinitperiod}{}{}{}{}}%
        {{hash=83d3606d048952a7d15d7e34562b2652}{Huss}{H\bibinitperiod}{Sophie}{S\bibinitperiod}{}{}{}{}}%
        {{hash=17ac4c08a68a5fe3faa177272c88864a}{Santos-Villarejo}{S\bibinithyphendelim V\bibinitperiod}{Angel}{A\bibinitperiod}{}{}{}{}}%
        {{hash=f1be1b647b77a5e62805e06ca2ce245a}{Mart{\'{\i}}n-Plaza}{M\bibinithyphendelim P\bibinitperiod}{Jos{\'{e}}\bibnamedelima Julio}{J\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=3a464467a05b17272248c688ea08c332}{Mendoza}{M\bibinitperiod}{Alfonso}{A\bibinitperiod}{}{}{}{}}%
        {{hash=d79950ba2c762d4afc001ef32e65a506}{Rebollo-Lopez}{R\bibinithyphendelim L\bibinitperiod}{Mar{\'{\i}}a\bibnamedelima Jos{\'{e}}}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=ff636669f7099d0d93590b54dc39d7bf}{Remui{\~{n}}an-Blanco}{R\bibinitperiod}{Modesto}{M\bibinitperiod}{}{}{}{}}%
        {{hash=f9f586da9a74a597b8e62502929c27e4}{Lavandera}{L\bibinitperiod}{Jos{\'{e}}\bibnamedelima Luis}{J\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=28464e2b203f48dfbc59175b10b19697}{P{\'{e}}rez-Herran}{P\bibinithyphendelim H\bibinitperiod}{Esther}{E\bibinitperiod}{}{}{}{}}%
        {{hash=28fbc29383d067537b378baa24acafb6}{Gamo-Benito}{G\bibinithyphendelim B\bibinitperiod}{Francisco\bibnamedelima Javier}{F\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=e2e605566c9852d6ccc362bfe8c7e4c3}{Garc{\'{\i}}a-Bustos}{G\bibinithyphendelim B\bibinitperiod}{Jos{\'{e}}\bibnamedelima Francisco}{J\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{hash=2a40f7c9a32e3db6619f4de4b1a71fc4}{Barros}{B\bibinitperiod}{David}{D\bibinitperiod}{}{}{}{}}%
        {{hash=2af59264b17833d1b508913a539cb353}{Castro}{C\bibinitperiod}{Julia\bibnamedelima P}{J\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=42e7056dbae76aad662a45566123a6e5}{Cammack}{C\bibinitperiod}{Nicholas}{N\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{24}{}{%
        {{hash=92f9f1ebf3e833237d95513e96fb2683}{Ballell}{B\bibinitperiod}{Llu{\'{\i}}s}{L\bibinitperiod}{}{}{}{}}%
        {{hash=efe2cecb5400eed22762474ccee551df}{Bates}{B\bibinitperiod}{Robert\bibnamedelima H}{R\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=a6a697dfcfe00f4eed02d45342907903}{Young}{Y\bibinitperiod}{Rob\bibnamedelima J}{R\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=d624b2a0fb75d41ac6f14b4ebb6c414e}{Alvarez-Gomez}{A\bibinithyphendelim G\bibinitperiod}{Daniel}{D\bibinitperiod}{}{}{}{}}%
        {{hash=f961b135ebec0ec2ea7cd846a7f18a40}{Alvarez-Ruiz}{A\bibinithyphendelim R\bibinitperiod}{Emilio}{E\bibinitperiod}{}{}{}{}}%
        {{hash=eb94738be4b5124a107198c7e147ee7e}{Barroso}{B\bibinitperiod}{Vanessa}{V\bibinitperiod}{}{}{}{}}%
        {{hash=db388038e9f9f9a2a5173ca4e78d8361}{Blanco}{B\bibinitperiod}{Delia}{D\bibinitperiod}{}{}{}{}}%
        {{hash=153dba706e242d0c063dba7b00df65bd}{Crespo}{C\bibinitperiod}{Benigno}{B\bibinitperiod}{}{}{}{}}%
        {{hash=2e9a080216c809365c08d8c86327aede}{Escribano}{E\bibinitperiod}{Jaime}{J\bibinitperiod}{}{}{}{}}%
        {{hash=47c28321b0d9453b21d5e5e486ca866c}{Gonz{\'{a}}lez}{G\bibinitperiod}{Rub{\'{e}}n}{R\bibinitperiod}{}{}{}{}}%
        {{hash=83234e74f41ee378970e4d4ad091c96f}{Lozano}{L\bibinitperiod}{Sonia}{S\bibinitperiod}{}{}{}{}}%
        {{hash=83d3606d048952a7d15d7e34562b2652}{Huss}{H\bibinitperiod}{Sophie}{S\bibinitperiod}{}{}{}{}}%
        {{hash=17ac4c08a68a5fe3faa177272c88864a}{Santos-Villarejo}{S\bibinithyphendelim V\bibinitperiod}{Angel}{A\bibinitperiod}{}{}{}{}}%
        {{hash=f1be1b647b77a5e62805e06ca2ce245a}{Mart{\'{\i}}n-Plaza}{M\bibinithyphendelim P\bibinitperiod}{Jos{\'{e}}\bibnamedelima Julio}{J\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=3a464467a05b17272248c688ea08c332}{Mendoza}{M\bibinitperiod}{Alfonso}{A\bibinitperiod}{}{}{}{}}%
        {{hash=d79950ba2c762d4afc001ef32e65a506}{Rebollo-Lopez}{R\bibinithyphendelim L\bibinitperiod}{Mar{\'{\i}}a\bibnamedelima Jos{\'{e}}}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=ff636669f7099d0d93590b54dc39d7bf}{Remui{\~{n}}an-Blanco}{R\bibinitperiod}{Modesto}{M\bibinitperiod}{}{}{}{}}%
        {{hash=f9f586da9a74a597b8e62502929c27e4}{Lavandera}{L\bibinitperiod}{Jos{\'{e}}\bibnamedelima Luis}{J\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=28464e2b203f48dfbc59175b10b19697}{P{\'{e}}rez-Herran}{P\bibinithyphendelim H\bibinitperiod}{Esther}{E\bibinitperiod}{}{}{}{}}%
        {{hash=28fbc29383d067537b378baa24acafb6}{Gamo-Benito}{G\bibinithyphendelim B\bibinitperiod}{Francisco\bibnamedelima Javier}{F\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=e2e605566c9852d6ccc362bfe8c7e4c3}{Garc{\'{\i}}a-Bustos}{G\bibinithyphendelim B\bibinitperiod}{Jos{\'{e}}\bibnamedelima Francisco}{J\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{hash=2a40f7c9a32e3db6619f4de4b1a71fc4}{Barros}{B\bibinitperiod}{David}{D\bibinitperiod}{}{}{}{}}%
        {{hash=2af59264b17833d1b508913a539cb353}{Castro}{C\bibinitperiod}{Julia\bibnamedelima P}{J\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=42e7056dbae76aad662a45566123a6e5}{Cammack}{C\bibinitperiod}{Nicholas}{N\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{00395da62851ee7dc7452487fbf270db}
      \strng{fullhash}{432d7012e25884411c70a1fb3c39dd6c}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Fueling open-source drug discovery: 177 small-molecule leads against tuberculosis.}}
      \field{abstract}{With the aim of fuelling open-source, translational, early-stage drug discovery activities, the results of the recently completed antimycobacterial phenotypic screening campaign against Mycobacterium bovis BCG with hit confirmation in M. tuberculosis H37Rv were made publicly accessible. A set of 177 potent non-cytotoxic H37Rv hits was identified and will be made available to maximize the potential impact of the compounds toward a chemical genetics/proteomics exercise, while at the same time providing a plethora of potential starting points for new synthetic lead-generation activities. Two additional drug-discovery-relevant datasets are included: a) a drug-like property analysis reflecting the latest lead-like guidelines and b) an early lead-generation package of the most promising hits within the clusters identified.}
      \field{issn}{1860-7187}
      \field{journaltitle}{ChemMedChem}
      \field{month}{03}
      \field{number}{2}
      \field{title}{{Fueling open-source drug discovery: 177 small-molecule leads against tuberculosis.}}
      \field{volume}{8}
      \field{year}{2013}
      \field{pages}{313\bibrangedash 21}
      \verb{doi}
      \verb 10.1002/cmdc.201200428
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Ballell et al. - 2013 - Fueling open-source drug discovery 177 small-molecule leads against tuberculosis.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3743164%7B%5C&%7Dtool=pmcentrez%7B%5C&%7Drendertype=abstract
      \endverb
    \endentry
    \entry{Park2015}{article}{}
      \name{labelname}{12}{}{%
        {{hash=b89a4a24f6008ea325d03ba9fe4809f2}{Park}{P\bibinitperiod}{Sae\bibnamedelima Woong}{S\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=934a8ad50c4b2116fff3eba8de09e7a0}{Casalena}{C\bibinitperiod}{Dominick\bibnamedelima E.}{D\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=0aeca80896b1de8b52db244238491f8b}{Wilson}{W\bibinitperiod}{Daniel\bibnamedelima J.}{D\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=f60e70f11c521708f7d9fe2df92a4138}{Dai}{D\bibinitperiod}{Ran}{R\bibinitperiod}{}{}{}{}}%
        {{hash=df193b65675892822947ec0cefd68e0c}{Nag}{N\bibinitperiod}{Partha\bibnamedelima P.}{P\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=8cfebbe54197d0a6e7c196b6fe8cf3a3}{Liu}{L\bibinitperiod}{Feng}{F\bibinitperiod}{}{}{}{}}%
        {{hash=a1c348fb1951fd1fa0634ecf3503f50e}{Boyce}{B\bibinitperiod}{Jim\bibnamedelima P.}{J\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=808f38a5826d1cf980d29bd0b3e6179e}{Bittker}{B\bibinitperiod}{Joshua\bibnamedelima A.}{J\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=f392e7ee4276c992292e4abaf6fb6b10}{Schreiber}{S\bibinitperiod}{Stuart\bibnamedelima L.}{S\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=f7e058592d83a0b30cea2057bfddac71}{Finzel}{F\bibinitperiod}{Barry\bibnamedelima C.}{B\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=b66fe07f682d19c587e7a028cd4e4dbf}{Schnappinger}{S\bibinitperiod}{Dirk}{D\bibinitperiod}{}{}{}{}}%
        {{hash=46f8a492a751adb3f8133a39e65ee030}{Aldrich}{A\bibinitperiod}{Courtney\bibnamedelima C.}{C\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{12}{}{%
        {{hash=b89a4a24f6008ea325d03ba9fe4809f2}{Park}{P\bibinitperiod}{Sae\bibnamedelima Woong}{S\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=934a8ad50c4b2116fff3eba8de09e7a0}{Casalena}{C\bibinitperiod}{Dominick\bibnamedelima E.}{D\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=0aeca80896b1de8b52db244238491f8b}{Wilson}{W\bibinitperiod}{Daniel\bibnamedelima J.}{D\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=f60e70f11c521708f7d9fe2df92a4138}{Dai}{D\bibinitperiod}{Ran}{R\bibinitperiod}{}{}{}{}}%
        {{hash=df193b65675892822947ec0cefd68e0c}{Nag}{N\bibinitperiod}{Partha\bibnamedelima P.}{P\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=8cfebbe54197d0a6e7c196b6fe8cf3a3}{Liu}{L\bibinitperiod}{Feng}{F\bibinitperiod}{}{}{}{}}%
        {{hash=a1c348fb1951fd1fa0634ecf3503f50e}{Boyce}{B\bibinitperiod}{Jim\bibnamedelima P.}{J\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=808f38a5826d1cf980d29bd0b3e6179e}{Bittker}{B\bibinitperiod}{Joshua\bibnamedelima A.}{J\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=f392e7ee4276c992292e4abaf6fb6b10}{Schreiber}{S\bibinitperiod}{Stuart\bibnamedelima L.}{S\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=f7e058592d83a0b30cea2057bfddac71}{Finzel}{F\bibinitperiod}{Barry\bibnamedelima C.}{B\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=b66fe07f682d19c587e7a028cd4e4dbf}{Schnappinger}{S\bibinitperiod}{Dirk}{D\bibinitperiod}{}{}{}{}}%
        {{hash=46f8a492a751adb3f8133a39e65ee030}{Aldrich}{A\bibinitperiod}{Courtney\bibnamedelima C.}{C\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{9b5169cc60e951ff54ce30108fce7ec2}
      \strng{fullhash}{336bbd95b23644c7550c6aaf425d92f0}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Target-Based Identification of Whole-Cell Active Inhibitors of Biotin Biosynthesis in Mycobacterium tuberculosis}}
      \field{abstract}{Summary Biotin biosynthesis is essential for survival and persistence of Mycobacterium tuberculosis (Mtb) invivo. The aminotransferase BioA, which catalyzes the antepenultimate step in the biotin pathway, has been established as a promising target due to its vulnerability to chemical inhibition. We performed high-throughput screening (HTS) employing a fluorescence displacement assay and identified a diverse set of potent inhibitors including many diversity-oriented synthesis (DOS) scaffolds. To efficiently select only hits targeting biotin biosynthesis, we then deployed a whole-cell counterscreen in biotin-free and biotin-containing medium against wild-type Mtb and in parallel with isogenic bioA Mtb strains that possess differential levels of BioA expression. This counterscreen proved crucial to filter out compounds whose whole-cell activity was off target as well as identify hits with weak, but measurable whole-cell activity in BioA-depleted strains. Several of the most promising hits were cocrystallized with BioA to provide a framework for future structure-based drug design efforts.}
      \field{issn}{1074-5521}
      \field{journaltitle}{Chemistry {\&} Biology}
      \field{month}{01}
      \field{number}{1}
      \field{title}{{Target-Based Identification of Whole-Cell Active Inhibitors of Biotin Biosynthesis in Mycobacterium tuberculosis}}
      \field{volume}{22}
      \field{year}{2015}
      \field{pages}{76\bibrangedash 86}
      \verb{doi}
      \verb http://dx.doi.org/10.1016/j.chembiol.2014.11.012
      \endverb
      \verb{url}
      \verb http://www.sciencedirect.com/science/article/pii/S1074552114004219
      \endverb
    \endentry
    \entry{Arora2014}{article}{}
      \name{labelname}{7}{}{%
        {{hash=5f5722e01e5e7e19f4c3fcf8bb90f5cc}{Arora}{A\bibinitperiod}{Garima}{G\bibinitperiod}{}{}{}{}}%
        {{hash=1a4de17540d71b6ba10cfa95fd25657e}{Tiwari}{T\bibinitperiod}{Prabhakar}{P\bibinitperiod}{}{}{}{}}%
        {{hash=e0b6ed6a34f5e85b20ac4922ae86a00d}{Mandal}{M\bibinitperiod}{Rahul\bibnamedelima Shubhra}{R\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=00ec883074119e48a096ec3ec50cf00a}{Gupta}{G\bibinitperiod}{Arpit}{A\bibinitperiod}{}{}{}{}}%
        {{hash=e59885af95460776d2989573c763e72e}{Sharma}{S\bibinitperiod}{Deepak}{D\bibinitperiod}{}{}{}{}}%
        {{hash=8b7c3e755091774e225b4b13f18b4b3b}{Saha}{S\bibinitperiod}{Sudipto}{S\bibinitperiod}{}{}{}{}}%
        {{hash=4be4b5b53ba30c69beccb869b653b137}{Singh}{S\bibinitperiod}{Ramandeep}{R\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{7}{}{%
        {{hash=5f5722e01e5e7e19f4c3fcf8bb90f5cc}{Arora}{A\bibinitperiod}{Garima}{G\bibinitperiod}{}{}{}{}}%
        {{hash=1a4de17540d71b6ba10cfa95fd25657e}{Tiwari}{T\bibinitperiod}{Prabhakar}{P\bibinitperiod}{}{}{}{}}%
        {{hash=e0b6ed6a34f5e85b20ac4922ae86a00d}{Mandal}{M\bibinitperiod}{Rahul\bibnamedelima Shubhra}{R\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=00ec883074119e48a096ec3ec50cf00a}{Gupta}{G\bibinitperiod}{Arpit}{A\bibinitperiod}{}{}{}{}}%
        {{hash=e59885af95460776d2989573c763e72e}{Sharma}{S\bibinitperiod}{Deepak}{D\bibinitperiod}{}{}{}{}}%
        {{hash=8b7c3e755091774e225b4b13f18b4b3b}{Saha}{S\bibinitperiod}{Sudipto}{S\bibinitperiod}{}{}{}{}}%
        {{hash=4be4b5b53ba30c69beccb869b653b137}{Singh}{S\bibinitperiod}{Ramandeep}{R\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{bd83ba22dc67c0942620aaf990cabc5f}
      \strng{fullhash}{2298394e04e0682df9a05b6f48196be3}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{High Throughput Screen Identifies Small Molecule Inhibitors Specific for Mycobacterium tuberculosis Phosphoserine Phosphatase}}
      \field{abstract}{The emergence of drug resistant strains of Mycobacterium tuberculosis (M. tuberculosis) makes identification and validation of newer drug targets a global priority. Phosphoserine phosphatase (PSP), a key essential metabolic enzyme involved in conversion of O-phospho-L-serine to L-serine was characterized in this study. The M. tuberculosis genome harbors all enzymes involved in L-serine biosynthesis including 2 PSP homologs, Rv0505c (SerB1) and Rv3042c (SerB2). In the present study we have biochemically characterized SerB2 enzyme and developed malachite green based high throughput assay system (HTS) to identify SerB2 inhibitors. We have identified 10 compounds that were structurally different from known PSP inhibitors and few of these scaffolds were highly specific in their ability to inhibit SerB2 enzyme, non-cytotoxic against mammalian cell lines and inhibited M. tuberculosis growth in vitro. Surface plasma resonance experiments demonstrated the relative binding for these inhibitors. The two best hits identified in our screen, clorobiocin and rosaniline were bactericidal in activity and killed intracellular bacteria in a dose dependent manner. We have also identified amino acid residues critical for these SerB2-small molecule interactions. This is the first study where we validate that M. tuberculosis SerB2 is a druggable and suitable target to pursue for further HTS screening.}
      \field{annotation}{10.1074/jbc.M114.597682}
      \field{journaltitle}{Journal of Biological Chemistry}
      \field{month}{07}
      \field{title}{{High Throughput Screen Identifies Small Molecule Inhibitors Specific for Mycobacterium tuberculosis Phosphoserine Phosphatase}}
      \field{year}{2014}
      \verb{doi}
      \verb 10.1074/jbc.M114.597682
      \endverb
      \verb{url}
      \verb http://www.jbc.org/content/early/2014/07/18/jbc.M114.597682.abstract
      \endverb
    \endentry
    \entry{Ekins2013}{article}{}
      \name{labelname}{3}{}{%
        {{hash=5752f3a4325e2b3630c5d6a2fbf20203}{Ekins}{E\bibinitperiod}{Sean}{S\bibinitperiod}{}{}{}{}}%
        {{hash=b29e3d2397d9dfe5f7aa31eb83854009}{Clark}{C\bibinitperiod}{Alex\bibnamedelima M}{A\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=2ee17840ffa0764e1766671301082834}{Sarker}{S\bibinitperiod}{Malabika}{M\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=5752f3a4325e2b3630c5d6a2fbf20203}{Ekins}{E\bibinitperiod}{Sean}{S\bibinitperiod}{}{}{}{}}%
        {{hash=b29e3d2397d9dfe5f7aa31eb83854009}{Clark}{C\bibinitperiod}{Alex\bibnamedelima M}{A\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=2ee17840ffa0764e1766671301082834}{Sarker}{S\bibinitperiod}{Malabika}{M\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{0c1d5cb8a64cafcba65a66466b4105e9}
      \strng{fullhash}{0c1d5cb8a64cafcba65a66466b4105e9}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{TB Mobile: a mobile app for anti-tuberculosis molecules with known targets}}
      \field{abstract}{An increasing number of researchers are focused on strategies for developing inhibitors of Mycobacterium tuberculosis (Mtb) as tuberculosis (TB) drugs.}
      \field{issn}{1758-2946}
      \field{journaltitle}{Journal of Cheminformatics}
      \field{number}{1}
      \field{title}{{TB Mobile: a mobile app for anti-tuberculosis molecules with known targets}}
      \field{volume}{5}
      \field{year}{2013}
      \field{pages}{1\bibrangedash 14}
      \verb{doi}
      \verb 10.1186/1758-2946-5-13
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1186/1758-2946-5-13
      \endverb
    \endentry
    \entry{Crowther2010}{article}{}
      \name{labelname}{11}{}{%
        {{hash=1e7d02cf40b803f7e666ba3456522cda}{Crowther}{C\bibinitperiod}{Gregory\bibnamedelima J}{G\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=c530077ac76e5b88ee07fd4b2a12221b}{Shanmugam}{S\bibinitperiod}{Dhanasekaran}{D\bibinitperiod}{}{}{}{}}%
        {{hash=18a2c6408fa9f72cacf90d163b0a6168}{Carmona}{C\bibinitperiod}{Santiago\bibnamedelima J}{S\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=baa80a5be2aa40a51a6d75320eb6e906}{Doyle}{D\bibinitperiod}{Maria\bibnamedelima A}{M\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=cab27c24778bcfc63d1cc662fe4dc2d3}{Hertz-Fowler}{H\bibinithyphendelim F\bibinitperiod}{Christiane}{C\bibinitperiod}{}{}{}{}}%
        {{hash=2434c07ae5efa48a249b1894ed10c6c0}{Berriman}{B\bibinitperiod}{Matthew}{M\bibinitperiod}{}{}{}{}}%
        {{hash=5e5aca67350d87e82feb0c1b99bff907}{Nwaka}{N\bibinitperiod}{Solomon}{S\bibinitperiod}{}{}{}{}}%
        {{hash=03ae736dd714fa0199036669c996aae5}{Ralph}{R\bibinitperiod}{Stuart\bibnamedelima A}{S\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=e52eafe861d8f59e41cc13b5b4f96450}{Roos}{R\bibinitperiod}{David\bibnamedelima S}{D\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=e45aa1fa6f62eb50825183bf05f7a5d9}{{Van\bibnamedelimb Voorhis}}{V\bibinitperiod}{Wesley\bibnamedelima C}{W\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=af5876c5e761cc3e2a6cc1edcc6022a1}{Ag\x{fffd}ero}{A\bibinitperiod}{Fern\x{fffd}n}{F\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{11}{}{%
        {{hash=1e7d02cf40b803f7e666ba3456522cda}{Crowther}{C\bibinitperiod}{Gregory\bibnamedelima J}{G\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=c530077ac76e5b88ee07fd4b2a12221b}{Shanmugam}{S\bibinitperiod}{Dhanasekaran}{D\bibinitperiod}{}{}{}{}}%
        {{hash=18a2c6408fa9f72cacf90d163b0a6168}{Carmona}{C\bibinitperiod}{Santiago\bibnamedelima J}{S\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=baa80a5be2aa40a51a6d75320eb6e906}{Doyle}{D\bibinitperiod}{Maria\bibnamedelima A}{M\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=cab27c24778bcfc63d1cc662fe4dc2d3}{Hertz-Fowler}{H\bibinithyphendelim F\bibinitperiod}{Christiane}{C\bibinitperiod}{}{}{}{}}%
        {{hash=2434c07ae5efa48a249b1894ed10c6c0}{Berriman}{B\bibinitperiod}{Matthew}{M\bibinitperiod}{}{}{}{}}%
        {{hash=5e5aca67350d87e82feb0c1b99bff907}{Nwaka}{N\bibinitperiod}{Solomon}{S\bibinitperiod}{}{}{}{}}%
        {{hash=03ae736dd714fa0199036669c996aae5}{Ralph}{R\bibinitperiod}{Stuart\bibnamedelima A}{S\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=e52eafe861d8f59e41cc13b5b4f96450}{Roos}{R\bibinitperiod}{David\bibnamedelima S}{D\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=e45aa1fa6f62eb50825183bf05f7a5d9}{{Van\bibnamedelimb Voorhis}}{V\bibinitperiod}{Wesley\bibnamedelima C}{W\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=af5876c5e761cc3e2a6cc1edcc6022a1}{Ag\x{fffd}ero}{A\bibinitperiod}{Fern\x{fffd}n}{F\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Public Library of Science}%
      }
      \strng{namehash}{16bf0feaed87493db379fb7a5fdf300c}
      \strng{fullhash}{10395e71a9450134924aafc51f1e1874}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Identification of Attractive Drug Targets in Neglected-Disease Pathogens Using an In Silico Approach}}
      \field{abstract}{In cell-based drug development, researchers attempt to create drugs that kill a pathogen without necessarily understanding the details of how the drugs work. In contrast, target-based drug development entails the search for compounds that act on a specific intracellular target?often a protein known or suspected to be required for survival of the pathogen. The latter approach to drug development has been facilitated greatly by the sequencing of many pathogen genomes and the incorporation of genome data into user-friendly databases. The present paper shows how the database TDRtargets.org can identify proteins that might be considered good drug targets for diseases such as African sleeping sickness, Chagas disease, parasitic worm infections, tuberculosis, and malaria. These proteins may score highly in searches of the database because they are dissimilar to human proteins, are structurally similar to other ?druggable? proteins, have functions that are easy to measure, and/or fulfill other criteria. Researchers can use the lists of high-scoring proteins as a basis for deciding which potential drug targets to pursue experimentally.}
      \field{journaltitle}{PLoS Negl Trop Dis}
      \field{month}{08}
      \field{number}{8}
      \field{title}{{Identification of Attractive Drug Targets in Neglected-Disease Pathogens Using an In Silico Approach}}
      \field{volume}{4}
      \field{year}{2010}
      \field{pages}{e804}
      \verb{url}
      \verb http://dx.doi.org/10.1371%7B%%7D2Fjournal.pntd.0000804
      \endverb
    \endentry
    \entry{Ekins2010}{article}{}
      \name{labelname}{8}{}{%
        {{hash=5752f3a4325e2b3630c5d6a2fbf20203}{Ekins}{E\bibinitperiod}{Sean}{S\bibinitperiod}{}{}{}{}}%
        {{hash=575e765c403d077a0daef3dec4661dcb}{Bradford}{B\bibinitperiod}{Justin}{J\bibinitperiod}{}{}{}{}}%
        {{hash=32e361699323ea60524fa7569b11556a}{Dole}{D\bibinitperiod}{Krishna}{K\bibinitperiod}{}{}{}{}}%
        {{hash=89a11b08ffad8bb37917985aefc9982a}{Spektor}{S\bibinitperiod}{Anna}{A\bibinitperiod}{}{}{}{}}%
        {{hash=e5b089155938ceb370607b18d545339c}{Gregory}{G\bibinitperiod}{Kellan}{K\bibinitperiod}{}{}{}{}}%
        {{hash=95174b6fa5d6202d60176a8e5780c412}{Blondeau}{B\bibinitperiod}{David}{D\bibinitperiod}{}{}{}{}}%
        {{hash=45dcab353d8e4f32e3c73d0676fe5b00}{Hohman}{H\bibinitperiod}{Moses}{M\bibinitperiod}{}{}{}{}}%
        {{hash=85fb36f668a6af1185cb14be5b242b31}{Bunin}{B\bibinitperiod}{Barry\bibnamedelima a}{B\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{8}{}{%
        {{hash=5752f3a4325e2b3630c5d6a2fbf20203}{Ekins}{E\bibinitperiod}{Sean}{S\bibinitperiod}{}{}{}{}}%
        {{hash=575e765c403d077a0daef3dec4661dcb}{Bradford}{B\bibinitperiod}{Justin}{J\bibinitperiod}{}{}{}{}}%
        {{hash=32e361699323ea60524fa7569b11556a}{Dole}{D\bibinitperiod}{Krishna}{K\bibinitperiod}{}{}{}{}}%
        {{hash=89a11b08ffad8bb37917985aefc9982a}{Spektor}{S\bibinitperiod}{Anna}{A\bibinitperiod}{}{}{}{}}%
        {{hash=e5b089155938ceb370607b18d545339c}{Gregory}{G\bibinitperiod}{Kellan}{K\bibinitperiod}{}{}{}{}}%
        {{hash=95174b6fa5d6202d60176a8e5780c412}{Blondeau}{B\bibinitperiod}{David}{D\bibinitperiod}{}{}{}{}}%
        {{hash=45dcab353d8e4f32e3c73d0676fe5b00}{Hohman}{H\bibinitperiod}{Moses}{M\bibinitperiod}{}{}{}{}}%
        {{hash=85fb36f668a6af1185cb14be5b242b31}{Bunin}{B\bibinitperiod}{Barry\bibnamedelima a}{B\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{0f369f193e1ab7717e2185c2797e8a90}
      \strng{fullhash}{adf749eb224dfc0c25732ba07c6be8f4}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{A collaborative database and computational models for tuberculosis drug discovery.}}
      \field{abstract}{The search for molecules with activity against Mycobacterium tuberculosis (Mtb) is employing many approaches in parallel including high throughput screening and computational methods. We have developed a database (CDD TB) to capture public and private Mtb data while enabling data mining and collaborations with other researchers. We have used the public data along with several cheminformatics approaches to produce models that describe active and inactive compounds. We have compared these datasets to those for known FDA approved drugs and between Mtb active and inactive compounds. The distribution of polar surface area and pK(a) of active compounds was found to be a statistically significant determinant of activity against Mtb. Hydrophobicity was not always statistically significant. Bayesian classification models for 220, 463 molecules were generated and tested with external molecules, and enabled the discrimination of active or inactive substructures from other datasets in the CDD TB. Computational pharmacophores based on known Mtb drugs were able to map to and retrieve a small subset of some of the Mtb datasets, including a high percentage of Mtb actives. The combination of the database, dataset analysis, Bayesian and pharmacophore models provides new insights into molecular properties and features that are determinants of activity in whole cells. This study provides novel insights into the key 1D molecular descriptors, 2D chemical substructures and 3D pharmacophores which can be used to mine the chemistry space, prioritizing those molecules with a higher probability of activity against Mtb.}
      \field{isbn}{1742-2051 (Electronic)$\backslash$r1742-2051 (Linking)}
      \field{issn}{1742-206X}
      \field{journaltitle}{Molecular bioSystems}
      \field{number}{5}
      \field{title}{{A collaborative database and computational models for tuberculosis drug discovery.}}
      \field{volume}{6}
      \field{year}{2010}
      \field{pages}{840\bibrangedash 851}
      \verb{doi}
      \verb 10.1039/b917766c
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/B917766C.pdf:pdf
      \endverb
    \endentry
    \entry{Kinnings2009}{article}{}
      \name{labelname}{6}{}{%
        {{hash=ccf49e1eef79216484c626f6dcd672cb}{Kinnings}{K\bibinitperiod}{Sarah\bibnamedelima L}{S\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=65c7e91544e551a0ae7b503838594258}{Liu}{L\bibinitperiod}{Nina}{N\bibinitperiod}{}{}{}{}}%
        {{hash=83c8552c3d65bca87bc1e7b45486b2f5}{Buchmeier}{B\bibinitperiod}{Nancy}{N\bibinitperiod}{}{}{}{}}%
        {{hash=c02fffc4f95fe946af461def20320345}{Tonge}{T\bibinitperiod}{Peter\bibnamedelima J}{P\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=d9501bb096bed7e71af1f43d9ee08d98}{Xie}{X\bibinitperiod}{Lei}{L\bibinitperiod}{}{}{}{}}%
        {{hash=7c11f3af2e76014f9f3869e767aba8c4}{Bourne}{B\bibinitperiod}{Philip\bibnamedelima E}{P\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{6}{}{%
        {{hash=ccf49e1eef79216484c626f6dcd672cb}{Kinnings}{K\bibinitperiod}{Sarah\bibnamedelima L}{S\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=65c7e91544e551a0ae7b503838594258}{Liu}{L\bibinitperiod}{Nina}{N\bibinitperiod}{}{}{}{}}%
        {{hash=83c8552c3d65bca87bc1e7b45486b2f5}{Buchmeier}{B\bibinitperiod}{Nancy}{N\bibinitperiod}{}{}{}{}}%
        {{hash=c02fffc4f95fe946af461def20320345}{Tonge}{T\bibinitperiod}{Peter\bibnamedelima J}{P\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=d9501bb096bed7e71af1f43d9ee08d98}{Xie}{X\bibinitperiod}{Lei}{L\bibinitperiod}{}{}{}{}}%
        {{hash=7c11f3af2e76014f9f3869e767aba8c4}{Bourne}{B\bibinitperiod}{Philip\bibnamedelima E}{P\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Public Library of Science}%
      }
      \strng{namehash}{5bd598bf589fd8282cb1ddda1203a564}
      \strng{fullhash}{9c882be9547cc23bc0899619e28d1445}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Drug Discovery Using Chemical Systems Biology: Repositioning the Safe Medicine Comtan to Treat Multi-Drug and Extensively Drug Resistant Tuberculosis}}
      \field{abstract}{{<}title{>}Author Summary{<}/title{>} {<}p{>}The rise of multi-drug resistant (MDR) and extensively drug resistant (XDR) tuberculosis around the world, including in industrialized nations, poses a great threat to human health. This resistance highlights the need to develop new, effective and inexpensive anti-tubercular agents. Unfortunately, conventional approaches have yielded very few successes in the field of anti-infective drug discovery. It is a challenge to design drugs with both efficacy and safety. These challenges are reflected in the high costs involved in bringing new drugs to market. It has been estimated that the cost to launch a successful new drug is in excess of US{\$}800 million. We have developed a novel computational strategy to systematically identify cross-reactivity between different drug target families. In this paper we demonstrate the strength of this approach through the discovery that existing commercially available drugs prescribed for the treatment of Parkinson's disease have the potential to treat MDR and XDR tuberculosis. The protocol described herein can be included in a drug discovery pipeline in an effort to accelerate the development of new drugs with reduced side effects.{<}/p{>}}
      \field{journaltitle}{PLoS Comput Biol}
      \field{month}{07}
      \field{number}{7}
      \field{title}{{Drug Discovery Using Chemical Systems Biology: Repositioning the Safe Medicine Comtan to Treat Multi-Drug and Extensively Drug Resistant Tuberculosis}}
      \field{volume}{5}
      \field{year}{2009}
      \field{pages}{e1000423}
      \verb{url}
      \verb http://dx.doi.org/10.1371%7B%%7D2Fjournal.pcbi.1000423
      \endverb
    \endentry
    \entry{DeJonge2007}{article}{}
      \name{labelname}{5}{}{%
        {{hash=73caf1b80ea52fdae4df55d563fe67e7}{Jonge}{J\bibinitperiod}{Marc\bibnamedelima R}{M\bibinitperiod\bibinitdelim R\bibinitperiod}{de}{d\bibinitperiod}{}{}}%
        {{hash=80f20d1ff5b9337f9705ea450375e585}{Koymans}{K\bibinitperiod}{Luc\bibnamedelimb H\bibnamedelima M}{L\bibinitperiod\bibinitdelim H\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=88f613460682846d13080244f7055659}{Guillemont}{G\bibinitperiod}{J{\'{e}}r{\^{o}}me\bibnamedelimb E\bibnamedelima G}{J\bibinitperiod\bibinitdelim E\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=624c57206eaf07675ab40e09cab6819b}{Koul}{K\bibinitperiod}{Anil}{A\bibinitperiod}{}{}{}{}}%
        {{hash=f96b7db4e4195d4fdf4e1566196ce2a0}{Andries}{A\bibinitperiod}{Koen}{K\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{5}{}{%
        {{hash=73caf1b80ea52fdae4df55d563fe67e7}{Jonge}{J\bibinitperiod}{Marc\bibnamedelima R}{M\bibinitperiod\bibinitdelim R\bibinitperiod}{de}{d\bibinitperiod}{}{}}%
        {{hash=80f20d1ff5b9337f9705ea450375e585}{Koymans}{K\bibinitperiod}{Luc\bibnamedelimb H\bibnamedelima M}{L\bibinitperiod\bibinitdelim H\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=88f613460682846d13080244f7055659}{Guillemont}{G\bibinitperiod}{J{\'{e}}r{\^{o}}me\bibnamedelimb E\bibnamedelima G}{J\bibinitperiod\bibinitdelim E\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=624c57206eaf07675ab40e09cab6819b}{Koul}{K\bibinitperiod}{Anil}{A\bibinitperiod}{}{}{}{}}%
        {{hash=f96b7db4e4195d4fdf4e1566196ce2a0}{Andries}{A\bibinitperiod}{Koen}{K\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Wiley Subscription Services, Inc., A Wiley Company}%
      }
      \strng{namehash}{4f379376ceabea6ff249c7e6e94d42a1}
      \strng{fullhash}{7c20964b0584fadf5f9bb498a3ae9350}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910}}
      \field{issn}{1097-0134}
      \field{journaltitle}{Proteins: Structure, Function, and Bioinformatics}
      \field{month}{06}
      \field{number}{4}
      \field{title}{{A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910}}
      \field{volume}{67}
      \field{year}{2007}
      \field{pages}{971\bibrangedash 980}
      \verb{doi}
      \verb 10.1002/prot.21376
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1002/prot.21376
      \endverb
    \endentry
    \entry{Kumar2009}{article}{}
      \name{labelname}{2}{}{%
        {{hash=19f536f34203969fcb522aabafe24ea3}{Kumar}{K\bibinitperiod}{Ashutosh}{A\bibinitperiod}{}{}{}{}}%
        {{hash=0254373fd95c4e9d15993d2559e0f4df}{Siddiqi}{S\bibinitperiod}{Mohammad\bibnamedelima Imran}{M\bibinitperiod\bibinitdelim I\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=19f536f34203969fcb522aabafe24ea3}{Kumar}{K\bibinitperiod}{Ashutosh}{A\bibinitperiod}{}{}{}{}}%
        {{hash=0254373fd95c4e9d15993d2559e0f4df}{Siddiqi}{S\bibinitperiod}{Mohammad\bibnamedelima Imran}{M\bibinitperiod\bibinitdelim I\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{0ec14916d38c0ecbb6af3980b58f110a}
      \strng{fullhash}{0ec14916d38c0ecbb6af3980b58f110a}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Receptor based 3D-QSAR to identify putative binders of Mycobacterium tuberculosis Enoyl acyl carrier protein reductase}}
      \field{abstract}{In the current study, the applicability and scope of 3D-QSAR models (CoMFA and CoMSIA) to complement virtual screening using 3D pharmacophore and molecular docking is examined and applied to identify potential hits against Mycobacterium tuberculosis Enoyl acyl carrier protein reductase (MtENR). Initially CoMFA and CoMSIA models were developed using series of structurally related arylamides as MtENR inhibitors. Docking studies were employed to position the inhibitors into MtENR active site to derive receptor based 3D-QSAR models. Both CoMFA and CoMSIA yielded significant cross validated q2 values of 0.663 and 0.639 and r2 values of 0.989 and 0.963, respectively. The statistically significant models were validated by a test set of eight compounds with predictive r2 value of 0.882 and 0.875 for CoMFA and CoMSIA. The contour maps from 3D-QSAR models in combination with docked binding structures help to better interpret the structure activity relationship. Integrated with CoMFA and CoMSIA predictive models structure based (3D-pharmacophore and molecular docking) virtual screening have been employed to explore potential hits against MtENR. A representative set of 20 compounds with high predicted IC50 values were sorted out in the present study.}
      \field{issn}{0948-5023}
      \field{journaltitle}{Journal of Molecular Modeling}
      \field{number}{5}
      \field{title}{{Receptor based 3D-QSAR to identify putative binders of Mycobacterium tuberculosis Enoyl acyl carrier protein reductase}}
      \field{volume}{16}
      \field{year}{2009}
      \field{pages}{877\bibrangedash 893}
      \verb{doi}
      \verb 10.1007/s00894-009-0584-0
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1007/s00894-009-0584-0
      \endverb
    \endentry
    \entry{Lew2011}{article}{}
      \name{labelname}{4}{}{%
        {{hash=8845b7662cd3d4cbd59b622b6697b4d1}{Lew}{L\bibinitperiod}{Jocelyne\bibnamedelima M}{J\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=2eecc063e9164b475a87c913e8c57ce9}{Kapopoulou}{K\bibinitperiod}{Adamandia}{A\bibinitperiod}{}{}{}{}}%
        {{hash=6b467b9459a68dd3ca4c7a31ab59624d}{Jones}{J\bibinitperiod}{Louis\bibnamedelima M}{L\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=5caaa32aa1fbff7fb189b8042c605dea}{Cole}{C\bibinitperiod}{Stewart\bibnamedelima T}{S\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=8845b7662cd3d4cbd59b622b6697b4d1}{Lew}{L\bibinitperiod}{Jocelyne\bibnamedelima M}{J\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=2eecc063e9164b475a87c913e8c57ce9}{Kapopoulou}{K\bibinitperiod}{Adamandia}{A\bibinitperiod}{}{}{}{}}%
        {{hash=6b467b9459a68dd3ca4c7a31ab59624d}{Jones}{J\bibinitperiod}{Louis\bibnamedelima M}{L\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=5caaa32aa1fbff7fb189b8042c605dea}{Cole}{C\bibinitperiod}{Stewart\bibnamedelima T}{S\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{9708996f9e7dc5f9b76ab50070c82b77}
      \strng{fullhash}{124869b2fcdc7d55d5827232a0bb6f19}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{TubercuList -- 10 years after}}
      \field{abstract}{Summary TubercuList (http://tuberculist.epfl.ch/), the relational database that presents genome-derived information about H37Rv, the paradigm strain of Mycobacterium tuberculosis, has been active for ten years and now presents its twentieth release. Here, we describe some of the recent changes that have resulted from manual annotation with information from the scientific literature. Through manual curation, TubercuList strives to provide current gene-based information and is thus distinguished from other online sources of genome sequence data for M. tuberculosis. New, mostly small, genes have been discovered and the coordinates of some existing coding sequences have been changed when bioinformatics or experimental data suggest that this is required. Nucleotides that are polymorphic between different sources of H37Rv are annotated and gene essentiality data have been updated. A host of functional information has been gleaned from the literature and many new activities of proteins and RNAs have been included. To facilitate basic and translational research, TubercuList also provides links to other specialized databases that present diverse datasets such as 3D-structures, expression profiles, drug development criteria and drug resistance information, in addition to direct access to PubMed articles pertinent to particular genes. TubercuList has been and remains a highly valuable tool for the tuberculosis research community with {>}75,000 visitors per month.}
      \field{issn}{1472-9792}
      \field{journaltitle}{Tuberculosis}
      \field{month}{01}
      \field{number}{1}
      \field{title}{{TubercuList -- 10 years after}}
      \field{volume}{91}
      \field{year}{2011}
      \field{pages}{1\bibrangedash 7}
      \verb{doi}
      \verb http://dx.doi.org/10.1016/j.tube.2010.09.008
      \endverb
      \verb{url}
      \verb http://www.sciencedirect.com/science/article/pii/S1472979210001113
      \endverb
    \endentry
    \entry{Radusky2014}{article}{}
      \name{labelname}{7}{}{%
        {{hash=fe5bb5a12cbac077e3386095ab5d5563}{Radusky}{R\bibinitperiod}{Leandro}{L\bibinitperiod}{}{}{}{}}%
        {{hash=24bc5c794d795856ef8ded69bd8840a9}{Defelipe}{D\bibinitperiod}{Lucas\bibnamedelima A}{L\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=bc5549d9852fb4f4a9fd54a0b8176944}{Lanzarotti}{L\bibinitperiod}{Esteban}{E\bibinitperiod}{}{}{}{}}%
        {{hash=60c3a2ca50ab034b548e7585d978f287}{Luque}{L\bibinitperiod}{Javier}{J\bibinitperiod}{}{}{}{}}%
        {{hash=632125ec5c0252102e633bb321b1e16a}{Barril}{B\bibinitperiod}{Xavier}{X\bibinitperiod}{}{}{}{}}%
        {{hash=8ff85b0022daa3e701ff0783543845bf}{Marti}{M\bibinitperiod}{Marcelo\bibnamedelima A}{M\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=9585bb94b9f85420b6de2a3aa078e646}{Turjanski}{T\bibinitperiod}{Adri{\'{a}}n\bibnamedelima G}{A\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{7}{}{%
        {{hash=fe5bb5a12cbac077e3386095ab5d5563}{Radusky}{R\bibinitperiod}{Leandro}{L\bibinitperiod}{}{}{}{}}%
        {{hash=24bc5c794d795856ef8ded69bd8840a9}{Defelipe}{D\bibinitperiod}{Lucas\bibnamedelima A}{L\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=bc5549d9852fb4f4a9fd54a0b8176944}{Lanzarotti}{L\bibinitperiod}{Esteban}{E\bibinitperiod}{}{}{}{}}%
        {{hash=60c3a2ca50ab034b548e7585d978f287}{Luque}{L\bibinitperiod}{Javier}{J\bibinitperiod}{}{}{}{}}%
        {{hash=632125ec5c0252102e633bb321b1e16a}{Barril}{B\bibinitperiod}{Xavier}{X\bibinitperiod}{}{}{}{}}%
        {{hash=8ff85b0022daa3e701ff0783543845bf}{Marti}{M\bibinitperiod}{Marcelo\bibnamedelima A}{M\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=9585bb94b9f85420b6de2a3aa078e646}{Turjanski}{T\bibinitperiod}{Adri{\'{a}}n\bibnamedelima G}{A\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{46285b9fe17da8a8af2f09f590aac11a}
      \strng{fullhash}{1fe33895d8c7979e88ab5fe6b6fffe47}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{TuberQ: a Mycobacterium tuberculosis protein druggability database}}
      \field{abstract}{In 2012 an estimated 8.6 million people developed tuberculosis (TB) and 1.3 million died from the disease [including 320\x{2009}000 deaths among human immunodeficiency virus (HIV)-positive people]. There is an urgent need for new anti-TB drugs owing to the following: the fact that current treatments have severe side effects, the increasing emergence of multidrug-resistant strains of Mycobacterium tuberculosis (Mtb), the negative drug--drug interactions with certain HIV (or other disease) treatments and the ineffectiveness against dormant Mtb. In this context we present here the TuberQ database, a novel resource for all researchers working in the field of drug development in TB. The main feature of TuberQ is to provide a druggability analysis of Mtb proteins in a consistent and effective manner, contributing to a better selection of potential drug targets for screening campaigns and the analysis of targets for structure-based drug design projects. The structural druggability analysis is combined with features related to the characteristics of putative inhibitor binding pockets and with functional and biological data of proteins. The structural analysis is performed on all available unique Mtb structures and high-quality structural homology-based models. This information is shown in an interactive manner, depicting the protein structure, the pockets and the associated characteristics for each protein. TuberQ also provides information about gene essentiality information, as determined from whole cell--based knockout experiments, and expression information obtained from microarray experiments done in different stress-related conditions. We hope that TuberQ will be a powerful tool for researchers working in TB and eventually will lead to the identification of novel putative targets and progresses in therapeutic activities.Database URL: http://tuberq.proteinq.com.ar/}
      \field{annotation}{10.1093/database/bau035}
      \field{journaltitle}{Database}
      \field{month}{01}
      \field{title}{{TuberQ: a Mycobacterium tuberculosis protein druggability database}}
      \field{volume}{2014}
      \field{year}{2014}
      \verb{doi}
      \verb 10.1093/database/bau035
      \endverb
      \verb{url}
      \verb http://database.oxfordjournals.org/content/2014/bau035.abstract
      \endverb
    \endentry
    \entry{Clark2014}{article}{}
      \name{labelname}{3}{}{%
        {{hash=e53f75dcb71c9fd5c97d2051342de065}{Clark}{C\bibinitperiod}{Alex\bibnamedelima M.}{A\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=2ee17840ffa0764e1766671301082834}{Sarker}{S\bibinitperiod}{Malabika}{M\bibinitperiod}{}{}{}{}}%
        {{hash=5752f3a4325e2b3630c5d6a2fbf20203}{Ekins}{E\bibinitperiod}{Sean}{S\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=e53f75dcb71c9fd5c97d2051342de065}{Clark}{C\bibinitperiod}{Alex\bibnamedelima M.}{A\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=2ee17840ffa0764e1766671301082834}{Sarker}{S\bibinitperiod}{Malabika}{M\bibinitperiod}{}{}{}{}}%
        {{hash=5752f3a4325e2b3630c5d6a2fbf20203}{Ekins}{E\bibinitperiod}{Sean}{S\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{cec6d90cb4b35f16382906d8d623df6b}
      \strng{fullhash}{cec6d90cb4b35f16382906d8d623df6b}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{New target prediction and visualization tools incorporating open source molecular fingerprints for TB Mobile 2.0}}
      \field{abstract}{BackgroundWe recently developed a freely available mobile app (TB Mobile) for both iOS and Android platforms that displays Mycobacterium tuberculosis (Mtb) active molecule structures and their targets with links to associated data. The app was developed to make target information available to as large an audience as possible.ResultsWe now report a major update of the iOS version of the app. This includes enhancements that use an implementation of ECFP{\_}6 fingerprints that we have made open source. Using these fingerprints, the user can propose compounds with possible anti-TB activity, and view the compounds within a cluster landscape. Proposed compounds can also be compared to existing target data, using a n?ive Bayesian scoring system to rank probable targets. We have curated an additional 60 new compounds and their targets for Mtb and added these to the original set of 745 compounds. We have also curated 20 further compounds (many without targets in TB Mobile) to evaluate this version of the app with 805 compounds and associated targets.Conclusions TB Mobile can now manage a small collection of compounds that can be imported from external sources, or exported by various means such as email or app-to-app inter-process communication. This means that TB Mobile can be used as a node within a growing ecosystem of mobile apps for cheminformatics. It can also cluster compounds and use internal algorithms to help identify potential targets based on molecular similarity. TB Mobile represents a valuable dataset, data-visualization aid and target prediction tool.}
      \field{isbn}{1758-2946}
      \field{issn}{17582946}
      \field{journaltitle}{Journal of Cheminformatics}
      \field{number}{1}
      \field{title}{{New target prediction and visualization tools incorporating open source molecular fingerprints for TB Mobile 2.0}}
      \field{volume}{6}
      \field{year}{2014}
      \field{pages}{1\bibrangedash 17}
      \verb{doi}
      \verb 10.1186/s13321-014-0038-2
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/art{\%}3A10.1186{\%}2Fs13321-014-0038-2.pdf:pdf
      \endverb
    \endentry
    \entry{Rebollo-Lopez2015}{article}{}
      \name{labelname}{24}{}{%
        {{hash=1f1f118c0318d0070d18e4dc30a77626}{Rebollo-Lopez}{R\bibinithyphendelim L\bibinitperiod}{Mar{\'{\i}}a\bibnamedelima Jose}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=57dbebc061f4e8b1479160d3078c3799}{Leli{\`{e}}vre}{L\bibinitperiod}{Jo{\"{e}}l}{J\bibinitperiod}{}{}{}{}}%
        {{hash=d624b2a0fb75d41ac6f14b4ebb6c414e}{Alvarez-Gomez}{A\bibinithyphendelim G\bibinitperiod}{Daniel}{D\bibinitperiod}{}{}{}{}}%
        {{hash=b76d24156916dabb996a815e5b481f90}{Castro-Pichel}{C\bibinithyphendelim P\bibinitperiod}{Julia}{J\bibinitperiod}{}{}{}{}}%
        {{hash=9f1694dcbbd71d71a2b23228fee9da83}{Mart{\'{\i}}nez-Jim{\'{e}}nez}{M\bibinithyphendelim J\bibinitperiod}{Francisco}{F\bibinitperiod}{}{}{}{}}%
        {{hash=d0d9d6fafa34670d65fe13aa0977dbe6}{Papadatos}{P\bibinitperiod}{George}{G\bibinitperiod}{}{}{}{}}%
        {{hash=08a43e8ef8e3a2d464e9e8800f2ab3c9}{Kumar}{K\bibinitperiod}{Vinod}{V\bibinitperiod}{}{}{}{}}%
        {{hash=0c4aa186b62fc42cabaa30bb0046188c}{Colmenarejo}{C\bibinitperiod}{Gonzalo}{G\bibinitperiod}{}{}{}{}}%
        {{hash=2391162477fc4444870064ffe139c2a7}{Mugumbate}{M\bibinitperiod}{Grace}{G\bibinitperiod}{}{}{}{}}%
        {{hash=14a873e8089ad9892c55a43c2d204744}{Hurle}{H\bibinitperiod}{Mark}{M\bibinitperiod}{}{}{}{}}%
        {{hash=eb94738be4b5124a107198c7e147ee7e}{Barroso}{B\bibinitperiod}{Vanessa}{V\bibinitperiod}{}{}{}{}}%
        {{hash=a6a697dfcfe00f4eed02d45342907903}{Young}{Y\bibinitperiod}{Rob\bibnamedelima J}{R\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=af516c68c69249247d8a15ac5ce24cca}{Martinez-Hoyos}{M\bibinithyphendelim H\bibinitperiod}{Mar{\'{\i}}a}{M\bibinitperiod}{}{}{}{}}%
        {{hash=617bd17a1027a151e6f6425da2465227}{{Gonz{\'{a}}lez\bibnamedelimb Del\bibnamedelimb R{\'{\i}}o}}{G\bibinitperiod}{Rub{\'{e}}n}{R\bibinitperiod}{}{}{}{}}%
        {{hash=efe2cecb5400eed22762474ccee551df}{Bates}{B\bibinitperiod}{Robert\bibnamedelima H}{R\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=53f20b82555faedfb12fbcacc78a23a1}{Lopez-Roman}{L\bibinithyphendelim R\bibinitperiod}{Eva\bibnamedelima Maria}{E\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=4827ece82fa835310f281a0eb5872155}{Mendoza-Losana}{M\bibinithyphendelim L\bibinitperiod}{Alfonso}{A\bibinitperiod}{}{}{}{}}%
        {{hash=34171cc7063378bfb9cfc8390ada4490}{Brown}{B\bibinitperiod}{James\bibnamedelima R}{J\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=f961b135ebec0ec2ea7cd846a7f18a40}{Alvarez-Ruiz}{A\bibinithyphendelim R\bibinitperiod}{Emilio}{E\bibinitperiod}{}{}{}{}}%
        {{hash=24f88df3c6af6a41f2b4b5d26f2b5d94}{Marti-Renom}{M\bibinithyphendelim R\bibinitperiod}{Marc\bibnamedelima A}{M\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=53d44917db2ed8d5ebb266672e3d6189}{Overington}{O\bibinitperiod}{John\bibnamedelima P}{J\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=42e7056dbae76aad662a45566123a6e5}{Cammack}{C\bibinitperiod}{Nicholas}{N\bibinitperiod}{}{}{}{}}%
        {{hash=92f9f1ebf3e833237d95513e96fb2683}{Ballell}{B\bibinitperiod}{Llu{\'{\i}}s}{L\bibinitperiod}{}{}{}{}}%
        {{hash=539d4f4009dfac77f29948f95ca2be6d}{Barros-Aguire}{B\bibinithyphendelim A\bibinitperiod}{David}{D\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{24}{}{%
        {{hash=1f1f118c0318d0070d18e4dc30a77626}{Rebollo-Lopez}{R\bibinithyphendelim L\bibinitperiod}{Mar{\'{\i}}a\bibnamedelima Jose}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=57dbebc061f4e8b1479160d3078c3799}{Leli{\`{e}}vre}{L\bibinitperiod}{Jo{\"{e}}l}{J\bibinitperiod}{}{}{}{}}%
        {{hash=d624b2a0fb75d41ac6f14b4ebb6c414e}{Alvarez-Gomez}{A\bibinithyphendelim G\bibinitperiod}{Daniel}{D\bibinitperiod}{}{}{}{}}%
        {{hash=b76d24156916dabb996a815e5b481f90}{Castro-Pichel}{C\bibinithyphendelim P\bibinitperiod}{Julia}{J\bibinitperiod}{}{}{}{}}%
        {{hash=9f1694dcbbd71d71a2b23228fee9da83}{Mart{\'{\i}}nez-Jim{\'{e}}nez}{M\bibinithyphendelim J\bibinitperiod}{Francisco}{F\bibinitperiod}{}{}{}{}}%
        {{hash=d0d9d6fafa34670d65fe13aa0977dbe6}{Papadatos}{P\bibinitperiod}{George}{G\bibinitperiod}{}{}{}{}}%
        {{hash=08a43e8ef8e3a2d464e9e8800f2ab3c9}{Kumar}{K\bibinitperiod}{Vinod}{V\bibinitperiod}{}{}{}{}}%
        {{hash=0c4aa186b62fc42cabaa30bb0046188c}{Colmenarejo}{C\bibinitperiod}{Gonzalo}{G\bibinitperiod}{}{}{}{}}%
        {{hash=2391162477fc4444870064ffe139c2a7}{Mugumbate}{M\bibinitperiod}{Grace}{G\bibinitperiod}{}{}{}{}}%
        {{hash=14a873e8089ad9892c55a43c2d204744}{Hurle}{H\bibinitperiod}{Mark}{M\bibinitperiod}{}{}{}{}}%
        {{hash=eb94738be4b5124a107198c7e147ee7e}{Barroso}{B\bibinitperiod}{Vanessa}{V\bibinitperiod}{}{}{}{}}%
        {{hash=a6a697dfcfe00f4eed02d45342907903}{Young}{Y\bibinitperiod}{Rob\bibnamedelima J}{R\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=af516c68c69249247d8a15ac5ce24cca}{Martinez-Hoyos}{M\bibinithyphendelim H\bibinitperiod}{Mar{\'{\i}}a}{M\bibinitperiod}{}{}{}{}}%
        {{hash=617bd17a1027a151e6f6425da2465227}{{Gonz{\'{a}}lez\bibnamedelimb Del\bibnamedelimb R{\'{\i}}o}}{G\bibinitperiod}{Rub{\'{e}}n}{R\bibinitperiod}{}{}{}{}}%
        {{hash=efe2cecb5400eed22762474ccee551df}{Bates}{B\bibinitperiod}{Robert\bibnamedelima H}{R\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=53f20b82555faedfb12fbcacc78a23a1}{Lopez-Roman}{L\bibinithyphendelim R\bibinitperiod}{Eva\bibnamedelima Maria}{E\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=4827ece82fa835310f281a0eb5872155}{Mendoza-Losana}{M\bibinithyphendelim L\bibinitperiod}{Alfonso}{A\bibinitperiod}{}{}{}{}}%
        {{hash=34171cc7063378bfb9cfc8390ada4490}{Brown}{B\bibinitperiod}{James\bibnamedelima R}{J\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=f961b135ebec0ec2ea7cd846a7f18a40}{Alvarez-Ruiz}{A\bibinithyphendelim R\bibinitperiod}{Emilio}{E\bibinitperiod}{}{}{}{}}%
        {{hash=24f88df3c6af6a41f2b4b5d26f2b5d94}{Marti-Renom}{M\bibinithyphendelim R\bibinitperiod}{Marc\bibnamedelima A}{M\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=53d44917db2ed8d5ebb266672e3d6189}{Overington}{O\bibinitperiod}{John\bibnamedelima P}{J\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=42e7056dbae76aad662a45566123a6e5}{Cammack}{C\bibinitperiod}{Nicholas}{N\bibinitperiod}{}{}{}{}}%
        {{hash=92f9f1ebf3e833237d95513e96fb2683}{Ballell}{B\bibinitperiod}{Llu{\'{\i}}s}{L\bibinitperiod}{}{}{}{}}%
        {{hash=539d4f4009dfac77f29948f95ca2be6d}{Barros-Aguire}{B\bibinithyphendelim A\bibinitperiod}{David}{D\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{576c44671206422b040af987ba7d3184}
      \strng{fullhash}{a1364df07416c4afa144396e7417dd52}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Release of 50 new, drug-like compounds and their computational target predictions for open source anti-tubercular drug discovery.}}
      \field{abstract}{As a follow up to the antimycobacterial screening exercise and the release of GSK{$\textasciiacute$}s first Tres Cantos Antimycobacterial Set (TCAMS-TB), this paper presents the results of a second antitubercular screening effort of two hundred and fifty thousand compounds recently added to the GSK collection. The compounds were further prioritized based on not only antitubercular potency but also on physicochemical characteristics. The 50 most attractive compounds were then progressed for evaluation in three different predictive computational biology algorithms based on structural similarity or GSK historical biological assay data in order to determine their possible mechanisms of action. This effort has resulted in the identification of novel compounds and their hypothesized targets that will hopefully fuel future TB drug discovery and target validation programs alike.}
      \field{isbn}{1932-6203 (Electronic)1932-6203 (Linking)}
      \field{issn}{1932-6203}
      \field{journaltitle}{PloS one}
      \field{number}{12}
      \field{title}{{Release of 50 new, drug-like compounds and their computational target predictions for open source anti-tubercular drug discovery.}}
      \field{volume}{10}
      \field{year}{2015}
      \field{pages}{e0142293}
      \verb{doi}
      \verb 10.1371/journal.pone.0142293
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Rebollo-Lopez et al. - 2015 - Release of 50 new, drug-like compounds and their computational target predictions for open source anti-tub.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/26642067
      \endverb
    \endentry
    \entry{WHO_CANCER}{report}{}
      \name{labelname}{1}{}{%
        {{hash=d61df84a19b345b1669aaec7c0e26f43}{{International\bibnamedelimb Agency\bibnamedelimb for\bibnamedelimb Research\bibnamedelimb on\bibnamedelimb Cancer.}}{I\bibinitperiod}{}{}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=d61df84a19b345b1669aaec7c0e26f43}{{International\bibnamedelimb Agency\bibnamedelimb for\bibnamedelimb Research\bibnamedelimb on\bibnamedelimb Cancer.}}{I\bibinitperiod}{}{}{}{}{}{}}%
      }
      \strng{namehash}{d61df84a19b345b1669aaec7c0e26f43}
      \strng{fullhash}{d61df84a19b345b1669aaec7c0e26f43}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{World Cancer Report 2014}}
      \field{title}{{World Cancer Report 2014}}
      \field{type}{techreport}
      \field{year}{2014}
    \endentry
    \entry{Scott2012}{article}{}
      \name{labelname}{3}{}{%
        {{hash=c2879cb0c04460bef911a04663f2b529}{Scott}{S\bibinitperiod}{A\bibnamedelima M}{A\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=e5f24d4a7c9817c33e3df1a1bace176f}{Wolchok}{W\bibinitperiod}{J\bibnamedelima D}{J\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=e93f5f6ff7d06fbe30598414c6c66ce5}{Old}{O\bibinitperiod}{L\bibnamedelima J}{L\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=c2879cb0c04460bef911a04663f2b529}{Scott}{S\bibinitperiod}{A\bibnamedelima M}{A\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=e5f24d4a7c9817c33e3df1a1bace176f}{Wolchok}{W\bibinitperiod}{J\bibnamedelima D}{J\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=e93f5f6ff7d06fbe30598414c6c66ce5}{Old}{O\bibinitperiod}{L\bibnamedelima J}{L\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group}%
      }
      \strng{namehash}{9b3113f68a0bc2c18bc3f22d6acff6c0}
      \strng{fullhash}{9b3113f68a0bc2c18bc3f22d6acff6c0}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Antibody therapy of cancer}}
      \field{abstract}{The use of monoclonal antibodies (mAbs) for cancer therapy has achieved considerable success in recent years. Antibody-drug conjugates are powerful new treatment options for lymphomas and solid tumours, and immunomodulatory antibodies have also recently achieved remarkable clinical success. The development of therapeutic antibodies requires a deep understanding of cancer serology, protein-engineering techniques, mechanisms of action and resistance, and the interplay between the immune system and cancer cells. This Review outlines the fundamental strategies that are required to develop antibody therapies for cancer patients through iterative approaches to target and antibody selection, extending from preclinical studies to human trials.}
      \field{isbn}{1474-1768 (Electronic)$\backslash$r1474-175X (Linking)}
      \field{issn}{1474-1768}
      \field{journaltitle}{Nat Rev Cancer}
      \field{number}{4}
      \field{title}{{Antibody therapy of cancer}}
      \field{volume}{12}
      \field{year}{2012}
      \field{pages}{278\bibrangedash 287}
      \verb{doi}
      \verb 10.1038/nrc3236
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/nrc3236.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/22437872
      \endverb
    \endentry
    \entry{Jonker2007}{article}{}
      \name{labelname}{15}{}{%
        {{hash=c6e9b799fa77d0c4610b27ff9b6e3e3a}{Jonker}{J\bibinitperiod}{Derek\bibnamedelima J}{D\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=d9a5e453b03655da31387662d9cc3a78}{O'Callaghan}{O\bibinitperiod}{Chris\bibnamedelima J}{C\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=69bfd6ca4a0982e2e124068cfcac251f}{Karapetis}{K\bibinitperiod}{Christos\bibnamedelima S}{C\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=cf001a2eb6a5bbbf502832fd598d994f}{Zalcberg}{Z\bibinitperiod}{John\bibnamedelima R}{J\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=6e580e6c8f80947c6d4390f8a6a1b594}{Tu}{T\bibinitperiod}{Dongsheng}{D\bibinitperiod}{}{}{}{}}%
        {{hash=893af5b39bba1f1b9703e2ef81a71bc4}{Au}{A\bibinitperiod}{Heather-Jane}{H\bibinithyphendelim J\bibinitperiod}{}{}{}{}}%
        {{hash=699404d477533a7283397ce9c14cbd29}{Berry}{B\bibinitperiod}{Scott\bibnamedelima R}{S\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=d6101a2eeee9c721cb7959e4ed97bc7e}{Krahn}{K\bibinitperiod}{Marianne}{M\bibinitperiod}{}{}{}{}}%
        {{hash=ad1098e31f8438fd3daace7d33281ded}{Price}{P\bibinitperiod}{Timothy}{T\bibinitperiod}{}{}{}{}}%
        {{hash=733968338f24bdb2bde63e0c10e249c8}{Simes}{S\bibinitperiod}{R\bibnamedelima John}{R\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=5aa6cac075472f40d29514d5c87cd394}{Tebbutt}{T\bibinitperiod}{Niall\bibnamedelima C}{N\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=51238d89ced2bd90995287231ed9a61c}{Hazel}{H\bibinitperiod}{Guy}{G\bibinitperiod}{van}{v\bibinitperiod}{}{}}%
        {{hash=5d6972f2c86aff4a10f50fb986728d77}{Wierzbicki}{W\bibinitperiod}{Rafal}{R\bibinitperiod}{}{}{}{}}%
        {{hash=d72a7cf38af6e6da4fb72b0ccdebee61}{Langer}{L\bibinitperiod}{Christiane}{C\bibinitperiod}{}{}{}{}}%
        {{hash=b2dce0962f84cbac2095d2c9ea065d47}{Moore}{M\bibinitperiod}{Malcolm\bibnamedelima J}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{15}{}{%
        {{hash=c6e9b799fa77d0c4610b27ff9b6e3e3a}{Jonker}{J\bibinitperiod}{Derek\bibnamedelima J}{D\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=d9a5e453b03655da31387662d9cc3a78}{O'Callaghan}{O\bibinitperiod}{Chris\bibnamedelima J}{C\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=69bfd6ca4a0982e2e124068cfcac251f}{Karapetis}{K\bibinitperiod}{Christos\bibnamedelima S}{C\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=cf001a2eb6a5bbbf502832fd598d994f}{Zalcberg}{Z\bibinitperiod}{John\bibnamedelima R}{J\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=6e580e6c8f80947c6d4390f8a6a1b594}{Tu}{T\bibinitperiod}{Dongsheng}{D\bibinitperiod}{}{}{}{}}%
        {{hash=893af5b39bba1f1b9703e2ef81a71bc4}{Au}{A\bibinitperiod}{Heather-Jane}{H\bibinithyphendelim J\bibinitperiod}{}{}{}{}}%
        {{hash=699404d477533a7283397ce9c14cbd29}{Berry}{B\bibinitperiod}{Scott\bibnamedelima R}{S\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=d6101a2eeee9c721cb7959e4ed97bc7e}{Krahn}{K\bibinitperiod}{Marianne}{M\bibinitperiod}{}{}{}{}}%
        {{hash=ad1098e31f8438fd3daace7d33281ded}{Price}{P\bibinitperiod}{Timothy}{T\bibinitperiod}{}{}{}{}}%
        {{hash=733968338f24bdb2bde63e0c10e249c8}{Simes}{S\bibinitperiod}{R\bibnamedelima John}{R\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=5aa6cac075472f40d29514d5c87cd394}{Tebbutt}{T\bibinitperiod}{Niall\bibnamedelima C}{N\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=51238d89ced2bd90995287231ed9a61c}{Hazel}{H\bibinitperiod}{Guy}{G\bibinitperiod}{van}{v\bibinitperiod}{}{}}%
        {{hash=5d6972f2c86aff4a10f50fb986728d77}{Wierzbicki}{W\bibinitperiod}{Rafal}{R\bibinitperiod}{}{}{}{}}%
        {{hash=d72a7cf38af6e6da4fb72b0ccdebee61}{Langer}{L\bibinitperiod}{Christiane}{C\bibinitperiod}{}{}{}{}}%
        {{hash=b2dce0962f84cbac2095d2c9ea065d47}{Moore}{M\bibinitperiod}{Malcolm\bibnamedelima J}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Massachusetts Medical Society}%
      }
      \strng{namehash}{634a3f810118ce9e64eea4c27878da7b}
      \strng{fullhash}{96fa606caabe707d7a28a04587f138b1}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Cetuximab for the Treatment of Colorectal Cancer}}
      \field{annotation}{doi: 10.1056/NEJMoa071834}
      \field{issn}{0028-4793}
      \field{journaltitle}{New England Journal of Medicine}
      \field{month}{11}
      \field{number}{20}
      \field{title}{{Cetuximab for the Treatment of Colorectal Cancer}}
      \field{volume}{357}
      \field{year}{2007}
      \field{pages}{2040\bibrangedash 2048}
      \verb{doi}
      \verb 10.1056/NEJMoa071834
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1056/NEJMoa071834
      \endverb
    \endentry
    \entry{Tejani2010}{article}{}
      \name{labelname}{3}{}{%
        {{hash=a53cea8ee1778ee656221ba5f62b0d59}{Tejani}{T\bibinitperiod}{Mohamedtaki\bibnamedelima A}{M\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=8ba6359b60241bf39c9056f9b0b50861}{Cohen}{C\bibinitperiod}{Roger\bibnamedelima B}{R\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=1fbc9c450ea738693452edf63e581bb5}{Mehra}{M\bibinitperiod}{Ranee}{R\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=a53cea8ee1778ee656221ba5f62b0d59}{Tejani}{T\bibinitperiod}{Mohamedtaki\bibnamedelima A}{M\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=8ba6359b60241bf39c9056f9b0b50861}{Cohen}{C\bibinitperiod}{Roger\bibnamedelima B}{R\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=1fbc9c450ea738693452edf63e581bb5}{Mehra}{M\bibinitperiod}{Ranee}{R\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Dove Medical Press}%
      }
      \strng{namehash}{7ca53ee8af2e6d31324538c94d3ef19a}
      \strng{fullhash}{7ca53ee8af2e6d31324538c94d3ef19a}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer}}
      \field{abstract}{Recurrent and/or metastatic squamous cell carcinoma of the head and neck (HNSCC) continues to be a source of significant morbidity and mortality worldwide. Agents that target the epidermal growth factor receptor (EGFR) have demonstrated beneficial effects in this setting. Cetuximab, a monoclonal antibody against the EGFR, improves locoregional control and overall survival when used as a radiation sensitizer in patients with locoregionally advanced HNSCC undergoing definitive radiation therapy with curative intent. Cetuximab is also active as monotherapy in patients whose cancer has progressed on platinum-containing therapy. In the first-line setting for incurable HNSCC, cetuximab added to platinum-based chemotherapy significantly improves overall survival compared with standard chemotherapy alone. These positive results have had a significant impact on the standard of care for advanced HNSCC. In this review, we will discuss the mechanism of action, clinical data and common toxicities that pertain to the use of cetuximab in the treatment of advanced incurable HNSCC.}
      \field{issn}{1177-5475}
      \field{journaltitle}{Biologics : Targets {\&} Therapy}
      \field{month}{08}
      \field{title}{{The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer}}
      \field{volume}{4}
      \field{year}{2010}
      \field{pages}{173\bibrangedash 185}
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2921255/
      \endverb
    \endentry
    \entry{Postow2015}{article}{}
      \name{labelname}{3}{}{%
        {{hash=fd2930a953d64909361cbf0683108878}{Postow}{P\bibinitperiod}{Michael\bibnamedelima A}{M\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=85d150de8f80fd8b247ca39c2e18b97f}{Callahan}{C\bibinitperiod}{Margaret\bibnamedelima K}{M\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=a050b2ff75bda8e77c969fa33ce9bccf}{Wolchok}{W\bibinitperiod}{Jedd\bibnamedelima D}{J\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=fd2930a953d64909361cbf0683108878}{Postow}{P\bibinitperiod}{Michael\bibnamedelima A}{M\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=85d150de8f80fd8b247ca39c2e18b97f}{Callahan}{C\bibinitperiod}{Margaret\bibnamedelima K}{M\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=a050b2ff75bda8e77c969fa33ce9bccf}{Wolchok}{W\bibinitperiod}{Jedd\bibnamedelima D}{J\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{dfb1be449dd939369d90a8101230efb4}
      \strng{fullhash}{dfb1be449dd939369d90a8101230efb4}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Immune Checkpoint Blockade in Cancer Therapy}}
      \field{abstract}{Immunologic checkpoint blockade with antibodies that target cytotoxic T lymphocyte--associated antigen 4 (CTLA-4) and the programmed cell death protein 1 pathway (PD-1/PD-L1) have demonstrated promise in a variety of malignancies. Ipilimumab (CTLA-4) and pembrolizumab (PD-1) are approved by the US Food and Drug Administration for the treatment of advanced melanoma, and additional regulatory approvals are expected across the oncologic spectrum for a variety of other agents that target these pathways. Treatment with both CTLA-4 and PD-1/PD-L1 blockade is associated with a unique pattern of adverse events called immune-related adverse events, and occasionally, unusual kinetics of tumor response are seen. Combination approaches involving CTLA-4 and PD-1/PD-L1 blockade are being investigated to determine whether they enhance the efficacy of either approach alone. Principles learned during the development of CTLA-4 and PD-1/PD-L1 approaches will likely be used as new immunologic checkpoint blocking antibodies begin clinical investigation.}
      \field{annotation}{10.1200/JCO.2014.59.4358}
      \field{journaltitle}{Journal of Clinical Oncology}
      \field{month}{01}
      \field{title}{{Immune Checkpoint Blockade in Cancer Therapy}}
      \field{year}{2015}
      \verb{doi}
      \verb 10.1200/JCO.2014.59.4358
      \endverb
      \verb{url}
      \verb http://jco.ascopubs.org/content/early/2015/01/20/JCO.2014.59.4358.abstract
      \endverb
    \endentry
    \entry{Demko2008}{article}{}
      \name{labelname}{4}{}{%
        {{hash=72ccad56c5750313d6698db300a32086}{Demko}{D\bibinitperiod}{Suzanne}{S\bibinitperiod}{}{}{}{}}%
        {{hash=7a086a0862d6af9a7e0942f4e8aacab5}{Summers}{S\bibinitperiod}{Jeffrey}{J\bibinitperiod}{}{}{}{}}%
        {{hash=681df724680c3d0b0f010a44eed156c6}{Keegan}{K\bibinitperiod}{Patricia}{P\bibinitperiod}{}{}{}{}}%
        {{hash=1c83ded9b78682dc95ab5f6263482297}{Pazdur}{P\bibinitperiod}{Richard}{R\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=72ccad56c5750313d6698db300a32086}{Demko}{D\bibinitperiod}{Suzanne}{S\bibinitperiod}{}{}{}{}}%
        {{hash=7a086a0862d6af9a7e0942f4e8aacab5}{Summers}{S\bibinitperiod}{Jeffrey}{J\bibinitperiod}{}{}{}{}}%
        {{hash=681df724680c3d0b0f010a44eed156c6}{Keegan}{K\bibinitperiod}{Patricia}{P\bibinitperiod}{}{}{}{}}%
        {{hash=1c83ded9b78682dc95ab5f6263482297}{Pazdur}{P\bibinitperiod}{Richard}{R\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{11edace4cb15c235b727c528d0c9af55}
      \strng{fullhash}{6d979bc47b7844bae92c9fe65f4587db}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{FDA Drug Approval Summary: Alemtuzumab as Single-Agent Treatment for B-Cell Chronic Lymphocytic Leukemia}}
      \field{abstract}{On September 19, 2007, the U.S. Food and Drug Administration granted regular approval and expanded labeling for alemtuzumab (Campath{{$\textregistered$}}; Genzyme Corporation, Cambridge, MA) as single-agent treatment for B-cell chronic lymphocytic leukemia (B-CLL). Alemtuzumab was initially approved in 2001 under accelerated approval regulations. Conversion to regular approval was based on a single study submitted to verify clinical benefit. Efficacy and safety were demonstrated in an open-label, international, multicenter, randomized trial of 297 patients with previously untreated, Rai stage I--IV B-CLL experiencing progression of their disease. Patients were randomized to either alemtuzumab, 30 mg i.v. over 2 hours three times per week on alternate days for a maximum of 12 weeks, or chlorambucil, 40 mg/m2 orally every 28 days for a maximum of 12 months. The progression-free survival time, the primary study endpoint, was significantly longer in the alemtuzumab arm than in the chlorambucil arm. Both the overall and complete response rates were also significantly higher in the alemtuzumab arm. No differences in survival were observed. There were no new safety signals identified in patients receiving alemtuzumab. The most serious, and sometimes fatal, toxicities of alemtuzumab are cytopenias, infusion reactions, and infections.}
      \field{annotation}{10.1634/theoncologist.2007-0218}
      \field{journaltitle}{The Oncologist}
      \field{month}{02}
      \field{number}{2}
      \field{title}{{FDA Drug Approval Summary: Alemtuzumab as Single-Agent Treatment for B-Cell Chronic Lymphocytic Leukemia}}
      \field{volume}{13}
      \field{year}{2008}
      \field{pages}{167\bibrangedash 174}
      \verb{doi}
      \verb 10.1634/theoncologist.2007-0218
      \endverb
      \verb{url}
      \verb http://theoncologist.alphamedpress.org/content/13/2/167.abstract
      \endverb
    \endentry
    \entry{Ferrara2004}{article}{}
      \name{labelname}{4}{}{%
        {{hash=b2a522ffc1a8087f44ce47bce13aac2a}{Ferrara}{F\bibinitperiod}{Napoleone}{N\bibinitperiod}{}{}{}{}}%
        {{hash=df9e45131e1cb39a36f3d6e271e41885}{Hillan}{H\bibinitperiod}{Kenneth\bibnamedelima J}{K\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=6aa9a7a85062864c38e5c7ad11693c9c}{Gerber}{G\bibinitperiod}{Hans-Peter}{H\bibinithyphendelim P\bibinitperiod}{}{}{}{}}%
        {{hash=aa84810acd391c68618d3e96db5fd2ff}{Novotny}{N\bibinitperiod}{William}{W\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=b2a522ffc1a8087f44ce47bce13aac2a}{Ferrara}{F\bibinitperiod}{Napoleone}{N\bibinitperiod}{}{}{}{}}%
        {{hash=df9e45131e1cb39a36f3d6e271e41885}{Hillan}{H\bibinitperiod}{Kenneth\bibnamedelima J}{K\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=6aa9a7a85062864c38e5c7ad11693c9c}{Gerber}{G\bibinitperiod}{Hans-Peter}{H\bibinithyphendelim P\bibinitperiod}{}{}{}{}}%
        {{hash=aa84810acd391c68618d3e96db5fd2ff}{Novotny}{N\bibinitperiod}{William}{W\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{706247e205c1c091a5abaf9c11900637}
      \strng{fullhash}{116bddec72fd976d38e5c0a517938412}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer}}
      \field{annotation}{10.1038/nrd1381}
      \field{issn}{1474-1776}
      \field{journaltitle}{Nat Rev Drug Discov}
      \field{month}{05}
      \field{number}{5}
      \field{title}{{Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer}}
      \field{volume}{3}
      \field{year}{2004}
      \field{pages}{391\bibrangedash 400}
      \verb{url}
      \verb http://dx.doi.org/10.1038/nrd1381
      \endverb
    \endentry
    \entry{Keating2014}{article}{}
      \name{labelname}{1}{}{%
        {{hash=1212c1603bc2a7ff9ecc8ca9658bad9a}{Keating}{K\bibinitperiod}{Gillian\bibnamedelima M}{G\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=1212c1603bc2a7ff9ecc8ca9658bad9a}{Keating}{K\bibinitperiod}{Gillian\bibnamedelima M}{G\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{1212c1603bc2a7ff9ecc8ca9658bad9a}
      \strng{fullhash}{1212c1603bc2a7ff9ecc8ca9658bad9a}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Bevacizumab: A Review of Its Use in Advanced Cancer}}
      \field{abstract}{The humanized monoclonal antibody bevacizumab (Avastin{{$\textregistered$}}) has been available in the EU since 2005. Results of phase III trials demonstrate that adding intravenous bevacizumab to antineoplastic agents improves progression-free survival and/or overall survival in patients with advanced cancer, including when used as first- or second-line therapy in metastatic colorectal cancer, as first-line therapy in advanced nonsquamous non-small cell lung cancer, as first-line therapy in metastatic renal cell carcinoma, as first-line therapy in metastatic breast cancer, and as first-line therapy in epithelial ovarian, fallopian tube or primary peritoneal cancer or in recurrent, platinum-sensitive or platinum-resistant disease. Results of these studies are supported by the findings of routine oncology practice studies conducted in real-world settings. The tolerability profile of bevacizumab is well defined and adverse events associated with its use (e.g. hypertension, proteinuria, haemorrhage, wound healing complications, arterial thromboembolism, gastrointestinal perforation) are generally manageable. In conclusion, bevacizumab remains an important option for use in patients with advanced cancer.}
      \field{issn}{1179-1950}
      \field{journaltitle}{Drugs}
      \field{number}{16}
      \field{title}{{Bevacizumab: A Review of Its Use in Advanced Cancer}}
      \field{volume}{74}
      \field{year}{2014}
      \field{pages}{1891\bibrangedash 1925}
      \verb{doi}
      \verb 10.1007/s40265-014-0302-9
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1007/s40265-014-0302-9
      \endverb
    \endentry
    \entry{Witzig2002}{article}{}
      \name{labelname}{11}{}{%
        {{hash=a5501d45dea767217a8dc453214b05ab}{Witzig}{W\bibinitperiod}{Thomas\bibnamedelima E}{T\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=4e157da32ee3dd419dffa84c1174e575}{Flinn}{F\bibinitperiod}{Ian\bibnamedelima W}{I\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=042e5e17ad292ca3d82a324d6c7d8475}{Gordon}{G\bibinitperiod}{Leo\bibnamedelima I}{L\bibinitperiod\bibinitdelim I\bibinitperiod}{}{}{}{}}%
        {{hash=42b800df62abeff7f982ee046c543048}{Emmanouilides}{E\bibinitperiod}{Christos}{C\bibinitperiod}{}{}{}{}}%
        {{hash=073dea46926e033deb955e7e824a014c}{Czuczman}{C\bibinitperiod}{Myron\bibnamedelima S}{M\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=d6f70fbc2e302273fb0361ca86c63936}{Saleh}{S\bibinitperiod}{Mansoor\bibnamedelima N}{M\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
        {{hash=37c73f41a49c1176cb4dc8527762e484}{Cripe}{C\bibinitperiod}{Larry}{L\bibinitperiod}{}{}{}{}}%
        {{hash=2d6d76a0e7ea136010c720691b44044a}{Wiseman}{W\bibinitperiod}{Gregory}{G\bibinitperiod}{}{}{}{}}%
        {{hash=ac8e0fc3cf4f98fce55593b31f30a387}{Olejnik}{O\bibinitperiod}{Teresa}{T\bibinitperiod}{}{}{}{}}%
        {{hash=c0e0ba3c4a509656d57586010d59ba34}{Multani}{M\bibinitperiod}{Pratik\bibnamedelima S}{P\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=5641b1c1cd0cf4267ea19a2223dbc7f3}{White}{W\bibinitperiod}{Christine\bibnamedelima A}{C\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{11}{}{%
        {{hash=a5501d45dea767217a8dc453214b05ab}{Witzig}{W\bibinitperiod}{Thomas\bibnamedelima E}{T\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=4e157da32ee3dd419dffa84c1174e575}{Flinn}{F\bibinitperiod}{Ian\bibnamedelima W}{I\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=042e5e17ad292ca3d82a324d6c7d8475}{Gordon}{G\bibinitperiod}{Leo\bibnamedelima I}{L\bibinitperiod\bibinitdelim I\bibinitperiod}{}{}{}{}}%
        {{hash=42b800df62abeff7f982ee046c543048}{Emmanouilides}{E\bibinitperiod}{Christos}{C\bibinitperiod}{}{}{}{}}%
        {{hash=073dea46926e033deb955e7e824a014c}{Czuczman}{C\bibinitperiod}{Myron\bibnamedelima S}{M\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=d6f70fbc2e302273fb0361ca86c63936}{Saleh}{S\bibinitperiod}{Mansoor\bibnamedelima N}{M\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
        {{hash=37c73f41a49c1176cb4dc8527762e484}{Cripe}{C\bibinitperiod}{Larry}{L\bibinitperiod}{}{}{}{}}%
        {{hash=2d6d76a0e7ea136010c720691b44044a}{Wiseman}{W\bibinitperiod}{Gregory}{G\bibinitperiod}{}{}{}{}}%
        {{hash=ac8e0fc3cf4f98fce55593b31f30a387}{Olejnik}{O\bibinitperiod}{Teresa}{T\bibinitperiod}{}{}{}{}}%
        {{hash=c0e0ba3c4a509656d57586010d59ba34}{Multani}{M\bibinitperiod}{Pratik\bibnamedelima S}{P\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=5641b1c1cd0cf4267ea19a2223dbc7f3}{White}{W\bibinitperiod}{Christine\bibnamedelima A}{C\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{a14c42100cf6586b7f23c9f356136702}
      \strng{fullhash}{1ddf54d4357679b161f9e61866d77bdc}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin's Lymphoma}}
      \field{abstract}{PURPOSE: Rituximab is commonly used as a single agent or in combination therapy for non-Hodgkin's lymphoma (NHL). Ibritumomab tiuxetan radioimmunotherapy targets the same antigen as rituximab and has demonstrated efficacy in rituximab-na{\"{\i}}ve NHL. This study evaluated ibritumomab tiuxetan in the treatment of rituximab-refractory follicular NHL.PATIENTS AND METHODS: Eligible patients were refractory to rituximab; this was defined as no objective response to rituximab (375 mg/m2 weekly for 4 weeks) or time to progression (TTP) of \x{2264} 6 months. The ibritumomab tiuxetan treatment regimen consisted of pretreatment with rituximab (250 mg/m2 intravenously on days 1 and 8) to deplete peripheral blood B cells, then yttrium-90 ibritumomab tiuxetan (0.4 mCi/kg; maximum, 32 mCi) intravenously on day 8, administered on an outpatient basis. An imaging/dosimetry dose of indium-111 ibritumomab tiuxetan (5 mCi) was injected after rituximab (day 1) in 28 patients.RESULTS: Fifty-seven patients were treated. The median age was 54 years, 74{\%} had tumors \x{2265} 5 cm, and all were extensively pretreated (median, four prior therapies; range, one to nine). The estimated radiation-absorbed doses to healthy organs were below the study-defined limit in all patients studied with dosimetry. The overall response rate for the 54 patients with follicular NHL was 74{\%} (15{\%} complete responses and 59{\%} partial responses). The Kaplan-Meier--estimated TTP was 6.8 months (range, 1.1 to \x{2265} 25.9 months) for all patients and 8.7 months for responders. Adverse events were primarily hematologic; the incidence of grade 4 neutropenia, thrombocytopenia, and anemia was 35{\%}, 9{\%}, and 4{\%}, respectively.CONCLUSION: Ibritumomab tiuxetan radioimmunotherapy is effective in rituximab-refractory patients. The only significant toxicity is hematologic.}
      \field{annotation}{10.1200/JCO.2002.11.017}
      \field{journaltitle}{Journal of Clinical Oncology}
      \field{month}{08}
      \field{number}{15}
      \field{title}{{Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin's Lymphoma}}
      \field{volume}{20}
      \field{year}{2002}
      \field{pages}{3262\bibrangedash 3269}
      \verb{doi}
      \verb 10.1200/JCO.2002.11.017
      \endverb
      \verb{url}
      \verb http://jco.ascopubs.org/content/20/15/3262.abstract
      \endverb
    \endentry
    \entry{Zhang2009}{article}{}
      \name{labelname}{3}{}{%
        {{hash=ac94487142bcc73ec00646f41c277977}{Zhang}{Z\bibinitperiod}{Jianming}{J\bibinitperiod}{}{}{}{}}%
        {{hash=60061fbf1aecd520b9add74fdc4f61eb}{Yang}{Y\bibinitperiod}{Priscilla\bibnamedelima L}{P\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=fabe6c6461e55d2d47e6c8fb604e93f8}{Gray}{G\bibinitperiod}{Nathanael\bibnamedelima S}{N\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=ac94487142bcc73ec00646f41c277977}{Zhang}{Z\bibinitperiod}{Jianming}{J\bibinitperiod}{}{}{}{}}%
        {{hash=60061fbf1aecd520b9add74fdc4f61eb}{Yang}{Y\bibinitperiod}{Priscilla\bibnamedelima L}{P\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=fabe6c6461e55d2d47e6c8fb604e93f8}{Gray}{G\bibinitperiod}{Nathanael\bibnamedelima S}{N\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{4737b124b9a903e114646b7add908b56}
      \strng{fullhash}{4737b124b9a903e114646b7add908b56}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Targeting cancer with small molecule kinase inhibitors.}}
      \field{abstract}{Deregulation of kinase activity has emerged as a major mechanism by which cancer cells evade normal physiological constraints on growth and survival. To date, 11 kinase inhibitors have received US Food and Drug Administration approval as cancer treatments, and there are considerable efforts to develop selective small molecule inhibitors for a host of other kinases that are implicated in cancer and other diseases. Herein we discuss the current challenges in the field, such as designing selective inhibitors and developing strategies to overcome resistance mutations. This Review provides a broad overview of some of the approaches currently used to discover and characterize new kinase inhibitors.}
      \field{isbn}{1474-1768 (Electronic)$\backslash$r1474-175X (Linking)}
      \field{issn}{1474-175X}
      \field{journaltitle}{Nature reviews. Cancer}
      \field{number}{1}
      \field{title}{{Targeting cancer with small molecule kinase inhibitors.}}
      \field{volume}{9}
      \field{year}{2009}
      \field{pages}{28\bibrangedash 39}
      \verb{doi}
      \verb 10.1038/nrc2559
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Zhang, Yang, Gray - 2009 - Targeting cancer with small molecule kinase inhibitors.pdf:pdf
      \endverb
    \endentry
    \entry{Weinstein2006}{article}{}
      \name{labelname}{2}{}{%
        {{hash=74d62037270ddb2e03fd11225533f92f}{Weinstein}{W\bibinitperiod}{I\bibnamedelima Bernard}{I\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=93296d435079f596cc8fa9d0f324ebde}{Joe}{J\bibinitperiod}{Andrew\bibnamedelima K}{A\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=74d62037270ddb2e03fd11225533f92f}{Weinstein}{W\bibinitperiod}{I\bibnamedelima Bernard}{I\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=93296d435079f596cc8fa9d0f324ebde}{Joe}{J\bibinitperiod}{Andrew\bibnamedelima K}{A\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group}%
      }
      \strng{namehash}{d21d5aa8f242645786db752a18086eb9}
      \strng{fullhash}{d21d5aa8f242645786db752a18086eb9}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Mechanisms of Disease: oncogene addiction, a rationale for molecular targeting in cancer therapy}}
      \field{annotation}{10.1038/ncponc0558}
      \field{issn}{1743-4254}
      \field{journaltitle}{Nat Clin Prac Oncol}
      \field{month}{08}
      \field{number}{8}
      \field{title}{{Mechanisms of Disease: oncogene addiction, a rationale for molecular targeting in cancer therapy}}
      \field{volume}{3}
      \field{year}{2006}
      \field{pages}{448\bibrangedash 457}
      \verb{url}
      \verb http://dx.doi.org/10.1038/ncponc0558
      \endverb
    \endentry
    \entry{Ascierto2012}{article}{}
      \name{labelname}{10}{}{%
        {{hash=63c3b9ff59855459e565e6ae64dd2713}{Ascierto}{A\bibinitperiod}{Paolo\bibnamedelima A}{P\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=892d9643aee836f231303fa78c56aac6}{Kirkwood}{K\bibinitperiod}{John\bibnamedelima M}{J\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=614521d0b379184a21884e77ad486c01}{Grob}{G\bibinitperiod}{Jean-Jacques}{J\bibinithyphendelim J\bibinitperiod}{}{}{}{}}%
        {{hash=16d2ea111feffd7f496d76ade0635e37}{Simeone}{S\bibinitperiod}{Ester}{E\bibinitperiod}{}{}{}{}}%
        {{hash=113ae64f180f9fc5faeb1e02d978a869}{Grimaldi}{G\bibinitperiod}{Antonio\bibnamedelima M}{A\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=7ea227bd53fa458e9cfd6f3c8c43a57b}{Maio}{M\bibinitperiod}{Michele}{M\bibinitperiod}{}{}{}{}}%
        {{hash=f495a50af03456104e9ff153638c407e}{Palmieri}{P\bibinitperiod}{Giuseppe}{G\bibinitperiod}{}{}{}{}}%
        {{hash=5b2142b1987d2960913536de79a02db8}{Testori}{T\bibinitperiod}{Alessandro}{A\bibinitperiod}{}{}{}{}}%
        {{hash=8b609333a7ea38d53e768bb289bebf47}{Marincola}{M\bibinitperiod}{Francesco\bibnamedelima M}{F\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=8613f2ab157d054968edfbbf9e57a3d8}{Mozzillo}{M\bibinitperiod}{Nicola}{N\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{10}{}{%
        {{hash=63c3b9ff59855459e565e6ae64dd2713}{Ascierto}{A\bibinitperiod}{Paolo\bibnamedelima A}{P\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=892d9643aee836f231303fa78c56aac6}{Kirkwood}{K\bibinitperiod}{John\bibnamedelima M}{J\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=614521d0b379184a21884e77ad486c01}{Grob}{G\bibinitperiod}{Jean-Jacques}{J\bibinithyphendelim J\bibinitperiod}{}{}{}{}}%
        {{hash=16d2ea111feffd7f496d76ade0635e37}{Simeone}{S\bibinitperiod}{Ester}{E\bibinitperiod}{}{}{}{}}%
        {{hash=113ae64f180f9fc5faeb1e02d978a869}{Grimaldi}{G\bibinitperiod}{Antonio\bibnamedelima M}{A\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=7ea227bd53fa458e9cfd6f3c8c43a57b}{Maio}{M\bibinitperiod}{Michele}{M\bibinitperiod}{}{}{}{}}%
        {{hash=f495a50af03456104e9ff153638c407e}{Palmieri}{P\bibinitperiod}{Giuseppe}{G\bibinitperiod}{}{}{}{}}%
        {{hash=5b2142b1987d2960913536de79a02db8}{Testori}{T\bibinitperiod}{Alessandro}{A\bibinitperiod}{}{}{}{}}%
        {{hash=8b609333a7ea38d53e768bb289bebf47}{Marincola}{M\bibinitperiod}{Francesco\bibnamedelima M}{F\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=8613f2ab157d054968edfbbf9e57a3d8}{Mozzillo}{M\bibinitperiod}{Nicola}{N\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {BioMed Central}%
      }
      \strng{namehash}{a2b5491fe1708e43f737202e70ceeb59}
      \strng{fullhash}{745972ce4d2d17f63870b976e88c91f1}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{The role of BRAF V600 mutation in melanoma}}
      \field{abstract}{BRAF is a serine/threonine protein kinase activating the MAP kinase/ERK-signaling pathway. About 50 {\%} of melanomas harbors activating BRAF mutations (over 90 {\%} V600E). BRAFV600E has been implicated in different mechanisms underlying melanomagenesis, most of which due to the deregulated activation of the downstream MEK/ERK effectors. The first selective inhibitor of mutant BRAF, vemurafenib, after highly encouraging results of the phase I and II trial, was compared to dacarbazine in a phase III trial in treatment-na{\"{\i}}ve patients (BRIM-3). The study results showed a relative reduction of 63 {\%} in risk of death and 74 {\%} in risk of tumor progression. Considering all trials so far completed, median overall survival reached approximately 16 months for vemurafenib compared to less than 10 months for dacarbazine treatment. Vemurafenib has been extensively tested on melanoma patients expressing the BRAFV600E mutated form; it has been demonstrated to be also effective in inhibiting melanomas carrying the V600K mutation. In 2011, both FDA and EMA therefore approved vemurafenib for metastatic melanoma carrying BRAFV600 mutations. Some findings suggest that continuation of vemurafenib treatment is potentially beneficial after local therapy in a subset of patients with disease progression (PD). Among who continued vemurafenib {>}30 days after local therapy of PD lesion(s), a median overall survival was not reached, with a median follow-up of 15.5 months from initiation of BRAF inhibitor therapy. For patients who did not continue treatment, median overall survival from the time of disease progression was 1.4 months. A clinical phase I/II trial is evaluating the safety, tolerability and efficacy of vemurafenib in combination with the CTLA-4 inhibitor mAb ipilimumab. In the BRIM-7 trial vemurafenib is tested in association with GDC-0973, a potent and highly selective inhibitor of MEK1/2. Preliminary data seem to indicate that an additional inhibitor of mutated BRAF, GSK2118436, might be also active on a wider range of BRAF mutations (V600E-K-D-R); actually, treatment with such a compound is under evaluation in a phase III study among stage III-IV melanoma patients positive for BRAF mutations. Overall, BRAF inhibitors were well tolerated; common adverse events are arthralgia, rash, fatigue, alopecia, keratoacanthoma or cutaneous squamous-cell carcinoma, photosensitivity, nausea, and diarrhea, with some variants between different inhibitors.}
      \field{issn}{1479-5876}
      \field{journaltitle}{Journal of Translational Medicine}
      \field{month}{07}
      \field{title}{{The role of BRAF V600 mutation in melanoma}}
      \field{volume}{10}
      \field{year}{2012}
      \field{pages}{85}
      \verb{doi}
      \verb 10.1186/1479-5876-10-85
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3391993/
      \endverb
    \endentry
    \entry{Bollag2010}{article}{}
      \name{labelname}{40}{}{%
        {{hash=87eae7f85b8231ace019d2d72e0de572}{Bollag}{B\bibinitperiod}{Gideon}{G\bibinitperiod}{}{}{}{}}%
        {{hash=7b8a5131c72993678d77bff47cac20f7}{Hirth}{H\bibinitperiod}{Peter}{P\bibinitperiod}{}{}{}{}}%
        {{hash=7c20d5b1c508ad9a8914cea147bb2dd3}{Tsai}{T\bibinitperiod}{James}{J\bibinitperiod}{}{}{}{}}%
        {{hash=3b399366aacf073f8da5d3e0ee2f3eec}{Zhang}{Z\bibinitperiod}{Jiazhong}{J\bibinitperiod}{}{}{}{}}%
        {{hash=d2e2eb7087f42caf9a6c71606091d126}{Ibrahim}{I\bibinitperiod}{Prabha\bibnamedelima N}{P\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
        {{hash=252ffb1473d8b9544ba246cd5158e473}{Cho}{C\bibinitperiod}{Hanna}{H\bibinitperiod}{}{}{}{}}%
        {{hash=5dfc986f8c544739a8675d0afd5fdf2e}{Spevak}{S\bibinitperiod}{Wayne}{W\bibinitperiod}{}{}{}{}}%
        {{hash=03ae9f31823ca904e5b163319d310224}{Zhang}{Z\bibinitperiod}{Chao}{C\bibinitperiod}{}{}{}{}}%
        {{hash=f5acec98b29ee91fa6b08b85a6a0adad}{Zhang}{Z\bibinitperiod}{Ying}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=1eb0c9b82ced713062f080e066664d80}{Habets}{H\bibinitperiod}{Gaston}{G\bibinitperiod}{}{}{}{}}%
        {{hash=fc89e83c71cb09b7d8465d074ac5a0c8}{Burton}{B\bibinitperiod}{Elizabeth\bibnamedelima A}{E\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=ee6353759c3087ce67e2db2f277d880d}{Wong}{W\bibinitperiod}{Bernice}{B\bibinitperiod}{}{}{}{}}%
        {{hash=d27dd54b9d4e22255c8d2e410652d6db}{Tsang}{T\bibinitperiod}{Garson}{G\bibinitperiod}{}{}{}{}}%
        {{hash=3453c1cc34c23f9197cca7b0a842b07d}{West}{W\bibinitperiod}{Brian\bibnamedelima L}{B\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=e791e27bf19423d01f64f67c8ca48055}{Powell}{P\bibinitperiod}{Ben}{B\bibinitperiod}{}{}{}{}}%
        {{hash=01ab9069dda9284968bc0e4e7387b7d4}{Shellooe}{S\bibinitperiod}{Rafe}{R\bibinitperiod}{}{}{}{}}%
        {{hash=1dad856b6a34915b8962f014f056b779}{Marimuthu}{M\bibinitperiod}{Adhirai}{A\bibinitperiod}{}{}{}{}}%
        {{hash=b2e1a075761da2ef6e3e90f4b6089f4b}{Nguyen}{N\bibinitperiod}{Hoa}{H\bibinitperiod}{}{}{}{}}%
        {{hash=fcc41521f7aac873314a8181cd094cc7}{Zhang}{Z\bibinitperiod}{Kam\bibnamedelimb Y\bibnamedelima J}{K\bibinitperiod\bibinitdelim Y\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=8786af2d83e2d764078241301d271b80}{Artis}{A\bibinitperiod}{Dean\bibnamedelima R}{D\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=0cfd2c2d149c4888fd0e8bfc386e0690}{Schlessinger}{S\bibinitperiod}{Joseph}{J\bibinitperiod}{}{}{}{}}%
        {{hash=7dcf47b56fc2673e72f25bf5f3f56e49}{Su}{S\bibinitperiod}{Fei}{F\bibinitperiod}{}{}{}{}}%
        {{hash=fa6114daca2d94260c5b8d12c72bbcc6}{Higgins}{H\bibinitperiod}{Brian}{B\bibinitperiod}{}{}{}{}}%
        {{hash=e597cc895e641cab9871d7d4075423b3}{Iyer}{I\bibinitperiod}{Raman}{R\bibinitperiod}{}{}{}{}}%
        {{hash=07c64dd64dccc22c5e81bdac6c0f047b}{D'Andrea}{D\bibinitperiod}{Kurt}{K\bibinitperiod}{}{}{}{}}%
        {{hash=b26d3f12a23488979e72644f21343763}{Koehler}{K\bibinitperiod}{Astrid}{A\bibinitperiod}{}{}{}{}}%
        {{hash=0cc180f816815b76057e4e06ff75d112}{Stumm}{S\bibinitperiod}{Michael}{M\bibinitperiod}{}{}{}{}}%
        {{hash=4e997825e4ba42e49d653136daa9c089}{Lin}{L\bibinitperiod}{Paul\bibnamedelima S}{P\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=ff62272db4d7d4cb49af4e92b3e4f64b}{Lee}{L\bibinitperiod}{Richard\bibnamedelima J}{R\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=9a4a0fc898413a88767a8ba750288e42}{Grippo}{G\bibinitperiod}{Joseph}{J\bibinitperiod}{}{}{}{}}%
        {{hash=5011e502a27870c9c6da22c66ae7c483}{Puzanov}{P\bibinitperiod}{Igor}{I\bibinitperiod}{}{}{}{}}%
        {{hash=b4102cb8ed7fee1c17a48ccdd2df2543}{Kim}{K\bibinitperiod}{Kevin\bibnamedelima B}{K\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=a38abcd070caaf3de4ecf67b7ab25769}{Ribas}{R\bibinitperiod}{Antoni}{A\bibinitperiod}{}{}{}{}}%
        {{hash=0bd57bd44ee5f635fa6f5347f408b088}{McArthur}{M\bibinitperiod}{Grant\bibnamedelima A}{G\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=239aa76222543444ec96b99fc03ad569}{Sosman}{S\bibinitperiod}{Jeffrey\bibnamedelima A}{J\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=ee9fa088a1d65fc575397e291a8f5814}{Chapman}{C\bibinitperiod}{Paul\bibnamedelima B}{P\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=af37fea3d029b2697b1732328a84e4d6}{Flaherty}{F\bibinitperiod}{Keith\bibnamedelima T}{K\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=2dda16c0a5d50fc830d0d4a3787937fa}{Xu}{X\bibinitperiod}{Xiaowei}{X\bibinitperiod}{}{}{}{}}%
        {{hash=841b09a91eb4536aedd3e3a2155670dd}{Nathanson}{N\bibinitperiod}{Katherine\bibnamedelima L}{K\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=4b199badbcdf6b350af9fe5140c1c83e}{Nolop}{N\bibinitperiod}{Keith}{K\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{40}{}{%
        {{hash=87eae7f85b8231ace019d2d72e0de572}{Bollag}{B\bibinitperiod}{Gideon}{G\bibinitperiod}{}{}{}{}}%
        {{hash=7b8a5131c72993678d77bff47cac20f7}{Hirth}{H\bibinitperiod}{Peter}{P\bibinitperiod}{}{}{}{}}%
        {{hash=7c20d5b1c508ad9a8914cea147bb2dd3}{Tsai}{T\bibinitperiod}{James}{J\bibinitperiod}{}{}{}{}}%
        {{hash=3b399366aacf073f8da5d3e0ee2f3eec}{Zhang}{Z\bibinitperiod}{Jiazhong}{J\bibinitperiod}{}{}{}{}}%
        {{hash=d2e2eb7087f42caf9a6c71606091d126}{Ibrahim}{I\bibinitperiod}{Prabha\bibnamedelima N}{P\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
        {{hash=252ffb1473d8b9544ba246cd5158e473}{Cho}{C\bibinitperiod}{Hanna}{H\bibinitperiod}{}{}{}{}}%
        {{hash=5dfc986f8c544739a8675d0afd5fdf2e}{Spevak}{S\bibinitperiod}{Wayne}{W\bibinitperiod}{}{}{}{}}%
        {{hash=03ae9f31823ca904e5b163319d310224}{Zhang}{Z\bibinitperiod}{Chao}{C\bibinitperiod}{}{}{}{}}%
        {{hash=f5acec98b29ee91fa6b08b85a6a0adad}{Zhang}{Z\bibinitperiod}{Ying}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=1eb0c9b82ced713062f080e066664d80}{Habets}{H\bibinitperiod}{Gaston}{G\bibinitperiod}{}{}{}{}}%
        {{hash=fc89e83c71cb09b7d8465d074ac5a0c8}{Burton}{B\bibinitperiod}{Elizabeth\bibnamedelima A}{E\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=ee6353759c3087ce67e2db2f277d880d}{Wong}{W\bibinitperiod}{Bernice}{B\bibinitperiod}{}{}{}{}}%
        {{hash=d27dd54b9d4e22255c8d2e410652d6db}{Tsang}{T\bibinitperiod}{Garson}{G\bibinitperiod}{}{}{}{}}%
        {{hash=3453c1cc34c23f9197cca7b0a842b07d}{West}{W\bibinitperiod}{Brian\bibnamedelima L}{B\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=e791e27bf19423d01f64f67c8ca48055}{Powell}{P\bibinitperiod}{Ben}{B\bibinitperiod}{}{}{}{}}%
        {{hash=01ab9069dda9284968bc0e4e7387b7d4}{Shellooe}{S\bibinitperiod}{Rafe}{R\bibinitperiod}{}{}{}{}}%
        {{hash=1dad856b6a34915b8962f014f056b779}{Marimuthu}{M\bibinitperiod}{Adhirai}{A\bibinitperiod}{}{}{}{}}%
        {{hash=b2e1a075761da2ef6e3e90f4b6089f4b}{Nguyen}{N\bibinitperiod}{Hoa}{H\bibinitperiod}{}{}{}{}}%
        {{hash=fcc41521f7aac873314a8181cd094cc7}{Zhang}{Z\bibinitperiod}{Kam\bibnamedelimb Y\bibnamedelima J}{K\bibinitperiod\bibinitdelim Y\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=8786af2d83e2d764078241301d271b80}{Artis}{A\bibinitperiod}{Dean\bibnamedelima R}{D\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=0cfd2c2d149c4888fd0e8bfc386e0690}{Schlessinger}{S\bibinitperiod}{Joseph}{J\bibinitperiod}{}{}{}{}}%
        {{hash=7dcf47b56fc2673e72f25bf5f3f56e49}{Su}{S\bibinitperiod}{Fei}{F\bibinitperiod}{}{}{}{}}%
        {{hash=fa6114daca2d94260c5b8d12c72bbcc6}{Higgins}{H\bibinitperiod}{Brian}{B\bibinitperiod}{}{}{}{}}%
        {{hash=e597cc895e641cab9871d7d4075423b3}{Iyer}{I\bibinitperiod}{Raman}{R\bibinitperiod}{}{}{}{}}%
        {{hash=07c64dd64dccc22c5e81bdac6c0f047b}{D'Andrea}{D\bibinitperiod}{Kurt}{K\bibinitperiod}{}{}{}{}}%
        {{hash=b26d3f12a23488979e72644f21343763}{Koehler}{K\bibinitperiod}{Astrid}{A\bibinitperiod}{}{}{}{}}%
        {{hash=0cc180f816815b76057e4e06ff75d112}{Stumm}{S\bibinitperiod}{Michael}{M\bibinitperiod}{}{}{}{}}%
        {{hash=4e997825e4ba42e49d653136daa9c089}{Lin}{L\bibinitperiod}{Paul\bibnamedelima S}{P\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=ff62272db4d7d4cb49af4e92b3e4f64b}{Lee}{L\bibinitperiod}{Richard\bibnamedelima J}{R\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=9a4a0fc898413a88767a8ba750288e42}{Grippo}{G\bibinitperiod}{Joseph}{J\bibinitperiod}{}{}{}{}}%
        {{hash=5011e502a27870c9c6da22c66ae7c483}{Puzanov}{P\bibinitperiod}{Igor}{I\bibinitperiod}{}{}{}{}}%
        {{hash=b4102cb8ed7fee1c17a48ccdd2df2543}{Kim}{K\bibinitperiod}{Kevin\bibnamedelima B}{K\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=a38abcd070caaf3de4ecf67b7ab25769}{Ribas}{R\bibinitperiod}{Antoni}{A\bibinitperiod}{}{}{}{}}%
        {{hash=0bd57bd44ee5f635fa6f5347f408b088}{McArthur}{M\bibinitperiod}{Grant\bibnamedelima A}{G\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=239aa76222543444ec96b99fc03ad569}{Sosman}{S\bibinitperiod}{Jeffrey\bibnamedelima A}{J\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=ee9fa088a1d65fc575397e291a8f5814}{Chapman}{C\bibinitperiod}{Paul\bibnamedelima B}{P\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=af37fea3d029b2697b1732328a84e4d6}{Flaherty}{F\bibinitperiod}{Keith\bibnamedelima T}{K\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=2dda16c0a5d50fc830d0d4a3787937fa}{Xu}{X\bibinitperiod}{Xiaowei}{X\bibinitperiod}{}{}{}{}}%
        {{hash=841b09a91eb4536aedd3e3a2155670dd}{Nathanson}{N\bibinitperiod}{Katherine\bibnamedelima L}{K\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=4b199badbcdf6b350af9fe5140c1c83e}{Nolop}{N\bibinitperiod}{Keith}{K\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{29c059e4fe5ebceec1a3730b1318f182}
      \strng{fullhash}{de091a97b15ee257c49fd8533dc1c32a}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma}}
      \field{abstract}{B-RAF is the most frequently mutated protein kinase in human cancers. The finding that oncogenic mutations in BRAF are common in melanoma followed by the demonstration that these tumors are dependent on the RAF/MEK/ERK pathway offered hope that inhibition of B-RAF kinase activity could benefit melanoma patients. Herein, we describe the structure-guided discovery of PLX4032 (RG7204), a potent inhibitor of oncogenic B-RAF kinase activity. Preclinical experiments demonstrated that PLX4032 selectively blocked the RAF/MEK/ERK pathway in BRAF mutant cells and caused regression of BRAF mutant xenografts. Toxicology studies confirmed a wide safety margin consistent with the high degree of selectivity, enabling Phase 1 clinical trials using a crystalline formulation of PLX4032. In a subset of melanoma patients, pathway inhibition was monitored in paired biopsy specimens collected before treatment initiation and following two weeks of treatment. This analysis revealed substantial inhibition of ERK phosphorylation, yet clinical evaluation did not show tumor regressions. At higher drug exposures afforded by a new amorphous drug formulation,, greater than 80{\%} inhibition of ERK phosphorylation in the tumors of patients correlated with clinical response. Indeed, the Phase 1 clinical data revealed a remarkably high 81{\%} response rate in metastatic melanoma patients treated at an oral dose of 960 mg twice daily. These data demonstrate that BRAF-mutant melanomas are highly dependent on B-RAF kinase activity.}
      \field{issn}{0028-0836}
      \field{journaltitle}{Nature}
      \field{month}{09}
      \field{number}{7315}
      \field{title}{{Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma}}
      \field{volume}{467}
      \field{year}{2010}
      \field{pages}{596\bibrangedash 599}
      \verb{doi}
      \verb 10.1038/nature09454
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948082/
      \endverb
    \endentry
    \entry{Gibney2013}{article}{}
      \name{labelname}{2}{}{%
        {{hash=7b54a8db80fc338d05786f622efe1bba}{Gibney}{G\bibinitperiod}{Geoffrey\bibnamedelima T}{G\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=3b9b7b60dbad2eb3daca4f22e81fac72}{Zager}{Z\bibinitperiod}{Jonathan\bibnamedelima S}{J\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=7b54a8db80fc338d05786f622efe1bba}{Gibney}{G\bibinitperiod}{Geoffrey\bibnamedelima T}{G\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=3b9b7b60dbad2eb3daca4f22e81fac72}{Zager}{Z\bibinitperiod}{Jonathan\bibnamedelima S}{J\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Taylor {\&} Francis}%
      }
      \strng{namehash}{b806110a0cbffb720b229f1825b2f262}
      \strng{fullhash}{b806110a0cbffb720b229f1825b2f262}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies}}
      \field{annotation}{doi: 10.1517/17425255.2013.794220}
      \field{issn}{1742-5255}
      \field{journaltitle}{Expert Opinion on Drug Metabolism {\&} Toxicology}
      \field{month}{07}
      \field{number}{7}
      \field{title}{{Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies}}
      \field{volume}{9}
      \field{year}{2013}
      \field{pages}{893\bibrangedash 899}
      \verb{doi}
      \verb 10.1517/17425255.2013.794220
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1517/17425255.2013.794220
      \endverb
    \endentry
    \entry{Flaherty2012}{article}{}
      \name{labelname}{26}{}{%
        {{hash=af37fea3d029b2697b1732328a84e4d6}{Flaherty}{F\bibinitperiod}{Keith\bibnamedelima T}{K\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=52ce1ebef3d3dfe875b314a657d67295}{Infante}{I\bibinitperiod}{Jeffery\bibnamedelima R}{J\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=b22849b0a5fa30474512b60ce07648f2}{Daud}{D\bibinitperiod}{Adil}{A\bibinitperiod}{}{}{}{}}%
        {{hash=99987b2325ec91684774bf5f4d447734}{Gonzalez}{G\bibinitperiod}{Rene}{R\bibinitperiod}{}{}{}{}}%
        {{hash=7e70df0b44df925b4f8f55afec492926}{Kefford}{K\bibinitperiod}{Richard\bibnamedelima F}{R\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{hash=c567956836367b92cd5a339551d90919}{Sosman}{S\bibinitperiod}{Jeffrey}{J\bibinitperiod}{}{}{}{}}%
        {{hash=80ba73c10aaa3a3b7a6742c8b9ce0957}{Hamid}{H\bibinitperiod}{Omid}{O\bibinitperiod}{}{}{}{}}%
        {{hash=9cd4723000b245dacc02a068b13ba466}{Schuchter}{S\bibinitperiod}{Lynn}{L\bibinitperiod}{}{}{}{}}%
        {{hash=0b40cc242a02d571991f3aba8e599375}{Cebon}{C\bibinitperiod}{Jonathan}{J\bibinitperiod}{}{}{}{}}%
        {{hash=1f159fec78726fa0bc44ee55c12c54f4}{Ibrahim}{I\bibinitperiod}{Nageatte}{N\bibinitperiod}{}{}{}{}}%
        {{hash=a7727317564fd8147127616148117b4c}{Kudchadkar}{K\bibinitperiod}{Ragini}{R\bibinitperiod}{}{}{}{}}%
        {{hash=14fc1cdca15a21565e2e72ecba6dd5cd}{Burris}{B\bibinitperiod}{Howard\bibnamedelima A}{H\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=c7c055a5722849810974ee9f003120e4}{Falchook}{F\bibinitperiod}{Gerald}{G\bibinitperiod}{}{}{}{}}%
        {{hash=b8d42fe6cd1117a4a42da8e549370279}{Algazi}{A\bibinitperiod}{Alain}{A\bibinitperiod}{}{}{}{}}%
        {{hash=b393ee1bd789f6ba3a67296a6d2de9a8}{Lewis}{L\bibinitperiod}{Karl}{K\bibinitperiod}{}{}{}{}}%
        {{hash=b91c620a281b517b74ae2c5e57c5ce5b}{Long}{L\bibinitperiod}{Georgina\bibnamedelima V}{G\bibinitperiod\bibinitdelim V\bibinitperiod}{}{}{}{}}%
        {{hash=5011e502a27870c9c6da22c66ae7c483}{Puzanov}{P\bibinitperiod}{Igor}{I\bibinitperiod}{}{}{}{}}%
        {{hash=886b0558afc22aecd4e6a5f3b5f8bdbc}{Lebowitz}{L\bibinitperiod}{Peter}{P\bibinitperiod}{}{}{}{}}%
        {{hash=726bb18dd2359b015847fcab6a297b79}{Singh}{S\bibinitperiod}{Ajay}{A\bibinitperiod}{}{}{}{}}%
        {{hash=f183bcaf32e2020502a9927ab9ff3110}{Little}{L\bibinitperiod}{Shonda}{S\bibinitperiod}{}{}{}{}}%
        {{hash=5918631c2d1cdd4eaddbfc27a01281ae}{Sun}{S\bibinitperiod}{Peng}{P\bibinitperiod}{}{}{}{}}%
        {{hash=b72925f033118199e873febd35cf07e5}{Allred}{A\bibinitperiod}{Alicia}{A\bibinitperiod}{}{}{}{}}%
        {{hash=74db56ecd41a02faf3da785946ab1234}{Ouellet}{O\bibinitperiod}{Daniele}{D\bibinitperiod}{}{}{}{}}%
        {{hash=b4102cb8ed7fee1c17a48ccdd2df2543}{Kim}{K\bibinitperiod}{Kevin\bibnamedelima B}{K\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=f5ef2d048872d2df7bb27d3f4625ce97}{Patel}{P\bibinitperiod}{Kiran}{K\bibinitperiod}{}{}{}{}}%
        {{hash=d8713e0ea49876ae4b04a92bbb329cf4}{Weber}{W\bibinitperiod}{Jeffrey}{J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{26}{}{%
        {{hash=af37fea3d029b2697b1732328a84e4d6}{Flaherty}{F\bibinitperiod}{Keith\bibnamedelima T}{K\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=52ce1ebef3d3dfe875b314a657d67295}{Infante}{I\bibinitperiod}{Jeffery\bibnamedelima R}{J\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=b22849b0a5fa30474512b60ce07648f2}{Daud}{D\bibinitperiod}{Adil}{A\bibinitperiod}{}{}{}{}}%
        {{hash=99987b2325ec91684774bf5f4d447734}{Gonzalez}{G\bibinitperiod}{Rene}{R\bibinitperiod}{}{}{}{}}%
        {{hash=7e70df0b44df925b4f8f55afec492926}{Kefford}{K\bibinitperiod}{Richard\bibnamedelima F}{R\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{hash=c567956836367b92cd5a339551d90919}{Sosman}{S\bibinitperiod}{Jeffrey}{J\bibinitperiod}{}{}{}{}}%
        {{hash=80ba73c10aaa3a3b7a6742c8b9ce0957}{Hamid}{H\bibinitperiod}{Omid}{O\bibinitperiod}{}{}{}{}}%
        {{hash=9cd4723000b245dacc02a068b13ba466}{Schuchter}{S\bibinitperiod}{Lynn}{L\bibinitperiod}{}{}{}{}}%
        {{hash=0b40cc242a02d571991f3aba8e599375}{Cebon}{C\bibinitperiod}{Jonathan}{J\bibinitperiod}{}{}{}{}}%
        {{hash=1f159fec78726fa0bc44ee55c12c54f4}{Ibrahim}{I\bibinitperiod}{Nageatte}{N\bibinitperiod}{}{}{}{}}%
        {{hash=a7727317564fd8147127616148117b4c}{Kudchadkar}{K\bibinitperiod}{Ragini}{R\bibinitperiod}{}{}{}{}}%
        {{hash=14fc1cdca15a21565e2e72ecba6dd5cd}{Burris}{B\bibinitperiod}{Howard\bibnamedelima A}{H\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=c7c055a5722849810974ee9f003120e4}{Falchook}{F\bibinitperiod}{Gerald}{G\bibinitperiod}{}{}{}{}}%
        {{hash=b8d42fe6cd1117a4a42da8e549370279}{Algazi}{A\bibinitperiod}{Alain}{A\bibinitperiod}{}{}{}{}}%
        {{hash=b393ee1bd789f6ba3a67296a6d2de9a8}{Lewis}{L\bibinitperiod}{Karl}{K\bibinitperiod}{}{}{}{}}%
        {{hash=b91c620a281b517b74ae2c5e57c5ce5b}{Long}{L\bibinitperiod}{Georgina\bibnamedelima V}{G\bibinitperiod\bibinitdelim V\bibinitperiod}{}{}{}{}}%
        {{hash=5011e502a27870c9c6da22c66ae7c483}{Puzanov}{P\bibinitperiod}{Igor}{I\bibinitperiod}{}{}{}{}}%
        {{hash=886b0558afc22aecd4e6a5f3b5f8bdbc}{Lebowitz}{L\bibinitperiod}{Peter}{P\bibinitperiod}{}{}{}{}}%
        {{hash=726bb18dd2359b015847fcab6a297b79}{Singh}{S\bibinitperiod}{Ajay}{A\bibinitperiod}{}{}{}{}}%
        {{hash=f183bcaf32e2020502a9927ab9ff3110}{Little}{L\bibinitperiod}{Shonda}{S\bibinitperiod}{}{}{}{}}%
        {{hash=5918631c2d1cdd4eaddbfc27a01281ae}{Sun}{S\bibinitperiod}{Peng}{P\bibinitperiod}{}{}{}{}}%
        {{hash=b72925f033118199e873febd35cf07e5}{Allred}{A\bibinitperiod}{Alicia}{A\bibinitperiod}{}{}{}{}}%
        {{hash=74db56ecd41a02faf3da785946ab1234}{Ouellet}{O\bibinitperiod}{Daniele}{D\bibinitperiod}{}{}{}{}}%
        {{hash=b4102cb8ed7fee1c17a48ccdd2df2543}{Kim}{K\bibinitperiod}{Kevin\bibnamedelima B}{K\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=f5ef2d048872d2df7bb27d3f4625ce97}{Patel}{P\bibinitperiod}{Kiran}{K\bibinitperiod}{}{}{}{}}%
        {{hash=d8713e0ea49876ae4b04a92bbb329cf4}{Weber}{W\bibinitperiod}{Jeffrey}{J\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Massachusetts Medical Society}%
      }
      \strng{namehash}{de5f4506102799b49046b1e24aec33b3}
      \strng{fullhash}{d085e71d7943310e76fee48b4700f135}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations}}
      \field{annotation}{doi: 10.1056/NEJMoa1210093}
      \field{issn}{0028-4793}
      \field{journaltitle}{New England Journal of Medicine}
      \field{month}{09}
      \field{number}{18}
      \field{title}{{Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations}}
      \field{volume}{367}
      \field{year}{2012}
      \field{pages}{1694\bibrangedash 1703}
      \verb{doi}
      \verb 10.1056/NEJMoa1210093
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1056/NEJMoa1210093
      \endverb
    \endentry
    \entry{Flaherty2012a}{article}{}
      \name{labelname}{25}{}{%
        {{hash=af37fea3d029b2697b1732328a84e4d6}{Flaherty}{F\bibinitperiod}{Keith\bibnamedelima T}{K\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=7713bc0c5b89e037abeb39d6d303482b}{Robert}{R\bibinitperiod}{Caroline}{C\bibinitperiod}{}{}{}{}}%
        {{hash=66adce8551a64b2cea34f5c8d76cdad5}{Hersey}{H\bibinitperiod}{Peter}{P\bibinitperiod}{}{}{}{}}%
        {{hash=89213a9b2f28640560f2414ad900b3c4}{Nathan}{N\bibinitperiod}{Paul}{P\bibinitperiod}{}{}{}{}}%
        {{hash=19684712620f686dd11abed002950c03}{Garbe}{G\bibinitperiod}{Claus}{C\bibinitperiod}{}{}{}{}}%
        {{hash=6d0259a6f8f355cc8eca61e7354d3df3}{Milhem}{M\bibinitperiod}{Mohammed}{M\bibinitperiod}{}{}{}{}}%
        {{hash=576d898ca397edb675164a402470c5ec}{Demidov}{D\bibinitperiod}{Lev\bibnamedelima V}{L\bibinitperiod\bibinitdelim V\bibinitperiod}{}{}{}{}}%
        {{hash=5d2ceb6e694e971753e78b3a304117d5}{Hassel}{H\bibinitperiod}{Jessica\bibnamedelima C}{J\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=dac9da33dceeb2c2eb61b7edfbb4f1e6}{Rutkowski}{R\bibinitperiod}{Piotr}{P\bibinitperiod}{}{}{}{}}%
        {{hash=ffaf33656d90745819c47c7e51e580dd}{Mohr}{M\bibinitperiod}{Peter}{P\bibinitperiod}{}{}{}{}}%
        {{hash=5bde0fb868f205866180a581118fc0b3}{Dummer}{D\bibinitperiod}{Reinhard}{R\bibinitperiod}{}{}{}{}}%
        {{hash=ef4ed559b78b2bf6ccd85b7acc0593dd}{Trefzer}{T\bibinitperiod}{Uwe}{U\bibinitperiod}{}{}{}{}}%
        {{hash=286baa65f4ba0dc9ba05a224c3f1fc92}{Larkin}{L\bibinitperiod}{James\bibnamedelimb M\bibnamedelima G}{J\bibinitperiod\bibinitdelim M\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=f94e2a10c3baf41595717b6af5896762}{Utikal}{U\bibinitperiod}{Jochen}{J\bibinitperiod}{}{}{}{}}%
        {{hash=76603730dfd457b0a43777f9763656bd}{Dreno}{D\bibinitperiod}{Brigitte}{B\bibinitperiod}{}{}{}{}}%
        {{hash=7967c11172ff5b2ea46331d45ab08c50}{Nyakas}{N\bibinitperiod}{Marta}{M\bibinitperiod}{}{}{}{}}%
        {{hash=7ff9840f801885e50da45c4bc55453eb}{Middleton}{M\bibinitperiod}{Mark\bibnamedelima R}{M\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=a2edf979a0fd451b5baa1048aa990c28}{Becker}{B\bibinitperiod}{J{\"{u}}rgen\bibnamedelima C}{J\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=8e8bc7d820d798f9aadf3488114e9922}{Casey}{C\bibinitperiod}{Michelle}{M\bibinitperiod}{}{}{}{}}%
        {{hash=17b76e6b12dce07f97e73f114d44b708}{Sherman}{S\bibinitperiod}{Laurie\bibnamedelima J}{L\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=723b4057040e7c3e8d3735caf029a637}{Wu}{W\bibinitperiod}{Frank\bibnamedelima S}{F\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=74db56ecd41a02faf3da785946ab1234}{Ouellet}{O\bibinitperiod}{Daniele}{D\bibinitperiod}{}{}{}{}}%
        {{hash=13295c390ea48215c3bc5c7ccb5fef0a}{Martin}{M\bibinitperiod}{Anne-Marie}{A\bibinithyphendelim M\bibinitperiod}{}{}{}{}}%
        {{hash=f5ef2d048872d2df7bb27d3f4625ce97}{Patel}{P\bibinitperiod}{Kiran}{K\bibinitperiod}{}{}{}{}}%
        {{hash=5e2b115df41d17855e2edeb91f539d7f}{Schadendorf}{S\bibinitperiod}{Dirk}{D\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{25}{}{%
        {{hash=af37fea3d029b2697b1732328a84e4d6}{Flaherty}{F\bibinitperiod}{Keith\bibnamedelima T}{K\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=7713bc0c5b89e037abeb39d6d303482b}{Robert}{R\bibinitperiod}{Caroline}{C\bibinitperiod}{}{}{}{}}%
        {{hash=66adce8551a64b2cea34f5c8d76cdad5}{Hersey}{H\bibinitperiod}{Peter}{P\bibinitperiod}{}{}{}{}}%
        {{hash=89213a9b2f28640560f2414ad900b3c4}{Nathan}{N\bibinitperiod}{Paul}{P\bibinitperiod}{}{}{}{}}%
        {{hash=19684712620f686dd11abed002950c03}{Garbe}{G\bibinitperiod}{Claus}{C\bibinitperiod}{}{}{}{}}%
        {{hash=6d0259a6f8f355cc8eca61e7354d3df3}{Milhem}{M\bibinitperiod}{Mohammed}{M\bibinitperiod}{}{}{}{}}%
        {{hash=576d898ca397edb675164a402470c5ec}{Demidov}{D\bibinitperiod}{Lev\bibnamedelima V}{L\bibinitperiod\bibinitdelim V\bibinitperiod}{}{}{}{}}%
        {{hash=5d2ceb6e694e971753e78b3a304117d5}{Hassel}{H\bibinitperiod}{Jessica\bibnamedelima C}{J\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=dac9da33dceeb2c2eb61b7edfbb4f1e6}{Rutkowski}{R\bibinitperiod}{Piotr}{P\bibinitperiod}{}{}{}{}}%
        {{hash=ffaf33656d90745819c47c7e51e580dd}{Mohr}{M\bibinitperiod}{Peter}{P\bibinitperiod}{}{}{}{}}%
        {{hash=5bde0fb868f205866180a581118fc0b3}{Dummer}{D\bibinitperiod}{Reinhard}{R\bibinitperiod}{}{}{}{}}%
        {{hash=ef4ed559b78b2bf6ccd85b7acc0593dd}{Trefzer}{T\bibinitperiod}{Uwe}{U\bibinitperiod}{}{}{}{}}%
        {{hash=286baa65f4ba0dc9ba05a224c3f1fc92}{Larkin}{L\bibinitperiod}{James\bibnamedelimb M\bibnamedelima G}{J\bibinitperiod\bibinitdelim M\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=f94e2a10c3baf41595717b6af5896762}{Utikal}{U\bibinitperiod}{Jochen}{J\bibinitperiod}{}{}{}{}}%
        {{hash=76603730dfd457b0a43777f9763656bd}{Dreno}{D\bibinitperiod}{Brigitte}{B\bibinitperiod}{}{}{}{}}%
        {{hash=7967c11172ff5b2ea46331d45ab08c50}{Nyakas}{N\bibinitperiod}{Marta}{M\bibinitperiod}{}{}{}{}}%
        {{hash=7ff9840f801885e50da45c4bc55453eb}{Middleton}{M\bibinitperiod}{Mark\bibnamedelima R}{M\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=a2edf979a0fd451b5baa1048aa990c28}{Becker}{B\bibinitperiod}{J{\"{u}}rgen\bibnamedelima C}{J\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=8e8bc7d820d798f9aadf3488114e9922}{Casey}{C\bibinitperiod}{Michelle}{M\bibinitperiod}{}{}{}{}}%
        {{hash=17b76e6b12dce07f97e73f114d44b708}{Sherman}{S\bibinitperiod}{Laurie\bibnamedelima J}{L\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=723b4057040e7c3e8d3735caf029a637}{Wu}{W\bibinitperiod}{Frank\bibnamedelima S}{F\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=74db56ecd41a02faf3da785946ab1234}{Ouellet}{O\bibinitperiod}{Daniele}{D\bibinitperiod}{}{}{}{}}%
        {{hash=13295c390ea48215c3bc5c7ccb5fef0a}{Martin}{M\bibinitperiod}{Anne-Marie}{A\bibinithyphendelim M\bibinitperiod}{}{}{}{}}%
        {{hash=f5ef2d048872d2df7bb27d3f4625ce97}{Patel}{P\bibinitperiod}{Kiran}{K\bibinitperiod}{}{}{}{}}%
        {{hash=5e2b115df41d17855e2edeb91f539d7f}{Schadendorf}{S\bibinitperiod}{Dirk}{D\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Massachusetts Medical Society}%
      }
      \strng{namehash}{de5f4506102799b49046b1e24aec33b3}
      \strng{fullhash}{80d56b83a288c936ba83efad2fc849bf}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma}}
      \field{annotation}{doi: 10.1056/NEJMoa1203421}
      \field{issn}{0028-4793}
      \field{journaltitle}{New England Journal of Medicine}
      \field{month}{06}
      \field{number}{2}
      \field{title}{{Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma}}
      \field{volume}{367}
      \field{year}{2012}
      \field{pages}{107\bibrangedash 114}
      \verb{doi}
      \verb 10.1056/NEJMoa1203421
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1056/NEJMoa1203421
      \endverb
    \endentry
    \entry{Ivy2009}{article}{}
      \name{labelname}{3}{}{%
        {{hash=a9f4ded756f023166e401e18736f301d}{Ivy}{I\bibinitperiod}{S.\bibnamedelimi Percy}{S\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=f7d2dfc1fbfdfe6b67aeaf7b4430e35d}{Wick}{W\bibinitperiod}{Jeannette\bibnamedelima Y.}{J\bibinitperiod\bibinitdelim Y\bibinitperiod}{}{}{}{}}%
        {{hash=63484592afcecc6a692da3a110fec431}{Kaufman}{K\bibinitperiod}{Bennett\bibnamedelima M.}{B\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=a9f4ded756f023166e401e18736f301d}{Ivy}{I\bibinitperiod}{S.\bibnamedelimi Percy}{S\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=f7d2dfc1fbfdfe6b67aeaf7b4430e35d}{Wick}{W\bibinitperiod}{Jeannette\bibnamedelima Y.}{J\bibinitperiod\bibinitdelim Y\bibinitperiod}{}{}{}{}}%
        {{hash=63484592afcecc6a692da3a110fec431}{Kaufman}{K\bibinitperiod}{Bennett\bibnamedelima M.}{B\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group}%
      }
      \strng{namehash}{b87d42234e8230e0f3207c09f24f170f}
      \strng{fullhash}{b87d42234e8230e0f3207c09f24f170f}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{An overview of small-molecule inhibitors of VEGFR signaling.}}
      \field{abstract}{VEGFR inhibitors are in broad use for the treatment of metastatic renal-cell carcinoma, gastrointestinal stromal tumors and hepatocellular carcinoma and in development in a number of other oncology indications, including colorectal cancer, non-small-cell lung cancer, pancreatic cancer, thyroid malignancies, ovarian cancer, breast cancer and sarcomas. This Review outlines the structure-activity relationships of the 44 VEGFR inhibitors currently in development. An overview of the pharmacokinetic profile of each molecule and its stage in development is provided. Phase III clinical trials being conducted for licensing of these agents for specific indications and phase III developmental efficacy trials are described in detailed tables that include the disease studied, trial design including combination therapy, study end points, and projected or final accrual. The relative frequency of on-target and off-target adverse events observed in 3,060 patients is described for a subset of agents in development in clinical trials sponsored by the National Cancer Institute. No interagent comparisons were undertaken and no data from pharmaceutical pharmacovigilance databases were used. The on-target effects seem to be mechanistically based and predicted by VEGFR inhibition. Small-molecule inhibitors of angiogenesis are active in a wide variety of malignancies and fill a unique niche for cancer therapeutics.}
      \field{isbn}{1759-4774}
      \field{issn}{1759-4782}
      \field{journaltitle}{Nature reviews. Clinical oncology}
      \field{number}{10}
      \field{title}{{An overview of small-molecule inhibitors of VEGFR signaling.}}
      \field{volume}{6}
      \field{year}{2009}
      \field{pages}{569\bibrangedash 79}
      \verb{doi}
      \verb 10.1038/nrclinonc.2009.130
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Ivy, Wick, Kaufman - 2009 - An overview of small-molecule inhibitors of VEGFR signaling.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.nature.com/doifinder/10.1038/nrclinonc.2009.130$%5Cbackslash$nhttp://www.ncbi.nlm.nih.gov/pubmed/19736552
      \endverb
    \endentry
    \entry{Holohan2013}{article}{}
      \name{labelname}{4}{}{%
        {{hash=6c32e713d24904dc6b3391437c574eb0}{Holohan}{H\bibinitperiod}{Caitriona}{C\bibinitperiod}{}{}{}{}}%
        {{hash=d4eae07cc0a417267219fda8277cd464}{{Van\bibnamedelimb Schaeybroeck}}{V\bibinitperiod}{Sandra}{S\bibinitperiod}{}{}{}{}}%
        {{hash=c4ce53d2e84389c0aa7202ee39161a56}{Longley}{L\bibinitperiod}{Daniel\bibnamedelima B}{D\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=fe74a923e323074806e55c1056c6e0fc}{Johnston}{J\bibinitperiod}{Patrick\bibnamedelima G}{P\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=6c32e713d24904dc6b3391437c574eb0}{Holohan}{H\bibinitperiod}{Caitriona}{C\bibinitperiod}{}{}{}{}}%
        {{hash=d4eae07cc0a417267219fda8277cd464}{{Van\bibnamedelimb Schaeybroeck}}{V\bibinitperiod}{Sandra}{S\bibinitperiod}{}{}{}{}}%
        {{hash=c4ce53d2e84389c0aa7202ee39161a56}{Longley}{L\bibinitperiod}{Daniel\bibnamedelima B}{D\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=fe74a923e323074806e55c1056c6e0fc}{Johnston}{J\bibinitperiod}{Patrick\bibnamedelima G}{P\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group}%
      }
      \strng{namehash}{18a6fca3287344fac5ec4d7f788e4c11}
      \strng{fullhash}{0e76ca14fc6d946a0764d9d679ed3edb}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Cancer drug resistance: an evolving paradigm.}}
      \field{abstract}{Resistance to chemotherapy and molecularly targeted therapies is a major problem facing current cancer research. The mechanisms of resistance to 'classical' cytotoxic chemotherapeutics and to therapies that are designed to be selective for specific molecular targets share many features, such as alterations in the drug target, activation of prosurvival pathways and ineffective induction of cell death. With the increasing arsenal of anticancer agents, improving preclinical models and the advent of powerful high-throughput screening techniques, there are now unprecedented opportunities to understand and overcome drug resistance through the clinical assessment of rational therapeutic drug combinations and the use of predictive biomarkers to enable patient stratification.}
      \field{issn}{1474-1768}
      \field{journaltitle}{Nature reviews. Cancer}
      \field{month}{10}
      \field{number}{10}
      \field{title}{{Cancer drug resistance: an evolving paradigm.}}
      \field{volume}{13}
      \field{year}{2013}
      \field{pages}{714\bibrangedash 26}
      \verb{doi}
      \verb 10.1038/nrc3599
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/nrc3599.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/24060863
      \endverb
    \endentry
    \entry{Manning2002}{article}{}
      \name{labelname}{1}{}{%
        {{hash=879316ae059a5d96fd637d6016cd9646}{Manning}{M\bibinitperiod}{G}{G\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=879316ae059a5d96fd637d6016cd9646}{Manning}{M\bibinitperiod}{G}{G\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{879316ae059a5d96fd637d6016cd9646}
      \strng{fullhash}{879316ae059a5d96fd637d6016cd9646}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{The Protein Kinase Complement of the Human Genome}}
      \field{abstract}{We have catalogued the protein kinase complement of the human genome (the "kinome") using public and proprietary genomic, complementary DNA, and expressed sequence tag (EST) sequences. This provides a starting point for comprehensive analysis of protein phosphorylation in normal and disease states, as well as a detailed view of the current state of human genome analysis through a focus on one large gene family. We identify 518 putative protein kinase genes, of which 71 have not previously been reported or described as kinases, and we extend or correct the protein sequences of 56 more kinases. New genes include members of well-studied families as well as previously unidentified families, some of which are conserved in model organisms. Classification and comparison with model organism kinomes identified orthologous groups and highlighted expansions specific to human and other lineages. We also identified 106 protein kinase pseudogenes. Chromosomal mapping revealed several small clusters of kinase genes and revealed that 244 kinases map to disease loci or cancer amplicons.}
      \field{isbn}{0036-8075}
      \field{issn}{00368075}
      \field{journaltitle}{Science}
      \field{number}{5600}
      \field{title}{{The Protein Kinase Complement of the Human Genome}}
      \field{volume}{298}
      \field{year}{2002}
      \field{pages}{1912\bibrangedash 1934}
      \verb{doi}
      \verb 10.1126/science.1075762
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Manning - 2002 - The Protein Kinase Complement of the Human Genome.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.sciencemag.org/content/298/5600/1912.abstract$%5Cbackslash$nhttp://www.ncbi.nlm.nih.gov/pubmed/12471243$%5Cbackslash$nhttp://www.sciencemag.org/cgi/doi/10.1126/science.1075762
      \endverb
    \endentry
    \entry{Muller2015}{article}{}
      \name{labelname}{4}{}{%
        {{hash=15d8b389fefa4ef8bf5081c868b8da11}{M{\"{u}}ller}{M\bibinitperiod}{Susanne}{S\bibinitperiod}{}{}{}{}}%
        {{hash=295e2a3621160b5fb9b3a73ff90a7817}{Chaikuad}{C\bibinitperiod}{Apirat}{A\bibinitperiod}{}{}{}{}}%
        {{hash=fabe6c6461e55d2d47e6c8fb604e93f8}{Gray}{G\bibinitperiod}{Nathanael\bibnamedelima S}{N\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=1a281309c878486e0f24ba3197554e32}{Knapp}{K\bibinitperiod}{Stefan}{S\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=15d8b389fefa4ef8bf5081c868b8da11}{M{\"{u}}ller}{M\bibinitperiod}{Susanne}{S\bibinitperiod}{}{}{}{}}%
        {{hash=295e2a3621160b5fb9b3a73ff90a7817}{Chaikuad}{C\bibinitperiod}{Apirat}{A\bibinitperiod}{}{}{}{}}%
        {{hash=fabe6c6461e55d2d47e6c8fb604e93f8}{Gray}{G\bibinitperiod}{Nathanael\bibnamedelima S}{N\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=1a281309c878486e0f24ba3197554e32}{Knapp}{K\bibinitperiod}{Stefan}{S\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group}%
      }
      \strng{namehash}{4a02dbc2ae46f45edad5d3fb92a7cd18}
      \strng{fullhash}{a649b356f2c48bb5e2cb65d0ceed60aa}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{The ins and outs of selective kinase inhibitor development}}
      \field{abstract}{Protein kinases have emerged as one of the most successful families of drug targets. To date, most selective kinase inhibitors have been discovered serendipitously either through broad selectivity screening or through the discovery of unique binding modes. Here we discuss design strategies that could lead to a broader coverage of the kinome with selective inhibitors and to a more rational approach for developing them. A berrant kinase function has been linked to the development of a large diversity of diseases and in particular to cancer, where recent large-scale sequencing efforts have highlighted protein kinases as one of the most frequently mutated proteins. However, the long time span from the discovery of kinases as oncogenes and as key players in tumorigenesis to the clinical approval of the first kinase small-molecule inhibitor imatinib (STI-571, Gleevec) in 2001 provides evidence of the difficult and controversial path to success in this area. The first crystal structure of a protein kinase domain (PKA) was published in 1991 and provided an initial model for inhibitor design 1}
      \field{isbn}{1552-4450}
      \field{issn}{1552-4450}
      \field{journaltitle}{NATURE CHEMICAL BIOLOGY www.nature.com/naturechemicalbiology}
      \field{number}{11}
      \field{title}{{The ins and outs of selective kinase inhibitor development}}
      \field{volume}{11}
      \field{year}{2015}
      \field{pages}{818\bibrangedash 821}
      \verb{doi}
      \verb 10.1038/nchembio.1938
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/M{\"{u}}ller et al. - 2015 - The ins and outs of selective kinase inhibitor development.pdf:pdf
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1038/nchembio.1938
      \endverb
    \endentry
    \entry{Lui1998}{article}{}
      \name{labelname}{5}{}{%
        {{hash=29bdd03a757ee4168cad6d145c3f26ac}{Liu}{L\bibinitperiod}{Y.}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=e2f25fe642500b4d9e8ba451aedd6777}{Shah}{S\bibinitperiod}{K.}{K\bibinitperiod}{}{}{}{}}%
        {{hash=eb5d5ae09823dbd21f6e0bbbf8a1b5ba}{Yang}{Y\bibinitperiod}{F.}{F\bibinitperiod}{}{}{}{}}%
        {{hash=e728a881568b2aee5597fd2766bc080a}{Witucki}{W\bibinitperiod}{L.}{L\bibinitperiod}{}{}{}{}}%
        {{hash=807e90962327b642875d2a2f4269b372}{Shokat}{S\bibinitperiod}{K.M.}{K\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{5}{}{%
        {{hash=29bdd03a757ee4168cad6d145c3f26ac}{Liu}{L\bibinitperiod}{Y.}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=e2f25fe642500b4d9e8ba451aedd6777}{Shah}{S\bibinitperiod}{K.}{K\bibinitperiod}{}{}{}{}}%
        {{hash=eb5d5ae09823dbd21f6e0bbbf8a1b5ba}{Yang}{Y\bibinitperiod}{F.}{F\bibinitperiod}{}{}{}{}}%
        {{hash=e728a881568b2aee5597fd2766bc080a}{Witucki}{W\bibinitperiod}{L.}{L\bibinitperiod}{}{}{}{}}%
        {{hash=807e90962327b642875d2a2f4269b372}{Shokat}{S\bibinitperiod}{K.M.}{K\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{c2a0d9b722896b4bbe76a68a02897bba}
      \strng{fullhash}{53b63aa19a4154b58e458a5a7010a937}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src}}
      \field{abstract}{Engineered proteins with specificity for unnatural substrates or ligands are useful tools for studying or manipulating complex biological systems. We have engineered the prototypical tyrosine kinase v-Src to accept an unnatural ATP analogue N6-(benzyl) ATP in order to identify v-Src's direct cellular substrates. Here we have used molecular modeling to analyze the binding mode of N6-(benzyl) ATP. Based on this modeling we proposed that a new ATP analogue (N6-(2-phenethyl) ATP might be a better substrate than N6-(benzyl) ATP for the I338G mutant of v-Src. In fact the newly proposed analogue (N6-(2-phenethyl) ATP is a somewhat improved substrate for the engineered kinase (kcat=0.6min{$\textminus$}1, KM=8$\mu$M). We also synthesized and screened three analogues of N6-(benzyl) ATP: N6-(2-methylbenzyl), ATP N6-(3-methylbenzyl), and ATP N6-(4-methylbenzyl) ATP to further probe the dimensions and shape of the introduced pocket. Results from screening newly synthesized ATP analogues agreed well with our modeling predictions. We conclude that rather than engineering a {$\textquoteleft$}new' pocket by mutation of Ile 338 in v-Src to the smaller Ala or Gly residues, the I338G and I338A mutants possess a {$\textquoteleft$}path' for the N6 substituent on ATP to gain access to an existing pocket in the ATP binding site. We expect to be able to extend the engineering of v-Src's ATP specificity to other kinase families based on our understanding of the binding modes of ATP analogues to engineered kinases.}
      \field{issn}{09680896}
      \field{journaltitle}{Bioorganic {\&} Medicinal Chemistry}
      \field{number}{8}
      \field{title}{{A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src}}
      \field{volume}{6}
      \field{year}{1998}
      \field{pages}{1219\bibrangedash 1226}
      \verb{doi}
      \verb 10.1016/S0968-0896(98)00099-6
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Liu et al. - 1998 - A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src.pdf:pdf
      \endverb
    \endentry
    \entry{Noble2004}{article}{}
      \name{labelname}{3}{}{%
        {{hash=96dfdcf58a38dbb27b542d68455aff50}{Noble}{N\bibinitperiod}{Martin\bibnamedelimb E\bibnamedelima M}{M\bibinitperiod\bibinitdelim E\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=8430039fbed85ecd02a2af03beb95a13}{Endicott}{E\bibinitperiod}{Jane\bibnamedelima A}{J\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=1beea9567dc3b6071b3b0995afa98d10}{Johnson}{J\bibinitperiod}{Louise\bibnamedelima N}{L\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=96dfdcf58a38dbb27b542d68455aff50}{Noble}{N\bibinitperiod}{Martin\bibnamedelimb E\bibnamedelima M}{M\bibinitperiod\bibinitdelim E\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=8430039fbed85ecd02a2af03beb95a13}{Endicott}{E\bibinitperiod}{Jane\bibnamedelima A}{J\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=1beea9567dc3b6071b3b0995afa98d10}{Johnson}{J\bibinitperiod}{Louise\bibnamedelima N}{L\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{c3fcedf29230e4e46cdece2deaea9157}
      \strng{fullhash}{c3fcedf29230e4e46cdece2deaea9157}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Protein Kinase Inhibitors: Insights into Drug Design from Structure}}
      \field{abstract}{Protein kinases are targets for treatment of a number of diseases. This review focuses on kinase inhibitors that are in the clinic or in clinical trials and for which structural information is available. Structures have informed drug design and have illuminated the mechanism of inhibition. We review progress with the receptor tyrosine kinases (growth factor receptors EGFR, VEGFR, and FGFR) and nonreceptor tyrosine kinases (Bcr-Abl), where advances have been made with cancer therapeutic agents such as Herceptin and Gleevec. Among the serine-threonine kinases, p38, Rho-kinase, cyclin-dependent kinases, and Chk1 have been targeted with productive results for inflammation and cancer. Structures have provided insights into targeting the inactive or active form of the kinase, for targeting the global constellation of residues at the ATP site or less conserved additional pockets or single residues, and into targeting noncatalytic domains.}
      \field{journaltitle}{Science}
      \field{month}{03}
      \field{number}{5665}
      \field{title}{{Protein Kinase Inhibitors: Insights into Drug Design from Structure}}
      \field{volume}{303}
      \field{year}{2004}
      \field{pages}{1800\bibrangedash 1805}
      \verb{file}
      \verb :home/fran/Downloads/1800.full.pdf:pdf
      \endverb
      \verb{url}
      \verb http://science.sciencemag.org/content/303/5665/1800.abstract
      \endverb
    \endentry
    \entry{Inhibitor2016}{article}{}
      \name{labelname}{5}{}{%
        {{hash=3e30c45974e4a692ce8cd1aa4d471d60}{Inhibitor}{I\bibinitperiod}{Kinase}{K\bibinitperiod}{}{}{}{}}%
        {{hash=51ed6c7e8e02a94ac110951fbb71fe2a}{Drug}{D\bibinitperiod}{Focused}{F\bibinitperiod}{}{}{}{}}%
        {{hash=fabe6c6461e55d2d47e6c8fb604e93f8}{Gray}{G\bibinitperiod}{Nathanael\bibnamedelima S}{N\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=c4637409a493a6bedef1eeb9c6777c93}{Ii}{I\bibinitperiod}{Type}{T\bibinitperiod}{}{}{}{}}%
        {{hash=87a27f91fc95364eba97cd887805a21f}{Link}{L\bibinitperiod}{Citable}{C\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{5}{}{%
        {{hash=3e30c45974e4a692ce8cd1aa4d471d60}{Inhibitor}{I\bibinitperiod}{Kinase}{K\bibinitperiod}{}{}{}{}}%
        {{hash=51ed6c7e8e02a94ac110951fbb71fe2a}{Drug}{D\bibinitperiod}{Focused}{F\bibinitperiod}{}{}{}{}}%
        {{hash=fabe6c6461e55d2d47e6c8fb604e93f8}{Gray}{G\bibinitperiod}{Nathanael\bibnamedelima S}{N\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=c4637409a493a6bedef1eeb9c6777c93}{Ii}{I\bibinitperiod}{Type}{T\bibinitperiod}{}{}{}{}}%
        {{hash=87a27f91fc95364eba97cd887805a21f}{Link}{L\bibinitperiod}{Citable}{C\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{716b901500560227fff45a638836fac0}
      \strng{fullhash}{153b06fe0e36da40559592fcb5d06450}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Exploration of Type II Binding Mode : A Privileged Approach for}}
      \field{title}{{Exploration of Type II Binding Mode : A Privileged Approach for}}
      \field{year}{2016}
      \verb{doi}
      \verb 10.1021/cb500129t
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/cb500129t.pdf:pdf
      \endverb
    \endentry
    \entry{Guimaraes2011}{article}{}
      \name{labelname}{7}{}{%
        {{hash=6714b8a850eb66a35c7a0a569b3db536}{Guimar{\~{a}}es}{G\bibinitperiod}{Cristiano\bibnamedelimb R\bibnamedelima W}{C\bibinitperiod\bibinitdelim R\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=e4c9a2a4a77c1977692c1ee55872c7cf}{Rai}{R\bibinitperiod}{Brajesh\bibnamedelima K}{B\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=a4a2bec23418efdd345e0c0c02342ee1}{Munchhof}{M\bibinitperiod}{Michael\bibnamedelima J}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=46936d907cca7347747a9ebdb9fdef9e}{Liu}{L\bibinitperiod}{Shenping}{S\bibinitperiod}{}{}{}{}}%
        {{hash=c33641e67eeaefc87b7821dc9b51ff90}{Wang}{W\bibinitperiod}{Jian}{J\bibinitperiod}{}{}{}{}}%
        {{hash=47e449adfc7f6d00654fe9e0b03f03af}{Bhattacharya}{B\bibinitperiod}{Samit\bibnamedelima K}{S\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=9ac1d3573df4addbb243ee5b7e42ef1c}{Buckbinder}{B\bibinitperiod}{Leonard}{L\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{7}{}{%
        {{hash=6714b8a850eb66a35c7a0a569b3db536}{Guimar{\~{a}}es}{G\bibinitperiod}{Cristiano\bibnamedelimb R\bibnamedelima W}{C\bibinitperiod\bibinitdelim R\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=e4c9a2a4a77c1977692c1ee55872c7cf}{Rai}{R\bibinitperiod}{Brajesh\bibnamedelima K}{B\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=a4a2bec23418efdd345e0c0c02342ee1}{Munchhof}{M\bibinitperiod}{Michael\bibnamedelima J}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=46936d907cca7347747a9ebdb9fdef9e}{Liu}{L\bibinitperiod}{Shenping}{S\bibinitperiod}{}{}{}{}}%
        {{hash=c33641e67eeaefc87b7821dc9b51ff90}{Wang}{W\bibinitperiod}{Jian}{J\bibinitperiod}{}{}{}{}}%
        {{hash=47e449adfc7f6d00654fe9e0b03f03af}{Bhattacharya}{B\bibinitperiod}{Samit\bibnamedelima K}{S\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=9ac1d3573df4addbb243ee5b7e42ef1c}{Buckbinder}{B\bibinitperiod}{Leonard}{L\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {American Chemical Society}%
      }
      \strng{namehash}{1136064ccf0c344a4c65be5a3bd96c0a}
      \strng{fullhash}{f6b17d0b5618c4635179a6f6348771fc}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Understanding the Impact of the P-loop Conformation on Kinase Selectivity}}
      \field{annotation}{doi: 10.1021/ci200153c}
      \field{issn}{1549-9596}
      \field{journaltitle}{Journal of Chemical Information and Modeling}
      \field{month}{06}
      \field{number}{6}
      \field{title}{{Understanding the Impact of the P-loop Conformation on Kinase Selectivity}}
      \field{volume}{51}
      \field{year}{2011}
      \field{pages}{1199\bibrangedash 1204}
      \verb{doi}
      \verb 10.1021/ci200153c
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1021/ci200153c
      \endverb
    \endentry
    \entry{Morris2013}{article}{}
      \name{labelname}{43}{}{%
        {{hash=2fba706f8426c242e73671fcd8f1e049}{Morris}{M\bibinitperiod}{Erick\bibnamedelima J}{E\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=2bdc8e1befcdf7ecfaa33fd2bd821389}{Jha}{J\bibinitperiod}{Sharda}{S\bibinitperiod}{}{}{}{}}%
        {{hash=bfc3adf7e3338acfe82ecb8f14b87664}{Restaino}{R\bibinitperiod}{Clifford\bibnamedelima R}{C\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=92f3ca905fb5b9384efc9b92e1a18b87}{Dayananth}{D\bibinitperiod}{Priya}{P\bibinitperiod}{}{}{}{}}%
        {{hash=1a5e6778ef2dbdeb988ab6152f69b704}{Zhu}{Z\bibinitperiod}{Hugh}{H\bibinitperiod}{}{}{}{}}%
        {{hash=d78505b492960cdf2af17b725dcb25e2}{Cooper}{C\bibinitperiod}{Alan}{A\bibinitperiod}{}{}{}{}}%
        {{hash=41db064db55748de19b9d1922fcff979}{Carr}{C\bibinitperiod}{Donna}{D\bibinitperiod}{}{}{}{}}%
        {{hash=4b68b1d48cbc3fe39144f8c68715d039}{Deng}{D\bibinitperiod}{Yongi}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=5430f20f8efcf371575f326dafa33961}{Jin}{J\bibinitperiod}{Weihong}{W\bibinitperiod}{}{}{}{}}%
        {{hash=a36f25a9ce1f4eb3a78b6d483b791bdc}{Black}{B\bibinitperiod}{Stuart}{S\bibinitperiod}{}{}{}{}}%
        {{hash=9072939c45d81cbe40d50191564b1f6e}{Long}{L\bibinitperiod}{Brian}{B\bibinitperiod}{}{}{}{}}%
        {{hash=b5543792063b78426cd607839a35ba1f}{Liu}{L\bibinitperiod}{Jenny}{J\bibinitperiod}{}{}{}{}}%
        {{hash=981aff289f0bbca9bb03706f6c549f52}{DiNunzio}{D\bibinitperiod}{Edward}{E\bibinitperiod}{}{}{}{}}%
        {{hash=bae6f6ea811839ec5b1c27f32ac8e052}{Windsor}{W\bibinitperiod}{William}{W\bibinitperiod}{}{}{}{}}%
        {{hash=1fd12bc1239dbd0f08abcac60417ae75}{Zhang}{Z\bibinitperiod}{Rumin}{R\bibinitperiod}{}{}{}{}}%
        {{hash=69fb872997eab8c14159c4bd2d4f2866}{Zhao}{Z\bibinitperiod}{Shuxia}{S\bibinitperiod}{}{}{}{}}%
        {{hash=ef231831072194eb8f3c0ab1fe0093e5}{Angagaw}{A\bibinitperiod}{Minilik\bibnamedelima H}{M\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=d9a6ba6a13e2314c6e37ca32542aacf7}{Pinheiro}{P\bibinitperiod}{Elaine\bibnamedelima M}{E\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=6438254b8cc79db0baf0c36538d2ceea}{Desai}{D\bibinitperiod}{Jagdish}{J\bibinitperiod}{}{}{}{}}%
        {{hash=047c3f96dd534550e148d9947507b71b}{Xiao}{X\bibinitperiod}{Li}{L\bibinitperiod}{}{}{}{}}%
        {{hash=ea2b00bf8aa2e15025ef3bd6d0d23286}{Shipps}{S\bibinitperiod}{Gerald}{G\bibinitperiod}{}{}{}{}}%
        {{hash=7875d1210578b9ca4cf558699172deaa}{Hruza}{H\bibinitperiod}{Alan}{A\bibinitperiod}{}{}{}{}}%
        {{hash=7060e413e4e24e85bae3d8b6948249b0}{Wang}{W\bibinitperiod}{James}{J\bibinitperiod}{}{}{}{}}%
        {{hash=88014343448e464ea0ffffcb3ba5e0c5}{Kelly}{K\bibinitperiod}{Joe}{J\bibinitperiod}{}{}{}{}}%
        {{hash=49624ce43ea0a0245a9df688619e7c8a}{Paliwal}{P\bibinitperiod}{Sunil}{S\bibinitperiod}{}{}{}{}}%
        {{hash=a48bc43fa4615a28c9419cd87c7d4953}{Gao}{G\bibinitperiod}{Xiaolei}{X\bibinitperiod}{}{}{}{}}%
        {{hash=5c588596e5af240702a536414e4264af}{Babu}{B\bibinitperiod}{Boga\bibnamedelima Sobhana}{B\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=0c0518a95690dc3847d1c6cfb569a20f}{Zhu}{Z\bibinitperiod}{Liang}{L\bibinitperiod}{}{}{}{}}%
        {{hash=eaf3ced246b5f73d107564a79e8f2876}{Daublain}{D\bibinitperiod}{Pierre}{P\bibinitperiod}{}{}{}{}}%
        {{hash=880bd45fc914edafbb19fcf1b8e46840}{Zhang}{Z\bibinitperiod}{Ling}{L\bibinitperiod}{}{}{}{}}%
        {{hash=af88169a5e1951e795a28ae4c08d41c8}{Lutterbach}{L\bibinitperiod}{Bart\bibnamedelima A}{B\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=6c6e577f8d6a689d27f9ad6cb11c7882}{Pelletier}{P\bibinitperiod}{Marc\bibnamedelima R}{M\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=4b090ad37eee879f2b17e848659ecfe4}{Philippar}{P\bibinitperiod}{Ulrike}{U\bibinitperiod}{}{}{}{}}%
        {{hash=424d1d288d24fab118dd52bb874e1ca8}{Siliphaivanh}{S\bibinitperiod}{Phieng}{P\bibinitperiod}{}{}{}{}}%
        {{hash=eb5be0f649b866d608a5abfe4fc539bd}{Witter}{W\bibinitperiod}{David}{D\bibinitperiod}{}{}{}{}}%
        {{hash=2bb70f3818f5ee08a460be8f9725dcb1}{Kirschmeier}{K\bibinitperiod}{Paul}{P\bibinitperiod}{}{}{}{}}%
        {{hash=6bbaadd6b27a7807134edff258ed5126}{Bishop}{B\bibinitperiod}{W\bibnamedelima Robert}{W\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=1388cfdd5819b42a4dd075c7781df682}{Hicklin}{H\bibinitperiod}{Daniel}{D\bibinitperiod}{}{}{}{}}%
        {{hash=a5d6eb7335c14be5ecc46a69cd4e0e23}{Gilliland}{G\bibinitperiod}{D\bibnamedelima Gary}{D\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=b8e7322b3827f15442019fe4c1dbac19}{Jayaraman}{J\bibinitperiod}{Lata}{L\bibinitperiod}{}{}{}{}}%
        {{hash=42b775c68fb9dfc89d9ca4d08b87357f}{Zawel}{Z\bibinitperiod}{Leigh}{L\bibinitperiod}{}{}{}{}}%
        {{hash=8fea27d8cbb1e30526dc2cc23f8b987d}{Fawell}{F\bibinitperiod}{Stephen}{S\bibinitperiod}{}{}{}{}}%
        {{hash=087b00608829544429140957c69508e3}{Samatar}{S\bibinitperiod}{Ahmed\bibnamedelima A}{A\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{43}{}{%
        {{hash=2fba706f8426c242e73671fcd8f1e049}{Morris}{M\bibinitperiod}{Erick\bibnamedelima J}{E\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=2bdc8e1befcdf7ecfaa33fd2bd821389}{Jha}{J\bibinitperiod}{Sharda}{S\bibinitperiod}{}{}{}{}}%
        {{hash=bfc3adf7e3338acfe82ecb8f14b87664}{Restaino}{R\bibinitperiod}{Clifford\bibnamedelima R}{C\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=92f3ca905fb5b9384efc9b92e1a18b87}{Dayananth}{D\bibinitperiod}{Priya}{P\bibinitperiod}{}{}{}{}}%
        {{hash=1a5e6778ef2dbdeb988ab6152f69b704}{Zhu}{Z\bibinitperiod}{Hugh}{H\bibinitperiod}{}{}{}{}}%
        {{hash=d78505b492960cdf2af17b725dcb25e2}{Cooper}{C\bibinitperiod}{Alan}{A\bibinitperiod}{}{}{}{}}%
        {{hash=41db064db55748de19b9d1922fcff979}{Carr}{C\bibinitperiod}{Donna}{D\bibinitperiod}{}{}{}{}}%
        {{hash=4b68b1d48cbc3fe39144f8c68715d039}{Deng}{D\bibinitperiod}{Yongi}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=5430f20f8efcf371575f326dafa33961}{Jin}{J\bibinitperiod}{Weihong}{W\bibinitperiod}{}{}{}{}}%
        {{hash=a36f25a9ce1f4eb3a78b6d483b791bdc}{Black}{B\bibinitperiod}{Stuart}{S\bibinitperiod}{}{}{}{}}%
        {{hash=9072939c45d81cbe40d50191564b1f6e}{Long}{L\bibinitperiod}{Brian}{B\bibinitperiod}{}{}{}{}}%
        {{hash=b5543792063b78426cd607839a35ba1f}{Liu}{L\bibinitperiod}{Jenny}{J\bibinitperiod}{}{}{}{}}%
        {{hash=981aff289f0bbca9bb03706f6c549f52}{DiNunzio}{D\bibinitperiod}{Edward}{E\bibinitperiod}{}{}{}{}}%
        {{hash=bae6f6ea811839ec5b1c27f32ac8e052}{Windsor}{W\bibinitperiod}{William}{W\bibinitperiod}{}{}{}{}}%
        {{hash=1fd12bc1239dbd0f08abcac60417ae75}{Zhang}{Z\bibinitperiod}{Rumin}{R\bibinitperiod}{}{}{}{}}%
        {{hash=69fb872997eab8c14159c4bd2d4f2866}{Zhao}{Z\bibinitperiod}{Shuxia}{S\bibinitperiod}{}{}{}{}}%
        {{hash=ef231831072194eb8f3c0ab1fe0093e5}{Angagaw}{A\bibinitperiod}{Minilik\bibnamedelima H}{M\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=d9a6ba6a13e2314c6e37ca32542aacf7}{Pinheiro}{P\bibinitperiod}{Elaine\bibnamedelima M}{E\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=6438254b8cc79db0baf0c36538d2ceea}{Desai}{D\bibinitperiod}{Jagdish}{J\bibinitperiod}{}{}{}{}}%
        {{hash=047c3f96dd534550e148d9947507b71b}{Xiao}{X\bibinitperiod}{Li}{L\bibinitperiod}{}{}{}{}}%
        {{hash=ea2b00bf8aa2e15025ef3bd6d0d23286}{Shipps}{S\bibinitperiod}{Gerald}{G\bibinitperiod}{}{}{}{}}%
        {{hash=7875d1210578b9ca4cf558699172deaa}{Hruza}{H\bibinitperiod}{Alan}{A\bibinitperiod}{}{}{}{}}%
        {{hash=7060e413e4e24e85bae3d8b6948249b0}{Wang}{W\bibinitperiod}{James}{J\bibinitperiod}{}{}{}{}}%
        {{hash=88014343448e464ea0ffffcb3ba5e0c5}{Kelly}{K\bibinitperiod}{Joe}{J\bibinitperiod}{}{}{}{}}%
        {{hash=49624ce43ea0a0245a9df688619e7c8a}{Paliwal}{P\bibinitperiod}{Sunil}{S\bibinitperiod}{}{}{}{}}%
        {{hash=a48bc43fa4615a28c9419cd87c7d4953}{Gao}{G\bibinitperiod}{Xiaolei}{X\bibinitperiod}{}{}{}{}}%
        {{hash=5c588596e5af240702a536414e4264af}{Babu}{B\bibinitperiod}{Boga\bibnamedelima Sobhana}{B\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=0c0518a95690dc3847d1c6cfb569a20f}{Zhu}{Z\bibinitperiod}{Liang}{L\bibinitperiod}{}{}{}{}}%
        {{hash=eaf3ced246b5f73d107564a79e8f2876}{Daublain}{D\bibinitperiod}{Pierre}{P\bibinitperiod}{}{}{}{}}%
        {{hash=880bd45fc914edafbb19fcf1b8e46840}{Zhang}{Z\bibinitperiod}{Ling}{L\bibinitperiod}{}{}{}{}}%
        {{hash=af88169a5e1951e795a28ae4c08d41c8}{Lutterbach}{L\bibinitperiod}{Bart\bibnamedelima A}{B\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=6c6e577f8d6a689d27f9ad6cb11c7882}{Pelletier}{P\bibinitperiod}{Marc\bibnamedelima R}{M\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=4b090ad37eee879f2b17e848659ecfe4}{Philippar}{P\bibinitperiod}{Ulrike}{U\bibinitperiod}{}{}{}{}}%
        {{hash=424d1d288d24fab118dd52bb874e1ca8}{Siliphaivanh}{S\bibinitperiod}{Phieng}{P\bibinitperiod}{}{}{}{}}%
        {{hash=eb5be0f649b866d608a5abfe4fc539bd}{Witter}{W\bibinitperiod}{David}{D\bibinitperiod}{}{}{}{}}%
        {{hash=2bb70f3818f5ee08a460be8f9725dcb1}{Kirschmeier}{K\bibinitperiod}{Paul}{P\bibinitperiod}{}{}{}{}}%
        {{hash=6bbaadd6b27a7807134edff258ed5126}{Bishop}{B\bibinitperiod}{W\bibnamedelima Robert}{W\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=1388cfdd5819b42a4dd075c7781df682}{Hicklin}{H\bibinitperiod}{Daniel}{D\bibinitperiod}{}{}{}{}}%
        {{hash=a5d6eb7335c14be5ecc46a69cd4e0e23}{Gilliland}{G\bibinitperiod}{D\bibnamedelima Gary}{D\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=b8e7322b3827f15442019fe4c1dbac19}{Jayaraman}{J\bibinitperiod}{Lata}{L\bibinitperiod}{}{}{}{}}%
        {{hash=42b775c68fb9dfc89d9ca4d08b87357f}{Zawel}{Z\bibinitperiod}{Leigh}{L\bibinitperiod}{}{}{}{}}%
        {{hash=8fea27d8cbb1e30526dc2cc23f8b987d}{Fawell}{F\bibinitperiod}{Stephen}{S\bibinitperiod}{}{}{}{}}%
        {{hash=087b00608829544429140957c69508e3}{Samatar}{S\bibinitperiod}{Ahmed\bibnamedelima A}{A\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{ba13d875669672c3a845b81ca014329c}
      \strng{fullhash}{09c280ace8df5e46744b1b8987dbe3f4}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors}}
      \field{abstract}{The high frequency of activating RAS or BRAF mutations in cancer provides strong rationale for targeting the mitogen-activated protein kinase (MAPK) pathway. Selective BRAF and MAP-ERK kinase (MEK) inhibitors have shown clinical efficacy in patients with melanoma. However, the majority of responses are transient, and resistance is often associated with pathway reactivation of the extracellular signal-regulated kinase (ERK) signaling pathway. Here, we describe the identification and characterization of SCH772984, a novel and selective inhibitor of ERK1/2 that displays behaviors of both type I and type II kinase inhibitors. SCH772984 has nanomolar cellular potency in tumor cells with mutations in BRAF, NRAS, or KRAS and induces tumor regressions in xenograft models at tolerated doses. Importantly, SCH772984 effectively inhibited MAPK signaling and cell proliferation in BRAF or MEK inhibitor--resistant models as well as in tumor cells resistant to concurrent treatment with BRAF and MEK inhibitors. These data support the clinical development of ERK inhibitors for tumors refractory to MAPK inhibitors.Significance: BRAF and MEK inhibitors have activity in MAPK-dependent cancers with BRAF or RAS mutations. However, resistance is associated with pathway alterations resulting in phospho-ERK reactivation. Here, we describe a novel ERK1/2 kinase inhibitor that has antitumor activity in MAPK inhibitor-na{\"{\i}}ve and MAPK inhibitor-resistant cells containing BRAF or RAS mutations. Cancer Discov; 3(7); 742--50. {{$\copyright$}}2013 AACR.See related commentary by Nissan et al., p. 719This article is highlighted in the In This Issue feature, p. 705}
      \field{annotation}{10.1158/2159-8290.CD-13-0070}
      \field{journaltitle}{Cancer Discovery}
      \field{month}{07}
      \field{number}{7}
      \field{title}{{Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors}}
      \field{volume}{3}
      \field{year}{2013}
      \field{pages}{742\bibrangedash 750}
      \verb{doi}
      \verb 10.1158/2159-8290.CD-13-0070
      \endverb
      \verb{url}
      \verb http://cancerdiscovery.aacrjournals.org/content/3/7/742.abstract
      \endverb
    \endentry
    \entry{Cohen2005}{article}{}
      \name{labelname}{4}{}{%
        {{hash=ab236f548fa11d536a6e77fbd2c5f7f3}{Cohen}{C\bibinitperiod}{Michael\bibnamedelima S}{M\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=03ae9f31823ca904e5b163319d310224}{Zhang}{Z\bibinitperiod}{Chao}{C\bibinitperiod}{}{}{}{}}%
        {{hash=b628d8bb864ec9dccf1a8dc3f40b048f}{Shokat}{S\bibinitperiod}{Kevan\bibnamedelima M}{K\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=29c7f7c59f424247bd56ec0a91afa32c}{Taunton}{T\bibinitperiod}{Jack}{J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=ab236f548fa11d536a6e77fbd2c5f7f3}{Cohen}{C\bibinitperiod}{Michael\bibnamedelima S}{M\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=03ae9f31823ca904e5b163319d310224}{Zhang}{Z\bibinitperiod}{Chao}{C\bibinitperiod}{}{}{}{}}%
        {{hash=b628d8bb864ec9dccf1a8dc3f40b048f}{Shokat}{S\bibinitperiod}{Kevan\bibnamedelima M}{K\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=29c7f7c59f424247bd56ec0a91afa32c}{Taunton}{T\bibinitperiod}{Jack}{J\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{3ccc923a5800e355aac8346c36b433dd}
      \strng{fullhash}{60029e827d0427391192108192debd5f}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors}}
      \field{abstract}{The active sites of 491 human protein kinase domains are highly conserved, which makes the design of selective inhibitors a formidable challenge. We used a structural bioinformatics approach to identify two selectivity filters, a threonine and a cysteine, at defined positions in the active site of p90 ribosomal protein S6 kinase (RSK). A fluoromethylketone inhibitor, designed to exploit both selectivity filters, potently and selectively inactivated RSK1 and RSK2 in mammalian cells. Kinases with only one selectivity filter were resistant to the inhibitor, yet they became sensitized after genetic introduction of the second selectivity filter. Thus, two amino acids that distinguish RSK from other protein kinases are sufficient to confer inhibitor sensitivity.}
      \field{journaltitle}{Science}
      \field{month}{05}
      \field{number}{5726}
      \field{title}{{Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors}}
      \field{volume}{308}
      \field{year}{2005}
      \field{pages}{1318\bibrangedash 1321}
      \verb{url}
      \verb http://science.sciencemag.org/content/308/5726/1318.abstract
      \endverb
    \endentry
    \entry{Potashman2009}{article}{}
      \name{labelname}{2}{}{%
        {{hash=ddeed5ccdc87520f813247afdb8457ca}{Potashman}{P\bibinitperiod}{Michele\bibnamedelima H}{M\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=6410f16304b86f5bd6428c314ac39114}{Duggan}{D\bibinitperiod}{Mark\bibnamedelima E}{M\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=ddeed5ccdc87520f813247afdb8457ca}{Potashman}{P\bibinitperiod}{Michele\bibnamedelima H}{M\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=6410f16304b86f5bd6428c314ac39114}{Duggan}{D\bibinitperiod}{Mark\bibnamedelima E}{M\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {American Chemical Society}%
      }
      \strng{namehash}{7f5cbfb2a750d1c11e330930f6ef47c3}
      \strng{fullhash}{7f5cbfb2a750d1c11e330930f6ef47c3}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Covalent Modifiers: An Orthogonal Approach to Drug Design}}
      \field{annotation}{doi: 10.1021/jm8008597}
      \field{issn}{0022-2623}
      \field{journaltitle}{Journal of Medicinal Chemistry}
      \field{month}{03}
      \field{number}{5}
      \field{title}{{Covalent Modifiers: An Orthogonal Approach to Drug Design}}
      \field{volume}{52}
      \field{year}{2009}
      \field{pages}{1231\bibrangedash 1246}
      \verb{doi}
      \verb 10.1021/jm8008597
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1021/jm8008597
      \endverb
    \endentry
    \entry{Liu2013a}{article}{}
      \name{labelname}{7}{}{%
        {{hash=a8f352e1725448281095f9e18d8cef49}{Liu}{L\bibinitperiod}{Qingsong}{Q\bibinitperiod}{}{}{}{}}%
        {{hash=e57a4ba10887c7f8b83e43af07be43d0}{Sabnis}{S\bibinitperiod}{Yogesh}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=31c53327fd1ea736e1e0863448529e06}{Zhao}{Z\bibinitperiod}{Zheng}{Z\bibinitperiod}{}{}{}{}}%
        {{hash=0042938c0c4b8a87b35f602200cc32c0}{Zhang}{Z\bibinitperiod}{Tinghu}{T\bibinitperiod}{}{}{}{}}%
        {{hash=2ab03a74c0063c98b0d1a0247040d79d}{Buhrlage}{B\bibinitperiod}{Sara\bibnamedelima J}{S\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=54f5f24da77b4658161f0a1df1d070e1}{Jones}{J\bibinitperiod}{Lyn\bibnamedelima H}{L\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=fabe6c6461e55d2d47e6c8fb604e93f8}{Gray}{G\bibinitperiod}{Nathanael\bibnamedelima S}{N\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{7}{}{%
        {{hash=a8f352e1725448281095f9e18d8cef49}{Liu}{L\bibinitperiod}{Qingsong}{Q\bibinitperiod}{}{}{}{}}%
        {{hash=e57a4ba10887c7f8b83e43af07be43d0}{Sabnis}{S\bibinitperiod}{Yogesh}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=31c53327fd1ea736e1e0863448529e06}{Zhao}{Z\bibinitperiod}{Zheng}{Z\bibinitperiod}{}{}{}{}}%
        {{hash=0042938c0c4b8a87b35f602200cc32c0}{Zhang}{Z\bibinitperiod}{Tinghu}{T\bibinitperiod}{}{}{}{}}%
        {{hash=2ab03a74c0063c98b0d1a0247040d79d}{Buhrlage}{B\bibinitperiod}{Sara\bibnamedelima J}{S\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=54f5f24da77b4658161f0a1df1d070e1}{Jones}{J\bibinitperiod}{Lyn\bibnamedelima H}{L\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=fabe6c6461e55d2d47e6c8fb604e93f8}{Gray}{G\bibinitperiod}{Nathanael\bibnamedelima S}{N\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{de4595f869ec02a67e3a3dc4684eb85f}
      \strng{fullhash}{1737dbb82507f654b8627473e7848aea}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Developing irreversible inhibitors of the protein kinase cysteinome}}
      \field{abstract}{Protein kinases are a large family of approximately 530 highly conserved enzymes that transfer a $\gamma$-phosphate group from ATP to a variety of amino acid residues such as tyrosine, serine and threonine which serves as a ubiquitous mechanism for cellular signal transduction. The clinical success of a number of kinase-directed drugs and the frequent observation of disease causing mutations in protein kinases suggest that a large number of kinases may represent therapeutically relevant targets. To-date the majority of clinical and preclinical kinase inhibitors are ATP-competitive, non-covalent inhibitors that achieve selectivity through recognition of unique features of particular protein kinases. Recently there has been renewed interest in the development of irreversible inhibitors that form covalent bonds with cysteine or other nucleophilic residues in the ATP-binding pocket. Irreversible kinase inhibitors have a number of potential advantages including prolonged pharmacodynamics, suitability for rational design, high potency and ability to validate pharmacological specificity through mutation of the reactive cysteine residue. Here we review recent efforts to develop cysteine-targeted irreversible protein kinase inhibitors and discuss their modes of recognizing the ATP-binding pocket and their biological activity profiles. In addition, we provided an informatics assessment of the potential {$\textquoteleft$}kinase-cysteinome' and discuss strategies for the efficient development of new covalent inhibitors.}
      \field{issn}{1074-5521}
      \field{journaltitle}{Chemistry {\&} biology}
      \field{month}{02}
      \field{number}{2}
      \field{title}{{Developing irreversible inhibitors of the protein kinase cysteinome}}
      \field{volume}{20}
      \field{year}{2013}
      \field{pages}{146\bibrangedash 159}
      \verb{doi}
      \verb 10.1016/j.chembiol.2012.12.006
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583020/
      \endverb
    \endentry
    \entry{Barf2012}{article}{}
      \name{labelname}{2}{}{%
        {{hash=51d3fa41f1c5bfdeaa4c3f806fccedd2}{Barf}{B\bibinitperiod}{Tjeerd}{T\bibinitperiod}{}{}{}{}}%
        {{hash=b05b95b4b1d470e8913951153975cf14}{Kaptein}{K\bibinitperiod}{Allard}{A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=51d3fa41f1c5bfdeaa4c3f806fccedd2}{Barf}{B\bibinitperiod}{Tjeerd}{T\bibinitperiod}{}{}{}{}}%
        {{hash=b05b95b4b1d470e8913951153975cf14}{Kaptein}{K\bibinitperiod}{Allard}{A\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{214122ddd9d7b2edd07cef70528d234f}
      \strng{fullhash}{214122ddd9d7b2edd07cef70528d234f}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Irreversible Protein Kinase Inhibitors: Balancing the Bene fi ts and Risks}}
      \field{journaltitle}{Journal of medicinal chemistry}
      \field{title}{{Irreversible Protein Kinase Inhibitors: Balancing the Bene fi ts and Risks}}
      \field{volume}{55}
      \field{year}{2012}
      \field{pages}{6243\bibrangedash 6262}
      \verb{doi}
      \verb 10.1021/jm3003203
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/barf2012.pdf:pdf
      \endverb
    \endentry
    \entry{Liebler2008}{article}{}
      \name{labelname}{1}{}{%
        {{hash=f65da1ad7ca8e22f4370d0a63fbeb3fe}{Liebler}{L\bibinitperiod}{Daniel\bibnamedelima C}{D\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=f65da1ad7ca8e22f4370d0a63fbeb3fe}{Liebler}{L\bibinitperiod}{Daniel\bibnamedelima C}{D\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {American Chemical Society}%
      }
      \strng{namehash}{f65da1ad7ca8e22f4370d0a63fbeb3fe}
      \strng{fullhash}{f65da1ad7ca8e22f4370d0a63fbeb3fe}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Protein Damage by Reactive Electrophiles: Targets and Consequences}}
      \field{annotation}{doi: 10.1021/tx700235t}
      \field{issn}{0893-228X}
      \field{journaltitle}{Chemical Research in Toxicology}
      \field{month}{01}
      \field{number}{1}
      \field{title}{{Protein Damage by Reactive Electrophiles: Targets and Consequences}}
      \field{volume}{21}
      \field{year}{2008}
      \field{pages}{117\bibrangedash 128}
      \verb{doi}
      \verb 10.1021/tx700235t
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1021/tx700235t
      \endverb
    \endentry
    \entry{Okamoto2015}{article}{}
      \name{labelname}{9}{}{%
        {{hash=847760bec6760f26981e737374bf5f2e}{Okamoto}{O\bibinitperiod}{Kiyoshi}{K\bibinitperiod}{}{}{}{}}%
        {{hash=2e62f64b5cfd1a844cfaae8ae4d8dbf6}{Ikemori-Kawada}{I\bibinithyphendelim K\bibinitperiod}{Megumi}{M\bibinitperiod}{}{}{}{}}%
        {{hash=d3bfdb3c8b4176ab67b0e9ee3f2eb853}{Jestel}{J\bibinitperiod}{Anja}{A\bibinitperiod}{}{}{}{}}%
        {{hash=10666611338f57b1c20bb1fbb3c4940c}{K{\"{o}}nig}{K\bibinitperiod}{Konstanze}{K\bibinitperiod}{von}{v\bibinitperiod}{}{}}%
        {{hash=fa27275fa2e95163f2da2b66e777d3f6}{Funahashi}{F\bibinitperiod}{Yasuhiro}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=7840fa6a87f4fe503cbbadd67ce6120d}{Matsushima}{M\bibinitperiod}{Tomohiro}{T\bibinitperiod}{}{}{}{}}%
        {{hash=47e6866c83f06074472fccc8ccc39c10}{Tsuruoka}{T\bibinitperiod}{Akihiko}{A\bibinitperiod}{}{}{}{}}%
        {{hash=59b33d139abbbde8a5474edc906bd604}{Inoue}{I\bibinitperiod}{Atsushi}{A\bibinitperiod}{}{}{}{}}%
        {{hash=2d43bf218e24c77f19192a5808786025}{Matsui}{M\bibinitperiod}{Junji}{J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{9}{}{%
        {{hash=847760bec6760f26981e737374bf5f2e}{Okamoto}{O\bibinitperiod}{Kiyoshi}{K\bibinitperiod}{}{}{}{}}%
        {{hash=2e62f64b5cfd1a844cfaae8ae4d8dbf6}{Ikemori-Kawada}{I\bibinithyphendelim K\bibinitperiod}{Megumi}{M\bibinitperiod}{}{}{}{}}%
        {{hash=d3bfdb3c8b4176ab67b0e9ee3f2eb853}{Jestel}{J\bibinitperiod}{Anja}{A\bibinitperiod}{}{}{}{}}%
        {{hash=10666611338f57b1c20bb1fbb3c4940c}{K{\"{o}}nig}{K\bibinitperiod}{Konstanze}{K\bibinitperiod}{von}{v\bibinitperiod}{}{}}%
        {{hash=fa27275fa2e95163f2da2b66e777d3f6}{Funahashi}{F\bibinitperiod}{Yasuhiro}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=7840fa6a87f4fe503cbbadd67ce6120d}{Matsushima}{M\bibinitperiod}{Tomohiro}{T\bibinitperiod}{}{}{}{}}%
        {{hash=47e6866c83f06074472fccc8ccc39c10}{Tsuruoka}{T\bibinitperiod}{Akihiko}{A\bibinitperiod}{}{}{}{}}%
        {{hash=59b33d139abbbde8a5474edc906bd604}{Inoue}{I\bibinitperiod}{Atsushi}{A\bibinitperiod}{}{}{}{}}%
        {{hash=2d43bf218e24c77f19192a5808786025}{Matsui}{M\bibinitperiod}{Junji}{J\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {American Chemical Society}%
      }
      \strng{namehash}{32e03266160c0426ab52620c46b6e003}
      \strng{fullhash}{ab5257c53c2d416d82ea1d6afd34501a}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Distinct Binding Mode of Multikinase Inhibitor Lenvatinib Revealed by Biochemical Characterization}}
      \field{abstract}{Lenvatinib is an oral multikinase inhibitor that selectively inhibits vascular endothelial growth factor (VEGF) receptors 1 to 3 and other proangiogenic and oncogenic pathway-related receptor tyrosine kinases. To elucidate the origin of the potency of lenvatinib in VEGF receptor 2 (VEGFR2) inhibition, we conducted a kinetic interaction analysis of lenvatinib with VEGFR2 and X-ray analysis of the crystal structure of VEGFR2--lenvatinib complexes. Kinetic analysis revealed that lenvatinib had a rapid association rate constant and a relatively slow dissociation rate constant in complex with VEGFR2. Co-crystal structure analysis demonstrated that lenvatinib binds at its ATP mimetic quinoline moiety to the ATP binding site and to the neighboring region via a cyclopropane ring, adopting an Asp-Phe-Gly (DFG)-{$\textquotedblleft$}in{$\textquotedblright$} conformation. These results suggest that lenvatinib is very distinct in its binding mode of interaction compared to the several approved VEGFR2 kinase inhibitors.}
      \field{issn}{1948-5875}
      \field{journaltitle}{ACS Medicinal Chemistry Letters}
      \field{month}{01}
      \field{number}{1}
      \field{title}{{Distinct Binding Mode of Multikinase Inhibitor Lenvatinib Revealed by Biochemical Characterization}}
      \field{volume}{6}
      \field{year}{2015}
      \field{pages}{89\bibrangedash 94}
      \verb{doi}
      \verb 10.1021/ml500394m
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4291723/
      \endverb
    \endentry
    \entry{Davis2011}{article}{}
      \name{labelname}{9}{}{%
        {{hash=0873b559d19f44effc0698b297cf54b5}{Davis}{D\bibinitperiod}{Mindy\bibnamedelima I}{M\bibinitperiod\bibinitdelim I\bibinitperiod}{}{}{}{}}%
        {{hash=84beb3ef02821b31444b556e4f5aa501}{Hunt}{H\bibinitperiod}{Jeremy\bibnamedelima P}{J\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=c94d2bf13a5fe9e4dd5d6302f3021036}{Herrgard}{H\bibinitperiod}{Sanna}{S\bibinitperiod}{}{}{}{}}%
        {{hash=eedf61a524cf71c6b7e19c33d5d10354}{Ciceri}{C\bibinitperiod}{Pietro}{P\bibinitperiod}{}{}{}{}}%
        {{hash=019c61c35d671cb404d9fd81fc9a06bc}{Wodicka}{W\bibinitperiod}{Lisa\bibnamedelima M}{L\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=65406820b865b00f94176716ba9fc8ec}{Pallares}{P\bibinitperiod}{Gabriel}{G\bibinitperiod}{}{}{}{}}%
        {{hash=fe2f95a46f2668f90196c63d3bb91908}{Hocker}{H\bibinitperiod}{Michael}{M\bibinitperiod}{}{}{}{}}%
        {{hash=281ffed0bab47ea010245e901dd06ced}{Treiber}{T\bibinitperiod}{Daniel\bibnamedelima K}{D\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=80d27d9db3f3649cf2b1c2fa9e1ff230}{Zarrinkar}{Z\bibinitperiod}{Patrick\bibnamedelima P}{P\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{9}{}{%
        {{hash=0873b559d19f44effc0698b297cf54b5}{Davis}{D\bibinitperiod}{Mindy\bibnamedelima I}{M\bibinitperiod\bibinitdelim I\bibinitperiod}{}{}{}{}}%
        {{hash=84beb3ef02821b31444b556e4f5aa501}{Hunt}{H\bibinitperiod}{Jeremy\bibnamedelima P}{J\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=c94d2bf13a5fe9e4dd5d6302f3021036}{Herrgard}{H\bibinitperiod}{Sanna}{S\bibinitperiod}{}{}{}{}}%
        {{hash=eedf61a524cf71c6b7e19c33d5d10354}{Ciceri}{C\bibinitperiod}{Pietro}{P\bibinitperiod}{}{}{}{}}%
        {{hash=019c61c35d671cb404d9fd81fc9a06bc}{Wodicka}{W\bibinitperiod}{Lisa\bibnamedelima M}{L\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=65406820b865b00f94176716ba9fc8ec}{Pallares}{P\bibinitperiod}{Gabriel}{G\bibinitperiod}{}{}{}{}}%
        {{hash=fe2f95a46f2668f90196c63d3bb91908}{Hocker}{H\bibinitperiod}{Michael}{M\bibinitperiod}{}{}{}{}}%
        {{hash=281ffed0bab47ea010245e901dd06ced}{Treiber}{T\bibinitperiod}{Daniel\bibnamedelima K}{D\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=80d27d9db3f3649cf2b1c2fa9e1ff230}{Zarrinkar}{Z\bibinitperiod}{Patrick\bibnamedelima P}{P\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.}%
      }
      \strng{namehash}{20769f4908436a68d1aef9abbf11660a}
      \strng{fullhash}{b35e6d44af0304ba5eb289002615c422}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Comprehensive analysis of kinase inhibitor selectivity}}
      \field{annotation}{10.1038/nbt.1990}
      \field{issn}{1087-0156}
      \field{journaltitle}{Nat Biotech}
      \field{month}{11}
      \field{number}{11}
      \field{title}{{Comprehensive analysis of kinase inhibitor selectivity}}
      \field{volume}{29}
      \field{year}{2011}
      \field{pages}{1046\bibrangedash 1051}
      \verb{url}
      \verb http://dx.doi.org/10.1038/nbt.1990%20http://www.nature.com/nbt/journal/v29/n11/abs/nbt.1990.html%7B%5C#%7Dsupplementary-information
      \endverb
    \endentry
    \entry{Zhang2009a}{article}{}
      \name{labelname}{3}{}{%
        {{hash=ac94487142bcc73ec00646f41c277977}{Zhang}{Z\bibinitperiod}{Jianming}{J\bibinitperiod}{}{}{}{}}%
        {{hash=60061fbf1aecd520b9add74fdc4f61eb}{Yang}{Y\bibinitperiod}{Priscilla\bibnamedelima L}{P\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=fabe6c6461e55d2d47e6c8fb604e93f8}{Gray}{G\bibinitperiod}{Nathanael\bibnamedelima S}{N\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=ac94487142bcc73ec00646f41c277977}{Zhang}{Z\bibinitperiod}{Jianming}{J\bibinitperiod}{}{}{}{}}%
        {{hash=60061fbf1aecd520b9add74fdc4f61eb}{Yang}{Y\bibinitperiod}{Priscilla\bibnamedelima L}{P\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=fabe6c6461e55d2d47e6c8fb604e93f8}{Gray}{G\bibinitperiod}{Nathanael\bibnamedelima S}{N\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group}%
      }
      \strng{namehash}{4737b124b9a903e114646b7add908b56}
      \strng{fullhash}{4737b124b9a903e114646b7add908b56}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Targeting cancer with small molecule kinase inhibitors}}
      \field{annotation}{10.1038/nrc2559}
      \field{issn}{1474-175X}
      \field{journaltitle}{Nat Rev Cancer}
      \field{month}{01}
      \field{number}{1}
      \field{title}{{Targeting cancer with small molecule kinase inhibitors}}
      \field{volume}{9}
      \field{year}{2009}
      \field{pages}{28\bibrangedash 39}
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Zhang, Yang, Gray - 2009 - Targeting cancer with small molecule kinase inhibitors.pdf:pdf
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1038/nrc2559%20http://www.nature.com/nrc/journal/v9/n1/suppinfo/nrc2559%7B%5C_%7DS1.html
      \endverb
    \endentry
    \entry{Gottesman2002}{article}{}
      \name{labelname}{1}{}{%
        {{hash=a1354f1c1b5296ca8179b1c7ffaf1bd6}{Gottesman}{G\bibinitperiod}{Michael\bibnamedelima M}{M\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=a1354f1c1b5296ca8179b1c7ffaf1bd6}{Gottesman}{G\bibinitperiod}{Michael\bibnamedelima M}{M\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Annual Reviews}%
      }
      \strng{namehash}{a1354f1c1b5296ca8179b1c7ffaf1bd6}
      \strng{fullhash}{a1354f1c1b5296ca8179b1c7ffaf1bd6}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Mechanisms of Cancer Drug Resistance}}
      \field{annotation}{doi: 10.1146/annurev.med.53.082901.103929}
      \field{issn}{0066-4219}
      \field{journaltitle}{Annual Review of Medicine}
      \field{month}{02}
      \field{number}{1}
      \field{title}{{Mechanisms of Cancer Drug Resistance}}
      \field{volume}{53}
      \field{year}{2002}
      \field{pages}{615\bibrangedash 627}
      \verb{doi}
      \verb 10.1146/annurev.med.53.082901.103929
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1146/annurev.med.53.082901.103929
      \endverb
    \endentry
    \entry{Lowe2004}{article}{}
      \name{labelname}{3}{}{%
        {{hash=8e267aad7e0431290c9a80dbe14198e5}{Lowe}{L\bibinitperiod}{Scott\bibnamedelima W}{S\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=15c91d0027dc4d881d0379c5e0894c4e}{Cepero}{C\bibinitperiod}{Enrique}{E\bibinitperiod}{}{}{}{}}%
        {{hash=f57536643371a452e08971b8ad5073da}{Evan}{E\bibinitperiod}{Gerard}{G\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=8e267aad7e0431290c9a80dbe14198e5}{Lowe}{L\bibinitperiod}{Scott\bibnamedelima W}{S\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=15c91d0027dc4d881d0379c5e0894c4e}{Cepero}{C\bibinitperiod}{Enrique}{E\bibinitperiod}{}{}{}{}}%
        {{hash=f57536643371a452e08971b8ad5073da}{Evan}{E\bibinitperiod}{Gerard}{G\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{591e6c4492d37ce584f753c14deebcb4}
      \strng{fullhash}{591e6c4492d37ce584f753c14deebcb4}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Intrinsic tumour suppression}}
      \field{annotation}{10.1038/nature03098}
      \field{issn}{0028-0836}
      \field{journaltitle}{Nature}
      \field{month}{11}
      \field{number}{7015}
      \field{title}{{Intrinsic tumour suppression}}
      \field{volume}{432}
      \field{year}{2004}
      \field{pages}{307\bibrangedash 315}
      \verb{url}
      \verb http://dx.doi.org/10.1038/nature03098
      \endverb
    \endentry
    \entry{Logue2012}{article}{}
      \name{labelname}{2}{}{%
        {{hash=f55da953001639a8f8362a83f5fd0fd4}{Logue}{L\bibinitperiod}{Jeremy\bibnamedelima S.}{J\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=10ea24437e630bf72ce6b5de74925beb}{Morrison}{M\bibinitperiod}{Deborah\bibnamedelima K.}{D\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=f55da953001639a8f8362a83f5fd0fd4}{Logue}{L\bibinitperiod}{Jeremy\bibnamedelima S.}{J\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=10ea24437e630bf72ce6b5de74925beb}{Morrison}{M\bibinitperiod}{Deborah\bibnamedelima K.}{D\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{ba59ee8f1d98fffbd59dcc5651d9b291}
      \strng{fullhash}{ba59ee8f1d98fffbd59dcc5651d9b291}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Complexity in the signaling network: Insights from the use of targeted inhibitors in cancer therapy}}
      \field{abstract}{Cancer often arises when normal cellular growth goes awry due to defects in critical signal transduction pathways. A growing number of inhibitors that target specific components of these pathways are in clinical use, but the success of these agents has been limited by the resistance to inhibitor therapy that ultimately develops. Studies have now shown that cancer cells respond to chronic drug treatment by adapting their signaling circuitry, taking advantage of pathway redundancy and routes of feedback and cross-talk to maintain their function. This review focuses on the compensatory signaling mechanisms highlighted by the use of targeted inhibitors in cancer therapy.}
      \field{isbn}{1549-5477 (Electronic)$\backslash$r0890-9369 (Linking)}
      \field{issn}{08909369}
      \field{journaltitle}{Genes and Development}
      \field{number}{7}
      \field{title}{{Complexity in the signaling network: Insights from the use of targeted inhibitors in cancer therapy}}
      \field{volume}{26}
      \field{year}{2012}
      \field{pages}{641\bibrangedash 650}
      \verb{doi}
      \verb 10.1101/gad.186965.112
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/Genes Dev.-2012-Logue-641-50.pdf:pdf
      \endverb
    \endentry
    \entry{McMillin2013}{article}{}
      \name{labelname}{3}{}{%
        {{hash=c30fb952510309c896ab0e40e4484cb6}{McMillin}{M\bibinitperiod}{Douglas\bibnamedelima W}{D\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=83b25172a11d5d9a84c82051d78c5cc1}{Negri}{N\bibinitperiod}{Joseph\bibnamedelima M}{J\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=3b6118fc53c59da93b95a8c510432bde}{Mitsiades}{M\bibinitperiod}{Constantine\bibnamedelima S}{C\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=c30fb952510309c896ab0e40e4484cb6}{McMillin}{M\bibinitperiod}{Douglas\bibnamedelima W}{D\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=83b25172a11d5d9a84c82051d78c5cc1}{Negri}{N\bibinitperiod}{Joseph\bibnamedelima M}{J\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=3b6118fc53c59da93b95a8c510432bde}{Mitsiades}{M\bibinitperiod}{Constantine\bibnamedelima S}{C\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.}%
      }
      \strng{namehash}{0b40abbb7f2bdc3045c07c6850a7343c}
      \strng{fullhash}{0b40abbb7f2bdc3045c07c6850a7343c}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{The role of tumour-stromal interactions in modifying drug response: challenges and opportunities}}
      \field{annotation}{10.1038/nrd3870}
      \field{issn}{1474-1776}
      \field{journaltitle}{Nat Rev Drug Discov}
      \field{month}{03}
      \field{number}{3}
      \field{title}{{The role of tumour-stromal interactions in modifying drug response: challenges and opportunities}}
      \field{volume}{12}
      \field{year}{2013}
      \field{pages}{217\bibrangedash 228}
      \verb{url}
      \verb http://dx.doi.org/10.1038/nrd3870
      \endverb
    \endentry
    \entry{Maier2005}{article}{}
      \name{labelname}{5}{}{%
        {{hash=e6332b3fbc053e818beb40d6b92306d1}{Maier}{M\bibinitperiod}{Sabine}{S\bibinitperiod}{}{}{}{}}%
        {{hash=1c9d9f1741c41277726c521dc7fbf4e1}{Dahlstroem}{D\bibinitperiod}{Christina}{C\bibinitperiod}{}{}{}{}}%
        {{hash=6ccd7e784b4fc236e90ebfc8cd3e0a62}{Haefliger}{H\bibinitperiod}{Carolina}{C\bibinitperiod}{}{}{}{}}%
        {{hash=27baf3e62a5cfa12c1e6f95b90b40284}{Plum}{P\bibinitperiod}{Achim}{A\bibinitperiod}{}{}{}{}}%
        {{hash=360e5b8f2e397dd0acdf2916097159f3}{Piepenbrock}{P\bibinitperiod}{Christian}{C\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{5}{}{%
        {{hash=e6332b3fbc053e818beb40d6b92306d1}{Maier}{M\bibinitperiod}{Sabine}{S\bibinitperiod}{}{}{}{}}%
        {{hash=1c9d9f1741c41277726c521dc7fbf4e1}{Dahlstroem}{D\bibinitperiod}{Christina}{C\bibinitperiod}{}{}{}{}}%
        {{hash=6ccd7e784b4fc236e90ebfc8cd3e0a62}{Haefliger}{H\bibinitperiod}{Carolina}{C\bibinitperiod}{}{}{}{}}%
        {{hash=27baf3e62a5cfa12c1e6f95b90b40284}{Plum}{P\bibinitperiod}{Achim}{A\bibinitperiod}{}{}{}{}}%
        {{hash=360e5b8f2e397dd0acdf2916097159f3}{Piepenbrock}{P\bibinitperiod}{Christian}{C\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{52dcbddef5b35796453038d1e1d55930}
      \strng{fullhash}{6a4b16c1e94efd70a593e8b47bc07817}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Identifying DNA Methylation Biomarkers of Cancer Drug Response}}
      \field{abstract}{In the last few years, DNA methylation has become one of the most studied gene regulation mechanisms in carcinogenesis as a result of the cumulative evidence produced by the scientific community. Moreover, advances in the technologies that allow detection of DNA methylation in a variety of analytes have opened the possibility of developing methylation-based tests. A number of studies have provided evidence that specific methylation changes can alter the response to different therapeutic agents in cancer and, therefore, be useful biomarkers. For example, the association of the methylation status of DNA repair genes such as MGMT and MLH1 illustrate the two main mechanisms of response to DNA damaging agents. Loss of methylation of MGMT, and the subsequent increase in gene expression, leads to a reduction in response to alkylating agents as a result of enhanced repair of drug-induced DNA damage. Conversely, the increase in methylation of MLH1 and its resulting loss of expression has been consistently observed in drug-resistant tumor cells. MLH1 encodes a mismatch repair enzyme activated in response to DNA damage; activation of MLH1 also induces apoptosis of tumor cells, and thus loss of its expression leads to resistance to DNA-damaging agents. Other methylation-regulated genes that could serve as biomarkers in cancer therapy include drug transporters, genes involved in microtubule formation and stability, and genes related to hormonal therapy response. These methylation markers have potential applications for disease prognosis, treatment response prediction, and the development of novel treatment strategies.}
      \field{issn}{1175-2203}
      \field{journaltitle}{American Journal of Pharmacogenomics}
      \field{number}{4}
      \field{title}{{Identifying DNA Methylation Biomarkers of Cancer Drug Response}}
      \field{volume}{5}
      \field{year}{2005}
      \field{pages}{223\bibrangedash 232}
      \verb{doi}
      \verb 10.2165/00129785-200505040-00003
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.2165/00129785-200505040-00003
      \endverb
    \endentry
    \entry{Koivisto1997}{article}{}
      \name{labelname}{11}{}{%
        {{hash=83021009def8842ea5ab4a483868842c}{Koivisto}{K\bibinitperiod}{Pasi}{P\bibinitperiod}{}{}{}{}}%
        {{hash=199a9152a2e6bb96b2beb4f09ed64b21}{Kononen}{K\bibinitperiod}{Juha}{J\bibinitperiod}{}{}{}{}}%
        {{hash=560d241e00d660bcd40521091c38c389}{Palmberg}{P\bibinitperiod}{Christian}{C\bibinitperiod}{}{}{}{}}%
        {{hash=3dad937f613791a00e74f7fe16642ba4}{Tammela}{T\bibinitperiod}{Teuvo}{T\bibinitperiod}{}{}{}{}}%
        {{hash=b932363a5f64dc893a8c8aa13826187c}{Hyytinen}{H\bibinitperiod}{Eija}{E\bibinitperiod}{}{}{}{}}%
        {{hash=69f651c5aa39ad29a55b83c4828d915e}{Isola}{I\bibinitperiod}{Jorma}{J\bibinitperiod}{}{}{}{}}%
        {{hash=c1fb4e38b6d63246deccbbf86d3b1575}{Trapman}{T\bibinitperiod}{Jan}{J\bibinitperiod}{}{}{}{}}%
        {{hash=56e94e52248ef6490dbd18cd2eaf7cce}{Cleutjens}{C\bibinitperiod}{Kitty}{K\bibinitperiod}{}{}{}{}}%
        {{hash=e63ad953054a2923b8a3c0b94fbb4df1}{Noordzij}{N\bibinitperiod}{Arjan}{A\bibinitperiod}{}{}{}{}}%
        {{hash=4fec5b3d1a4c9169a688d0827889c1fa}{Visakorpi}{V\bibinitperiod}{Tapio}{T\bibinitperiod}{}{}{}{}}%
        {{hash=f5dd63ebcc739e6edbd7ae920b10490d}{Kallioniemi}{K\bibinitperiod}{Olli-P.}{O\bibinithyphendelim P\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{11}{}{%
        {{hash=83021009def8842ea5ab4a483868842c}{Koivisto}{K\bibinitperiod}{Pasi}{P\bibinitperiod}{}{}{}{}}%
        {{hash=199a9152a2e6bb96b2beb4f09ed64b21}{Kononen}{K\bibinitperiod}{Juha}{J\bibinitperiod}{}{}{}{}}%
        {{hash=560d241e00d660bcd40521091c38c389}{Palmberg}{P\bibinitperiod}{Christian}{C\bibinitperiod}{}{}{}{}}%
        {{hash=3dad937f613791a00e74f7fe16642ba4}{Tammela}{T\bibinitperiod}{Teuvo}{T\bibinitperiod}{}{}{}{}}%
        {{hash=b932363a5f64dc893a8c8aa13826187c}{Hyytinen}{H\bibinitperiod}{Eija}{E\bibinitperiod}{}{}{}{}}%
        {{hash=69f651c5aa39ad29a55b83c4828d915e}{Isola}{I\bibinitperiod}{Jorma}{J\bibinitperiod}{}{}{}{}}%
        {{hash=c1fb4e38b6d63246deccbbf86d3b1575}{Trapman}{T\bibinitperiod}{Jan}{J\bibinitperiod}{}{}{}{}}%
        {{hash=56e94e52248ef6490dbd18cd2eaf7cce}{Cleutjens}{C\bibinitperiod}{Kitty}{K\bibinitperiod}{}{}{}{}}%
        {{hash=e63ad953054a2923b8a3c0b94fbb4df1}{Noordzij}{N\bibinitperiod}{Arjan}{A\bibinitperiod}{}{}{}{}}%
        {{hash=4fec5b3d1a4c9169a688d0827889c1fa}{Visakorpi}{V\bibinitperiod}{Tapio}{T\bibinitperiod}{}{}{}{}}%
        {{hash=f5dd63ebcc739e6edbd7ae920b10490d}{Kallioniemi}{K\bibinitperiod}{Olli-P.}{O\bibinithyphendelim P\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{f895be2a33ad75758813678735d6b15c}
      \strng{fullhash}{14ddaf44959bd07e3b2a7424581b777f}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Androgen Receptor Gene Amplification: A Possible Molecular Mechanism for Androgen Deprivation Therapy Failure in Prostate Cancer}}
      \field{abstract}{Progression of prostate cancer during endocrine therapy is a major clinical problem, the molecular mechanisms of which remain poorly understood. Amplification of the androgen receptor (AR) gene was recently described in recurrent prostate carcinomas from patients who had failed androgen deprivation therapy. To evaluate the hypothesis that amplification of the AR gene is a cause for the failure of androgen deprivation therapy in prostate cancer, we studied whether AR amplification leads to gene overexpression, whether the amplified AR gene is structurally intact, and whether tumors with AR amplification have distinct biological and clinical characteristics. Tumor specimens were collected from 54 prostate cancer patients at the time of a local recurrence following therapy failure. In 26 cases, paired primary tumor specimens from the same patients prior to therapy were also available. Fifteen (28{\%}) of the recurrent therapy-resistant tumors, but none of the untreated primary tumors, contained AR gene amplification as determined by fluorescence in situ hybridization. According to single-stranded conformation polymorphism analysis, the AR gene was wild type in all but one of the 13 AR amplified cases studied. In one tumor, a presumed mutation in the hormone-binding domain at codon 674 leading to a Gly \x{2192} Ala substitution was found, but functional studies indicated that this mutation did not change the transactivational properties of the receptor. AR amplification was associated with a substantially increased level of mRNA expression of the gene by in situ hybridization. Clinicopathological correlations indicated that AR amplification was most likely to occur in tumors that had initially responded well to endocrine therapy and whose response duration was more than 12 months. Tumors that recurred earlier or those that showed no initial therapy response did not contain AR amplification. The median survival time after recurrence was two times longer for patients with AR amplification in comparison to those with no amplification (P = 0.03, Willcoxon-Breslow test). In conclusion, failure of conventional androgen deprivation therapy in prostate cancer may be caused by a clonal expansion of tumor cells that are able to continue androgen-dependent growth despite of the low concentrations of serum androgens. Amplification and the increased expression of a wild-type AR gene may play a key role in this process. {{$\copyright$}}1997 American Association for Cancer Research.}
      \field{journaltitle}{Cancer Research}
      \field{month}{01}
      \field{number}{2}
      \field{title}{{Androgen Receptor Gene Amplification: A Possible Molecular Mechanism for Androgen Deprivation Therapy Failure in Prostate Cancer}}
      \field{volume}{57}
      \field{year}{1997}
      \field{pages}{314\bibrangedash 319}
      \verb{url}
      \verb http://cancerres.aacrjournals.org/content/57/2/314.abstract
      \endverb
    \endentry
    \entry{Schmitt2015}{article}{}
      \name{labelname}{3}{}{%
        {{hash=a36e66a0f1ebea79542937d112f33c2c}{Schmitt}{S\bibinitperiod}{Michael\bibnamedelima W.}{M\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=6e4eb2931bf50ae5d848b0b3f3dc1524}{Loeb}{L\bibinitperiod}{Lawrence\bibnamedelima A.}{L\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=47a3e5c261ea08656d36bccde039469f}{Salk}{S\bibinitperiod}{Jesse\bibnamedelima J.}{J\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=a36e66a0f1ebea79542937d112f33c2c}{Schmitt}{S\bibinitperiod}{Michael\bibnamedelima W.}{M\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=6e4eb2931bf50ae5d848b0b3f3dc1524}{Loeb}{L\bibinitperiod}{Lawrence\bibnamedelima A.}{L\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=47a3e5c261ea08656d36bccde039469f}{Salk}{S\bibinitperiod}{Jesse\bibnamedelima J.}{J\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group}%
      }
      \strng{namehash}{ebe5644efcdc41f0769afe7616e82668}
      \strng{fullhash}{ebe5644efcdc41f0769afe7616e82668}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{The influence of subclonal resistance mutations on targeted cancer therapy.}}
      \field{abstract}{Clinical oncology is being revolutionized by the increasing use of molecularly targeted therapies. This paradigm holds great promise for improving cancer treatment; however, allocating specific therapies to the patients who are most likely to derive a durable benefit continues to represent a considerable challenge. Evidence continues to emerge that cancers are characterized by extensive intratumour genetic heterogeneity, and that patients being considered for treatment with a targeted agent might, therefore, already possess resistance to the drug in a minority of cells. Indeed, multiple examples of pre-existing subclonal resistance mutations to various molecularly targeted agents have been described, which we review herein. Early detection of pre-existing or emerging drug resistance could enable more personalized use of targeted cancer therapy, as patients could be stratified to receive the therapies that are most likely to be effective. We consider how monitoring of drug resistance could be incorporated into clinical practice to optimize the use of targeted therapies in individual patients.}
      \field{issn}{1759-4782}
      \field{journaltitle}{Nature reviews. Clinical oncology}
      \field{title}{{The influence of subclonal resistance mutations on targeted cancer therapy.}}
      \field{year}{2015}
      \verb{doi}
      \verb 10.1038/nrclinonc.2015.175
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/schmitt2015.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.nature.com/doifinder/10.1038/nrclinonc.2015.175$%5Cbackslash$nhttp://www.ncbi.nlm.nih.gov/pubmed/26483300
      \endverb
    \endentry
    \entry{Chen2011}{article}{}
      \name{labelname}{2}{}{%
        {{hash=838eb8b79df802c3fc789123cb8868dd}{Chen}{C\bibinitperiod}{Yi-fan}{Y\bibinithyphendelim f\bibinitperiod}{}{}{}{}}%
        {{hash=346db2d2a87e22a9250e7bfe471beb3e}{Fu}{F\bibinitperiod}{Li-wu}{L\bibinithyphendelim w\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=838eb8b79df802c3fc789123cb8868dd}{Chen}{C\bibinitperiod}{Yi-fan}{Y\bibinithyphendelim f\bibinitperiod}{}{}{}{}}%
        {{hash=346db2d2a87e22a9250e7bfe471beb3e}{Fu}{F\bibinitperiod}{Li-wu}{L\bibinithyphendelim w\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{5cbefd25773cc49085ba67de0a1c5560}
      \strng{fullhash}{5cbefd25773cc49085ba67de0a1c5560}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Mechanisms of acquired resistance to tyrosine kinase inhibitors}}
      \field{issn}{2211-3835}
      \field{journaltitle}{Acta Pharmaceutica Sinica B}
      \field{month}{12}
      \field{number}{4}
      \field{title}{{Mechanisms of acquired resistance to tyrosine kinase inhibitors}}
      \field{volume}{1}
      \field{year}{2011}
      \field{pages}{197\bibrangedash 207}
      \verb{doi}
      \verb http://dx.doi.org/10.1016/j.apsb.2011.10.007
      \endverb
      \verb{url}
      \verb http://www.sciencedirect.com/science/article/pii/S2211383511000876
      \endverb
    \endentry
    \entry{Barouch-Bentov2011a}{article}{}
      \name{labelname}{2}{}{%
        {{hash=f1c3e5165a862ff0406acf074bc1a4ff}{Barouch-Bentov}{B\bibinithyphendelim B\bibinitperiod}{Rina}{R\bibinitperiod}{}{}{}{}}%
        {{hash=0f5bf5358f926234ff2094c55b885010}{Sauer}{S\bibinitperiod}{Karsten}{K\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=f1c3e5165a862ff0406acf074bc1a4ff}{Barouch-Bentov}{B\bibinithyphendelim B\bibinitperiod}{Rina}{R\bibinitperiod}{}{}{}{}}%
        {{hash=0f5bf5358f926234ff2094c55b885010}{Sauer}{S\bibinitperiod}{Karsten}{K\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{b996fa312837b24998517323bb416ace}
      \strng{fullhash}{b996fa312837b24998517323bb416ace}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Mechanisms of Drug-Resistance in Kinases}}
      \field{abstract}{INTRODUCTION: Because of their important roles in disease and excellent {$\textquotedblleft$}druggability{$\textquotedblright$}, kinases have become the second-largest drug target family. The great success of the BCR-ABL inhibitor imatinib in treating CML illustrates the high potential of kinase inhibitor (KI) therapeutics, but also unveiled a major limitation: the development of drug-resistance. This is a significant concern as KIs reach large patient populations for an expanding array of indications. AREAS COVERED: We provide an up-to-date understanding of the mechanisms through which KIs function, and through which cells can become KI-resistant. We review current and future approaches to overcome KI-resistance, focussing on currently approved KIs and KIs in clinical trials. We then discuss approaches to improve KI efficacy and overcome drug-resistance and novel approaches to develop less drug-resistance prone KI-therapeutics. EXPERT OPINION: Although drug-resistance is a concern for current KI-therapeutics, recent progress in our understanding of the underlying mechanisms and promising technological advances may overcome this limitation and provide powerful new therapeutics.}
      \field{issn}{1354-3784}
      \field{journaltitle}{Expert opinion on investigational drugs}
      \field{month}{02}
      \field{number}{2}
      \field{title}{{Mechanisms of Drug-Resistance in Kinases}}
      \field{volume}{20}
      \field{year}{2011}
      \field{pages}{153\bibrangedash 208}
      \verb{doi}
      \verb 10.1517/13543784.2011.546344
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3095104/
      \endverb
    \endentry
    \entry{Gorre2001}{article}{}
      \name{labelname}{7}{}{%
        {{hash=c8a9cbad8cfa2b5a8ad09452a9533cb9}{Gorre}{G\bibinitperiod}{Mercedes\bibnamedelima E}{M\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=c0b63a80cf33f0666a50c643d6e6c798}{Mohammed}{M\bibinitperiod}{Mansoor}{M\bibinitperiod}{}{}{}{}}%
        {{hash=71c6d88cef5acaa8bc18e9be42d8dde8}{Ellwood}{E\bibinitperiod}{Katharine}{K\bibinitperiod}{}{}{}{}}%
        {{hash=ac7a2252da43c90b85c4b1f6d31df7fc}{Hsu}{H\bibinitperiod}{Nicholas}{N\bibinitperiod}{}{}{}{}}%
        {{hash=cc11273b857b652546513e2e2f73129a}{Paquette}{P\bibinitperiod}{Ron}{R\bibinitperiod}{}{}{}{}}%
        {{hash=35aa2081393170f21bb85d865876677a}{Rao}{R\bibinitperiod}{P\bibnamedelima Nagesh}{P\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
        {{hash=f22edf6d53eef45e28e683b05a6365ea}{Sawyers}{S\bibinitperiod}{Charles\bibnamedelima L}{C\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{7}{}{%
        {{hash=c8a9cbad8cfa2b5a8ad09452a9533cb9}{Gorre}{G\bibinitperiod}{Mercedes\bibnamedelima E}{M\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=c0b63a80cf33f0666a50c643d6e6c798}{Mohammed}{M\bibinitperiod}{Mansoor}{M\bibinitperiod}{}{}{}{}}%
        {{hash=71c6d88cef5acaa8bc18e9be42d8dde8}{Ellwood}{E\bibinitperiod}{Katharine}{K\bibinitperiod}{}{}{}{}}%
        {{hash=ac7a2252da43c90b85c4b1f6d31df7fc}{Hsu}{H\bibinitperiod}{Nicholas}{N\bibinitperiod}{}{}{}{}}%
        {{hash=cc11273b857b652546513e2e2f73129a}{Paquette}{P\bibinitperiod}{Ron}{R\bibinitperiod}{}{}{}{}}%
        {{hash=35aa2081393170f21bb85d865876677a}{Rao}{R\bibinitperiod}{P\bibnamedelima Nagesh}{P\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
        {{hash=f22edf6d53eef45e28e683b05a6365ea}{Sawyers}{S\bibinitperiod}{Charles\bibnamedelima L}{C\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{a45409e6edc0726bd1b561df7fd2346a}
      \strng{fullhash}{6c01aee90bc8caab0fcc46be97b7b672}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification}}
      \field{abstract}{Clinical studies with the Abl tyrosine kinase inhibitor STI-571 in chronic myeloid leukemia demonstrate that many patients with advanced stage disease respond initially but then relapse. Through biochemical and molecular analysis of clinical material, we find that drug resistance is associated with the reactivation of BCR-ABL signal transduction in all cases examined. In six of nine patients, resistance was associated with a single amino acid substitution in a threonine residue of the Abl kinase domain known to form a critical hydrogen bond with the drug. This substitution of threonine with isoleucine was sufficient to confer STI-571 resistance in a reconstitution experiment. In three patients, resistance was associated with progressiveBCR-ABL gene amplification. These studies provide evidence that genetically complex cancers retain dependence on an initial oncogenic event and suggest a strategy for identifying inhibitors of STI-571 resistance.}
      \field{journaltitle}{Science}
      \field{month}{08}
      \field{number}{5531}
      \field{title}{{Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification}}
      \field{volume}{293}
      \field{year}{2001}
      \field{pages}{876\bibrangedash 880}
      \verb{url}
      \verb http://science.sciencemag.org/content/293/5531/876.abstract
      \endverb
    \endentry
    \entry{Soverini2016}{article}{}
      \name{labelname}{9}{}{%
        {{hash=0a9e9a02e71800c149bfaff090a05e47}{Soverini}{S\bibinitperiod}{Simona}{S\bibinitperiod}{}{}{}{}}%
        {{hash=42e17c34d483c3fb2aa376c78b8043f1}{Branford}{B\bibinitperiod}{Susan}{S\bibinitperiod}{}{}{}{}}%
        {{hash=0cde4574b87e87e5767dd9e024f4427a}{Nicolini}{N\bibinitperiod}{Franck\bibnamedelima E}{F\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=c35a3fbc1bf6528c77e1b61ae7f77709}{Talpaz}{T\bibinitperiod}{Moshe}{M\bibinitperiod}{}{}{}{}}%
        {{hash=249fe77ad183fc6795a8499b6863eb90}{Deininger}{D\bibinitperiod}{Michael\bibnamedelimb W\bibnamedelima N}{M\bibinitperiod\bibinitdelim W\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
        {{hash=032a8d086021b639c99eec77315a3f32}{Martinelli}{M\bibinitperiod}{Giovanni}{G\bibinitperiod}{}{}{}{}}%
        {{hash=ed21f2add1c5b9222c502609601b029b}{M{\"{u}}ller}{M\bibinitperiod}{Martin\bibnamedelima C}{M\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=494cfc6fb18817448568dbf4e911e819}{Radich}{R\bibinitperiod}{Jerald\bibnamedelima P}{J\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=09d68d1fdd85e495ccf25e270b1f2023}{Shah}{S\bibinitperiod}{Neil\bibnamedelima P}{N\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{9}{}{%
        {{hash=0a9e9a02e71800c149bfaff090a05e47}{Soverini}{S\bibinitperiod}{Simona}{S\bibinitperiod}{}{}{}{}}%
        {{hash=42e17c34d483c3fb2aa376c78b8043f1}{Branford}{B\bibinitperiod}{Susan}{S\bibinitperiod}{}{}{}{}}%
        {{hash=0cde4574b87e87e5767dd9e024f4427a}{Nicolini}{N\bibinitperiod}{Franck\bibnamedelima E}{F\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=c35a3fbc1bf6528c77e1b61ae7f77709}{Talpaz}{T\bibinitperiod}{Moshe}{M\bibinitperiod}{}{}{}{}}%
        {{hash=249fe77ad183fc6795a8499b6863eb90}{Deininger}{D\bibinitperiod}{Michael\bibnamedelimb W\bibnamedelima N}{M\bibinitperiod\bibinitdelim W\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
        {{hash=032a8d086021b639c99eec77315a3f32}{Martinelli}{M\bibinitperiod}{Giovanni}{G\bibinitperiod}{}{}{}{}}%
        {{hash=ed21f2add1c5b9222c502609601b029b}{M{\"{u}}ller}{M\bibinitperiod}{Martin\bibnamedelima C}{M\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=494cfc6fb18817448568dbf4e911e819}{Radich}{R\bibinitperiod}{Jerald\bibnamedelima P}{J\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=09d68d1fdd85e495ccf25e270b1f2023}{Shah}{S\bibinitperiod}{Neil\bibnamedelima P}{N\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Elsevier}%
      }
      \strng{namehash}{e652330e53b4fb86088418234ea76d68}
      \strng{fullhash}{e75f7f2ddf7f6afd77a7f16cf54902b1}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia}}
      \field{annotation}{doi: 10.1016/j.leukres.2013.09.011}
      \field{issn}{0145-2126}
      \field{journaltitle}{Leukemia Research}
      \field{month}{07}
      \field{number}{1}
      \field{title}{{Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia}}
      \field{volume}{38}
      \field{year}{2016}
      \field{pages}{10\bibrangedash 20}
      \verb{doi}
      \verb 10.1016/j.leukres.2013.09.011
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1016/j.leukres.2013.09.011
      \endverb
    \endentry
    \entry{Shih2005}{article}{}
      \name{labelname}{3}{}{%
        {{hash=097b13d55a363aeef488832a2555978e}{Shih}{S\bibinitperiod}{Jin-Yuan}{J\bibinithyphendelim Y\bibinitperiod}{}{}{}{}}%
        {{hash=26255e7a3c1ba4e8e0e0f5fa63a741d6}{Gow}{G\bibinitperiod}{Chien-Hung}{C\bibinithyphendelim H\bibinitperiod}{}{}{}{}}%
        {{hash=8c7b09ba94093e2119b6af7becca215a}{Yang}{Y\bibinitperiod}{Pan-Chyr}{P\bibinithyphendelim C\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=097b13d55a363aeef488832a2555978e}{Shih}{S\bibinitperiod}{Jin-Yuan}{J\bibinithyphendelim Y\bibinitperiod}{}{}{}{}}%
        {{hash=26255e7a3c1ba4e8e0e0f5fa63a741d6}{Gow}{G\bibinitperiod}{Chien-Hung}{C\bibinithyphendelim H\bibinitperiod}{}{}{}{}}%
        {{hash=8c7b09ba94093e2119b6af7becca215a}{Yang}{Y\bibinitperiod}{Pan-Chyr}{P\bibinithyphendelim C\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Massachusetts Medical Society}%
      }
      \strng{namehash}{d06c803369769e84025216ed5637b6a9}
      \strng{fullhash}{d06c803369769e84025216ed5637b6a9}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{EGFR Mutation Conferring Primary Resistance to Gefitinib in Non--Small-Cell Lung Cancer}}
      \field{annotation}{doi: 10.1056/NEJM200507143530217}
      \field{issn}{0028-4793}
      \field{journaltitle}{New England Journal of Medicine}
      \field{month}{07}
      \field{number}{2}
      \field{title}{{EGFR Mutation Conferring Primary Resistance to Gefitinib in Non--Small-Cell Lung Cancer}}
      \field{volume}{353}
      \field{year}{2005}
      \field{pages}{207\bibrangedash 208}
      \verb{doi}
      \verb 10.1056/NEJM200507143530217
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1056/NEJM200507143530217
      \endverb
    \endentry
    \entry{Walter2013}{article}{}
      \name{labelname}{30}{}{%
        {{hash=cca789921c494236ec14c7db5c2878fc}{Walter}{W\bibinitperiod}{Annette\bibnamedelima O}{A\bibinitperiod\bibinitdelim O\bibinitperiod}{}{}{}{}}%
        {{hash=cf677020cb59ee903228bd940483f261}{Sjin}{S\bibinitperiod}{Robert\bibnamedelimb Tjin\bibnamedelima Tham}{R\bibinitperiod\bibinitdelim T\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=6c5b4f554b577226a962e927ad4b196d}{Haringsma}{H\bibinitperiod}{Henry\bibnamedelima J}{H\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=bf7ffa68555d1660e1f6f0dcdf1a38e2}{Ohashi}{O\bibinitperiod}{Kadoaki}{K\bibinitperiod}{}{}{}{}}%
        {{hash=65ea74598909191bc1e0ad5a2d66e922}{Sun}{S\bibinitperiod}{Jing}{J\bibinitperiod}{}{}{}{}}%
        {{hash=bfe1058ef5492d64f1e0f193c736faa8}{Lee}{L\bibinitperiod}{Kwangho}{K\bibinitperiod}{}{}{}{}}%
        {{hash=f0e5e463196c34f4b907df07394a20df}{Dubrovskiy}{D\bibinitperiod}{Aleksandr}{A\bibinitperiod}{}{}{}{}}%
        {{hash=5cbdfca8ebe0f2869d00f9107338bcdc}{Labenski}{L\bibinitperiod}{Matthew}{M\bibinitperiod}{}{}{}{}}%
        {{hash=ba72e8d8a8abe30d9d20832861803a72}{Zhu}{Z\bibinitperiod}{Zhendong}{Z\bibinitperiod}{}{}{}{}}%
        {{hash=9f4446a6d583221d3d173f806ecf8627}{Wang}{W\bibinitperiod}{Zhigang}{Z\bibinitperiod}{}{}{}{}}%
        {{hash=317a92fa1f91c6949eb2bcdb302df34c}{Sheets}{S\bibinitperiod}{Michael}{M\bibinitperiod}{}{}{}{}}%
        {{hash=8fd09416626a0e5bd54a542296e3cc02}{{St\bibnamedelimb Martin}}{S\bibinitperiod}{Thia}{T\bibinitperiod}{}{}{}{}}%
        {{hash=d320eb9999cfa2b9ca9eada10017fc88}{Karp}{K\bibinitperiod}{Russell}{R\bibinitperiod}{}{}{}{}}%
        {{hash=32a6fa3fb0519b0f2ad00732902c571c}{Kalken}{K\bibinitperiod}{Dan}{D\bibinitperiod}{van}{v\bibinitperiod}{}{}}%
        {{hash=74e8771eabf644b9966df55877434537}{Chaturvedi}{C\bibinitperiod}{Prasoon}{P\bibinitperiod}{}{}{}{}}%
        {{hash=ab6c13a43e4a88eadf82c6c7aaf2976e}{Niu}{N\bibinitperiod}{Deqiang}{D\bibinitperiod}{}{}{}{}}%
        {{hash=230219635bc09a341b8b87210877a101}{Nacht}{N\bibinitperiod}{Mariana}{M\bibinitperiod}{}{}{}{}}%
        {{hash=f048e1809ed2d21d092a20d30987b9ab}{Petter}{P\bibinitperiod}{Russell\bibnamedelima C}{R\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=4e88a62d4f3a7f529b3c5a77a2c5a2d8}{Westlin}{W\bibinitperiod}{William}{W\bibinitperiod}{}{}{}{}}%
        {{hash=68434cdeb7a3c089fd99baba0e0a4a3b}{Lin}{L\bibinitperiod}{Kevin}{K\bibinitperiod}{}{}{}{}}%
        {{hash=4666719f28c34e4f94e852bc4fc18b8e}{Jaw-Tsai}{J\bibinithyphendelim T\bibinitperiod}{Sarah}{S\bibinitperiod}{}{}{}{}}%
        {{hash=67b202c72147e9c0a41f943ef7d2da50}{Raponi}{R\bibinitperiod}{Mitch}{M\bibinitperiod}{}{}{}{}}%
        {{hash=f5efe5ccfcb886b6e498c802a46ec7ec}{{Van\bibnamedelimb Dyke}}{V\bibinitperiod}{Terry}{T\bibinitperiod}{}{}{}{}}%
        {{hash=841fb4e62a9a5d592b9e89194f7b13aa}{Etter}{E\bibinitperiod}{Jeff}{J\bibinitperiod}{}{}{}{}}%
        {{hash=edc177d9163f251894097883fa6a592f}{Weaver}{W\bibinitperiod}{Zoe}{Z\bibinitperiod}{}{}{}{}}%
        {{hash=1f9445cbbdbb17a9eb7353afdab8a763}{Pao}{P\bibinitperiod}{William}{W\bibinitperiod}{}{}{}{}}%
        {{hash=ba7cc9c093b23938d671bf86afa5b3fd}{Singh}{S\bibinitperiod}{Juswinder}{J\bibinitperiod}{}{}{}{}}%
        {{hash=60be570203dbd7412e376dc3051fce5f}{Simmons}{S\bibinitperiod}{Andrew\bibnamedelima D}{A\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=5d71d3960f01caa4ecafb3fcf8986f1d}{Harding}{H\bibinitperiod}{Thomas\bibnamedelima C}{T\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=d2c136ce91bb9434800c7bbb5529e412}{Allen}{A\bibinitperiod}{Andrew}{A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{30}{}{%
        {{hash=cca789921c494236ec14c7db5c2878fc}{Walter}{W\bibinitperiod}{Annette\bibnamedelima O}{A\bibinitperiod\bibinitdelim O\bibinitperiod}{}{}{}{}}%
        {{hash=cf677020cb59ee903228bd940483f261}{Sjin}{S\bibinitperiod}{Robert\bibnamedelimb Tjin\bibnamedelima Tham}{R\bibinitperiod\bibinitdelim T\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=6c5b4f554b577226a962e927ad4b196d}{Haringsma}{H\bibinitperiod}{Henry\bibnamedelima J}{H\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=bf7ffa68555d1660e1f6f0dcdf1a38e2}{Ohashi}{O\bibinitperiod}{Kadoaki}{K\bibinitperiod}{}{}{}{}}%
        {{hash=65ea74598909191bc1e0ad5a2d66e922}{Sun}{S\bibinitperiod}{Jing}{J\bibinitperiod}{}{}{}{}}%
        {{hash=bfe1058ef5492d64f1e0f193c736faa8}{Lee}{L\bibinitperiod}{Kwangho}{K\bibinitperiod}{}{}{}{}}%
        {{hash=f0e5e463196c34f4b907df07394a20df}{Dubrovskiy}{D\bibinitperiod}{Aleksandr}{A\bibinitperiod}{}{}{}{}}%
        {{hash=5cbdfca8ebe0f2869d00f9107338bcdc}{Labenski}{L\bibinitperiod}{Matthew}{M\bibinitperiod}{}{}{}{}}%
        {{hash=ba72e8d8a8abe30d9d20832861803a72}{Zhu}{Z\bibinitperiod}{Zhendong}{Z\bibinitperiod}{}{}{}{}}%
        {{hash=9f4446a6d583221d3d173f806ecf8627}{Wang}{W\bibinitperiod}{Zhigang}{Z\bibinitperiod}{}{}{}{}}%
        {{hash=317a92fa1f91c6949eb2bcdb302df34c}{Sheets}{S\bibinitperiod}{Michael}{M\bibinitperiod}{}{}{}{}}%
        {{hash=8fd09416626a0e5bd54a542296e3cc02}{{St\bibnamedelimb Martin}}{S\bibinitperiod}{Thia}{T\bibinitperiod}{}{}{}{}}%
        {{hash=d320eb9999cfa2b9ca9eada10017fc88}{Karp}{K\bibinitperiod}{Russell}{R\bibinitperiod}{}{}{}{}}%
        {{hash=32a6fa3fb0519b0f2ad00732902c571c}{Kalken}{K\bibinitperiod}{Dan}{D\bibinitperiod}{van}{v\bibinitperiod}{}{}}%
        {{hash=74e8771eabf644b9966df55877434537}{Chaturvedi}{C\bibinitperiod}{Prasoon}{P\bibinitperiod}{}{}{}{}}%
        {{hash=ab6c13a43e4a88eadf82c6c7aaf2976e}{Niu}{N\bibinitperiod}{Deqiang}{D\bibinitperiod}{}{}{}{}}%
        {{hash=230219635bc09a341b8b87210877a101}{Nacht}{N\bibinitperiod}{Mariana}{M\bibinitperiod}{}{}{}{}}%
        {{hash=f048e1809ed2d21d092a20d30987b9ab}{Petter}{P\bibinitperiod}{Russell\bibnamedelima C}{R\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=4e88a62d4f3a7f529b3c5a77a2c5a2d8}{Westlin}{W\bibinitperiod}{William}{W\bibinitperiod}{}{}{}{}}%
        {{hash=68434cdeb7a3c089fd99baba0e0a4a3b}{Lin}{L\bibinitperiod}{Kevin}{K\bibinitperiod}{}{}{}{}}%
        {{hash=4666719f28c34e4f94e852bc4fc18b8e}{Jaw-Tsai}{J\bibinithyphendelim T\bibinitperiod}{Sarah}{S\bibinitperiod}{}{}{}{}}%
        {{hash=67b202c72147e9c0a41f943ef7d2da50}{Raponi}{R\bibinitperiod}{Mitch}{M\bibinitperiod}{}{}{}{}}%
        {{hash=f5efe5ccfcb886b6e498c802a46ec7ec}{{Van\bibnamedelimb Dyke}}{V\bibinitperiod}{Terry}{T\bibinitperiod}{}{}{}{}}%
        {{hash=841fb4e62a9a5d592b9e89194f7b13aa}{Etter}{E\bibinitperiod}{Jeff}{J\bibinitperiod}{}{}{}{}}%
        {{hash=edc177d9163f251894097883fa6a592f}{Weaver}{W\bibinitperiod}{Zoe}{Z\bibinitperiod}{}{}{}{}}%
        {{hash=1f9445cbbdbb17a9eb7353afdab8a763}{Pao}{P\bibinitperiod}{William}{W\bibinitperiod}{}{}{}{}}%
        {{hash=ba7cc9c093b23938d671bf86afa5b3fd}{Singh}{S\bibinitperiod}{Juswinder}{J\bibinitperiod}{}{}{}{}}%
        {{hash=60be570203dbd7412e376dc3051fce5f}{Simmons}{S\bibinitperiod}{Andrew\bibnamedelima D}{A\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=5d71d3960f01caa4ecafb3fcf8986f1d}{Harding}{H\bibinitperiod}{Thomas\bibnamedelima C}{T\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=d2c136ce91bb9434800c7bbb5529e412}{Allen}{A\bibinitperiod}{Andrew}{A\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{3d4581139d53d7d61cf2c68faa01469b}
      \strng{fullhash}{0f0805436004ca10cc2cb6cc18dd3b53}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC}}
      \field{abstract}{Patients with non--small cell lung cancer (NSCLC) with activating EGF receptor (EGFR) mutations initially respond to first-generation reversible EGFR tyrosine kinase inhibitors. However, clinical efficacy is limited by acquired resistance, frequently driven by the EGFRT790M mutation. CO-1686 is a novel, irreversible, and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR, including T790M, while exhibiting minimal activity toward the wild-type (WT) receptor. Oral administration of CO-1686 as single agent induces tumor regression in EGFR-mutated NSCLC tumor xenograft and transgenic models. Minimal activity of CO-1686 against the WT EGFR receptor was observed. In NSCLC cells with acquired resistance to CO-1686 in vitro, there was no evidence of additional mutations or amplification of the EGFR gene, but resistant cells exhibited signs of epithelial--mesenchymal transition and demonstrated increased sensitivity to AKT inhibitors. These results suggest that CO-1686 may offer a novel therapeutic option for patients with mutant EGFR NSCLC.Significance: We report the preclinical development of a novel covalent inhibitor, CO-1686, that irreversibly and selectively inhibits mutant EGFR, in particular the T790M drug-resistance mutation, in NSCLC models. CO-1686 is the first drug of its class in clinical development for the treatment of T790M-positive NSCLC, potentially offering potent inhibition of mutant EGFR while avoiding the on-target toxicity observed with inhibition of the WT EGFR. Cancer Discov; 3(12); 1404--15. {{$\copyright$}}2013 AACR.This article is highlighted in the In This Issue feature, p. 1317}
      \field{annotation}{10.1158/2159-8290.CD-13-0314}
      \field{journaltitle}{Cancer Discovery}
      \field{month}{12}
      \field{number}{12}
      \field{title}{{Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC}}
      \field{volume}{3}
      \field{year}{2013}
      \field{pages}{1404\bibrangedash 1415}
      \verb{doi}
      \verb 10.1158/2159-8290.CD-13-0314
      \endverb
      \verb{url}
      \verb http://cancerdiscovery.aacrjournals.org/content/3/12/1404.abstract
      \endverb
    \endentry
    \entry{Cross2014}{article}{}
      \name{labelname}{26}{}{%
        {{hash=730caf584e659bb8c7b2cdb21a2ff85d}{Cross}{C\bibinitperiod}{Darren\bibnamedelimb A\bibnamedelima E}{D\bibinitperiod\bibinitdelim A\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=e6f89ccdf09de3450bd4678c362348b7}{Ashton}{A\bibinitperiod}{Susan\bibnamedelima E}{S\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=bfb954977cc0afc320caed7d1cdd92ec}{Ghiorghiu}{G\bibinitperiod}{Serban}{S\bibinitperiod}{}{}{}{}}%
        {{hash=b7cd7e931130b100968ab68e7990179f}{Eberlein}{E\bibinitperiod}{Cath}{C\bibinitperiod}{}{}{}{}}%
        {{hash=b1f53e50947052b0dd53ab4c54700f39}{Nebhan}{N\bibinitperiod}{Caroline\bibnamedelima A}{C\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=07f181f03d9209e0bd608cb46864ed93}{Spitzler}{S\bibinitperiod}{Paula\bibnamedelima J}{P\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=4be7ed8315ea23f658c28349ee55a98a}{Orme}{O\bibinitperiod}{Jonathon\bibnamedelima P}{J\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=e47976f1fe8587c931d63fb1814246a6}{Finlay}{F\bibinitperiod}{M\bibnamedelima Raymond\bibnamedelima V}{M\bibinitperiod\bibinitdelim R\bibinitperiod\bibinitdelim V\bibinitperiod}{}{}{}{}}%
        {{hash=bbf0958ea69ace728ec58e0199b72027}{Ward}{W\bibinitperiod}{Richard\bibnamedelima A}{R\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=5314d8131e9a6633cb2ac83521f7ce03}{Mellor}{M\bibinitperiod}{Martine\bibnamedelima J}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=0c9e04c7b5619196867412acc6ee5817}{Hughes}{H\bibinitperiod}{Gareth}{G\bibinitperiod}{}{}{}{}}%
        {{hash=30e3b5e08e476aa6ede3ad8c7fb7caed}{Rahi}{R\bibinitperiod}{Amar}{A\bibinitperiod}{}{}{}{}}%
        {{hash=f2804395ed5443db24e7009f329c591f}{Jacobs}{J\bibinitperiod}{Vivien\bibnamedelima N}{V\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
        {{hash=1c2895c17d684dfbb5f680286e6481ab}{Brewer}{B\bibinitperiod}{Monica\bibnamedelima Red}{M\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=a5a098895ee1f55efcfcd84e6320b4fc}{Ichihara}{I\bibinitperiod}{Eiki}{E\bibinitperiod}{}{}{}{}}%
        {{hash=65ea74598909191bc1e0ad5a2d66e922}{Sun}{S\bibinitperiod}{Jing}{J\bibinitperiod}{}{}{}{}}%
        {{hash=46869c5054f2de0c51621d9b60bab602}{Jin}{J\bibinitperiod}{Hailing}{H\bibinitperiod}{}{}{}{}}%
        {{hash=c4395e579ca44aaced064425a258dbf3}{Ballard}{B\bibinitperiod}{Peter}{P\bibinitperiod}{}{}{}{}}%
        {{hash=f8e5d2280281be9b381647bab8a611e6}{Al-Kadhimi}{A\bibinithyphendelim K\bibinitperiod}{Katherine}{K\bibinitperiod}{}{}{}{}}%
        {{hash=baf2684715e4619413119a2f21224c2a}{Rowlinson}{R\bibinitperiod}{Rachel}{R\bibinitperiod}{}{}{}{}}%
        {{hash=bad48efd2b68f1a54ec4f11cded655bb}{Klinowska}{K\bibinitperiod}{Teresa}{T\bibinitperiod}{}{}{}{}}%
        {{hash=df2cf1b98d260362cf694cd3e6461184}{Richmond}{R\bibinitperiod}{Graham\bibnamedelimb H\bibnamedelima P}{G\bibinitperiod\bibinitdelim H\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=c2bfc744d84c6bd9ec7d9f83404255fd}{Cantarini}{C\bibinitperiod}{Mireille}{M\bibinitperiod}{}{}{}{}}%
        {{hash=d2229394934f5465cb16aa426b2fd68c}{Kim}{K\bibinitperiod}{Dong-Wan}{D\bibinithyphendelim W\bibinitperiod}{}{}{}{}}%
        {{hash=7cbad32221d61c4cd3aaded9d5222573}{Ranson}{R\bibinitperiod}{Malcolm\bibnamedelima R}{M\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=1f9445cbbdbb17a9eb7353afdab8a763}{Pao}{P\bibinitperiod}{William}{W\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{26}{}{%
        {{hash=730caf584e659bb8c7b2cdb21a2ff85d}{Cross}{C\bibinitperiod}{Darren\bibnamedelimb A\bibnamedelima E}{D\bibinitperiod\bibinitdelim A\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=e6f89ccdf09de3450bd4678c362348b7}{Ashton}{A\bibinitperiod}{Susan\bibnamedelima E}{S\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=bfb954977cc0afc320caed7d1cdd92ec}{Ghiorghiu}{G\bibinitperiod}{Serban}{S\bibinitperiod}{}{}{}{}}%
        {{hash=b7cd7e931130b100968ab68e7990179f}{Eberlein}{E\bibinitperiod}{Cath}{C\bibinitperiod}{}{}{}{}}%
        {{hash=b1f53e50947052b0dd53ab4c54700f39}{Nebhan}{N\bibinitperiod}{Caroline\bibnamedelima A}{C\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=07f181f03d9209e0bd608cb46864ed93}{Spitzler}{S\bibinitperiod}{Paula\bibnamedelima J}{P\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=4be7ed8315ea23f658c28349ee55a98a}{Orme}{O\bibinitperiod}{Jonathon\bibnamedelima P}{J\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=e47976f1fe8587c931d63fb1814246a6}{Finlay}{F\bibinitperiod}{M\bibnamedelima Raymond\bibnamedelima V}{M\bibinitperiod\bibinitdelim R\bibinitperiod\bibinitdelim V\bibinitperiod}{}{}{}{}}%
        {{hash=bbf0958ea69ace728ec58e0199b72027}{Ward}{W\bibinitperiod}{Richard\bibnamedelima A}{R\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=5314d8131e9a6633cb2ac83521f7ce03}{Mellor}{M\bibinitperiod}{Martine\bibnamedelima J}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=0c9e04c7b5619196867412acc6ee5817}{Hughes}{H\bibinitperiod}{Gareth}{G\bibinitperiod}{}{}{}{}}%
        {{hash=30e3b5e08e476aa6ede3ad8c7fb7caed}{Rahi}{R\bibinitperiod}{Amar}{A\bibinitperiod}{}{}{}{}}%
        {{hash=f2804395ed5443db24e7009f329c591f}{Jacobs}{J\bibinitperiod}{Vivien\bibnamedelima N}{V\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
        {{hash=1c2895c17d684dfbb5f680286e6481ab}{Brewer}{B\bibinitperiod}{Monica\bibnamedelima Red}{M\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=a5a098895ee1f55efcfcd84e6320b4fc}{Ichihara}{I\bibinitperiod}{Eiki}{E\bibinitperiod}{}{}{}{}}%
        {{hash=65ea74598909191bc1e0ad5a2d66e922}{Sun}{S\bibinitperiod}{Jing}{J\bibinitperiod}{}{}{}{}}%
        {{hash=46869c5054f2de0c51621d9b60bab602}{Jin}{J\bibinitperiod}{Hailing}{H\bibinitperiod}{}{}{}{}}%
        {{hash=c4395e579ca44aaced064425a258dbf3}{Ballard}{B\bibinitperiod}{Peter}{P\bibinitperiod}{}{}{}{}}%
        {{hash=f8e5d2280281be9b381647bab8a611e6}{Al-Kadhimi}{A\bibinithyphendelim K\bibinitperiod}{Katherine}{K\bibinitperiod}{}{}{}{}}%
        {{hash=baf2684715e4619413119a2f21224c2a}{Rowlinson}{R\bibinitperiod}{Rachel}{R\bibinitperiod}{}{}{}{}}%
        {{hash=bad48efd2b68f1a54ec4f11cded655bb}{Klinowska}{K\bibinitperiod}{Teresa}{T\bibinitperiod}{}{}{}{}}%
        {{hash=df2cf1b98d260362cf694cd3e6461184}{Richmond}{R\bibinitperiod}{Graham\bibnamedelimb H\bibnamedelima P}{G\bibinitperiod\bibinitdelim H\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=c2bfc744d84c6bd9ec7d9f83404255fd}{Cantarini}{C\bibinitperiod}{Mireille}{M\bibinitperiod}{}{}{}{}}%
        {{hash=d2229394934f5465cb16aa426b2fd68c}{Kim}{K\bibinitperiod}{Dong-Wan}{D\bibinithyphendelim W\bibinitperiod}{}{}{}{}}%
        {{hash=7cbad32221d61c4cd3aaded9d5222573}{Ranson}{R\bibinitperiod}{Malcolm\bibnamedelima R}{M\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=1f9445cbbdbb17a9eb7353afdab8a763}{Pao}{P\bibinitperiod}{William}{W\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{697190affcef5e8252710cdce4259277}
      \strng{fullhash}{177280f9b627870fec550c1f70fbce25}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer}}
      \field{abstract}{First generation EGF receptor tyrosine kinase inhibitors (EGFR TKIs) provide significant clinical benefit in patients with advanced EGFR mutant (EGFRm+) non-small cell lung cancer (NSCLC). Patients ultimately develop disease progression, often driven by acquisition of a second T790M EGFR TKI resistance mutation. AZD9291 is a novel oral, potent and selective third generation irreversible inhibitor of both EGFRm+ sensitizing and T790M resistance mutants that spares wild-type EGFR. This monoanilino-pyrimidine compound is structurally distinct from other third generation EGFR TKIs and offers a pharmacologically differentiated profile from earlier generation EGFR TKIs. Pre-clinically, the drug potently inhibits signaling pathways and cellular growth in both EGFRm+ and EGFRm+/T790M mutant cell lines in vitro, with lower activity against wild-type EGFR lines, translating into profound and sustained tumor regression in EGFR mutant tumor xenograft and transgenic models. The treatment of two patients with advanced EGFRm T790M+ NSCLC is described as proof of principle.}
      \field{issn}{2159-8274}
      \field{journaltitle}{Cancer discovery}
      \field{month}{09}
      \field{number}{9}
      \field{title}{{AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer}}
      \field{volume}{4}
      \field{year}{2014}
      \field{pages}{1046\bibrangedash 1061}
      \verb{doi}
      \verb 10.1158/2159-8290.CD-14-0337
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315625/
      \endverb
    \endentry
    \entry{Ercan2015}{article}{}
      \name{labelname}{8}{}{%
        {{hash=808dd167f023b8edc89c9fa87362ad69}{Ercan}{E\bibinitperiod}{Dalia}{D\bibinitperiod}{}{}{}{}}%
        {{hash=1ec3602d84fa696e9d0277bed04f6485}{Choi}{C\bibinitperiod}{Hwan\bibnamedelima Geun}{H\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=c6ba104fde2bb4aba691518a73c8ae34}{Yun}{Y\bibinitperiod}{Cai-Hong}{C\bibinithyphendelim H\bibinitperiod}{}{}{}{}}%
        {{hash=c09d676ff94346afdb4de7d73029253c}{Capelletti}{C\bibinitperiod}{Marzia}{M\bibinitperiod}{}{}{}{}}%
        {{hash=141eee66b6dff86df5d983d145e98b14}{Xie}{X\bibinitperiod}{Ting}{T\bibinitperiod}{}{}{}{}}%
        {{hash=17a71501a921f463a4ec3f0da1ce20b0}{Eck}{E\bibinitperiod}{Michael\bibnamedelima J}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=fabe6c6461e55d2d47e6c8fb604e93f8}{Gray}{G\bibinitperiod}{Nathanael\bibnamedelima S}{N\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=ad239ed98ae02c67ea857442596c2084}{J{\"{a}}nne}{J\bibinitperiod}{Pasi\bibnamedelima A}{P\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{8}{}{%
        {{hash=808dd167f023b8edc89c9fa87362ad69}{Ercan}{E\bibinitperiod}{Dalia}{D\bibinitperiod}{}{}{}{}}%
        {{hash=1ec3602d84fa696e9d0277bed04f6485}{Choi}{C\bibinitperiod}{Hwan\bibnamedelima Geun}{H\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=c6ba104fde2bb4aba691518a73c8ae34}{Yun}{Y\bibinitperiod}{Cai-Hong}{C\bibinithyphendelim H\bibinitperiod}{}{}{}{}}%
        {{hash=c09d676ff94346afdb4de7d73029253c}{Capelletti}{C\bibinitperiod}{Marzia}{M\bibinitperiod}{}{}{}{}}%
        {{hash=141eee66b6dff86df5d983d145e98b14}{Xie}{X\bibinitperiod}{Ting}{T\bibinitperiod}{}{}{}{}}%
        {{hash=17a71501a921f463a4ec3f0da1ce20b0}{Eck}{E\bibinitperiod}{Michael\bibnamedelima J}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=fabe6c6461e55d2d47e6c8fb604e93f8}{Gray}{G\bibinitperiod}{Nathanael\bibnamedelima S}{N\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=ad239ed98ae02c67ea857442596c2084}{J{\"{a}}nne}{J\bibinitperiod}{Pasi\bibnamedelima A}{P\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{6d089ab0a02f4ec52a6769af8e9be120}
      \strng{fullhash}{5ae70d9fb45ded5c9f2de36a991b8521}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors}}
      \field{abstract}{Purpose: Mutant selective irreversible pyrimidine-based EGFR kinase inhibitors, including WZ4002, CO-1686, and AZD9291, are effective in preclinical models and in lung cancer patients harboring the EGFR T790M gefitinib/erlotinib resistance mutation. However, little is known about how cancers develop acquired resistance to this class of EGFR inhibitors. We sought to identify and study EGFR mutations that confer resistance to this class of agents.Experimental Design: We performed an N-ethyl-N-nitrosourea (ENU) mutagenesis screen in EGFR-mutant (sensitizing alone or with concurrent EGFR T790M) Ba/F3 cells and selected drug-resistant clones. We evaluated the sensitivity of EGFR inhibitors in models harboring drug-resistant EGFR mutations.Results: We identified 3 major drug resistance mutations. EGFR L718Q, L844V, and C797S cause resistance to both WZ4002 and CO-1686 while, in contrast, only EGFR C797S leads to AZD9291 resistance. Cells containing an EGFR-sensitizing mutation, Del 19 or L858R, in conjunction with L718Q, L844V, or C797S retain sensitivity to quinazoline-based EGFR inhibitors, gefitinib and afatinib. The C797S mutation, in the presence of Del 19 or L858R and T790M, causes resistance to all current EGFR inhibitors, but L858R/T790M/C797S remains partially sensitive to cetuximab which leads to disruption of EGFR dimerization.Conclusions: Our findings provide insights into resistance mechanisms to irreversible pyrimidine-based EGFR inhibitors and identify specific genomic contexts in which sensitivity is retained to existing clinical EGFR inhibitors. These findings will guide the development of new strategies to inhibit EGFR. Clin Cancer Res; 21(17); 3913--23. {{$\copyright$}}2015 AACR.See related commentary by Ayeni et al., p. 3818}
      \field{journaltitle}{American Association for Cancer Research}
      \field{month}{08}
      \field{number}{17}
      \field{title}{{EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors}}
      \field{volume}{21}
      \field{year}{2015}
      \field{pages}{3913\bibrangedash 3923}
      \verb{url}
      \verb http://clincancerres.aacrjournals.org/content/21/17/3913.abstract
      \endverb
    \endentry
    \entry{Doebele2012}{article}{}
      \name{labelname}{12}{}{%
        {{hash=f892e20c7878cac4291dda2df8fbdef5}{Doebele}{D\bibinitperiod}{Robert\bibnamedelima C}{R\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=216659548df74f70e7a623d2446cb70d}{Pilling}{P\bibinitperiod}{Amanda\bibnamedelima B}{A\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=baf1d10fe98ea3a7760799186bf079de}{Aisner}{A\bibinitperiod}{Dara\bibnamedelima L}{D\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=dd1f8f0af2081da6eb220367e77eb810}{Kutateladze}{K\bibinitperiod}{Tatiana\bibnamedelima G}{T\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=bcf6cfac0921c31fa4fa843326ff1e53}{Le}{L\bibinitperiod}{Anh\bibnamedelima T}{A\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=e954de5d35aaa129ef458465cceb1e60}{Weickhardt}{W\bibinitperiod}{Andrew\bibnamedelima J}{A\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=38b6ded2c677b77673850a6ab04a0a74}{Kondo}{K\bibinitperiod}{Kimi\bibnamedelima L}{K\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=83c192b18189cdb1cf5950da79bd6e5c}{Linderman}{L\bibinitperiod}{Derek}{D\bibinitperiod}{}{}{}{}}%
        {{hash=c8cc87dc86b444764638b45566c27fde}{Heasley}{H\bibinitperiod}{Lynn\bibnamedelima E}{L\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=d11bb39ad713123dd66c6ed6e58e3631}{Franklin}{F\bibinitperiod}{Wilbur\bibnamedelima A}{W\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=3e77a7f396c134c410c592e1702ebe5f}{Varella-Garcia}{V\bibinithyphendelim G\bibinitperiod}{Marileila}{M\bibinitperiod}{}{}{}{}}%
        {{hash=84655618e0bd5c0cc9da2cfa927b74a2}{Camidge}{C\bibinitperiod}{D\bibnamedelima Ross}{D\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{12}{}{%
        {{hash=f892e20c7878cac4291dda2df8fbdef5}{Doebele}{D\bibinitperiod}{Robert\bibnamedelima C}{R\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=216659548df74f70e7a623d2446cb70d}{Pilling}{P\bibinitperiod}{Amanda\bibnamedelima B}{A\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=baf1d10fe98ea3a7760799186bf079de}{Aisner}{A\bibinitperiod}{Dara\bibnamedelima L}{D\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=dd1f8f0af2081da6eb220367e77eb810}{Kutateladze}{K\bibinitperiod}{Tatiana\bibnamedelima G}{T\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=bcf6cfac0921c31fa4fa843326ff1e53}{Le}{L\bibinitperiod}{Anh\bibnamedelima T}{A\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=e954de5d35aaa129ef458465cceb1e60}{Weickhardt}{W\bibinitperiod}{Andrew\bibnamedelima J}{A\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=38b6ded2c677b77673850a6ab04a0a74}{Kondo}{K\bibinitperiod}{Kimi\bibnamedelima L}{K\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=83c192b18189cdb1cf5950da79bd6e5c}{Linderman}{L\bibinitperiod}{Derek}{D\bibinitperiod}{}{}{}{}}%
        {{hash=c8cc87dc86b444764638b45566c27fde}{Heasley}{H\bibinitperiod}{Lynn\bibnamedelima E}{L\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=d11bb39ad713123dd66c6ed6e58e3631}{Franklin}{F\bibinitperiod}{Wilbur\bibnamedelima A}{W\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=3e77a7f396c134c410c592e1702ebe5f}{Varella-Garcia}{V\bibinithyphendelim G\bibinitperiod}{Marileila}{M\bibinitperiod}{}{}{}{}}%
        {{hash=84655618e0bd5c0cc9da2cfa927b74a2}{Camidge}{C\bibinitperiod}{D\bibnamedelima Ross}{D\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{120caf6315ae2e6d57408e32031cd129}
      \strng{fullhash}{7eae89ff4006f12ee9898e9a15623174}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer}}
      \field{abstract}{PURPOSE: Patients with anaplastic lymphoma kinase (ALK) gene rearrangements often manifest dramatic responses to crizotinib, a small molecule ALK inhibitor. Unfortunately, not every patient responds and acquired drug resistance inevitably develops in those that do respond. This study aimed to define molecular mechanisms of resistance to crizotinib in ALK+ non-small cell lung cancer (NSCLC) patients. EXPERIMENTAL DESIGN: We analyzed tissue obtained from 14 ALK+ NSCLC patients demonstrating evidence of radiologic progression while on crizotinib in order to define mechanisms of intrinsic and acquired resistance to crizotinib. RESULTS: Eleven patients had material evaluable for molecular analysis. Four patients (36{\%}) developed secondary mutations in the tyrosine kinase domain of ALK. A novel mutation in the ALK kinase domain, encoding a G1269A amino acid substitution that confers resistance to crizotinib in vitro, was identified in two of these cases. Two patients, one with a resistance mutation, exhibited new onset ALK copy number gain (CNG). One patient demonstrated outgrowth of EGFR mutant NSCLC without evidence of a persistent ALK gene rearrangement. Two patients exhibited a KRAS mutation, one of which occurred without evidence of a persisting ALK gene rearrangement. One patient demonstrated the emergence of an ALK gene fusion negative tumor compared to the baseline sample, but with no identifiable alternate driver. Two patients retained ALK positivity with no identifiable resistance mechanism. CONCLUSIONS: Crizotinib resistance in ALK+ NSCLC occurs through somatic kinase domain mutations, ALK gene fusion CNG, and emergence of separate oncogenic drivers.}
      \field{issn}{1078-0432}
      \field{journaltitle}{Clinical cancer research : an official journal of the American Association for Cancer Research}
      \field{month}{03}
      \field{number}{5}
      \field{title}{{Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer}}
      \field{volume}{18}
      \field{year}{2012}
      \field{pages}{1472\bibrangedash 1482}
      \verb{doi}
      \verb 10.1158/1078-0432.CCR-11-2906
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3311875/
      \endverb
    \endentry
    \entry{Shaw2015}{article}{}
      \name{labelname}{23}{}{%
        {{hash=26810537245ab20bf81e7bc8e77adffb}{Shaw}{S\bibinitperiod}{Alice\bibnamedelima T}{A\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=915aefadf29c81dc868d8a8eca13d1e7}{Friboulet}{F\bibinitperiod}{Luc}{L\bibinitperiod}{}{}{}{}}%
        {{hash=e163f9bc8578bee284cfa1f841c68524}{Leshchiner}{L\bibinitperiod}{Ignaty}{I\bibinitperiod}{}{}{}{}}%
        {{hash=2255d1786ea59311825c0de0a6981b20}{Gainor}{G\bibinitperiod}{Justin\bibnamedelima F}{J\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{hash=d2760dd5145b66f69ed28ac840afa8d7}{Bergqvist}{B\bibinitperiod}{Simon}{S\bibinitperiod}{}{}{}{}}%
        {{hash=7138cc2aaba25ecf23ed78f144293fa0}{Brooun}{B\bibinitperiod}{Alexei}{A\bibinitperiod}{}{}{}{}}%
        {{hash=046a9f5a5e167367d798dda9e8fde3b6}{Burke}{B\bibinitperiod}{Benjamin\bibnamedelima J}{B\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=7ac189797c74a23b96bfd1b112e2a193}{Deng}{D\bibinitperiod}{Ya-Li}{Y\bibinithyphendelim L\bibinitperiod}{}{}{}{}}%
        {{hash=c0e0d23e2d09e45e6f51cc2bcea6d9f9}{Liu}{L\bibinitperiod}{Wei}{W\bibinitperiod}{}{}{}{}}%
        {{hash=6afff24c6bc00877b2c2f81a2decd2bb}{Dardaei}{D\bibinitperiod}{Leila}{L\bibinitperiod}{}{}{}{}}%
        {{hash=4d183c60447231d5bf4e0f5037677953}{Frias}{F\bibinitperiod}{Rosa\bibnamedelima L}{R\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=d560c7653af3480f5acbd25c31689704}{Schultz}{S\bibinitperiod}{Kate\bibnamedelima R}{K\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=503503487c354e1aa8da3e34cfc8f81e}{Logan}{L\bibinitperiod}{Jennifer}{J\bibinitperiod}{}{}{}{}}%
        {{hash=c0019f9fcf669c64ce2bc05be2375ac4}{James}{J\bibinitperiod}{Leonard\bibnamedelima P}{L\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=046ffda9473dee948b6a769a271f034e}{Smeal}{S\bibinitperiod}{Tod}{T\bibinitperiod}{}{}{}{}}%
        {{hash=0e424fe6d9f257edfdf865c3eda64ba3}{Timofeevski}{T\bibinitperiod}{Sergei}{S\bibinitperiod}{}{}{}{}}%
        {{hash=01a8ed53b680160f06cf011f5b4afbdc}{Katayama}{K\bibinitperiod}{Ryohei}{R\bibinitperiod}{}{}{}{}}%
        {{hash=aa9ff97c722ae958e8b5ee11ffe17fe7}{Iafrate}{I\bibinitperiod}{A\bibnamedelima John}{A\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=7cbbab8bcab15c08539869f2516e3198}{Le}{L\bibinitperiod}{Long}{L\bibinitperiod}{}{}{}{}}%
        {{hash=12d296ee4a7efdab147aa264767917d2}{McTigue}{M\bibinitperiod}{Michele}{M\bibinitperiod}{}{}{}{}}%
        {{hash=6aa396b9c7916e3eec93b398e26b1bbf}{Getz}{G\bibinitperiod}{Gad}{G\bibinitperiod}{}{}{}{}}%
        {{hash=d71ca7bb52a670820a0fc3e9b3964fc6}{Johnson}{J\bibinitperiod}{Ted\bibnamedelima W}{T\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=f3074982fe5e4cd63eb33357cd7bfcd4}{Engelman}{E\bibinitperiod}{Jeffrey\bibnamedelima A}{J\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{23}{}{%
        {{hash=26810537245ab20bf81e7bc8e77adffb}{Shaw}{S\bibinitperiod}{Alice\bibnamedelima T}{A\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=915aefadf29c81dc868d8a8eca13d1e7}{Friboulet}{F\bibinitperiod}{Luc}{L\bibinitperiod}{}{}{}{}}%
        {{hash=e163f9bc8578bee284cfa1f841c68524}{Leshchiner}{L\bibinitperiod}{Ignaty}{I\bibinitperiod}{}{}{}{}}%
        {{hash=2255d1786ea59311825c0de0a6981b20}{Gainor}{G\bibinitperiod}{Justin\bibnamedelima F}{J\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{hash=d2760dd5145b66f69ed28ac840afa8d7}{Bergqvist}{B\bibinitperiod}{Simon}{S\bibinitperiod}{}{}{}{}}%
        {{hash=7138cc2aaba25ecf23ed78f144293fa0}{Brooun}{B\bibinitperiod}{Alexei}{A\bibinitperiod}{}{}{}{}}%
        {{hash=046a9f5a5e167367d798dda9e8fde3b6}{Burke}{B\bibinitperiod}{Benjamin\bibnamedelima J}{B\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=7ac189797c74a23b96bfd1b112e2a193}{Deng}{D\bibinitperiod}{Ya-Li}{Y\bibinithyphendelim L\bibinitperiod}{}{}{}{}}%
        {{hash=c0e0d23e2d09e45e6f51cc2bcea6d9f9}{Liu}{L\bibinitperiod}{Wei}{W\bibinitperiod}{}{}{}{}}%
        {{hash=6afff24c6bc00877b2c2f81a2decd2bb}{Dardaei}{D\bibinitperiod}{Leila}{L\bibinitperiod}{}{}{}{}}%
        {{hash=4d183c60447231d5bf4e0f5037677953}{Frias}{F\bibinitperiod}{Rosa\bibnamedelima L}{R\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=d560c7653af3480f5acbd25c31689704}{Schultz}{S\bibinitperiod}{Kate\bibnamedelima R}{K\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=503503487c354e1aa8da3e34cfc8f81e}{Logan}{L\bibinitperiod}{Jennifer}{J\bibinitperiod}{}{}{}{}}%
        {{hash=c0019f9fcf669c64ce2bc05be2375ac4}{James}{J\bibinitperiod}{Leonard\bibnamedelima P}{L\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=046ffda9473dee948b6a769a271f034e}{Smeal}{S\bibinitperiod}{Tod}{T\bibinitperiod}{}{}{}{}}%
        {{hash=0e424fe6d9f257edfdf865c3eda64ba3}{Timofeevski}{T\bibinitperiod}{Sergei}{S\bibinitperiod}{}{}{}{}}%
        {{hash=01a8ed53b680160f06cf011f5b4afbdc}{Katayama}{K\bibinitperiod}{Ryohei}{R\bibinitperiod}{}{}{}{}}%
        {{hash=aa9ff97c722ae958e8b5ee11ffe17fe7}{Iafrate}{I\bibinitperiod}{A\bibnamedelima John}{A\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=7cbbab8bcab15c08539869f2516e3198}{Le}{L\bibinitperiod}{Long}{L\bibinitperiod}{}{}{}{}}%
        {{hash=12d296ee4a7efdab147aa264767917d2}{McTigue}{M\bibinitperiod}{Michele}{M\bibinitperiod}{}{}{}{}}%
        {{hash=6aa396b9c7916e3eec93b398e26b1bbf}{Getz}{G\bibinitperiod}{Gad}{G\bibinitperiod}{}{}{}{}}%
        {{hash=d71ca7bb52a670820a0fc3e9b3964fc6}{Johnson}{J\bibinitperiod}{Ted\bibnamedelima W}{T\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=f3074982fe5e4cd63eb33357cd7bfcd4}{Engelman}{E\bibinitperiod}{Jeffrey\bibnamedelima A}{J\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Massachusetts Medical Society}%
      }
      \strng{namehash}{6a05b6280e2339afbb0c4f5367b76a80}
      \strng{fullhash}{df9598c765f62fb003fd5ae6ada321c7}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F}}
      \field{annotation}{doi: 10.1056/NEJMoa1508887}
      \field{issn}{0028-4793}
      \field{journaltitle}{New England Journal of Medicine}
      \field{month}{12}
      \field{number}{1}
      \field{title}{{Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F}}
      \field{volume}{374}
      \field{year}{2015}
      \field{pages}{54\bibrangedash 61}
      \verb{doi}
      \verb 10.1056/NEJMoa1508887
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1056/NEJMoa1508887
      \endverb
    \endentry
    \entry{Wu2016}{article}{}
      \name{labelname}{3}{}{%
        {{hash=f16c2583d9abd02d089eb43170a7c6c3}{Wu}{W\bibinitperiod}{Jingjing}{J\bibinitperiod}{}{}{}{}}%
        {{hash=bcc5f6dee5c229c5ef57f91d6303ad98}{Savooji}{S\bibinitperiod}{John}{J\bibinitperiod}{}{}{}{}}%
        {{hash=60c6c6c68cab254f94d65859f51062e6}{Liu}{L\bibinitperiod}{Delong}{D\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=f16c2583d9abd02d089eb43170a7c6c3}{Wu}{W\bibinitperiod}{Jingjing}{J\bibinitperiod}{}{}{}{}}%
        {{hash=bcc5f6dee5c229c5ef57f91d6303ad98}{Savooji}{S\bibinitperiod}{John}{J\bibinitperiod}{}{}{}{}}%
        {{hash=60c6c6c68cab254f94d65859f51062e6}{Liu}{L\bibinitperiod}{Delong}{D\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{d2cb8568e7de25d94074687c187de256}
      \strng{fullhash}{d2cb8568e7de25d94074687c187de256}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Second- and third-generation ALK inhibitors for non-small cell lung cancer}}
      \field{abstract}{Crizotinib as the first-generation ALK inhibitor has shown significant activity in ALK-mutated non-small cell lung cancer (NSCLC). Second- and third-generation ALK inhibitors are entering clinical applications for ALK+ NSCLC. In addition, a third-generation ALK inhibitor, lorlatinib (PF-06463922), was reported to resensitize NSCLC to crizotinib. This review provided a summary of clinical development of alectinib, ceritinib, brigatinib (AP26113), and lorlatinib.}
      \field{issn}{1756-8722}
      \field{journaltitle}{Journal of Hematology {\{}{\&}{\}} Oncology}
      \field{number}{1}
      \field{title}{{Second- and third-generation ALK inhibitors for non-small cell lung cancer}}
      \field{volume}{9}
      \field{year}{2016}
      \field{pages}{1\bibrangedash 7}
      \verb{doi}
      \verb 10.1186/s13045-016-0251-8
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1186/s13045-016-0251-8
      \endverb
    \endentry
    \entry{Burrell2014}{article}{}
      \name{labelname}{2}{}{%
        {{hash=0f242162379eb537f3b68ff29dd5c3ee}{Burrell}{B\bibinitperiod}{Rebecca\bibnamedelima a.}{R\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
        {{hash=41ddb60dd242de6b2d07fa4624f293ee}{Swanton}{S\bibinitperiod}{Charles}{C\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=0f242162379eb537f3b68ff29dd5c3ee}{Burrell}{B\bibinitperiod}{Rebecca\bibnamedelima a.}{R\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
        {{hash=41ddb60dd242de6b2d07fa4624f293ee}{Swanton}{S\bibinitperiod}{Charles}{C\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Elsevier B.V}%
      }
      \strng{namehash}{3683470ab6043aa378f3628065fcaf57}
      \strng{fullhash}{3683470ab6043aa378f3628065fcaf57}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Tumour heterogeneity and the evolution of polyclonal drug resistance}}
      \field{abstract}{Cancer drug resistance is a major problem, with the majority of patients with metastatic disease ultimately developing multidrug resistance and succumbing to their disease. Our understanding of molecular events underpinning treatment failure has been enhanced by new genomic technologies and pre-clinical studies. Intratumour genetic heterogeneity (ITH) is a prominent contributor to therapeutic failure, and it is becoming increasingly apparent that individual tumours may achieve resistance via multiple routes simultaneously - termed polyclonal resistance. Efforts to target single resistance mechanisms to overcome therapeutic failure may therefore yield only limited success. Clinical studies with sequential analysis of tumour material are needed to enhance our understanding of inter-clonal functional relationships and tumour evolution during therapy, and to improve drug development strategies in cancer medicine. {{$\copyright$}} 2014 Federation of European Biochemical Societies.}
      \field{isbn}{1878-0261 (Electronic) 1574-7891 (Linking)}
      \field{issn}{15747891}
      \field{journaltitle}{Molecular Oncology}
      \field{number}{6}
      \field{title}{{Tumour heterogeneity and the evolution of polyclonal drug resistance}}
      \field{volume}{8}
      \field{year}{2014}
      \field{pages}{1095\bibrangedash 1111}
      \verb{doi}
      \verb 10.1016/j.molonc.2014.06.005
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/1-s2.0-S157478911400129X-main.pdf:pdf
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1016/j.molonc.2014.06.005
      \endverb
    \endentry
    \entry{Cortes2016}{article}{}
      \name{labelname}{2}{}{%
        {{hash=e6c0605ffc29f41e440d2bfa79a33019}{Cortes}{C\bibinitperiod}{Javier}{J\bibinitperiod}{}{}{}{}}%
        {{hash=694e773657fa47f470964c25a884a0b0}{Roch{\'{e}}}{R\bibinitperiod}{Henri}{H\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=e6c0605ffc29f41e440d2bfa79a33019}{Cortes}{C\bibinitperiod}{Javier}{J\bibinitperiod}{}{}{}{}}%
        {{hash=694e773657fa47f470964c25a884a0b0}{Roch{\'{e}}}{R\bibinitperiod}{Henri}{H\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Elsevier}%
      }
      \strng{namehash}{ff279e9ef02c0ba92429875e73b5402a}
      \strng{fullhash}{ff279e9ef02c0ba92429875e73b5402a}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Docetaxel combined with targeted therapies in metastatic breast cancer}}
      \field{annotation}{doi: 10.1016/j.ctrv.2011.08.001}
      \field{issn}{0305-7372}
      \field{journaltitle}{Cancer Treatment Reviews}
      \field{month}{07}
      \field{number}{5}
      \field{title}{{Docetaxel combined with targeted therapies in metastatic breast cancer}}
      \field{volume}{38}
      \field{year}{2016}
      \field{pages}{387\bibrangedash 396}
      \verb{doi}
      \verb 10.1016/j.ctrv.2011.08.001
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1016/j.ctrv.2011.08.001
      \endverb
    \endentry
    \entry{Vanneman2012}{article}{}
      \name{labelname}{2}{}{%
        {{hash=46f8ff0cb7dd578f72e1e8927d67d160}{Vanneman}{V\bibinitperiod}{Matthew}{M\bibinitperiod}{}{}{}{}}%
        {{hash=080baedac5a0a38b397977f2e21dd992}{Dranoff}{D\bibinitperiod}{Glenn}{G\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=46f8ff0cb7dd578f72e1e8927d67d160}{Vanneman}{V\bibinitperiod}{Matthew}{M\bibinitperiod}{}{}{}{}}%
        {{hash=080baedac5a0a38b397977f2e21dd992}{Dranoff}{D\bibinitperiod}{Glenn}{G\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.}%
      }
      \strng{namehash}{863ab2bf4acd5fca5370190f970254af}
      \strng{fullhash}{863ab2bf4acd5fca5370190f970254af}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Combining immunotherapy and targeted therapies in cancer treatment}}
      \field{annotation}{10.1038/nrc3237}
      \field{issn}{1474-175X}
      \field{journaltitle}{Nat Rev Cancer}
      \field{month}{04}
      \field{number}{4}
      \field{title}{{Combining immunotherapy and targeted therapies in cancer treatment}}
      \field{volume}{12}
      \field{year}{2012}
      \field{pages}{237\bibrangedash 251}
      \verb{url}
      \verb http://dx.doi.org/10.1038/nrc3237
      \endverb
    \endentry
    \entry{Al-Lazikani2012}{article}{}
      \name{labelname}{3}{}{%
        {{hash=6c2de189b3311c216fbbd5bfb9f79020}{Al-Lazikani}{A\bibinithyphendelim L\bibinitperiod}{Bissan}{B\bibinitperiod}{}{}{}{}}%
        {{hash=ec9ac9b8c704d8f7877d547d357f8519}{Banerji}{B\bibinitperiod}{Udai}{U\bibinitperiod}{}{}{}{}}%
        {{hash=82e2e3df21abbbdbbcb18fa631e52f4c}{Workman}{W\bibinitperiod}{Paul}{P\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=6c2de189b3311c216fbbd5bfb9f79020}{Al-Lazikani}{A\bibinithyphendelim L\bibinitperiod}{Bissan}{B\bibinitperiod}{}{}{}{}}%
        {{hash=ec9ac9b8c704d8f7877d547d357f8519}{Banerji}{B\bibinitperiod}{Udai}{U\bibinitperiod}{}{}{}{}}%
        {{hash=82e2e3df21abbbdbbcb18fa631e52f4c}{Workman}{W\bibinitperiod}{Paul}{P\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group}%
      }
      \strng{namehash}{1edc8eb6018e1b2d6c574787701a2abd}
      \strng{fullhash}{1edc8eb6018e1b2d6c574787701a2abd}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Combinatorial drug therapy for cancer in the post-genomic era.}}
      \field{abstract}{Over the past decade, whole genome sequencing and other 'omics' technologies have defined pathogenic driver mutations to which tumor cells are addicted. Such addictions, synthetic lethalities and other tumor vulnerabilities have yielded novel targets for a new generation of cancer drugs to treat discrete, genetically defined patient subgroups. This personalized cancer medicine strategy could eventually replace the conventional one-size-fits-all cytotoxic chemotherapy approach. However, the extraordinary intratumor genetic heterogeneity in cancers revealed by deep sequencing explains why de novo and acquired resistance arise with molecularly targeted drugs and cytotoxic chemotherapy, limiting their utility. One solution to the enduring challenge of polygenic cancer drug resistance is rational combinatorial targeted therapy.}
      \field{issn}{1546-1696}
      \field{journaltitle}{Nature biotechnology}
      \field{month}{07}
      \field{number}{7}
      \field{title}{{Combinatorial drug therapy for cancer in the post-genomic era.}}
      \field{volume}{30}
      \field{year}{2012}
      \field{pages}{679\bibrangedash 92}
      \verb{doi}
      \verb 10.1038/nbt.2284
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Al-Lazikani, Banerji, Workman - 2012 - Combinatorial drug therapy for cancer in the post-genomic era.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/22781697
      \endverb
    \endentry
    \entry{Bozic2013}{article}{}
      \name{labelname}{15}{}{%
        {{hash=68e6e98a8496a5e2b7a31ec49920b885}{Bozic}{B\bibinitperiod}{Ivana}{I\bibinitperiod}{}{}{}{}}%
        {{hash=df507dfaaa3258432a4e78ff9589492b}{Reiter}{R\bibinitperiod}{Johannes\bibnamedelima G}{J\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=1490d61b4eb7b6c927b241c8e711d29e}{Allen}{A\bibinitperiod}{Benjamin}{B\bibinitperiod}{}{}{}{}}%
        {{hash=7329ef74890275905474a437d24df996}{Antal}{A\bibinitperiod}{Tibor}{T\bibinitperiod}{}{}{}{}}%
        {{hash=1a126fe7ca5387e01e1bebcd84f3c49b}{Chatterjee}{C\bibinitperiod}{Krishnendu}{K\bibinitperiod}{}{}{}{}}%
        {{hash=dd4e818268f6b510c00a07613cf841ad}{Shah}{S\bibinitperiod}{Preya}{P\bibinitperiod}{}{}{}{}}%
        {{hash=4d9e1b11e4acc2813fcf000e6b76513c}{Moon}{M\bibinitperiod}{Yo\bibnamedelima Sup}{Y\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=ff91ee166610cd9392869f6fb00d40af}{Yaqubie}{Y\bibinitperiod}{Amin}{A\bibinitperiod}{}{}{}{}}%
        {{hash=d42507249ea0823ee5d1d3589b753606}{Kelly}{K\bibinitperiod}{Nicole}{N\bibinitperiod}{}{}{}{}}%
        {{hash=2e3dc5069a4f903531f63c3883d753cf}{Le}{L\bibinitperiod}{Dung\bibnamedelima T}{D\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=ffd284352533a71c8e201fef2aca5ea6}{Lipson}{L\bibinitperiod}{Evan\bibnamedelima J}{E\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=ee9fa088a1d65fc575397e291a8f5814}{Chapman}{C\bibinitperiod}{Paul\bibnamedelima B}{P\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=fdae98f5ebe82221cebdb75592836d1d}{Diaz}{D\bibinitperiod}{Luis\bibnamedelima a}{L\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
        {{hash=bbb27aa05dcd963d1c27727276613af6}{Vogelstein}{V\bibinitperiod}{Bert}{B\bibinitperiod}{}{}{}{}}%
        {{hash=13b6956393e41bce59dba670da9ce424}{Nowak}{N\bibinitperiod}{Martin\bibnamedelima a}{M\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{15}{}{%
        {{hash=68e6e98a8496a5e2b7a31ec49920b885}{Bozic}{B\bibinitperiod}{Ivana}{I\bibinitperiod}{}{}{}{}}%
        {{hash=df507dfaaa3258432a4e78ff9589492b}{Reiter}{R\bibinitperiod}{Johannes\bibnamedelima G}{J\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=1490d61b4eb7b6c927b241c8e711d29e}{Allen}{A\bibinitperiod}{Benjamin}{B\bibinitperiod}{}{}{}{}}%
        {{hash=7329ef74890275905474a437d24df996}{Antal}{A\bibinitperiod}{Tibor}{T\bibinitperiod}{}{}{}{}}%
        {{hash=1a126fe7ca5387e01e1bebcd84f3c49b}{Chatterjee}{C\bibinitperiod}{Krishnendu}{K\bibinitperiod}{}{}{}{}}%
        {{hash=dd4e818268f6b510c00a07613cf841ad}{Shah}{S\bibinitperiod}{Preya}{P\bibinitperiod}{}{}{}{}}%
        {{hash=4d9e1b11e4acc2813fcf000e6b76513c}{Moon}{M\bibinitperiod}{Yo\bibnamedelima Sup}{Y\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=ff91ee166610cd9392869f6fb00d40af}{Yaqubie}{Y\bibinitperiod}{Amin}{A\bibinitperiod}{}{}{}{}}%
        {{hash=d42507249ea0823ee5d1d3589b753606}{Kelly}{K\bibinitperiod}{Nicole}{N\bibinitperiod}{}{}{}{}}%
        {{hash=2e3dc5069a4f903531f63c3883d753cf}{Le}{L\bibinitperiod}{Dung\bibnamedelima T}{D\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=ffd284352533a71c8e201fef2aca5ea6}{Lipson}{L\bibinitperiod}{Evan\bibnamedelima J}{E\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=ee9fa088a1d65fc575397e291a8f5814}{Chapman}{C\bibinitperiod}{Paul\bibnamedelima B}{P\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=fdae98f5ebe82221cebdb75592836d1d}{Diaz}{D\bibinitperiod}{Luis\bibnamedelima a}{L\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
        {{hash=bbb27aa05dcd963d1c27727276613af6}{Vogelstein}{V\bibinitperiod}{Bert}{B\bibinitperiod}{}{}{}{}}%
        {{hash=13b6956393e41bce59dba670da9ce424}{Nowak}{N\bibinitperiod}{Martin\bibnamedelima a}{M\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{31b47cfc022ca05e5f642b4972129694}
      \strng{fullhash}{f4c2db33bb2e7bd5c2335b22f5c959bf}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Evolutionary dynamics of cancer in response to targeted combination therapy.}}
      \field{abstract}{In solid tumors, targeted treatments can lead to dramatic regressions, but responses are often short-lived because resistant cancer cells arise. The major strategy proposed for overcoming resistance is combination therapy. We present a mathematical model describing the evolutionary dynamics of lesions in response to treatment. We first studied 20 melanoma patients receiving vemurafenib. We then applied our model to an independent set of pancreatic, colorectal, and melanoma cancer patients with metastatic disease. We find that dual therapy results in long-term disease control for most patients, if there are no single mutations that cause cross-resistance to both drugs; in patients with large disease burden, triple therapy is needed. We also find that simultaneous therapy with two drugs is much more effective than sequential therapy. Our results provide realistic expectations for the efficacy of new drug combinations and inform the design of trials for new cancer therapeutics. DOI:http://dx.doi.org/10.7554/eLife.00747.001.}
      \field{issn}{2050-084X}
      \field{journaltitle}{eLife}
      \field{month}{01}
      \field{title}{{Evolutionary dynamics of cancer in response to targeted combination therapy.}}
      \field{volume}{2}
      \field{year}{2013}
      \field{pages}{e00747}
      \verb{doi}
      \verb 10.7554/eLife.00747
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Bozic et al. - 2013 - Evolutionary dynamics of cancer in response to targeted combination therapy.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3691570%7B%5C&%7Dtool=pmcentrez%7B%5C&%7Drendertype=abstract
      \endverb
    \endentry
    \entry{Komarova2014}{article}{}
      \name{labelname}{3}{}{%
        {{hash=d3fe554da5d742f167abeb0a3802c9f8}{Komarova}{K\bibinitperiod}{Natalia\bibnamedelima L}{N\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=fbdd48dd1614a394a021c262168379a9}{Burger}{B\bibinitperiod}{Jan\bibnamedelima a}{J\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
        {{hash=ad7577549d55738f7b64bb2bea284096}{Wodarz}{W\bibinitperiod}{Dominik}{D\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=d3fe554da5d742f167abeb0a3802c9f8}{Komarova}{K\bibinitperiod}{Natalia\bibnamedelima L}{N\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=fbdd48dd1614a394a021c262168379a9}{Burger}{B\bibinitperiod}{Jan\bibnamedelima a}{J\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
        {{hash=ad7577549d55738f7b64bb2bea284096}{Wodarz}{W\bibinitperiod}{Dominik}{D\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{73f793b478302f6a80b1f1958bf3c2fa}
      \strng{fullhash}{73f793b478302f6a80b1f1958bf3c2fa}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL).}}
      \field{abstract}{The Bruton tyrosine kinase inhibitor (BTKi) ibrutinib is a new targeted therapy for patients with chronic lymphocytic leukemia (CLL). Ibrutinib is given orally on a continuous schedule and induces durable remissions in the majority of CLL patients. However, a small proportion of patients initially responds to the BTKi and then develops resistance. Estimating the frequency, timing, and individual risk of developing resistance to ibrutinib, therefore, would be valuable for long-term management of patients. Computational evolutionary models, based on measured kinetic parameters of patients, allow us to approach these questions and to develop a roadmap for personalized prognosis and treatment management. Our kinetic models predict that BTKi-resistant mutants exist before initiation of ibrutinib therapy, although they only comprise a minority of the overall tumor burden. Furthermore, we can estimate the time required for resistant cells to grow to detectable levels. We predict that this can be highly variable, depending mostly on growth and death rates of the individual CLL cell clone. For a specific patient, this time can be predicted with a high degree of certainty. Our model can thus be used to predict for how long ibrutinib can suppress the disease in individual patients. Furthermore, the model can suggest whether prior debulking of the tumor with chemo-immunotherapy can prolong progression-free survival under ibrutinib. Finally, by applying the models to data that document progression during ibrutinib therapy, we estimated that resistant mutants might have a small ({<}2{\%}) mean fitness advantage in the absence of treatment, compared with sensitive cells.}
      \field{isbn}{1091-6490 (Electronic)$\backslash$r0027-8424 (Linking)}
      \field{issn}{1091-6490}
      \field{journaltitle}{Proceedings of the National Academy of Sciences of the United States of America}
      \field{number}{38}
      \field{title}{{Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL).}}
      \field{volume}{111}
      \field{year}{2014}
      \field{pages}{13906\bibrangedash 11}
      \verb{doi}
      \verb 10.1073/pnas.1409362111
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/PNAS-2014-Komarova-13906-11.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.pnas.org/content/111/38/13906.full
      \endverb
    \endentry
    \entry{Williams2016}{article}{}
      \name{labelname}{5}{}{%
        {{hash=8139164a9c076731730b62026958123d}{Williams}{W\bibinitperiod}{Marc\bibnamedelima J}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=88c3eeda7ffbd7d3b63a22e2527e8c0d}{Werner}{W\bibinitperiod}{Benjamin}{B\bibinitperiod}{}{}{}{}}%
        {{hash=8341669a3d0db82e877ef918042cb0d0}{Barnes}{B\bibinitperiod}{Chris\bibnamedelima P}{C\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=d45c7a9db3287943efa6f23bc445ebe3}{Graham}{G\bibinitperiod}{Trevor\bibnamedelima A}{T\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=04d31891bb580b2c600eb251525541cc}{Sottoriva}{S\bibinitperiod}{Andrea}{A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{5}{}{%
        {{hash=8139164a9c076731730b62026958123d}{Williams}{W\bibinitperiod}{Marc\bibnamedelima J}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=88c3eeda7ffbd7d3b63a22e2527e8c0d}{Werner}{W\bibinitperiod}{Benjamin}{B\bibinitperiod}{}{}{}{}}%
        {{hash=8341669a3d0db82e877ef918042cb0d0}{Barnes}{B\bibinitperiod}{Chris\bibnamedelima P}{C\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=d45c7a9db3287943efa6f23bc445ebe3}{Graham}{G\bibinitperiod}{Trevor\bibnamedelima A}{T\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=04d31891bb580b2c600eb251525541cc}{Sottoriva}{S\bibinitperiod}{Andrea}{A\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group}%
      }
      \strng{namehash}{a21d2b84a026855aabc92edef03d3c31}
      \strng{fullhash}{fc9cef6209e6caf27201949e93091af8}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Identification of neutral tumor evolution across cancer types}}
      \field{issn}{1061-4036}
      \field{journaltitle}{Nature Genetics}
      \field{number}{August 2015}
      \field{title}{{Identification of neutral tumor evolution across cancer types}}
      \field{year}{2016}
      \verb{doi}
      \verb 10.1038/ng.3489
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/ng.3489.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.nature.com/doifinder/10.1038/ng.3489
      \endverb
    \endentry
    \entry{Attolini2010}{article}{}
      \name{labelname}{8}{}{%
        {{hash=975800e80bf529794e733782f1f3cb3d}{Attolini}{A\bibinitperiod}{Camille\bibnamedelima Stephan-Otto}{C\bibinitperiod\bibinitdelim S\bibinithyphendelim O\bibinitperiod}{}{}{}{}}%
        {{hash=e6d5182250a998c6626c67d681de50cf}{Cheng}{C\bibinitperiod}{Yu-Kang}{Y\bibinithyphendelim K\bibinitperiod}{}{}{}{}}%
        {{hash=1e251929d54a7f11c024d2fa3b4d56fb}{Beroukhim}{B\bibinitperiod}{Rameen}{R\bibinitperiod}{}{}{}{}}%
        {{hash=6aa396b9c7916e3eec93b398e26b1bbf}{Getz}{G\bibinitperiod}{Gad}{G\bibinitperiod}{}{}{}{}}%
        {{hash=6789a07c9dab853530704b1c78787681}{Abdel-Wahab}{A\bibinithyphendelim W\bibinitperiod}{Omar}{O\bibinitperiod}{}{}{}{}}%
        {{hash=d1b60a109e1b35c0e933fedf71910788}{Levine}{L\bibinitperiod}{Ross\bibnamedelima L}{R\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=ee89127e205377bb0b3e577b649211de}{Mellinghoff}{M\bibinitperiod}{Ingo\bibnamedelima K}{I\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=9d9e35b29002d128ad9fe36ab6636cdb}{Michor}{M\bibinitperiod}{Franziska}{F\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{8}{}{%
        {{hash=975800e80bf529794e733782f1f3cb3d}{Attolini}{A\bibinitperiod}{Camille\bibnamedelima Stephan-Otto}{C\bibinitperiod\bibinitdelim S\bibinithyphendelim O\bibinitperiod}{}{}{}{}}%
        {{hash=e6d5182250a998c6626c67d681de50cf}{Cheng}{C\bibinitperiod}{Yu-Kang}{Y\bibinithyphendelim K\bibinitperiod}{}{}{}{}}%
        {{hash=1e251929d54a7f11c024d2fa3b4d56fb}{Beroukhim}{B\bibinitperiod}{Rameen}{R\bibinitperiod}{}{}{}{}}%
        {{hash=6aa396b9c7916e3eec93b398e26b1bbf}{Getz}{G\bibinitperiod}{Gad}{G\bibinitperiod}{}{}{}{}}%
        {{hash=6789a07c9dab853530704b1c78787681}{Abdel-Wahab}{A\bibinithyphendelim W\bibinitperiod}{Omar}{O\bibinitperiod}{}{}{}{}}%
        {{hash=d1b60a109e1b35c0e933fedf71910788}{Levine}{L\bibinitperiod}{Ross\bibnamedelima L}{R\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=ee89127e205377bb0b3e577b649211de}{Mellinghoff}{M\bibinitperiod}{Ingo\bibnamedelima K}{I\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=9d9e35b29002d128ad9fe36ab6636cdb}{Michor}{M\bibinitperiod}{Franziska}{F\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{13c6b9ef7a2638b9dc28c34f1286a85c}
      \strng{fullhash}{e8e38c47c28a5ea076a10ef28e2c9fb1}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{A mathematical framework to determine the temporal sequence of somatic genetic events in cancer.}}
      \field{abstract}{Human cancer is caused by the accumulation of genetic alterations in cells. Of special importance are changes that occur early during malignant transformation because they may result in oncogene addiction and represent promising targets for therapeutic intervention. Here we describe a computational approach, called Retracing the Evolutionary Steps in Cancer (RESIC), to deduce the temporal sequence of genetic events during tumorigenesis from cross-sectional genomic data of tumors at their fully transformed stage. When applied to a dataset of 70 advanced colorectal cancers, our algorithm accurately predicts the sequence of APC, KRAS, and TP53 mutations previously defined by analyzing tumors at different stages of colon cancer formation. We further validate the method with glioblastoma and leukemia sample data and then apply it to complex integrated genomics databases, finding that high-level EGFR amplification appears to be a late event in primary glioblastomas. RESIC represents the first evolutionary mathematical approach to identify the temporal sequence of mutations driving tumorigenesis and may be useful to guide the validation of candidate genes emerging from cancer genome surveys.}
      \field{isbn}{1091-6490 (Electronic)$\backslash$r0027-8424 (Linking)}
      \field{issn}{1091-6490}
      \field{journaltitle}{Proceedings of the National Academy of Sciences of the United States of America}
      \field{number}{41}
      \field{title}{{A mathematical framework to determine the temporal sequence of somatic genetic events in cancer.}}
      \field{volume}{107}
      \field{year}{2010}
      \field{pages}{17604\bibrangedash 9}
      \verb{doi}
      \verb 10.1073/pnas.1009117107
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/PNAS-2010-Attolini-17604-9.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.pnas.org/content/107/41/17604.short
      \endverb
    \endentry
    \entry{Chmielecki2011}{article}{}
      \name{labelname}{21}{}{%
        {{hash=9a086f1a7b8d9fb0825d4452a78f2b63}{Chmielecki}{C\bibinitperiod}{J}{J\bibinitperiod}{}{}{}{}}%
        {{hash=fd6a63d1461212912feb7c2302828083}{Foo}{F\bibinitperiod}{J}{J\bibinitperiod}{}{}{}{}}%
        {{hash=dfbb33f9fc881c14fe6d7535f53f3883}{Oxnard}{O\bibinitperiod}{G\bibnamedelima R}{G\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=0b5c884b29882d20c71a528dd92ecf7e}{Hutchinson}{H\bibinitperiod}{K}{K\bibinitperiod}{}{}{}{}}%
        {{hash=d8e0d15ee4f29113f38d60cec221e7c7}{Ohashi}{O\bibinitperiod}{K}{K\bibinitperiod}{}{}{}{}}%
        {{hash=a8affc3fc78b3f4e86493eb8d1906ba9}{Somwar}{S\bibinitperiod}{R}{R\bibinitperiod}{}{}{}{}}%
        {{hash=9a75ee293f2555f40976345739087998}{Wang}{W\bibinitperiod}{L}{L\bibinitperiod}{}{}{}{}}%
        {{hash=3d0aeaec88009b0fbfc640d0526f719c}{Amato}{A\bibinitperiod}{K\bibnamedelima R}{K\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=38863ca09bf5073bad14cb06549d4475}{Arcila}{A\bibinitperiod}{M}{M\bibinitperiod}{}{}{}{}}%
        {{hash=e8d9c38a8e6d44a078d2d5ed69ff571b}{Sos}{S\bibinitperiod}{M\bibnamedelima L}{M\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=81c253f629b2ee52336d2b48eea7988f}{Socci}{S\bibinitperiod}{N\bibnamedelima D}{N\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=57e5addee1980e87e6fcf6858471ef34}{Viale}{V\bibinitperiod}{A}{A\bibinitperiod}{}{}{}{}}%
        {{hash=6c10f60ead9a51403f62087cb53526ed}{Stanchina}{S\bibinitperiod}{E}{E\bibinitperiod}{de}{d\bibinitperiod}{}{}}%
        {{hash=99828276fde6a68a349bc9be059cfb99}{Ginsberg}{G\bibinitperiod}{M\bibnamedelima S}{M\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=0908cad7841cf466eba5ddb1b8d38f99}{Thomas}{T\bibinitperiod}{R\bibnamedelima K}{R\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=b790cf9fd0a0c3c87ae06a795e127291}{Kris}{K\bibinitperiod}{M\bibnamedelima G}{M\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=c7ebbcf27e16d8bfdb741fe3c6b64ad1}{Inoue}{I\bibinitperiod}{A}{A\bibinitperiod}{}{}{}{}}%
        {{hash=729b8ed4020054f201287dd9d18840ba}{Ladanyi}{L\bibinitperiod}{M}{M\bibinitperiod}{}{}{}{}}%
        {{hash=c3c4d58a922b273acb4efd15a2c2b87f}{Miller}{M\bibinitperiod}{V\bibnamedelima A}{V\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=b0c14ffcabc8dcf4ecbc94cfca60b7a2}{Michor}{M\bibinitperiod}{F}{F\bibinitperiod}{}{}{}{}}%
        {{hash=4b039dea98b86daf174454351be8e3b5}{Pao}{P\bibinitperiod}{W}{W\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{21}{}{%
        {{hash=9a086f1a7b8d9fb0825d4452a78f2b63}{Chmielecki}{C\bibinitperiod}{J}{J\bibinitperiod}{}{}{}{}}%
        {{hash=fd6a63d1461212912feb7c2302828083}{Foo}{F\bibinitperiod}{J}{J\bibinitperiod}{}{}{}{}}%
        {{hash=dfbb33f9fc881c14fe6d7535f53f3883}{Oxnard}{O\bibinitperiod}{G\bibnamedelima R}{G\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=0b5c884b29882d20c71a528dd92ecf7e}{Hutchinson}{H\bibinitperiod}{K}{K\bibinitperiod}{}{}{}{}}%
        {{hash=d8e0d15ee4f29113f38d60cec221e7c7}{Ohashi}{O\bibinitperiod}{K}{K\bibinitperiod}{}{}{}{}}%
        {{hash=a8affc3fc78b3f4e86493eb8d1906ba9}{Somwar}{S\bibinitperiod}{R}{R\bibinitperiod}{}{}{}{}}%
        {{hash=9a75ee293f2555f40976345739087998}{Wang}{W\bibinitperiod}{L}{L\bibinitperiod}{}{}{}{}}%
        {{hash=3d0aeaec88009b0fbfc640d0526f719c}{Amato}{A\bibinitperiod}{K\bibnamedelima R}{K\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=38863ca09bf5073bad14cb06549d4475}{Arcila}{A\bibinitperiod}{M}{M\bibinitperiod}{}{}{}{}}%
        {{hash=e8d9c38a8e6d44a078d2d5ed69ff571b}{Sos}{S\bibinitperiod}{M\bibnamedelima L}{M\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=81c253f629b2ee52336d2b48eea7988f}{Socci}{S\bibinitperiod}{N\bibnamedelima D}{N\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=57e5addee1980e87e6fcf6858471ef34}{Viale}{V\bibinitperiod}{A}{A\bibinitperiod}{}{}{}{}}%
        {{hash=6c10f60ead9a51403f62087cb53526ed}{Stanchina}{S\bibinitperiod}{E}{E\bibinitperiod}{de}{d\bibinitperiod}{}{}}%
        {{hash=99828276fde6a68a349bc9be059cfb99}{Ginsberg}{G\bibinitperiod}{M\bibnamedelima S}{M\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=0908cad7841cf466eba5ddb1b8d38f99}{Thomas}{T\bibinitperiod}{R\bibnamedelima K}{R\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=b790cf9fd0a0c3c87ae06a795e127291}{Kris}{K\bibinitperiod}{M\bibnamedelima G}{M\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=c7ebbcf27e16d8bfdb741fe3c6b64ad1}{Inoue}{I\bibinitperiod}{A}{A\bibinitperiod}{}{}{}{}}%
        {{hash=729b8ed4020054f201287dd9d18840ba}{Ladanyi}{L\bibinitperiod}{M}{M\bibinitperiod}{}{}{}{}}%
        {{hash=c3c4d58a922b273acb4efd15a2c2b87f}{Miller}{M\bibinitperiod}{V\bibnamedelima A}{V\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=b0c14ffcabc8dcf4ecbc94cfca60b7a2}{Michor}{M\bibinitperiod}{F}{F\bibinitperiod}{}{}{}{}}%
        {{hash=4b039dea98b86daf174454351be8e3b5}{Pao}{P\bibinitperiod}{W}{W\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{5659e3e73545fe2a5fd8b5b3de0d70e5}
      \strng{fullhash}{55e6e3060a1f9269aea72d91084a23e5}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling}}
      \field{abstract}{Non-small cell lung cancers (NSCLCs) that harbor mutations within the epidermal growth factor receptor (EGFR) gene are sensitive to the tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib. Unfortunately, all patients treated with these drugs will acquire resistance, most commonly as a result of a secondary mutation within EGFR (T790M). Because both drugs were developed to target wild-type EGFR, we hypothesized that current dosing schedules were not optimized for mutant EGFR or to prevent resistance. To investigate this further, we developed isogenic TKI-sensitive and TKI-resistant pairs of cell lines that mimic the behavior of human tumors. We determined that the drug-sensitive and drug-resistant EGFR-mutant cells exhibited differential growth kinetics, with the drug-resistant cells showing slower growth. We incorporated these data into evolutionary mathematical cancer models with constraints derived from clinical data sets. This modeling predicted alternative therapeutic strategies that could prolong the clinical benefit of TKIs against EGFR-mutant NSCLCs by delaying the development of resistance.}
      \field{isbn}{1946-6242 (Electronic)$\backslash$r1946-6234 (Linking)}
      \field{issn}{1946-6242}
      \field{journaltitle}{Sci Transl Med}
      \field{number}{90}
      \field{title}{{Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling}}
      \field{volume}{3}
      \field{year}{2011}
      \field{pages}{90ra59}
      \verb{doi}
      \verb 10.1126/scitranslmed.3002356
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/10.1126@scitranslmed.3002356.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/21734175$%5Cbackslash$nhttp://stm.sciencemag.org/content/3/90/90ra59
      \endverb
    \endentry
    \entry{Huang2007}{article}{}
      \name{labelname}{8}{}{%
        {{hash=af617c9a6fae2c31fbb58a2ba5f8ba92}{Huang}{H\bibinitperiod}{Paul\bibnamedelima H}{P\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=f93291da17e39eab8f6eb3cfedaed924}{Mukasa}{M\bibinitperiod}{Akitake}{A\bibinitperiod}{}{}{}{}}%
        {{hash=47bd53e7f31eef9a1bdc631f03c59de3}{Bonavia}{B\bibinitperiod}{Rudy}{R\bibinitperiod}{}{}{}{}}%
        {{hash=68b461a1ba1fb05aeb9fc32692b74a1c}{Flynn}{F\bibinitperiod}{Ryan\bibnamedelima A}{R\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=242d4df9c693b242ef52791700453be8}{Brewer}{B\bibinitperiod}{Zachary\bibnamedelima E}{Z\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=0a8d39f7f39bff02e8a413dd3209b779}{Cavenee}{C\bibinitperiod}{Webster\bibnamedelima K}{W\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=5e60849b76da3aa3ddda17128e3ed1e9}{Furnari}{F\bibinitperiod}{Frank\bibnamedelima B}{F\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=71977f6db130f1938b761df4fbd091f9}{White}{W\bibinitperiod}{Forest\bibnamedelima M}{F\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{8}{}{%
        {{hash=af617c9a6fae2c31fbb58a2ba5f8ba92}{Huang}{H\bibinitperiod}{Paul\bibnamedelima H}{P\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=f93291da17e39eab8f6eb3cfedaed924}{Mukasa}{M\bibinitperiod}{Akitake}{A\bibinitperiod}{}{}{}{}}%
        {{hash=47bd53e7f31eef9a1bdc631f03c59de3}{Bonavia}{B\bibinitperiod}{Rudy}{R\bibinitperiod}{}{}{}{}}%
        {{hash=68b461a1ba1fb05aeb9fc32692b74a1c}{Flynn}{F\bibinitperiod}{Ryan\bibnamedelima A}{R\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=242d4df9c693b242ef52791700453be8}{Brewer}{B\bibinitperiod}{Zachary\bibnamedelima E}{Z\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=0a8d39f7f39bff02e8a413dd3209b779}{Cavenee}{C\bibinitperiod}{Webster\bibnamedelima K}{W\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=5e60849b76da3aa3ddda17128e3ed1e9}{Furnari}{F\bibinitperiod}{Frank\bibnamedelima B}{F\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=71977f6db130f1938b761df4fbd091f9}{White}{W\bibinitperiod}{Forest\bibnamedelima M}{F\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{81238470218aad60ccc8674ee84becf7}
      \strng{fullhash}{852d2abc47e7b223df408f562178279f}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma}}
      \field{abstract}{Glioblastoma multiforme (GBM) is the most aggressive brain tumor in adults and remains incurable despite multimodal intensive treatment regimens. EGFRvIII is a truncated extracellular mutant of the EGF receptor (EGFR) commonly found in GBMs that confers enhanced tumorigenic behavior. To gain a molecular understanding of the mechanisms by which EGFRvIII acts, we have performed a large-scale analysis of EGFRvIII-activated phosphotyrosine-mediated signaling pathways and thereby have identified and quantified 99 phosphorylation sites on 69 proteins. Distinct signaling responses were observed as a function of titrated EGFRvIII receptor levels with the phosphatidylinositol 3-kinase pathway being dominant over the MAPK and STAT3 pathways at a high level of EGFRvIII expression. Within this data set, the activating phosphorylation site on the c-Met receptor was found to be highly responsive to EGFRvIII levels, indicating cross-activation of the c-Met receptor tyrosine kinase by EGFRvIII. To determine the significance of this finding, we devised a combined treatment regimen that used a c-Met kinase inhibitor and either an EGFR kinase inhibitor or cisplatin. This regimen resulted in enhanced cytotoxicity of EGFRvIII-expressing cells compared with treatment with either compound alone. These results suggest that the clinical use of c-Met kinase inhibitors in combination with either EGFR inhibitors or standard chemotherapeutics might represent a previously undescribed therapeutic approach to overcome the observed chemoresistance in patients with GBMs expressing EGFRvIII.}
      \field{annotation}{10.1073/pnas.0705158104}
      \field{journaltitle}{Proceedings of the National Academy of Sciences}
      \field{month}{07}
      \field{number}{31}
      \field{title}{{Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma}}
      \field{volume}{104}
      \field{year}{2007}
      \field{pages}{12867\bibrangedash 12872}
      \verb{doi}
      \verb 10.1073/pnas.0705158104
      \endverb
      \verb{url}
      \verb http://www.pnas.org/content/104/31/12867.abstract
      \endverb
    \endentry
  \endsortlist
  \sortlist{none}{none}
    \entry{kessel2010}{book}{}
      \name{labelname}{2}{}{%
        {{hash=09d96aa5b560f746a81c4f0086d6aeb4}{Kessel}{K\bibinitperiod}{A}{A\bibinitperiod}{}{}{}{}}%
        {{hash=adc989901810b45b4084e719b53e6668}{Ben-Tal}{B\bibinithyphendelim T\bibinitperiod}{N}{N\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=09d96aa5b560f746a81c4f0086d6aeb4}{Kessel}{K\bibinitperiod}{A}{A\bibinitperiod}{}{}{}{}}%
        {{hash=adc989901810b45b4084e719b53e6668}{Ben-Tal}{B\bibinithyphendelim T\bibinitperiod}{N}{N\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {CRC Press}%
      }
      \strng{namehash}{f607c969a2c8cea129a86878a4c3fb63}
      \strng{fullhash}{f607c969a2c8cea129a86878a4c3fb63}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Introduction to Proteins: Structure, Function, and Motion}}
      \field{isbn}{9781439810729}
      \field{series}{Chapman {\&} Hall/CRC Mathematical and Computational Biology}
      \field{title}{{Introduction to Proteins: Structure, Function, and Motion}}
      \field{year}{2010}
      \verb{url}
      \verb https://books.google.es/books?id=cMMgypIrxocC
      \endverb
    \endentry
    \entry{thecell2008}{book}{}
      \name{labelname}{1}{}{%
        {{hash=f351b421c470c2f155156f0ed44b791f}{Alberts}{A\bibinitperiod}{B.}{B\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=f351b421c470c2f155156f0ed44b791f}{Alberts}{A\bibinitperiod}{B.}{B\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Garland Science}%
      }
      \strng{namehash}{f351b421c470c2f155156f0ed44b791f}
      \strng{fullhash}{f351b421c470c2f155156f0ed44b791f}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{Molecular Biology of the Cell: Reference edition}
      \field{isbn}{9780815341116}
      \field{number}{v. 1}
      \field{series}{Molecular Biology of the Cell: Reference Edition}
      \field{title}{Molecular Biology of the Cell: Reference edition}
      \field{year}{2008}
      \verb{url}
      \verb https://books.google.es/books?id=iepqmRfP3ZoC
      \endverb
    \endentry
    \entry{DSSP}{article}{}
      \name{labelname}{2}{}{%
        {{hash=7f410e758870d5022f40f18e19d55197}{Kabsch}{K\bibinitperiod}{Wolfgang}{W\bibinitperiod}{}{}{}{}}%
        {{hash=fe52d1a32f8a4d5b93db74a3f31bdb50}{Sander}{S\bibinitperiod}{Christian}{C\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=7f410e758870d5022f40f18e19d55197}{Kabsch}{K\bibinitperiod}{Wolfgang}{W\bibinitperiod}{}{}{}{}}%
        {{hash=fe52d1a32f8a4d5b93db74a3f31bdb50}{Sander}{S\bibinitperiod}{Christian}{C\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Wiley Subscription Services, Inc., A Wiley Company}%
      }
      \strng{namehash}{5ce8be718914c8a388f5d1b1455152fc}
      \strng{fullhash}{5ce8be718914c8a388f5d1b1455152fc}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Dictionary of protein secondary structure: Pattern recognition of hydrogen-bonded and geometrical features}}
      \field{issn}{1097-0282}
      \field{journaltitle}{Biopolymers}
      \field{number}{12}
      \field{title}{{Dictionary of protein secondary structure: Pattern recognition of hydrogen-bonded and geometrical features}}
      \field{volume}{22}
      \field{year}{1983}
      \field{pages}{2577\bibrangedash 2637}
      \verb{doi}
      \verb 10.1002/bip.360221211
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1002/bip.360221211
      \endverb
    \endentry
    \entry{Dill1990}{article}{}
      \name{labelname}{1}{}{%
        {{hash=9a39ef1b41588121d5d2cefe3071d1b6}{Dill}{D\bibinitperiod}{K\bibnamedelima A}{K\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=9a39ef1b41588121d5d2cefe3071d1b6}{Dill}{D\bibinitperiod}{K\bibnamedelima A}{K\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{9a39ef1b41588121d5d2cefe3071d1b6}
      \strng{fullhash}{9a39ef1b41588121d5d2cefe3071d1b6}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Dominant forces in protein folding.}}
      \field{abstract}{PMID: 2207096}
      \field{isbn}{0006-2960}
      \field{issn}{0006-2960}
      \field{journaltitle}{Biochemistry}
      \field{number}{31}
      \field{title}{{Dominant forces in protein folding.}}
      \field{volume}{29}
      \field{year}{1990}
      \field{pages}{7133\bibrangedash 7155}
      \verb{doi}
      \verb 10.1021/bi00483a001
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/bi00483a001.pdf:pdf
      \endverb
    \endentry
    \entry{StructureSequence}{article}{}
      \name{labelname}{2}{}{%
        {{hash=76acb31aa7f188100748edec31345f05}{Chothial}{C\bibinitperiod}{Cyrus}{C\bibinitperiod}{}{}{}{}}%
        {{hash=80caa77742ed8b6aef79492d161c7bb3}{Lesk}{L\bibinitperiod}{Arthur\bibnamedelima M}{A\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=76acb31aa7f188100748edec31345f05}{Chothial}{C\bibinitperiod}{Cyrus}{C\bibinitperiod}{}{}{}{}}%
        {{hash=80caa77742ed8b6aef79492d161c7bb3}{Lesk}{L\bibinitperiod}{Arthur\bibnamedelima M}{A\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{dc0fd253e013d7e6a32a8dc8c6b770ee}
      \strng{fullhash}{dc0fd253e013d7e6a32a8dc8c6b770ee}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{proteins}
      \field{number}{4}
      \field{title}{proteins}
      \field{volume}{5}
      \field{year}{1986}
      \field{pages}{823\bibrangedash 826}
      \verb{file}
      \verb :home/fran/Downloads/emboj00167-0187.pdf:pdf
      \endverb
    \endentry
    \entry{conservPPI}{article}{}
      \name{labelname}{4}{}{%
        {{hash=cdbd829290aac4452bad6ad432b8f3b7}{Ma}{M\bibinitperiod}{Buyong}{B\bibinitperiod}{}{}{}{}}%
        {{hash=30f8080ada0f81c014ad52a0e4ae30c8}{Elkayam}{E\bibinitperiod}{Tal}{T\bibinitperiod}{}{}{}{}}%
        {{hash=c7dad2d76c9f649d2d5e2eda8598c14f}{Wolfson}{W\bibinitperiod}{Haim}{H\bibinitperiod}{}{}{}{}}%
        {{hash=5df4f003753b6d9cfad61f047a6dab01}{Nussinov}{N\bibinitperiod}{Ruth}{R\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=cdbd829290aac4452bad6ad432b8f3b7}{Ma}{M\bibinitperiod}{Buyong}{B\bibinitperiod}{}{}{}{}}%
        {{hash=30f8080ada0f81c014ad52a0e4ae30c8}{Elkayam}{E\bibinitperiod}{Tal}{T\bibinitperiod}{}{}{}{}}%
        {{hash=c7dad2d76c9f649d2d5e2eda8598c14f}{Wolfson}{W\bibinitperiod}{Haim}{H\bibinitperiod}{}{}{}{}}%
        {{hash=5df4f003753b6d9cfad61f047a6dab01}{Nussinov}{N\bibinitperiod}{Ruth}{R\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{305706773835f47aca04bcfde0824ada}
      \strng{fullhash}{811e01ddc6d2e367c99bb2fa8c0aeda8}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Protein -- protein interactions : Structurally conserved residues distinguish between binding sites and exposed protein surfaces}}
      \field{number}{Track II}
      \field{title}{{Protein -- protein interactions : Structurally conserved residues distinguish between binding sites and exposed protein surfaces}}
      \field{year}{2003}
      \verb{file}
      \verb :home/fran/Downloads/PNAS-2003-Ma-5772-7.pdf:pdf
      \endverb
    \endentry
    \entry{Raj2007}{article}{}
      \name{labelname}{2}{}{%
        {{hash=e1f7f25c7909b5dd589dbb0dcfc6c78a}{Sasidharan}{S\bibinitperiod}{Rajkumar}{R\bibinitperiod}{}{}{}{}}%
        {{hash=e7519839a5afb3dc61bb297b7fb4f313}{Chothia}{C\bibinitperiod}{Cyrus}{C\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=e1f7f25c7909b5dd589dbb0dcfc6c78a}{Sasidharan}{S\bibinitperiod}{Rajkumar}{R\bibinitperiod}{}{}{}{}}%
        {{hash=e7519839a5afb3dc61bb297b7fb4f313}{Chothia}{C\bibinitperiod}{Cyrus}{C\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{7aeadfdcc51d156d5f4e5e485d5a4b53}
      \strng{fullhash}{7aeadfdcc51d156d5f4e5e485d5a4b53}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{The selection of acceptable protein mutations}}
      \field{isbn}{0703737104}
      \field{title}{{The selection of acceptable protein mutations}}
      \field{volume}{2007}
      \field{year}{2007}
      \verb{file}
      \verb :home/fran/Downloads/zpq10080.pdf:pdf
      \endverb
    \endentry
    \entry{Todd2001}{article}{}
      \name{labelname}{3}{}{%
        {{hash=84dbfdfd9d845898fa36a2b8db9952d4}{Todd}{T\bibinitperiod}{Annabel\bibnamedelima E}{A\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=299543f55499c67e26036baabc306fe2}{Orengo}{O\bibinitperiod}{Christine\bibnamedelima A}{C\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=57d4b2a8608ed46ecd78623269176506}{Thornton}{T\bibinitperiod}{Janet\bibnamedelima M}{J\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=84dbfdfd9d845898fa36a2b8db9952d4}{Todd}{T\bibinitperiod}{Annabel\bibnamedelima E}{A\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=299543f55499c67e26036baabc306fe2}{Orengo}{O\bibinitperiod}{Christine\bibnamedelima A}{C\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=57d4b2a8608ed46ecd78623269176506}{Thornton}{T\bibinitperiod}{Janet\bibnamedelima M}{J\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{9d2da1dcd3a2355eb7347cd582d14844}
      \strng{fullhash}{9d2da1dcd3a2355eb7347cd582d14844}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Evolution of Function in Protein Superfamilies , from a Structural Perspective}}
      \field{title}{{Evolution of Function in Protein Superfamilies , from a Structural Perspective}}
      \field{year}{2001}
      \verb{doi}
      \verb 10.1006/jmbi.2001.4513
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/1-s2.0-S0022283601945139-main.pdf:pdf
      \endverb
    \endentry
    \entry{KENDREW1960}{article}{}
      \name{labelname}{7}{}{%
        {{hash=d97ded3f06f615e6609b1bf284577c25}{KENDREW}{K\bibinitperiod}{J\bibnamedelima C}{J\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=b7c2e0891cd46c21469e5e30a355155a}{DICKERSON}{D\bibinitperiod}{R\bibnamedelima E}{R\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=7511ac0193595ce2c4ea22730cdb7cb9}{STRANDBERG}{S\bibinitperiod}{B\bibnamedelima E}{B\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=526f673eaa0c43849ccaa2f3dce8992d}{HART}{H\bibinitperiod}{R\bibnamedelima G}{R\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=55a9b522b46075bf8bf2975b7a1b6f9a}{DAVIES}{D\bibinitperiod}{D\bibnamedelima R}{D\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=308e6c65fb56dea4b04a8b9b95a73ce8}{PHILLIPS}{P\bibinitperiod}{D\bibnamedelima C}{D\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=93c04c434b431a5d51578d3211ea0e79}{SHORE}{S\bibinitperiod}{V\bibnamedelima C}{V\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{7}{}{%
        {{hash=d97ded3f06f615e6609b1bf284577c25}{KENDREW}{K\bibinitperiod}{J\bibnamedelima C}{J\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=b7c2e0891cd46c21469e5e30a355155a}{DICKERSON}{D\bibinitperiod}{R\bibnamedelima E}{R\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=7511ac0193595ce2c4ea22730cdb7cb9}{STRANDBERG}{S\bibinitperiod}{B\bibnamedelima E}{B\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=526f673eaa0c43849ccaa2f3dce8992d}{HART}{H\bibinitperiod}{R\bibnamedelima G}{R\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=55a9b522b46075bf8bf2975b7a1b6f9a}{DAVIES}{D\bibinitperiod}{D\bibnamedelima R}{D\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=308e6c65fb56dea4b04a8b9b95a73ce8}{PHILLIPS}{P\bibinitperiod}{D\bibnamedelima C}{D\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=93c04c434b431a5d51578d3211ea0e79}{SHORE}{S\bibinitperiod}{V\bibnamedelima C}{V\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{8287f11a7247c594a2dcc77e4400b2f4}
      \strng{fullhash}{b8a00f7a56e6a4af8a30f421c882006d}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Structure of Myoglobin: A Three-Dimensional Fourier Synthesis at 2 [angst]. Resolution}}
      \field{annotation}{10.1038/185422a0}
      \field{journaltitle}{Nature}
      \field{month}{02}
      \field{number}{4711}
      \field{title}{{Structure of Myoglobin: A Three-Dimensional Fourier Synthesis at 2 [angst]. Resolution}}
      \field{volume}{185}
      \field{year}{1960}
      \field{pages}{422\bibrangedash 427}
      \verb{url}
      \verb http://dx.doi.org/10.1038/185422a0
      \endverb
    \endentry
    \entry{Berman2000}{article}{}
      \name{labelname}{8}{}{%
        {{hash=0363d036b24e1191b76fc6f4bb86cd79}{Berman}{B\bibinitperiod}{Helen\bibnamedelima M}{H\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=cafb3691e83b5fe5369b6ddfbd7c7fec}{Westbrook}{W\bibinitperiod}{John}{J\bibinitperiod}{}{}{}{}}%
        {{hash=3468c1fce34977da673dea11e3fc64b0}{Feng}{F\bibinitperiod}{Zukang}{Z\bibinitperiod}{}{}{}{}}%
        {{hash=ef13e40589ce50a74a82205ece5f053d}{Gilliland}{G\bibinitperiod}{Gary}{G\bibinitperiod}{}{}{}{}}%
        {{hash=0febc6fc4d8962b7459c9ea72d71fd2e}{Bhat}{B\bibinitperiod}{T\bibnamedelima N}{T\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
        {{hash=f6cfd7bb473bc51e886cbc11b1c76cb8}{Weissig}{W\bibinitperiod}{Helge}{H\bibinitperiod}{}{}{}{}}%
        {{hash=50ae25b4d890af1d9462cb8025df09c6}{Shindyalov}{S\bibinitperiod}{Ilya\bibnamedelima N}{I\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
        {{hash=7c11f3af2e76014f9f3869e767aba8c4}{Bourne}{B\bibinitperiod}{Philip\bibnamedelima E}{P\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{8}{}{%
        {{hash=0363d036b24e1191b76fc6f4bb86cd79}{Berman}{B\bibinitperiod}{Helen\bibnamedelima M}{H\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=cafb3691e83b5fe5369b6ddfbd7c7fec}{Westbrook}{W\bibinitperiod}{John}{J\bibinitperiod}{}{}{}{}}%
        {{hash=3468c1fce34977da673dea11e3fc64b0}{Feng}{F\bibinitperiod}{Zukang}{Z\bibinitperiod}{}{}{}{}}%
        {{hash=ef13e40589ce50a74a82205ece5f053d}{Gilliland}{G\bibinitperiod}{Gary}{G\bibinitperiod}{}{}{}{}}%
        {{hash=0febc6fc4d8962b7459c9ea72d71fd2e}{Bhat}{B\bibinitperiod}{T\bibnamedelima N}{T\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
        {{hash=f6cfd7bb473bc51e886cbc11b1c76cb8}{Weissig}{W\bibinitperiod}{Helge}{H\bibinitperiod}{}{}{}{}}%
        {{hash=50ae25b4d890af1d9462cb8025df09c6}{Shindyalov}{S\bibinitperiod}{Ilya\bibnamedelima N}{I\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
        {{hash=7c11f3af2e76014f9f3869e767aba8c4}{Bourne}{B\bibinitperiod}{Philip\bibnamedelima E}{P\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{a85430ce9df4b0d45d7353531c90d416}
      \strng{fullhash}{c3cdddbde2be0f288eb6b69c4dad7edc}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{The Protein Data Bank}}
      \field{abstract}{The Protein Data Bank (PDB; http://www.rcsb.org/pdb/ ) is the single worldwide archive of structural data of biological macromolecules. This paper describes the goals of the PDB, the systems in place for data deposition and access, how to obtain further information, and near-term plans for the future development of the resource.}
      \field{annotation}{10.1093/nar/28.1.235}
      \field{journaltitle}{Nucleic Acids Research}
      \field{month}{01}
      \field{number}{1}
      \field{title}{{The Protein Data Bank}}
      \field{volume}{28}
      \field{year}{2000}
      \field{pages}{235\bibrangedash 242}
      \verb{doi}
      \verb 10.1093/nar/28.1.235
      \endverb
      \verb{url}
      \verb http://nar.oxfordjournals.org/content/28/1/235.abstract
      \endverb
    \endentry
    \entry{Norvell2007}{article}{}
      \name{labelname}{2}{}{%
        {{hash=f0595b02cbe9d16d4e5c13037b5806b5}{Norvell}{N\bibinitperiod}{John\bibnamedelima C}{J\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=8029c37c392881fde147ecc3e41a40f9}{Berg}{B\bibinitperiod}{Jeremy\bibnamedelima M}{J\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=f0595b02cbe9d16d4e5c13037b5806b5}{Norvell}{N\bibinitperiod}{John\bibnamedelima C}{J\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=8029c37c392881fde147ecc3e41a40f9}{Berg}{B\bibinitperiod}{Jeremy\bibnamedelima M}{J\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{29a1cccbf417eed7e7c20b8c2f1e7d0e}
      \strng{fullhash}{29a1cccbf417eed7e7c20b8c2f1e7d0e}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Update on the Protein Structure Initiative}}
      \field{issn}{0969-2126}
      \field{journaltitle}{Structure}
      \field{month}{12}
      \field{number}{12}
      \field{title}{{Update on the Protein Structure Initiative}}
      \field{volume}{15}
      \field{year}{2007}
      \field{pages}{1519\bibrangedash 1522}
      \verb{doi}
      \verb http://dx.doi.org/10.1016/j.str.2007.11.004
      \endverb
      \verb{url}
      \verb http://www.sciencedirect.com/science/article/pii/S0969212607004248
      \endverb
    \endentry
    \entry{GIleadi2007}{article}{}
      \name{labelname}{7}{}{%
        {{hash=5b90178f5994899b8224fe4dd3effa66}{Gileadi}{G\bibinitperiod}{Opher}{O\bibinitperiod}{}{}{}{}}%
        {{hash=6068b3859996527329cb4fd5aa5d1064}{Knapp}{K\bibinitperiod}{{{\AE}}\bibnamedelima Stefan}{{\AE}\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=27612d4b580cb4cd938ad1009d4ee213}{Hwa}{H\bibinitperiod}{{{\AE}}\bibnamedelima Wen}{{\AE}\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=4628a07a56b645837725e1a38b0fe75a}{Brian}{B\bibinitperiod}{Lee\bibnamedelima {{\AE}}}{L\bibinitperiod\bibinitdelim {\AE}\bibinitperiod}{}{}{}{}}%
        {{hash=6aeabe2d7df1947b6032b00243a31779}{Frank}{F\bibinitperiod}{{{\AE}}}{{\AE}\bibinitperiod}{}{}{}{}}%
        {{hash=5a9cbf8143dba13439402928b7c6158b}{Kathryn}{K\bibinitperiod}{H\bibnamedelima Niesen\bibnamedelima {{\AE}}}{H\bibinitperiod\bibinitdelim N\bibinitperiod\bibinitdelim {\AE}\bibinitperiod}{}{}{}{}}%
        {{hash=861cc6383aea70c7af97a60eeaaa0f3d}{Linda}{L\bibinitperiod}{L\bibnamedelima Kavanagh\bibnamedelima {{\AE}}}{L\bibinitperiod\bibinitdelim K\bibinitperiod\bibinitdelim {\AE}\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{7}{}{%
        {{hash=5b90178f5994899b8224fe4dd3effa66}{Gileadi}{G\bibinitperiod}{Opher}{O\bibinitperiod}{}{}{}{}}%
        {{hash=6068b3859996527329cb4fd5aa5d1064}{Knapp}{K\bibinitperiod}{{{\AE}}\bibnamedelima Stefan}{{\AE}\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=27612d4b580cb4cd938ad1009d4ee213}{Hwa}{H\bibinitperiod}{{{\AE}}\bibnamedelima Wen}{{\AE}\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=4628a07a56b645837725e1a38b0fe75a}{Brian}{B\bibinitperiod}{Lee\bibnamedelima {{\AE}}}{L\bibinitperiod\bibinitdelim {\AE}\bibinitperiod}{}{}{}{}}%
        {{hash=6aeabe2d7df1947b6032b00243a31779}{Frank}{F\bibinitperiod}{{{\AE}}}{{\AE}\bibinitperiod}{}{}{}{}}%
        {{hash=5a9cbf8143dba13439402928b7c6158b}{Kathryn}{K\bibinitperiod}{H\bibnamedelima Niesen\bibnamedelima {{\AE}}}{H\bibinitperiod\bibinitdelim N\bibinitperiod\bibinitdelim {\AE}\bibinitperiod}{}{}{}{}}%
        {{hash=861cc6383aea70c7af97a60eeaaa0f3d}{Linda}{L\bibinitperiod}{L\bibnamedelima Kavanagh\bibnamedelima {{\AE}}}{L\bibinitperiod\bibinitdelim K\bibinitperiod\bibinitdelim {\AE}\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{10a02661ba9d1113255cc71153ab4c82}
      \strng{fullhash}{16e89ad6bdd930aa18cadb60d2f1f79c}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{The scientific impact of the Structural Genomics Consortium : a protein family and ligand-centered approach to medically-relevant human proteins}}
      \field{title}{{The scientific impact of the Structural Genomics Consortium : a protein family and ligand-centered approach to medically-relevant human proteins}}
      \field{year}{2007}
      \field{pages}{107\bibrangedash 119}
      \verb{doi}
      \verb 10.1007/s10969-007-9027-2
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/art{\%}3A10.1007{\%}2Fs10969-007-9027-2.pdf:pdf
      \endverb
    \endentry
    \entry{Smyth2000}{article}{}
      \name{labelname}{2}{}{%
        {{hash=52c300e5d6fb78024ef538c5d298915a}{Smyth}{S\bibinitperiod}{M\bibnamedelima S}{M\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=bfaa7649e6d28f67106ac1fbaa12b55b}{Martin}{M\bibinitperiod}{J\bibnamedelima H\bibnamedelima J}{J\bibinitperiod\bibinitdelim H\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=52c300e5d6fb78024ef538c5d298915a}{Smyth}{S\bibinitperiod}{M\bibnamedelima S}{M\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=bfaa7649e6d28f67106ac1fbaa12b55b}{Martin}{M\bibinitperiod}{J\bibnamedelima H\bibnamedelima J}{J\bibinitperiod\bibinitdelim H\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{e5f299614d3278c44659ca169ec477ed}
      \strng{fullhash}{e5f299614d3278c44659ca169ec477ed}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{x Ray crystallography}}
      \field{abstract}{x Ray crystallography is currently the most favoured technique for structure determination of proteins and biological macromolecules. Increasingly, those interested in all branches of the biological sciences require structural information to shed light on previously unanswered questions. Furthermore, the availability of a protein structure can provide a more detailed focus for future research. The extension of the technique to systems such as viruses, immune complexes, and protein--nucleic acid complexes serves only to widen the appeal of crystallography. Structure based drug design, site directed mutagenesis, elucidation of enzyme mechanisms, and specificity of protein--ligand interactions are just a few of the areas in which x ray crystallography has provided clarification.}
      \field{annotation}{10.1136/mp.53.1.8}
      \field{journaltitle}{Molecular Pathology}
      \field{month}{02}
      \field{number}{1}
      \field{title}{{x Ray crystallography}}
      \field{volume}{53}
      \field{year}{2000}
      \field{pages}{8\bibrangedash 14}
      \verb{doi}
      \verb 10.1136/mp.53.1.8
      \endverb
      \verb{url}
      \verb http://mp.bmj.com/content/53/1/8.abstract
      \endverb
    \endentry
    \entry{Bill2011}{article}{}
      \name{labelname}{10}{}{%
        {{hash=06a311949828d59b7e4b3b1a9efd3125}{Bill}{B\bibinitperiod}{Roslyn\bibnamedelima M}{R\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=503311d75248be397b1b4d4509d184f3}{Henderson}{H\bibinitperiod}{Peter\bibnamedelimb J\bibnamedelima F}{P\bibinitperiod\bibinitdelim J\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{hash=ebe4aed96b9022ddfb50caed802e3801}{Iwata}{I\bibinitperiod}{So}{S\bibinitperiod}{}{}{}{}}%
        {{hash=4503b328233c1043ca7a2b5960dea646}{Kunji}{K\bibinitperiod}{Edmund\bibnamedelimb R\bibnamedelima S}{E\bibinitperiod\bibinitdelim R\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=64b31a537509f887e6991ce1e6955272}{Michel}{M\bibinitperiod}{Hartmut}{H\bibinitperiod}{}{}{}{}}%
        {{hash=8050fec8b521b49653b69709bdf45d26}{Neutze}{N\bibinitperiod}{Richard}{R\bibinitperiod}{}{}{}{}}%
        {{hash=834ea5365b8a63582d9ddfad8736b1e8}{Newstead}{N\bibinitperiod}{Simon}{S\bibinitperiod}{}{}{}{}}%
        {{hash=c5b90a84288d961f7e7e5b88c0d01f9d}{Poolman}{P\bibinitperiod}{Bert}{B\bibinitperiod}{}{}{}{}}%
        {{hash=7d0a773ead80f40a3aa3630081b806bc}{Tate}{T\bibinitperiod}{Christopher\bibnamedelima G}{C\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=3e03ba5604e981fd33254810cf11ad35}{Vogel}{V\bibinitperiod}{Horst}{H\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{10}{}{%
        {{hash=06a311949828d59b7e4b3b1a9efd3125}{Bill}{B\bibinitperiod}{Roslyn\bibnamedelima M}{R\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=503311d75248be397b1b4d4509d184f3}{Henderson}{H\bibinitperiod}{Peter\bibnamedelimb J\bibnamedelima F}{P\bibinitperiod\bibinitdelim J\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{hash=ebe4aed96b9022ddfb50caed802e3801}{Iwata}{I\bibinitperiod}{So}{S\bibinitperiod}{}{}{}{}}%
        {{hash=4503b328233c1043ca7a2b5960dea646}{Kunji}{K\bibinitperiod}{Edmund\bibnamedelimb R\bibnamedelima S}{E\bibinitperiod\bibinitdelim R\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=64b31a537509f887e6991ce1e6955272}{Michel}{M\bibinitperiod}{Hartmut}{H\bibinitperiod}{}{}{}{}}%
        {{hash=8050fec8b521b49653b69709bdf45d26}{Neutze}{N\bibinitperiod}{Richard}{R\bibinitperiod}{}{}{}{}}%
        {{hash=834ea5365b8a63582d9ddfad8736b1e8}{Newstead}{N\bibinitperiod}{Simon}{S\bibinitperiod}{}{}{}{}}%
        {{hash=c5b90a84288d961f7e7e5b88c0d01f9d}{Poolman}{P\bibinitperiod}{Bert}{B\bibinitperiod}{}{}{}{}}%
        {{hash=7d0a773ead80f40a3aa3630081b806bc}{Tate}{T\bibinitperiod}{Christopher\bibnamedelima G}{C\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=3e03ba5604e981fd33254810cf11ad35}{Vogel}{V\bibinitperiod}{Horst}{H\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group}%
      }
      \strng{namehash}{7ca5bd6a5c186afc9d0627a4a279195e}
      \strng{fullhash}{5cc7eef09f59e4a5d25c41ae1013ae0b}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{perspective Overcoming barriers to membrane protein structure determination}}
      \field{issn}{1087-0156}
      \field{journaltitle}{Nature Biotechnology}
      \field{number}{4}
      \field{title}{{perspective Overcoming barriers to membrane protein structure determination}}
      \field{volume}{29}
      \field{year}{2011}
      \field{pages}{335\bibrangedash 340}
      \verb{doi}
      \verb 10.1038/nbt.1833
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/nbt.1833.pdf:pdf
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1038/nbt.1833
      \endverb
    \endentry
    \entry{Yaffe2005}{article}{}
      \name{labelname}{1}{}{%
        {{hash=784e1463079a6f278a7dd8546a176806}{Yaffe}{Y\bibinitperiod}{Michael\bibnamedelima B}{M\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=784e1463079a6f278a7dd8546a176806}{Yaffe}{Y\bibinitperiod}{Michael\bibnamedelima B}{M\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{784e1463079a6f278a7dd8546a176806}
      \strng{fullhash}{784e1463079a6f278a7dd8546a176806}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{X-ray crystallography and structural biology}}
      \field{issn}{0090-3493}
      \field{journaltitle}{Critical Care Medicine}
      \field{number}{12}
      \field{title}{{X-ray crystallography and structural biology}}
      \field{volume}{33}
      \field{year}{2005}
      \verb{url}
      \verb http://journals.lww.com/ccmjournal/Fulltext/2005/12001/X%7B%5C_%7Dray%7B%5C_%7Dcrystallography%7B%5C_%7Dand%7B%5C_%7Dstructural%7B%5C_%7Dbiology.13.aspx
      \endverb
    \endentry
    \entry{Morris1992}{article}{}
      \name{labelname}{4}{}{%
        {{hash=ca545d3f9551f8f6ce94efdbbc4a346c}{Morris}{M\bibinitperiod}{A\bibnamedelima L}{A\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=5c4eb1cd238e391dc3c289863ad4ac4a}{MacArthur}{M\bibinitperiod}{M\bibnamedelima W}{M\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=9992b643c702bf350318bbcf30cb5d11}{Hutchinson}{H\bibinitperiod}{E\bibnamedelima G}{E\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=4e0a85c4306de0b0c0b90e73ab079396}{Thornton}{T\bibinitperiod}{J\bibnamedelima M}{J\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=ca545d3f9551f8f6ce94efdbbc4a346c}{Morris}{M\bibinitperiod}{A\bibnamedelima L}{A\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=5c4eb1cd238e391dc3c289863ad4ac4a}{MacArthur}{M\bibinitperiod}{M\bibnamedelima W}{M\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=9992b643c702bf350318bbcf30cb5d11}{Hutchinson}{H\bibinitperiod}{E\bibnamedelima G}{E\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=4e0a85c4306de0b0c0b90e73ab079396}{Thornton}{T\bibinitperiod}{J\bibnamedelima M}{J\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{a62f2c8f696c5112bc444536a3637d4d}
      \strng{fullhash}{7c4392cedd5e2971f3b15807f2e9aa91}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Stereochemical quality of protein structure coordinates.}}
      \field{abstract}{Methods have been developed to assess the stereochemical quality of any protein structure both globally and locally using various criteria. Several parameters can be derived from the coordinates of a given structure. Global parameters include the distribution of phi, psi and chi 1 torsion angles, and hydrogen bond energies. There are clear correlations between these parameters and resolution; as the resolution improves, the distribution of the parameters becomes more clustered. These features show a broad distribution about ideal values derived from high-resolution structures. Some structures have tightly clustered distributions even at relatively low resolutions, while others show abnormal scatter though the data go to high resolution. Additional indicators of local irregularity include proline phi angles, peptide bond planarities, disulfide bond lengths, and their chi 3 torsion angles. These stereochemical parameters have been used to generate measures of stereochemical quality which provide a simple guide as to the reliability of a structure, in addition to the most important measures, resolution and R-factor. The parameters used in this evaluation are not novel, and are easily calculated from structure coordinates. A program suite is currently being developed which will quickly check a given structure, highlighting unusual stereochemistry and possible errors.}
      \field{issn}{0887-3585}
      \field{journaltitle}{Proteins}
      \field{month}{04}
      \field{number}{4}
      \field{title}{{Stereochemical quality of protein structure coordinates.}}
      \field{volume}{12}
      \field{year}{1992}
      \field{pages}{345\bibrangedash 64}
      \verb{doi}
      \verb 10.1002/prot.340120407
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/1579569
      \endverb
    \endentry
    \entry{Wider2000}{article}{}
      \name{labelname}{1}{}{%
        {{hash=8ff508576e15ddc36a991d63efec7a65}{Wider}{W\bibinitperiod}{Gerhard}{G\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=8ff508576e15ddc36a991d63efec7a65}{Wider}{W\bibinitperiod}{Gerhard}{G\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{8ff508576e15ddc36a991d63efec7a65}
      \strng{fullhash}{8ff508576e15ddc36a991d63efec7a65}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Structure Determination of Biological Macromolecules in Solution Using NMR spectroscopy}}
      \field{title}{{Structure Determination of Biological Macromolecules in Solution Using NMR spectroscopy}}
      \field{volume}{1294}
      \field{year}{2000}
      \field{pages}{1278\bibrangedash 1294}
      \verb{file}
      \verb :home/fran/Downloads/Guide-1997-Wider.pdf:pdf
      \endverb
    \endentry
    \entry{Gadian1993}{inbook}{}
      \name{labelname}{4}{}{%
        {{hash=ea789d788f1dbb6421322e0b21f5892c}{Gadian}{G\bibinitperiod}{David\bibnamedelima G}{D\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=55ef8ad51e26dc13ed256093d4dbb331}{Williams}{W\bibinitperiod}{S\bibnamedelima R}{S\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=c46b279e69384c924ebbee8dc9bec2b4}{Bates}{B\bibinitperiod}{T\bibnamedelima E}{T\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=cc834580c06e9234687d5bac41c708ba}{Kauppinen}{K\bibinitperiod}{R\bibnamedelima A}{R\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=ea789d788f1dbb6421322e0b21f5892c}{Gadian}{G\bibinitperiod}{David\bibnamedelima G}{D\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=55ef8ad51e26dc13ed256093d4dbb331}{Williams}{W\bibinitperiod}{S\bibnamedelima R}{S\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=c46b279e69384c924ebbee8dc9bec2b4}{Bates}{B\bibinitperiod}{T\bibnamedelima E}{T\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=cc834580c06e9234687d5bac41c708ba}{Kauppinen}{K\bibinitperiod}{R\bibnamedelima A}{R\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \name{editor}{3}{}{%
        {{hash=b883c437ea4b18bb330c9f183700926d}{Baethmann}{B\bibinitperiod}{Alexander}{A\bibinitperiod}{}{}{}{}}%
        {{hash=42cf7795e55b1bbb8433ec56e271ea90}{Kempski}{K\bibinitperiod}{Oliver}{O\bibinitperiod}{}{}{}{}}%
        {{hash=6d5b254ce5ca2b62a527c52392e63f66}{Sch{\"{u}}rer}{S\bibinitperiod}{Ludwig}{L\bibinitperiod}{}{}{}{}}%
      }
      \list{location}{1}{%
        {Vienna}%
      }
      \list{publisher}{1}{%
        {Springer Vienna}%
      }
      \strng{namehash}{cf3674bd64b3eb0f6d286a9085ce672b}
      \strng{fullhash}{6161b0c0af55feabf8f34f4305d690c5}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Mechanisms of Secondary Brain Damage: Current State}}
      \field{chapter}{NMR Spectr}
      \field{isbn}{978-3-7091-9266-5}
      \field{title}{{Mechanisms of Secondary Brain Damage: Current State}}
      \field{year}{1993}
      \field{pages}{1\bibrangedash 8}
      \verb{doi}
      \verb 10.1007/978-3-7091-9266-5_1
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1007/978-3-7091-9266-5%7B%5C_%7D1
      \endverb
    \endentry
    \entry{CryoEM}{article}{}
      \name{labelname}{4}{}{%
        {{hash=c9d0a219c4a539032eb0d79df4277ea3}{Up}{U\bibinitperiod}{Kicking}{K\bibinitperiod}{}{}{}{}}%
        {{hash=d250e4bf2382052ed37179e39ab71c4e}{In}{I\bibinitperiod}{A\bibnamedelima Storm}{A\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=37c7ce0c1e3d1f0f8cb1c3955b956511}{By}{B\bibinitperiod}{Biology}{B\bibinitperiod}{}{}{}{}}%
        {{hash=78ec7ea12d0fab6eff5bad8482c174d9}{The}{T\bibinitperiod}{Revealing}{R\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=c9d0a219c4a539032eb0d79df4277ea3}{Up}{U\bibinitperiod}{Kicking}{K\bibinitperiod}{}{}{}{}}%
        {{hash=d250e4bf2382052ed37179e39ab71c4e}{In}{I\bibinitperiod}{A\bibnamedelima Storm}{A\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=37c7ce0c1e3d1f0f8cb1c3955b956511}{By}{B\bibinitperiod}{Biology}{B\bibinitperiod}{}{}{}{}}%
        {{hash=78ec7ea12d0fab6eff5bad8482c174d9}{The}{T\bibinitperiod}{Revealing}{R\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{805315148e84bccbed827e82f5ef10eb}
      \strng{fullhash}{1e07bca05729a3ceb20708c44d371aa3}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{THE REVOLUTION WILL NOT BE CRYSTALLIZED}}
      \field{title}{{THE REVOLUTION WILL NOT BE CRYSTALLIZED}}
      \field{year}{2015}
      \field{pages}{7\bibrangedash 9}
      \verb{file}
      \verb :home/fran/Downloads/525172a.pdf:pdf
      \endverb
    \endentry
    \entry{Khatter2015}{article}{}
      \name{labelname}{4}{}{%
        {{hash=1237b30a79f31cc24e88f9fb5b2a979c}{Khatter}{K\bibinitperiod}{Heena}{H\bibinitperiod}{}{}{}{}}%
        {{hash=ab22a119ed136babaf1d53f74bcecc46}{Myasnikov}{M\bibinitperiod}{Alexander\bibnamedelima G}{A\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=7c017909f5c7c1d9050f654cdd840e71}{Natchiar}{N\bibinitperiod}{S\bibnamedelima Kundhavai}{S\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=7f33303a33f9674830d02e59631ee840}{Klaholz}{K\bibinitperiod}{Bruno\bibnamedelima P}{B\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=1237b30a79f31cc24e88f9fb5b2a979c}{Khatter}{K\bibinitperiod}{Heena}{H\bibinitperiod}{}{}{}{}}%
        {{hash=ab22a119ed136babaf1d53f74bcecc46}{Myasnikov}{M\bibinitperiod}{Alexander\bibnamedelima G}{A\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=7c017909f5c7c1d9050f654cdd840e71}{Natchiar}{N\bibinitperiod}{S\bibnamedelima Kundhavai}{S\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=7f33303a33f9674830d02e59631ee840}{Klaholz}{K\bibinitperiod}{Bruno\bibnamedelima P}{B\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.}%
      }
      \strng{namehash}{ad25b6b27717e671bc5d8c3638b26d0a}
      \strng{fullhash}{51acb4591ac4e0e4974e151566d9aa00}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Structure of the human 80S ribosome}}
      \field{abstract}{Ribosomes are translational machineries that catalyse protein synthesis. Ribosome structures from various species are known at the atomic level, but obtaining the structure of the human ribosome has remained a challenge; efforts to address this would be highly relevant with regard to human diseases. Here we report the near-atomic structure of the human ribosome derived from high-resolution single-particle cryo-electron microscopy and atomic model building. The structure has an average resolution of 3.6 A, reaching 2.9 A resolution in the most stable regions. It provides unprecedented insights into ribosomal RNA entities and amino acid side chains, notably of the transfer RNA binding sites and specific molecular interactions with the exit site tRNA. It reveals atomic details of the subunit interface, which is seen to remodel strongly upon rotational movements of the ribosomal subunits. Furthermore, the structure paves the way for analysing antibiotic side effects and diseases associated with deregulated protein synthesis.}
      \field{issn}{0028-0836}
      \field{journaltitle}{Nature}
      \field{month}{04}
      \field{number}{7549}
      \field{title}{{Structure of the human 80S ribosome}}
      \field{volume}{520}
      \field{year}{2015}
      \field{pages}{640\bibrangedash 645}
      \verb{url}
      \verb http://dx.doi.org/10.1038/nature14427%2010.1038/nature14427
      \endverb
    \endentry
    \entry{Zhao2015}{article}{}
      \name{labelname}{3}{}{%
        {{hash=69572537c7bd6eb7c3adb629938f30c0}{Zhao}{Z\bibinitperiod}{Jianhua}{J\bibinitperiod}{}{}{}{}}%
        {{hash=9e0844847d80f069f7d6f12741860d10}{Benlekbir}{B\bibinitperiod}{Samir}{S\bibinitperiod}{}{}{}{}}%
        {{hash=1b76f2f19d82e39b7328494a644bba77}{Rubinstein}{R\bibinitperiod}{John\bibnamedelima L}{J\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=69572537c7bd6eb7c3adb629938f30c0}{Zhao}{Z\bibinitperiod}{Jianhua}{J\bibinitperiod}{}{}{}{}}%
        {{hash=9e0844847d80f069f7d6f12741860d10}{Benlekbir}{B\bibinitperiod}{Samir}{S\bibinitperiod}{}{}{}{}}%
        {{hash=1b76f2f19d82e39b7328494a644bba77}{Rubinstein}{R\bibinitperiod}{John\bibnamedelima L}{J\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.}%
      }
      \strng{namehash}{71082dd705473c5fc1d8a14571322223}
      \strng{fullhash}{71082dd705473c5fc1d8a14571322223}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Electron cryomicroscopy observation of rotational states in a eukaryotic V-ATPase}}
      \field{issn}{0028-0836}
      \field{journaltitle}{Nature}
      \field{month}{05}
      \field{number}{7551}
      \field{title}{{Electron cryomicroscopy observation of rotational states in a eukaryotic V-ATPase}}
      \field{volume}{521}
      \field{year}{2015}
      \field{pages}{241\bibrangedash 245}
      \verb{url}
      \verb http://dx.doi.org/10.1038/nature14365%2010.1038/nature14365%20http://www.nature.com/nature/journal/v521/n7551/abs/nature14365.html%7B%5C#%7Dsupplementary-information
      \endverb
    \endentry
    \entry{Liao2013}{article}{}
      \name{labelname}{4}{}{%
        {{hash=89839d096b28899d33ce9b0189dc510c}{Liao}{L\bibinitperiod}{Maofu}{M\bibinitperiod}{}{}{}{}}%
        {{hash=7043918d8850265dec994752bffd5273}{Cao}{C\bibinitperiod}{Erhu}{E\bibinitperiod}{}{}{}{}}%
        {{hash=40a54a2081cceaeb2d7b4dbbe61aae12}{Julius}{J\bibinitperiod}{David}{D\bibinitperiod}{}{}{}{}}%
        {{hash=e02c0c0762e7a0f83481d4d0fd26fc71}{Cheng}{C\bibinitperiod}{Yifan}{Y\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=89839d096b28899d33ce9b0189dc510c}{Liao}{L\bibinitperiod}{Maofu}{M\bibinitperiod}{}{}{}{}}%
        {{hash=7043918d8850265dec994752bffd5273}{Cao}{C\bibinitperiod}{Erhu}{E\bibinitperiod}{}{}{}{}}%
        {{hash=40a54a2081cceaeb2d7b4dbbe61aae12}{Julius}{J\bibinitperiod}{David}{D\bibinitperiod}{}{}{}{}}%
        {{hash=e02c0c0762e7a0f83481d4d0fd26fc71}{Cheng}{C\bibinitperiod}{Yifan}{Y\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.}%
      }
      \strng{namehash}{bb30bf2bd4392e52357379a16d5fe8aa}
      \strng{fullhash}{4ec89c1c903023c6b4bd70aa24e7454a}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Structure of the TRPV1 ion channel determined by electron cryo-microscopy}}
      \field{abstract}{Transient receptor potential (TRP) channels are sensors for a wide range of cellular and environmental signals, but elucidating how these channels respond to physical and chemical stimuli has been hampered by a lack of detailed structural information. Here we exploit advances in electron cryo-microscopy to determine the structure of a mammalian TRP channel, TRPV1, at 3.4[thinsp]A resolution, breaking the side-chain resolution barrier for membrane proteins without crystallization. Like voltage-gated channels, TRPV1 exhibits four-fold symmetry around a central ion pathway formed by transmembrane segments 5-6 (S5-S6) and the intervening pore loop, which is flanked by S1-S4 voltage-sensor-like domains. TRPV1 has a wide extracellular /`mouth/' with a short selectivity filter. The conserved /`TRP domain/' interacts with the S4-S5 linker, consistent with its contribution to allosteric modulation. Subunit organization is facilitated by interactions among cytoplasmic domains, including amino-terminal ankyrin repeats. These observations provide a structural blueprint for understanding unique aspects of TRP channel function.}
      \field{issn}{0028-0836}
      \field{journaltitle}{Nature}
      \field{month}{12}
      \field{number}{7478}
      \field{title}{{Structure of the TRPV1 ion channel determined by electron cryo-microscopy}}
      \field{volume}{504}
      \field{year}{2013}
      \field{pages}{107\bibrangedash 112}
      \verb{url}
      \verb http://dx.doi.org/10.1038/nature12822%2010.1038/nature12822
      \endverb
    \endentry
    \entry{Bai2015}{article}{}
      \name{labelname}{9}{}{%
        {{hash=618573f5c4d28040ba3d1987d367698d}{Bai}{B\bibinitperiod}{Xiao-chen}{X\bibinithyphendelim c\bibinitperiod}{}{}{}{}}%
        {{hash=a2499a066e63e3b7cb4dec037bb0ad0b}{Yan}{Y\bibinitperiod}{Chuangye}{C\bibinitperiod}{}{}{}{}}%
        {{hash=a086c2fb30943a9ec11a79d3c7bb1cc6}{Yang}{Y\bibinitperiod}{Guanghui}{G\bibinitperiod}{}{}{}{}}%
        {{hash=480d6622a7b9e66fbafc3caca77c1649}{Lu}{L\bibinitperiod}{Peilong}{P\bibinitperiod}{}{}{}{}}%
        {{hash=943e61c0dd3e3cb0a693aed25ec1c0ce}{Ma}{M\bibinitperiod}{Dan}{D\bibinitperiod}{}{}{}{}}%
        {{hash=a6dcdd240f56bc8f342b864416f1e18a}{Sun}{S\bibinitperiod}{Linfeng}{L\bibinitperiod}{}{}{}{}}%
        {{hash=cdb7d456d9550085d585ecff364a3de5}{Zhou}{Z\bibinitperiod}{Rui}{R\bibinitperiod}{}{}{}{}}%
        {{hash=3e32b03d218a1690fd03a982dee8338e}{Scheres}{S\bibinitperiod}{Sjors\bibnamedelimb H\bibnamedelima W}{S\bibinitperiod\bibinitdelim H\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=14866a4828424fc08a8278c4dc04e309}{Shi}{S\bibinitperiod}{Yigong}{Y\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{9}{}{%
        {{hash=618573f5c4d28040ba3d1987d367698d}{Bai}{B\bibinitperiod}{Xiao-chen}{X\bibinithyphendelim c\bibinitperiod}{}{}{}{}}%
        {{hash=a2499a066e63e3b7cb4dec037bb0ad0b}{Yan}{Y\bibinitperiod}{Chuangye}{C\bibinitperiod}{}{}{}{}}%
        {{hash=a086c2fb30943a9ec11a79d3c7bb1cc6}{Yang}{Y\bibinitperiod}{Guanghui}{G\bibinitperiod}{}{}{}{}}%
        {{hash=480d6622a7b9e66fbafc3caca77c1649}{Lu}{L\bibinitperiod}{Peilong}{P\bibinitperiod}{}{}{}{}}%
        {{hash=943e61c0dd3e3cb0a693aed25ec1c0ce}{Ma}{M\bibinitperiod}{Dan}{D\bibinitperiod}{}{}{}{}}%
        {{hash=a6dcdd240f56bc8f342b864416f1e18a}{Sun}{S\bibinitperiod}{Linfeng}{L\bibinitperiod}{}{}{}{}}%
        {{hash=cdb7d456d9550085d585ecff364a3de5}{Zhou}{Z\bibinitperiod}{Rui}{R\bibinitperiod}{}{}{}{}}%
        {{hash=3e32b03d218a1690fd03a982dee8338e}{Scheres}{S\bibinitperiod}{Sjors\bibnamedelimb H\bibnamedelima W}{S\bibinitperiod\bibinitdelim H\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=14866a4828424fc08a8278c4dc04e309}{Shi}{S\bibinitperiod}{Yigong}{Y\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.}%
      }
      \strng{namehash}{34b482037e84f119ac569db9dfa544c1}
      \strng{fullhash}{a473d7a9e4782bd0cc5bbebd22c09d17}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{An atomic structure of human [ggr]-secretase}}
      \field{abstract}{Dysfunction of the intramembrane protease [ggr]-secretase is thought to cause Alzheimer/'s disease, with most mutations derived from Alzheimer/'s disease mapping to the catalytic subunit presenilin 1 (PS1). Here we report an atomic structure of human [ggr]-secretase at 3.4 A resolution, determined by single-particle cryo-electron microscopy. Mutations derived from Alzheimer/'s disease affect residues at two hotspots in PS1, each located at the centre of a distinct four transmembrane segment (TM) bundle. TM2 and, to a lesser extent, TM6 exhibit considerable flexibility, yielding a plastic active site and adaptable surrounding elements. The active site of PS1 is accessible from the convex side of the TM horseshoe, suggesting considerable conformational changes in nicastrin extracellular domain after substrate recruitment. Component protein APH-1 serves as a scaffold, anchoring the lone transmembrane helix from nicastrin and supporting the flexible conformation of PS1. Ordered phospholipids stabilize the complex inside the membrane. Our structure serves as a molecular basis for mechanistic understanding of [ggr]-secretase function.}
      \field{issn}{0028-0836}
      \field{journaltitle}{Nature}
      \field{month}{09}
      \field{number}{7568}
      \field{title}{{An atomic structure of human [ggr]-secretase}}
      \field{volume}{525}
      \field{year}{2015}
      \field{pages}{212\bibrangedash 217}
      \verb{url}
      \verb http://dx.doi.org/10.1038/nature14892%2010.1038/nature14892
      \endverb
    \endentry
    \entry{Jones1992}{article}{}
      \name{labelname}{3}{}{%
        {{hash=af16bd4867635ba09445f9fff6c0335a}{Jones}{J\bibinitperiod}{D\bibnamedelima T}{D\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=4d2e06bbca95a0136a88c069edaf5605}{Taylort}{T\bibinitperiod}{W\bibnamedelima R}{W\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=4e0a85c4306de0b0c0b90e73ab079396}{Thornton}{T\bibinitperiod}{J\bibnamedelima M}{J\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=af16bd4867635ba09445f9fff6c0335a}{Jones}{J\bibinitperiod}{D\bibnamedelima T}{D\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=4d2e06bbca95a0136a88c069edaf5605}{Taylort}{T\bibinitperiod}{W\bibnamedelima R}{W\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=4e0a85c4306de0b0c0b90e73ab079396}{Thornton}{T\bibinitperiod}{J\bibnamedelima M}{J\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{9efd91eb936bd31081c84ffa45dba8ba}
      \strng{fullhash}{9efd91eb936bd31081c84ffa45dba8ba}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{A new approach to protein fold recognition}}
      \field{annotation}{10.1038/358086a0}
      \field{journaltitle}{Nature}
      \field{month}{07}
      \field{number}{6381}
      \field{title}{{A new approach to protein fold recognition}}
      \field{volume}{358}
      \field{year}{1992}
      \field{pages}{86\bibrangedash 89}
      \verb{url}
      \verb http://dx.doi.org/10.1038/358086a0
      \endverb
    \endentry
    \entry{Bowie1991}{article}{}
      \name{labelname}{3}{}{%
        {{hash=d4bd76546b4d6b82d6d0c044b5b616d5}{Bowie}{B\bibinitperiod}{J\bibnamedelima U}{J\bibinitperiod\bibinitdelim U\bibinitperiod}{}{}{}{}}%
        {{hash=fa8afe37484dda68472af72f14bedb31}{Luthy}{L\bibinitperiod}{R}{R\bibinitperiod}{}{}{}{}}%
        {{hash=5011b825249e7610f91f155dda93271e}{Eisenberg}{E\bibinitperiod}{D}{D\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=d4bd76546b4d6b82d6d0c044b5b616d5}{Bowie}{B\bibinitperiod}{J\bibnamedelima U}{J\bibinitperiod\bibinitdelim U\bibinitperiod}{}{}{}{}}%
        {{hash=fa8afe37484dda68472af72f14bedb31}{Luthy}{L\bibinitperiod}{R}{R\bibinitperiod}{}{}{}{}}%
        {{hash=5011b825249e7610f91f155dda93271e}{Eisenberg}{E\bibinitperiod}{D}{D\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{661ebff2c790fa080dede730f9e75a72}
      \strng{fullhash}{661ebff2c790fa080dede730f9e75a72}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{A method to identify protein sequences that fold into a known three-dimensional structure}}
      \field{abstract}{The inverse protein folding problem, the problem of finding which amino acid sequences fold into a known three-dimensional (3D) structure, can be effectively attacked by finding sequences that are most compatible with the environments of the residues in the 3D structure. The environments are described by: (i) the area of the residue buried in the protein and inaccessible to solvent; (ii) the fraction of side-chain area that is covered by polar atoms (O and N); and (iii) the local secondary structure. Examples of this 3D profile method are presented for four families of proteins: the globins, cyclic AMP (adenosine 3',5'-monophosphate) receptor-like proteins, the periplasmic binding proteins, and the actins. This method is able to detect the structural similarity of the actins and 70- kilodalton heat shock proteins, even though these protein families share no detectable sequence similarity.}
      \field{journaltitle}{Science}
      \field{month}{07}
      \field{number}{5016}
      \field{title}{{A method to identify protein sequences that fold into a known three-dimensional structure}}
      \field{volume}{253}
      \field{year}{1991}
      \field{pages}{164\bibrangedash 170}
      \verb{url}
      \verb http://science.sciencemag.org/content/253/5016/164.abstract
      \endverb
    \endentry
    \entry{Lee2009}{inbook}{}
      \name{labelname}{3}{}{%
        {{hash=5b2f0d528aea9e816f7016945db7adf6}{Lee}{L\bibinitperiod}{Jooyoung}{J\bibinitperiod}{}{}{}{}}%
        {{hash=8f4ebdd0f614f53d548b9dd8d0f9159c}{Wu}{W\bibinitperiod}{Sitao}{S\bibinitperiod}{}{}{}{}}%
        {{hash=e760d38078aff4a5b24c867aa5178c26}{Zhang}{Z\bibinitperiod}{Yang}{Y\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=5b2f0d528aea9e816f7016945db7adf6}{Lee}{L\bibinitperiod}{Jooyoung}{J\bibinitperiod}{}{}{}{}}%
        {{hash=8f4ebdd0f614f53d548b9dd8d0f9159c}{Wu}{W\bibinitperiod}{Sitao}{S\bibinitperiod}{}{}{}{}}%
        {{hash=e760d38078aff4a5b24c867aa5178c26}{Zhang}{Z\bibinitperiod}{Yang}{Y\bibinitperiod}{}{}{}{}}%
      }
      \name{editor}{1}{}{%
        {{hash=a072ee8766bfb7d578e1e2752d5a1260}{Rigden}{R\bibinitperiod}{Daniel\bibnamedelima John}{D\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \list{location}{1}{%
        {Dordrecht}%
      }
      \list{publisher}{1}{%
        {Springer Netherlands}%
      }
      \strng{namehash}{db657250955c52e88732249c8c7c252e}
      \strng{fullhash}{db657250955c52e88732249c8c7c252e}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{From Protein Structure to Function with Bioinformatics}}
      \field{chapter}{Ab Initio}
      \field{isbn}{978-1-4020-9058-5}
      \field{title}{{From Protein Structure to Function with Bioinformatics}}
      \field{year}{2009}
      \field{pages}{3\bibrangedash 25}
      \verb{doi}
      \verb 10.1007/978-1-4020-9058-5_1
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1007/978-1-4020-9058-5%7B%5C_%7D1
      \endverb
    \endentry
    \entry{Russel2012}{article}{}
      \name{labelname}{8}{}{%
        {{hash=f03be77275b8afe021f4c417188f9554}{Russel}{R\bibinitperiod}{Daniel}{D\bibinitperiod}{}{}{}{}}%
        {{hash=f89fb0914c74069d2ac17a2c57dff5fc}{Lasker}{L\bibinitperiod}{Keren}{K\bibinitperiod}{}{}{}{}}%
        {{hash=f6202d41c7a5dbee0cec6179ce443b0e}{Webb}{W\bibinitperiod}{Ben}{B\bibinitperiod}{}{}{}{}}%
        {{hash=3cc9460302d940cf170600a38d4053d9}{Vel{\'{a}}zquez-Muriel}{V\bibinithyphendelim M\bibinitperiod}{Javier}{J\bibinitperiod}{}{}{}{}}%
        {{hash=8b7ff375921119bc24ba872b664b0f66}{Tjioe}{T\bibinitperiod}{Elina}{E\bibinitperiod}{}{}{}{}}%
        {{hash=1e1d535f241b3723b64dee3eb90da671}{Schneidman-Duhovny}{S\bibinithyphendelim D\bibinitperiod}{Dina}{D\bibinitperiod}{}{}{}{}}%
        {{hash=3402d6e6862fca8a38f6ce7b41f181b6}{Peterson}{P\bibinitperiod}{Bret}{B\bibinitperiod}{}{}{}{}}%
        {{hash=f3bdee19cfffe5535eb11a4f1ee54225}{Sali}{S\bibinitperiod}{Andrej}{A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{8}{}{%
        {{hash=f03be77275b8afe021f4c417188f9554}{Russel}{R\bibinitperiod}{Daniel}{D\bibinitperiod}{}{}{}{}}%
        {{hash=f89fb0914c74069d2ac17a2c57dff5fc}{Lasker}{L\bibinitperiod}{Keren}{K\bibinitperiod}{}{}{}{}}%
        {{hash=f6202d41c7a5dbee0cec6179ce443b0e}{Webb}{W\bibinitperiod}{Ben}{B\bibinitperiod}{}{}{}{}}%
        {{hash=3cc9460302d940cf170600a38d4053d9}{Vel{\'{a}}zquez-Muriel}{V\bibinithyphendelim M\bibinitperiod}{Javier}{J\bibinitperiod}{}{}{}{}}%
        {{hash=8b7ff375921119bc24ba872b664b0f66}{Tjioe}{T\bibinitperiod}{Elina}{E\bibinitperiod}{}{}{}{}}%
        {{hash=1e1d535f241b3723b64dee3eb90da671}{Schneidman-Duhovny}{S\bibinithyphendelim D\bibinitperiod}{Dina}{D\bibinitperiod}{}{}{}{}}%
        {{hash=3402d6e6862fca8a38f6ce7b41f181b6}{Peterson}{P\bibinitperiod}{Bret}{B\bibinitperiod}{}{}{}{}}%
        {{hash=f3bdee19cfffe5535eb11a4f1ee54225}{Sali}{S\bibinitperiod}{Andrej}{A\bibinitperiod}{}{}{}{}}%
      }
      \list{location}{1}{%
        {San Francisco, USA}%
      }
      \list{publisher}{1}{%
        {Public Library of Science}%
      }
      \strng{namehash}{5507ec60e7c19a3fb2f0f99ecc5b6b00}
      \strng{fullhash}{f5716bdb278d1800851f7a5fc72bed65}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Putting the Pieces Together: Integrative Modeling Platform Software for Structure Determination of Macromolecular Assemblies}}
      \field{abstract}{A set of software tools for building and distributing models of macromolecular assemblies uses an integrative structure modeling approach, which casts the building of models as a computational optimization problem where information is encoded into a scoring function used to evaluate candidate models.}
      \field{issn}{1544-9173}
      \field{journaltitle}{PLoS Biology}
      \field{month}{01}
      \field{number}{1}
      \field{title}{{Putting the Pieces Together: Integrative Modeling Platform Software for Structure Determination of Macromolecular Assemblies}}
      \field{volume}{10}
      \field{year}{2012}
      \field{pages}{e1001244}
      \verb{doi}
      \verb 10.1371/journal.pbio.1001244
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3260315/
      \endverb
    \endentry
    \entry{Eswar2007}{article}{}
      \name{labelname}{8}{}{%
        {{hash=40e29ff69658648458afc77145a5471a}{Eswar}{E\bibinitperiod}{Narayanan}{N\bibinitperiod}{}{}{}{}}%
        {{hash=f6202d41c7a5dbee0cec6179ce443b0e}{Webb}{W\bibinitperiod}{Ben}{B\bibinitperiod}{}{}{}{}}%
        {{hash=24f88df3c6af6a41f2b4b5d26f2b5d94}{Marti-Renom}{M\bibinithyphendelim R\bibinitperiod}{Marc\bibnamedelima A}{M\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=8fbaaf817a730509f1555c4a4cd49933}{Madhusudhan}{M\bibinitperiod}{M\bibnamedelima S}{M\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=0bd28561b7fb607311714f5d813b411a}{Eramian}{E\bibinitperiod}{David}{D\bibinitperiod}{}{}{}{}}%
        {{hash=01c11c5217d66a703779cd4b09590db5}{Shen}{S\bibinitperiod}{Min-Yi}{M\bibinithyphendelim Y\bibinitperiod}{}{}{}{}}%
        {{hash=ed697f1b151831b61b4a519f41fdb295}{Pieper}{P\bibinitperiod}{Ursula}{U\bibinitperiod}{}{}{}{}}%
        {{hash=f3bdee19cfffe5535eb11a4f1ee54225}{Sali}{S\bibinitperiod}{Andrej}{A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{8}{}{%
        {{hash=40e29ff69658648458afc77145a5471a}{Eswar}{E\bibinitperiod}{Narayanan}{N\bibinitperiod}{}{}{}{}}%
        {{hash=f6202d41c7a5dbee0cec6179ce443b0e}{Webb}{W\bibinitperiod}{Ben}{B\bibinitperiod}{}{}{}{}}%
        {{hash=24f88df3c6af6a41f2b4b5d26f2b5d94}{Marti-Renom}{M\bibinithyphendelim R\bibinitperiod}{Marc\bibnamedelima A}{M\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=8fbaaf817a730509f1555c4a4cd49933}{Madhusudhan}{M\bibinitperiod}{M\bibnamedelima S}{M\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=0bd28561b7fb607311714f5d813b411a}{Eramian}{E\bibinitperiod}{David}{D\bibinitperiod}{}{}{}{}}%
        {{hash=01c11c5217d66a703779cd4b09590db5}{Shen}{S\bibinitperiod}{Min-Yi}{M\bibinithyphendelim Y\bibinitperiod}{}{}{}{}}%
        {{hash=ed697f1b151831b61b4a519f41fdb295}{Pieper}{P\bibinitperiod}{Ursula}{U\bibinitperiod}{}{}{}{}}%
        {{hash=f3bdee19cfffe5535eb11a4f1ee54225}{Sali}{S\bibinitperiod}{Andrej}{A\bibinitperiod}{}{}{}{}}%
      }
      \list{language}{1}{%
        {en}%
      }
      \list{publisher}{1}{%
        {John Wiley {\&} Sons, Inc.}%
      }
      \strng{namehash}{c175c9991d3fff01a7ea1bd6a1acf03c}
      \strng{fullhash}{7a068769b56299e2a5067882575d7f68}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Comparative protein structure modeling using MODELLER.}}
      \field{abstract}{Functional characterization of a protein sequence is a common goal in biology, and is usually facilitated by having an accurate three-dimensional (3-D) structure of the studied protein. In the absence of an experimentally determined structure, comparative or homology modeling can sometimes provide a useful 3-D model for a protein that is related to at least one known protein structure. Comparative modeling predicts the 3-D structure of a given protein sequence (target) based primarily on its alignment to one or more proteins of known structure (templates). The prediction process consists of fold assignment, target-template alignment, model building, and model evaluation. This unit describes how to calculate comparative models using the program MODELLER and discusses all four steps of comparative modeling, frequently observed errors, and some applications. Modeling lactate dehydrogenase from Trichomonas vaginalis (TvLDH) is described as an example. The download and installation of the MODELLER software is also described.}
      \field{isbn}{9780471140863}
      \field{issn}{1934-3663}
      \field{journaltitle}{Current protocols in protein science / editorial board, John E. Coligan ... [et al.]}
      \field{month}{12}
      \field{title}{{Comparative protein structure modeling using MODELLER.}}
      \field{volume}{Chapter 2}
      \field{year}{2007}
      \field{pages}{Unit 2.9}
      \verb{doi}
      \verb 10.1002/0471140864.ps0209s50
      \endverb
      \verb{url}
      \verb http://onlinelibrary.wiley.com/doi/10.1002/0471140864.ps0209s50/full
      \endverb
    \endentry
    \entry{Baker2001}{article}{}
      \name{labelname}{1}{}{%
        {{hash=a4ae2debe1c7f5174d0b3d98accdb733}{Baker}{B\bibinitperiod}{D}{D\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=a4ae2debe1c7f5174d0b3d98accdb733}{Baker}{B\bibinitperiod}{D}{D\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{a4ae2debe1c7f5174d0b3d98accdb733}
      \strng{fullhash}{a4ae2debe1c7f5174d0b3d98accdb733}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Protein structure prediction and structural genomics}}
      \field{abstract}{Genome sequencing projects are producing linear amino acid sequences, but full understanding of the biological role of these proteins will require knowledge of their structure and function. Although experimental structure determination methods are providing high-resolution structure information about a subset of the proteins, computational structure prediction methods will provide valuable information for the large fraction of sequences whose structures will not be determined experimentally. The first class of protein structure prediction methods, including threading and comparative modeling, rely on detectable similarity spanning most of the modeled sequence and at least one known structure. The second class of methods, de novo or ab initio methods, predict the structure from sequence alone, without relying on similarity at the fold level between the modeled sequence and any of the known structures. In this Viewpoint, we begin by describing the essential features of the methods, the accuracy of the models, and their application to the prediction and understanding of protein function, both for single proteins and on the scale of whole genomes. We then discuss the important role that protein structure prediction methods play in the growing worldwide effort in structural genomics.}
      \field{isbn}{0036-8075 (Print)$\backslash$n0036-8075 (Linking)}
      \field{issn}{00368075}
      \field{journaltitle}{Science}
      \field{title}{{Protein structure prediction and structural genomics}}
      \field{volume}{294}
      \field{year}{2001}
      \field{pages}{93\bibrangedash 96}
      \verb{doi}
      \verb 10.1126/science.1065659
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/93.full.pdf:pdf
      \endverb
    \endentry
    \entry{twilight1996}{article}{}
      \name{labelname}{2}{}{%
        {{hash=33b59b34f9681453b77f82a576780fe1}{Chung}{C\bibinitperiod}{Su\bibnamedelima Yun}{S\bibinitperiod\bibinitdelim Y\bibinitperiod}{}{}{}{}}%
        {{hash=56286ad2cb905e2bba8546f13b6487aa}{Subbiah}{S\bibinitperiod}{S}{S\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=33b59b34f9681453b77f82a576780fe1}{Chung}{C\bibinitperiod}{Su\bibnamedelima Yun}{S\bibinitperiod\bibinitdelim Y\bibinitperiod}{}{}{}{}}%
        {{hash=56286ad2cb905e2bba8546f13b6487aa}{Subbiah}{S\bibinitperiod}{S}{S\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{fa4026a43546ea25682396e3985f69cf}
      \strng{fullhash}{fa4026a43546ea25682396e3985f69cf}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{A structural explanation for the twilight zone of protein sequence homology}}
      \field{abstract}{Homology modeling of protein structures as a function of sequence breaks down at the twilight zone limit of sequence identity between the template and target proteins. Our results suggest that protein sequences that have diverged from a common ancestor beyond the twilight zone may adopt side-chain interactions that are very different from those endowed by the ancestral sequence.}
      \field{issn}{09692126}
      \field{journaltitle}{Structure}
      \field{month}{10}
      \field{number}{10}
      \field{title}{{A structural explanation for the twilight zone of protein sequence homology}}
      \field{volume}{4}
      \field{year}{1996}
      \field{pages}{1123\bibrangedash 1127}
      \verb{doi}
      \verb 10.1016/S0969-2126(96)00119-0
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Chung, Subbiah - 1996 - A structural explanation for the twilight zone of protein sequence homology.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.sciencedirect.com/science/article/pii/S0969212696001190
      \endverb
    \endentry
    \entry{Sander1991}{article}{}
      \name{labelname}{2}{}{%
        {{hash=31a874f827fdd07d0136f7e2a1beb6a1}{Sander}{S\bibinitperiod}{C}{C\bibinitperiod}{}{}{}{}}%
        {{hash=a00cee35baadb952574e0c6f19b304c0}{Schneider}{S\bibinitperiod}{R}{R\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=31a874f827fdd07d0136f7e2a1beb6a1}{Sander}{S\bibinitperiod}{C}{C\bibinitperiod}{}{}{}{}}%
        {{hash=a00cee35baadb952574e0c6f19b304c0}{Schneider}{S\bibinitperiod}{R}{R\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{d628a87baec1b75e4e30b019f12c7a26}
      \strng{fullhash}{d628a87baec1b75e4e30b019f12c7a26}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Database of homology-derived protein structures and the structural meaning of sequence alignment.}}
      \field{abstract}{The database of known protein three-dimensional structures can be significantly increased by the use of sequence homology, based on the following observations. (1) The database of known sequences, currently at more than 12,000 proteins, is two orders of magnitude larger than the database of known structures. (2) The currently most powerful method of predicting protein structures is model building by homology. (3) Structural homology can be inferred from the level of sequence similarity. (4) The threshold of sequence similarity sufficient for structural homology depends strongly on the length of the alignment. Here, we first quantify the relation between sequence similarity, structure similarity, and alignment length by an exhaustive survey of alignments between proteins of known structure and report a homology threshold curve as a function of alignment length. We then produce a database of homology-derived secondary structure of proteins (HSSP) by aligning to each protein of known structure all sequences deemed homologous on the basis of the threshold curve. For each known protein structure, the derived database contains the aligned sequences, secondary structure, sequence variability, and sequence profile. Tertiary structures of the aligned sequences are implied, but not modeled explicitly. The database effectively increases the number of known protein structures by a factor of five to more than 1800. The results may be useful in assessing the structural significance of matches in sequence database searches, in deriving preferences and patterns for structure prediction, in elucidating the structural role of conserved residues, and in modeling three-dimensional detail by homology.}
      \field{issn}{0887-3585}
      \field{journaltitle}{Proteins}
      \field{month}{01}
      \field{number}{1}
      \field{title}{{Database of homology-derived protein structures and the structural meaning of sequence alignment.}}
      \field{volume}{9}
      \field{year}{1991}
      \field{pages}{56\bibrangedash 68}
      \verb{doi}
      \verb 10.1002/prot.340090107
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/2017436
      \endverb
    \endentry
    \entry{PRO1410}{article}{}
      \name{labelname}{2}{}{%
        {{hash=ed874de6afebf6119f7e51dd153e71cd}{Ferrada}{F\bibinitperiod}{Evandro}{E\bibinitperiod}{}{}{}{}}%
        {{hash=021094801a7b30af836225098951e626}{Melo}{M\bibinitperiod}{Francisco}{F\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=ed874de6afebf6119f7e51dd153e71cd}{Ferrada}{F\bibinitperiod}{Evandro}{E\bibinitperiod}{}{}{}{}}%
        {{hash=021094801a7b30af836225098951e626}{Melo}{M\bibinitperiod}{Francisco}{F\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Cold Spring Harbor Laboratory Press}%
      }
      \strng{namehash}{0f90a37fb41046e4f0175876923e05c9}
      \strng{fullhash}{0f90a37fb41046e4f0175876923e05c9}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Nonbonded terms extrapolated from nonlocal knowledge-based energy functions improve error detection in near-native protein structure models}}
      \field{issn}{1469-896X}
      \field{journaltitle}{Protein Science}
      \field{number}{7}
      \field{title}{{Nonbonded terms extrapolated from nonlocal knowledge-based energy functions improve error detection in near-native protein structure models}}
      \field{volume}{16}
      \field{year}{2007}
      \field{pages}{1410\bibrangedash 1421}
      \verb{doi}
      \verb 10.1110/ps.062735907
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1110/ps.062735907
      \endverb
    \endentry
    \entry{Fiser2000}{article}{}
      \name{labelname}{3}{}{%
        {{hash=e517b392b84f852e678aa3386139ef84}{Fiser}{F\bibinitperiod}{A}{A\bibinitperiod}{}{}{}{}}%
        {{hash=62cbc31614526d6298eb31e942719390}{Do}{D\bibinitperiod}{R\bibnamedelima K}{R\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=a62b855d7bfef6fb576bae4790097131}{Sali}{S\bibinitperiod}{A}{A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=e517b392b84f852e678aa3386139ef84}{Fiser}{F\bibinitperiod}{A}{A\bibinitperiod}{}{}{}{}}%
        {{hash=62cbc31614526d6298eb31e942719390}{Do}{D\bibinitperiod}{R\bibnamedelima K}{R\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=a62b855d7bfef6fb576bae4790097131}{Sali}{S\bibinitperiod}{A}{A\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{8353bfb31ac3e76ac7c791a114f69de7}
      \strng{fullhash}{8353bfb31ac3e76ac7c791a114f69de7}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Modeling of loops in protein structures.}}
      \field{abstract}{Comparative protein structure prediction is limited mostly by the errors in alignment and loop modeling. We describe here a new automated modeling technique that significantly improves the accuracy of loop predictions in protein structures. The positions of all nonhydrogen atoms of the loop are optimized in a fixed environment with respect to a pseudo energy function. The energy is a sum of many spatial restraints that include the bond length, bond angle, and improper dihedral angle terms from the CHARMM-22 force field, statistical preferences for the main-chain and side-chain dihedral angles, and statistical preferences for nonbonded atomic contacts that depend on the two atom types, their distance through space, and separation in sequence. The energy function is optimized with the method of conjugate gradients combined with molecular dynamics and simulated annealing. Typically, the predicted loop conformation corresponds to the lowest energy conformation among 500 independent optimizations. Predictions were made for 40 loops of known structure at each length from 1 to 14 residues. The accuracy of loop predictions is evaluated as a function of thoroughness of conformational sampling, loop length, and structural properties of native loops. When accuracy is measured by local superposition of the model on the native loop, 100, 90, and 30{\%} of 4-, 8-, and 12-residue loop predictions, respectively, had {<}2 A RMSD error for the mainchain N, C(alpha), C, and O atoms; the average accuracies were 0.59 +/- 0.05, 1.16 +/- 0.10, and 2.61 +/- 0.16 A, respectively. To simulate real comparative modeling problems, the method was also evaluated by predicting loops of known structure in only approximately correct environments with errors typical of comparative modeling without misalignment. When the RMSD distortion of the main-chain stem atoms is 2.5 A, the average loop prediction error increased by 180, 25, and 3{\%} for 4-, 8-, and 12-residue loops, respectively. The accuracy of the lowest energy prediction for a given loop can be estimated from the structural variability among a number of low energy predictions. The relative value of the present method is gauged by (1) comparing it with one of the most successful previously described methods, and (2) describing its accuracy in recent blind predictions of protein structure. Finally, it is shown that the average accuracy of prediction is limited primarily by the accuracy of the energy function rather than by the extent of conformational sampling.}
      \field{issn}{0961-8368}
      \field{journaltitle}{Protein science : a publication of the Protein Society}
      \field{month}{09}
      \field{number}{9}
      \field{title}{{Modeling of loops in protein structures.}}
      \field{volume}{9}
      \field{year}{2000}
      \field{pages}{1753\bibrangedash 73}
      \verb{doi}
      \verb 10.1110/ps.9.9.1753
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Fiser, Do, Sali - 2000 - Modeling of loops in protein structures.pdf:pdf
      \endverb
      \verb{url}
      \verb http://doi.wiley.com/10.1110/ps.9.9.1753
      \endverb
    \endentry
    \entry{Kidera1995}{article}{}
      \name{labelname}{1}{}{%
        {{hash=c8282476e68c4b209aeb46e585725654}{Kidera}{K\bibinitperiod}{A}{A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=c8282476e68c4b209aeb46e585725654}{Kidera}{K\bibinitperiod}{A}{A\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{c8282476e68c4b209aeb46e585725654}
      \strng{fullhash}{c8282476e68c4b209aeb46e585725654}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Enhanced conformational sampling in Monte Carlo simulations of proteins: application to a constrained peptide.}}
      \field{abstract}{A Monte Carlo simulation method for globular proteins, called extended-scaled-collective-variable (ESCV) Monte Carlo, is proposed. This method combines two Monte Carlo algorithms known as entropy-sampling and scaled-collective-variable algorithms. Entropy-sampling Monte Carlo is able to sample a large configurational space even in a disordered system that has a large number of potential barriers. In contrast, scaled-collective-variable Monte Carlo provides an efficient sampling for a system whose dynamics is highly cooperative. Because a globular protein is a disordered system whose dynamics is characterized by collective motions, a combination of these two algorithms could provide an optimal Monte Carlo simulation for a globular protein. As a test case, we have carried out an ESCV Monte Carlo simulation for a cell adhesive Arg-Gly-Asp-containing peptide, Lys-Arg-Cys-Arg-Gly-Asp-Cys-Met-Asp, and determined the conformational distribution at 300 K. The peptide contains a disulfide bridge between the two cysteine residues. This bond mimics the strong geometrical constraints that result from a protein's globular nature and give rise to highly cooperative dynamics. Computation results show that the ESCV Monte Carlo was not trapped at any local minimum and that the canonical distribution was correctly determined.}
      \field{issn}{0027-8424}
      \field{journaltitle}{Proceedings of the National Academy of Sciences of the United States of America}
      \field{month}{10}
      \field{number}{21}
      \field{title}{{Enhanced conformational sampling in Monte Carlo simulations of proteins: application to a constrained peptide.}}
      \field{volume}{92}
      \field{year}{1995}
      \field{pages}{9886\bibrangedash 9889}
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC40907/
      \endverb
    \endentry
    \entry{McGarrah1993}{article}{}
      \name{labelname}{2}{}{%
        {{hash=afa2565c534a053018d91d67a2814411}{McGarrah}{M\bibinitperiod}{D.B.}{D\bibinitperiod}{}{}{}{}}%
        {{hash=7bf5a3f7da10e7f2d2b6890edcb1a7e7}{Judson}{J\bibinitperiod}{R.S.}{R\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=afa2565c534a053018d91d67a2814411}{McGarrah}{M\bibinitperiod}{D.B.}{D\bibinitperiod}{}{}{}{}}%
        {{hash=7bf5a3f7da10e7f2d2b6890edcb1a7e7}{Judson}{J\bibinitperiod}{R.S.}{R\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{b557d80f46ce10a1e6cf0a02d5e9542e}
      \strng{fullhash}{b557d80f46ce10a1e6cf0a02d5e9542e}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Analysis of the genetic algorithm method of molecular conformation determination}}
      \field{issn}{0192-8651}
      \field{journaltitle}{Journal of Computational Chemistry}
      \field{month}{11}
      \field{number}{11}
      \field{title}{{Analysis of the genetic algorithm method of molecular conformation determination}}
      \field{volume}{14}
      \field{year}{1993}
      \field{pages}{1385\bibrangedash 1395}
      \verb{doi}
      \verb 10.1002/jcc.540141115
      \endverb
      \verb{url}
      \verb http://doi.wiley.com/10.1002/jcc.540141115
      \endverb
    \endentry
    \entry{PROT21669}{article}{}
      \name{labelname}{4}{}{%
        {{hash=12359cfa1c314fa9ffa69f64abcf8575}{Cozzetto}{C\bibinitperiod}{Domenico}{D\bibinitperiod}{}{}{}{}}%
        {{hash=ba6a5be81953dca645cba617720be57e}{Kryshtafovych}{K\bibinitperiod}{Andriy}{A\bibinitperiod}{}{}{}{}}%
        {{hash=27c340ebfd002c512570fec269643a08}{Ceriani}{C\bibinitperiod}{Michele}{M\bibinitperiod}{}{}{}{}}%
        {{hash=5d268ce86b3c3897806533826d1f6dbf}{Tramontano}{T\bibinitperiod}{Anna}{A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=12359cfa1c314fa9ffa69f64abcf8575}{Cozzetto}{C\bibinitperiod}{Domenico}{D\bibinitperiod}{}{}{}{}}%
        {{hash=ba6a5be81953dca645cba617720be57e}{Kryshtafovych}{K\bibinitperiod}{Andriy}{A\bibinitperiod}{}{}{}{}}%
        {{hash=27c340ebfd002c512570fec269643a08}{Ceriani}{C\bibinitperiod}{Michele}{M\bibinitperiod}{}{}{}{}}%
        {{hash=5d268ce86b3c3897806533826d1f6dbf}{Tramontano}{T\bibinitperiod}{Anna}{A\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Wiley Subscription Services, Inc., A Wiley Company}%
      }
      \strng{namehash}{b427c3b1eca69ff97cfa451eb3b896bf}
      \strng{fullhash}{873712a7e5f4ae4075b44fd1321b4c3e}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Assessment of predictions in the model quality assessment category}}
      \field{issn}{1097-0134}
      \field{journaltitle}{Proteins: Structure, Function, and Bioinformatics}
      \field{number}{S8}
      \field{title}{{Assessment of predictions in the model quality assessment category}}
      \field{volume}{69}
      \field{year}{2007}
      \field{pages}{175\bibrangedash 183}
      \verb{doi}
      \verb 10.1002/prot.21669
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1002/prot.21669
      \endverb
    \endentry
    \entry{Melo2002}{article}{}
      \name{labelname}{3}{}{%
        {{hash=021094801a7b30af836225098951e626}{Melo}{M\bibinitperiod}{Francisco}{F\bibinitperiod}{}{}{}{}}%
        {{hash=9c025a3feb761e31b3dadda76221a12e}{S{\'{a}}nchez}{S\bibinitperiod}{Roberto}{R\bibinitperiod}{}{}{}{}}%
        {{hash=f3bdee19cfffe5535eb11a4f1ee54225}{Sali}{S\bibinitperiod}{Andrej}{A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=021094801a7b30af836225098951e626}{Melo}{M\bibinitperiod}{Francisco}{F\bibinitperiod}{}{}{}{}}%
        {{hash=9c025a3feb761e31b3dadda76221a12e}{S{\'{a}}nchez}{S\bibinitperiod}{Roberto}{R\bibinitperiod}{}{}{}{}}%
        {{hash=f3bdee19cfffe5535eb11a4f1ee54225}{Sali}{S\bibinitperiod}{Andrej}{A\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{cb2016e390357806a2ae00bb310baf4f}
      \strng{fullhash}{cb2016e390357806a2ae00bb310baf4f}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Statistical potentials for fold assessment.}}
      \field{abstract}{A protein structure model generally needs to be evaluated to assess whether or not it has the correct fold. To improve fold assessment, four types of a residue-level statistical potential were optimized, including distance-dependent, contact, Phi/Psi dihedral angle, and accessible surface statistical potentials. Approximately 10,000 test models with the correct and incorrect folds were built by automated comparative modeling of protein sequences of known structure. The criterion used to discriminate between the correct and incorrect models was the Z-score of the model energy. The performance of a Z-score was determined as a function of many variables in the derivation and use of the corresponding statistical potential. The performance was measured by the fractions of the correctly and incorrectly assessed test models. The most discriminating combination of any one of the four tested potentials is the sum of the normalized distance-dependent and accessible surface potentials. The distance-dependent potential that is optimal for assessing models of all sizes uses both C(alpha) and C(beta) atoms as interaction centers, distinguishes between all 20 standard residue types, has the distance range of 30 A, and is derived and used by taking into account the sequence separation of the interacting atom pairs. The terms for the sequentially local interactions are significantly less informative than those for the sequentially nonlocal interactions. The accessible surface potential that is optimal for assessing models of all sizes uses C(beta) atoms as interaction centers and distinguishes between all 20 standard residue types. The performance of the tested statistical potentials is not likely to improve significantly with an increase in the number of known protein structures used in their derivation. The parameters of fold assessment whose optimal values vary significantly with model size include the size of the known protein structures used to derive the potential and the distance range of the accessible surface potential. Fold assessment by statistical potentials is most difficult for the very small models. This difficulty presents a challenge to fold assessment in large-scale comparative modeling, which produces many small and incomplete models. The results described in this study provide a basis for an optimal use of statistical potentials in fold assessment.}
      \field{issn}{0961-8368}
      \field{journaltitle}{Protein science : a publication of the Protein Society}
      \field{month}{03}
      \field{number}{2}
      \field{title}{{Statistical potentials for fold assessment.}}
      \field{volume}{11}
      \field{year}{2002}
      \field{pages}{430\bibrangedash 48}
      \verb{doi}
      \verb 10.1002/pro.110430
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Melo, S{\'{a}}nchez, Sali - 2002 - Statistical potentials for fold assessment.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2373452%7B%5C&%7Dtool=pmcentrez%7B%5C&%7Drendertype=abstract
      \endverb
    \endentry
    \entry{Samudrala1998}{article}{}
      \name{labelname}{2}{}{%
        {{hash=4686b65e891cc32a515a532dc45bdd4d}{Samudrala}{S\bibinitperiod}{R}{R\bibinitperiod}{}{}{}{}}%
        {{hash=5a9caa6978492f08cfed191ff7c57cc8}{Moult}{M\bibinitperiod}{J}{J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=4686b65e891cc32a515a532dc45bdd4d}{Samudrala}{S\bibinitperiod}{R}{R\bibinitperiod}{}{}{}{}}%
        {{hash=5a9caa6978492f08cfed191ff7c57cc8}{Moult}{M\bibinitperiod}{J}{J\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{0b201f2a39a0643ac8358aefca502064}
      \strng{fullhash}{0b201f2a39a0643ac8358aefca502064}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{An all-atom distance-dependent conditional probability discriminatory function for protein structure prediction.}}
      \field{abstract}{We present a formalism to compute the probability of an amino acid sequence conformation being native-like, given a set of pairwise atom-atom distances. The formalism is used to derive three discriminatory functions with different types of representations for the atom-atom contacts observed in a database of protein structures. These functions include two virtual atom representations and one all-heavy atom representation. When applied to six different decoy sets containing a range of correct and incorrect conformations of amino acid sequences, the all-atom distance-dependent discriminatory function is able to identify correct from incorrect more often than the discriminatory functions using approximate representations. We illustrate the importance of using a detailed atomic description for obtaining the most accurate discrimination, and the necessity for testing discriminatory functions against a wide variety of decoys. The discriminatory function is also shown to be capable of capturing the fine details of atom-atom preferences. These results suggest that the all-atom distance-dependent discriminatory function will be useful for protein structure prediction and model refinement.}
      \field{issn}{0022-2836}
      \field{journaltitle}{Journal of molecular biology}
      \field{month}{02}
      \field{number}{5}
      \field{title}{{An all-atom distance-dependent conditional probability discriminatory function for protein structure prediction.}}
      \field{volume}{275}
      \field{year}{1998}
      \field{pages}{895\bibrangedash 916}
      \verb{doi}
      \verb 10.1006/jmbi.1997.1479
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Samudrala, Moult - 1998 - An all-atom distance-dependent conditional probability discriminatory function for protein structure predictio.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.sciencedirect.com/science/article/pii/S0022283697914790
      \endverb
    \endentry
    \entry{CASE2005}{article}{}
      \name{labelname}{10}{}{%
        {{hash=afbf75d7017415fc860e6a64510eabb9}{CASE}{C\bibinitperiod}{DAVID\bibnamedelima A}{D\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=2a3b350b0d9f9a1caeee0850b8f68133}{CHEATHAM}{C\bibinitperiod}{THOMAS\bibnamedelima E}{T\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=520a880201c03cb5ffb801d8f0b42aaf}{DARDEN}{D\bibinitperiod}{T\bibnamedelima O\bibnamedelima M}{T\bibinitperiod\bibinitdelim O\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=cf891775c1d840e5e86598f49a71c507}{GOHLKE}{G\bibinitperiod}{HOLGER}{H\bibinitperiod}{}{}{}{}}%
        {{hash=054487ae1fa27aa51403cd95b63e5353}{LUO}{L\bibinitperiod}{R\bibnamedelima A\bibnamedelima Y}{R\bibinitperiod\bibinitdelim A\bibinitperiod\bibinitdelim Y\bibinitperiod}{}{}{}{}}%
        {{hash=73373d35a0232230946c0e7be8c66e9d}{MERZ}{M\bibinitperiod}{KENNETH\bibnamedelima M}{K\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=dfc15a926f24420e0d9e9d7f1f5f40a8}{ONUFRIEV}{O\bibinitperiod}{ALEXEY}{A\bibinitperiod}{}{}{}{}}%
        {{hash=1a2b5ec1ebee175aa142c3339abd5ea0}{SIMMERLING}{S\bibinitperiod}{CARLOS}{C\bibinitperiod}{}{}{}{}}%
        {{hash=27e5b55bf04eafe15cfcbd85e82afa2a}{WANG}{W\bibinitperiod}{BING}{B\bibinitperiod}{}{}{}{}}%
        {{hash=d8b8461422b971d2decef4f1c5c50780}{WOODS}{W\bibinitperiod}{ROBERT\bibnamedelima J}{R\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{10}{}{%
        {{hash=afbf75d7017415fc860e6a64510eabb9}{CASE}{C\bibinitperiod}{DAVID\bibnamedelima A}{D\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=2a3b350b0d9f9a1caeee0850b8f68133}{CHEATHAM}{C\bibinitperiod}{THOMAS\bibnamedelima E}{T\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=520a880201c03cb5ffb801d8f0b42aaf}{DARDEN}{D\bibinitperiod}{T\bibnamedelima O\bibnamedelima M}{T\bibinitperiod\bibinitdelim O\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=cf891775c1d840e5e86598f49a71c507}{GOHLKE}{G\bibinitperiod}{HOLGER}{H\bibinitperiod}{}{}{}{}}%
        {{hash=054487ae1fa27aa51403cd95b63e5353}{LUO}{L\bibinitperiod}{R\bibnamedelima A\bibnamedelima Y}{R\bibinitperiod\bibinitdelim A\bibinitperiod\bibinitdelim Y\bibinitperiod}{}{}{}{}}%
        {{hash=73373d35a0232230946c0e7be8c66e9d}{MERZ}{M\bibinitperiod}{KENNETH\bibnamedelima M}{K\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=dfc15a926f24420e0d9e9d7f1f5f40a8}{ONUFRIEV}{O\bibinitperiod}{ALEXEY}{A\bibinitperiod}{}{}{}{}}%
        {{hash=1a2b5ec1ebee175aa142c3339abd5ea0}{SIMMERLING}{S\bibinitperiod}{CARLOS}{C\bibinitperiod}{}{}{}{}}%
        {{hash=27e5b55bf04eafe15cfcbd85e82afa2a}{WANG}{W\bibinitperiod}{BING}{B\bibinitperiod}{}{}{}{}}%
        {{hash=d8b8461422b971d2decef4f1c5c50780}{WOODS}{W\bibinitperiod}{ROBERT\bibnamedelima J}{R\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{d6ab83104171a1ae7f329995dbd3efa5}
      \strng{fullhash}{8fac7a6e9fe4cd0745d478213ab1aadf}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{The Amber Biomolecular Simulation Programs}}
      \field{abstract}{We describe the development, current features, and some directions for future development of the Amber package of computer programs. This package evolved from a program that was constructed in the late 1970s to do Assisted Model Building with Energy Refinement, and now contains a group of programs embodying a number of powerful tools of modern computational chemistry, focused on molecular dynamics and free energy calculations of proteins, nucleic acids, and carbohydrates.}
      \field{issn}{0192-8651}
      \field{journaltitle}{Journal of computational chemistry}
      \field{month}{12}
      \field{number}{16}
      \field{title}{{The Amber Biomolecular Simulation Programs}}
      \field{volume}{26}
      \field{year}{2005}
      \field{pages}{1668\bibrangedash 1688}
      \verb{doi}
      \verb 10.1002/jcc.20290
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1989667/
      \endverb
    \endentry
    \entry{Brooks1983}{article}{}
      \name{labelname}{6}{}{%
        {{hash=1389ef60927aa2662a371d4342c55037}{Brooks}{B\bibinitperiod}{Bernard\bibnamedelima R.}{B\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=2417da553beb849755a5b169592d1baf}{Bruccoleri}{B\bibinitperiod}{Robert\bibnamedelima E.}{R\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=d2dab0cdd0820888b399d5fdc25a32af}{Olafson}{O\bibinitperiod}{Barry\bibnamedelima D.}{B\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=d44b9be3654b44a716d9118bdfbe8708}{States}{S\bibinitperiod}{David\bibnamedelima J.}{D\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=f73c3ad8bb4bba4c8dbd40ecf5a28662}{Swaminathan}{S\bibinitperiod}{S.}{S\bibinitperiod}{}{}{}{}}%
        {{hash=5743d79be0ffa377a441f1fe37a0d8cd}{Karplus}{K\bibinitperiod}{Martin}{M\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{6}{}{%
        {{hash=1389ef60927aa2662a371d4342c55037}{Brooks}{B\bibinitperiod}{Bernard\bibnamedelima R.}{B\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=2417da553beb849755a5b169592d1baf}{Bruccoleri}{B\bibinitperiod}{Robert\bibnamedelima E.}{R\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=d2dab0cdd0820888b399d5fdc25a32af}{Olafson}{O\bibinitperiod}{Barry\bibnamedelima D.}{B\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=d44b9be3654b44a716d9118bdfbe8708}{States}{S\bibinitperiod}{David\bibnamedelima J.}{D\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=f73c3ad8bb4bba4c8dbd40ecf5a28662}{Swaminathan}{S\bibinitperiod}{S.}{S\bibinitperiod}{}{}{}{}}%
        {{hash=5743d79be0ffa377a441f1fe37a0d8cd}{Karplus}{K\bibinitperiod}{Martin}{M\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{8b84e15f99b2ac77e2514f794aaa3250}
      \strng{fullhash}{03869cc9823daab579933399e29b261e}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{CHARMM: A program for macromolecular energy, minimization, and dynamics calculations}}
      \field{issn}{0192-8651}
      \field{journaltitle}{Journal of Computational Chemistry}
      \field{number}{2}
      \field{title}{{CHARMM: A program for macromolecular energy, minimization, and dynamics calculations}}
      \field{volume}{4}
      \field{year}{1983}
      \field{pages}{187\bibrangedash 217}
      \verb{doi}
      \verb 10.1002/jcc.540040211
      \endverb
      \verb{url}
      \verb http://doi.wiley.com/10.1002/jcc.540040211
      \endverb
    \endentry
    \entry{Fogolari2003}{article}{}
      \name{labelname}{3}{}{%
        {{hash=b0a19adab2b43ba18a8d19175bf30eec}{Fogolari}{F\bibinitperiod}{Federico}{F\bibinitperiod}{}{}{}{}}%
        {{hash=3fc9fe51666c0f664516555fa88b7f00}{Brigo}{B\bibinitperiod}{Alessandro}{A\bibinitperiod}{}{}{}{}}%
        {{hash=dcdabdb877b70c13a41d1aec410043b9}{Molinari}{M\bibinitperiod}{Henriette}{H\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=b0a19adab2b43ba18a8d19175bf30eec}{Fogolari}{F\bibinitperiod}{Federico}{F\bibinitperiod}{}{}{}{}}%
        {{hash=3fc9fe51666c0f664516555fa88b7f00}{Brigo}{B\bibinitperiod}{Alessandro}{A\bibinitperiod}{}{}{}{}}%
        {{hash=dcdabdb877b70c13a41d1aec410043b9}{Molinari}{M\bibinitperiod}{Henriette}{H\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{e30fd074a9b6ff83afefc3e237d489e2}
      \strng{fullhash}{e30fd074a9b6ff83afefc3e237d489e2}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Protocol for MM/PBSA molecular dynamics simulations of proteins.}}
      \field{abstract}{Continuum solvent models have been employed in past years for understanding processes such as protein folding or biomolecular association. In the last decade, several attempts have been made to merge atomic detail molecular dynamics simulations with solvent continuum models. Among continuum models, the Poisson-Boltzmann solvent accessible surface area model is one of the oldest and most fundamental. Notwithstanding its wide usage for simulation of biomolecular electrostatic potential, the Poisson-Boltzmann equation has been very seldom used to obtain solvation forces for molecular dynamics simulation. We propose here a fast and reliable methodology to implement continuum forces in standard molecular mechanics and dynamics algorithms. Results for a totally unrestrained 1 ns molecular dynamics simulation of a small protein are quantitatively similar to results obtained by explicit solvent molecular dynamics simulations.}
      \field{issn}{0006-3495}
      \field{journaltitle}{Biophysical journal}
      \field{month}{07}
      \field{number}{1}
      \field{title}{{Protocol for MM/PBSA molecular dynamics simulations of proteins.}}
      \field{volume}{85}
      \field{year}{2003}
      \field{pages}{159\bibrangedash 66}
      \verb{doi}
      \verb 10.1016/S0006-3495(03)74462-2
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Fogolari, Brigo, Molinari - 2003 - Protocol for MMPBSA molecular dynamics simulations of proteins.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.sciencedirect.com/science/article/pii/S0006349503744622
      \endverb
    \endentry
    \entry{Thomas1996}{article}{}
      \name{labelname}{2}{}{%
        {{hash=1113f5f32914572528c35375f4f2235e}{Thomas}{T\bibinitperiod}{P\bibnamedelima D}{P\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=9a39ef1b41588121d5d2cefe3071d1b6}{Dill}{D\bibinitperiod}{K\bibnamedelima A}{K\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=1113f5f32914572528c35375f4f2235e}{Thomas}{T\bibinitperiod}{P\bibnamedelima D}{P\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=9a39ef1b41588121d5d2cefe3071d1b6}{Dill}{D\bibinitperiod}{K\bibnamedelima A}{K\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{3d422cf20eb10f05439de205b25a7a2d}
      \strng{fullhash}{3d422cf20eb10f05439de205b25a7a2d}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Statistical potentials extracted from protein structures: how accurate are they?}}
      \field{abstract}{"Statistical potentials" are energies widely used in computer algorithms to fold, dock, or recognize protein structures. They are derived from: (1) observed pairing frequencies of the 20 amino acids in databases of known protein structures, and (2) approximations and assumptions about the physical process that these quantities measure. Using exact lattice models, we construct a rigorous test of those assumptions and approximations. We find that statistical potentials often correctly rank-order the relative strengths of interresidue interactions, but they do not reflect the true underlying energies because of systematic errors arising from the neglect of excluded volume in proteins. We find that complex residue-residue distance dependences observed in statistical potentials, even those among charged groups, can be largely explained as an indirect consequence of the burial of non-polar groups. Our results suggest that current statistical potentials may have limited value in protein folding algorithms and wherever they are used to provide energy-like quantities.}
      \field{issn}{0022-2836}
      \field{journaltitle}{Journal of molecular biology}
      \field{month}{03}
      \field{number}{2}
      \field{title}{{Statistical potentials extracted from protein structures: how accurate are they?}}
      \field{volume}{257}
      \field{year}{1996}
      \field{pages}{457\bibrangedash 69}
      \verb{doi}
      \verb 10.1006/jmbi.1996.0175
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Thomas, Dill - 1996 - Statistical potentials extracted from protein structures how accurate are they.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.sciencedirect.com/science/article/pii/S0022283696901758
      \endverb
    \endentry
    \entry{Shen2006}{article}{}
      \name{labelname}{2}{}{%
        {{hash=6529665068922e70b8d60070c8f3c1bc}{Shen}{S\bibinitperiod}{Min-yi}{M\bibinithyphendelim y\bibinitperiod}{}{}{}{}}%
        {{hash=f3bdee19cfffe5535eb11a4f1ee54225}{Sali}{S\bibinitperiod}{Andrej}{A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=6529665068922e70b8d60070c8f3c1bc}{Shen}{S\bibinitperiod}{Min-yi}{M\bibinithyphendelim y\bibinitperiod}{}{}{}{}}%
        {{hash=f3bdee19cfffe5535eb11a4f1ee54225}{Sali}{S\bibinitperiod}{Andrej}{A\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Blackwell Publishing}%
      }
      \strng{namehash}{d980f1da7c156433669b8b153bf33028}
      \strng{fullhash}{d980f1da7c156433669b8b153bf33028}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Statistical potential for assessment and prediction of protein structures}}
      \field{abstract}{Protein structures in the Protein Data Bank provide a wealth of data about the interactions that determine the native states of proteins. Using the probability theory, we derive an atomic distance-dependent statistical potential from a sample of native structures that does not depend on any adjustable parameters (Discrete Optimized Protein Energy, or DOPE). DOPE is based on an improved reference state that corresponds to noninteracting atoms in a homogeneous sphere with the radius dependent on a sample native structure; it thus accounts for the finite and spherical shape of the native structures. The DOPE potential was extracted from a nonredundant set of 1472 crystallographic structures. We tested DOPE and five other scoring functions by the detection of the native state among six multiple target decoy sets, the correlation between the score and model error, and the identification of the most accurate non-native structure in the decoy set. For all decoy sets, DOPE is the best performing function in terms of all criteria, except for a tie in one criterion for one decoy set. To facilitate its use in various applications, such as model assessment, loop modeling, and fitting into cryo-electron microscopy mass density maps combined with comparative protein structure modeling, DOPE was incorporated into the modeling package MODELLER-8.}
      \field{issn}{0961-8368}
      \field{journaltitle}{Protein Science : A Publication of the Protein Society}
      \field{month}{11}
      \field{number}{11}
      \field{title}{{Statistical potential for assessment and prediction of protein structures}}
      \field{volume}{15}
      \field{year}{2006}
      \field{pages}{2507\bibrangedash 2524}
      \verb{doi}
      \verb 10.1110/ps.062416606
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2242414/
      \endverb
    \endentry
    \entry{Zhou2002}{article}{}
      \name{labelname}{2}{}{%
        {{hash=df8e91a61dfc6515a464839aaba565ce}{Zhou}{Z\bibinitperiod}{Hongyi}{H\bibinitperiod}{}{}{}{}}%
        {{hash=ce7558f60198035c0f0a04b2acfdca0f}{Zhou}{Z\bibinitperiod}{Yaoqi}{Y\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=df8e91a61dfc6515a464839aaba565ce}{Zhou}{Z\bibinitperiod}{Hongyi}{H\bibinitperiod}{}{}{}{}}%
        {{hash=ce7558f60198035c0f0a04b2acfdca0f}{Zhou}{Z\bibinitperiod}{Yaoqi}{Y\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{45802cd4f4878477bd12b4fe648e19ae}
      \strng{fullhash}{45802cd4f4878477bd12b4fe648e19ae}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Distance-scaled, finite ideal-gas reference state improves structure-derived potentials of mean force for structure selection and stability prediction.}}
      \field{abstract}{The distance-dependent structure-derived potentials developed so far all employed a reference state that can be characterized as a residue (atom)-averaged state. Here, we establish a new reference state called the distance-scaled, finite ideal-gas reference (DFIRE) state. The reference state is used to construct a residue-specific all-atom potential of mean force from a database of 1011 nonhomologous (less than 30{\%} homology) protein structures with resolution less than 2 A. The new all-atom potential recognizes more native proteins from 32 multiple decoy sets, and raises an average Z-score by 1.4 units more than two previously developed, residue-specific, all-atom knowledge-based potentials. When only backbone and C(beta) atoms are used in scoring, the performance of the DFIRE-based potential, although is worse than that of the all-atom version, is comparable to those of the previously developed potentials on the all-atom level. In addition, the DFIRE-based all-atom potential provides the most accurate prediction of the stabilities of 895 mutants among three knowledge-based all-atom potentials. Comparison with several physical-based potentials is made.}
      \field{issn}{0961-8368}
      \field{journaltitle}{Protein science : a publication of the Protein Society}
      \field{month}{12}
      \field{number}{11}
      \field{title}{{Distance-scaled, finite ideal-gas reference state improves structure-derived potentials of mean force for structure selection and stability prediction.}}
      \field{volume}{11}
      \field{year}{2002}
      \field{pages}{2714\bibrangedash 26}
      \verb{doi}
      \verb 10.1110/ps.0217002
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Zhou, Zhou - 2002 - Distance-scaled, finite ideal-gas reference state improves structure-derived potentials of mean force for structure.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2373736%7B%5C&%7Dtool=pmcentrez%7B%5C&%7Drendertype=abstract
      \endverb
    \endentry
    \entry{Sippl1995}{article}{}
      \name{labelname}{1}{}{%
        {{hash=8e55892f5d151274795af5e5648e0d79}{Sippl}{S\bibinitperiod}{Manfred\bibnamedelima J}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=8e55892f5d151274795af5e5648e0d79}{Sippl}{S\bibinitperiod}{Manfred\bibnamedelima J}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{8e55892f5d151274795af5e5648e0d79}
      \strng{fullhash}{8e55892f5d151274795af5e5648e0d79}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Knowledge-based potentials for proteins}}
      \field{abstract}{Knowledge based potentials and energy functions are extracted from a number of databases of known protein structures. Recent developments have shown that this type of potential is successful in many areas of protein structure research. Among these are quality assessment and error recognition of folds and the prediction of unknown structures by fold-recognition techniques.}
      \field{issn}{0959440X}
      \field{journaltitle}{Current Opinion in Structural Biology}
      \field{month}{04}
      \field{number}{2}
      \field{title}{{Knowledge-based potentials for proteins}}
      \field{volume}{5}
      \field{year}{1995}
      \field{pages}{229\bibrangedash 235}
      \verb{doi}
      \verb 10.1016/0959-440X(95)80081-6
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Sippl - 1995 - Knowledge-based potentials for proteins.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.sciencedirect.com/science/article/pii/0959440X95800816
      \endverb
    \endentry
    \entry{Du2012}{article}{}
      \name{labelname}{2}{}{%
        {{hash=2736bf88ecd6e7286f45cd9d073cbc29}{Du}{D\bibinitperiod}{Changsheng}{C\bibinitperiod}{}{}{}{}}%
        {{hash=575a5ee21fb18fa9d777a9a1a1c55273}{Xie}{X\bibinitperiod}{Xin}{X\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=2736bf88ecd6e7286f45cd9d073cbc29}{Du}{D\bibinitperiod}{Changsheng}{C\bibinitperiod}{}{}{}{}}%
        {{hash=575a5ee21fb18fa9d777a9a1a1c55273}{Xie}{X\bibinitperiod}{Xin}{X\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences}%
      }
      \strng{namehash}{5cb5b09bb0795e7d48f5943207b56549}
      \strng{fullhash}{5cb5b09bb0795e7d48f5943207b56549}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{G protein-coupled receptors as therapeutic targets for multiple sclerosis}}
      \field{issn}{1001-0602}
      \field{journaltitle}{Cell Res}
      \field{month}{06}
      \field{number}{7}
      \field{title}{{G protein-coupled receptors as therapeutic targets for multiple sclerosis}}
      \field{volume}{22}
      \field{year}{2012}
      \field{pages}{1108\bibrangedash 1128}
      \verb{url}
      \verb http://dx.doi.org/10.1038/cr.2012.87
      \endverb
    \endentry
    \entry{Kampen2011}{article}{}
      \name{labelname}{1}{}{%
        {{hash=6faf1f529ac51f2ada4a7ef12dc34733}{Kampen}{K\bibinitperiod}{Kim\bibnamedelima R}{K\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=6faf1f529ac51f2ada4a7ef12dc34733}{Kampen}{K\bibinitperiod}{Kim\bibnamedelima R}{K\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{6faf1f529ac51f2ada4a7ef12dc34733}
      \strng{fullhash}{6faf1f529ac51f2ada4a7ef12dc34733}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Membrane Proteins: The Key Players of a Cancer Cell}}
      \field{abstract}{Membrane proteins are involved in the prognosis of the most common forms of cancer. Membrane proteins are the hallmark of a cancer cell. The overexpressed membrane receptors are becoming increasingly important in cancer cell therapy. Current renewing therapy approaches based on receptor overexpression include; antibody therapy, nanocarrier drug delivery, and fluorescent tumor imaging in surgery. Gene profiling reveals cancer specific signatures and may identify membrane proteins that are related to cancer progression and lead to the development of improved therapy strategies in the future.}
      \field{issn}{1432-1424}
      \field{journaltitle}{The Journal of Membrane Biology}
      \field{number}{2}
      \field{title}{{Membrane Proteins: The Key Players of a Cancer Cell}}
      \field{volume}{242}
      \field{year}{2011}
      \field{pages}{69\bibrangedash 74}
      \verb{doi}
      \verb 10.1007/s00232-011-9381-7
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1007/s00232-011-9381-7
      \endverb
    \endentry
    \entry{Leman2015}{article}{}
      \name{labelname}{3}{}{%
        {{hash=04b64b548d25da9e9da8769cb47701f6}{Leman}{L\bibinitperiod}{Julia\bibnamedelima Koehler}{J\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=13a6189e01d1f11e15d62379f62fb5f4}{Ulmschneider}{U\bibinitperiod}{Martin\bibnamedelima B}{M\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=d068a2b0cc92b1384f4242acfcd42f18}{Gray}{G\bibinitperiod}{Jeffrey\bibnamedelima J}{J\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=04b64b548d25da9e9da8769cb47701f6}{Leman}{L\bibinitperiod}{Julia\bibnamedelima Koehler}{J\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=13a6189e01d1f11e15d62379f62fb5f4}{Ulmschneider}{U\bibinitperiod}{Martin\bibnamedelima B}{M\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=d068a2b0cc92b1384f4242acfcd42f18}{Gray}{G\bibinitperiod}{Jeffrey\bibnamedelima J}{J\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{49252d59e07f87e1e3962d9a136638b9}
      \strng{fullhash}{49252d59e07f87e1e3962d9a136638b9}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Computational modeling of membrane proteins}}
      \field{abstract}{The determination of membrane protein (MP) structures has always trailed that of soluble proteins due to difficulties in their overexpression, reconstitution into membrane mimetics, and subsequent structure determination. The percentage of MP structures in the protein databank (PDB) has been at a constant 1-2{\%} for the last decade. In contrast, over half of all drugs target MPs, only highlighting how little we understand about drug-specific effects in the human body. To reduce this gap, researchers have attempted to predict structural features of MPs even before the first structure was experimentally elucidated. In this review, we present current computational methods to predict MP structure, starting with secondary structure prediction, prediction of trans-membrane spans, and topology. Even though these methods generate reliable predictions, challenges such as predicting kinks or precise beginnings and ends of secondary structure elements are still waiting to be addressed. We describe recent developments in the prediction of 3D structures of both $\alpha$-helical MPs as well as $\beta$-barrels using comparative modeling techniques, de novo methods, and molecular dynamics (MD) simulations. The increase of MP structures has (1) facilitated comparative modeling due to availability of more and better templates, and (2) improved the statistics for knowledge-based scoring functions. Moreover, de novo methods have benefitted from the use of correlated mutations as restraints. Finally, we outline current advances that will likely shape the field in the forthcoming decade.}
      \field{issn}{0887-3585}
      \field{journaltitle}{Proteins}
      \field{month}{01}
      \field{number}{1}
      \field{title}{{Computational modeling of membrane proteins}}
      \field{volume}{83}
      \field{year}{2015}
      \field{pages}{1\bibrangedash 24}
      \verb{doi}
      \verb 10.1002/prot.24703
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4270820/
      \endverb
    \endentry
    \entry{Marti-Renom2000}{article}{}
      \name{labelname}{6}{}{%
        {{hash=5461b6b5d70b5f6a29c839ffa86a0f19}{Mart{\'{\i}}-Renom}{M\bibinithyphendelim R\bibinitperiod}{Marc\bibnamedelima A}{M\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=35af4cbf9d6f921414f47c2a8ed0bba3}{Stuart}{S\bibinitperiod}{Ashley\bibnamedelima C}{A\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=99fdd219dd063e730ce1c4561adc7bce}{Fiser}{F\bibinitperiod}{Andr{\'{a}}s}{A\bibinitperiod}{}{}{}{}}%
        {{hash=9c025a3feb761e31b3dadda76221a12e}{S{\'{a}}nchez}{S\bibinitperiod}{Roberto}{R\bibinitperiod}{}{}{}{}}%
        {{hash=021094801a7b30af836225098951e626}{Melo}{M\bibinitperiod}{Francisco}{F\bibinitperiod}{}{}{}{}}%
        {{hash=e3a033f64b8a1952a2f23a82a0e89b0d}{{\v{S}}ali}{\v{S}\bibinitperiod}{Andrej}{A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{6}{}{%
        {{hash=5461b6b5d70b5f6a29c839ffa86a0f19}{Mart{\'{\i}}-Renom}{M\bibinithyphendelim R\bibinitperiod}{Marc\bibnamedelima A}{M\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=35af4cbf9d6f921414f47c2a8ed0bba3}{Stuart}{S\bibinitperiod}{Ashley\bibnamedelima C}{A\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=99fdd219dd063e730ce1c4561adc7bce}{Fiser}{F\bibinitperiod}{Andr{\'{a}}s}{A\bibinitperiod}{}{}{}{}}%
        {{hash=9c025a3feb761e31b3dadda76221a12e}{S{\'{a}}nchez}{S\bibinitperiod}{Roberto}{R\bibinitperiod}{}{}{}{}}%
        {{hash=021094801a7b30af836225098951e626}{Melo}{M\bibinitperiod}{Francisco}{F\bibinitperiod}{}{}{}{}}%
        {{hash=e3a033f64b8a1952a2f23a82a0e89b0d}{{\v{S}}ali}{\v{S}\bibinitperiod}{Andrej}{A\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Annual Reviews}%
      }
      \strng{namehash}{f41a3e5a842bfad97bea612d8fb25b3a}
      \strng{fullhash}{fbf17a2a63c3d668cc93a16c3e4bf91a}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Comparative Protein Structure Modeling of Genes and Genomes}}
      \field{annotation}{doi: 10.1146/annurev.biophys.29.1.291}
      \field{issn}{1056-8700}
      \field{journaltitle}{Annual Review of Biophysics and Biomolecular Structure}
      \field{month}{06}
      \field{number}{1}
      \field{title}{{Comparative Protein Structure Modeling of Genes and Genomes}}
      \field{volume}{29}
      \field{year}{2000}
      \field{pages}{291\bibrangedash 325}
      \verb{doi}
      \verb 10.1146/annurev.biophys.29.1.291
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1146/annurev.biophys.29.1.291
      \endverb
    \endentry
    \entry{Malmstrom2010}{article}{}
      \name{labelname}{2}{}{%
        {{hash=50909ec1aeaa7f40002966c164db28a1}{Malmstr{\"{o}}m}{M\bibinitperiod}{Lars}{L\bibinitperiod}{}{}{}{}}%
        {{hash=b7abecd7ba3e2d20a76b6aa99be8a0c7}{Goodlett}{G\bibinitperiod}{David\bibnamedelima R}{D\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=50909ec1aeaa7f40002966c164db28a1}{Malmstr{\"{o}}m}{M\bibinitperiod}{Lars}{L\bibinitperiod}{}{}{}{}}%
        {{hash=b7abecd7ba3e2d20a76b6aa99be8a0c7}{Goodlett}{G\bibinitperiod}{David\bibnamedelima R}{D\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{6ac46e7b81e0b55e9135150d2281a4e9}
      \strng{fullhash}{6ac46e7b81e0b55e9135150d2281a4e9}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Protein structure modeling.}}
      \field{abstract}{The tertiary structure of proteins can reveal information that is hard to detect in a linear sequence. Knowing the tertiary structure is valuable when generating hypothesis and interpreting data. Unfortunately, the gap between the number of known protein sequences and their associated structures is widening. One way to bridge this gap is to use computer-generated structure models of proteins. Here we present concepts and online resources that can be used to identify structural domains in proteins and to create structure models of those domains.}
      \field{isbn}{9789812778772}
      \field{issn}{1940-6029}
      \field{journaltitle}{Methods in molecular biology (Clifton, N.J.)}
      \field{title}{{Protein structure modeling.}}
      \field{volume}{673}
      \field{year}{2010}
      \field{pages}{63\bibrangedash 72}
      \verb{doi}
      \verb 10.1007/978-1-60761-842-3_5
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/6659{\_}chap01.pdf:pdf
      \endverb
    \endentry
    \entry{Sali1993}{article}{}
      \name{labelname}{2}{}{%
        {{hash=a62b855d7bfef6fb576bae4790097131}{Sali}{S\bibinitperiod}{A}{A\bibinitperiod}{}{}{}{}}%
        {{hash=22bf569e666f3d049884d611ba3c6232}{Blundell}{B\bibinitperiod}{T\bibnamedelima L}{T\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=a62b855d7bfef6fb576bae4790097131}{Sali}{S\bibinitperiod}{A}{A\bibinitperiod}{}{}{}{}}%
        {{hash=22bf569e666f3d049884d611ba3c6232}{Blundell}{B\bibinitperiod}{T\bibnamedelima L}{T\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{0d8f75433cffdb520aad9363ee32a09d}
      \strng{fullhash}{0d8f75433cffdb520aad9363ee32a09d}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Comparative protein modelling by satisfaction of spatial restraints.}}
      \field{abstract}{We describe a comparative protein modelling method designed to find the most probable structure for a sequence given its alignment with related structures. The three-dimensional (3D) model is obtained by optimally satisfying spatial restraints derived from the alignment and expressed as probability density functions (pdfs) for the features restrained. For example, the probabilities for main-chain conformations of a modelled residue may be restrained by its residue type, main-chain conformation of an equivalent residue in a related protein, and the local similarity between the two sequences. Several such pdfs are obtained from the correlations between structural features in 17 families of homologous proteins which have been aligned on the basis of their 3D structures. The pdfs restrain C alpha-C alpha distances, main-chain N-O distances, main-chain and side-chain dihedral angles. A smoothing procedure is used in the derivation of these relationships to minimize the problem of a sparse database. The 3D model of a protein is obtained by optimization of the molecular pdf such that the model violates the input restraints as little as possible. The molecular pdf is derived as a combination of pdfs restraining individual spatial features of the whole molecule. The optimization procedure is a variable target function method that applies the conjugate gradients algorithm to positions of all non-hydrogen atoms. The method is automated and is illustrated by the modelling of trypsin from two other serine proteinases.}
      \field{issn}{0022-2836}
      \field{journaltitle}{Journal of molecular biology}
      \field{month}{12}
      \field{number}{3}
      \field{title}{{Comparative protein modelling by satisfaction of spatial restraints.}}
      \field{volume}{234}
      \field{year}{1993}
      \field{pages}{779\bibrangedash 815}
      \verb{doi}
      \verb 10.1006/jmbi.1993.1626
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Sali, Blundell - 1993 - Comparative protein modelling by satisfaction of spatial restraints.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.sciencedirect.com/science/article/pii/S0022283683716268
      \endverb
    \endentry
    \entry{Biasini2014}{article}{}
      \name{labelname}{11}{}{%
        {{hash=8c5c2e3281ac90e7e047326cb8521061}{Biasini}{B\bibinitperiod}{Marco}{M\bibinitperiod}{}{}{}{}}%
        {{hash=e17c8faf02e044a87dc3538d9eaa17ad}{Bienert}{B\bibinitperiod}{Stefan}{S\bibinitperiod}{}{}{}{}}%
        {{hash=3f5f2d064275270f946fff614f447695}{Waterhouse}{W\bibinitperiod}{Andrew}{A\bibinitperiod}{}{}{}{}}%
        {{hash=bb290d8c6f623fe5716fac818a936550}{Arnold}{A\bibinitperiod}{Konstantin}{K\bibinitperiod}{}{}{}{}}%
        {{hash=1ced0d8807b5d18b90fa0eff110760ec}{Studer}{S\bibinitperiod}{Gabriel}{G\bibinitperiod}{}{}{}{}}%
        {{hash=b30253c75a6934483ba798b3afe56cd3}{Schmidt}{S\bibinitperiod}{Tobias}{T\bibinitperiod}{}{}{}{}}%
        {{hash=c7f06671679c5a76978a676d7e876574}{Kiefer}{K\bibinitperiod}{Florian}{F\bibinitperiod}{}{}{}{}}%
        {{hash=5f57a74cb6d6e11dd14892836edd8945}{Cassarino}{C\bibinitperiod}{Tiziano\bibnamedelima Gallo}{T\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=576452f85aa87f2c057793940f04cbba}{Bertoni}{B\bibinitperiod}{Martino}{M\bibinitperiod}{}{}{}{}}%
        {{hash=bb7862e6edfdd811260dee5da9e55634}{Bordoli}{B\bibinitperiod}{Lorenza}{L\bibinitperiod}{}{}{}{}}%
        {{hash=ac78e4bbb3a5578563150b327b14e1b8}{Schwede}{S\bibinitperiod}{Torsten}{T\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{11}{}{%
        {{hash=8c5c2e3281ac90e7e047326cb8521061}{Biasini}{B\bibinitperiod}{Marco}{M\bibinitperiod}{}{}{}{}}%
        {{hash=e17c8faf02e044a87dc3538d9eaa17ad}{Bienert}{B\bibinitperiod}{Stefan}{S\bibinitperiod}{}{}{}{}}%
        {{hash=3f5f2d064275270f946fff614f447695}{Waterhouse}{W\bibinitperiod}{Andrew}{A\bibinitperiod}{}{}{}{}}%
        {{hash=bb290d8c6f623fe5716fac818a936550}{Arnold}{A\bibinitperiod}{Konstantin}{K\bibinitperiod}{}{}{}{}}%
        {{hash=1ced0d8807b5d18b90fa0eff110760ec}{Studer}{S\bibinitperiod}{Gabriel}{G\bibinitperiod}{}{}{}{}}%
        {{hash=b30253c75a6934483ba798b3afe56cd3}{Schmidt}{S\bibinitperiod}{Tobias}{T\bibinitperiod}{}{}{}{}}%
        {{hash=c7f06671679c5a76978a676d7e876574}{Kiefer}{K\bibinitperiod}{Florian}{F\bibinitperiod}{}{}{}{}}%
        {{hash=5f57a74cb6d6e11dd14892836edd8945}{Cassarino}{C\bibinitperiod}{Tiziano\bibnamedelima Gallo}{T\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=576452f85aa87f2c057793940f04cbba}{Bertoni}{B\bibinitperiod}{Martino}{M\bibinitperiod}{}{}{}{}}%
        {{hash=bb7862e6edfdd811260dee5da9e55634}{Bordoli}{B\bibinitperiod}{Lorenza}{L\bibinitperiod}{}{}{}{}}%
        {{hash=ac78e4bbb3a5578563150b327b14e1b8}{Schwede}{S\bibinitperiod}{Torsten}{T\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Oxford University Press}%
      }
      \strng{namehash}{fc6df58544ad5fe1e1fcdf8f6d018e7b}
      \strng{fullhash}{2d0b0732151e429a0a1fe908e52e33ef}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information}}
      \field{abstract}{Protein structure homology modelling has become a routine technique to generate 3D models for proteins when experimental structures are not available. Fully automated servers such as SWISS-MODEL with user-friendly web interfaces generate reliable models without the need for complex software packages or downloading large databases. Here, we describe the latest version of the SWISS-MODEL expert system for protein structure modelling. The SWISS-MODEL template library provides annotation of quaternary structure and essential ligands and co-factors to allow for building of complete structural models, including their oligomeric structure. The improved SWISS-MODEL pipeline makes extensive use of model quality estimation for selection of the most suitable templates and provides estimates of the expected accuracy of the resulting models. The accuracy of the models generated by SWISS-MODEL is continuously evaluated by the CAMEO system. The new web site allows users to interactively search for templates, cluster them by sequence similarity, structurally compare alternative templates and select the ones to be used for model building. In cases where multiple alternative template structures are available for a protein of interest, a user-guided template selection step allows building models in different functional states. SWISS-MODEL is available at http://swissmodel.expasy.org/.}
      \field{issn}{0305-1048}
      \field{journaltitle}{Nucleic Acids Research}
      \field{month}{07}
      \field{number}{Web Server issue}
      \field{title}{{SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information}}
      \field{volume}{42}
      \field{year}{2014}
      \field{pages}{W252\bibrangedash W258}
      \verb{doi}
      \verb 10.1093/nar/gku340
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086089/
      \endverb
    \endentry
    \entry{Soding2005}{article}{}
      \name{labelname}{3}{}{%
        {{hash=61f1ee7ce63e60c4b4dae9a4a0cfaef0}{S{\"{o}}ding}{S\bibinitperiod}{Johannes}{J\bibinitperiod}{}{}{}{}}%
        {{hash=6486032f1fd7b53b2499d56d8a872253}{Biegert}{B\bibinitperiod}{Andreas}{A\bibinitperiod}{}{}{}{}}%
        {{hash=8081813a444f5747b912efbb7db96323}{Lupas}{L\bibinitperiod}{Andrei\bibnamedelima N}{A\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=61f1ee7ce63e60c4b4dae9a4a0cfaef0}{S{\"{o}}ding}{S\bibinitperiod}{Johannes}{J\bibinitperiod}{}{}{}{}}%
        {{hash=6486032f1fd7b53b2499d56d8a872253}{Biegert}{B\bibinitperiod}{Andreas}{A\bibinitperiod}{}{}{}{}}%
        {{hash=8081813a444f5747b912efbb7db96323}{Lupas}{L\bibinitperiod}{Andrei\bibnamedelima N}{A\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Oxford University Press}%
      }
      \strng{namehash}{0f06a60cfcf41812e52313df1fdf7c89}
      \strng{fullhash}{0f06a60cfcf41812e52313df1fdf7c89}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{The HHpred interactive server for protein homology detection and structure prediction}}
      \field{abstract}{HHpred is a fast server for remote protein homology detection and structure prediction and is the first to implement pairwise comparison of profile hidden Markov models (HMMs). It allows to search a wide choice of databases, such as the PDB, SCOP, Pfam, SMART, COGs and CDD. It accepts a single query sequence or a multiple alignment as input. Within only a few minutes it returns the search results in a user-friendly format similar to that of PSI-BLAST. Search options include local or global alignment and scoring secondary structure similarity. HHpred can produce pairwise query-template alignments, multiple alignments of the query with a set of templates selected from the search results, as well as 3D structural models that are calculated by the MODELLER software from these alignments. A detailed help facility is available. As a demonstration, we analyze the sequence of SpoVT, a transcriptional regulator from Bacillus subtilis. HHpred can be accessed at .}
      \field{issn}{0305-1048}
      \field{journaltitle}{Nucleic Acids Research}
      \field{month}{07}
      \field{number}{Web Server issue}
      \field{title}{{The HHpred interactive server for protein homology detection and structure prediction}}
      \field{volume}{33}
      \field{year}{2005}
      \field{pages}{W244\bibrangedash W248}
      \verb{doi}
      \verb 10.1093/nar/gki408
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1160169/
      \endverb
    \endentry
    \entry{Yang2015a}{article}{}
      \name{labelname}{6}{}{%
        {{hash=382479cb8879c413d413cc0d65c513e6}{Yang}{Y\bibinitperiod}{Jianyi}{J\bibinitperiod}{}{}{}{}}%
        {{hash=2d6f2067dafb0b13323e1d1b1f3d9de9}{Yan}{Y\bibinitperiod}{Renxiang}{R\bibinitperiod}{}{}{}{}}%
        {{hash=32b724aac9cf1ba7e73e7fbb0fda1b1a}{Roy}{R\bibinitperiod}{Ambrish}{A\bibinitperiod}{}{}{}{}}%
        {{hash=be17c750657847fd489802d414210d61}{Xu}{X\bibinitperiod}{Dong}{D\bibinitperiod}{}{}{}{}}%
        {{hash=69ee6e7891fcac9735315c26f786415d}{Poisson}{P\bibinitperiod}{Jonathan}{J\bibinitperiod}{}{}{}{}}%
        {{hash=e760d38078aff4a5b24c867aa5178c26}{Zhang}{Z\bibinitperiod}{Yang}{Y\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{6}{}{%
        {{hash=382479cb8879c413d413cc0d65c513e6}{Yang}{Y\bibinitperiod}{Jianyi}{J\bibinitperiod}{}{}{}{}}%
        {{hash=2d6f2067dafb0b13323e1d1b1f3d9de9}{Yan}{Y\bibinitperiod}{Renxiang}{R\bibinitperiod}{}{}{}{}}%
        {{hash=32b724aac9cf1ba7e73e7fbb0fda1b1a}{Roy}{R\bibinitperiod}{Ambrish}{A\bibinitperiod}{}{}{}{}}%
        {{hash=be17c750657847fd489802d414210d61}{Xu}{X\bibinitperiod}{Dong}{D\bibinitperiod}{}{}{}{}}%
        {{hash=69ee6e7891fcac9735315c26f786415d}{Poisson}{P\bibinitperiod}{Jonathan}{J\bibinitperiod}{}{}{}{}}%
        {{hash=e760d38078aff4a5b24c867aa5178c26}{Zhang}{Z\bibinitperiod}{Yang}{Y\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.}%
      }
      \strng{namehash}{2a370f297e2c905c67d9f3acea8245a9}
      \strng{fullhash}{6410a1a9ea2bbeb9b8536a073ecb62c9}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{The I-TASSER Suite: protein structure and function prediction}}
      \field{issn}{1548-7091}
      \field{journaltitle}{Nat Meth}
      \field{month}{01}
      \field{number}{1}
      \field{title}{{The I-TASSER Suite: protein structure and function prediction}}
      \field{volume}{12}
      \field{year}{2015}
      \field{pages}{7\bibrangedash 8}
      \verb{url}
      \verb http://dx.doi.org/10.1038/nmeth.3213%2010.1038/nmeth.3213%20http://www.nature.com/nmeth/journal/v12/n1/abs/nmeth.3213.html%7B%5C#%7Dsupplementary-information
      \endverb
    \endentry
    \entry{Roy2010}{article}{}
      \name{labelname}{3}{}{%
        {{hash=32b724aac9cf1ba7e73e7fbb0fda1b1a}{Roy}{R\bibinitperiod}{Ambrish}{A\bibinitperiod}{}{}{}{}}%
        {{hash=4c65e01cb598a5ee95e78fa42f50b50e}{Kucukural}{K\bibinitperiod}{Alper}{A\bibinitperiod}{}{}{}{}}%
        {{hash=e760d38078aff4a5b24c867aa5178c26}{Zhang}{Z\bibinitperiod}{Yang}{Y\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=32b724aac9cf1ba7e73e7fbb0fda1b1a}{Roy}{R\bibinitperiod}{Ambrish}{A\bibinitperiod}{}{}{}{}}%
        {{hash=4c65e01cb598a5ee95e78fa42f50b50e}{Kucukural}{K\bibinitperiod}{Alper}{A\bibinitperiod}{}{}{}{}}%
        {{hash=e760d38078aff4a5b24c867aa5178c26}{Zhang}{Z\bibinitperiod}{Yang}{Y\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{eab520074224de5113b6a930159d48da}
      \strng{fullhash}{eab520074224de5113b6a930159d48da}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{I-TASSER: a unified platform for automated protein structure and function prediction}}
      \field{abstract}{The I-TASSER server is an integrated platform for automated protein structure and function prediction based on the sequence-to-structure-to-function paradigm. Starting from an amino acid sequence, I-TASSER first generates three-dimensional atomic models from multiple threading alignments and iterative structural assembly simulations. The function of the protein is then inferred by structurally matching the 3D models with other known proteins. The output from a typical server run contains full-length secondary and tertiary structure predictions, and functional annotations on ligand-binding sites, Enzyme Commission numbers and Gene Ontology terms. An estimate of accuracy of the predictions is provided based on the confidence score of the modeling. This protocol provides new insights and guidelines for designing of on-line server systems for the state-of-the-art protein structure and function predictions. The server is available at http://zhang.bioinformatics.ku.edu/I-TASSER.}
      \field{issn}{1754-2189}
      \field{journaltitle}{Nature protocols}
      \field{month}{04}
      \field{number}{4}
      \field{title}{{I-TASSER: a unified platform for automated protein structure and function prediction}}
      \field{volume}{5}
      \field{year}{2010}
      \field{pages}{725\bibrangedash 738}
      \verb{doi}
      \verb 10.1038/nprot.2010.5
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2849174/
      \endverb
    \endentry
    \entry{Zhang2008}{article}{}
      \name{labelname}{1}{}{%
        {{hash=e760d38078aff4a5b24c867aa5178c26}{Zhang}{Z\bibinitperiod}{Yang}{Y\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=e760d38078aff4a5b24c867aa5178c26}{Zhang}{Z\bibinitperiod}{Yang}{Y\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {BioMed Central}%
      }
      \strng{namehash}{e760d38078aff4a5b24c867aa5178c26}
      \strng{fullhash}{e760d38078aff4a5b24c867aa5178c26}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{I-TASSER server for protein 3D structure prediction}}
      \field{abstract}{BACKGROUND: Prediction of 3-dimensional protein structures from amino acid sequences represents one of the most important problems in computational structural biology. The community-wide Critical Assessment of Structure Prediction (CASP) experiments have been designed to obtain an objective assessment of the state-of-the-art of the field, where I-TASSER was ranked as the best method in the server section of the recent 7th CASP experiment. Our laboratory has since then received numerous requests about the public availability of the I-TASSER algorithm and the usage of the I-TASSER predictions. RESULTS: An on-line version of I-TASSER is developed at the KU Center for Bioinformatics which has generated protein structure predictions for thousands of modeling requests from more than 35 countries. A scoring function (C-score) based on the relative clustering structural density and the consensus significance score of multiple threading templates is introduced to estimate the accuracy of the I-TASSER predictions. A large-scale benchmark test demonstrates a strong correlation between the C-score and the TM-score (a structural similarity measurement with values in [0, 1]) of the first models with a correlation coefficient of 0.91. Using a C-score cutoff {>} -1.5 for the models of correct topology, both false positive and false negative rates are below 0.1. Combining C-score and protein length, the accuracy of the I-TASSER models can be predicted with an average error of 0.08 for TM-score and 2 {\r{A}} for RMSD. CONCLUSION: The I-TASSER server has been developed to generate automated full-length 3D protein structural predictions where the benchmarked scoring system helps users to obtain quantitative assessments of the I-TASSER models. The output of the I-TASSER server for each query includes up to five full-length models, the confidence score, the estimated TM-score and RMSD, and the standard deviation of the estimations. The I-TASSER server is freely available to the academic community at .}
      \field{issn}{1471-2105}
      \field{journaltitle}{BMC Bioinformatics}
      \field{month}{01}
      \field{title}{{I-TASSER server for protein 3D structure prediction}}
      \field{volume}{9}
      \field{year}{2008}
      \field{pages}{40}
      \verb{doi}
      \verb 10.1186/1471-2105-9-40
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2245901/
      \endverb
    \endentry
    \entry{Kim2004}{article}{}
      \name{labelname}{3}{}{%
        {{hash=339e12ef3231908dc13e1e8d9f327d03}{Kim}{K\bibinitperiod}{David\bibnamedelima E}{D\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=384871ed5ad08f441a9752c0ef6144f0}{Chivian}{C\bibinitperiod}{Dylan}{D\bibinitperiod}{}{}{}{}}%
        {{hash=db711af07f28528a9ee5cf2922c529a3}{Baker}{B\bibinitperiod}{David}{D\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=339e12ef3231908dc13e1e8d9f327d03}{Kim}{K\bibinitperiod}{David\bibnamedelima E}{D\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=384871ed5ad08f441a9752c0ef6144f0}{Chivian}{C\bibinitperiod}{Dylan}{D\bibinitperiod}{}{}{}{}}%
        {{hash=db711af07f28528a9ee5cf2922c529a3}{Baker}{B\bibinitperiod}{David}{D\bibinitperiod}{}{}{}{}}%
      }
      \list{location}{1}{%
        {Oxford, UK}%
      }
      \list{publisher}{1}{%
        {Oxford University Press}%
      }
      \strng{namehash}{69f279c6d47da3b36a34d9bdf2e8d521}
      \strng{fullhash}{69f279c6d47da3b36a34d9bdf2e8d521}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Protein structure prediction and analysis using the Robetta server}}
      \field{abstract}{The Robetta server (http://robetta.bakerlab.org) provides automated tools for protein structure prediction and analysis. For structure prediction, sequences submitted to the server are parsed into putative domains and structural models are generated using either comparative modeling or de novo structure prediction methods. If a confident match to a protein of known structure is found using BLAST, PSI-BLAST, FFAS03 or 3D-Jury, it is used as a template for comparative modeling. If no match is found, structure predictions are made using the de novo Rosetta fragment insertion method. Experimental nuclear magnetic resonance (NMR) constraints data can also be submitted with a query sequence for RosettaNMR de novo structure determination. Other current capabilities include the prediction of the effects of mutations on protein--protein interactions using computational interface alanine scanning. The Rosetta protein design and protein--protein docking methodologies will soon be available through the server as well.}
      \field{issn}{0305-1048}
      \field{journaltitle}{Nucleic Acids Research}
      \field{month}{07}
      \field{number}{Web Server issue}
      \field{title}{{Protein structure prediction and analysis using the Robetta server}}
      \field{volume}{32}
      \field{year}{2004}
      \field{pages}{W526\bibrangedash W531}
      \verb{doi}
      \verb 10.1093/nar/gkh468
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC441606/
      \endverb
    \endentry
    \entry{Kallberg2014}{inbook}{}
      \name{labelname}{5}{}{%
        {{hash=ff40308fdc7de968f78476a252f035f7}{K{\"{a}}llberg}{K\bibinitperiod}{Morten}{M\bibinitperiod}{}{}{}{}}%
        {{hash=4b8c1ea1ad36d2610a71726f6042de8d}{Margaryan}{M\bibinitperiod}{Gohar}{G\bibinitperiod}{}{}{}{}}%
        {{hash=6bf0d8a8573aa1ba9713d0e20811cdb7}{Wang}{W\bibinitperiod}{Sheng}{S\bibinitperiod}{}{}{}{}}%
        {{hash=4110e2c106851274d8af7b534f7a748e}{Ma}{M\bibinitperiod}{Jianzhu}{J\bibinitperiod}{}{}{}{}}%
        {{hash=716306a09f303b9d16a4e7585e74f403}{Xu}{X\bibinitperiod}{Jinbo}{J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{5}{}{%
        {{hash=ff40308fdc7de968f78476a252f035f7}{K{\"{a}}llberg}{K\bibinitperiod}{Morten}{M\bibinitperiod}{}{}{}{}}%
        {{hash=4b8c1ea1ad36d2610a71726f6042de8d}{Margaryan}{M\bibinitperiod}{Gohar}{G\bibinitperiod}{}{}{}{}}%
        {{hash=6bf0d8a8573aa1ba9713d0e20811cdb7}{Wang}{W\bibinitperiod}{Sheng}{S\bibinitperiod}{}{}{}{}}%
        {{hash=4110e2c106851274d8af7b534f7a748e}{Ma}{M\bibinitperiod}{Jianzhu}{J\bibinitperiod}{}{}{}{}}%
        {{hash=716306a09f303b9d16a4e7585e74f403}{Xu}{X\bibinitperiod}{Jinbo}{J\bibinitperiod}{}{}{}{}}%
      }
      \name{editor}{1}{}{%
        {{hash=d34e70d4f763f52fcf8a13a10907d7ae}{Kihara}{K\bibinitperiod}{Daisuke}{D\bibinitperiod}{}{}{}{}}%
      }
      \list{location}{1}{%
        {New York, NY}%
      }
      \list{publisher}{1}{%
        {Springer New York}%
      }
      \strng{namehash}{7bb6df332ee33a3b3bc8e2d81c94d48c}
      \strng{fullhash}{3e3d22eed4312ada18428808833ac5b3}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Protein Structure Prediction}}
      \field{chapter}{RaptorX se}
      \field{isbn}{978-1-4939-0366-5}
      \field{title}{{Protein Structure Prediction}}
      \field{year}{2014}
      \field{pages}{17\bibrangedash 27}
      \verb{doi}
      \verb 10.1007/978-1-4939-0366-5_2
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1007/978-1-4939-0366-5%7B%5C_%7D2
      \endverb
    \endentry
    \entry{Bates2001}{article}{}
      \name{labelname}{4}{}{%
        {{hash=514eeb149ed44638917f125adb1a3e26}{Bates}{B\bibinitperiod}{P\bibnamedelima A}{P\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=63a108e094225e08eb00471327dc1e56}{Kelley}{K\bibinitperiod}{L\bibnamedelima A}{L\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=a48db3f3e2769a224c0eed1abbce2c02}{MacCallum}{M\bibinitperiod}{R\bibnamedelima M}{R\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=060ac14ca776c9fb01d20f6f8bc50aa9}{Sternberg}{S\bibinitperiod}{M\bibnamedelima J}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=514eeb149ed44638917f125adb1a3e26}{Bates}{B\bibinitperiod}{P\bibnamedelima A}{P\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=63a108e094225e08eb00471327dc1e56}{Kelley}{K\bibinitperiod}{L\bibnamedelima A}{L\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=a48db3f3e2769a224c0eed1abbce2c02}{MacCallum}{M\bibinitperiod}{R\bibnamedelima M}{R\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=060ac14ca776c9fb01d20f6f8bc50aa9}{Sternberg}{S\bibinitperiod}{M\bibnamedelima J}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{48d90d351452ad0636a9dfd616cfd232}
      \strng{fullhash}{90e3d3083b08d660b1ac39657cd6f690}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Enhancement of protein modeling by human intervention in applying the automatic programs 3D-JIGSAW and 3D-PSSM.}}
      \field{abstract}{Fourteen models were constructed and analyzed for the comparative modeling section of Critical Assessment of Techniques for Protein Structure Prediction (CASP4). Sequence identity between each target and the best possible parent(s) ranged between 55 and 13{\%}, and the root-mean-square deviation between model and target was from 0.8 to 17.9 A. In the fold recognition section, 10 of the 11 remote homologues were recognized. The modeling protocols are a combination of automated computer algorithms, 3D-JIGSAW (for comparative modeling) and 3D-PSSM (for fold recognition), with human intervention at certain critical stages. In particular, intervention is required to check superfamily assignment, best possible parents from which to model, sequence alignments to those parents and take-off regions for modeling variable regions. There now is a convergence of algorithms for comparative modeling and fold recognition, particularly in the region of remote homology.}
      \field{issn}{0887-3585}
      \field{journaltitle}{Proteins}
      \field{month}{01}
      \field{title}{{Enhancement of protein modeling by human intervention in applying the automatic programs 3D-JIGSAW and 3D-PSSM.}}
      \field{volume}{Suppl 5}
      \field{year}{2001}
      \field{pages}{39\bibrangedash 46}
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/11835480
      \endverb
    \endentry
    \entry{Vriend1990}{article}{}
      \name{labelname}{1}{}{%
        {{hash=6cc0e7fcba697b2730c1dbec3a1726d7}{Vriend}{V\bibinitperiod}{G.}{G\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=6cc0e7fcba697b2730c1dbec3a1726d7}{Vriend}{V\bibinitperiod}{G.}{G\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{6cc0e7fcba697b2730c1dbec3a1726d7}
      \strng{fullhash}{6cc0e7fcba697b2730c1dbec3a1726d7}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{WHAT IF: A molecular modeling and drug design program}}
      \field{abstract}{A FORTRAN 77 computer program has been written to aid with macromolecular modeling and drug design. Called WHAT IF, it provides an intelligent and flexible environment for displaying, manipulating, and analyzing small molecules, proteins, nucleic acids, and their interactions. A relational protein structure database is incorporated to be queried. The program is suitable for most common crystallographic work. The menu-driven operation of WHAT IF, combined with the use of default values wherever user input is required, makes it very easy to use for a novice user while keeping full flexibility for more sophisticated studies. Although there are not too many unique features in WHAT IF, the fact that everything is integrated in one program makes it a unique tool for many purposes.}
      \field{issn}{02637855}
      \field{journaltitle}{Journal of Molecular Graphics}
      \field{month}{03}
      \field{number}{1}
      \field{title}{{WHAT IF: A molecular modeling and drug design program}}
      \field{volume}{8}
      \field{year}{1990}
      \field{pages}{52\bibrangedash 56}
      \verb{doi}
      \verb 10.1016/0263-7855(90)80070-V
      \endverb
      \verb{url}
      \verb http://www.sciencedirect.com/science/article/pii/026378559080070V
      \endverb
    \endentry
    \entry{Richardson1981}{book}{}
      \name{labelname}{1}{}{%
        {{hash=1942b77d65e62ed294185de18324007a}{Richardson}{R\bibinitperiod}{Jane\bibnamedelima S.}{J\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=1942b77d65e62ed294185de18324007a}{Richardson}{R\bibinitperiod}{Jane\bibnamedelima S.}{J\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{1942b77d65e62ed294185de18324007a}
      \strng{fullhash}{1942b77d65e62ed294185de18324007a}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Advances in Protein Chemistry Volume 34}}
      \field{abstract}{This chapter investigates the anatomy and taxonomy of protein structures. A protein is a polypeptide chain made up of amino acid residues linked together in a definite sequence. Amino acids are {$\textquotedblleft$}handed,{$\textquotedblright$} and naturally occurring proteins contain only L-amino acids. A simple mnemonic for that purpose is the {$\textquotedblleft$}corncrib.{$\textquotedblright$} The sequence of side chains determines all that is unique about a particular protein, including its biological function and its specific three-dimensional structure. The major possible routes to knowledge of three-dimensional protein structure are prediction from the amino acid sequence and analysis of spectroscopic measurements such as circular dichroism, laser Raman spectroscopy, and nuclear magnetic resonance. The analysis and discussion of protein structure is based on the results of three-dimensional X-ray crystallography of globular proteins. The basic elements of protein structures are discussed. The most useful level at which protein structures are to be categorized is the domain, as there are many cases of multiple-domain proteins in which each separate domain resembles other entire smaller proteins. The simplest type of stable protein structure consists of polypeptide backbone wrapped more or less uniformly around the outside of a single hydrophobic core. The outline of the taxonomy is also provided in the chapter.}
      \field{booktitle}{Advances in Protein Chemistry}
      \field{isbn}{9780120342341}
      \field{issn}{00653233}
      \field{title}{{Advances in Protein Chemistry Volume 34}}
      \field{volume}{34}
      \field{year}{1981}
      \field{pages}{167\bibrangedash 339}
      \verb{doi}
      \verb 10.1016/S0065-3233(08)60520-3
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/richardson1981.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.sciencedirect.com/science/article/pii/S0065323308605203
      \endverb
    \endentry
    \entry{That1991}{article}{}
      \name{labelname}{2}{}{%
        {{hash=7be716f68dbba1528c49b2b89583be8a}{That}{T\bibinitperiod}{Extracellular\bibnamedelima Proteins}{E\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=064b675fcb4b96f4755f7e10884b94db}{Interactions}{I\bibinitperiod}{Modulate\bibnamedelima Cell-matrix}{M\bibinitperiod\bibinitdelim C\bibinithyphendelim m\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=7be716f68dbba1528c49b2b89583be8a}{That}{T\bibinitperiod}{Extracellular\bibnamedelima Proteins}{E\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=064b675fcb4b96f4755f7e10884b94db}{Interactions}{I\bibinitperiod}{Modulate\bibnamedelima Cell-matrix}{M\bibinitperiod\bibinitdelim C\bibinithyphendelim m\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{5c4382f6ad563e2fbf1264a7315b9096}
      \strng{fullhash}{5c4382f6ad563e2fbf1264a7315b9096}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Extracellular Proteins That}}
      \field{isbn}{0014579391}
      \field{number}{23}
      \field{title}{{Extracellular Proteins That}}
      \field{volume}{266}
      \field{year}{1991}
      \field{pages}{15\bibrangedash 18}
      \verb{file}
      \verb :home/fran/Downloads/feb2001457939180937x.pdf:pdf
      \endverb
    \endentry
    \entry{DomainDef}{article}{}
      \name{labelname}{1}{}{%
        {{hash=b7c7eb2a631e8b995a080136f28071f0}{Wetlaufer}{W\bibinitperiod}{D\bibnamedelima B}{D\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=b7c7eb2a631e8b995a080136f28071f0}{Wetlaufer}{W\bibinitperiod}{D\bibnamedelima B}{D\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{b7c7eb2a631e8b995a080136f28071f0}
      \strng{fullhash}{b7c7eb2a631e8b995a080136f28071f0}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Nucleation, rapid folding, and globular intrachain regions in proteins.}}
      \field{abstract}{Distinct structural regions have been found in several globular proteins composed of single polypeptide chains. The existence of such regions and the continuity of peptide chain within them, coupled with kinetic arguments, suggests that the early stages of three-dimensional structure formation (nucleation) occur independently in separate parts of these molecules. A nucleus can grow rapidly by adding peptide chain segments that are close to the nucleus in aminoacid sequence. Such a process would generate three-dimensional (native) protein structures that contain separate regions of continuous peptide chain. Possible means of testing this hypothesis are discussed.}
      \field{issn}{0027-8424}
      \field{journaltitle}{Proceedings of the National Academy of Sciences of the United States of America}
      \field{number}{3}
      \field{title}{{Nucleation, rapid folding, and globular intrachain regions in proteins.}}
      \field{volume}{70}
      \field{year}{1973}
      \field{pages}{697\bibrangedash 701}
      \verb{doi}
      \verb 10.1073/pnas.70.3.697
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/PNAS-1973-Wetlaufer-697-701.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=433338%7B%5C&%7Dtool=pmcentrez%7B%5C&%7Drendertype=abstract
      \endverb
    \endentry
    \entry{Islam1995}{article}{}
      \name{labelname}{5}{}{%
        {{hash=60ec6bc1b20fb6fea05a648850a77b3a}{Islam}{I\bibinitperiod}{Suhail\bibnamedelima A}{S\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=7669ad50b7c3c5960975148ae5ff650c}{Luo}{L\bibinitperiod}{Jingchu}{J\bibinitperiod}{}{}{}{}}%
        {{hash=ce3ba6c2553ffabc0b04f57ac5aa78c2}{Michael}{M\bibinitperiod}{J\bibnamedelima E\bibnamedelima S}{J\bibinitperiod\bibinitdelim E\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=5a9d607dd3bf84039e2eea05b6fd9db6}{Fields}{F\bibinitperiod}{Inn}{I\bibinitperiod}{}{}{}{}}%
        {{hash=352220d8df95e4341bb6fd1bd7a7824f}{Wca}{W\bibinitperiod}{London}{L\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{5}{}{%
        {{hash=60ec6bc1b20fb6fea05a648850a77b3a}{Islam}{I\bibinitperiod}{Suhail\bibnamedelima A}{S\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=7669ad50b7c3c5960975148ae5ff650c}{Luo}{L\bibinitperiod}{Jingchu}{J\bibinitperiod}{}{}{}{}}%
        {{hash=ce3ba6c2553ffabc0b04f57ac5aa78c2}{Michael}{M\bibinitperiod}{J\bibnamedelima E\bibnamedelima S}{J\bibinitperiod\bibinitdelim E\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=5a9d607dd3bf84039e2eea05b6fd9db6}{Fields}{F\bibinitperiod}{Inn}{I\bibinitperiod}{}{}{}{}}%
        {{hash=352220d8df95e4341bb6fd1bd7a7824f}{Wca}{W\bibinitperiod}{London}{L\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{88a4ab26d2afe794fca9bd47e80f5465}
      \strng{fullhash}{61dd19938af845aba752b158acf1e2f6}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Identification and analysis of domains in proteins presented to identify domains in proteins}}
      \field{number}{6}
      \field{title}{{Identification and analysis of domains in proteins presented to identify domains in proteins}}
      \field{volume}{8}
      \field{year}{1995}
      \field{pages}{513\bibrangedash 525}
      \verb{file}
      \verb :home/fran/Downloads/islam1995.pdf:pdf
      \endverb
    \endentry
    \entry{Han2007}{article}{}
      \name{labelname}{5}{}{%
        {{hash=1a1fc9219f4ad5c54b013e9aedb81b96}{Han}{H\bibinitperiod}{Jung-Hoon}{J\bibinithyphendelim H\bibinitperiod}{}{}{}{}}%
        {{hash=dbfbb4cf0629c9e7fd499ce6fa01d6da}{Batey}{B\bibinitperiod}{Sarah}{S\bibinitperiod}{}{}{}{}}%
        {{hash=80035313591885d16e25f8faafa989ce}{Nickson}{N\bibinitperiod}{Adrian\bibnamedelima a}{A\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
        {{hash=c2f5cd48e8daabc6e9d7f794465a9647}{Teichmann}{T\bibinitperiod}{Sarah\bibnamedelima a}{S\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
        {{hash=1f7cf7004ea1f6288a78d10bcd247212}{Clarke}{C\bibinitperiod}{Jane}{J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{5}{}{%
        {{hash=1a1fc9219f4ad5c54b013e9aedb81b96}{Han}{H\bibinitperiod}{Jung-Hoon}{J\bibinithyphendelim H\bibinitperiod}{}{}{}{}}%
        {{hash=dbfbb4cf0629c9e7fd499ce6fa01d6da}{Batey}{B\bibinitperiod}{Sarah}{S\bibinitperiod}{}{}{}{}}%
        {{hash=80035313591885d16e25f8faafa989ce}{Nickson}{N\bibinitperiod}{Adrian\bibnamedelima a}{A\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
        {{hash=c2f5cd48e8daabc6e9d7f794465a9647}{Teichmann}{T\bibinitperiod}{Sarah\bibnamedelima a}{S\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
        {{hash=1f7cf7004ea1f6288a78d10bcd247212}{Clarke}{C\bibinitperiod}{Jane}{J\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{34c454b290fbed90ebb25b13f611aff2}
      \strng{fullhash}{2c4440340e1ff3b3831064ad7a75fe30}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{The folding and evolution of multidomain proteins.}}
      \field{abstract}{Analyses of genomes show that more than 70{\%} of eukaryotic proteins are composed of multiple domains. However, most studies of protein folding focus on individual domains and do not consider how interactions between domains might affect folding. Here, we address this by analysing the three-dimensional structures of multidomain proteins that have been characterized experimentally and observe that where the interface is small and loosely packed, or unstructured, the folding of the domains is independent. Furthermore, recent studies indicate that multidomain proteins have evolved mechanisms to minimize the problems of interdomain misfolding.}
      \field{issn}{1471-0072}
      \field{journaltitle}{Nature reviews. Molecular cell biology}
      \field{number}{4}
      \field{title}{{The folding and evolution of multidomain proteins.}}
      \field{volume}{8}
      \field{year}{2007}
      \field{pages}{319\bibrangedash 330}
      \verb{doi}
      \verb 10.1038/nrm2144
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/nrm2144.pdf:pdf
      \endverb
    \endentry
    \entry{Chothia2003}{article}{}
      \name{labelname}{4}{}{%
        {{hash=e7519839a5afb3dc61bb297b7fb4f313}{Chothia}{C\bibinitperiod}{Cyrus}{C\bibinitperiod}{}{}{}{}}%
        {{hash=d555f8ccbc9d14ac20a0f70424b46e75}{Gough}{G\bibinitperiod}{Julian}{J\bibinitperiod}{}{}{}{}}%
        {{hash=b631f76e3a5923ac7e82caac9f5d6600}{Vogel}{V\bibinitperiod}{Christine}{C\bibinitperiod}{}{}{}{}}%
        {{hash=c2f5cd48e8daabc6e9d7f794465a9647}{Teichmann}{T\bibinitperiod}{Sarah\bibnamedelima a}{S\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=e7519839a5afb3dc61bb297b7fb4f313}{Chothia}{C\bibinitperiod}{Cyrus}{C\bibinitperiod}{}{}{}{}}%
        {{hash=d555f8ccbc9d14ac20a0f70424b46e75}{Gough}{G\bibinitperiod}{Julian}{J\bibinitperiod}{}{}{}{}}%
        {{hash=b631f76e3a5923ac7e82caac9f5d6600}{Vogel}{V\bibinitperiod}{Christine}{C\bibinitperiod}{}{}{}{}}%
        {{hash=c2f5cd48e8daabc6e9d7f794465a9647}{Teichmann}{T\bibinitperiod}{Sarah\bibnamedelima a}{S\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{6407dacea043bf1cdf1480a479796cc6}
      \strng{fullhash}{9433c49cf099ddc98c2612479ca165cc}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Evolution of the protein repertoire.}}
      \field{issn}{1095-9203}
      \field{journaltitle}{Science (New York, N.Y.)}
      \field{number}{5626}
      \field{title}{{Evolution of the protein repertoire.}}
      \field{volume}{300}
      \field{year}{2003}
      \field{pages}{1701\bibrangedash 3}
      \verb{doi}
      \verb 10.1126/science.1085371
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/1701.full.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/12805536
      \endverb
    \endentry
    \entry{Vogel2004}{article}{}
      \name{labelname}{5}{}{%
        {{hash=b631f76e3a5923ac7e82caac9f5d6600}{Vogel}{V\bibinitperiod}{Christine}{C\bibinitperiod}{}{}{}{}}%
        {{hash=567527bbc47ea3a86d781dbcfbeeecd5}{Bashton}{B\bibinitperiod}{Matthew}{M\bibinitperiod}{}{}{}{}}%
        {{hash=a14d3c6cfa9248bdd6df783471d74676}{Kerrison}{K\bibinitperiod}{Nicola\bibnamedelima D.}{N\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=e7519839a5afb3dc61bb297b7fb4f313}{Chothia}{C\bibinitperiod}{Cyrus}{C\bibinitperiod}{}{}{}{}}%
        {{hash=297bedd4a585ea429676a28716291cc1}{Teichmann}{T\bibinitperiod}{Sarah\bibnamedelima A.}{S\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{5}{}{%
        {{hash=b631f76e3a5923ac7e82caac9f5d6600}{Vogel}{V\bibinitperiod}{Christine}{C\bibinitperiod}{}{}{}{}}%
        {{hash=567527bbc47ea3a86d781dbcfbeeecd5}{Bashton}{B\bibinitperiod}{Matthew}{M\bibinitperiod}{}{}{}{}}%
        {{hash=a14d3c6cfa9248bdd6df783471d74676}{Kerrison}{K\bibinitperiod}{Nicola\bibnamedelima D.}{N\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=e7519839a5afb3dc61bb297b7fb4f313}{Chothia}{C\bibinitperiod}{Cyrus}{C\bibinitperiod}{}{}{}{}}%
        {{hash=297bedd4a585ea429676a28716291cc1}{Teichmann}{T\bibinitperiod}{Sarah\bibnamedelima A.}{S\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{2fec1062bda54de126927ac9a9f99178}
      \strng{fullhash}{39592d1af1fe60179c0e93bc784a8b9f}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Structure, function and evolution of multidomain proteins}}
      \field{abstract}{Proteins are composed of evolutionary units called domains; the majority of proteins consist of at least two domains. These domains and nature of their interactions determine the function of the protein. The roles that combinations of domains play in the formation of the protein repertoire have been found by analysis of domain assignments to genome sequences. Additional findings on the geometry of domains have been gained from examination of three-dimensional protein structures. Future work will require a domain-centric functional classification scheme and efforts to determine structures of domain combinations.}
      \field{issn}{0959440X}
      \field{journaltitle}{Current Opinion in Structural Biology}
      \field{number}{2}
      \field{title}{{Structure, function and evolution of multidomain proteins}}
      \field{volume}{14}
      \field{year}{2004}
      \field{pages}{208\bibrangedash 216}
      \verb{doi}
      \verb 10.1016/j.sbi.2004.03.011
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/160{\_}cosb{\_}14{\_}208{\_}04.pdf:pdf
      \endverb
    \endentry
    \entry{Apic2001}{article}{}
      \name{labelname}{3}{}{%
        {{hash=efcbb06bb1ea6e9715bdd02e9dd88814}{Apic}{A\bibinitperiod}{G}{G\bibinitperiod}{}{}{}{}}%
        {{hash=dd105c1a4f8e69affb33bb12ab748ccf}{Gough}{G\bibinitperiod}{J}{J\bibinitperiod}{}{}{}{}}%
        {{hash=d7ad71301f2645f8897b81854d6ab6cf}{Teichmann}{T\bibinitperiod}{S\bibnamedelima a}{S\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=efcbb06bb1ea6e9715bdd02e9dd88814}{Apic}{A\bibinitperiod}{G}{G\bibinitperiod}{}{}{}{}}%
        {{hash=dd105c1a4f8e69affb33bb12ab748ccf}{Gough}{G\bibinitperiod}{J}{J\bibinitperiod}{}{}{}{}}%
        {{hash=d7ad71301f2645f8897b81854d6ab6cf}{Teichmann}{T\bibinitperiod}{S\bibnamedelima a}{S\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{f431ae4c3e719ffdcaa9e8da5219bbba}
      \strng{fullhash}{f431ae4c3e719ffdcaa9e8da5219bbba}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Domain combinations in archaeal, eubacterial and eukaryotic proteomes.}}
      \field{abstract}{There is a limited repertoire of domain families that are duplicated and combined in different ways to form the set of proteins in a genome. Proteins are gene products, and at the level of genes, duplication, recombination, fusion and fission are the processes that produce new genes. We attempt to gain an overview of these processes by studying the evolutionary units in proteins, domains, in the protein sequences of 40 genomes. The domain and superfamily definitions in the Structural Classification of Proteins Database are used, so that we can view all pairs of adjacent domains in genome sequences in terms of their superfamily combinations. We find 783 out of the 859 superfamilies in SCOP in these genomes, and the 783 families occur in 1307 pairwise combinations. Most families are observed in combination with one or two other families, while a few families are very versatile in their combinatorial behaviour; 209 families do not make combinations with other families. This type of pattern can be described as a scale-free network. We also study the N to C-terminal orientation of domain pairs and domain repeats. The phylogenetic distribution of domain combinations is surveyed, to establish the extent of common and kingdom-specific combinations. Of the kingdom-specific combinations, significantly more combinations consist of families present in all three kingdoms than of families present in one or two kingdoms. Hence, we are led to conclude that recombination between common families, as compared to the invention of new families and recombination among these, has also been a major contribution to the evolution of kingdom-specific and species-specific functions in organisms in all three kingdoms. Finally, we compare the set of the domain combinations in the genomes to those in the RCSB Protein Data Bank, and discuss the implications for structural genomics.}
      \field{issn}{0022-2836}
      \field{journaltitle}{Journal of molecular biology}
      \field{number}{2}
      \field{title}{{Domain combinations in archaeal, eubacterial and eukaryotic proteomes.}}
      \field{volume}{310}
      \field{year}{2001}
      \field{pages}{311\bibrangedash 325}
      \verb{doi}
      \verb 10.1006/jmbi.2001.4776
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/1-s2.0-S002228360194776X-main.pdf:pdf
      \endverb
    \endentry
    \entry{Murzin1995}{article}{}
      \name{labelname}{4}{}{%
        {{hash=42b7f51d15c595136efc59e73a14de59}{Murzin}{M\bibinitperiod}{Alexey\bibnamedelima G.}{A\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=eaa050d847c04a972f7923961fd20e5c}{Brenner}{B\bibinitperiod}{Steven\bibnamedelima E.}{S\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=ea8c6f86565db567f286380a1200bde2}{Hubbard}{H\bibinitperiod}{Tim}{T\bibinitperiod}{}{}{}{}}%
        {{hash=e7519839a5afb3dc61bb297b7fb4f313}{Chothia}{C\bibinitperiod}{Cyrus}{C\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=42b7f51d15c595136efc59e73a14de59}{Murzin}{M\bibinitperiod}{Alexey\bibnamedelima G.}{A\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=eaa050d847c04a972f7923961fd20e5c}{Brenner}{B\bibinitperiod}{Steven\bibnamedelima E.}{S\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=ea8c6f86565db567f286380a1200bde2}{Hubbard}{H\bibinitperiod}{Tim}{T\bibinitperiod}{}{}{}{}}%
        {{hash=e7519839a5afb3dc61bb297b7fb4f313}{Chothia}{C\bibinitperiod}{Cyrus}{C\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{ee746f630cfdbaeb6b971463fe66ae82}
      \strng{fullhash}{7e82c14f0c89c460f251127c1d401a0c}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{SCOP: A structural classification of proteins database for the investigation of sequences and structures}}
      \field{issn}{00222836}
      \field{journaltitle}{Journal of Molecular Biology}
      \field{number}{4}
      \field{title}{{SCOP: A structural classification of proteins database for the investigation of sequences and structures}}
      \field{volume}{247}
      \field{year}{1995}
      \field{pages}{536\bibrangedash 540}
      \verb{doi}
      \verb 10.1016/S0022-2836(05)80134-2
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/murzin1995.pdf:pdf
      \endverb
    \endentry
    \entry{Orengo1997}{article}{}
      \name{labelname}{6}{}{%
        {{hash=919c26011075f6007f9ab8fd83661920}{Orengo}{O\bibinitperiod}{Ca}{C\bibinitperiod}{}{}{}{}}%
        {{hash=70bfe79af73cfaedcd77fd4a0f2f9904}{Michie}{M\bibinitperiod}{Ad}{A\bibinitperiod}{}{}{}{}}%
        {{hash=34ac6afd6fa2a04708410458765f2c91}{Jones}{J\bibinitperiod}{S}{S\bibinitperiod}{}{}{}{}}%
        {{hash=3a16cbc5d72721281ac685fbeeb35975}{Jones}{J\bibinitperiod}{Dt}{D\bibinitperiod}{}{}{}{}}%
        {{hash=884beffdd9846c9fb86206fddfe93a98}{Swindells}{S\bibinitperiod}{Mb}{M\bibinitperiod}{}{}{}{}}%
        {{hash=029dc3641f9bd9ee9f780eff69c66151}{Thornton}{T\bibinitperiod}{Jm}{J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{6}{}{%
        {{hash=919c26011075f6007f9ab8fd83661920}{Orengo}{O\bibinitperiod}{Ca}{C\bibinitperiod}{}{}{}{}}%
        {{hash=70bfe79af73cfaedcd77fd4a0f2f9904}{Michie}{M\bibinitperiod}{Ad}{A\bibinitperiod}{}{}{}{}}%
        {{hash=34ac6afd6fa2a04708410458765f2c91}{Jones}{J\bibinitperiod}{S}{S\bibinitperiod}{}{}{}{}}%
        {{hash=3a16cbc5d72721281ac685fbeeb35975}{Jones}{J\bibinitperiod}{Dt}{D\bibinitperiod}{}{}{}{}}%
        {{hash=884beffdd9846c9fb86206fddfe93a98}{Swindells}{S\bibinitperiod}{Mb}{M\bibinitperiod}{}{}{}{}}%
        {{hash=029dc3641f9bd9ee9f780eff69c66151}{Thornton}{T\bibinitperiod}{Jm}{J\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{062fd1321b616555f7ae3d86dd31d88a}
      \strng{fullhash}{642168b9f8af74b9310a4ec88457999f}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{CATH - a hierarchic classification of protein domain structures}}
      \field{isbn}{0969-2126}
      \field{issn}{09692126}
      \field{journaltitle}{Structure}
      \field{number}{March}
      \field{title}{{CATH - a hierarchic classification of protein domain structures}}
      \field{year}{1997}
      \field{pages}{1093\bibrangedash 1109}
      \verb{doi}
      \verb 10.1016/S0969-2126(97)00260-8
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/1-s2.0-S0969212697002608-main.pdf:pdf
      \endverb
      \verb{url}
      \verb http://discovery.ucl.ac.uk/170914/
      \endverb
    \endentry
    \entry{Bateman2002}{article}{}
      \name{labelname}{14}{}{%
        {{hash=7aa94dfe398db505f1e5cac138d3ffc3}{Bateman}{B\bibinitperiod}{A}{A\bibinitperiod}{}{}{}{}}%
        {{hash=38d9b4f76963eda738134c8361436ae7}{Birney}{B\bibinitperiod}{E}{E\bibinitperiod}{}{}{}{}}%
        {{hash=d0cc3bd390785b9edf80dd933ac556a2}{Durbin}{D\bibinitperiod}{R}{R\bibinitperiod}{}{}{}{}}%
        {{hash=b14e84d528aad327fd0a1a9a76072adb}{Eddy}{E\bibinitperiod}{S\bibnamedelima R}{S\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=9dbdc8511f53f0e6bc96be475c82c48b}{Howe}{H\bibinitperiod}{K\bibnamedelima L}{K\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=b5c7a880e14a298ece95f41d15ffc0c3}{Sonnhammer}{S\bibinitperiod}{E\bibnamedelima L}{E\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=cbaaf82c8572f48c8890546e7ee5c201}{Cerruti}{C\bibinitperiod}{L}{L\bibinitperiod}{}{}{}{}}%
        {{hash=d0cc3bd390785b9edf80dd933ac556a2}{Durbin}{D\bibinitperiod}{R}{R\bibinitperiod}{}{}{}{}}%
        {{hash=58b3b2b8cfe8430a48abcd1e3333ecf6}{Etwiller}{E\bibinitperiod}{L}{L\bibinitperiod}{}{}{}{}}%
        {{hash=b14e84d528aad327fd0a1a9a76072adb}{Eddy}{E\bibinitperiod}{S\bibnamedelima R}{S\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=56e1e30c7e35ef73c9897f8bc5c82d2d}{Griffiths-Jones}{G\bibinithyphendelim J\bibinitperiod}{S}{S\bibinitperiod}{}{}{}{}}%
        {{hash=9dbdc8511f53f0e6bc96be475c82c48b}{Howe}{H\bibinitperiod}{K\bibnamedelima L}{K\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=a2db27cb04781e0fc0e516fdf26b7e7c}{Marshall}{M\bibinitperiod}{M}{M\bibinitperiod}{}{}{}{}}%
        {{hash=b5c7a880e14a298ece95f41d15ffc0c3}{Sonnhammer}{S\bibinitperiod}{E\bibnamedelima L}{E\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{14}{}{%
        {{hash=7aa94dfe398db505f1e5cac138d3ffc3}{Bateman}{B\bibinitperiod}{A}{A\bibinitperiod}{}{}{}{}}%
        {{hash=38d9b4f76963eda738134c8361436ae7}{Birney}{B\bibinitperiod}{E}{E\bibinitperiod}{}{}{}{}}%
        {{hash=d0cc3bd390785b9edf80dd933ac556a2}{Durbin}{D\bibinitperiod}{R}{R\bibinitperiod}{}{}{}{}}%
        {{hash=b14e84d528aad327fd0a1a9a76072adb}{Eddy}{E\bibinitperiod}{S\bibnamedelima R}{S\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=9dbdc8511f53f0e6bc96be475c82c48b}{Howe}{H\bibinitperiod}{K\bibnamedelima L}{K\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=b5c7a880e14a298ece95f41d15ffc0c3}{Sonnhammer}{S\bibinitperiod}{E\bibnamedelima L}{E\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=cbaaf82c8572f48c8890546e7ee5c201}{Cerruti}{C\bibinitperiod}{L}{L\bibinitperiod}{}{}{}{}}%
        {{hash=d0cc3bd390785b9edf80dd933ac556a2}{Durbin}{D\bibinitperiod}{R}{R\bibinitperiod}{}{}{}{}}%
        {{hash=58b3b2b8cfe8430a48abcd1e3333ecf6}{Etwiller}{E\bibinitperiod}{L}{L\bibinitperiod}{}{}{}{}}%
        {{hash=b14e84d528aad327fd0a1a9a76072adb}{Eddy}{E\bibinitperiod}{S\bibnamedelima R}{S\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=56e1e30c7e35ef73c9897f8bc5c82d2d}{Griffiths-Jones}{G\bibinithyphendelim J\bibinitperiod}{S}{S\bibinitperiod}{}{}{}{}}%
        {{hash=9dbdc8511f53f0e6bc96be475c82c48b}{Howe}{H\bibinitperiod}{K\bibnamedelima L}{K\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=a2db27cb04781e0fc0e516fdf26b7e7c}{Marshall}{M\bibinitperiod}{M}{M\bibinitperiod}{}{}{}{}}%
        {{hash=b5c7a880e14a298ece95f41d15ffc0c3}{Sonnhammer}{S\bibinitperiod}{E\bibnamedelima L}{E\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{ac1f75dec5abaa6fae284f3762a05a5a}
      \strng{fullhash}{d1c9970cbfd214b3a3ff79f3f819a5aa}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{The Pfam protein families database}}
      \field{isbn}{1362-4962 (Electronic)}
      \field{issn}{0305-1048 (Print) 0305-1048 (Linking)}
      \field{journaltitle}{Nucleic Acids Research}
      \field{number}{1}
      \field{title}{{The Pfam protein families database}}
      \field{volume}{28}
      \field{year}{2002}
      \field{pages}{276\bibrangedash 280}
      \verb{doi}
      \verb gkd038 [pii]
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/Nucl. Acids Res.-2002-Bateman-276-80.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve%7B%5C&%7Ddb=PubMed%7B%5C&%7Ddopt=Citation%7B%5C&%7Dlist%7B%5C_%7Duids=11752314%20http://www.ncbi.nlm.nih.gov/pubmed/10592242
      \endverb
    \endentry
    \entry{Hunter2009}{article}{}
      \name{labelname}{38}{}{%
        {{hash=4232913ae552b928ff5101e7d581375f}{Hunter}{H\bibinitperiod}{Sarah}{S\bibinitperiod}{}{}{}{}}%
        {{hash=88e451f539cb133a865445c7b4a72945}{Apweiler}{A\bibinitperiod}{Rolf}{R\bibinitperiod}{}{}{}{}}%
        {{hash=0d2826c48375171a50da9d818710ac95}{Attwood}{A\bibinitperiod}{Teresa\bibnamedelima K.}{T\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=b2ebd3ba772b0e00ce7ff11062d7bb7e}{Bairoch}{B\bibinitperiod}{Amos}{A\bibinitperiod}{}{}{}{}}%
        {{hash=1ced5c37e13ed96f4cb024911c267029}{Bateman}{B\bibinitperiod}{Alex}{A\bibinitperiod}{}{}{}{}}%
        {{hash=8ac693a590925614d5eab4124b16d815}{Binns}{B\bibinitperiod}{David}{D\bibinitperiod}{}{}{}{}}%
        {{hash=e661978528e2df38a8c66036d9e7c3a2}{Bork}{B\bibinitperiod}{Peer}{P\bibinitperiod}{}{}{}{}}%
        {{hash=070cb6ad7a7d5d2d766209c073611eb1}{Das}{D\bibinitperiod}{Ujjwal}{U\bibinitperiod}{}{}{}{}}%
        {{hash=3181a4e63e23edf46ad3a0ab584a861d}{Daugherty}{D\bibinitperiod}{Louise}{L\bibinitperiod}{}{}{}{}}%
        {{hash=a0324e3154f8264b92b921f82b7485ac}{Duquenne}{D\bibinitperiod}{Lauranne}{L\bibinitperiod}{}{}{}{}}%
        {{hash=f0db7057368bb4f4edb12e97a28cbf3b}{Finn}{F\bibinitperiod}{Robert\bibnamedelima D.}{R\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=d555f8ccbc9d14ac20a0f70424b46e75}{Gough}{G\bibinitperiod}{Julian}{J\bibinitperiod}{}{}{}{}}%
        {{hash=c23f9faa75b1688ba9504d8cf32b1bfd}{Haft}{H\bibinitperiod}{Daniel}{D\bibinitperiod}{}{}{}{}}%
        {{hash=284b9e8e35db019d7497fde6cb5b9983}{Hulo}{H\bibinitperiod}{Nicolas}{N\bibinitperiod}{}{}{}{}}%
        {{hash=e703131d4a240ed85e6dc263888115bf}{Kahn}{K\bibinitperiod}{Daniel}{D\bibinitperiod}{}{}{}{}}%
        {{hash=f8ed66e6c7d354ed4455da12896952be}{Kelly}{K\bibinitperiod}{Elizabeth}{E\bibinitperiod}{}{}{}{}}%
        {{hash=8492bc72a9da536e7e9f199a0fc1f4c9}{Laugraud}{L\bibinitperiod}{Aur??lie}{A\bibinitperiod}{}{}{}{}}%
        {{hash=90a16251283487ab24f75284582c22c5}{Letunic}{L\bibinitperiod}{Ivica}{I\bibinitperiod}{}{}{}{}}%
        {{hash=a56293848f9dcd3094d2283c3fc99db3}{Lonsdale}{L\bibinitperiod}{David}{D\bibinitperiod}{}{}{}{}}%
        {{hash=17a3cab6e1f118259eff98d86f83696c}{Lopez}{L\bibinitperiod}{Rodrigo}{R\bibinitperiod}{}{}{}{}}%
        {{hash=9a4d3938b52ce74c36efbba638833ed1}{Madera}{M\bibinitperiod}{Martin}{M\bibinitperiod}{}{}{}{}}%
        {{hash=0455dbb54f5f8b6810eacc4653fabbcc}{Maslen}{M\bibinitperiod}{John}{J\bibinitperiod}{}{}{}{}}%
        {{hash=1286b3ab4e9a1d3695545852236fc928}{Mcanulla}{M\bibinitperiod}{Craig}{C\bibinitperiod}{}{}{}{}}%
        {{hash=7954fac33104571b85919358e4bf2ad3}{McDowall}{M\bibinitperiod}{Jennifer}{J\bibinitperiod}{}{}{}{}}%
        {{hash=8ca0b214376f4df31410b35ef1c9fe1d}{Mistry}{M\bibinitperiod}{Jaina}{J\bibinitperiod}{}{}{}{}}%
        {{hash=1f91e7dd8020f782dbfef26202b0be20}{Mitchell}{M\bibinitperiod}{Alex}{A\bibinitperiod}{}{}{}{}}%
        {{hash=b8af15e2018255691770ceb0e69f4993}{Mulder}{M\bibinitperiod}{Nicola}{N\bibinitperiod}{}{}{}{}}%
        {{hash=3c129c48ae7c6572216c11dddccbd601}{Natale}{N\bibinitperiod}{Darren}{D\bibinitperiod}{}{}{}{}}%
        {{hash=bddfe32932b7ca216def972d9c89c31c}{Orengo}{O\bibinitperiod}{Christine}{C\bibinitperiod}{}{}{}{}}%
        {{hash=f1f1b82004db81a90bccbddfa0c38753}{Quinn}{Q\bibinitperiod}{Antony\bibnamedelima F.}{A\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{hash=e2a4bdc6dab085ac91ceff07a8cadc05}{Selengut}{S\bibinitperiod}{Jeremy\bibnamedelima D.}{J\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=fe189056a4a73122866483d01a3cc1d0}{Sigrist}{S\bibinitperiod}{Christian\bibnamedelimb J\bibnamedelima A}{C\bibinitperiod\bibinitdelim J\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=150d07436146618a8d675e6dfd355c06}{Thimma}{T\bibinitperiod}{Manjula}{M\bibinitperiod}{}{}{}{}}%
        {{hash=b059cba4d10ec33a57140580b6c247d0}{Thomas}{T\bibinitperiod}{Paul\bibnamedelima D.}{P\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=4abd71267b7194c5014fc3cef027d93d}{Valentin}{V\bibinitperiod}{Franck}{F\bibinitperiod}{}{}{}{}}%
        {{hash=f7787f6390ae7ef739a0836d9eb8c07a}{Wilson}{W\bibinitperiod}{Derek}{D\bibinitperiod}{}{}{}{}}%
        {{hash=326b210a8fa7b9a4c03903af7b374ee7}{Wu}{W\bibinitperiod}{Cathy\bibnamedelima H.}{C\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=9b8386d82c2d30d29a7c1f6ef50a8373}{Yeats}{Y\bibinitperiod}{Corin}{C\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{38}{}{%
        {{hash=4232913ae552b928ff5101e7d581375f}{Hunter}{H\bibinitperiod}{Sarah}{S\bibinitperiod}{}{}{}{}}%
        {{hash=88e451f539cb133a865445c7b4a72945}{Apweiler}{A\bibinitperiod}{Rolf}{R\bibinitperiod}{}{}{}{}}%
        {{hash=0d2826c48375171a50da9d818710ac95}{Attwood}{A\bibinitperiod}{Teresa\bibnamedelima K.}{T\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=b2ebd3ba772b0e00ce7ff11062d7bb7e}{Bairoch}{B\bibinitperiod}{Amos}{A\bibinitperiod}{}{}{}{}}%
        {{hash=1ced5c37e13ed96f4cb024911c267029}{Bateman}{B\bibinitperiod}{Alex}{A\bibinitperiod}{}{}{}{}}%
        {{hash=8ac693a590925614d5eab4124b16d815}{Binns}{B\bibinitperiod}{David}{D\bibinitperiod}{}{}{}{}}%
        {{hash=e661978528e2df38a8c66036d9e7c3a2}{Bork}{B\bibinitperiod}{Peer}{P\bibinitperiod}{}{}{}{}}%
        {{hash=070cb6ad7a7d5d2d766209c073611eb1}{Das}{D\bibinitperiod}{Ujjwal}{U\bibinitperiod}{}{}{}{}}%
        {{hash=3181a4e63e23edf46ad3a0ab584a861d}{Daugherty}{D\bibinitperiod}{Louise}{L\bibinitperiod}{}{}{}{}}%
        {{hash=a0324e3154f8264b92b921f82b7485ac}{Duquenne}{D\bibinitperiod}{Lauranne}{L\bibinitperiod}{}{}{}{}}%
        {{hash=f0db7057368bb4f4edb12e97a28cbf3b}{Finn}{F\bibinitperiod}{Robert\bibnamedelima D.}{R\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=d555f8ccbc9d14ac20a0f70424b46e75}{Gough}{G\bibinitperiod}{Julian}{J\bibinitperiod}{}{}{}{}}%
        {{hash=c23f9faa75b1688ba9504d8cf32b1bfd}{Haft}{H\bibinitperiod}{Daniel}{D\bibinitperiod}{}{}{}{}}%
        {{hash=284b9e8e35db019d7497fde6cb5b9983}{Hulo}{H\bibinitperiod}{Nicolas}{N\bibinitperiod}{}{}{}{}}%
        {{hash=e703131d4a240ed85e6dc263888115bf}{Kahn}{K\bibinitperiod}{Daniel}{D\bibinitperiod}{}{}{}{}}%
        {{hash=f8ed66e6c7d354ed4455da12896952be}{Kelly}{K\bibinitperiod}{Elizabeth}{E\bibinitperiod}{}{}{}{}}%
        {{hash=8492bc72a9da536e7e9f199a0fc1f4c9}{Laugraud}{L\bibinitperiod}{Aur??lie}{A\bibinitperiod}{}{}{}{}}%
        {{hash=90a16251283487ab24f75284582c22c5}{Letunic}{L\bibinitperiod}{Ivica}{I\bibinitperiod}{}{}{}{}}%
        {{hash=a56293848f9dcd3094d2283c3fc99db3}{Lonsdale}{L\bibinitperiod}{David}{D\bibinitperiod}{}{}{}{}}%
        {{hash=17a3cab6e1f118259eff98d86f83696c}{Lopez}{L\bibinitperiod}{Rodrigo}{R\bibinitperiod}{}{}{}{}}%
        {{hash=9a4d3938b52ce74c36efbba638833ed1}{Madera}{M\bibinitperiod}{Martin}{M\bibinitperiod}{}{}{}{}}%
        {{hash=0455dbb54f5f8b6810eacc4653fabbcc}{Maslen}{M\bibinitperiod}{John}{J\bibinitperiod}{}{}{}{}}%
        {{hash=1286b3ab4e9a1d3695545852236fc928}{Mcanulla}{M\bibinitperiod}{Craig}{C\bibinitperiod}{}{}{}{}}%
        {{hash=7954fac33104571b85919358e4bf2ad3}{McDowall}{M\bibinitperiod}{Jennifer}{J\bibinitperiod}{}{}{}{}}%
        {{hash=8ca0b214376f4df31410b35ef1c9fe1d}{Mistry}{M\bibinitperiod}{Jaina}{J\bibinitperiod}{}{}{}{}}%
        {{hash=1f91e7dd8020f782dbfef26202b0be20}{Mitchell}{M\bibinitperiod}{Alex}{A\bibinitperiod}{}{}{}{}}%
        {{hash=b8af15e2018255691770ceb0e69f4993}{Mulder}{M\bibinitperiod}{Nicola}{N\bibinitperiod}{}{}{}{}}%
        {{hash=3c129c48ae7c6572216c11dddccbd601}{Natale}{N\bibinitperiod}{Darren}{D\bibinitperiod}{}{}{}{}}%
        {{hash=bddfe32932b7ca216def972d9c89c31c}{Orengo}{O\bibinitperiod}{Christine}{C\bibinitperiod}{}{}{}{}}%
        {{hash=f1f1b82004db81a90bccbddfa0c38753}{Quinn}{Q\bibinitperiod}{Antony\bibnamedelima F.}{A\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{hash=e2a4bdc6dab085ac91ceff07a8cadc05}{Selengut}{S\bibinitperiod}{Jeremy\bibnamedelima D.}{J\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=fe189056a4a73122866483d01a3cc1d0}{Sigrist}{S\bibinitperiod}{Christian\bibnamedelimb J\bibnamedelima A}{C\bibinitperiod\bibinitdelim J\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=150d07436146618a8d675e6dfd355c06}{Thimma}{T\bibinitperiod}{Manjula}{M\bibinitperiod}{}{}{}{}}%
        {{hash=b059cba4d10ec33a57140580b6c247d0}{Thomas}{T\bibinitperiod}{Paul\bibnamedelima D.}{P\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=4abd71267b7194c5014fc3cef027d93d}{Valentin}{V\bibinitperiod}{Franck}{F\bibinitperiod}{}{}{}{}}%
        {{hash=f7787f6390ae7ef739a0836d9eb8c07a}{Wilson}{W\bibinitperiod}{Derek}{D\bibinitperiod}{}{}{}{}}%
        {{hash=326b210a8fa7b9a4c03903af7b374ee7}{Wu}{W\bibinitperiod}{Cathy\bibnamedelima H.}{C\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=9b8386d82c2d30d29a7c1f6ef50a8373}{Yeats}{Y\bibinitperiod}{Corin}{C\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{df938e0e62460dd9cefdb865bfd431cb}
      \strng{fullhash}{c8ffd207d43b4a706de7f7ac7aeaf01e}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{InterPro: The integrative protein signature database}}
      \field{isbn}{1362-4962 (Electronic)$\backslash$r0305-1048 (Linking)}
      \field{issn}{03051048}
      \field{journaltitle}{Nucleic Acids Research}
      \field{number}{SUPPL. 1}
      \field{title}{{InterPro: The integrative protein signature database}}
      \field{volume}{37}
      \field{year}{2009}
      \field{pages}{211\bibrangedash 215}
      \verb{doi}
      \verb 10.1093/nar/gkn785
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/gkn785.pdf:pdf
      \endverb
    \endentry
    \entry{Cramer1994}{incollection}{}
      \name{labelname}{1}{}{%
        {{hash=c9fa1cbc09ce354850b917005441be71}{Cramer}{C\bibinitperiod}{Friedrich}{F\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=c9fa1cbc09ce354850b917005441be71}{Cramer}{C\bibinitperiod}{Friedrich}{F\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {John Wiley {\&} Sons, Ltd.}%
      }
      \strng{namehash}{c9fa1cbc09ce354850b917005441be71}
      \strng{fullhash}{c9fa1cbc09ce354850b917005441be71}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Emil Fischer's Lock and Key Hypothesis after 100 years towards a Supracellular Chemistry}}
      \field{booktitle}{Perspectives in Supramolecular Chemistry}
      \field{isbn}{9780470511411}
      \field{title}{{Emil Fischer's Lock and Key Hypothesis after 100 years towards a Supracellular Chemistry}}
      \field{year}{1994}
      \field{pages}{1\bibrangedash 23}
      \verb{doi}
      \verb 10.1002/9780470511411.ch1
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1002/9780470511411.ch1
      \endverb
    \endentry
    \entry{Koshland1959}{article}{}
      \name{labelname}{1}{}{%
        {{hash=f8f7e8410315321d421d14b84914faf4}{Koshland}{K\bibinitperiod}{D\bibnamedelima E}{D\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=f8f7e8410315321d421d14b84914faf4}{Koshland}{K\bibinitperiod}{D\bibnamedelima E}{D\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{2}{%
        {The Wistar Institute of Anatomy}%
        {Biology}%
      }
      \strng{namehash}{f8f7e8410315321d421d14b84914faf4}
      \strng{fullhash}{f8f7e8410315321d421d14b84914faf4}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Enzyme flexibility and enzyme action}}
      \field{issn}{1553-0809}
      \field{journaltitle}{Journal of Cellular and Comparative Physiology}
      \field{month}{12}
      \field{number}{S1}
      \field{title}{{Enzyme flexibility and enzyme action}}
      \field{volume}{54}
      \field{year}{1959}
      \field{pages}{245\bibrangedash 258}
      \verb{doi}
      \verb 10.1002/jcp.1030540420
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1002/jcp.1030540420
      \endverb
    \endentry
    \entry{Monod1965}{article}{}
      \name{labelname}{3}{}{%
        {{hash=2c505e4db5966573609da0412ee1568d}{Monod}{M\bibinitperiod}{Jacque}{J\bibinitperiod}{}{}{}{}}%
        {{hash=4ed7d3878e536a84daaa5e605c7547c3}{Wyman}{W\bibinitperiod}{Jeffries}{J\bibinitperiod}{}{}{}{}}%
        {{hash=d92fb554aa564df22347ceae22fe7221}{Changeux}{C\bibinitperiod}{Jean-Pierre}{J\bibinithyphendelim P\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=2c505e4db5966573609da0412ee1568d}{Monod}{M\bibinitperiod}{Jacque}{J\bibinitperiod}{}{}{}{}}%
        {{hash=4ed7d3878e536a84daaa5e605c7547c3}{Wyman}{W\bibinitperiod}{Jeffries}{J\bibinitperiod}{}{}{}{}}%
        {{hash=d92fb554aa564df22347ceae22fe7221}{Changeux}{C\bibinitperiod}{Jean-Pierre}{J\bibinithyphendelim P\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{ce5ff2a4ea836bfca74c7d4045054c31}
      \strng{fullhash}{ce5ff2a4ea836bfca74c7d4045054c31}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{On the nature of allosteric transitions: A plausible model}}
      \field{issn}{00222836}
      \field{journaltitle}{Journal of Molecular Biology}
      \field{month}{05}
      \field{number}{1}
      \field{title}{{On the nature of allosteric transitions: A plausible model}}
      \field{volume}{12}
      \field{year}{1965}
      \field{pages}{88\bibrangedash 118}
      \verb{doi}
      \verb 10.1016/S0022-2836(65)80285-6
      \endverb
      \verb{url}
      \verb http://www.sciencedirect.com/science/article/pii/S0022283665802856
      \endverb
    \endentry
    \entry{Kitao1998}{article}{}
      \name{labelname}{3}{}{%
        {{hash=4e8a018e6e6fe8c69d308ada76ffd8b7}{Kitao}{K\bibinitperiod}{Akio}{A\bibinitperiod}{}{}{}{}}%
        {{hash=483931f5b0b7f43dab6ab46bfc54189f}{Hayward}{H\bibinitperiod}{Steven}{S\bibinitperiod}{}{}{}{}}%
        {{hash=5fce22464821b5b3e5134afc17d6cd88}{Go}{G\bibinitperiod}{Nobuhiro}{N\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=4e8a018e6e6fe8c69d308ada76ffd8b7}{Kitao}{K\bibinitperiod}{Akio}{A\bibinitperiod}{}{}{}{}}%
        {{hash=483931f5b0b7f43dab6ab46bfc54189f}{Hayward}{H\bibinitperiod}{Steven}{S\bibinitperiod}{}{}{}{}}%
        {{hash=5fce22464821b5b3e5134afc17d6cd88}{Go}{G\bibinitperiod}{Nobuhiro}{N\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Wiley Subscription Services, Inc., A Wiley Company}%
      }
      \strng{namehash}{7e58475201f84e936c0ebed3a041ce3e}
      \strng{fullhash}{7e58475201f84e936c0ebed3a041ce3e}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Energy landscape of a native protein: Jumping among minima model}}
      \field{issn}{1097-0134}
      \field{journaltitle}{Proteins: Structure, Function, and Bioinformatics}
      \field{month}{12}
      \field{number}{4}
      \field{title}{{Energy landscape of a native protein: Jumping among minima model}}
      \field{volume}{33}
      \field{year}{1998}
      \field{pages}{496\bibrangedash 517}
      \verb{doi}
      \verb 10.1002/(SICI)1097-0134(19981201)33:4<496::AID-PROT4>3.0.CO;2-1
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1002/(SICI)1097-0134(19981201)33:4%7B%3C%7D496::AID-PROT4%7B%3E%7D3.0.CO%202-1
      \endverb
    \endentry
    \entry{Petsko1984}{article}{}
      \name{labelname}{2}{}{%
        {{hash=1476d6945186dfdf31bd995b819295a1}{Petsko}{P\bibinitperiod}{G\bibnamedelima A}{G\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=1ec96b11f9665fb1c877ecd5608d8912}{Ringe}{R\bibinitperiod}{D}{D\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=1476d6945186dfdf31bd995b819295a1}{Petsko}{P\bibinitperiod}{G\bibnamedelima A}{G\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=1ec96b11f9665fb1c877ecd5608d8912}{Ringe}{R\bibinitperiod}{D}{D\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Annual Reviews}%
      }
      \strng{namehash}{9b5f7b7d156c9107dfe4f76434f6608f}
      \strng{fullhash}{9b5f7b7d156c9107dfe4f76434f6608f}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Fluctuations in Protein Structure from X-Ray Diffraction}}
      \field{annotation}{doi: 10.1146/annurev.bb.13.060184.001555}
      \field{issn}{0084-6589}
      \field{journaltitle}{Annual Review of Biophysics and Bioengineering}
      \field{month}{06}
      \field{number}{1}
      \field{title}{{Fluctuations in Protein Structure from X-Ray Diffraction}}
      \field{volume}{13}
      \field{year}{1984}
      \field{pages}{331\bibrangedash 371}
      \verb{doi}
      \verb 10.1146/annurev.bb.13.060184.001555
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1146/annurev.bb.13.060184.001555
      \endverb
    \endentry
    \entry{Foote1994}{article}{}
      \name{labelname}{2}{}{%
        {{hash=2b272101783e033fafd5c54f6cd0cd87}{Foote}{F\bibinitperiod}{J}{J\bibinitperiod}{}{}{}{}}%
        {{hash=b0cac038b408d96f8bc86a87be5e1e95}{Milstein}{M\bibinitperiod}{C}{C\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=2b272101783e033fafd5c54f6cd0cd87}{Foote}{F\bibinitperiod}{J}{J\bibinitperiod}{}{}{}{}}%
        {{hash=b0cac038b408d96f8bc86a87be5e1e95}{Milstein}{M\bibinitperiod}{C}{C\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{263aeb0429687da4df891051919f0e95}
      \strng{fullhash}{263aeb0429687da4df891051919f0e95}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Conformational isomerism and the diversity of antibodies.}}
      \field{abstract}{The fact that one cell encodes a single antibody sequence does not necessarily mean that the resulting antibody folds into a single structure, although this is a common assumption. Here we challenge this view and suggest that many antibodies do not have a single conformation at the combining site. The basis for this proposal comes from the kinetic analysis of a set of murine hybridomas derived from defined stages of the immune response to 2-phenyl-5-oxazolone (Ox). Among them we have identified three antibodies that exhibit complex hapten-binding kinetics. We observed biphasic or triphasic reactions in stopped-flow fluorescence experiments, indicating that ligand binding involved isomerization, as well as associative steps. The existence of an equilibrium between at least two antibody conformations, with ligands binding preferentially to one form, was deduced from the variation with hapten concentration of the apparent rate of each phase.}
      \field{issn}{0027-8424}
      \field{journaltitle}{Proceedings of the National Academy of Sciences of the United States of America}
      \field{month}{10}
      \field{number}{22}
      \field{title}{{Conformational isomerism and the diversity of antibodies.}}
      \field{volume}{91}
      \field{year}{1994}
      \field{pages}{10370\bibrangedash 10374}
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC45021/
      \endverb
    \endentry
    \entry{James2003}{article}{}
      \name{labelname}{3}{}{%
        {{hash=3712dfaed00c7d94986d5cf9ac76aa5f}{James}{J\bibinitperiod}{Leo\bibnamedelima C}{L\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=44320ac15125b5ba914c711bfcc388aa}{Roversi}{R\bibinitperiod}{Pietro}{P\bibinitperiod}{}{}{}{}}%
        {{hash=91cd6a4a953369f963f48e0bc013c72d}{Tawfik}{T\bibinitperiod}{Dan\bibnamedelima S}{D\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=3712dfaed00c7d94986d5cf9ac76aa5f}{James}{J\bibinitperiod}{Leo\bibnamedelima C}{L\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=44320ac15125b5ba914c711bfcc388aa}{Roversi}{R\bibinitperiod}{Pietro}{P\bibinitperiod}{}{}{}{}}%
        {{hash=91cd6a4a953369f963f48e0bc013c72d}{Tawfik}{T\bibinitperiod}{Dan\bibnamedelima S}{D\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{2ccea57ab2d9e24bb363b19b680455a8}
      \strng{fullhash}{2ccea57ab2d9e24bb363b19b680455a8}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Antibody Multispecificity Mediated by Conformational Diversity}}
      \field{journaltitle}{Science}
      \field{month}{02}
      \field{number}{5611}
      \field{title}{{Antibody Multispecificity Mediated by Conformational Diversity}}
      \field{volume}{299}
      \field{year}{2003}
      \field{pages}{1362\bibrangedash 1367}
      \verb{url}
      \verb http://science.sciencemag.org/content/299/5611/1362.abstract
      \endverb
    \endentry
    \entry{Dunn2001}{incollection}{}
      \name{labelname}{1}{}{%
        {{hash=46ec57e109a0eb5deef09da9dfe6d092}{Dunn}{D\bibinitperiod}{Michael\bibnamedelima F}{M\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=46ec57e109a0eb5deef09da9dfe6d092}{Dunn}{D\bibinitperiod}{Michael\bibnamedelima F}{M\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {John Wiley {\&} Sons, Ltd}%
      }
      \strng{namehash}{46ec57e109a0eb5deef09da9dfe6d092}
      \strng{fullhash}{46ec57e109a0eb5deef09da9dfe6d092}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Protein-Ligand Interactions: General Description}}
      \field{booktitle}{eLS}
      \field{isbn}{9780470015902}
      \field{title}{{Protein-Ligand Interactions: General Description}}
      \field{year}{2001}
      \verb{doi}
      \verb 10.1038/npg.els.0001340
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1038/npg.els.0001340
      \endverb
    \endentry
    \entry{Michel2009a}{article}{}
      \name{labelname}{3}{}{%
        {{hash=0cfceab6b7b504ed285ed70f6b525631}{Michel}{M\bibinitperiod}{Julien}{J\bibinitperiod}{}{}{}{}}%
        {{hash=fa07f5dac805ae2d3948eb372fed4252}{Tirado-Rives}{T\bibinithyphendelim R\bibinitperiod}{Julian}{J\bibinitperiod}{}{}{}{}}%
        {{hash=c19e67db2cc0994d3900bcf8da4333bc}{Jorgensen}{J\bibinitperiod}{William\bibnamedelima L}{W\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=0cfceab6b7b504ed285ed70f6b525631}{Michel}{M\bibinitperiod}{Julien}{J\bibinitperiod}{}{}{}{}}%
        {{hash=fa07f5dac805ae2d3948eb372fed4252}{Tirado-Rives}{T\bibinithyphendelim R\bibinitperiod}{Julian}{J\bibinitperiod}{}{}{}{}}%
        {{hash=c19e67db2cc0994d3900bcf8da4333bc}{Jorgensen}{J\bibinitperiod}{William\bibnamedelima L}{W\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{c45d5bf953b08e681565b5aed5f55440}
      \strng{fullhash}{c45d5bf953b08e681565b5aed5f55440}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Energetics of Displacing Water Molecules from Protein Binding Sites: Consequences for Ligand Optimization}}
      \field{issn}{0002-7863}
      \field{journaltitle}{Journal of the American Chemical Society}
      \field{month}{10}
      \field{number}{42}
      \field{title}{{Energetics of Displacing Water Molecules from Protein Binding Sites: Consequences for Ligand Optimization}}
      \field{volume}{131}
      \field{year}{2009}
      \field{pages}{15403\bibrangedash 15411}
      \verb{doi}
      \verb 10.1021/ja906058w
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2783447/
      \endverb
    \endentry
    \entry{Ravindranathan2011}{article}{}
      \name{labelname}{4}{}{%
        {{hash=d8e71ece1e236ff5b18f3b2fdb5d3d7b}{Ravindranathan}{R\bibinitperiod}{Krishna}{K\bibinitperiod}{}{}{}{}}%
        {{hash=fa07f5dac805ae2d3948eb372fed4252}{Tirado-Rives}{T\bibinithyphendelim R\bibinitperiod}{Julian}{J\bibinitperiod}{}{}{}{}}%
        {{hash=c19e67db2cc0994d3900bcf8da4333bc}{Jorgensen}{J\bibinitperiod}{William\bibnamedelima L}{W\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=6714b8a850eb66a35c7a0a569b3db536}{Guimar{\~{a}}es}{G\bibinitperiod}{Cristiano\bibnamedelimb R\bibnamedelima W}{C\bibinitperiod\bibinitdelim R\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=d8e71ece1e236ff5b18f3b2fdb5d3d7b}{Ravindranathan}{R\bibinitperiod}{Krishna}{K\bibinitperiod}{}{}{}{}}%
        {{hash=fa07f5dac805ae2d3948eb372fed4252}{Tirado-Rives}{T\bibinithyphendelim R\bibinitperiod}{Julian}{J\bibinitperiod}{}{}{}{}}%
        {{hash=c19e67db2cc0994d3900bcf8da4333bc}{Jorgensen}{J\bibinitperiod}{William\bibnamedelima L}{W\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=6714b8a850eb66a35c7a0a569b3db536}{Guimar{\~{a}}es}{G\bibinitperiod}{Cristiano\bibnamedelimb R\bibnamedelima W}{C\bibinitperiod\bibinitdelim R\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{f1fa3fed6d367a23959254d353414454}
      \strng{fullhash}{808dafe0e66cb9e4321c1114ac7c2e8a}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Improving MM-GB SA Scoring through the Application of the Variable Dielectric Model}}
      \field{abstract}{A variable dielectric model based on residue types for better description of protein-ligand electrostatics in MM-GBSA scoring is reported. The variable dielectric approach provides better correlation with binding data and reduces the score dynamic range, typically observed in the standard MM-GB/SA method. The latter supports the view that exaggerated enthalpic separation between weak and potent compounds due to the lack of shielding effects in the model is greatly responsible for the wide scoring spread.}
      \field{issn}{1549-9618}
      \field{journaltitle}{Journal of chemical theory and computation}
      \field{month}{12}
      \field{number}{12}
      \field{title}{{Improving MM-GB SA Scoring through the Application of the Variable Dielectric Model}}
      \field{volume}{7}
      \field{year}{2011}
      \field{pages}{3859\bibrangedash 3865}
      \verb{doi}
      \verb 10.1021/ct200565u
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3351111/
      \endverb
    \endentry
    \entry{Michel2006}{article}{}
      \name{labelname}{3}{}{%
        {{hash=0cfceab6b7b504ed285ed70f6b525631}{Michel}{M\bibinitperiod}{Julien}{J\bibinitperiod}{}{}{}{}}%
        {{hash=1950e3a3242a1047913c14da60b68015}{Verdonk}{V\bibinitperiod}{Marcel\bibnamedelima L}{M\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=d5933f58df57a2fed80a7bc91e9fdb34}{Essex}{E\bibinitperiod}{Jonathan\bibnamedelima W}{J\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=0cfceab6b7b504ed285ed70f6b525631}{Michel}{M\bibinitperiod}{Julien}{J\bibinitperiod}{}{}{}{}}%
        {{hash=1950e3a3242a1047913c14da60b68015}{Verdonk}{V\bibinitperiod}{Marcel\bibnamedelima L}{M\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=d5933f58df57a2fed80a7bc91e9fdb34}{Essex}{E\bibinitperiod}{Jonathan\bibnamedelima W}{J\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {American Chemical Society}%
      }
      \strng{namehash}{1c60f373ca2302344f96a386c3ea86a1}
      \strng{fullhash}{1c60f373ca2302344f96a386c3ea86a1}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Protein Ligand Binding Affinity Predictions by Implicit Solvent Simulations: A Tool for Lead Optimization}}
      \field{annotation}{doi: 10.1021/jm061021s}
      \field{issn}{0022-2623}
      \field{journaltitle}{Journal of Medicinal Chemistry}
      \field{month}{12}
      \field{number}{25}
      \field{title}{{Protein Ligand Binding Affinity Predictions by Implicit Solvent Simulations: A Tool for Lead Optimization}}
      \field{volume}{49}
      \field{year}{2006}
      \field{pages}{7427\bibrangedash 7439}
      \verb{doi}
      \verb 10.1021/jm061021s
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1021/jm061021s
      \endverb
    \endentry
    \entry{Liu2009}{article}{}
      \name{labelname}{3}{}{%
        {{hash=6aa49f9f28cc919cecad2a76567a5114}{Liu}{L\bibinitperiod}{Hao-Yang}{H\bibinithyphendelim Y\bibinitperiod}{}{}{}{}}%
        {{hash=47adf8eb924c34a05a4f673de9cee38b}{Grinter}{G\bibinitperiod}{Sam\bibnamedelima Z}{S\bibinitperiod\bibinitdelim Z\bibinitperiod}{}{}{}{}}%
        {{hash=d15cbe55cf4442531f4a92a782a22ece}{Zou}{Z\bibinitperiod}{Xiaoqin}{X\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=6aa49f9f28cc919cecad2a76567a5114}{Liu}{L\bibinitperiod}{Hao-Yang}{H\bibinithyphendelim Y\bibinitperiod}{}{}{}{}}%
        {{hash=47adf8eb924c34a05a4f673de9cee38b}{Grinter}{G\bibinitperiod}{Sam\bibnamedelima Z}{S\bibinitperiod\bibinitdelim Z\bibinitperiod}{}{}{}{}}%
        {{hash=d15cbe55cf4442531f4a92a782a22ece}{Zou}{Z\bibinitperiod}{Xiaoqin}{X\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{c9f797fb69980044cd1c83cd47bdfe11}
      \strng{fullhash}{c9f797fb69980044cd1c83cd47bdfe11}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Multiscale generalized Born modeling of ligand binding energies for virtual database screening}}
      \field{issn}{1520-6106}
      \field{journaltitle}{The journal of physical chemistry. B}
      \field{month}{09}
      \field{number}{35}
      \field{title}{{Multiscale generalized Born modeling of ligand binding energies for virtual database screening}}
      \field{volume}{113}
      \field{year}{2009}
      \field{pages}{11793\bibrangedash 11799}
      \verb{doi}
      \verb 10.1021/jp901212t
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2763608/
      \endverb
    \endentry
    \entry{Lu2007}{article}{}
      \name{labelname}{4}{}{%
        {{hash=7af7df921c83cc455a4c4de1e072c4ac}{Lu}{L\bibinitperiod}{Yipin}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=4ab84d11d93fb5236a319ffca24e31ad}{Wang}{W\bibinitperiod}{Renxiao}{R\bibinitperiod}{}{}{}{}}%
        {{hash=bae857a0cb56934c2102ac6ad924f2fb}{Yang}{Y\bibinitperiod}{Chao-Yie}{C\bibinithyphendelim Y\bibinitperiod}{}{}{}{}}%
        {{hash=c5c6a61f0a352dfd208ab4e65ed64df7}{Wang}{W\bibinitperiod}{Shaomeng}{S\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=7af7df921c83cc455a4c4de1e072c4ac}{Lu}{L\bibinitperiod}{Yipin}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=4ab84d11d93fb5236a319ffca24e31ad}{Wang}{W\bibinitperiod}{Renxiao}{R\bibinitperiod}{}{}{}{}}%
        {{hash=bae857a0cb56934c2102ac6ad924f2fb}{Yang}{Y\bibinitperiod}{Chao-Yie}{C\bibinithyphendelim Y\bibinitperiod}{}{}{}{}}%
        {{hash=c5c6a61f0a352dfd208ab4e65ed64df7}{Wang}{W\bibinitperiod}{Shaomeng}{S\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {American Chemical Society}%
      }
      \strng{namehash}{148341607dd551f60a2ae90ae91576c3}
      \strng{fullhash}{f1ceb3a8a3eb0edd73cded4e95e5271a}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Analysis of Ligand-Bound Water Molecules in High-Resolution Crystal Structures of Protein-Ligand Complexes}}
      \field{annotation}{doi: 10.1021/ci6003527}
      \field{issn}{1549-9596}
      \field{journaltitle}{Journal of Chemical Information and Modeling}
      \field{month}{03}
      \field{number}{2}
      \field{title}{{Analysis of Ligand-Bound Water Molecules in High-Resolution Crystal Structures of Protein-Ligand Complexes}}
      \field{volume}{47}
      \field{year}{2007}
      \field{pages}{668\bibrangedash 675}
      \verb{doi}
      \verb 10.1021/ci6003527
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1021/ci6003527
      \endverb
    \endentry
    \entry{Sharp1990}{article}{}
      \name{labelname}{2}{}{%
        {{hash=d45d7d88903e633ac60e4f7ef9ccee81}{Sharp}{S\bibinitperiod}{Kim\bibnamedelima A}{K\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=1d96e1e0a77ad2809933313618d93d17}{Honig}{H\bibinitperiod}{Barry.}{B\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=d45d7d88903e633ac60e4f7ef9ccee81}{Sharp}{S\bibinitperiod}{Kim\bibnamedelima A}{K\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=1d96e1e0a77ad2809933313618d93d17}{Honig}{H\bibinitperiod}{Barry.}{B\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {American Chemical Society}%
      }
      \strng{namehash}{8acd8027f3b2e897de04377c1ec364ce}
      \strng{fullhash}{8acd8027f3b2e897de04377c1ec364ce}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Calculating total electrostatic energies with the nonlinear Poisson-Boltzmann equation}}
      \field{annotation}{doi: 10.1021/j100382a068}
      \field{issn}{0022-3654}
      \field{journaltitle}{The Journal of Physical Chemistry}
      \field{month}{09}
      \field{number}{19}
      \field{title}{{Calculating total electrostatic energies with the nonlinear Poisson-Boltzmann equation}}
      \field{volume}{94}
      \field{year}{1990}
      \field{pages}{7684\bibrangedash 7692}
      \verb{doi}
      \verb 10.1021/j100382a068
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1021/j100382a068
      \endverb
    \endentry
    \entry{Bashford2000}{article}{}
      \name{labelname}{2}{}{%
        {{hash=d5aa9c2314a5d50215a7550ba5dc1fab}{Bashford}{B\bibinitperiod}{Donald}{D\bibinitperiod}{}{}{}{}}%
        {{hash=4d8f9f3e905177579a487e2df19e8b27}{Case}{C\bibinitperiod}{David\bibnamedelima A}{D\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=d5aa9c2314a5d50215a7550ba5dc1fab}{Bashford}{B\bibinitperiod}{Donald}{D\bibinitperiod}{}{}{}{}}%
        {{hash=4d8f9f3e905177579a487e2df19e8b27}{Case}{C\bibinitperiod}{David\bibnamedelima A}{D\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Annual Reviews}%
      }
      \strng{namehash}{250297f747c3e68e467cb6aca100f5be}
      \strng{fullhash}{250297f747c3e68e467cb6aca100f5be}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{GENERALIZED BORN MODELS OF MACROMOLECULAR SOLVATION EFFECTS}}
      \field{annotation}{doi: 10.1146/annurev.physchem.51.1.129}
      \field{issn}{0066-426X}
      \field{journaltitle}{Annual Review of Physical Chemistry}
      \field{month}{10}
      \field{number}{1}
      \field{title}{{GENERALIZED BORN MODELS OF MACROMOLECULAR SOLVATION EFFECTS}}
      \field{volume}{51}
      \field{year}{2000}
      \field{pages}{129\bibrangedash 152}
      \verb{doi}
      \verb 10.1146/annurev.physchem.51.1.129
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1146/annurev.physchem.51.1.129
      \endverb
    \endentry
    \entry{Friesner2004}{article}{}
      \name{labelname}{13}{}{%
        {{hash=d1293cea8ffd0a3608d02a91d7819106}{Friesner}{F\bibinitperiod}{Richard\bibnamedelima A.}{R\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=b7210133fdb29b7248e1b762a3d4e9a6}{Banks}{B\bibinitperiod}{Jay\bibnamedelima L.}{J\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=93227c851ae44852868eb9785c256d4d}{Murphy}{M\bibinitperiod}{Robert\bibnamedelima B.}{R\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=8de40fc87416f72bcef748b942f8e50a}{Halgren}{H\bibinitperiod}{Thomas\bibnamedelima A.}{T\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=fa269921f9343f9b11a9772f83c66efa}{Klicic}{K\bibinitperiod}{Jasna\bibnamedelima J.}{J\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=76bb5d98594a0c8563d7e9aec9c640d6}{Mainz}{M\bibinitperiod}{Daniel\bibnamedelima T.}{D\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=5249e50dc29069a18e2fdb7e293707d0}{Repasky}{R\bibinitperiod}{Matthew\bibnamedelima P.}{M\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=b1b245f78dd9ca0acbfa6f6c82e5db90}{Knoll}{K\bibinitperiod}{Eric\bibnamedelima H.}{E\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=eb40ad6d772a89176a112def5f30c030}{Shelley}{S\bibinitperiod}{Mee}{M\bibinitperiod}{}{}{}{}}%
        {{hash=ae625a89c24572d1d2aa86b4a4ce7c94}{Perry}{P\bibinitperiod}{Jason\bibnamedelima K.}{J\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=d14c2080ec5f9fa3e2c7dad904c9cc89}{Shaw}{S\bibinitperiod}{David\bibnamedelima E.}{D\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=a4a4610ec2e43b70aa3a990de22060ce}{Francis}{F\bibinitperiod}{Perry}{P\bibinitperiod}{}{}{}{}}%
        {{hash=aef3da4748b2d9801d1eff8cc30670c4}{Shenkin}{S\bibinitperiod}{Peter\bibnamedelima S.}{P\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{13}{}{%
        {{hash=d1293cea8ffd0a3608d02a91d7819106}{Friesner}{F\bibinitperiod}{Richard\bibnamedelima A.}{R\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=b7210133fdb29b7248e1b762a3d4e9a6}{Banks}{B\bibinitperiod}{Jay\bibnamedelima L.}{J\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=93227c851ae44852868eb9785c256d4d}{Murphy}{M\bibinitperiod}{Robert\bibnamedelima B.}{R\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=8de40fc87416f72bcef748b942f8e50a}{Halgren}{H\bibinitperiod}{Thomas\bibnamedelima A.}{T\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=fa269921f9343f9b11a9772f83c66efa}{Klicic}{K\bibinitperiod}{Jasna\bibnamedelima J.}{J\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=76bb5d98594a0c8563d7e9aec9c640d6}{Mainz}{M\bibinitperiod}{Daniel\bibnamedelima T.}{D\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=5249e50dc29069a18e2fdb7e293707d0}{Repasky}{R\bibinitperiod}{Matthew\bibnamedelima P.}{M\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=b1b245f78dd9ca0acbfa6f6c82e5db90}{Knoll}{K\bibinitperiod}{Eric\bibnamedelima H.}{E\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=eb40ad6d772a89176a112def5f30c030}{Shelley}{S\bibinitperiod}{Mee}{M\bibinitperiod}{}{}{}{}}%
        {{hash=ae625a89c24572d1d2aa86b4a4ce7c94}{Perry}{P\bibinitperiod}{Jason\bibnamedelima K.}{J\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=d14c2080ec5f9fa3e2c7dad904c9cc89}{Shaw}{S\bibinitperiod}{David\bibnamedelima E.}{D\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=a4a4610ec2e43b70aa3a990de22060ce}{Francis}{F\bibinitperiod}{Perry}{P\bibinitperiod}{}{}{}{}}%
        {{hash=aef3da4748b2d9801d1eff8cc30670c4}{Shenkin}{S\bibinitperiod}{Peter\bibnamedelima S.}{P\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{958b6cb56862ed1d8fb3b4b415e9d4ad}
      \strng{fullhash}{7d4703db8320284ee13fd8f26daedb07}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Glide: A New Approach for Rapid, Accurate Docking and Scoring}}
      \field{abstract}{Unlike other methods for docking ligands to the rigid 3D structure of a known protein receptor, Glide approximates a complete systematic search of the conformational, orientational, and positional space of the docked ligand. In this search, an initial rough positioning and scoring phase that dramatically narrows the search space is followed by torsionally flexible energy optimization on an OPLS-AA nonbonded potential grid for a few hundred surviving candidate poses. The very best candidates are further refined via a Monte Carlo sampling of pose conformation; in some cases, this is crucial to obtaining an accurate docked pose. Selection of the best docked pose uses a model energy function that combines empirical and force-field-based terms. Docking accuracy is assessed by redocking ligands from 282 cocrystallized PDB complexes starting from conformationally optimized ligand geometries that bear no memory of the correctly docked pose. Errors in geometry for the top-ranked pose are less than 1 A in nearly half of the cases and are greater than 2 A in only about one-third of them. Comparisons to published data on rms deviations show that Glide is nearly twice as accurate as GOLD and more than twice as accurate as FlexX for ligands having up to 20 rotatable bonds. Glide is also found to be more accurate than the recently described Surflex method.}
      \field{eprinttype}{arXiv}
      \field{isbn}{0022-2623}
      \field{issn}{00222623}
      \field{journaltitle}{Journal of Medicinal Chemistry}
      \field{number}{7}
      \field{title}{{Glide: A New Approach for Rapid, Accurate Docking and Scoring}}
      \field{volume}{47}
      \field{year}{2004}
      \field{pages}{1739\bibrangedash 1749}
      \verb{doi}
      \verb 10.1021/jm0306430
      \endverb
      \verb{eprint}
      \verb arXiv:1011.1669v3
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/jm0306430.pdf:pdf
      \endverb
    \endentry
    \entry{Steffen2010}{article}{}
      \name{labelname}{6}{}{%
        {{hash=f0200b90cce0c7ed201c36567c484f44}{Steffen}{S\bibinitperiod}{Claudia}{C\bibinitperiod}{}{}{}{}}%
        {{hash=02ba2568b23db03323306bcf110af8f2}{Thomas}{T\bibinitperiod}{Klaus}{K\bibinitperiod}{}{}{}{}}%
        {{hash=e506e505f3239ec54b030e93af7d4dd1}{Huniar}{H\bibinitperiod}{Uwe}{U\bibinitperiod}{}{}{}{}}%
        {{hash=26cb7261125c49065b71e481f2cae976}{Hellweg}{H\bibinitperiod}{Arnim}{A\bibinitperiod}{}{}{}{}}%
        {{hash=bfa810d090d2bb6fc1235b5f7abd5ccc}{Rubner}{R\bibinitperiod}{Oliver}{O\bibinitperiod}{}{}{}{}}%
        {{hash=f31907787de502bf384bbe5b5c8e4d15}{Schroer}{S\bibinitperiod}{Alexander}{A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{6}{}{%
        {{hash=f0200b90cce0c7ed201c36567c484f44}{Steffen}{S\bibinitperiod}{Claudia}{C\bibinitperiod}{}{}{}{}}%
        {{hash=02ba2568b23db03323306bcf110af8f2}{Thomas}{T\bibinitperiod}{Klaus}{K\bibinitperiod}{}{}{}{}}%
        {{hash=e506e505f3239ec54b030e93af7d4dd1}{Huniar}{H\bibinitperiod}{Uwe}{U\bibinitperiod}{}{}{}{}}%
        {{hash=26cb7261125c49065b71e481f2cae976}{Hellweg}{H\bibinitperiod}{Arnim}{A\bibinitperiod}{}{}{}{}}%
        {{hash=bfa810d090d2bb6fc1235b5f7abd5ccc}{Rubner}{R\bibinitperiod}{Oliver}{O\bibinitperiod}{}{}{}{}}%
        {{hash=f31907787de502bf384bbe5b5c8e4d15}{Schroer}{S\bibinitperiod}{Alexander}{A\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{ef5643eef482a6309ddfcbbc92e33e9b}
      \strng{fullhash}{bb15e46f5a2c536a77598498ba074c6a}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{TmoleX a graphical user interface for TURBOMOLE.}}
      \field{abstract}{We herein present the graphical user interface (GUI) TmoleX for the quantum chemical program package TURBOMOLE. TmoleX allows users to execute the complete workflow of a quantum chemical investigation from the initial building of a structure to the visualization of the results in a user friendly graphical front end. The purpose of TmoleX is to make TURBOMOLE easy to use and to provide a high degree of flexibility. Hence, it should be a valuable tool for most users from beginners to experts. The program is developed in Java and runs on Linux, Windows, and Mac platforms. It can be used to run calculations on local desktops as well as on remote computers.}
      \field{eprinttype}{arXiv}
      \field{isbn}{1096-987X}
      \field{issn}{1096-987X}
      \field{journaltitle}{Journal of computational chemistry}
      \field{number}{16}
      \field{title}{{TmoleX a graphical user interface for TURBOMOLE.}}
      \field{volume}{31}
      \field{year}{2010}
      \field{pages}{2967\bibrangedash 2970}
      \verb{doi}
      \verb 10.1002/jcc
      \endverb
      \verb{eprint}
      \verb NIHMS150003
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/277.pdf:pdf
      \endverb
    \endentry
    \entry{Csermely2013}{article}{}
      \name{labelname}{5}{}{%
        {{hash=d54b624e57b038f5da8e8aa7d328d5f1}{Csermely}{C\bibinitperiod}{Peter}{P\bibinitperiod}{}{}{}{}}%
        {{hash=21927bd3d3ef7bd76a9c5c9aed5afe76}{Korcsmros}{K\bibinitperiod}{Tams}{T\bibinitperiod}{}{}{}{}}%
        {{hash=7cf2327f4e582c91594bee4bfa69b341}{Kiss}{K\bibinitperiod}{Huba\bibnamedelimb J\bibnamedelima M}{H\bibinitperiod\bibinitdelim J\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=6557ef9cb3cef4f9d0febc5527188b3f}{London}{L\bibinitperiod}{Gbor}{G\bibinitperiod}{}{}{}{}}%
        {{hash=5df4f003753b6d9cfad61f047a6dab01}{Nussinov}{N\bibinitperiod}{Ruth}{R\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{5}{}{%
        {{hash=d54b624e57b038f5da8e8aa7d328d5f1}{Csermely}{C\bibinitperiod}{Peter}{P\bibinitperiod}{}{}{}{}}%
        {{hash=21927bd3d3ef7bd76a9c5c9aed5afe76}{Korcsmros}{K\bibinitperiod}{Tams}{T\bibinitperiod}{}{}{}{}}%
        {{hash=7cf2327f4e582c91594bee4bfa69b341}{Kiss}{K\bibinitperiod}{Huba\bibnamedelimb J\bibnamedelima M}{H\bibinitperiod\bibinitdelim J\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=6557ef9cb3cef4f9d0febc5527188b3f}{London}{L\bibinitperiod}{Gbor}{G\bibinitperiod}{}{}{}{}}%
        {{hash=5df4f003753b6d9cfad61f047a6dab01}{Nussinov}{N\bibinitperiod}{Ruth}{R\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Elsevier Inc.}%
      }
      \strng{namehash}{129ff8392ff1b456d9c7c15403a12d6f}
      \strng{fullhash}{6fd99be197a52f60871a499b626e7654}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Structure and dynamics of molecular networks: A novel paradigm of drug discovery: A comprehensive review}}
      \field{abstract}{Despite considerable progress in genome- and proteome-based high-throughput screening methods and in rational drug design, the increase in approved drugs in the past decade did not match the increase of drug development costs. Network description and analysis not only give a systems-level understanding of drug action and disease complexity, but can also help to improve the efficiency of drug design. We give a comprehensive assessment of the analytical tools of network topology and dynamics. The state-of-the-art use of chemical similarity, protein structure, protein-protein interaction, signaling, genetic interaction and metabolic networks in the discovery of drug targets is summarized. We propose that network targeting follows two basic strategies. The "central hit strategy" selectively targets central nodes/edges of the flexible networks of infectious agents or cancer cells to kill them. The "network influence strategy" works against other diseases, where an efficient reconfiguration of rigid networks needs to be achieved by targeting the neighbors of central nodes/edges. It is shown how network techniques can help in the identification of single-target, edgetic, multi-target and allo-network drug target candidates. We review the recent boom in network methods helping hit identification, lead selection optimizing drug efficacy, as well as minimizing side-effects and drug toxicity. Successful network-based drug development strategies are shown through the examples of infections, cancer, metabolic diseases, neurodegenerative diseases and aging. Summarizing {>}1200 references we suggest an optimized protocol of network-aided drug development, and provide a list of systems-level hallmarks of drug quality. Finally, we highlight network-related drug development trends helping to achieve these hallmarks by a cohesive, global approach. ?? 2013 Elsevier Inc.}
      \field{eprinttype}{arXiv}
      \field{isbn}{0163-7258}
      \field{issn}{01637258}
      \field{journaltitle}{Pharmacology and Therapeutics}
      \field{number}{3}
      \field{title}{{Structure and dynamics of molecular networks: A novel paradigm of drug discovery: A comprehensive review}}
      \field{volume}{138}
      \field{year}{2013}
      \field{pages}{333\bibrangedash 408}
      \verb{doi}
      \verb 10.1016/j.pharmthera.2013.01.016
      \endverb
      \verb{eprint}
      \verb 1210.0330
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/1-s2.0-S0163725813000284-main.pdf:pdf
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1016/j.pharmthera.2013.01.016
      \endverb
    \endentry
    \entry{prathipati2015}{article}{}
      \name{labelname}{2}{}{%
        {{hash=8700385450dadae64b1eb678712f5dfc}{Prathipati}{P\bibinitperiod}{Philip}{P\bibinitperiod}{}{}{}{}}%
        {{hash=427dd8e854a414f1427f3a59e3dc0bd3}{Mizuguchi}{M\bibinitperiod}{Kenji}{K\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=8700385450dadae64b1eb678712f5dfc}{Prathipati}{P\bibinitperiod}{Philip}{P\bibinitperiod}{}{}{}{}}%
        {{hash=427dd8e854a414f1427f3a59e3dc0bd3}{Mizuguchi}{M\bibinitperiod}{Kenji}{K\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{c4340dbd543cf3ec96416529947c29aa}
      \strng{fullhash}{c4340dbd543cf3ec96416529947c29aa}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Systems Biology Approaches to a Rational Drug Discovery Paradigm}}
      \field{abstract}{Ligand- and structure-based drug design approaches complement phenotypic and target screens, respectively, and are the two major frameworks for guiding early-stage drug discovery efforts. Since the beginning of this century, the advent of the genomic era has presented researchers with a myriad of high throughput biological data (parts lists and their interaction networks) to address efficacy and toxicity, augmenting the traditional ligand- and structure-based approaches. This data rich era has also presented us with challenges related to integrating and analyzing these multi-platform and multi-dimensional datasets and translating them into viable hypotheses. Hence in the present paper, we review these existing approaches to drug discovery research and argue the case for a new systems biology based approach. We present the basic principles and the foundational arguments/underlying assumptions of the systems biology based approaches to drug design. Also discussed are systems biology data types (key entities, their attributes and their relationships with each other, and data models/representations), software and tools used for both retrospective and prospective analysis, and the hypotheses that can be inferred. In addition, we summarize some of the existing resources for a systems biology based drug discovery paradigm (open TG-GATEs, DrugMatrix, CMap and LINCs) in terms of their strengths and limitations.}
      \field{journaltitle}{Current Topics in Medicinal Chemistry}
      \field{number}{9}
      \field{title}{{Systems Biology Approaches to a Rational Drug Discovery Paradigm}}
      \field{volume}{16}
      \field{pages}{1009\bibrangedash 1025}
      \verb{url}
      \verb http://www.ingentaconnect.com/content/ben/ctmc/2016/00000016/00000009/art00012
      \endverb
    \endentry
    \entry{Bento2014}{article}{}
      \name{labelname}{14}{}{%
        {{hash=95ff9989a925f87f836accdd15f930ee}{Bento}{B\bibinitperiod}{A\bibnamedelima Patr{\'{\i}}cia}{A\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=ef090f0c6ff6138278103ca580237c79}{Gaulton}{G\bibinitperiod}{Anna}{A\bibinitperiod}{}{}{}{}}%
        {{hash=26c46675e41f83087572952ccbdfe62c}{Hersey}{H\bibinitperiod}{Anne}{A\bibinitperiod}{}{}{}{}}%
        {{hash=bbdff51456c268530cdc846c556ca68e}{Bellis}{B\bibinitperiod}{Louisa\bibnamedelima J}{L\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=f2013483442290f22126dc84887e4935}{Chambers}{C\bibinitperiod}{Jon}{J\bibinitperiod}{}{}{}{}}%
        {{hash=48f427e0352f9d97eb37585a65f73622}{Davies}{D\bibinitperiod}{Mark}{M\bibinitperiod}{}{}{}{}}%
        {{hash=01c03eabbe420a5ccc38c7cd40b53fc6}{Kr{\"{u}}ger}{K\bibinitperiod}{Felix\bibnamedelima A}{F\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=2f075c18cc8850e81a86667c17e24508}{Light}{L\bibinitperiod}{Yvonne}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=ec7cfcedc898a233332987e1a85bfbcf}{Mak}{M\bibinitperiod}{Lora}{L\bibinitperiod}{}{}{}{}}%
        {{hash=b02717f1abad23d3f3931a27cd38d61d}{McGlinchey}{M\bibinitperiod}{Shaun}{S\bibinitperiod}{}{}{}{}}%
        {{hash=0c091af453037cf6cc5190a176b46209}{Nowotka}{N\bibinitperiod}{Michal}{M\bibinitperiod}{}{}{}{}}%
        {{hash=d0d9d6fafa34670d65fe13aa0977dbe6}{Papadatos}{P\bibinitperiod}{George}{G\bibinitperiod}{}{}{}{}}%
        {{hash=5a34c22daf2cec5307b183940a765c62}{Santos}{S\bibinitperiod}{Rita}{R\bibinitperiod}{}{}{}{}}%
        {{hash=53d44917db2ed8d5ebb266672e3d6189}{Overington}{O\bibinitperiod}{John\bibnamedelima P}{J\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{14}{}{%
        {{hash=95ff9989a925f87f836accdd15f930ee}{Bento}{B\bibinitperiod}{A\bibnamedelima Patr{\'{\i}}cia}{A\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=ef090f0c6ff6138278103ca580237c79}{Gaulton}{G\bibinitperiod}{Anna}{A\bibinitperiod}{}{}{}{}}%
        {{hash=26c46675e41f83087572952ccbdfe62c}{Hersey}{H\bibinitperiod}{Anne}{A\bibinitperiod}{}{}{}{}}%
        {{hash=bbdff51456c268530cdc846c556ca68e}{Bellis}{B\bibinitperiod}{Louisa\bibnamedelima J}{L\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=f2013483442290f22126dc84887e4935}{Chambers}{C\bibinitperiod}{Jon}{J\bibinitperiod}{}{}{}{}}%
        {{hash=48f427e0352f9d97eb37585a65f73622}{Davies}{D\bibinitperiod}{Mark}{M\bibinitperiod}{}{}{}{}}%
        {{hash=01c03eabbe420a5ccc38c7cd40b53fc6}{Kr{\"{u}}ger}{K\bibinitperiod}{Felix\bibnamedelima A}{F\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=2f075c18cc8850e81a86667c17e24508}{Light}{L\bibinitperiod}{Yvonne}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=ec7cfcedc898a233332987e1a85bfbcf}{Mak}{M\bibinitperiod}{Lora}{L\bibinitperiod}{}{}{}{}}%
        {{hash=b02717f1abad23d3f3931a27cd38d61d}{McGlinchey}{M\bibinitperiod}{Shaun}{S\bibinitperiod}{}{}{}{}}%
        {{hash=0c091af453037cf6cc5190a176b46209}{Nowotka}{N\bibinitperiod}{Michal}{M\bibinitperiod}{}{}{}{}}%
        {{hash=d0d9d6fafa34670d65fe13aa0977dbe6}{Papadatos}{P\bibinitperiod}{George}{G\bibinitperiod}{}{}{}{}}%
        {{hash=5a34c22daf2cec5307b183940a765c62}{Santos}{S\bibinitperiod}{Rita}{R\bibinitperiod}{}{}{}{}}%
        {{hash=53d44917db2ed8d5ebb266672e3d6189}{Overington}{O\bibinitperiod}{John\bibnamedelima P}{J\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{52c9e03829d425622c35c53599414b01}
      \strng{fullhash}{e2d1e2fbbd6e1c245c403d434751e5f5}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{The ChEMBL bioactivity database: an update}}
      \field{issn}{0305-1048}
      \field{journaltitle}{Nucleic acids research}
      \field{month}{01}
      \field{number}{Database issue}
      \field{title}{{The ChEMBL bioactivity database: an update}}
      \field{volume}{42}
      \field{year}{2014}
      \field{pages}{D1083\bibrangedash 90}
      \verb{doi}
      \verb 10.1093/nar/gkt1031
      \endverb
      \verb{url}
      \verb http://europepmc.org/articles/PMC3965067
      \endverb
    \endentry
    \entry{Zhu2012a}{article}{}
      \name{labelname}{13}{}{%
        {{hash=c527382ce6a2bdfc4548a1f28e479d85}{Zhu}{Z\bibinitperiod}{Feng}{F\bibinitperiod}{}{}{}{}}%
        {{hash=d7cede02af5ba10feb48d4309c5f06dd}{Shi}{S\bibinitperiod}{Zhe}{Z\bibinitperiod}{}{}{}{}}%
        {{hash=5a9f53dda42b5b759ecf58ae8ca52191}{Qin}{Q\bibinitperiod}{Chu}{C\bibinitperiod}{}{}{}{}}%
        {{hash=c879b58bfbb585f308159c96a3e6c234}{Tao}{T\bibinitperiod}{Lin}{L\bibinitperiod}{}{}{}{}}%
        {{hash=4f1e33032cdd17c1c4c17fe05bd0772d}{Liu}{L\bibinitperiod}{Xin}{X\bibinitperiod}{}{}{}{}}%
        {{hash=7b489e462941f869f448a19abc85df4b}{Xu}{X\bibinitperiod}{Feng}{F\bibinitperiod}{}{}{}{}}%
        {{hash=32a08717e0d6dcde59bc98b96800ed6c}{Zhang}{Z\bibinitperiod}{Li}{L\bibinitperiod}{}{}{}{}}%
        {{hash=7dacbb5a6e92ab16944d46ba03705563}{Song}{S\bibinitperiod}{Yang}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=fb4c22e0b090d2ed34486344670fbcf6}{Liu}{L\bibinitperiod}{Xianghui}{X\bibinitperiod}{}{}{}{}}%
        {{hash=74060cf382134f36b5ad81a18b247ff7}{Zhang}{Z\bibinitperiod}{Jingxian}{J\bibinitperiod}{}{}{}{}}%
        {{hash=9887eb306f0532aca8eee77da4783f20}{Han}{H\bibinitperiod}{Bucong}{B\bibinitperiod}{}{}{}{}}%
        {{hash=f189b293bd3263254702f8c5fe1d714b}{Zhang}{Z\bibinitperiod}{Peng}{P\bibinitperiod}{}{}{}{}}%
        {{hash=5b8d30ffe6c857e26131901598abfc5a}{Chen}{C\bibinitperiod}{Yuzong}{Y\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{13}{}{%
        {{hash=c527382ce6a2bdfc4548a1f28e479d85}{Zhu}{Z\bibinitperiod}{Feng}{F\bibinitperiod}{}{}{}{}}%
        {{hash=d7cede02af5ba10feb48d4309c5f06dd}{Shi}{S\bibinitperiod}{Zhe}{Z\bibinitperiod}{}{}{}{}}%
        {{hash=5a9f53dda42b5b759ecf58ae8ca52191}{Qin}{Q\bibinitperiod}{Chu}{C\bibinitperiod}{}{}{}{}}%
        {{hash=c879b58bfbb585f308159c96a3e6c234}{Tao}{T\bibinitperiod}{Lin}{L\bibinitperiod}{}{}{}{}}%
        {{hash=4f1e33032cdd17c1c4c17fe05bd0772d}{Liu}{L\bibinitperiod}{Xin}{X\bibinitperiod}{}{}{}{}}%
        {{hash=7b489e462941f869f448a19abc85df4b}{Xu}{X\bibinitperiod}{Feng}{F\bibinitperiod}{}{}{}{}}%
        {{hash=32a08717e0d6dcde59bc98b96800ed6c}{Zhang}{Z\bibinitperiod}{Li}{L\bibinitperiod}{}{}{}{}}%
        {{hash=7dacbb5a6e92ab16944d46ba03705563}{Song}{S\bibinitperiod}{Yang}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=fb4c22e0b090d2ed34486344670fbcf6}{Liu}{L\bibinitperiod}{Xianghui}{X\bibinitperiod}{}{}{}{}}%
        {{hash=74060cf382134f36b5ad81a18b247ff7}{Zhang}{Z\bibinitperiod}{Jingxian}{J\bibinitperiod}{}{}{}{}}%
        {{hash=9887eb306f0532aca8eee77da4783f20}{Han}{H\bibinitperiod}{Bucong}{B\bibinitperiod}{}{}{}{}}%
        {{hash=f189b293bd3263254702f8c5fe1d714b}{Zhang}{Z\bibinitperiod}{Peng}{P\bibinitperiod}{}{}{}{}}%
        {{hash=5b8d30ffe6c857e26131901598abfc5a}{Chen}{C\bibinitperiod}{Yuzong}{Y\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Oxford University Press}%
      }
      \strng{namehash}{a01d75b0f79d0fd687dc7c4961e4ff4e}
      \strng{fullhash}{0810e2df3544a4fdfe343f0a738a922c}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery}}
      \field{abstract}{Knowledge and investigation of therapeutic targets (responsible for drug efficacy) and the targeted drugs facilitate target and drug discovery and validation. Therapeutic Target Database (TTD, http://bidd.nus.edu.sg/group/ttd/ttd.asp) has been developed to provide comprehensive information about efficacy targets and the corresponding approved, clinical trial and investigative drugs. Since its last update, major improvements and updates have been made to TTD. In addition to the significant increase of data content (from 1894 targets and 5028 drugs to 2025 targets and 17\x{2009}816 drugs), we added target validation information (drug potency against target, effect against disease models and effect of target knockout, knockdown or genetic variations) for 932 targets, and 841 quantitative structure activity relationship models for active compounds of 228 chemical types against 121 targets. Moreover, we added the data from our previous drug studies including 3681 multi-target agents against 108 target pairs, 116 drug combinations with their synergistic, additive, antagonistic, potentiative or reductive mechanisms, 1427 natural product-derived approved, clinical trial and pre-clinical drugs and cross-links to the clinical trial information page in the ClinicalTrials.gov database for 770 clinical trial drugs. These updates are useful for facilitating target discovery and validation, drug lead discovery and optimization, and the development of multi-target drugs and drug combinations.}
      \field{issn}{0305-1048}
      \field{journaltitle}{Nucleic Acids Research}
      \field{month}{01}
      \field{number}{Database issue}
      \field{title}{{Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery}}
      \field{volume}{40}
      \field{year}{2012}
      \field{pages}{D1128\bibrangedash D1136}
      \verb{doi}
      \verb 10.1093/nar/gkr797
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3245130/
      \endverb
    \endentry
    \entry{Hu2005}{article}{}
      \name{labelname}{5}{}{%
        {{hash=ef9dd8fe86cd22d7d1773bd23067921a}{Hu}{H\bibinitperiod}{Liegi}{L\bibinitperiod}{}{}{}{}}%
        {{hash=d52e68ba646f66e80500383fab929c6c}{Benson}{B\bibinitperiod}{Mark\bibnamedelima L}{M\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=ce98a703a81a0863e1ec0a89210327f2}{Smith}{S\bibinitperiod}{Richard\bibnamedelima D}{R\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=fd6f7744f9ba408fd1be6d9669e3b695}{Lerner}{L\bibinitperiod}{Michael\bibnamedelima G}{M\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=c09e5daf6c7da2989e1eb4f4394d6b1e}{Carlson}{C\bibinitperiod}{Heather\bibnamedelima a}{H\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{5}{}{%
        {{hash=ef9dd8fe86cd22d7d1773bd23067921a}{Hu}{H\bibinitperiod}{Liegi}{L\bibinitperiod}{}{}{}{}}%
        {{hash=d52e68ba646f66e80500383fab929c6c}{Benson}{B\bibinitperiod}{Mark\bibnamedelima L}{M\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=ce98a703a81a0863e1ec0a89210327f2}{Smith}{S\bibinitperiod}{Richard\bibnamedelima D}{R\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=fd6f7744f9ba408fd1be6d9669e3b695}{Lerner}{L\bibinitperiod}{Michael\bibnamedelima G}{M\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=c09e5daf6c7da2989e1eb4f4394d6b1e}{Carlson}{C\bibinitperiod}{Heather\bibnamedelima a}{H\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{a87d083a97f95c4c75dc01f5d9b2fa1a}
      \strng{fullhash}{7914cb502efc76c8aa5f6e2fa2ad3294}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Binding MOAD (Mother Of All Databases).}}
      \field{abstract}{Binding MOAD (Mother of All Databases) is the largest collection of high-quality, protein-ligand complexes available from the Protein Data Bank. At this time, Binding MOAD contains 5331 protein-ligand complexes comprised of 1780 unique protein families and 2630 unique ligands. We have searched the crystallography papers for all 5000+ structures and compiled binding data for 1375 (26{\%}) of the protein-ligand complexes. The binding-affinity data ranges 13 orders of magnitude. This is the largest collection of binding data reported to date in the literature. We have also addressed the issue of redundancy in the data. To create a nonredundant dataset, one protein from each of the 1780 protein families was chosen as a representative. Representatives were chosen by tightest binding, best resolution, etc. For the 1780 "best" complexes that comprise the nonredundant version of Binding MOAD, 475 (27{\%}) have binding data. This significant collection of protein-ligand complexes will be very useful in elucidating the biophysical patterns of molecular recognition and enzymatic regulation. The complexes with binding-affinity data will help in the development of improved scoring functions and structure-based drug discovery techniques. The dataset can be accessed at http://www.BindingMOAD.org.}
      \field{issn}{1097-0134}
      \field{journaltitle}{Proteins}
      \field{month}{08}
      \field{number}{3}
      \field{title}{{Binding MOAD (Mother Of All Databases).}}
      \field{volume}{60}
      \field{year}{2005}
      \field{pages}{333\bibrangedash 40}
      \verb{doi}
      \verb 10.1002/prot.20512
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Hu et al. - 2005 - Binding MOAD (Mother Of All Databases).pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/15971202
      \endverb
    \endentry
    \entry{Liu2007}{article}{}
      \name{labelname}{5}{}{%
        {{hash=7433e3fa80fd3d4838fc6e0b0af5b9cc}{Liu}{L\bibinitperiod}{Tiqing}{T\bibinitperiod}{}{}{}{}}%
        {{hash=a3872d9500c273cabec4a3b50f18dec8}{Lin}{L\bibinitperiod}{Yuhmei}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=9494e496566b0e2237ecf0c82781bae2}{Wen}{W\bibinitperiod}{Xin}{X\bibinitperiod}{}{}{}{}}%
        {{hash=8403fbc76c8802a3fe88cc7c34e86d4f}{Jorissen}{J\bibinitperiod}{Robert\bibnamedelima N}{R\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
        {{hash=850fbb308817a3e08f16b6b51602269c}{Gilson}{G\bibinitperiod}{Michael\bibnamedelima K}{M\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{5}{}{%
        {{hash=7433e3fa80fd3d4838fc6e0b0af5b9cc}{Liu}{L\bibinitperiod}{Tiqing}{T\bibinitperiod}{}{}{}{}}%
        {{hash=a3872d9500c273cabec4a3b50f18dec8}{Lin}{L\bibinitperiod}{Yuhmei}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=9494e496566b0e2237ecf0c82781bae2}{Wen}{W\bibinitperiod}{Xin}{X\bibinitperiod}{}{}{}{}}%
        {{hash=8403fbc76c8802a3fe88cc7c34e86d4f}{Jorissen}{J\bibinitperiod}{Robert\bibnamedelima N}{R\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
        {{hash=850fbb308817a3e08f16b6b51602269c}{Gilson}{G\bibinitperiod}{Michael\bibnamedelima K}{M\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Oxford University Press}%
      }
      \strng{namehash}{1afb7c1714b22c94c9791bdd67ea533b}
      \strng{fullhash}{b2b37650f574e74445de7a7a3613c788}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{BindingDB: a web-accessible database of experimentally determined protein--ligand binding affinities}}
      \field{abstract}{BindingDB () is a publicly accessible database currently containing \x{223c}20\x{2009}000 experimentally determined binding affinities of protein--ligand complexes, for 110 protein targets including isoforms and mutational variants, and \x{223c}11\x{2009}000 small molecule ligands. The data are extracted from the scientific literature, data collection focusing on proteins that are drug-targets or candidate drug-targets and for which structural data are present in the Protein Data Bank. The BindingDB website supports a range of query types, including searches by chemical structure, substructure and similarity; protein sequence; ligand and protein names; affinity ranges and molecular weight. Data sets generated by BindingDB queries can be downloaded in the form of annotated SDfiles for further analysis, or used as the basis for virtual screening of a compound database uploaded by the user. The data in BindingDB are linked both to structural data in the PDB via PDB IDs and chemical and sequence searches, and to the literature in PubMed via PubMed IDs.}
      \field{issn}{0305-1048}
      \field{journaltitle}{Nucleic Acids Research}
      \field{month}{01}
      \field{number}{Database issue}
      \field{title}{{BindingDB: a web-accessible database of experimentally determined protein--ligand binding affinities}}
      \field{volume}{35}
      \field{year}{2007}
      \field{pages}{D198\bibrangedash D201}
      \verb{doi}
      \verb 10.1093/nar/gkl999
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1751547/
      \endverb
    \endentry
    \entry{Kim2016}{article}{}
      \name{labelname}{14}{}{%
        {{hash=03fd2567460f66228ee7a405a947f9b5}{Kim}{K\bibinitperiod}{Sunghwan}{S\bibinitperiod}{}{}{}{}}%
        {{hash=1f5fafc5dbbd3ca99d5f8dc5888d11c6}{Thiessen}{T\bibinitperiod}{Paul\bibnamedelima A}{P\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=3027a54196efa284df3d27b56180e4ef}{Bolton}{B\bibinitperiod}{Evan\bibnamedelima E}{E\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=f12458352bf48d8ebe2ba46b11310c19}{Chen}{C\bibinitperiod}{Jie}{J\bibinitperiod}{}{}{}{}}%
        {{hash=213a62ce5c316d5c0e7389e9440f1c9b}{Fu}{F\bibinitperiod}{Gang}{G\bibinitperiod}{}{}{}{}}%
        {{hash=06d44bae1ca2d0d4da9e5e271fca4dc3}{Gindulyte}{G\bibinitperiod}{Asta}{A\bibinitperiod}{}{}{}{}}%
        {{hash=a15423f068081a7a507e9c3e831edf4a}{Han}{H\bibinitperiod}{Lianyi}{L\bibinitperiod}{}{}{}{}}%
        {{hash=3da461cd3979f8980d1f0705330de22f}{He}{H\bibinitperiod}{Jane}{J\bibinitperiod}{}{}{}{}}%
        {{hash=e0d752ea39e238941a430432bc1fbe0e}{He}{H\bibinitperiod}{Siqian}{S\bibinitperiod}{}{}{}{}}%
        {{hash=697bf0d3621c45b573d759f72b6e28a0}{Shoemaker}{S\bibinitperiod}{Benjamin\bibnamedelima A}{B\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=b6e8cb3a4bf918cb95447db412013a03}{Wang}{W\bibinitperiod}{Jiyao}{J\bibinitperiod}{}{}{}{}}%
        {{hash=acae0d16fe2fdc8a53507106044e646c}{Yu}{Y\bibinitperiod}{Bo}{B\bibinitperiod}{}{}{}{}}%
        {{hash=112faefb37293f52cd92c3bb36fcc08b}{Zhang}{Z\bibinitperiod}{Jian}{J\bibinitperiod}{}{}{}{}}%
        {{hash=16f15656f80743960f12e4414e72d477}{Bryant}{B\bibinitperiod}{Stephen\bibnamedelima H}{S\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{14}{}{%
        {{hash=03fd2567460f66228ee7a405a947f9b5}{Kim}{K\bibinitperiod}{Sunghwan}{S\bibinitperiod}{}{}{}{}}%
        {{hash=1f5fafc5dbbd3ca99d5f8dc5888d11c6}{Thiessen}{T\bibinitperiod}{Paul\bibnamedelima A}{P\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=3027a54196efa284df3d27b56180e4ef}{Bolton}{B\bibinitperiod}{Evan\bibnamedelima E}{E\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=f12458352bf48d8ebe2ba46b11310c19}{Chen}{C\bibinitperiod}{Jie}{J\bibinitperiod}{}{}{}{}}%
        {{hash=213a62ce5c316d5c0e7389e9440f1c9b}{Fu}{F\bibinitperiod}{Gang}{G\bibinitperiod}{}{}{}{}}%
        {{hash=06d44bae1ca2d0d4da9e5e271fca4dc3}{Gindulyte}{G\bibinitperiod}{Asta}{A\bibinitperiod}{}{}{}{}}%
        {{hash=a15423f068081a7a507e9c3e831edf4a}{Han}{H\bibinitperiod}{Lianyi}{L\bibinitperiod}{}{}{}{}}%
        {{hash=3da461cd3979f8980d1f0705330de22f}{He}{H\bibinitperiod}{Jane}{J\bibinitperiod}{}{}{}{}}%
        {{hash=e0d752ea39e238941a430432bc1fbe0e}{He}{H\bibinitperiod}{Siqian}{S\bibinitperiod}{}{}{}{}}%
        {{hash=697bf0d3621c45b573d759f72b6e28a0}{Shoemaker}{S\bibinitperiod}{Benjamin\bibnamedelima A}{B\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=b6e8cb3a4bf918cb95447db412013a03}{Wang}{W\bibinitperiod}{Jiyao}{J\bibinitperiod}{}{}{}{}}%
        {{hash=acae0d16fe2fdc8a53507106044e646c}{Yu}{Y\bibinitperiod}{Bo}{B\bibinitperiod}{}{}{}{}}%
        {{hash=112faefb37293f52cd92c3bb36fcc08b}{Zhang}{Z\bibinitperiod}{Jian}{J\bibinitperiod}{}{}{}{}}%
        {{hash=16f15656f80743960f12e4414e72d477}{Bryant}{B\bibinitperiod}{Stephen\bibnamedelima H}{S\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{abaf1427cf681c4ae7181842fbd523c2}
      \strng{fullhash}{41f2f5838e09d4a8fc45813860ceada8}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{PubChem Substance and Compound databases}}
      \field{abstract}{PubChem (https://pubchem.ncbi.nlm.nih.gov) is a public repository for information on chemical substances and their biological activities, launched in 2004 as a component of the Molecular Libraries Roadmap Initiatives of the US National Institutes of Health (NIH). For the past 11 years, PubChem has grown to a sizable system, serving as a chemical information resource for the scientific research community. PubChem consists of three inter-linked databases, Substance, Compound and BioAssay. The Substance database contains chemical information deposited by individual data contributors to PubChem, and the Compound database stores unique chemical structures extracted from the Substance database. Biological activity data of chemical substances tested in assay experiments are contained in the BioAssay database. This paper provides an overview of the PubChem Substance and Compound databases, including data sources and contents, data organization, data submission using PubChem Upload, chemical structure standardization, web-based interfaces for textual and non-textual searches, and programmatic access. It also gives a brief description of PubChem3D, a resource derived from theoretical three-dimensional structures of compounds in PubChem, as well as PubChemRDF, Resource Description Framework (RDF)-formatted PubChem data for data sharing, analysis and integration with information contained in other databases.}
      \field{annotation}{10.1093/nar/gkv951}
      \field{journaltitle}{Nucleic Acids Research}
      \field{month}{01}
      \field{number}{D1}
      \field{title}{{PubChem Substance and Compound databases}}
      \field{volume}{44}
      \field{year}{2016}
      \field{pages}{D1202\bibrangedash D1213}
      \verb{doi}
      \verb 10.1093/nar/gkv951
      \endverb
      \verb{url}
      \verb http://nar.oxfordjournals.org/content/44/D1/D1202.abstract
      \endverb
    \endentry
    \entry{Wang2014}{article}{}
      \name{labelname}{9}{}{%
        {{hash=51d6921349f3514f95ec5892d20fc20a}{Wang}{W\bibinitperiod}{Yanli}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=2d981543ac40b7dfe8b9fcf6cebc6ce9}{Suzek}{S\bibinitperiod}{Tugba}{T\bibinitperiod}{}{}{}{}}%
        {{hash=112faefb37293f52cd92c3bb36fcc08b}{Zhang}{Z\bibinitperiod}{Jian}{J\bibinitperiod}{}{}{}{}}%
        {{hash=b6e8cb3a4bf918cb95447db412013a03}{Wang}{W\bibinitperiod}{Jiyao}{J\bibinitperiod}{}{}{}{}}%
        {{hash=e0d752ea39e238941a430432bc1fbe0e}{He}{H\bibinitperiod}{Siqian}{S\bibinitperiod}{}{}{}{}}%
        {{hash=6695a445237a5fda0e23ec879f8c15ab}{Cheng}{C\bibinitperiod}{Tiejun}{T\bibinitperiod}{}{}{}{}}%
        {{hash=697bf0d3621c45b573d759f72b6e28a0}{Shoemaker}{S\bibinitperiod}{Benjamin\bibnamedelima A}{B\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=06d44bae1ca2d0d4da9e5e271fca4dc3}{Gindulyte}{G\bibinitperiod}{Asta}{A\bibinitperiod}{}{}{}{}}%
        {{hash=16f15656f80743960f12e4414e72d477}{Bryant}{B\bibinitperiod}{Stephen\bibnamedelima H}{S\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{9}{}{%
        {{hash=51d6921349f3514f95ec5892d20fc20a}{Wang}{W\bibinitperiod}{Yanli}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=2d981543ac40b7dfe8b9fcf6cebc6ce9}{Suzek}{S\bibinitperiod}{Tugba}{T\bibinitperiod}{}{}{}{}}%
        {{hash=112faefb37293f52cd92c3bb36fcc08b}{Zhang}{Z\bibinitperiod}{Jian}{J\bibinitperiod}{}{}{}{}}%
        {{hash=b6e8cb3a4bf918cb95447db412013a03}{Wang}{W\bibinitperiod}{Jiyao}{J\bibinitperiod}{}{}{}{}}%
        {{hash=e0d752ea39e238941a430432bc1fbe0e}{He}{H\bibinitperiod}{Siqian}{S\bibinitperiod}{}{}{}{}}%
        {{hash=6695a445237a5fda0e23ec879f8c15ab}{Cheng}{C\bibinitperiod}{Tiejun}{T\bibinitperiod}{}{}{}{}}%
        {{hash=697bf0d3621c45b573d759f72b6e28a0}{Shoemaker}{S\bibinitperiod}{Benjamin\bibnamedelima A}{B\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=06d44bae1ca2d0d4da9e5e271fca4dc3}{Gindulyte}{G\bibinitperiod}{Asta}{A\bibinitperiod}{}{}{}{}}%
        {{hash=16f15656f80743960f12e4414e72d477}{Bryant}{B\bibinitperiod}{Stephen\bibnamedelima H}{S\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Oxford University Press}%
      }
      \strng{namehash}{370f88cf498160f6ce133b0b20ee3778}
      \strng{fullhash}{032789d7c8490b71f0ab59fdaf37b474}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{PubChem BioAssay: 2014 update}}
      \field{abstract}{PubChem's BioAssay database (http://pubchem.ncbi.nlm.nih.gov) is a public repository for archiving biological tests of small molecules generated through high-throughput screening experiments, medicinal chemistry studies, chemical biology research and drug discovery programs. In addition, the BioAssay database contains data from high-throughput RNA interference screening aimed at identifying critical genes responsible for a biological process or disease condition. The mission of PubChem is to serve the community by providing free and easy access to all deposited data. To this end, PubChem BioAssay is integrated into the National Center for Biotechnology Information retrieval system, making them searchable by Entrez queries and cross-linked to other biomedical information archived at National Center for Biotechnology Information. Moreover, PubChem BioAssay provides web-based and programmatic tools allowing users to search, access and analyze bioassay test results and metadata. In this work, we provide an update for the PubChem BioAssay resource, such as information content growth, new developments supporting data integration and search, and the recently deployed PubChem Upload to streamline chemical structure and bioassay submissions.}
      \field{issn}{0305-1048}
      \field{journaltitle}{Nucleic Acids Research}
      \field{month}{01}
      \field{number}{Database issue}
      \field{title}{{PubChem BioAssay: 2014 update}}
      \field{volume}{42}
      \field{year}{2014}
      \field{pages}{D1075\bibrangedash D1082}
      \verb{doi}
      \verb 10.1093/nar/gkt978
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3965008/
      \endverb
    \endentry
    \entry{Irwin2012}{article}{}
      \name{labelname}{5}{}{%
        {{hash=7b74817dd0fa7af0c4a9b1281fb251c4}{Irwin}{I\bibinitperiod}{John\bibnamedelima J}{J\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=1d62ad764ccb3d47cb78bde11bbf44fc}{Sterling}{S\bibinitperiod}{Teague}{T\bibinitperiod}{}{}{}{}}%
        {{hash=e44925a0755085539287a089d962cf31}{Mysinger}{M\bibinitperiod}{Michael\bibnamedelima M}{M\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=20b1c7f5ec87097efbd4c645a63e035f}{Bolstad}{B\bibinitperiod}{Erin\bibnamedelima S}{E\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=721483d264b0eebd22c8d7754e1bd898}{Coleman}{C\bibinitperiod}{Ryan\bibnamedelima G}{R\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{5}{}{%
        {{hash=7b74817dd0fa7af0c4a9b1281fb251c4}{Irwin}{I\bibinitperiod}{John\bibnamedelima J}{J\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=1d62ad764ccb3d47cb78bde11bbf44fc}{Sterling}{S\bibinitperiod}{Teague}{T\bibinitperiod}{}{}{}{}}%
        {{hash=e44925a0755085539287a089d962cf31}{Mysinger}{M\bibinitperiod}{Michael\bibnamedelima M}{M\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=20b1c7f5ec87097efbd4c645a63e035f}{Bolstad}{B\bibinitperiod}{Erin\bibnamedelima S}{E\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=721483d264b0eebd22c8d7754e1bd898}{Coleman}{C\bibinitperiod}{Ryan\bibnamedelima G}{R\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {American Chemical Society}%
      }
      \strng{namehash}{c8793a7809366b5fb3fc9811e90d3619}
      \strng{fullhash}{4ebf734cdd61a3fbe265c6e7d7052934}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{ZINC: A Free Tool to Discover Chemistry for Biology}}
      \field{annotation}{doi: 10.1021/ci3001277}
      \field{issn}{1549-9596}
      \field{journaltitle}{Journal of Chemical Information and Modeling}
      \field{month}{07}
      \field{number}{7}
      \field{title}{{ZINC: A Free Tool to Discover Chemistry for Biology}}
      \field{volume}{52}
      \field{year}{2012}
      \field{pages}{1757\bibrangedash 1768}
      \verb{doi}
      \verb 10.1021/ci3001277
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1021/ci3001277
      \endverb
    \endentry
    \entry{Alonso2006}{article}{}
      \name{labelname}{3}{}{%
        {{hash=16449e4444ae8019c5981d6bf8b71daf}{Alonso}{A\bibinitperiod}{Hern{\'{a}}n}{H\bibinitperiod}{}{}{}{}}%
        {{hash=5258d97ecb19feb40752e1ad8779abfa}{Bliznyuk}{B\bibinitperiod}{Andrey\bibnamedelima A.}{A\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=b14503906adf5d4bb5c59fc0c85f2f74}{Gready}{G\bibinitperiod}{Jill\bibnamedelima E.}{J\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=16449e4444ae8019c5981d6bf8b71daf}{Alonso}{A\bibinitperiod}{Hern{\'{a}}n}{H\bibinitperiod}{}{}{}{}}%
        {{hash=5258d97ecb19feb40752e1ad8779abfa}{Bliznyuk}{B\bibinitperiod}{Andrey\bibnamedelima A.}{A\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=b14503906adf5d4bb5c59fc0c85f2f74}{Gready}{G\bibinitperiod}{Jill\bibnamedelima E.}{J\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{6454e718290aafe1833903ce9cd08121}
      \strng{fullhash}{6454e718290aafe1833903ce9cd08121}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Combining docking and molecular dynamic simulations in drug design}}
      \field{abstract}{A rational approach is needed to maximize the chances of finding new drugs, and to exploit the opportunities of potential new drug targets emerging from genomic and proteomic initiatives, and from the large libraries of small compounds now readily available through combinatorial chemistry. Despite a shaky early history, computer-aided drug design techniques can now be effective in reducing costs and speeding up drug discovery. This happy outcome results from development of more accurate and reliable algorithms, use of more thoughtfully planned strategies to apply them, and greatly increased computer power to allow studies with the necessary reliability to be performed. Our review focuses on applications and protocols, with the main emphasis on critical analysis of recent studies where docking calculations and molecular dynamics (MD) simulations were combined to dock small molecules into protein receptors. We highlight successes to demonstrate what is possible now, but also point out drawbacks and future directions. The review is structured to lead the reader from the simpler to more compute-intensive methods. Thus, while inexpensive and fast docking algorithms can be used to scan large compound libraries and reduce their size, more accurate but expensive MD simulations can be applied when a few selected ligand candidates remain. MD simulations can be used: during the preparation of the protein receptor before docking, to optimize its structure and account for protein flexibility; for the refinement of docked complexes, to include solvent effects and account for induced fit; to calculate binding free energies, to provide an accurate ranking of the potential ligands; and in the latest developments, during the docking process itself to find the binding site and correctly dock the ligand a priori.}
      \field{isbn}{0198-6325}
      \field{issn}{01986325}
      \field{journaltitle}{Medicinal Research Reviews}
      \field{number}{5}
      \field{title}{{Combining docking and molecular dynamic simulations in drug design}}
      \field{volume}{26}
      \field{year}{2006}
      \field{pages}{531\bibrangedash 568}
      \verb{doi}
      \verb 10.1002/med.20067
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/20067{\_}ftp.pdf:pdf
      \endverb
    \endentry
    \entry{Morris2009}{article}{}
      \name{labelname}{7}{}{%
        {{hash=03875878cdd3ca1814f4d19b2b707378}{Morris}{M\bibinitperiod}{Garrett\bibnamedelima M}{G\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=abfe839ffd42235f7ccf52fd38c70880}{Huey}{H\bibinitperiod}{Ruth}{R\bibinitperiod}{}{}{}{}}%
        {{hash=7ce3f604e3542482b2e574077c087c59}{Lindstrom}{L\bibinitperiod}{William}{W\bibinitperiod}{}{}{}{}}%
        {{hash=3dfc8441c51c12ddc628b0f54cfbae9c}{Sanner}{S\bibinitperiod}{Michel\bibnamedelima F}{M\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{hash=a96e4886230504267de9e02ab5572d86}{Belew}{B\bibinitperiod}{Richard\bibnamedelima K}{R\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=099ad0f327ebce4a161a3ee9fcdaf3ae}{Goodsell}{G\bibinitperiod}{David\bibnamedelima S}{D\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=33425ff8f67a18e0e5fd479e2b7e19ed}{Olson}{O\bibinitperiod}{Arthur\bibnamedelima J}{A\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{7}{}{%
        {{hash=03875878cdd3ca1814f4d19b2b707378}{Morris}{M\bibinitperiod}{Garrett\bibnamedelima M}{G\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=abfe839ffd42235f7ccf52fd38c70880}{Huey}{H\bibinitperiod}{Ruth}{R\bibinitperiod}{}{}{}{}}%
        {{hash=7ce3f604e3542482b2e574077c087c59}{Lindstrom}{L\bibinitperiod}{William}{W\bibinitperiod}{}{}{}{}}%
        {{hash=3dfc8441c51c12ddc628b0f54cfbae9c}{Sanner}{S\bibinitperiod}{Michel\bibnamedelima F}{M\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{hash=a96e4886230504267de9e02ab5572d86}{Belew}{B\bibinitperiod}{Richard\bibnamedelima K}{R\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=099ad0f327ebce4a161a3ee9fcdaf3ae}{Goodsell}{G\bibinitperiod}{David\bibnamedelima S}{D\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=33425ff8f67a18e0e5fd479e2b7e19ed}{Olson}{O\bibinitperiod}{Arthur\bibnamedelima J}{A\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{23b02cde1d1079d91e1b7646f16cabfd}
      \strng{fullhash}{bf3c0b6869056c842e862e3ff241219a}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility}}
      \field{abstract}{We describe the testing and release of AutoDock4 and the accompanying graphical user interface AutoDockTools. AutoDock4 incorporates limited flexibility in the receptor. Several tests are reported here, including a redocking experiment with 188 diverse ligand-protein complexes and a cross-docking experiment using flexible sidechains in 87 HIV protease complexes. We also report its utility in analysis of covalently-bound ligands, using both a grid-based docking method and a modification of the flexible sidechain technique.}
      \field{issn}{0192-8651}
      \field{journaltitle}{Journal of computational chemistry}
      \field{month}{12}
      \field{number}{16}
      \field{title}{{AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility}}
      \field{volume}{30}
      \field{year}{2009}
      \field{pages}{2785\bibrangedash 2791}
      \verb{doi}
      \verb 10.1002/jcc.21256
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2760638/
      \endverb
    \endentry
    \entry{Trott2010}{article}{}
      \name{labelname}{2}{}{%
        {{hash=4a4f9e841fae09e46988ea87c501122e}{Trott}{T\bibinitperiod}{Oleg}{O\bibinitperiod}{}{}{}{}}%
        {{hash=33425ff8f67a18e0e5fd479e2b7e19ed}{Olson}{O\bibinitperiod}{Arthur\bibnamedelima J}{A\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=4a4f9e841fae09e46988ea87c501122e}{Trott}{T\bibinitperiod}{Oleg}{O\bibinitperiod}{}{}{}{}}%
        {{hash=33425ff8f67a18e0e5fd479e2b7e19ed}{Olson}{O\bibinitperiod}{Arthur\bibnamedelima J}{A\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{33edd37cdbf195a31f3e025a1c785fa9}
      \strng{fullhash}{33edd37cdbf195a31f3e025a1c785fa9}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading}}
      \field{abstract}{AutoDock Vina, a new program for molecular docking and virtual screening, is presented. AutoDock Vina achieves an approximately two orders of magnitude speed-up compared to the molecular docking software previously developed in our lab (AutoDock 4), while also significantly improving the accuracy of the binding mode predictions, judging by our tests on the training set used in AutoDock 4 development. Further speed-up is achieved from parallelism, by using multithreading on multi-core machines. AutoDock Vina automatically calculates the grid maps and clusters the results in a way transparent to the user.}
      \field{issn}{0192-8651}
      \field{journaltitle}{Journal of computational chemistry}
      \field{month}{01}
      \field{number}{2}
      \field{title}{{AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading}}
      \field{volume}{31}
      \field{year}{2010}
      \field{pages}{455\bibrangedash 461}
      \verb{doi}
      \verb 10.1002/jcc.21334
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3041641/
      \endverb
    \endentry
    \entry{Ewing1997}{article}{}
      \name{labelname}{2}{}{%
        {{hash=dba045c922a8481d53b876410ad27d10}{Ewing}{E\bibinitperiod}{Todd\bibnamedelimb J\bibnamedelima a.}{T\bibinitperiod\bibinitdelim J\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
        {{hash=66f58288a79e7a0da002535ed008780c}{Kuntz}{K\bibinitperiod}{Irwin\bibnamedelima D}{I\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=dba045c922a8481d53b876410ad27d10}{Ewing}{E\bibinitperiod}{Todd\bibnamedelimb J\bibnamedelima a.}{T\bibinitperiod\bibinitdelim J\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
        {{hash=66f58288a79e7a0da002535ed008780c}{Kuntz}{K\bibinitperiod}{Irwin\bibnamedelima D}{I\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{f786628caf79940a091f9aed5a9ea487}
      \strng{fullhash}{f786628caf79940a091f9aed5a9ea487}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Critical evaluation of search algorithms for automated molecular docking and database screening}}
      \field{abstract}{The DOCK program explores possible orientations of a molecule within a macromolecular active site by superimposing atoms onto precomputed site points. Here we compare a number of different search methods, including an exhaustive matching algorithm based on a single docking graph. We evaluate the performance of each method by screening a small database of molecules to a variety of macromolecular targets. By varying the amount of sampling, we can monitor the time convergence of scores and rankings. We not only show that the site point\x{e05d}directed search is tenfold faster than a random search, but that the single graph matching algorithm boosts the speed of database screening up to 60-fold. The new algorithm, in fact, outperforms the bipartite graph matching algorithm currently used in DOCK. The results indicate that a critical issue for rapid database screening is the extent to which a search method biases run time toward the highest-ranking molecules. The single docking graph matching algorithm will be incorporated into DOCK version 4.0.}
      \field{isbn}{1096-987X}
      \field{issn}{0192-8651}
      \field{journaltitle}{Journal of Computational Chemistry}
      \field{title}{{Critical evaluation of search algorithms for automated molecular docking and database screening}}
      \field{volume}{18}
      \field{year}{1997}
      \field{pages}{1175\bibrangedash 1189}
      \verb{doi}
      \verb 10.1002/(SICI)1096-987X(19970715)18:9<1175::AID-JCC6>3.0.CO;2-O
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/10.1.1.639.8641.pdf:pdf
      \endverb
      \verb{url}
      \verb http://doi.wiley.com/10.1002/(SICI)1096-987X(19970715)18:9%7B%3C%7D1175::AID-JCC6%7B%3E%7D3.0.CO;2-O
      \endverb
    \endentry
    \entry{Rarey1996}{article}{}
      \name{labelname}{4}{}{%
        {{hash=3f75acc2c1dd637578817bce878cfbf9}{Rarey}{R\bibinitperiod}{Matthias}{M\bibinitperiod}{}{}{}{}}%
        {{hash=835ed9811dc9c10081202aa3f000b0aa}{Kramer}{K\bibinitperiod}{Bernd}{B\bibinitperiod}{}{}{}{}}%
        {{hash=523d57c46fd06417e60e5209d0122f34}{Lengauer}{L\bibinitperiod}{Thomas}{T\bibinitperiod}{}{}{}{}}%
        {{hash=93001fe15285ce67c1470749a34acf5c}{Klebe}{K\bibinitperiod}{Gerhard}{G\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=3f75acc2c1dd637578817bce878cfbf9}{Rarey}{R\bibinitperiod}{Matthias}{M\bibinitperiod}{}{}{}{}}%
        {{hash=835ed9811dc9c10081202aa3f000b0aa}{Kramer}{K\bibinitperiod}{Bernd}{B\bibinitperiod}{}{}{}{}}%
        {{hash=523d57c46fd06417e60e5209d0122f34}{Lengauer}{L\bibinitperiod}{Thomas}{T\bibinitperiod}{}{}{}{}}%
        {{hash=93001fe15285ce67c1470749a34acf5c}{Klebe}{K\bibinitperiod}{Gerhard}{G\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{73331c045801d26208890eb0368fd661}
      \strng{fullhash}{a5d7d69f7d4dce46d07e6797d593c3b0}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{A Fast Flexible Docking Method using an Incremental Construction Algorithm}}
      \field{abstract}{We present an automatic method for docking organic ligands into protein binding sites. The method can be used in the design process of specific protein ligands. It combines an appropriate model of the physico-chemical properties of the docked molecules with efficient methods for sampling the conformational space of the ligand. If the ligand is flexible, it can adopt a large variety of different conformations. Each such minimum in conformational space presents a potential candidate for the conformation of the ligand in the complexed state. Our docking method samples the conformation space of the ligand on the basis of a discrete model and uses a tree-search technique for placing the ligand incrementally into the active site. For placing the first fragment of the ligand into the protein, we use hashing techniques adapted from computer vision. The incremental construction algorithm is based on a greedy strategy combined with efficient methods for overlap detection and for the search of new interactions. We present results on 19 complexes of which the binding geometry has been crystallographically determined. All considered ligands are docked in at most three minutes on a current workstation. The experimentally observed binding mode of the ligand is reproduced with 0.5 to 1.2 {\r{A}} rms deviation. It is almost always found among the highest-ranking conformations computed.}
      \field{issn}{0022-2836}
      \field{journaltitle}{Journal of Molecular Biology}
      \field{month}{08}
      \field{number}{3}
      \field{title}{{A Fast Flexible Docking Method using an Incremental Construction Algorithm}}
      \field{volume}{261}
      \field{year}{1996}
      \field{pages}{470\bibrangedash 489}
      \verb{doi}
      \verb http://dx.doi.org/10.1006/jmbi.1996.0477
      \endverb
      \verb{url}
      \verb http://www.sciencedirect.com/science/article/pii/S0022283696904775
      \endverb
    \endentry
    \entry{Jones1997}{article}{}
      \name{labelname}{5}{}{%
        {{hash=f88a014a24f604954783c16ad0524d80}{Jones}{J\bibinitperiod}{G}{G\bibinitperiod}{}{}{}{}}%
        {{hash=bc95329d7c7bb64be647e9af3e6d66c7}{Willett}{W\bibinitperiod}{P}{P\bibinitperiod}{}{}{}{}}%
        {{hash=9642b54c498ba7e775da8d582d81f459}{Glen}{G\bibinitperiod}{R\bibnamedelima C}{R\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=a2ae35575b01b3ae1a6f1b799c6d173b}{Leach}{L\bibinitperiod}{A\bibnamedelima R}{A\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=96687293a6bacd111cb2a3c218f41763}{Taylor}{T\bibinitperiod}{R}{R\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{5}{}{%
        {{hash=f88a014a24f604954783c16ad0524d80}{Jones}{J\bibinitperiod}{G}{G\bibinitperiod}{}{}{}{}}%
        {{hash=bc95329d7c7bb64be647e9af3e6d66c7}{Willett}{W\bibinitperiod}{P}{P\bibinitperiod}{}{}{}{}}%
        {{hash=9642b54c498ba7e775da8d582d81f459}{Glen}{G\bibinitperiod}{R\bibnamedelima C}{R\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=a2ae35575b01b3ae1a6f1b799c6d173b}{Leach}{L\bibinitperiod}{A\bibnamedelima R}{A\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=96687293a6bacd111cb2a3c218f41763}{Taylor}{T\bibinitperiod}{R}{R\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{9d473c267249894dfe464c0b4ec98886}
      \strng{fullhash}{8dd2f51111a00512a78442e2bda72730}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Development and validation of a genetic algorithm for flexible docking.}}
      \field{abstract}{Prediction of small molecule binding modes to macromolecules of known three-dimensional structure is a problem of paramount importance in rational drug design (the "docking" problem). We report the development and validation of the program GOLD (Genetic Optimisation for Ligand Docking). GOLD is an automated ligand docking program that uses a genetic algorithm to explore the full range of ligand conformational flexibility with partial flexibility of the protein, and satisfies the fundamental requirement that the ligand must displace loosely bound water on binding. Numerous enhancements and modifications have been applied to the original technique resulting in a substantial increase in the reliability and the applicability of the algorithm. The advanced algorithm has been tested on a dataset of 100 complexes extracted from the Brookhaven Protein DataBank. When used to dock the ligand back into the binding site, GOLD achieved a 71{\%} success rate in identifying the experimental binding mode.}
      \field{issn}{0022-2836}
      \field{journaltitle}{Journal of molecular biology}
      \field{month}{04}
      \field{number}{3}
      \field{title}{{Development and validation of a genetic algorithm for flexible docking.}}
      \field{volume}{267}
      \field{year}{1997}
      \field{pages}{727\bibrangedash 48}
      \verb{doi}
      \verb 10.1006/jmbi.1996.0897
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Jones et al. - 1997 - Development and validation of a genetic algorithm for flexible docking.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.sciencedirect.com/science/article/pii/S0022283696908979
      \endverb
    \endentry
    \entry{Schames2004}{article}{}
      \name{labelname}{6}{}{%
        {{hash=25e2b872bb563a410ef59ebd2a104348}{Schames}{S\bibinitperiod}{Julie\bibnamedelima R}{J\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=c1b05c08b8caf0ef031dd8a0667848ef}{Henchman}{H\bibinitperiod}{Richard\bibnamedelima H}{R\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=5017cd6da2aab5899f7819c52db8e302}{Siegel}{S\bibinitperiod}{Jay\bibnamedelima S}{J\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=351681bce3e0a85122e52033b32dba26}{Sotriffer}{S\bibinitperiod}{Christoph\bibnamedelima A}{C\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=3c0d462e7ec04da0fb68d0b0f4ea3452}{Ni}{N\bibinitperiod}{Haihong}{H\bibinitperiod}{}{}{}{}}%
        {{hash=ce37dc17080f7261773ea665c47a3b8f}{McCammon}{M\bibinitperiod}{J\bibnamedelima Andrew}{J\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{6}{}{%
        {{hash=25e2b872bb563a410ef59ebd2a104348}{Schames}{S\bibinitperiod}{Julie\bibnamedelima R}{J\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=c1b05c08b8caf0ef031dd8a0667848ef}{Henchman}{H\bibinitperiod}{Richard\bibnamedelima H}{R\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=5017cd6da2aab5899f7819c52db8e302}{Siegel}{S\bibinitperiod}{Jay\bibnamedelima S}{J\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=351681bce3e0a85122e52033b32dba26}{Sotriffer}{S\bibinitperiod}{Christoph\bibnamedelima A}{C\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=3c0d462e7ec04da0fb68d0b0f4ea3452}{Ni}{N\bibinitperiod}{Haihong}{H\bibinitperiod}{}{}{}{}}%
        {{hash=ce37dc17080f7261773ea665c47a3b8f}{McCammon}{M\bibinitperiod}{J\bibnamedelima Andrew}{J\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{fa07db4662657dd6ceeea9e5e3296b4f}
      \strng{fullhash}{4864a1764a1d258f55b948c7e5d4b1be}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Discovery of a novel binding trench in HIV integrase.}}
      \field{abstract}{Docking of the 5CITEP inhibitor to snapshots of a 2 ns HIV-1 integrase MD trajectory indicated a previously uncharacterized trench adjacent to the active site that intermittently opens. Further docking studies of novel ligands with the potential to bind to both regions showed greater selective affinity when able to bind to the trench. Our ranking of ligands is open to experimental testing, and our approach suggests a new target for HIV-1 therapeutics.}
      \field{issn}{0022-2623}
      \field{journaltitle}{Journal of medicinal chemistry}
      \field{month}{04}
      \field{number}{8}
      \field{title}{{Discovery of a novel binding trench in HIV integrase.}}
      \field{volume}{47}
      \field{year}{2004}
      \field{pages}{1879\bibrangedash 81}
      \verb{doi}
      \verb 10.1021/jm0341913
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/15055986
      \endverb
    \endentry
    \entry{Enyedy2001}{article}{}
      \name{labelname}{14}{}{%
        {{hash=cccf019e920cf7f70685b6246efb298d}{Enyedy}{E\bibinitperiod}{Istvan\bibnamedelima J}{I\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=c694d2c3eb473e57844e782b31a92fba}{Ling}{L\bibinitperiod}{Yan}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=fecc59c070cac4d1c4a97a9e61edb558}{Nacro}{N\bibinitperiod}{Kassoum}{K\bibinitperiod}{}{}{}{}}%
        {{hash=edb66759a7b93be5cc4e2c1b5ccdd85b}{Tomita}{T\bibinitperiod}{York}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=be81dcecc1a8eb047716a69c86263cf3}{Wu}{W\bibinitperiod}{Xihan}{X\bibinitperiod}{}{}{}{}}%
        {{hash=99ce062a587c0af7a6385e1f8a7744b4}{Cao}{C\bibinitperiod}{Yeyu}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=fb78758065389ccf8aed41797ee6959d}{Guo}{G\bibinitperiod}{Ribo}{R\bibinitperiod}{}{}{}{}}%
        {{hash=f4ca30a8e501af9789454143e86ff623}{Li}{L\bibinitperiod}{Bihua}{B\bibinitperiod}{}{}{}{}}%
        {{hash=44fa4398633b23ed4ba8cb6975596172}{Zhu}{Z\bibinitperiod}{Xiaofeng}{X\bibinitperiod}{}{}{}{}}%
        {{hash=07da2ad0d080188097acdb1ce63432a9}{Huang}{H\bibinitperiod}{Ying}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=d39fadee94b51b745305d60070ec4ecf}{Long}{L\bibinitperiod}{Ya-Qiu}{Y\bibinithyphendelim Q\bibinitperiod}{}{}{}{}}%
        {{hash=6042de6c9a438a594f3061e7018fd632}{Roller}{R\bibinitperiod}{Peter\bibnamedelima P}{P\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=224bfac0a6322d270dc6a455104fb85f}{Yang}{Y\bibinitperiod}{Dajun}{D\bibinitperiod}{}{}{}{}}%
        {{hash=c5c6a61f0a352dfd208ab4e65ed64df7}{Wang}{W\bibinitperiod}{Shaomeng}{S\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{14}{}{%
        {{hash=cccf019e920cf7f70685b6246efb298d}{Enyedy}{E\bibinitperiod}{Istvan\bibnamedelima J}{I\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=c694d2c3eb473e57844e782b31a92fba}{Ling}{L\bibinitperiod}{Yan}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=fecc59c070cac4d1c4a97a9e61edb558}{Nacro}{N\bibinitperiod}{Kassoum}{K\bibinitperiod}{}{}{}{}}%
        {{hash=edb66759a7b93be5cc4e2c1b5ccdd85b}{Tomita}{T\bibinitperiod}{York}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=be81dcecc1a8eb047716a69c86263cf3}{Wu}{W\bibinitperiod}{Xihan}{X\bibinitperiod}{}{}{}{}}%
        {{hash=99ce062a587c0af7a6385e1f8a7744b4}{Cao}{C\bibinitperiod}{Yeyu}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=fb78758065389ccf8aed41797ee6959d}{Guo}{G\bibinitperiod}{Ribo}{R\bibinitperiod}{}{}{}{}}%
        {{hash=f4ca30a8e501af9789454143e86ff623}{Li}{L\bibinitperiod}{Bihua}{B\bibinitperiod}{}{}{}{}}%
        {{hash=44fa4398633b23ed4ba8cb6975596172}{Zhu}{Z\bibinitperiod}{Xiaofeng}{X\bibinitperiod}{}{}{}{}}%
        {{hash=07da2ad0d080188097acdb1ce63432a9}{Huang}{H\bibinitperiod}{Ying}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=d39fadee94b51b745305d60070ec4ecf}{Long}{L\bibinitperiod}{Ya-Qiu}{Y\bibinithyphendelim Q\bibinitperiod}{}{}{}{}}%
        {{hash=6042de6c9a438a594f3061e7018fd632}{Roller}{R\bibinitperiod}{Peter\bibnamedelima P}{P\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=224bfac0a6322d270dc6a455104fb85f}{Yang}{Y\bibinitperiod}{Dajun}{D\bibinitperiod}{}{}{}{}}%
        {{hash=c5c6a61f0a352dfd208ab4e65ed64df7}{Wang}{W\bibinitperiod}{Shaomeng}{S\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {American Chemical Society}%
      }
      \strng{namehash}{f9da54e365ba9e602528a302353ed4b8}
      \strng{fullhash}{a48895d6899040b4e3f47bedc272c9e3}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Discovery of Small-Molecule Inhibitors of Bcl-2 through Structure-Based Computer Screening}}
      \field{annotation}{doi: 10.1021/jm010016f}
      \field{issn}{0022-2623}
      \field{journaltitle}{Journal of Medicinal Chemistry}
      \field{month}{12}
      \field{number}{25}
      \field{title}{{Discovery of Small-Molecule Inhibitors of Bcl-2 through Structure-Based Computer Screening}}
      \field{volume}{44}
      \field{year}{2001}
      \field{pages}{4313\bibrangedash 4324}
      \verb{doi}
      \verb 10.1021/jm010016f
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1021/jm010016f
      \endverb
    \endentry
    \entry{Vangrevelinghe2003}{article}{}
      \name{labelname}{6}{}{%
        {{hash=416ae76db4e5bfac620e322ce3d2255f}{Vangrevelinghe}{V\bibinitperiod}{Eric}{E\bibinitperiod}{}{}{}{}}%
        {{hash=99329fab5807f1c1cddc960e56e8cf97}{Zimmermann}{Z\bibinitperiod}{Kaspar}{K\bibinitperiod}{}{}{}{}}%
        {{hash=ffa0a96cf758bed67725638480d2c761}{Schoepfer}{S\bibinitperiod}{Joseph}{J\bibinitperiod}{}{}{}{}}%
        {{hash=34d8013be664b59d9d2b15c004928a65}{Portmann}{P\bibinitperiod}{Robert}{R\bibinitperiod}{}{}{}{}}%
        {{hash=5d41ce0abc7c6487d82cac05657b4128}{Fabbro}{F\bibinitperiod}{Doriano}{D\bibinitperiod}{}{}{}{}}%
        {{hash=5d7c345aebbee9f07f5d2f193ce19f2c}{Furet}{F\bibinitperiod}{Pascal}{P\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{6}{}{%
        {{hash=416ae76db4e5bfac620e322ce3d2255f}{Vangrevelinghe}{V\bibinitperiod}{Eric}{E\bibinitperiod}{}{}{}{}}%
        {{hash=99329fab5807f1c1cddc960e56e8cf97}{Zimmermann}{Z\bibinitperiod}{Kaspar}{K\bibinitperiod}{}{}{}{}}%
        {{hash=ffa0a96cf758bed67725638480d2c761}{Schoepfer}{S\bibinitperiod}{Joseph}{J\bibinitperiod}{}{}{}{}}%
        {{hash=34d8013be664b59d9d2b15c004928a65}{Portmann}{P\bibinitperiod}{Robert}{R\bibinitperiod}{}{}{}{}}%
        {{hash=5d41ce0abc7c6487d82cac05657b4128}{Fabbro}{F\bibinitperiod}{Doriano}{D\bibinitperiod}{}{}{}{}}%
        {{hash=5d7c345aebbee9f07f5d2f193ce19f2c}{Furet}{F\bibinitperiod}{Pascal}{P\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {American Chemical Society}%
      }
      \strng{namehash}{d99e57891711703298ad52220db47a3e}
      \strng{fullhash}{8c154f5a3bc93810bccec8ca776853c1}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Discovery of a Potent and Selective Protein Kinase CK2 Inhibitor by High-Throughput Docking}}
      \field{annotation}{doi: 10.1021/jm030827e}
      \field{issn}{0022-2623}
      \field{journaltitle}{Journal of Medicinal Chemistry}
      \field{month}{06}
      \field{number}{13}
      \field{title}{{Discovery of a Potent and Selective Protein Kinase CK2 Inhibitor by High-Throughput Docking}}
      \field{volume}{46}
      \field{year}{2003}
      \field{pages}{2656\bibrangedash 2662}
      \verb{doi}
      \verb 10.1021/jm030827e
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1021/jm030827e
      \endverb
    \endentry
    \entry{Kitchen2004}{article}{}
      \name{labelname}{4}{}{%
        {{hash=fb875aae80088d06b6f38ba9e8b99512}{Kitchen}{K\bibinitperiod}{D}{D\bibinitperiod}{}{}{}{}}%
        {{hash=2a362dc9d3c737b94c4856350d6b11c6}{Decornez}{D\bibinitperiod}{H}{H\bibinitperiod}{}{}{}{}}%
        {{hash=d0d071f4c19665e202a4e902352309c6}{Furr}{F\bibinitperiod}{J}{J\bibinitperiod}{}{}{}{}}%
        {{hash=73602a565d4438564ee5eee7cfb36d57}{Bajorath}{B\bibinitperiod}{J}{J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=fb875aae80088d06b6f38ba9e8b99512}{Kitchen}{K\bibinitperiod}{D}{D\bibinitperiod}{}{}{}{}}%
        {{hash=2a362dc9d3c737b94c4856350d6b11c6}{Decornez}{D\bibinitperiod}{H}{H\bibinitperiod}{}{}{}{}}%
        {{hash=d0d071f4c19665e202a4e902352309c6}{Furr}{F\bibinitperiod}{J}{J\bibinitperiod}{}{}{}{}}%
        {{hash=73602a565d4438564ee5eee7cfb36d57}{Bajorath}{B\bibinitperiod}{J}{J\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{729980ccbae263fe121457afa5d0f544}
      \strng{fullhash}{1d20d8b3ac59460a1c72f90db50effd5}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Docking and scoring in virtual screening for drug discovery: methods and applications}}
      \field{abstract}{Computational approaches that 'dock' small molecules into the structures of macromolecular targets and 'score' their potential complementarity to binding sites are widely used in hit identification and lead optimization. Indeed, there are now a number of drugs whose development was heavily influenced by or based on structure-based design and screening strategies, such as HIV protease inhibitors. Nevertheless, there remain significant challenges in the application of these approaches, in particular in relation to current scoring schemes. Here, we review key concepts and specific features of small-molecule-protein docking methods, highlight selected applications and discuss recent advances that aim to address the acknowledged limitations of established approaches.}
      \field{isbn}{1474-1776}
      \field{issn}{1474-1784}
      \field{journaltitle}{Nature Reviews Drug Discovery}
      \field{number}{11}
      \field{title}{{Docking and scoring in virtual screening for drug discovery: methods and applications}}
      \field{volume}{3}
      \field{year}{2004}
      \field{pages}{935\bibrangedash 949}
      \verb{doi}
      \verb 10.1038/nrd1549
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/nrd1549.pdf:pdf
      \endverb
      \verb{url}
      \verb papers://ae875177-834e-4ba8-8523-120292c79891/Paper/p6840
      \endverb
    \endentry
    \entry{Reardon2013}{article}{}
      \name{labelname}{1}{}{%
        {{hash=31d7884c35df263e6201d4313efff9b8}{Reardon}{R\bibinitperiod}{Sara}{S\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=31d7884c35df263e6201d4313efff9b8}{Reardon}{R\bibinitperiod}{Sara}{S\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{31d7884c35df263e6201d4313efff9b8}
      \strng{fullhash}{31d7884c35df263e6201d4313efff9b8}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Project ranks billions of drug interactions.}}
      \field{abstract}{Drugable.com predicts mechanisms through computation.}
      \field{isbn}{0028-0836, 1476-4687}
      \field{issn}{1476-4687}
      \field{journaltitle}{Nature}
      \field{number}{7477}
      \field{title}{{Project ranks billions of drug interactions.}}
      \field{volume}{503}
      \field{year}{2013}
      \field{pages}{449\bibrangedash 50}
      \verb{doi}
      \verb 10.1038/503449a
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/503449a.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/24284710
      \endverb
    \endentry
    \entry{Drews2000}{article}{}
      \name{labelname}{1}{}{%
        {{hash=7f737abe1c40888301694155f653bf67}{Drews}{D\bibinitperiod}{J}{J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=7f737abe1c40888301694155f653bf67}{Drews}{D\bibinitperiod}{J}{J\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{7f737abe1c40888301694155f653bf67}
      \strng{fullhash}{7f737abe1c40888301694155f653bf67}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Drug discovery: a historical perspective.}}
      \field{abstract}{Driven by chemistry but increasingly guided by pharmacology and the clinical sciences, drug research has contributed more to the progress of medicine during the past century than any other scientific factor. The advent of molecular biology and, in particular, of genomic sciences is having a deep impact on drug discovery. Recombinant proteins and monoclonal antibodies have greatly enriched our therapeutic armamentarium. Genome sciences, combined with bioinformatic tools, allow us to dissect the genetic basis of multifactorial diseases and to determine the most suitable points of attack for future medicines, thereby increasing the number of treatment options. The dramatic increase in the complexity of drug research is enforcing changes in the institutional basis of this interdisciplinary endeavor. The biotech industry is establishing itself as the discovery arm of the pharmaceutical industry. In bridging the gap between academia and large pharmaceutical companies, the biotech firms have been effective instruments of technology transfer.}
      \field{isbn}{0036-8075 (Print)$\backslash$r0036-8075 (Linking)}
      \field{issn}{0036-8075}
      \field{journaltitle}{Science}
      \field{number}{5460}
      \field{title}{{Drug discovery: a historical perspective.}}
      \field{volume}{287}
      \field{year}{2000}
      \field{pages}{1960\bibrangedash 64}
      \verb{doi}
      \verb 10.1126/science.287.5460.1960
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Drews - 2000 - Drug discovery a historical perspective.pdf:pdf
      \endverb
    \endentry
    \entry{Patrick2001}{incollection}{}
      \name{labelname}{1}{}{%
        {{hash=4465ab199916481254817ec67ee5b8cd}{Patrick}{P\bibinitperiod}{Graham\bibnamedelima L}{G\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=4465ab199916481254817ec67ee5b8cd}{Patrick}{P\bibinitperiod}{Graham\bibnamedelima L}{G\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {John Wiley {\&} Sons, Ltd}%
      }
      \strng{namehash}{4465ab199916481254817ec67ee5b8cd}
      \strng{fullhash}{4465ab199916481254817ec67ee5b8cd}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{History of Drug Discovery}}
      \field{booktitle}{eLS}
      \field{isbn}{9780470015902}
      \field{title}{{History of Drug Discovery}}
      \field{year}{2001}
      \verb{doi}
      \verb 10.1002/9780470015902.a0003090.pub2
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1002/9780470015902.a0003090.pub2
      \endverb
    \endentry
    \entry{Hutchinson2011}{article}{}
      \name{labelname}{2}{}{%
        {{hash=7a84fb05e00d19e09c13f2308cea00a9}{Hutchinson}{H\bibinitperiod}{Lisa}{L\bibinitperiod}{}{}{}{}}%
        {{hash=15158fb6261af364cae4159e52b2b4f7}{Kirk}{K\bibinitperiod}{Rebecca}{R\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=7a84fb05e00d19e09c13f2308cea00a9}{Hutchinson}{H\bibinitperiod}{Lisa}{L\bibinitperiod}{}{}{}{}}%
        {{hash=15158fb6261af364cae4159e52b2b4f7}{Kirk}{K\bibinitperiod}{Rebecca}{R\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.}%
      }
      \strng{namehash}{bd3222581da1ea760a8d32c3da4e431a}
      \strng{fullhash}{bd3222581da1ea760a8d32c3da4e431a}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{High drug attrition rates[mdash]where are we going wrong?}}
      \field{annotation}{10.1038/nrclinonc.2011.34}
      \field{issn}{1759-4774}
      \field{journaltitle}{Nat Rev Clin Oncol}
      \field{month}{04}
      \field{number}{4}
      \field{title}{{High drug attrition rates[mdash]where are we going wrong?}}
      \field{volume}{8}
      \field{year}{2011}
      \field{pages}{189\bibrangedash 190}
      \verb{url}
      \verb http://dx.doi.org/10.1038/nrclinonc.2011.34
      \endverb
    \endentry
    \entry{Lindsay2003}{article}{}
      \name{labelname}{1}{}{%
        {{hash=a5155f6dc3e790f98b57e7cb5acff83f}{Lindsay}{L\bibinitperiod}{Mark\bibnamedelima A}{M\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=a5155f6dc3e790f98b57e7cb5acff83f}{Lindsay}{L\bibinitperiod}{Mark\bibnamedelima A}{M\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{a5155f6dc3e790f98b57e7cb5acff83f}
      \strng{fullhash}{a5155f6dc3e790f98b57e7cb5acff83f}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Target discovery}}
      \field{annotation}{10.1038/nrd1202}
      \field{issn}{1474-1776}
      \field{journaltitle}{Nat Rev Drug Discov}
      \field{month}{10}
      \field{number}{10}
      \field{title}{{Target discovery}}
      \field{volume}{2}
      \field{year}{2003}
      \field{pages}{831\bibrangedash 838}
      \verb{url}
      \verb http://dx.doi.org/10.1038/nrd1202
      \endverb
    \endentry
    \entry{Hughes2011}{article}{}
      \name{labelname}{4}{}{%
        {{hash=92719bef4f321d41abd3ecd5f8a324e8}{Hughes}{H\bibinitperiod}{J.\bibnamedelimi P.}{J\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=58af7fb877b52267ca0802270218e792}{Rees}{R\bibinitperiod}{S.\bibnamedelimi S.}{S\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=b87a82c50fd2be81651acc86f9f447ab}{Kalindjian}{K\bibinitperiod}{S.\bibnamedelimi B.}{S\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=756bec188428515abb80c02e107b6d5f}{Philpott}{P\bibinitperiod}{K.\bibnamedelimi L.}{K\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=92719bef4f321d41abd3ecd5f8a324e8}{Hughes}{H\bibinitperiod}{J.\bibnamedelimi P.}{J\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=58af7fb877b52267ca0802270218e792}{Rees}{R\bibinitperiod}{S.\bibnamedelimi S.}{S\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=b87a82c50fd2be81651acc86f9f447ab}{Kalindjian}{K\bibinitperiod}{S.\bibnamedelimi B.}{S\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=756bec188428515abb80c02e107b6d5f}{Philpott}{P\bibinitperiod}{K.\bibnamedelimi L.}{K\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{0d9256a110c28d0a71b5d61772955000}
      \strng{fullhash}{7616c217328de39ddfa3cd656893c4df}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Principles of early drug discovery}}
      \field{abstract}{Developing a new drug from original idea to the launch of a finished product is a complex process which can take 12-15 years and cost in excess of {\$}1 billion. The idea for a target can come from a variety of sources including academic and clinical research and from the commercial sector. It may take many years to build up a body of supporting evidence before selecting a target for a costly drug discovery programme. Once a target has been chosen, the pharmaceutical industry and more recently some academic centres have streamlined a number of early processes to identify molecules which possess suitable characteristics to make acceptable drugs. This review will look at key preclinical stages of the drug discovery process, from initial target identification and validation, through assay development, high throughput screening, hit identification, lead optimization and finally the selection of a candidate molecule for clinical development.}
      \field{isbn}{1476-5381 (Electronic)$\backslash$r0007-1188 (Linking)}
      \field{issn}{00071188}
      \field{journaltitle}{British Journal of Pharmacology}
      \field{number}{6}
      \field{title}{{Principles of early drug discovery}}
      \field{volume}{162}
      \field{year}{2011}
      \field{pages}{1239\bibrangedash 1249}
      \verb{doi}
      \verb 10.1111/j.1476-5381.2010.01127.x
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/bph0162-1239.pdf:pdf
      \endverb
    \endentry
    \entry{Imming2006}{article}{}
      \name{labelname}{3}{}{%
        {{hash=1a19a796268a240beeaedfb8c0675724}{Imming}{I\bibinitperiod}{Peter}{P\bibinitperiod}{}{}{}{}}%
        {{hash=907a669a7856a85ad150b785a05d657d}{Sinning}{S\bibinitperiod}{Christian}{C\bibinitperiod}{}{}{}{}}%
        {{hash=83eb7db208fafcc3e91592718cec9e20}{Meyer}{M\bibinitperiod}{Achim}{A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=1a19a796268a240beeaedfb8c0675724}{Imming}{I\bibinitperiod}{Peter}{P\bibinitperiod}{}{}{}{}}%
        {{hash=907a669a7856a85ad150b785a05d657d}{Sinning}{S\bibinitperiod}{Christian}{C\bibinitperiod}{}{}{}{}}%
        {{hash=83eb7db208fafcc3e91592718cec9e20}{Meyer}{M\bibinitperiod}{Achim}{A\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{db3a3f86fa1154cd45ce750cce8c6cd3}
      \strng{fullhash}{db3a3f86fa1154cd45ce750cce8c6cd3}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Drugs, their targets and the nature and number of drug targets.}}
      \field{abstract}{What is a drug target? And how many such targets are there? Here, we consider the nature of drug targets, and by classifying known drug substances on the basis of the discussed principles we provide an estimation of the total number of current drug targets.}
      \field{isbn}{1474-1776}
      \field{issn}{1474-1776}
      \field{journaltitle}{Nature reviews. Drug discovery}
      \field{number}{10}
      \field{title}{{Drugs, their targets and the nature and number of drug targets.}}
      \field{volume}{5}
      \field{year}{2006}
      \field{pages}{821\bibrangedash 834}
      \verb{doi}
      \verb 10.1038/nrd2132
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/nrd2132.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.nature.com/doifinder/10.1038/nrd2132$%5Cbackslash$nhttp://www.ncbi.nlm.nih.gov/pubmed/17016423
      \endverb
    \endentry
    \entry{Klees1997}{article}{}
      \name{labelname}{2}{}{%
        {{hash=a1ef150710a6594730f2284153694ac5}{Klees}{K\bibinitperiod}{J\bibnamedelima E}{J\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=87a5182bfc881678b1f525597597e1bc}{Joines}{J\bibinitperiod}{R}{R\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=a1ef150710a6594730f2284153694ac5}{Klees}{K\bibinitperiod}{J\bibnamedelima E}{J\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=87a5182bfc881678b1f525597597e1bc}{Joines}{J\bibinitperiod}{R}{R\bibinitperiod}{}{}{}{}}%
      }
      \list{language}{1}{%
        {eng}%
      }
      \list{location}{1}{%
        {BASF Corporation Mount Olive, New Jersey, USA.}%
      }
      \strng{namehash}{b24ddfa983616a7c94b39fb7165d4288}
      \strng{fullhash}{b24ddfa983616a7c94b39fb7165d4288}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Occupational health issues in the pharmaceutical research and development process}}
      \field{issn}{0885-114X}
      \field{journaltitle}{Occupational medicine (Philadelphia, Pa.)}
      \field{number}{1}
      \field{title}{{Occupational health issues in the pharmaceutical research and development process}}
      \field{volume}{12}
      \field{year}{1997}
      \field{pages}{5\bibrangedash 27}
      \verb{url}
      \verb http://europepmc.org/abstract/MED/9153050
      \endverb
    \endentry
    \entry{Paul2010}{article}{}
      \name{labelname}{7}{}{%
        {{hash=b366568bb7c37bec2692f4b4ce012674}{Paul}{P\bibinitperiod}{Steven\bibnamedelima M}{S\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=688f1f09f5e342999801d127e72095a3}{Mytelka}{M\bibinitperiod}{Daniel\bibnamedelima S}{D\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=a3b55c4ad2ad4184c60822cd8551ae05}{Dunwiddie}{D\bibinitperiod}{Christopher\bibnamedelima T}{C\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=351d5da2feb8a3e00527230bb23ac3c6}{Persinger}{P\bibinitperiod}{Charles\bibnamedelima C}{C\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=6cde7adaa226a2ab0c7d0a811628733d}{Munos}{M\bibinitperiod}{Bernard\bibnamedelima H}{B\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=f3097c95f17ec534d356f865a2b8b86a}{Lindborg}{L\bibinitperiod}{Stacy\bibnamedelima R}{S\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=7d4c963a6c590a9ba12f4f19d7f07185}{Schacht}{S\bibinitperiod}{Aaron\bibnamedelima L}{A\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{7}{}{%
        {{hash=b366568bb7c37bec2692f4b4ce012674}{Paul}{P\bibinitperiod}{Steven\bibnamedelima M}{S\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=688f1f09f5e342999801d127e72095a3}{Mytelka}{M\bibinitperiod}{Daniel\bibnamedelima S}{D\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=a3b55c4ad2ad4184c60822cd8551ae05}{Dunwiddie}{D\bibinitperiod}{Christopher\bibnamedelima T}{C\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=351d5da2feb8a3e00527230bb23ac3c6}{Persinger}{P\bibinitperiod}{Charles\bibnamedelima C}{C\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=6cde7adaa226a2ab0c7d0a811628733d}{Munos}{M\bibinitperiod}{Bernard\bibnamedelima H}{B\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=f3097c95f17ec534d356f865a2b8b86a}{Lindborg}{L\bibinitperiod}{Stacy\bibnamedelima R}{S\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=7d4c963a6c590a9ba12f4f19d7f07185}{Schacht}{S\bibinitperiod}{Aaron\bibnamedelima L}{A\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{ec0c820d22c5ffc3bd4acba8e8c8f62b}
      \strng{fullhash}{b4542eeb6d87f80aa6d2ad603c5b0e1e}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{How to improve R{\&}D productivity: the pharmaceutical industry's grand challenge.}}
      \field{abstract}{The pharmaceutical industry is under growing pressure from a range of environmental issues, including major losses of revenue owing to patent expirations, increasingly cost-constrained healthcare systems and more demanding regulatory requirements. In our view, the key to tackling the challenges such issues pose to both the future viability of the pharmaceutical industry and advances in healthcare is to substantially increase the number and quality of innovative, cost-effective new medicines, without incurring unsustainable R{\&}D costs. However, it is widely acknowledged that trends in industry R{\&}D productivity have been moving in the opposite direction for a number of years. Here, we present a detailed analysis based on comprehensive, recent, industry-wide data to identify the relative contributions of each of the steps in the drug discovery and development process to overall R{\&}D productivity. We then propose specific strategies that could have the most substantial impact in improving R{\&}D productivity.}
      \field{isbn}{1474-1776}
      \field{issn}{1474-1776}
      \field{journaltitle}{Nature reviews. Drug discovery}
      \field{number}{3}
      \field{title}{{How to improve R{\&}D productivity: the pharmaceutical industry's grand challenge.}}
      \field{volume}{9}
      \field{year}{2010}
      \field{pages}{203\bibrangedash 214}
      \verb{doi}
      \verb 10.1038/nrd3078
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Paul et al. - 2010 - How to improve R{\&}D productivity the pharmaceutical industry's grand challenge.pdf:pdf
      \endverb
    \endentry
    \entry{Scannell2012}{article}{}
      \name{labelname}{4}{}{%
        {{hash=bbafbad45bc890a624d6cad5d0f09816}{Scannell}{S\bibinitperiod}{Jack\bibnamedelima W}{J\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=a02e1cbb665aa678d8b4e57a143360c6}{Blanckley}{B\bibinitperiod}{Alex}{A\bibinitperiod}{}{}{}{}}%
        {{hash=f42f13c8d7d443a29d13d5b7c2131465}{Boldon}{B\bibinitperiod}{Helen}{H\bibinitperiod}{}{}{}{}}%
        {{hash=5eb39bacb2b338ede1118e9d772cabd3}{Warrington}{W\bibinitperiod}{Brian}{B\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=bbafbad45bc890a624d6cad5d0f09816}{Scannell}{S\bibinitperiod}{Jack\bibnamedelima W}{J\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=a02e1cbb665aa678d8b4e57a143360c6}{Blanckley}{B\bibinitperiod}{Alex}{A\bibinitperiod}{}{}{}{}}%
        {{hash=f42f13c8d7d443a29d13d5b7c2131465}{Boldon}{B\bibinitperiod}{Helen}{H\bibinitperiod}{}{}{}{}}%
        {{hash=5eb39bacb2b338ede1118e9d772cabd3}{Warrington}{W\bibinitperiod}{Brian}{B\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group}%
      }
      \strng{namehash}{37dbe186f18e6efb263daba350860b38}
      \strng{fullhash}{758a96d05a4a23a98d44fbd1b3a74f04}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Diagnosing the decline in pharmaceutical R{\&}D efficiency.}}
      \field{abstract}{The past 60 years have seen huge advances in many of the scientific, technological and managerial factors that should tend to raise the efficiency of commercial drug research and development (RD). Yet the number of new drugs approved per billion US dollars spent on RD has halved roughly every 9 years since 1950, falling around 80-fold in inflation-adjusted terms. There have been many proposed solutions to the problem of declining RD efficiency. However, their apparent lack of impact so far and the contrast between improving inputs and declining output in terms of the number of new drugs make it sensible to ask whether the underlying problems have been correctly diagnosed. Here, we discuss four factors that we consider to be primary causes, which we call the 'better than the Beatles' problem; the 'cautious regulator' problem; the 'throw money at it' tendency; and the 'basic research-brute force' bias. Our aim is to provoke a more systematic analysis of the causes of the decline in RD efficiency.}
      \field{isbn}{1474-1784 (Electronic)$\backslash$r1474-1776 (Linking)}
      \field{issn}{1474-1784}
      \field{journaltitle}{Nature reviews. Drug discovery}
      \field{number}{3}
      \field{title}{{Diagnosing the decline in pharmaceutical R{\&}D efficiency.}}
      \field{volume}{11}
      \field{year}{2012}
      \field{pages}{191\bibrangedash 200}
      \verb{doi}
      \verb 10.1038/nrd3681
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Scannell et al. - 2012 - Diagnosing the decline in pharmaceutical R{\&}D efficiency.pdf:pdf
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1038/nrd3681
      \endverb
    \endentry
    \entry{Sliwoski2014}{article}{}
      \name{labelname}{4}{}{%
        {{hash=4b72c860300008db45ec8dae84b81b6d}{Sliwoski}{S\bibinitperiod}{Gregory}{G\bibinitperiod}{}{}{}{}}%
        {{hash=58f90429c84a9d8496428bfcfed58f15}{Kothiwale}{K\bibinitperiod}{Sandeepkumar}{S\bibinitperiod}{}{}{}{}}%
        {{hash=26b1ee76f095f43650e27a349d54e2dc}{Meiler}{M\bibinitperiod}{Jens}{J\bibinitperiod}{}{}{}{}}%
        {{hash=1894d4b0a31806b728983bf32041617f}{Lowe}{L\bibinitperiod}{Edward\bibnamedelima W}{E\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=4b72c860300008db45ec8dae84b81b6d}{Sliwoski}{S\bibinitperiod}{Gregory}{G\bibinitperiod}{}{}{}{}}%
        {{hash=58f90429c84a9d8496428bfcfed58f15}{Kothiwale}{K\bibinitperiod}{Sandeepkumar}{S\bibinitperiod}{}{}{}{}}%
        {{hash=26b1ee76f095f43650e27a349d54e2dc}{Meiler}{M\bibinitperiod}{Jens}{J\bibinitperiod}{}{}{}{}}%
        {{hash=1894d4b0a31806b728983bf32041617f}{Lowe}{L\bibinitperiod}{Edward\bibnamedelima W}{E\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{8ee8ee539dc8e3ec7eed19c478dd9f0e}
      \strng{fullhash}{27770022ff03415f231ba4291b0f85b5}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Computational Methods in Drug Discovery}}
      \field{number}{January}
      \field{title}{{Computational Methods in Drug Discovery}}
      \field{year}{2014}
      \field{pages}{334\bibrangedash 395}
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Sliwoski et al. - 2014 - Computational Methods in Drug Discovery.pdf:pdf
      \endverb
    \endentry
    \entry{Yang2009}{article}{}
      \name{labelname}{3}{}{%
        {{hash=2d98df2198aa3bf03b8bd576c1004d84}{Yang}{Y\bibinitperiod}{Yongliang}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=f679baa07793b941fa308dc9844d8d6a}{Adelstein}{A\bibinitperiod}{S.\bibnamedelimi James}{S\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=5fa6ef59d0a6bd6225c42d516cbb0747}{Kassis}{K\bibinitperiod}{Amin\bibnamedelima I.}{A\bibinitperiod\bibinitdelim I\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=2d98df2198aa3bf03b8bd576c1004d84}{Yang}{Y\bibinitperiod}{Yongliang}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=f679baa07793b941fa308dc9844d8d6a}{Adelstein}{A\bibinitperiod}{S.\bibnamedelimi James}{S\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=5fa6ef59d0a6bd6225c42d516cbb0747}{Kassis}{K\bibinitperiod}{Amin\bibnamedelima I.}{A\bibinitperiod\bibinitdelim I\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{4a70b9a937ed48a12bb0131e86595b43}
      \strng{fullhash}{4a70b9a937ed48a12bb0131e86595b43}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Target discovery from data mining approaches}}
      \field{abstract}{Data mining of available biomedical data and information has greatly boosted target discovery in the 'omics' era. Target discovery is the key step in the biomarker and drug discovery pipeline to diagnose and fight human diseases. In biomedical science, the 'target' is a broad concept ranging from molecular entities (such as genes, proteins and miRNAs) to biological phenomena (such as molecular functions, pathways and phenotypes). Within the context of biomedical science, data mining refers to a bioinformatics approach that combines biological concepts with computer tools or statistical methods that are mainly used to discover, select and prioritize targets. In response to the huge demand of data mining for target discovery in the 'omics' era, this review explicates various data mining approaches and their applications to target discovery with emphasis on text and microarray data analysis. Two emerging data mining approaches, chemogenomic data mining and proteomic data mining, are briefly introduced. Also discussed are the limitations of various data mining approaches found in the level of database integration, the quality of data annotation, sample heterogeneity and the performance of analytical and mining tools. Tentative strategies of integrating different data sources for target discovery, such as integrated text mining with high-throughput data analysis and integrated mining with pathway databases, are introduced.}
      \field{isbn}{1878-5832 (Electronic)$\backslash$r1359-6446 (Linking)}
      \field{issn}{13596446}
      \field{journaltitle}{Drug Discovery Today}
      \field{number}{3-4}
      \field{title}{{Target discovery from data mining approaches}}
      \field{volume}{14}
      \field{year}{2009}
      \field{pages}{147\bibrangedash 154}
      \verb{doi}
      \verb 10.1016/j.drudis.2008.12.005
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/1-s2.0-S1359644608004133-main.pdf:pdf
      \endverb
    \endentry
    \entry{predict}{misc}{}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{PREDICT: a method for inferring novel drug indications with application to personalized medicine}}
      \field{title}{{PREDICT: a method for inferring novel drug indications with application to personalized medicine}}
    \endentry
    \entry{Zhang2011}{article}{}
      \name{labelname}{5}{}{%
        {{hash=922b74338e14a4c81b03a7487c18522b}{Zhang}{Z\bibinitperiod}{M}{M\bibinitperiod}{}{}{}{}}%
        {{hash=9c4f74447bd064e137b853534877a881}{Zhu}{Z\bibinitperiod}{C}{C\bibinitperiod}{}{}{}{}}%
        {{hash=fd2da39b0bac9019c7c792d123b2a20f}{Jacomy}{J\bibinitperiod}{A}{A\bibinitperiod}{}{}{}{}}%
        {{hash=770b46a0ab1ecc2cd8f72f396a95c6d9}{Lu}{L\bibinitperiod}{L\bibnamedelima J}{L\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=d52cad485c9a2636b603840bbf05271f}{Jegga}{J\bibinitperiod}{A\bibnamedelima G}{A\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{5}{}{%
        {{hash=922b74338e14a4c81b03a7487c18522b}{Zhang}{Z\bibinitperiod}{M}{M\bibinitperiod}{}{}{}{}}%
        {{hash=9c4f74447bd064e137b853534877a881}{Zhu}{Z\bibinitperiod}{C}{C\bibinitperiod}{}{}{}{}}%
        {{hash=fd2da39b0bac9019c7c792d123b2a20f}{Jacomy}{J\bibinitperiod}{A}{A\bibinitperiod}{}{}{}{}}%
        {{hash=770b46a0ab1ecc2cd8f72f396a95c6d9}{Lu}{L\bibinitperiod}{L\bibnamedelima J}{L\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=d52cad485c9a2636b603840bbf05271f}{Jegga}{J\bibinitperiod}{A\bibnamedelima G}{A\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{0ac61aa61d59b1cc2166a7777538626d}
      \strng{fullhash}{7220fbdfab8f0dc92e69d7c2f4f1b63b}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{The orphan disease networks}}
      \field{journaltitle}{Am J Hum Genet}
      \field{title}{{The orphan disease networks}}
      \field{volume}{88}
      \field{year}{2011}
      \verb{doi}
      \verb 10.1016/j.ajhg.2011.05.006
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1016/j.ajhg.2011.05.006
      \endverb
    \endentry
    \entry{YutakaFukuoka2013}{article}{}
      \name{labelname}{2}{}{%
        {{hash=7ff2181b937c079f5f6ae90e299d0484}{{Yutaka\bibnamedelimb Fukuoka}}{Y\bibinitperiod}{D\bibnamedelima T}{D\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=4f445702a463193accf05d949e14c770}{Hisamichi}{H\bibinitperiod}{O\bibnamedelima g.\bibnamedelimi a.\bibnamedelimi w.\bibnamedelimi a.}{O\bibinitperiod\bibinitdelim g\bibinitperiod\bibinitdelim a\bibinitperiod\bibinitdelim w\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=7ff2181b937c079f5f6ae90e299d0484}{{Yutaka\bibnamedelimb Fukuoka}}{Y\bibinitperiod}{D\bibnamedelima T}{D\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=4f445702a463193accf05d949e14c770}{Hisamichi}{H\bibinitperiod}{O\bibnamedelima g.\bibnamedelimi a.\bibnamedelimi w.\bibnamedelimi a.}{O\bibinitperiod\bibinitdelim g\bibinitperiod\bibinitdelim a\bibinitperiod\bibinitdelim w\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{251b2e9209f5e64a31b2ac1c0ce1cc5a}
      \strng{fullhash}{251b2e9209f5e64a31b2ac1c0ce1cc5a}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{A two-step drug repositioning method based on a protein-protein interaction network of genes shared by two diseases and the similarity of drugs}}
      \field{journaltitle}{Bioinformation}
      \field{title}{{A two-step drug repositioning method based on a protein-protein interaction network of genes shared by two diseases and the similarity of drugs}}
      \field{volume}{9}
      \field{year}{2013}
      \verb{doi}
      \verb 10.6026/97320630009089
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.6026/97320630009089
      \endverb
    \endentry
    \entry{Raman2008}{article}{}
      \name{labelname}{2}{}{%
        {{hash=059e831bb53855ce1b1223bae01bbe86}{Raman}{R\bibinitperiod}{K}{K\bibinitperiod}{}{}{}{}}%
        {{hash=3a1567ea429d962cf6a5e13bafa47f4c}{Chandra}{C\bibinitperiod}{N}{N\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=059e831bb53855ce1b1223bae01bbe86}{Raman}{R\bibinitperiod}{K}{K\bibinitperiod}{}{}{}{}}%
        {{hash=3a1567ea429d962cf6a5e13bafa47f4c}{Chandra}{C\bibinitperiod}{N}{N\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{c6910bb9d7b410a664066360979bbcf6}
      \strng{fullhash}{c6910bb9d7b410a664066360979bbcf6}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Mycobacterium tuberculosis interactome analysis unravels potential pathways to drug resistance}}
      \field{journaltitle}{BMC Microbiology}
      \field{title}{{Mycobacterium tuberculosis interactome analysis unravels potential pathways to drug resistance}}
      \field{volume}{8}
      \field{year}{2008}
    \endentry
    \entry{Phaiphinit2016}{article}{}
      \name{labelname}{4}{}{%
        {{hash=e5ed77ddbbf18ff43ab9dc731da8c143}{Phaiphinit}{P\bibinitperiod}{Suthat}{S\bibinitperiod}{}{}{}{}}%
        {{hash=915cbf3f1cfddbc79bc362f13cdf5b16}{Pattaradilokrat}{P\bibinitperiod}{Sittiporn}{S\bibinitperiod}{}{}{}{}}%
        {{hash=8cdca83642a199ccac594a23d984a5f5}{Lursinsap}{L\bibinitperiod}{Chidchanok}{C\bibinitperiod}{}{}{}{}}%
        {{hash=8bf664d45f580dc651a9430da44b9877}{Plaimas}{P\bibinitperiod}{Kitiporn}{K\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=e5ed77ddbbf18ff43ab9dc731da8c143}{Phaiphinit}{P\bibinitperiod}{Suthat}{S\bibinitperiod}{}{}{}{}}%
        {{hash=915cbf3f1cfddbc79bc362f13cdf5b16}{Pattaradilokrat}{P\bibinitperiod}{Sittiporn}{S\bibinitperiod}{}{}{}{}}%
        {{hash=8cdca83642a199ccac594a23d984a5f5}{Lursinsap}{L\bibinitperiod}{Chidchanok}{C\bibinitperiod}{}{}{}{}}%
        {{hash=8bf664d45f580dc651a9430da44b9877}{Plaimas}{P\bibinitperiod}{Kitiporn}{K\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{42361eb902dda635feb087312bffdd95}
      \strng{fullhash}{d43bf1a2d16b52f8b42afb9d63ced04b}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{In silico multiple-targets identification for heme detoxification in the human malaria parasite Plasmodium falciparum}}
      \field{issn}{1567-1348}
      \field{journaltitle}{Infection, Genetics and Evolution}
      \field{month}{01}
      \field{title}{{In silico multiple-targets identification for heme detoxification in the human malaria parasite Plasmodium falciparum}}
      \field{volume}{37}
      \field{year}{2016}
      \field{pages}{237\bibrangedash 244}
      \verb{doi}
      \verb http://dx.doi.org/10.1016/j.meegid.2015.11.025
      \endverb
      \verb{url}
      \verb http://www.sciencedirect.com/science/article/pii/S1567134815300551
      \endverb
    \endentry
    \entry{Jeon2014}{article}{}
      \name{labelname}{8}{}{%
        {{hash=0bbcbd2ef5dd87550374f54bc88ee251}{Jeon}{J\bibinitperiod}{Jouhyun}{J\bibinitperiod}{}{}{}{}}%
        {{hash=fa91ad558556dc32d1088c177961236f}{Nim}{N\bibinitperiod}{Satra}{S\bibinitperiod}{}{}{}{}}%
        {{hash=0ae5567bddd0faad885a9e2c240038be}{Teyra}{T\bibinitperiod}{Joan}{J\bibinitperiod}{}{}{}{}}%
        {{hash=131347f30ebd8eae2646981716c60166}{Datti}{D\bibinitperiod}{Alessandro}{A\bibinitperiod}{}{}{}{}}%
        {{hash=d7a174b422ffe9ba5cb16c66f91b6783}{Wrana}{W\bibinitperiod}{Jeffrey\bibnamedelima L}{J\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=f3ecd7ac05beb6f1477644abc12c9859}{Sidhu}{S\bibinitperiod}{Sachdev\bibnamedelima S}{S\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=37c4fced035824080cfd955b315fcf34}{Moffat}{M\bibinitperiod}{Jason}{J\bibinitperiod}{}{}{}{}}%
        {{hash=9adc2c77fe970ba23f5da498e6a6748c}{Kim}{K\bibinitperiod}{Philip\bibnamedelima M}{P\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{8}{}{%
        {{hash=0bbcbd2ef5dd87550374f54bc88ee251}{Jeon}{J\bibinitperiod}{Jouhyun}{J\bibinitperiod}{}{}{}{}}%
        {{hash=fa91ad558556dc32d1088c177961236f}{Nim}{N\bibinitperiod}{Satra}{S\bibinitperiod}{}{}{}{}}%
        {{hash=0ae5567bddd0faad885a9e2c240038be}{Teyra}{T\bibinitperiod}{Joan}{J\bibinitperiod}{}{}{}{}}%
        {{hash=131347f30ebd8eae2646981716c60166}{Datti}{D\bibinitperiod}{Alessandro}{A\bibinitperiod}{}{}{}{}}%
        {{hash=d7a174b422ffe9ba5cb16c66f91b6783}{Wrana}{W\bibinitperiod}{Jeffrey\bibnamedelima L}{J\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=f3ecd7ac05beb6f1477644abc12c9859}{Sidhu}{S\bibinitperiod}{Sachdev\bibnamedelima S}{S\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=37c4fced035824080cfd955b315fcf34}{Moffat}{M\bibinitperiod}{Jason}{J\bibinitperiod}{}{}{}{}}%
        {{hash=9adc2c77fe970ba23f5da498e6a6748c}{Kim}{K\bibinitperiod}{Philip\bibnamedelima M}{P\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{7c461db0d4499d9c0fbf087d8bbfb76c}
      \strng{fullhash}{5dee8c21e13c0801e4f733a102a0f8fb}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{A systematic approach to identify novel cancer drug targets using machine learning, inhibitor design and high-throughput screening}}
      \field{abstract}{We present an integrated approach that predicts and validates novel anti-cancer drug targets. We first built a classifier that integrates a variety of genomic and systematic datasets to prioritize drug targets specific for breast, pancreatic and ovarian cancer. We then devised strategies to inhibit these anti-cancer drug targets and selected a set of targets that are amenable to inhibition by small molecules, antibodies and synthetic peptides. We validated the predicted drug targets by showing strong anti-proliferative effects of both synthetic peptide and small molecule inhibitors against our predicted targets.}
      \field{issn}{1756-994X}
      \field{journaltitle}{Genome Medicine}
      \field{number}{7}
      \field{title}{{A systematic approach to identify novel cancer drug targets using machine learning, inhibitor design and high-throughput screening}}
      \field{volume}{6}
      \field{year}{2014}
      \field{pages}{1\bibrangedash 18}
      \verb{doi}
      \verb 10.1186/s13073-014-0057-7
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1186/s13073-014-0057-7
      \endverb
    \endentry
    \entry{Augustin2012}{article}{}
      \name{labelname}{8}{}{%
        {{hash=f4c3f007e64456fd3e21baff78f54b45}{Augustin}{A\bibinitperiod}{Regina}{R\bibinitperiod}{}{}{}{}}%
        {{hash=f1d9d1d92014214edb3eb43c9465f889}{Endres}{E\bibinitperiod}{Kristina}{K\bibinitperiod}{}{}{}{}}%
        {{hash=a888634c7e54a5c7dc9e9e9e8d757768}{Reinhardt}{R\bibinitperiod}{Sven}{S\bibinitperiod}{}{}{}{}}%
        {{hash=23f5b35687a70026c45beaeaac63bb12}{Kuhn}{K\bibinitperiod}{Peer-Hendrik}{P\bibinithyphendelim H\bibinitperiod}{}{}{}{}}%
        {{hash=d5b0de48d76049730d1120d8da0901e0}{Lichtenthaler}{L\bibinitperiod}{Stefan\bibnamedelima F}{S\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{hash=2ea2c73d8388a5bf85d22232b986b28b}{Hansen}{H\bibinitperiod}{Jens}{J\bibinitperiod}{}{}{}{}}%
        {{hash=39f0264772b09e386b77fb16f7814c46}{Wurst}{W\bibinitperiod}{Wolfgang}{W\bibinitperiod}{}{}{}{}}%
        {{hash=b7a2bfdc63606d74ab85e02ecc423c2a}{Tr{\"{u}}mbach}{T\bibinitperiod}{Dietrich}{D\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{8}{}{%
        {{hash=f4c3f007e64456fd3e21baff78f54b45}{Augustin}{A\bibinitperiod}{Regina}{R\bibinitperiod}{}{}{}{}}%
        {{hash=f1d9d1d92014214edb3eb43c9465f889}{Endres}{E\bibinitperiod}{Kristina}{K\bibinitperiod}{}{}{}{}}%
        {{hash=a888634c7e54a5c7dc9e9e9e8d757768}{Reinhardt}{R\bibinitperiod}{Sven}{S\bibinitperiod}{}{}{}{}}%
        {{hash=23f5b35687a70026c45beaeaac63bb12}{Kuhn}{K\bibinitperiod}{Peer-Hendrik}{P\bibinithyphendelim H\bibinitperiod}{}{}{}{}}%
        {{hash=d5b0de48d76049730d1120d8da0901e0}{Lichtenthaler}{L\bibinitperiod}{Stefan\bibnamedelima F}{S\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{hash=2ea2c73d8388a5bf85d22232b986b28b}{Hansen}{H\bibinitperiod}{Jens}{J\bibinitperiod}{}{}{}{}}%
        {{hash=39f0264772b09e386b77fb16f7814c46}{Wurst}{W\bibinitperiod}{Wolfgang}{W\bibinitperiod}{}{}{}{}}%
        {{hash=b7a2bfdc63606d74ab85e02ecc423c2a}{Tr{\"{u}}mbach}{T\bibinitperiod}{Dietrich}{D\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{27ab1d2fe1a1f3949c13cfef9478bc6f}
      \strng{fullhash}{1de2a36306ce71a308b45e5c5a1d14fb}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Computational identification and experimental validation of microRNAs binding to the Alzheimer-related gene ADAM10}}
      \field{abstract}{MicroRNAs (miRNAs) are post-transcriptional regulators involved in numerous biological processes including the pathogenesis of Alzheimer's disease (AD). A key gene of AD, ADAM10, controls the proteolytic processing of APP and the formation of the amyloid plaques and is known to be regulated by miRNA in hepatic cancer cell lines. To predict miRNAs regulating ADAM10 expression concerning AD, we developed a computational approach.}
      \field{issn}{1471-2350}
      \field{journaltitle}{BMC Medical Genetics}
      \field{number}{1}
      \field{title}{{Computational identification and experimental validation of microRNAs binding to the Alzheimer-related gene ADAM10}}
      \field{volume}{13}
      \field{year}{2012}
      \field{pages}{1\bibrangedash 12}
      \verb{doi}
      \verb 10.1186/1471-2350-13-35
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1186/1471-2350-13-35
      \endverb
    \endentry
    \entry{Martinez-Jimenez2013}{article}{}
      \name{labelname}{10}{}{%
        {{hash=9f1694dcbbd71d71a2b23228fee9da83}{Mart{\'{\i}}nez-Jim{\'{e}}nez}{M\bibinithyphendelim J\bibinitperiod}{Francisco}{F\bibinitperiod}{}{}{}{}}%
        {{hash=d0d9d6fafa34670d65fe13aa0977dbe6}{Papadatos}{P\bibinitperiod}{George}{G\bibinitperiod}{}{}{}{}}%
        {{hash=8b737472161f9411595cc50369d7322c}{Yang}{Y\bibinitperiod}{Lun}{L\bibinitperiod}{}{}{}{}}%
        {{hash=afeee9102ae93cefcca6135bb08c25c1}{Wallace}{W\bibinitperiod}{Iain\bibnamedelima M.}{I\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=08a43e8ef8e3a2d464e9e8800f2ab3c9}{Kumar}{K\bibinitperiod}{Vinod}{V\bibinitperiod}{}{}{}{}}%
        {{hash=ed697f1b151831b61b4a519f41fdb295}{Pieper}{P\bibinitperiod}{Ursula}{U\bibinitperiod}{}{}{}{}}%
        {{hash=f3bdee19cfffe5535eb11a4f1ee54225}{Sali}{S\bibinitperiod}{Andrej}{A\bibinitperiod}{}{}{}{}}%
        {{hash=7eaedf0fe73ed481fe8ca70fe96db5f9}{Brown}{B\bibinitperiod}{James\bibnamedelima R.}{J\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=e4e933dff0b707e6aa02a1448b3f48af}{Overington}{O\bibinitperiod}{John\bibnamedelima P.}{J\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=a0f6156def7676c24698f54ed6b75e41}{Marti-Renom}{M\bibinithyphendelim R\bibinitperiod}{Marc\bibnamedelima a.}{M\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{10}{}{%
        {{hash=9f1694dcbbd71d71a2b23228fee9da83}{Mart{\'{\i}}nez-Jim{\'{e}}nez}{M\bibinithyphendelim J\bibinitperiod}{Francisco}{F\bibinitperiod}{}{}{}{}}%
        {{hash=d0d9d6fafa34670d65fe13aa0977dbe6}{Papadatos}{P\bibinitperiod}{George}{G\bibinitperiod}{}{}{}{}}%
        {{hash=8b737472161f9411595cc50369d7322c}{Yang}{Y\bibinitperiod}{Lun}{L\bibinitperiod}{}{}{}{}}%
        {{hash=afeee9102ae93cefcca6135bb08c25c1}{Wallace}{W\bibinitperiod}{Iain\bibnamedelima M.}{I\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=08a43e8ef8e3a2d464e9e8800f2ab3c9}{Kumar}{K\bibinitperiod}{Vinod}{V\bibinitperiod}{}{}{}{}}%
        {{hash=ed697f1b151831b61b4a519f41fdb295}{Pieper}{P\bibinitperiod}{Ursula}{U\bibinitperiod}{}{}{}{}}%
        {{hash=f3bdee19cfffe5535eb11a4f1ee54225}{Sali}{S\bibinitperiod}{Andrej}{A\bibinitperiod}{}{}{}{}}%
        {{hash=7eaedf0fe73ed481fe8ca70fe96db5f9}{Brown}{B\bibinitperiod}{James\bibnamedelima R.}{J\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=e4e933dff0b707e6aa02a1448b3f48af}{Overington}{O\bibinitperiod}{John\bibnamedelima P.}{J\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=a0f6156def7676c24698f54ed6b75e41}{Marti-Renom}{M\bibinithyphendelim R\bibinitperiod}{Marc\bibnamedelima a.}{M\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
      }
      \name{editor}{1}{}{%
        {{hash=41e57eef71f3ac9e59df91591a0eef68}{MacKerell}{M\bibinitperiod}{Alexander\bibnamedelima Donald}{A\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{c4595e912fd12973b6d1290fbc255c59}
      \strng{fullhash}{9f652e7aaece5cbb7e9e7eefdc8d6da0}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Target Prediction for an Open Access Set of Compounds Active against Mycobacterium tuberculosis}}
      \field{issn}{1553-7358}
      \field{journaltitle}{PLoS Computational Biology}
      \field{month}{10}
      \field{number}{10}
      \field{title}{{Target Prediction for an Open Access Set of Compounds Active against Mycobacterium tuberculosis}}
      \field{volume}{9}
      \field{year}{2013}
      \field{pages}{e1003253}
      \verb{doi}
      \verb 10.1371/journal.pcbi.1003253
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Mart{\'{\i}}nez-Jim{\'{e}}nez et al. - 2013 - Target Prediction for an Open Access Set of Compounds Active against Mycobacterium tuberculosis.pdf:pdf
      \endverb
      \verb{url}
      \verb http://dx.plos.org/10.1371/journal.pcbi.1003253
      \endverb
    \endentry
    \entry{Perkins2003}{article}{}
      \name{labelname}{4}{}{%
        {{hash=93a6b9064c4ba4ae360171f4dba83592}{Perkins}{P\bibinitperiod}{Roger}{R\bibinitperiod}{}{}{}{}}%
        {{hash=daeda31120dc0a0452eabb3c271893e1}{Fang}{F\bibinitperiod}{Hong}{H\bibinitperiod}{}{}{}{}}%
        {{hash=50b19a795924bc4d7edf515869228fdb}{Tong}{T\bibinitperiod}{Weida}{W\bibinitperiod}{}{}{}{}}%
        {{hash=9d6b5c73cc393314dd90d2c84a91a96f}{Welsh}{W\bibinitperiod}{William\bibnamedelima J}{W\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=93a6b9064c4ba4ae360171f4dba83592}{Perkins}{P\bibinitperiod}{Roger}{R\bibinitperiod}{}{}{}{}}%
        {{hash=daeda31120dc0a0452eabb3c271893e1}{Fang}{F\bibinitperiod}{Hong}{H\bibinitperiod}{}{}{}{}}%
        {{hash=50b19a795924bc4d7edf515869228fdb}{Tong}{T\bibinitperiod}{Weida}{W\bibinitperiod}{}{}{}{}}%
        {{hash=9d6b5c73cc393314dd90d2c84a91a96f}{Welsh}{W\bibinitperiod}{William\bibnamedelima J}{W\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{a3e22706c755f53be5aa3f1fc9f1e301}
      \strng{fullhash}{978f1ced5a8d72c3b27e0b1710978734}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Quantitative structure-activity relationship methods: perspectives on drug discovery and toxicology.}}
      \field{abstract}{Quantitative structure-activity relationships (QSARs) attempt to correlate chemical structure with activity using statistical approaches. The QSAR models are useful for various purposes including the prediction of activities of untested chemicals. Quantitative structure-activity relationships and other related approaches have attracted broad scientific interest, particularly in the pharmaceutical industry for drug discovery and in toxicology and environmental science for risk assessment. An assortment of new QSAR methods have been developed during the past decade, most of them focused on drug discovery. Besides advancing our fundamental knowledge of QSARs, these scientific efforts have stimulated their application in a wider range of disciplines, such as toxicology, where QSARs have not yet gained full appreciation. In this review, we attempt to summarize the status of QSAR with emphasis on illuminating the utility and limitations of QSAR technology. We will first review two-dimensional (2D) QSAR with a discussion of the availability and appropriate selection of molecular descriptors. We will then proceed to describe three-dimensional (3D) QSAR and key issues associated with this technology, then compare the relative suitability of 2D and 3D QSAR for different applications. Given the recent technological advances in biological research for rapid identification of drug targets, we mention several examples in which QSAR approaches are employed in conjunction with improved knowledge of the structure and function of the target receptor. The review will conclude by discussing statistical validation of QSAR models, a topic that has received sparse attention in recent years despite its critical importance.}
      \field{isbn}{0730-7268}
      \field{issn}{1092-874X}
      \field{journaltitle}{Environmental toxicology and chemistry / SETAC}
      \field{number}{8}
      \field{title}{{Quantitative structure-activity relationship methods: perspectives on drug discovery and toxicology.}}
      \field{volume}{22}
      \field{year}{2003}
      \field{pages}{1666\bibrangedash 1679}
      \verb{doi}
      \verb 10.1897/01-171
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/5620220803{\_}ftp.pdf:pdf
      \endverb
    \endentry
    \entry{Penzotti2004}{article}{}
      \name{labelname}{3}{}{%
        {{hash=38f22595d16d6c5cc281e7764b7a8e74}{Penzotti}{P\bibinitperiod}{Julie\bibnamedelima E}{J\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=aa786c6f173bc576888dd16bd420ad27}{Landrum}{L\bibinitperiod}{Gregory\bibnamedelima A}{G\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=90a663a593b89a86a84aecfaa3d93a43}{Putta}{P\bibinitperiod}{Santosh}{S\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=38f22595d16d6c5cc281e7764b7a8e74}{Penzotti}{P\bibinitperiod}{Julie\bibnamedelima E}{J\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=aa786c6f173bc576888dd16bd420ad27}{Landrum}{L\bibinitperiod}{Gregory\bibnamedelima A}{G\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=90a663a593b89a86a84aecfaa3d93a43}{Putta}{P\bibinitperiod}{Santosh}{S\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{3266b94a9237736c603a243f2cdcb61d}
      \strng{fullhash}{3266b94a9237736c603a243f2cdcb61d}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Building predictive ADMET models for early decisions in drug discovery}}
      \field{issn}{1367-6733}
      \field{journaltitle}{Current opinion in drug discovery {\&} development}
      \field{month}{01}
      \field{number}{1}
      \field{title}{{Building predictive ADMET models for early decisions in drug discovery}}
      \field{volume}{7}
      \field{year}{2004}
      \field{pages}{49\bibrangedash 61}
      \verb{url}
      \verb http://europepmc.org/abstract/MED/14982148
      \endverb
    \endentry
    \entry{Obrezanova2007}{article}{}
      \name{labelname}{4}{}{%
        {{hash=456ba92b104ba4d7c7ba0e5e22746ed5}{Obrezanova}{O\bibinitperiod}{Olga}{O\bibinitperiod}{}{}{}{}}%
        {{hash=fc446f82b9fe56cf46041ff1e8828309}{Cs{\'{a}}nyi}{C\bibinitperiod}{G{\'{a}}bor}{G\bibinitperiod}{}{}{}{}}%
        {{hash=b678a582e926cffdfd575b2e798e45db}{Gola}{G\bibinitperiod}{Joelle\bibnamedelimb M\bibnamedelima R}{J\bibinitperiod\bibinitdelim M\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=fbfb1c3587a7bbd308400d55877ec2f1}{Segall}{S\bibinitperiod}{Matthew\bibnamedelima D}{M\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=456ba92b104ba4d7c7ba0e5e22746ed5}{Obrezanova}{O\bibinitperiod}{Olga}{O\bibinitperiod}{}{}{}{}}%
        {{hash=fc446f82b9fe56cf46041ff1e8828309}{Cs{\'{a}}nyi}{C\bibinitperiod}{G{\'{a}}bor}{G\bibinitperiod}{}{}{}{}}%
        {{hash=b678a582e926cffdfd575b2e798e45db}{Gola}{G\bibinitperiod}{Joelle\bibnamedelimb M\bibnamedelima R}{J\bibinitperiod\bibinitdelim M\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=fbfb1c3587a7bbd308400d55877ec2f1}{Segall}{S\bibinitperiod}{Matthew\bibnamedelima D}{M\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {American Chemical Society}%
      }
      \strng{namehash}{d283ac5d758854ffb61c9d3fcf4514b3}
      \strng{fullhash}{f3723e8f8ea576e85c41c473c2ad878b}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Gaussian Processes: A Method for Automatic QSAR Modeling of ADME Properties}}
      \field{annotation}{doi: 10.1021/ci7000633}
      \field{issn}{1549-9596}
      \field{journaltitle}{Journal of Chemical Information and Modeling}
      \field{month}{09}
      \field{number}{5}
      \field{title}{{Gaussian Processes: A Method for Automatic QSAR Modeling of ADME Properties}}
      \field{volume}{47}
      \field{year}{2007}
      \field{pages}{1847\bibrangedash 1857}
      \verb{doi}
      \verb 10.1021/ci7000633
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1021/ci7000633
      \endverb
    \endentry
    \entry{Yoshida2000}{article}{}
      \name{labelname}{2}{}{%
        {{hash=8a8c5fdcb9640b2d39d99f6264bf7403}{Yoshida}{Y\bibinitperiod}{Fumitaka}{F\bibinitperiod}{}{}{}{}}%
        {{hash=5d795b56025859873fe1a139fd0f4d96}{Topliss}{T\bibinitperiod}{John\bibnamedelima G}{J\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=8a8c5fdcb9640b2d39d99f6264bf7403}{Yoshida}{Y\bibinitperiod}{Fumitaka}{F\bibinitperiod}{}{}{}{}}%
        {{hash=5d795b56025859873fe1a139fd0f4d96}{Topliss}{T\bibinitperiod}{John\bibnamedelima G}{J\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {American Chemical Society}%
      }
      \strng{namehash}{f0b9c2ea6c0c4cfdb865df1139ef4d72}
      \strng{fullhash}{f0b9c2ea6c0c4cfdb865df1139ef4d72}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{QSAR Model for Drug Human Oral Bioavailability}}
      \field{annotation}{doi: 10.1021/jm0000564}
      \field{issn}{0022-2623}
      \field{journaltitle}{Journal of Medicinal Chemistry}
      \field{month}{06}
      \field{number}{13}
      \field{title}{{QSAR Model for Drug Human Oral Bioavailability}}
      \field{volume}{43}
      \field{year}{2000}
      \field{pages}{2575\bibrangedash 2585}
      \verb{doi}
      \verb 10.1021/jm0000564
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1021/jm0000564
      \endverb
    \endentry
    \entry{Verma2010}{article}{}
      \name{labelname}{3}{}{%
        {{hash=490d387acf664c6cad74c3b5674d4528}{Verma}{V\bibinitperiod}{Jitender}{J\bibinitperiod}{}{}{}{}}%
        {{hash=6dce28ee747b135ed562325fcb7c9c40}{Khedkar}{K\bibinitperiod}{Vijay\bibnamedelima M.}{V\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=6b264a1bf78d58d121eb4791382d93d1}{Coutinho}{C\bibinitperiod}{Evans\bibnamedelima C.}{E\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=490d387acf664c6cad74c3b5674d4528}{Verma}{V\bibinitperiod}{Jitender}{J\bibinitperiod}{}{}{}{}}%
        {{hash=6dce28ee747b135ed562325fcb7c9c40}{Khedkar}{K\bibinitperiod}{Vijay\bibnamedelima M.}{V\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=6b264a1bf78d58d121eb4791382d93d1}{Coutinho}{C\bibinitperiod}{Evans\bibnamedelima C.}{E\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{1aafa1ec9835a8d2f7b83f3c63ec8e3c}
      \strng{fullhash}{1aafa1ec9835a8d2f7b83f3c63ec8e3c}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{3D-QSAR in Drug Design}}
      \field{abstract}{Quantitative structure-activity relationships (QSAR) have been applied for decades in the development of relationships between physicochemical properties of chemical substances and their biological activities to obtain a reliable statistical model for prediction of the activities of new chemical entities. The fundamental principle underlying the formalism is that the difference in structural properties is responsible for the variations in biological activities of the compounds. In the classical QSAR studies, affinities of ligands to their binding sites, inhibition constants, rate constants, and other biological end points, with atomic, group or molecular properties such as lipophilicity, polarizability, electronic and steric properties (Hansch analysis) or with certain structural features (Free-Wilson analysis) have been correlated. However such an approach has only a limited utility for designing a new molecule due to the lack of consideration of the 3D structure of the molecules. 3D-QSAR has emerged as a natural extension to the classical Hansch and Free-Wilson approaches, which exploits the three-dimensional properties of the ligands to predict their biological activities using robust chemometric techniques such as PLS, G/PLS, ANN etc. It has served as a valuable predictive tool in the design of pharmaceuticals and agrochemicals. Although the trial and error factor involved in the development of a new drug cannot be ignored completely, QSAR certainly decreases the number of compounds to be synthesized by facilitating the selection of the most promising candidates. Several success stories of QSAR have attracted the medicinal chemists to investigate the relationships of structural properties with biological activity. This review seeks to provide a bird's eye view of the different 3D-QSAR approaches employed within the current drug discovery community to construct predictive structure-activity relationships and also discusses the limitations that are fundamental to these approaches, as well as those that might be overcome with the improved strategies. The components involved in building a useful 3D-QSAR model are discussed, including the validation techniques available for this purpose.}
      \field{isbn}{1568-0266}
      \field{issn}{15680266}
      \field{journaltitle}{Current Topics in Medicinal Chemistry}
      \field{number}{1}
      \field{title}{{3D-QSAR in Drug Design}}
      \field{volume}{10}
      \field{year}{2010}
      \field{pages}{95\bibrangedash 115}
      \verb{doi}
      \verb 10.2174/156802610790232260
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/2010{\_}CTMC{\_}3D{\_}QSAR{\_}Review.pdf:pdf
      \endverb
    \endentry
    \entry{Cramer1988}{article}{}
      \name{labelname}{3}{}{%
        {{hash=7c96c92cf1e36e5a905da7a182862f73}{Cramer}{C\bibinitperiod}{R\bibnamedelima D}{R\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=725b72bfc786ce8d4c6aa6d0db2a9eca}{Patterson}{P\bibinitperiod}{D\bibnamedelima E}{D\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=7ff36b92b953e370cb5b8d6d2f6d5ff3}{Bunce}{B\bibinitperiod}{J\bibnamedelima D}{J\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=7c96c92cf1e36e5a905da7a182862f73}{Cramer}{C\bibinitperiod}{R\bibnamedelima D}{R\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=725b72bfc786ce8d4c6aa6d0db2a9eca}{Patterson}{P\bibinitperiod}{D\bibnamedelima E}{D\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=7ff36b92b953e370cb5b8d6d2f6d5ff3}{Bunce}{B\bibinitperiod}{J\bibnamedelima D}{J\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{e1f27be58dce3b83bdbd05d8bf887b94}
      \strng{fullhash}{e1f27be58dce3b83bdbd05d8bf887b94}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Comparative molecular field analysis (CoMFA)}}
      \field{abstract}{Comparative molecular field analysis (CoMFA) is a promising new approach to structure/activity correlation. Its characteristic features are (1) representation of ligand molecules by their steric and electrostatic fields, sampled at the intersections of a three-dimensional lattice, (2) a new "field fit{$\textquotedblright$} technique, allowing optimal mutual alignment within a series, by minimizing the RMS field differences between molecules, (3) data analysis by partial least squares (PLS), using cross-validation to maximize the likelihood that the results have predictive validity, and (4) graphic representation of results, as contoured three-dimensional coefficient plots. CoMFA is exemplified by analyses of the affinities of 21 varied steroids to corticosteroid- and testosterone-binding globulins. Also described are the sensitivities of results to the nature of the field and the definition of the lattice and, for comparison, analyses of the same data using various combinations of other parameters. From these results, a set of ten steroid-binding affinity values unknown to us during the CoMFA analysis were well predicted.}
      \field{isbn}{0002-7863 (Print)$\backslash$n0002-7863 (Linking)}
      \field{issn}{0002-7863}
      \field{journaltitle}{Journal of the American Chemical Society}
      \field{number}{18}
      \field{title}{{Comparative molecular field analysis (CoMFA)}}
      \field{volume}{110}
      \field{year}{1988}
      \field{pages}{5959\bibrangedash 5967}
      \verb{doi}
      \verb 10.1021/ja00226a005
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/ja00226a005.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/22148765
      \endverb
    \endentry
    \entry{Hopfinger1997}{article}{}
      \name{labelname}{7}{}{%
        {{hash=2dda2e0640d5a5cad16afa3e6e7db64d}{Hopfinger}{H\bibinitperiod}{A\bibnamedelima J}{A\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=2f2bb9422125d3f4e6a018760477a75e}{Wang}{W\bibinitperiod}{Shen}{S\bibinitperiod}{}{}{}{}}%
        {{hash=5e31da4d4a0b69c4cfe621baf8a22455}{Tokarski}{T\bibinitperiod}{John\bibnamedelima S}{J\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=e58fb480fe41d902c4833aef64fb209e}{Jin}{J\bibinitperiod}{Baiqiang}{B\bibinitperiod}{}{}{}{}}%
        {{hash=8cf843e5137701c8962e2719f8ffaeaf}{Albuquerque}{A\bibinitperiod}{Magaly}{M\bibinitperiod}{}{}{}{}}%
        {{hash=04337ce14b1653cfa67b4654554c92b2}{Madhav}{M\bibinitperiod}{Prakash\bibnamedelima J}{P\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=6daa0ddf57ef31532bd252cb6847f8bb}{Duraiswami}{D\bibinitperiod}{Chaya}{C\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{7}{}{%
        {{hash=2dda2e0640d5a5cad16afa3e6e7db64d}{Hopfinger}{H\bibinitperiod}{A\bibnamedelima J}{A\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=2f2bb9422125d3f4e6a018760477a75e}{Wang}{W\bibinitperiod}{Shen}{S\bibinitperiod}{}{}{}{}}%
        {{hash=5e31da4d4a0b69c4cfe621baf8a22455}{Tokarski}{T\bibinitperiod}{John\bibnamedelima S}{J\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=e58fb480fe41d902c4833aef64fb209e}{Jin}{J\bibinitperiod}{Baiqiang}{B\bibinitperiod}{}{}{}{}}%
        {{hash=8cf843e5137701c8962e2719f8ffaeaf}{Albuquerque}{A\bibinitperiod}{Magaly}{M\bibinitperiod}{}{}{}{}}%
        {{hash=04337ce14b1653cfa67b4654554c92b2}{Madhav}{M\bibinitperiod}{Prakash\bibnamedelima J}{P\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=6daa0ddf57ef31532bd252cb6847f8bb}{Duraiswami}{D\bibinitperiod}{Chaya}{C\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {American Chemical Society}%
      }
      \strng{namehash}{ec2d004ee532e0a88785ea95607cc964}
      \strng{fullhash}{ed74c6cc2eee5ad2eefd3f983b842d98}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Construction of 3D-QSAR Models Using the 4D-QSAR Analysis Formalism}}
      \field{annotation}{doi: 10.1021/ja9718937}
      \field{issn}{0002-7863}
      \field{journaltitle}{Journal of the American Chemical Society}
      \field{month}{10}
      \field{number}{43}
      \field{title}{{Construction of 3D-QSAR Models Using the 4D-QSAR Analysis Formalism}}
      \field{volume}{119}
      \field{year}{1997}
      \field{pages}{10509\bibrangedash 10524}
      \verb{doi}
      \verb 10.1021/ja9718937
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1021/ja9718937
      \endverb
    \endentry
    \entry{Ekins2000}{article}{}
      \name{labelname}{7}{}{%
        {{hash=5752f3a4325e2b3630c5d6a2fbf20203}{Ekins}{E\bibinitperiod}{Sean}{S\bibinitperiod}{}{}{}{}}%
        {{hash=18ca03abd85f692b5667f4bb09f63418}{Bravi}{B\bibinitperiod}{Gianpaolo}{G\bibinitperiod}{}{}{}{}}%
        {{hash=0a6da73a9b1724f1e7ef2eb7efc1a5b5}{Binkley}{B\bibinitperiod}{Shelly}{S\bibinitperiod}{}{}{}{}}%
        {{hash=d6f3f9848d030b0011df81901208bbd0}{Gillespie}{G\bibinitperiod}{Jennifer\bibnamedelima S}{J\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=50a37297a321d8ce109721c297ef455d}{Ring}{R\bibinitperiod}{Barbara\bibnamedelima J}{B\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=20649076d2d797eef2c9eb0345a6d392}{Wikel}{W\bibinitperiod}{James\bibnamedelima H}{J\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=0b9891ae2d4d3d5e726fddd8d807c66d}{Wrighton}{W\bibinitperiod}{Steven\bibnamedelima A}{S\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{7}{}{%
        {{hash=5752f3a4325e2b3630c5d6a2fbf20203}{Ekins}{E\bibinitperiod}{Sean}{S\bibinitperiod}{}{}{}{}}%
        {{hash=18ca03abd85f692b5667f4bb09f63418}{Bravi}{B\bibinitperiod}{Gianpaolo}{G\bibinitperiod}{}{}{}{}}%
        {{hash=0a6da73a9b1724f1e7ef2eb7efc1a5b5}{Binkley}{B\bibinitperiod}{Shelly}{S\bibinitperiod}{}{}{}{}}%
        {{hash=d6f3f9848d030b0011df81901208bbd0}{Gillespie}{G\bibinitperiod}{Jennifer\bibnamedelima S}{J\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=50a37297a321d8ce109721c297ef455d}{Ring}{R\bibinitperiod}{Barbara\bibnamedelima J}{B\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=20649076d2d797eef2c9eb0345a6d392}{Wikel}{W\bibinitperiod}{James\bibnamedelima H}{J\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=0b9891ae2d4d3d5e726fddd8d807c66d}{Wrighton}{W\bibinitperiod}{Steven\bibnamedelima A}{S\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{0f369f193e1ab7717e2185c2797e8a90}
      \strng{fullhash}{2aba0cf411b7bc672478fb3c45d2cc6f}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Three-and Four-Dimensional Quantitative Structure Activity Relationship (3D/4D-QSAR) Analyses of CYP2C9 Inhibitors}}
      \field{abstract}{The interaction of competitive type inhibitors with the active site of cytochrome P450 (CYP) 2C9 has been predicted using three- and four-dimensional quantitative structure activity relationship (3D-/4D-QSAR) models constructed using previously unreported and literature-derived data. 3D-QSAR pharmacophore models of the common structural features of CYP2C9 inhibitors were built using the program Catalyst and compared with 3D- and 4D-QSAR partial least-squares models, which use molecular surface-weighted holistic invariant molecular descriptors of the size and shape of inhibitors. The Catalyst models generated from multiple conformers of competitive inhibitors of CYP2C9 activities contained at least one hydrophobic and two hydrogen bond acceptor/donor regions. Catalyst model 1 was constructed with Ki(apparent) values for inhibitors of tolbutamide and diclofenac 4\x{2032}-hydroxylation (n = 9). Catalyst model 2 was generated from literature Ki(apparent) values for (S)-warfarin 7-hydroxylation (n = 29), and Catalyst model 3 from literature IC50 values for tolbutamide 4-hydroxylation (n = 13). These three models illustrated correlation values of observed and predicted inhibition for CYP2C9 of r = 0.91, 0.89, and 0.71, respectively. Catalyst pharmacophores generated withKi(apparent) values were validated by predicting the Ki(apparent) value of a test set of CYP2C9 inhibitors also derived from the literature (n = 14). Twelve of fourteen of theseKi(apparent) values were predicted to be within 1 log residual of the observed value using Catalyst model 1, whereas Catalyst model 2 predicted 10 of 14Ki(apparent) values. The corresponding partial least-squares molecular surface-weighted holistic invariant molecular 3D- and 4D-QSAR models for all CYP2C9 data sets yielded predictable models as assessed using cross-validation. These 3D- and 4D-QSAR models of CYP inhibition will aid in future prediction of drug-drug interactions.}
      \field{journaltitle}{Drug Metabolism and Disposition}
      \field{month}{08}
      \field{number}{8}
      \field{title}{{Three-and Four-Dimensional Quantitative Structure Activity Relationship (3D/4D-QSAR) Analyses of CYP2C9 Inhibitors}}
      \field{volume}{28}
      \field{year}{2000}
      \field{pages}{994\bibrangedash 1002}
      \verb{url}
      \verb http://dmd.aspetjournals.org/content/28/8/994.abstract
      \endverb
    \endentry
    \entry{Iyer2007}{article}{}
      \name{labelname}{2}{}{%
        {{hash=ec9c6ac53e43bc585db8f58df037639e}{Iyer}{I\bibinitperiod}{Manisha}{M\bibinitperiod}{}{}{}{}}%
        {{hash=2dda2e0640d5a5cad16afa3e6e7db64d}{Hopfinger}{H\bibinitperiod}{A\bibnamedelima J}{A\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=ec9c6ac53e43bc585db8f58df037639e}{Iyer}{I\bibinitperiod}{Manisha}{M\bibinitperiod}{}{}{}{}}%
        {{hash=2dda2e0640d5a5cad16afa3e6e7db64d}{Hopfinger}{H\bibinitperiod}{A\bibnamedelima J}{A\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {American Chemical Society}%
      }
      \strng{namehash}{44b75f3e30b89f1d268432584bd5433a}
      \strng{fullhash}{44b75f3e30b89f1d268432584bd5433a}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Treating Chemical Diversity in QSAR Analysis Modeling Diverse HIV-1 Integrase Inhibitors Using 4D Fingerprints}}
      \field{annotation}{doi: 10.1021/ci700153g}
      \field{issn}{1549-9596}
      \field{journaltitle}{Journal of Chemical Information and Modeling}
      \field{month}{09}
      \field{number}{5}
      \field{title}{{Treating Chemical Diversity in QSAR Analysis Modeling Diverse HIV-1 Integrase Inhibitors Using 4D Fingerprints}}
      \field{volume}{47}
      \field{year}{2007}
      \field{pages}{1945\bibrangedash 1960}
      \verb{doi}
      \verb 10.1021/ci700153g
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1021/ci700153g
      \endverb
    \endentry
    \entry{Romeiro2010}{article}{}
      \name{labelname}{5}{}{%
        {{hash=21e31c66ecbfd4c0bf13d6e72bfc46a9}{Romeiro}{R\bibinitperiod}{Nelilma\bibnamedelima Correia}{N\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=8d5f0a4dc5ad47de506efacf4b8aff07}{Albuquerque}{A\bibinitperiod}{Magaly\bibnamedelima Gir{\~{a}}o}{M\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=e7e870482fd645741388b25c4d7e055c}{Alencastro}{A\bibinitperiod}{Ricardo\bibnamedelima Bicca}{R\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=a0c51f7d307e44f3129c39b3ea28ffba}{Ravi}{R\bibinitperiod}{Malini}{M\bibinitperiod}{}{}{}{}}%
        {{hash=9a02dcf0a348a631715a06bddb58b441}{Hopfinger}{H\bibinitperiod}{Anton\bibnamedelima J}{A\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{5}{}{%
        {{hash=21e31c66ecbfd4c0bf13d6e72bfc46a9}{Romeiro}{R\bibinitperiod}{Nelilma\bibnamedelima Correia}{N\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=8d5f0a4dc5ad47de506efacf4b8aff07}{Albuquerque}{A\bibinitperiod}{Magaly\bibnamedelima Gir{\~{a}}o}{M\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=e7e870482fd645741388b25c4d7e055c}{Alencastro}{A\bibinitperiod}{Ricardo\bibnamedelima Bicca}{R\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=a0c51f7d307e44f3129c39b3ea28ffba}{Ravi}{R\bibinitperiod}{Malini}{M\bibinitperiod}{}{}{}{}}%
        {{hash=9a02dcf0a348a631715a06bddb58b441}{Hopfinger}{H\bibinitperiod}{Anton\bibnamedelima J}{A\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{201510b9dd8ce89d71e511c817b901e4}
      \strng{fullhash}{43f38db42194bf55fec06621be5d3bfe}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Construction of 4D-QSAR Models for Use in the Design of Novel p38-MAPK Inhibitors}}
      \field{abstract}{The p38-mitogen-activated protein kinase (p38-MAPK) plays a key role in lipopolysaccharide-induced tumor necrosis factor-{\$}\alpha{\$} (TNF-{\$}\alpha{\$}) and interleukin{$\textminus$}1 (IL{$\textminus$}1) release during the inflammatory process, emerging as an attractive target for new anti-inflammatory agents. Four-dimensional quantitative structure-activity relationship (4D-QSAR) analysis [Hopfinger et al., J. Am. Chem. Soc., 119 (1997) 10509] was applied to a series of 33 (a training set of 28 and a test set of 5) pyridinyl-imidazole and pyrimidinyl-imidazole inhibitors of p38-MAPK, with IC50 ranging from 0.11 to 2100 nM [Liverton et al., J. Med. Chem., 42 (1999) 2180]. Five thousand conformations of each analogue were sampled from a molecular dynamics simulation (MDS) during 50 ps at a constant temperature of 303 K. Each conformation was placed in a 2 {\{}{\r{A}}{\}} grid cell lattice for each of three trial alignments. 4D-QSAR models were constructed by genetic algorithm (GA) optimization and partial least squares (PLS) fitting, and evaluated by leave-one-out cross-validation technique. In the best models, with three to six terms, the adjusted cross-validated squared correlation coefficients, Q2adj, ranged from 0.67 to 0.85. Model D (Q2adj = 0.84) was identified as the most robust model from alignment 1, and it is representative of the other best models. This model encompasses new molecular regions as containing pharmacophore sites, such as the amino-benzyl moiety of pyrimidine analogs and the N1-substituent in the imidazole ring. These regions of the ligands should be further explored to identify better anti-inflammatory inhibitors of p38-MAPK.}
      \field{issn}{1573-4951}
      \field{journaltitle}{Journal of Computer-Aided Molecular Design}
      \field{number}{6}
      \field{title}{{Construction of 4D-QSAR Models for Use in the Design of Novel p38-MAPK Inhibitors}}
      \field{volume}{19}
      \field{pages}{385\bibrangedash 400}
      \verb{doi}
      \verb 10.1007/s10822-005-7927-4
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1007/s10822-005-7927-4
      \endverb
    \endentry
    \entry{Andrade2010}{article}{}
      \name{labelname}{4}{}{%
        {{hash=fea9b4c54be4bb2dc9cc223f99083028}{Andrade}{A\bibinitperiod}{Carolina\bibnamedelima H.}{C\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=6ec6e66ae3eddf5b2f1f56df2bce3ec5}{Pasqualoto}{P\bibinitperiod}{Kerly\bibnamedelimb F\bibnamedelima M}{K\bibinitperiod\bibinitdelim F\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=821f8346c9a6a886ab45fb499efaf6e1}{Ferreira}{F\bibinitperiod}{Elizabeth\bibnamedelima I.}{E\bibinitperiod\bibinitdelim I\bibinitperiod}{}{}{}{}}%
        {{hash=7ceabe347b7cab78254b799dcfe4a8c3}{Hopfinger}{H\bibinitperiod}{Anton\bibnamedelima J.}{A\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=fea9b4c54be4bb2dc9cc223f99083028}{Andrade}{A\bibinitperiod}{Carolina\bibnamedelima H.}{C\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=6ec6e66ae3eddf5b2f1f56df2bce3ec5}{Pasqualoto}{P\bibinitperiod}{Kerly\bibnamedelimb F\bibnamedelima M}{K\bibinitperiod\bibinitdelim F\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=821f8346c9a6a886ab45fb499efaf6e1}{Ferreira}{F\bibinitperiod}{Elizabeth\bibnamedelima I.}{E\bibinitperiod\bibinitdelim I\bibinitperiod}{}{}{}{}}%
        {{hash=7ceabe347b7cab78254b799dcfe4a8c3}{Hopfinger}{H\bibinitperiod}{Anton\bibnamedelima J.}{A\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{6e32ec912ceb8e32d326d69253794f1b}
      \strng{fullhash}{5999086021afd434c0ae700d792d84f2}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{4D-QSAR: Perspectives in drug design}}
      \field{abstract}{Drug design is a process driven by innovation and technological breakthroughs involving a combination of advanced experimental and computational methods. A broad variety of medicinal chemistry approaches can be used for the identification of hits, generation of leads, as well as to accelerate the optimization of leads into drug candidates. The quantitative structure-activity relationship (QSAR) formalisms are among the most important strategies that can be applied for the successful design new molecules. This review provides a comprehensive review on the evolution and current status of 4D-QSAR, highlighting present challenges and new opportunities in drug design.}
      \field{isbn}{1420-3049}
      \field{issn}{14203049}
      \field{journaltitle}{Molecules}
      \field{number}{5}
      \field{title}{{4D-QSAR: Perspectives in drug design}}
      \field{volume}{15}
      \field{year}{2010}
      \field{pages}{3281\bibrangedash 3294}
      \verb{doi}
      \verb 10.3390/molecules15053281
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/molecules-15-03281.pdf:pdf
      \endverb
    \endentry
    \entry{Vedani2002}{article}{}
      \name{labelname}{2}{}{%
        {{hash=9da2354f5ea78e4dba1b3a03ec5ea9e7}{Vedani}{V\bibinitperiod}{Angelo}{A\bibinitperiod}{}{}{}{}}%
        {{hash=e30e899a058f5e333f376cd77542eb42}{Dobler}{D\bibinitperiod}{Max}{M\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=9da2354f5ea78e4dba1b3a03ec5ea9e7}{Vedani}{V\bibinitperiod}{Angelo}{A\bibinitperiod}{}{}{}{}}%
        {{hash=e30e899a058f5e333f376cd77542eb42}{Dobler}{D\bibinitperiod}{Max}{M\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {American Chemical Society}%
      }
      \strng{namehash}{6e10480c48847e09fdb06143fdd2894c}
      \strng{fullhash}{6e10480c48847e09fdb06143fdd2894c}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{5D-QSAR: The Key for Simulating Induced Fit}}
      \field{annotation}{doi: 10.1021/jm011005p}
      \field{issn}{0022-2623}
      \field{journaltitle}{Journal of Medicinal Chemistry}
      \field{month}{05}
      \field{number}{11}
      \field{title}{{5D-QSAR: The Key for Simulating Induced Fit}}
      \field{volume}{45}
      \field{year}{2002}
      \field{pages}{2139\bibrangedash 2149}
      \verb{doi}
      \verb 10.1021/jm011005p
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1021/jm011005p
      \endverb
    \endentry
    \entry{Vedani2005}{article}{}
      \name{labelname}{3}{}{%
        {{hash=9da2354f5ea78e4dba1b3a03ec5ea9e7}{Vedani}{V\bibinitperiod}{Angelo}{A\bibinitperiod}{}{}{}{}}%
        {{hash=e30e899a058f5e333f376cd77542eb42}{Dobler}{D\bibinitperiod}{Max}{M\bibinitperiod}{}{}{}{}}%
        {{hash=6a4745ef07a905b67e20d77c91389abb}{Lill}{L\bibinitperiod}{Markus\bibnamedelima A}{M\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=9da2354f5ea78e4dba1b3a03ec5ea9e7}{Vedani}{V\bibinitperiod}{Angelo}{A\bibinitperiod}{}{}{}{}}%
        {{hash=e30e899a058f5e333f376cd77542eb42}{Dobler}{D\bibinitperiod}{Max}{M\bibinitperiod}{}{}{}{}}%
        {{hash=6a4745ef07a905b67e20d77c91389abb}{Lill}{L\bibinitperiod}{Markus\bibnamedelima A}{M\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {American Chemical Society}%
      }
      \strng{namehash}{76727a5529264ad14d8aded49651b207}
      \strng{fullhash}{76727a5529264ad14d8aded49651b207}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Combining Protein Modeling and 6D-QSAR. Simulating the Binding of Structurally Diverse Ligands to the Estrogen Receptor}}
      \field{annotation}{doi: 10.1021/jm050185q}
      \field{issn}{0022-2623}
      \field{journaltitle}{Journal of Medicinal Chemistry}
      \field{month}{06}
      \field{number}{11}
      \field{title}{{Combining Protein Modeling and 6D-QSAR. Simulating the Binding of Structurally Diverse Ligands to the Estrogen Receptor}}
      \field{volume}{48}
      \field{year}{2005}
      \field{pages}{3700\bibrangedash 3703}
      \verb{doi}
      \verb 10.1021/jm050185q
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1021/jm050185q
      \endverb
    \endentry
    \entry{Lipinski2004}{article}{}
      \name{labelname}{1}{}{%
        {{hash=e142db5f9f7ef18bfd0d219865780a4d}{Lipinski}{L\bibinitperiod}{Christopher\bibnamedelima A}{C\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=e142db5f9f7ef18bfd0d219865780a4d}{Lipinski}{L\bibinitperiod}{Christopher\bibnamedelima A}{C\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{e142db5f9f7ef18bfd0d219865780a4d}
      \strng{fullhash}{e142db5f9f7ef18bfd0d219865780a4d}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Lead and drug-like compounds: the rule of five revolution.}}
      \field{abstract}{Citations in CAS SciFinder to the rule-of-five (RO5) publication will exceed 1000 by year-end 2004. Trends in the RO5 literature explosion that can be discerned are the further definitions of drug-like. This topic is explored in terms of drug-like physicochemical features, drug-like structural features, a comparison of drug-like and non-drug-like in drug discovery and a discussion of how drug-like features relate to clinical success. Physicochemical features of CNS drugs and features related to CNS blood-brain transporter affinity are briefly reviewed. Recent literature on features of non-oral drugs is reviewed and how features of lead-like compounds differ from those of drug-like compounds is discussed. Most recently, partly driven by NIH roadmap initiatives, considerations have arisen as to what tool-like means in the search for chemical tools to probe biology space. All these topics frame the scope of this short review/perspective.:}
      \field{issn}{1740-6749}
      \field{journaltitle}{Drug discovery today. Technologies}
      \field{month}{12}
      \field{number}{4}
      \field{title}{{Lead and drug-like compounds: the rule of five revolution.}}
      \field{volume}{1}
      \field{year}{2004}
      \field{pages}{337\bibrangedash 41}
      \verb{doi}
      \verb 10.1016/j.ddtec.2004.11.007
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Lipinski - 2004 - Lead- and drug-like compounds the rule-of-five revolution.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.sciencedirect.com/science/article/pii/S1740674904000551
      \endverb
    \endentry
    \entry{Bickerton2012}{article}{}
      \name{labelname}{5}{}{%
        {{hash=e73d95976fb8fbb4d667630d4cb6e096}{Bickerton}{B\bibinitperiod}{G\bibnamedelima Richard}{G\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=575584f83412d66c419135b776befb96}{Paolini}{P\bibinitperiod}{Gaia\bibnamedelima V}{G\bibinitperiod\bibinitdelim V\bibinitperiod}{}{}{}{}}%
        {{hash=d5006548cd462007283b82e3c471cf8c}{Besnard}{B\bibinitperiod}{J{\'{e}}r{\'{e}}my}{J\bibinitperiod}{}{}{}{}}%
        {{hash=282b768c71f849d8ff9a440e5e1e3933}{Muresan}{M\bibinitperiod}{Sorel}{S\bibinitperiod}{}{}{}{}}%
        {{hash=6242c3a4009e8510e5776bb8a9cbafcf}{Hopkins}{H\bibinitperiod}{Andrew\bibnamedelima L}{A\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{5}{}{%
        {{hash=e73d95976fb8fbb4d667630d4cb6e096}{Bickerton}{B\bibinitperiod}{G\bibnamedelima Richard}{G\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=575584f83412d66c419135b776befb96}{Paolini}{P\bibinitperiod}{Gaia\bibnamedelima V}{G\bibinitperiod\bibinitdelim V\bibinitperiod}{}{}{}{}}%
        {{hash=d5006548cd462007283b82e3c471cf8c}{Besnard}{B\bibinitperiod}{J{\'{e}}r{\'{e}}my}{J\bibinitperiod}{}{}{}{}}%
        {{hash=282b768c71f849d8ff9a440e5e1e3933}{Muresan}{M\bibinitperiod}{Sorel}{S\bibinitperiod}{}{}{}{}}%
        {{hash=6242c3a4009e8510e5776bb8a9cbafcf}{Hopkins}{H\bibinitperiod}{Andrew\bibnamedelima L}{A\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \list{language}{1}{%
        {en}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group}%
      }
      \strng{namehash}{18ea0a3208375660a81fc45cbdfea5dc}
      \strng{fullhash}{2f0b58b1549fd7837e5aeba2ded33d25}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Quantifying the chemical beauty of drugs.}}
      \field{abstract}{Drug-likeness is a key consideration when selecting compounds during the early stages of drug discovery. However, evaluation of drug-likeness in absolute terms does not reflect adequately the whole spectrum of compound quality. More worryingly, widely used rules may inadvertently foster undesirable molecular property inflation as they permit the encroachment of rule-compliant compounds towards their boundaries. We propose a measure of drug-likeness based on the concept of desirability called the quantitative estimate of drug-likeness (QED). The empirical rationale of QED reflects the underlying distribution of molecular properties. QED is intuitive, transparent, straightforward to implement in many practical settings and allows compounds to be ranked by their relative merit. We extended the utility of QED by applying it to the problem of molecular target druggability assessment by prioritizing a large set of published bioactive compounds. The measure may also capture the abstract notion of aesthetics in medicinal chemistry.}
      \field{issn}{1755-4349}
      \field{journaltitle}{Nature chemistry}
      \field{month}{02}
      \field{number}{2}
      \field{title}{{Quantifying the chemical beauty of drugs.}}
      \field{volume}{4}
      \field{year}{2012}
      \field{pages}{90\bibrangedash 8}
      \verb{doi}
      \verb 10.1038/nchem.1243
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Bickerton et al. - 2012 - Quantifying the chemical beauty of drugs.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.nature.com/nchem/journal/v4/n2/full/nchem.1243.html?WT.mc%7B%5C_%7Did=TWT%7B%5C_%7DNatureChemistry
      \endverb
    \endentry
    \entry{Besnard2012b}{article}{}
      \name{labelname}{21}{}{%
        {{hash=d5006548cd462007283b82e3c471cf8c}{Besnard}{B\bibinitperiod}{J{\'{e}}r{\'{e}}my}{J\bibinitperiod}{}{}{}{}}%
        {{hash=08054e5669853818f072a4c1d4f0df86}{Ruda}{R\bibinitperiod}{Gian\bibnamedelima Filippo}{G\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{hash=ee903c7f559bcebca827e0067ec05dca}{Setola}{S\bibinitperiod}{Vincent}{V\bibinitperiod}{}{}{}{}}%
        {{hash=ca07ae4ae926637c055d7be0e01507d4}{Abecassis}{A\bibinitperiod}{Keren}{K\bibinitperiod}{}{}{}{}}%
        {{hash=35718e9506f7b2951182e9538363f836}{Rodriguiz}{R\bibinitperiod}{Ramona\bibnamedelima M.}{R\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=b1fb53b3cf40d964af67dd2479659fa1}{Huang}{H\bibinitperiod}{Xi-Ping}{X\bibinithyphendelim P\bibinitperiod}{}{}{}{}}%
        {{hash=285eca0a185b2ab488c05cc120d48728}{Norval}{N\bibinitperiod}{Suzanne}{S\bibinitperiod}{}{}{}{}}%
        {{hash=67671917b139cb1760f866593e612b9d}{Sassano}{S\bibinitperiod}{Maria\bibnamedelima F.}{M\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{hash=ae9770de6f7a479fe69da708c3b85fba}{Shin}{S\bibinitperiod}{Antony\bibnamedelima I.}{A\bibinitperiod\bibinitdelim I\bibinitperiod}{}{}{}{}}%
        {{hash=9c9ebb2286e075ae496f617263e53496}{Webster}{W\bibinitperiod}{Lauren\bibnamedelima A.}{L\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=d4b977a258dfe2407739581e9d47389c}{Simeons}{S\bibinitperiod}{Frederick\bibnamedelimb R.\bibnamedelimi C.}{F\bibinitperiod\bibinitdelim R\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=54b35da39f8650b65a2d286cb46f2b82}{Stojanovski}{S\bibinitperiod}{Laste}{L\bibinitperiod}{}{}{}{}}%
        {{hash=aa6bfa9790824a126372733b41c0d781}{Prat}{P\bibinitperiod}{Annik}{A\bibinitperiod}{}{}{}{}}%
        {{hash=29f3098b90e8281da191cafe70d4b10c}{Seidah}{S\bibinitperiod}{Nabil\bibnamedelima G.}{N\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=d2c204cf0e3f1548ca344fbe459ebdb7}{Constam}{C\bibinitperiod}{Daniel\bibnamedelima B.}{D\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=fe7e1e4127617490b7e563671953f314}{Bickerton}{B\bibinitperiod}{G.\bibnamedelimi Richard}{G\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=6b4e0c286f037b5402e02ee42c8d04e1}{Read}{R\bibinitperiod}{Kevin\bibnamedelima D.}{K\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=eda0d80a51ce0731e10eb77c78c2b21c}{Wetsel}{W\bibinitperiod}{William\bibnamedelima C.}{W\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=3fa4b087c4607fcfba0059962a4696db}{Gilbert}{G\bibinitperiod}{Ian\bibnamedelima H.}{I\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=a59443df0f459116914d03c622bd8323}{Roth}{R\bibinitperiod}{Bryan\bibnamedelima L.}{B\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=4104a8f39c11c7d7f247db1307dfa8c7}{Hopkins}{H\bibinitperiod}{Andrew\bibnamedelima L.}{A\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{21}{}{%
        {{hash=d5006548cd462007283b82e3c471cf8c}{Besnard}{B\bibinitperiod}{J{\'{e}}r{\'{e}}my}{J\bibinitperiod}{}{}{}{}}%
        {{hash=08054e5669853818f072a4c1d4f0df86}{Ruda}{R\bibinitperiod}{Gian\bibnamedelima Filippo}{G\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{hash=ee903c7f559bcebca827e0067ec05dca}{Setola}{S\bibinitperiod}{Vincent}{V\bibinitperiod}{}{}{}{}}%
        {{hash=ca07ae4ae926637c055d7be0e01507d4}{Abecassis}{A\bibinitperiod}{Keren}{K\bibinitperiod}{}{}{}{}}%
        {{hash=35718e9506f7b2951182e9538363f836}{Rodriguiz}{R\bibinitperiod}{Ramona\bibnamedelima M.}{R\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=b1fb53b3cf40d964af67dd2479659fa1}{Huang}{H\bibinitperiod}{Xi-Ping}{X\bibinithyphendelim P\bibinitperiod}{}{}{}{}}%
        {{hash=285eca0a185b2ab488c05cc120d48728}{Norval}{N\bibinitperiod}{Suzanne}{S\bibinitperiod}{}{}{}{}}%
        {{hash=67671917b139cb1760f866593e612b9d}{Sassano}{S\bibinitperiod}{Maria\bibnamedelima F.}{M\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{hash=ae9770de6f7a479fe69da708c3b85fba}{Shin}{S\bibinitperiod}{Antony\bibnamedelima I.}{A\bibinitperiod\bibinitdelim I\bibinitperiod}{}{}{}{}}%
        {{hash=9c9ebb2286e075ae496f617263e53496}{Webster}{W\bibinitperiod}{Lauren\bibnamedelima A.}{L\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=d4b977a258dfe2407739581e9d47389c}{Simeons}{S\bibinitperiod}{Frederick\bibnamedelimb R.\bibnamedelimi C.}{F\bibinitperiod\bibinitdelim R\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=54b35da39f8650b65a2d286cb46f2b82}{Stojanovski}{S\bibinitperiod}{Laste}{L\bibinitperiod}{}{}{}{}}%
        {{hash=aa6bfa9790824a126372733b41c0d781}{Prat}{P\bibinitperiod}{Annik}{A\bibinitperiod}{}{}{}{}}%
        {{hash=29f3098b90e8281da191cafe70d4b10c}{Seidah}{S\bibinitperiod}{Nabil\bibnamedelima G.}{N\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=d2c204cf0e3f1548ca344fbe459ebdb7}{Constam}{C\bibinitperiod}{Daniel\bibnamedelima B.}{D\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=fe7e1e4127617490b7e563671953f314}{Bickerton}{B\bibinitperiod}{G.\bibnamedelimi Richard}{G\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=6b4e0c286f037b5402e02ee42c8d04e1}{Read}{R\bibinitperiod}{Kevin\bibnamedelima D.}{K\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=eda0d80a51ce0731e10eb77c78c2b21c}{Wetsel}{W\bibinitperiod}{William\bibnamedelima C.}{W\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=3fa4b087c4607fcfba0059962a4696db}{Gilbert}{G\bibinitperiod}{Ian\bibnamedelima H.}{I\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=a59443df0f459116914d03c622bd8323}{Roth}{R\bibinitperiod}{Bryan\bibnamedelima L.}{B\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=4104a8f39c11c7d7f247db1307dfa8c7}{Hopkins}{H\bibinitperiod}{Andrew\bibnamedelima L.}{A\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{4dafac3533ea8726a8c0138e2025cce1}
      \strng{fullhash}{c37ef82aa8ecceb0afeb702fcc72764c}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Automated design of ligands to polypharmacological profiles}}
      \field{abstract}{The clinical efficacy and safety of a drug is determined by its activity profile across many proteins in the proteome. However, designing drugs with a specific multi-target profile is both complex and difficult. Therefore methods to design drugs rationally a priori against profiles of several proteins would have immense value in drug discovery. Here we describe a new approach for the automated design of ligands against profiles of multiple drug targets. The method is demonstrated by the evolution of an approved acetylcholinesterase inhibitor drug into brain-penetrable ligands with either specific polypharmacology or exquisite selectivity profiles for G-protein-coupled receptors. Overall, 800 ligand-target predictions of prospectively designed ligands were tested experimentally, of which 75{\%} were confirmed to be correct. We also demonstrate target engagement in vivo. The approach can be a useful source of drug leads when multi-target profiles are required to achieve either selectivity over other drug targets or a desired polypharmacology.}
      \field{issn}{0028-0836}
      \field{journaltitle}{Nature}
      \field{month}{12}
      \field{number}{7428}
      \field{title}{{Automated design of ligands to polypharmacological profiles}}
      \field{volume}{492}
      \field{year}{2012}
      \field{pages}{215\bibrangedash 220}
      \verb{doi}
      \verb 10.1038/nature11691
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Besnard et al. - 2012 - Automated design of ligands to polypharmacological profiles.pdf:pdf
      \endverb
      \verb{url}
      \verb http://f1000.com/prime/717967952
      \endverb
    \endentry
    \entry{Lewandowski2015}{article}{}
      \name{labelname}{3}{}{%
        {{hash=72484d0fc7af300bc89ff39acc8a72c0}{Lewandowski}{L\bibinitperiod}{Clare\bibnamedelima M.}{C\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=8f76ccd109247a6c6bec053141ee8558}{Co-investigator}{C\bibinithyphendelim i\bibinitperiod}{New}{N\bibinitperiod}{}{}{}{}}%
        {{hash=72484d0fc7af300bc89ff39acc8a72c0}{Lewandowski}{L\bibinitperiod}{Clare\bibnamedelima M.}{C\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=72484d0fc7af300bc89ff39acc8a72c0}{Lewandowski}{L\bibinitperiod}{Clare\bibnamedelima M.}{C\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=8f76ccd109247a6c6bec053141ee8558}{Co-investigator}{C\bibinithyphendelim i\bibinitperiod}{New}{N\bibinitperiod}{}{}{}{}}%
        {{hash=72484d0fc7af300bc89ff39acc8a72c0}{Lewandowski}{L\bibinitperiod}{Clare\bibnamedelima M.}{C\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{cce07b5cd75af09fae07660bc0659e1a}
      \strng{fullhash}{cce07b5cd75af09fae07660bc0659e1a}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{WHO Glocal tuberculosis report 2015}}
      \field{abstract}{Predicting the binding mode of flexible polypeptides to proteins is an important task that falls outside the domain of applicability of most small molecule and protein{$\textminus$}protein docking tools. Here, we test the small molecule flexible ligand docking program Glide on a set of 19 non-$\alpha$-helical peptides and systematically improve pose prediction accuracy by enhancing Glide sampling for flexible polypeptides. In addition, scoring of the poses was improved by post-processing with physics-based implicit solvent MM- GBSA calculations. Using the best RMSD among the top 10 scoring poses as a metric, the success rate (RMSD \x{2264} 2.0 {\r{A}} for the interface backbone atoms) increased from 21{\%} with default Glide SP settings to 58{\%} with the enhanced peptide sampling and scoring protocol in the case of redocking to the native protein structure. This approaches the accuracy of the recently developed Rosetta FlexPepDock method (63{\%} success for these 19 peptides) while being over 100 times faster. Cross-docking was performed for a subset of cases where an unbound receptor structure was available, and in that case, 40{\%} of peptides were docked successfully. We analyze the results and find that the optimized polypeptide protocol is most accurate for extended peptides of limited size and number of formal charges, defining a domain of applicability for this approach.}
      \field{eprinttype}{arXiv}
      \field{isbn}{9788578110796}
      \field{issn}{1098-6596}
      \field{journaltitle}{The effects of brief mindfulness intervention on acute pain experience: An examination of individual difference}
      \field{title}{{WHO Glocal tuberculosis report 2015}}
      \field{volume}{1}
      \field{year}{2015}
      \field{pages}{1689\bibrangedash 1699}
      \verb{doi}
      \verb 10.1017/CBO9781107415324.004
      \endverb
      \verb{eprint}
      \verb arXiv:1011.1669v3
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/9789241565059{\_}eng.pdf:pdf
      \endverb
    \endentry
    \entry{Connell2011}{article}{}
      \name{labelname}{4}{}{%
        {{hash=5c18ef067f87e83c217b92ca8df4cf07}{Connell}{C\bibinitperiod}{D\bibnamedelima W}{D\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=c39b5bef0dadef3d5a4f70afa0a11abe}{Berry}{B\bibinitperiod}{M}{M\bibinitperiod}{}{}{}{}}%
        {{hash=b7e14b84d88f10d6e308a40ce78e9b03}{Cooke}{C\bibinitperiod}{G}{G\bibinitperiod}{}{}{}{}}%
        {{hash=9fc9304114a8019453109d0d8f76caee}{Kon}{K\bibinitperiod}{O\bibnamedelima M}{O\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=5c18ef067f87e83c217b92ca8df4cf07}{Connell}{C\bibinitperiod}{D\bibnamedelima W}{D\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=c39b5bef0dadef3d5a4f70afa0a11abe}{Berry}{B\bibinitperiod}{M}{M\bibinitperiod}{}{}{}{}}%
        {{hash=b7e14b84d88f10d6e308a40ce78e9b03}{Cooke}{C\bibinitperiod}{G}{G\bibinitperiod}{}{}{}{}}%
        {{hash=9fc9304114a8019453109d0d8f76caee}{Kon}{K\bibinitperiod}{O\bibnamedelima M}{O\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{59a0285a7c20865102d657a24581fe04}
      \strng{fullhash}{6d6f70257140b5df15fff96ac7020613}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Update on tuberculosis: TB in the early 21st century}}
      \field{abstract}{Mycobacterium tuberculosis infection remains a major cause of global mortality and morbidity and the resulting disease, tuberculosis (TB), caused an estimated 1.7 million deaths in 2009 [1]. However, the majority of the 2 billion people estimated to be infected with M. tuberculosis have asymptomatic infection, termed latent TB infection (LTBI) [2, 3]. Traditionally, LTBI has been defined by evidence of a cellular immune response to M. tuberculosis-derived antigens, for example by the tuberculin skin test (TST) in asymptomatic individuals who have been potentially exposed to M. tuberculosis. For these individuals, the life time risk of progression from LTBI to active, symptomatic disease is only 10{\%}; however, defects in cellular immunity can increase this risk significantly [4, 5]. Of these, the most important is HIV infection, and the ongoing HIV epidemic has helped to fuel the spread of TB globally over the past 40 yrs with 0.38 million deaths in HIV co-infected individuals in 2009 [1].Despite dramatic falls in the overall prevalence of TB over the past 100 yrs in Europe, TB is no longer a disease of historical interest and the European region defined by the World Health Organization (WHO) saw a 2.7{\%} mean annual increase in cases from 2004--2008 [6]. Of concern, an estimated 3.6{\%} of all new cases globally were multi-drug resistant (MDR) [1, 7].With this in mind, we present an update on a selection of important areas in TB clinical practice and clinical research today, with particular relevance to Europe. We will review some of the important epidemiological features of TB, with a focus on migration and recent work on factors which might influence the burden of TB at a population level, such as cigarette smoking/biomass fuel {\ldots}}
      \field{journaltitle}{European Respiratory Review}
      \field{month}{06}
      \field{number}{120}
      \field{title}{{Update on tuberculosis: TB in the early 21st century}}
      \field{volume}{20}
      \field{year}{2011}
      \field{pages}{71\bibrangedash 84}
      \verb{url}
      \verb http://err.ersjournals.com/content/20/120/71.abstract
      \endverb
    \endentry
    \entry{Berry2009}{article}{}
      \name{labelname}{2}{}{%
        {{hash=c39b5bef0dadef3d5a4f70afa0a11abe}{Berry}{B\bibinitperiod}{M}{M\bibinitperiod}{}{}{}{}}%
        {{hash=9fc9304114a8019453109d0d8f76caee}{Kon}{K\bibinitperiod}{O\bibnamedelima M}{O\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=c39b5bef0dadef3d5a4f70afa0a11abe}{Berry}{B\bibinitperiod}{M}{M\bibinitperiod}{}{}{}{}}%
        {{hash=9fc9304114a8019453109d0d8f76caee}{Kon}{K\bibinitperiod}{O\bibnamedelima M}{O\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{2f5e3885ef2face4232318b0326b2ba5}
      \strng{fullhash}{2f5e3885ef2face4232318b0326b2ba5}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Multidrug- and extensively drug-resistant tuberculosis: an emerging threat}}
      \field{abstract}{Despite dramatic improvements in public health and medical care, Mycobacterium tuberculosis remains as much of a threat in the 21st century as it was when first identified as a pathogen by Koch [1] in 1882. Tuberculosis was reported to be the seventh leading cause of death worldwide by the World Health Organization (WHO) in 2004 [2]. Recent figures show an increase in the total number of cases, with an estimated 9.2 million new cases and 1.7 million deaths attributed to tuberculosis in 2006 [3]. Drug-resistant strains of Mycobacterium tuberculosis represent an emerging problem in the struggle to contain tuberculosis. In this issue of the European Respiratory Review, Sasse and Teichmann [4] describe their experience of managing a patient infected with a strain of Mycobacterium tuberculosis with a wide spectrum of drug resistance. The latest estimates based on survey data report that 11.1{\%} of new tuberculosis cases showed resistance to any drug, which rises to 25.1{\%} in previously treated cases. 1.6{\%} of new cases and 11.7{\%} of previously treated cases met the definition of multidrug-resistant tuberculosis (MDR-TB), this being resistance to rifampicin and isoniazid, the two most potent first-line antituberculosis drugs. Much of this burden is carried by eastern Europe, where 45.5{\%} of previously treated tuberculosis cases meet the definition for MDR-TB. The patient described by Sasse and Teichmann [4] was originally from Burma, where MDR-TB accounts for 4{\%} of new tuberculosis cases [5]. Outcomes in MDR-TB are worse than for non-MDR-TB, with one retrospective study in Estonia finding a cure rate of 83.4{\%} in non-MDR-TB, compared with only 57.4{\%} in MDR-TB [6]. More recently, attention has been drawn to the emergence of a form of MDR-TB that has a more {\ldots}}
      \field{journaltitle}{European Respiratory Review}
      \field{month}{11}
      \field{number}{114}
      \field{title}{{Multidrug- and extensively drug-resistant tuberculosis: an emerging threat}}
      \field{volume}{18}
      \field{year}{2009}
      \field{pages}{195\bibrangedash 197}
      \verb{url}
      \verb http://err.ersjournals.com/content/18/114/195.abstract
      \endverb
    \endentry
    \entry{Trouiller2016}{article}{}
      \name{labelname}{6}{}{%
        {{hash=1422f4f91dc5f13dda8e2b9a037ebfc4}{Trouiller}{T\bibinitperiod}{Patrice}{P\bibinitperiod}{}{}{}{}}%
        {{hash=0cdfde7c9cc5e8b8862878155561437b}{Olliaro}{O\bibinitperiod}{Piero}{P\bibinitperiod}{}{}{}{}}%
        {{hash=d071a3ebb5a009a00717f4e6dfc7e6bc}{Torreele}{T\bibinitperiod}{Els}{E\bibinitperiod}{}{}{}{}}%
        {{hash=1c5ed1178a09ae8098ab692906819f73}{Orbinski}{O\bibinitperiod}{James}{J\bibinitperiod}{}{}{}{}}%
        {{hash=c6fa729d5bd15441c948243b4ce244de}{Laing}{L\bibinitperiod}{Richard}{R\bibinitperiod}{}{}{}{}}%
        {{hash=1d50af60eff1012adc613ec74df429ea}{Ford}{F\bibinitperiod}{Nathan}{N\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{6}{}{%
        {{hash=1422f4f91dc5f13dda8e2b9a037ebfc4}{Trouiller}{T\bibinitperiod}{Patrice}{P\bibinitperiod}{}{}{}{}}%
        {{hash=0cdfde7c9cc5e8b8862878155561437b}{Olliaro}{O\bibinitperiod}{Piero}{P\bibinitperiod}{}{}{}{}}%
        {{hash=d071a3ebb5a009a00717f4e6dfc7e6bc}{Torreele}{T\bibinitperiod}{Els}{E\bibinitperiod}{}{}{}{}}%
        {{hash=1c5ed1178a09ae8098ab692906819f73}{Orbinski}{O\bibinitperiod}{James}{J\bibinitperiod}{}{}{}{}}%
        {{hash=c6fa729d5bd15441c948243b4ce244de}{Laing}{L\bibinitperiod}{Richard}{R\bibinitperiod}{}{}{}{}}%
        {{hash=1d50af60eff1012adc613ec74df429ea}{Ford}{F\bibinitperiod}{Nathan}{N\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Elsevier}%
      }
      \strng{namehash}{828973d64a8acc532e0760c360337f0d}
      \strng{fullhash}{b7c4a0250805db9352931f5b99668f64}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Drug development for neglected diseases: a deficient market and a public-health policy failure}}
      \field{annotation}{doi: 10.1016/S0140-6736(02)09096-7}
      \field{issn}{01406736}
      \field{journaltitle}{The Lancet}
      \field{month}{06}
      \field{number}{9324}
      \field{title}{{Drug development for neglected diseases: a deficient market and a public-health policy failure}}
      \field{volume}{359}
      \field{year}{2002}
      \field{pages}{2188\bibrangedash 2194}
      \verb{doi}
      \verb 10.1016/S0140-6736(02)09096-7
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1016/S0140-6736(02)09096-7%20http://linkinghub.elsevier.com/retrieve/pii/S0140673602090967
      \endverb
    \endentry
    \entry{Lewis2013}{article}{}
      \name{labelname}{1}{}{%
        {{hash=088dcc553932f421594707259a1309e8}{Lewis}{L\bibinitperiod}{Kim}{K\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=088dcc553932f421594707259a1309e8}{Lewis}{L\bibinitperiod}{Kim}{K\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.}%
      }
      \strng{namehash}{088dcc553932f421594707259a1309e8}
      \strng{fullhash}{088dcc553932f421594707259a1309e8}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Platforms for antibiotic discovery}}
      \field{issn}{1474-1776}
      \field{journaltitle}{Nat Rev Drug Discov}
      \field{month}{05}
      \field{number}{5}
      \field{title}{{Platforms for antibiotic discovery}}
      \field{volume}{12}
      \field{year}{2013}
      \field{pages}{371\bibrangedash 387}
      \verb{url}
      \verb http://dx.doi.org/10.1038/nrd3975%20http://10.1038/nrd3975
      \endverb
    \endentry
    \entry{Conly2005}{article}{}
      \name{labelname}{2}{}{%
        {{hash=c40927d8c551299c9d394b5e770407cc}{Conly}{C\bibinitperiod}{J\bibnamedelima M}{J\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=1dbbe9995e9bb5dd0e47aa9cae2258f2}{Johnston}{J\bibinitperiod}{B\bibnamedelima L}{B\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=c40927d8c551299c9d394b5e770407cc}{Conly}{C\bibinitperiod}{J\bibnamedelima M}{J\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=1dbbe9995e9bb5dd0e47aa9cae2258f2}{Johnston}{J\bibinitperiod}{B\bibnamedelima L}{B\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Pulsus Group Inc}%
      }
      \strng{namehash}{e0d192517669ea66a91f9b5d20254f61}
      \strng{fullhash}{e0d192517669ea66a91f9b5d20254f61}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Where are all the new antibiotics? The new antibiotic paradox}}
      \field{issn}{1712-9532}
      \field{journaltitle}{The Canadian Journal of Infectious Diseases {\&} Medical Microbiology}
      \field{month}{03}
      \field{number}{3}
      \field{title}{{Where are all the new antibiotics? The new antibiotic paradox}}
      \field{volume}{16}
      \field{year}{2005}
      \field{pages}{159\bibrangedash 160}
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2095020/
      \endverb
    \endentry
    \entry{Ling2015a}{article}{}
      \name{labelname}{20}{}{%
        {{hash=96171523cc203e5dcc637c8fd70a2610}{Ling}{L\bibinitperiod}{Losee\bibnamedelima L}{L\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=8300572fa7a4e6ca345805ae3f2a27c4}{Schneider}{S\bibinitperiod}{Tanja}{T\bibinitperiod}{}{}{}{}}%
        {{hash=98be8e2ca7eeaa848d4bb7ddca3c4874}{Peoples}{P\bibinitperiod}{Aaron\bibnamedelima J}{A\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=6d7cc6e3d7e2887d60bbf50b1825ed1f}{Spoering}{S\bibinitperiod}{Amy\bibnamedelima L}{A\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=0e55e0555530d1700952c1f4ff29e443}{Engels}{E\bibinitperiod}{Ina}{I\bibinitperiod}{}{}{}{}}%
        {{hash=2a82def793abf5f62edccd035a7e7052}{Conlon}{C\bibinitperiod}{Brian\bibnamedelima P}{B\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=2153258d8d736bf1c8c7434a4c6873a4}{Mueller}{M\bibinitperiod}{Anna}{A\bibinitperiod}{}{}{}{}}%
        {{hash=36c75068299fd777c119d2d736014efb}{Hughes}{H\bibinitperiod}{Dallas\bibnamedelima E}{D\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=57942143f1d62d2ec8607ff56234a4f0}{Epstein}{E\bibinitperiod}{Slava}{S\bibinitperiod}{}{}{}{}}%
        {{hash=5a25bc91f524ca6dfc2ecf9f4a13903c}{Jones}{J\bibinitperiod}{Michael}{M\bibinitperiod}{}{}{}{}}%
        {{hash=8112656e2d7f3a37a8f154a150b8f9ce}{Lazarides}{L\bibinitperiod}{Linos}{L\bibinitperiod}{}{}{}{}}%
        {{hash=a51158fddd717ce5a31702b0871df294}{Steadman}{S\bibinitperiod}{Victoria\bibnamedelima a}{V\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
        {{hash=2cab3283d5958e1b28e6e16dfc792f2e}{Cohen}{C\bibinitperiod}{Douglas\bibnamedelima R}{D\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=e7d3aae82cc0c6d7c7a0c8a607a1721f}{Felix}{F\bibinitperiod}{Cintia\bibnamedelima R}{C\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=c87d008cd794bbfd7af4c3cc1ddd8de2}{Fetterman}{F\bibinitperiod}{K\bibnamedelima Ashley}{K\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=ad69b472a89fcbd0d800e1f5d4188d6c}{Millett}{M\bibinitperiod}{William\bibnamedelima P}{W\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=c7bfe1615207c8075856ec94f5b5df8d}{Nitti}{N\bibinitperiod}{Anthony\bibnamedelima G}{A\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=12fedc32d83672f9af47bb3ba5b89993}{Zullo}{Z\bibinitperiod}{Ashley\bibnamedelima M}{A\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=531c7be3c2524682e36a7baa8d7ab92f}{Chen}{C\bibinitperiod}{Chao}{C\bibinitperiod}{}{}{}{}}%
        {{hash=088dcc553932f421594707259a1309e8}{Lewis}{L\bibinitperiod}{Kim}{K\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{20}{}{%
        {{hash=96171523cc203e5dcc637c8fd70a2610}{Ling}{L\bibinitperiod}{Losee\bibnamedelima L}{L\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=8300572fa7a4e6ca345805ae3f2a27c4}{Schneider}{S\bibinitperiod}{Tanja}{T\bibinitperiod}{}{}{}{}}%
        {{hash=98be8e2ca7eeaa848d4bb7ddca3c4874}{Peoples}{P\bibinitperiod}{Aaron\bibnamedelima J}{A\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=6d7cc6e3d7e2887d60bbf50b1825ed1f}{Spoering}{S\bibinitperiod}{Amy\bibnamedelima L}{A\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=0e55e0555530d1700952c1f4ff29e443}{Engels}{E\bibinitperiod}{Ina}{I\bibinitperiod}{}{}{}{}}%
        {{hash=2a82def793abf5f62edccd035a7e7052}{Conlon}{C\bibinitperiod}{Brian\bibnamedelima P}{B\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=2153258d8d736bf1c8c7434a4c6873a4}{Mueller}{M\bibinitperiod}{Anna}{A\bibinitperiod}{}{}{}{}}%
        {{hash=36c75068299fd777c119d2d736014efb}{Hughes}{H\bibinitperiod}{Dallas\bibnamedelima E}{D\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=57942143f1d62d2ec8607ff56234a4f0}{Epstein}{E\bibinitperiod}{Slava}{S\bibinitperiod}{}{}{}{}}%
        {{hash=5a25bc91f524ca6dfc2ecf9f4a13903c}{Jones}{J\bibinitperiod}{Michael}{M\bibinitperiod}{}{}{}{}}%
        {{hash=8112656e2d7f3a37a8f154a150b8f9ce}{Lazarides}{L\bibinitperiod}{Linos}{L\bibinitperiod}{}{}{}{}}%
        {{hash=a51158fddd717ce5a31702b0871df294}{Steadman}{S\bibinitperiod}{Victoria\bibnamedelima a}{V\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
        {{hash=2cab3283d5958e1b28e6e16dfc792f2e}{Cohen}{C\bibinitperiod}{Douglas\bibnamedelima R}{D\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=e7d3aae82cc0c6d7c7a0c8a607a1721f}{Felix}{F\bibinitperiod}{Cintia\bibnamedelima R}{C\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=c87d008cd794bbfd7af4c3cc1ddd8de2}{Fetterman}{F\bibinitperiod}{K\bibnamedelima Ashley}{K\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=ad69b472a89fcbd0d800e1f5d4188d6c}{Millett}{M\bibinitperiod}{William\bibnamedelima P}{W\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=c7bfe1615207c8075856ec94f5b5df8d}{Nitti}{N\bibinitperiod}{Anthony\bibnamedelima G}{A\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=12fedc32d83672f9af47bb3ba5b89993}{Zullo}{Z\bibinitperiod}{Ashley\bibnamedelima M}{A\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=531c7be3c2524682e36a7baa8d7ab92f}{Chen}{C\bibinitperiod}{Chao}{C\bibinitperiod}{}{}{}{}}%
        {{hash=088dcc553932f421594707259a1309e8}{Lewis}{L\bibinitperiod}{Kim}{K\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{37c3e2e580611af4d73b24c221639f1d}
      \strng{fullhash}{cb47d8917d15735d603b480168a4985b}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{A new antibiotic kills pathogens without detectable resistance}}
      \field{abstract}{Antibiotic resistance is spreading faster than the introduction of new compounds into clinical practice, causing a public health crisis. Most antibiotics were produced by screening soil microorganisms, but this limited resource of cultivable bacteria was overmined by the 1960s. Synthetic approaches to produce antibiotics have been unable to replace this platform. Uncultured bacteria make up approximately 99{\%} of all species in external environments, and are an untapped source of new antibiotics. Wedeveloped several methods to grow uncultured organisms by cultivation in situ or by using specific growth factors. Here we report a new antibiotic that we term teixobactin, discovered in a screen of uncultured bacteria. Teixobactin inhibits cell wall synthesis by binding to a highly conserved motif of lipid II (precursor of peptidoglycan) and lipid III (precursor of cell wall teichoic acid). We did not obtain any mutants of Staphylococcus aureus or Mycobacterium tuberculosis resistant to teixobactin. The properties of this compound suggest a path towards developing antibiotics that are likely to avoid development of resistance.}
      \field{isbn}{1476-4687 (Electronic)$\backslash$r0028-0836 (Linking)}
      \field{issn}{1476-4687}
      \field{journaltitle}{Nature}
      \field{number}{7535}
      \field{title}{{A new antibiotic kills pathogens without detectable resistance}}
      \field{volume}{517}
      \field{year}{2015}
      \field{pages}{455\bibrangedash 459}
      \verb{doi}
      \verb 10.1038/nature14098
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/nature14098.pdf:pdf
      \endverb
    \endentry
    \entry{BroadInstitute}{misc}{}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Philanthropists unite to accelerate global fight against tuberculosis with combined {\$}20 million gift to Broad Institute - https://www.broadinstitute.org/news/6981 -}}
      \field{title}{{Philanthropists unite to accelerate global fight against tuberculosis with combined {\$}20 million gift to Broad Institute - https://www.broadinstitute.org/news/6981 -}}
      \verb{url}
      \verb https://www.broadinstitute.org/news/6981
      \endverb
    \endentry
    \entry{Karki2007}{article}{}
      \name{labelname}{5}{}{%
        {{hash=78218bb7562a9b79c7469e40819eb583}{Karki}{K\bibinitperiod}{Deepak\bibnamedelima K}{D\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=724c78a5b336f2554da7519386581962}{Mirzoev}{M\bibinitperiod}{Tolib\bibnamedelima N}{T\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
        {{hash=c2e8db7da2de663dad83fb3ac1d87c78}{Green}{G\bibinitperiod}{Andrew\bibnamedelima T}{A\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=29569a538f5fc1af33f66eba38916b25}{Newell}{N\bibinitperiod}{James\bibnamedelima N}{J\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
        {{hash=ae45aaef42b7e4471c0664b236ec97f0}{Baral}{B\bibinitperiod}{Sushil\bibnamedelima C}{S\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{5}{}{%
        {{hash=78218bb7562a9b79c7469e40819eb583}{Karki}{K\bibinitperiod}{Deepak\bibnamedelima K}{D\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=724c78a5b336f2554da7519386581962}{Mirzoev}{M\bibinitperiod}{Tolib\bibnamedelima N}{T\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
        {{hash=c2e8db7da2de663dad83fb3ac1d87c78}{Green}{G\bibinitperiod}{Andrew\bibnamedelima T}{A\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=29569a538f5fc1af33f66eba38916b25}{Newell}{N\bibinitperiod}{James\bibnamedelima N}{J\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
        {{hash=ae45aaef42b7e4471c0664b236ec97f0}{Baral}{B\bibinitperiod}{Sushil\bibnamedelima C}{S\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{30149b31413806a1e66bb7c5f80d777a}
      \strng{fullhash}{d1598db3fc4016d7b04a1f513d1edebe}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Costs of a successful public-private partnership for TB control in an urban setting in Nepal}}
      \field{abstract}{In South Asia a large number of patients seek treatment for TB from private practitioners (PPs), and there is increasing international interest in involving PPs in TB control. To evaluate the feasibility, effectiveness and costs of public-private partnerships (PPPs) for TB control, a PPP was developed in Lalitpur municipality, Nepal, where it is estimated that 50{\%} of patients with TB are managed in the private sector. From the clinical perspective the PPP was shown to be effective. The aim of this paper is to assess and report on the costs involved in the PPP scheme.}
      \field{issn}{1471-2458}
      \field{journaltitle}{BMC Public Health}
      \field{number}{1}
      \field{title}{{Costs of a successful public-private partnership for TB control in an urban setting in Nepal}}
      \field{volume}{7}
      \field{year}{2007}
      \field{pages}{1\bibrangedash 12}
      \verb{doi}
      \verb 10.1186/1471-2458-7-84
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1186/1471-2458-7-84
      \endverb
    \endentry
    \entry{Murthy2001}{article}{}
      \name{labelname}{4}{}{%
        {{hash=8af5754bf339a98c52f8164d8ea8a52f}{Murthy}{M\bibinitperiod}{K.\bibnamedelimi J\bibnamedelima R}{K\bibinitperiod\bibinitdelim J\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=8b8bd58537f01d5c0d2cece922b7b68c}{Frieden}{F\bibinitperiod}{T.\bibnamedelimi R.}{T\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=0e1bc3b44a1c003c5b0563892209d5a7}{Yazdani}{Y\bibinitperiod}{A.}{A\bibinitperiod}{}{}{}{}}%
        {{hash=c0cf65429b7c080b192a768cee7a7a46}{Hreshikesh}{H\bibinitperiod}{P.}{P\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=8af5754bf339a98c52f8164d8ea8a52f}{Murthy}{M\bibinitperiod}{K.\bibnamedelimi J\bibnamedelima R}{K\bibinitperiod\bibinitdelim J\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=8b8bd58537f01d5c0d2cece922b7b68c}{Frieden}{F\bibinitperiod}{T.\bibnamedelimi R.}{T\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=0e1bc3b44a1c003c5b0563892209d5a7}{Yazdani}{Y\bibinitperiod}{A.}{A\bibinitperiod}{}{}{}{}}%
        {{hash=c0cf65429b7c080b192a768cee7a7a46}{Hreshikesh}{H\bibinitperiod}{P.}{P\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{5a6507293e9aa14c43142ca79bcac1c7}
      \strng{fullhash}{d950bedbfcafd587ada86718d87ee191}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Public-private partnership in tuberculosis control: Experience in Hyderabad, India}}
      \field{abstract}{SETTING: Hyderabad, India. OBJECTIVE: To determine whether private practitioners and the government can collaborate with a nongovernmental intermediary to implement DOTS effectively. DESIGN: A non-profit hospital provided DOTS services to a population of 100000 for 3 years, then expanded coverage to 500000 in October 1998. A hospital physician visited all private practitioners, encouraged them to refer patients, and gave feedback on each patient referred. After diagnosis, patients received directly observed treatment free of charge at the trust hospital or at 30 conveniently located small hospitals operated by local private practitioners. No financial incentives were used to encourage physicians to refer patients or to provide treatment observation. Diagnosis, treatment, and case and outcome definitions were performed as per DOTS policies; medicines and laboratory reagents were provided by the government. RESULTS: All 244 allopathic and 114 non-allopathic physicians practising in the area agreed to participate; 59{\%} referred at least one patient. Of 2244 persons referred, 969 (43{\%}) had tuberculosis. Physicians had obtained chest radiographs on 80{\%} of patients before referral for sputum microscopy. The detection rate increased from 50 to 200/100000 over the first 2-3 years of the project, and has increased gradually since expansion; 90{\%} of new smear-positive patients and 77{\%} of re-treatment patients were successfully treated. Compared with those treated at a neighbouring government DOTS centre, patients in this project paid less for diagnosis ({\$}5 vs. {\$}20) and treatment ({\$}1 vs. {\$}11), largely due to lower transport costs. CONCLUSIONS: Collaborative efforts between private practitioners and the government can achieve moderate-high rates of case detection and high rates of treatment success. Public-private services appeared to be more convenient to patients, who paid less for care and were less likely to miss work in order to participate in DOTS. Clearly defined roles and expectations and frequent communication are essential to success. An institution such as a non-profit hospital can serve as an effective intermediary between the government DOTS programme and private practitioners.}
      \field{isbn}{1027-3719}
      \field{issn}{10273719}
      \field{journaltitle}{International Journal of Tuberculosis and Lung Disease}
      \field{number}{4}
      \field{title}{{Public-private partnership in tuberculosis control: Experience in Hyderabad, India}}
      \field{volume}{5}
      \field{year}{2001}
      \field{pages}{354\bibrangedash 359}
      \verb{file}
      \verb :home/fran/Downloads/s10.pdf:pdf
      \endverb
    \endentry
    \entry{Lei2015}{article}{}
      \name{labelname}{7}{}{%
        {{hash=185062bab6a304a91919ac0c872b80d4}{Lei}{L\bibinitperiod}{Xun}{X\bibinitperiod}{}{}{}{}}%
        {{hash=e2d6477b8aa1e334fb8a5f13e09aa386}{Liu}{L\bibinitperiod}{Qin}{Q\bibinitperiod}{}{}{}{}}%
        {{hash=0016e634cdee11fbf15990223f3de121}{Escobar}{E\bibinitperiod}{Erin}{E\bibinitperiod}{}{}{}{}}%
        {{hash=15aac5574a434a4812279f669dff432c}{Philogene}{P\bibinitperiod}{Johane}{J\bibinitperiod}{}{}{}{}}%
        {{hash=bec5e6e4ddd93c61bd281e176a4cc608}{Zhu}{Z\bibinitperiod}{Hang}{H\bibinitperiod}{}{}{}{}}%
        {{hash=a84866b4900b3fe9a714de1f78dbf282}{Wang}{W\bibinitperiod}{Yang}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=333300ff1f906993ca996a007d36545c}{Tang}{T\bibinitperiod}{Shenglan}{S\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{7}{}{%
        {{hash=185062bab6a304a91919ac0c872b80d4}{Lei}{L\bibinitperiod}{Xun}{X\bibinitperiod}{}{}{}{}}%
        {{hash=e2d6477b8aa1e334fb8a5f13e09aa386}{Liu}{L\bibinitperiod}{Qin}{Q\bibinitperiod}{}{}{}{}}%
        {{hash=0016e634cdee11fbf15990223f3de121}{Escobar}{E\bibinitperiod}{Erin}{E\bibinitperiod}{}{}{}{}}%
        {{hash=15aac5574a434a4812279f669dff432c}{Philogene}{P\bibinitperiod}{Johane}{J\bibinitperiod}{}{}{}{}}%
        {{hash=bec5e6e4ddd93c61bd281e176a4cc608}{Zhu}{Z\bibinitperiod}{Hang}{H\bibinitperiod}{}{}{}{}}%
        {{hash=a84866b4900b3fe9a714de1f78dbf282}{Wang}{W\bibinitperiod}{Yang}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=333300ff1f906993ca996a007d36545c}{Tang}{T\bibinitperiod}{Shenglan}{S\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{4e90874f440e4bb60b92995fe72c8a97}
      \strng{fullhash}{66d0e285646e64a04d1e980808af6d6e}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Public--private mix for tuberculosis care and control: a systematic review}}
      \field{abstract}{SummaryBackground Public--private mix (PPM), recommended by the World Health Organization (WHO), was introduced to cope with the tuberculosis (TB) epidemic worldwide. In many developing countries, PPM has played a powerful role in TB control, while in others it has failed to meet expectations. Thus we performed a systematic review to determine the mechanisms used by global PPM programs implemented in different countries and to evaluate their performance. Methods A comprehensive search of the current literature for original studies published up to May 2014 was done using electronic databases and online resources; these publications were then screened using rigorous criteria. Descriptive information and evaluative outcomes data were extracted from eligible studies for synthesis and analysis. Results A total of 78 eligible studies were included in the final review. These assessed 48 PPM TB programs worldwide, subsequently categorized into three mechanisms based on collaborative characteristics: support, contract, and multi-partner group. Furthermore, we assessed the effectiveness of PPM programs against six health system themes, including utilization of the directly observed treatment strategy (DOTS), case detection, treatment outcomes, case management, costs, and access and equity, under the different collaborative mechanisms. Analysis of the comparative studies suggested that PPM could improve overall outcomes of a TB service, and multiple collaborative mechanisms may significantly promote case detection, treatment, referral, and service accessibility, especially in resource-limited areas. However, the less positive outcomes of several programs indicated limited funding and poor governance to be the predominant reasons. Conclusions PPM is a promising strategy to strengthen global TB care and control, but is affected by contextual characteristics in different areas. The scaling-up of PPM should contain essential commonalities, particularly substantial financial support and continuous material input. Additionally, it is important to improve program governance and training for the health providers involved, through integrated collaborative mechanisms.}
      \field{issn}{1201-9712}
      \field{journaltitle}{International Journal of Infectious Diseases}
      \field{month}{05}
      \field{title}{{Public--private mix for tuberculosis care and control: a systematic review}}
      \field{volume}{34}
      \field{year}{2015}
      \field{pages}{20\bibrangedash 32}
      \verb{doi}
      \verb http://dx.doi.org/10.1016/j.ijid.2015.02.015
      \endverb
      \verb{url}
      \verb http://www.sciencedirect.com/science/article/pii/S1201971215000521
      \endverb
    \endentry
    \entry{Zuniga2015}{article}{}
      \name{labelname}{3}{}{%
        {{hash=16fd1a328586cd0d43a3fe015d66d3b9}{Zuniga}{Z\bibinitperiod}{Edison\bibnamedelima S}{E\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=d5b7aab61b590c9c104d90acff319162}{Early}{E\bibinitperiod}{Julie}{J\bibinitperiod}{}{}{}{}}%
        {{hash=02eac32a41cfc8d6d68a9f3ce8eb7e5a}{Parish}{P\bibinitperiod}{Tanya}{T\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=16fd1a328586cd0d43a3fe015d66d3b9}{Zuniga}{Z\bibinitperiod}{Edison\bibnamedelima S}{E\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=d5b7aab61b590c9c104d90acff319162}{Early}{E\bibinitperiod}{Julie}{J\bibinitperiod}{}{}{}{}}%
        {{hash=02eac32a41cfc8d6d68a9f3ce8eb7e5a}{Parish}{P\bibinitperiod}{Tanya}{T\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{0e2282e0007fd844be73c30ff232cf9b}
      \strng{fullhash}{0e2282e0007fd844be73c30ff232cf9b}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{The future for early-stage tuberculosis drug discovery}}
      \field{abstract}{There is an urgent need for new and better drugs to treat tuberculosis due to lengthy and complex treatment regimens and a rising problem of drug resistance. Drug discovery efforts have increased over the past few years, with a larger focus on modern high-throughput screening technologies. A combination of target-based approaches, with the traditional empirical means of drug identification, has been complemented by the use of target-based phenotypic screens only recently made possibly with newer genetic tools. Using these approaches, a number of promising compound series have been discovered. However, significant problems remain in developing these into drugs. This review highlights recent advances in TB drug discovery, including an overview of screening campaigns, lessons learned and future directions.}
      \field{issn}{1746-0913}
      \field{journaltitle}{Future Microbiology}
      \field{number}{2}
      \field{title}{{The future for early-stage tuberculosis drug discovery}}
      \field{volume}{10}
      \field{year}{2015}
      \field{pages}{217\bibrangedash 229}
      \verb{doi}
      \verb 10.2217/fmb.14.125
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Zuniga, Early, Parish - 2015 - The future for early-stage tuberculosis drug discovery.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.futuremedicine.com/doi/abs/10.2217/fmb.14.125
      \endverb
    \endentry
    \entry{Brennan2003}{article}{}
      \name{labelname}{1}{}{%
        {{hash=42c77fbe69a810cdf6bcd47e1de3de4e}{Brennan}{B\bibinitperiod}{P\bibnamedelima J}{P\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=42c77fbe69a810cdf6bcd47e1de3de4e}{Brennan}{B\bibinitperiod}{P\bibnamedelima J}{P\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{42c77fbe69a810cdf6bcd47e1de3de4e}
      \strng{fullhash}{42c77fbe69a810cdf6bcd47e1de3de4e}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis}}
      \field{abstract}{Much of the early structural definition of the cell wall of Mycobacterium spp. was initiated in the 1960s and 1970s. There was a long period of inactivity, but more recent developments in NMR and mass spectral analysis and definition of the M. tuberculosis genome have resulted in a thorough understanding, not only of the structure of the mycobacterial cell wall and its lipids but also the basic genetics and biosynthesis. Our understanding nowadays of cell-wall architecture amounts to a massive {$\textquotedblleft$}core{$\textquotedblright$} comprised of peptidoglycan covalently attached via a linker unit (l-Rha--d-GlcNAc-P) to a linear galactofuran, in turn attached to several strands of a highly branched arabinofuran, in turn attached to mycolic acids. The mycolic acids are oriented perpendicular to the plane of the membrane and provide a truly special lipid barrier responsible for many of the physiological and disease-inducing aspects of M. tuberculosis. Intercalated within this lipid environment are the lipids that have intrigued researchers for over five decades: the phthiocerol dimycocerosate, cord factor/dimycolyltrehalose, the sulfolipids, the phosphatidylinositol mannosides, etc. Knowledge of their roles in {$\textquotedblleft$}signaling{$\textquotedblright$} events, in pathogenesis, and in the immune response is now emerging, sometimes piecemeal and sometimes in an organized fashion. Some of the more intriguing observations are those demonstrating that mycolic acids are recognized by CD1-restricted T-cells, that antigen 85, one of the most powerful protective antigens of M. tuberculosis, is a mycolyltransferase, and that lipoarabinomannan (LAM), when {$\textquotedblleft$}capped{$\textquotedblright$} with short mannose oligosaccharides, is involved in phagocytosis of M. tuberculosis. Definition of the genome of M. tuberculosis has greatly aided efforts to define the biosynthetic pathways for all of these exotic molecules: the mycolic acids, the mycocerosates, phthiocerol, LAM, and the polyprenyl phosphates. For example, we know that synthesis of the entire core is initiated on a decaprenyl-P with synthesis of the linker unit, and then there is concomitant extension of the galactan and arabinan chains while this intermediate is transported through the cytoplasmic membrane. The final steps in these events, the attachment of mycolic acids and ligation to peptidoglycan, await definition and will prove to be excellent targets for a new generation of anti-tuberculosis drugs.}
      \field{issn}{1472-9792}
      \field{journaltitle}{Tuberculosis}
      \field{month}{02}
      \field{number}{1--3}
      \field{title}{{Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis}}
      \field{volume}{83}
      \field{year}{2003}
      \field{pages}{91\bibrangedash 97}
      \verb{doi}
      \verb http://dx.doi.org/10.1016/S1472-9792(02)00089-6
      \endverb
      \verb{url}
      \verb http://www.sciencedirect.com/science/article/pii/S1472979202000896
      \endverb
    \endentry
    \entry{Rodrigues2012}{article}{}
      \name{labelname}{5}{}{%
        {{hash=c074f3d972f6f68eac9a32bed4f106df}{Rodrigues}{R\bibinitperiod}{Liliana}{L\bibinitperiod}{}{}{}{}}%
        {{hash=39e8925451501613253c9181da8a4cbb}{Machado}{M\bibinitperiod}{Diana}{D\bibinitperiod}{}{}{}{}}%
        {{hash=1146737ee3f12db6060676fab2893385}{Couto}{C\bibinitperiod}{Isabel}{I\bibinitperiod}{}{}{}{}}%
        {{hash=52f35d1d4eb225a6d06246d3fb9dd3e4}{Amaral}{A\bibinitperiod}{Leonard}{L\bibinitperiod}{}{}{}{}}%
        {{hash=0f76bf06e80070831d3bee09aebbedeb}{Viveiros}{V\bibinitperiod}{Miguel}{M\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{5}{}{%
        {{hash=c074f3d972f6f68eac9a32bed4f106df}{Rodrigues}{R\bibinitperiod}{Liliana}{L\bibinitperiod}{}{}{}{}}%
        {{hash=39e8925451501613253c9181da8a4cbb}{Machado}{M\bibinitperiod}{Diana}{D\bibinitperiod}{}{}{}{}}%
        {{hash=1146737ee3f12db6060676fab2893385}{Couto}{C\bibinitperiod}{Isabel}{I\bibinitperiod}{}{}{}{}}%
        {{hash=52f35d1d4eb225a6d06246d3fb9dd3e4}{Amaral}{A\bibinitperiod}{Leonard}{L\bibinitperiod}{}{}{}{}}%
        {{hash=0f76bf06e80070831d3bee09aebbedeb}{Viveiros}{V\bibinitperiod}{Miguel}{M\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{3798080aec9095fd19060364cc1e91dc}
      \strng{fullhash}{acf04b2740aa2cf98a37508cd3b4e0c2}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Contribution of efflux activity to isoniazid resistance in the Mycobacterium tuberculosis complex}}
      \field{abstract}{Resistance to isoniazid (INH), one of the main drugs used in tuberculosis (TB) therapy, is mostly due to chromosomal mutations in target genes. However, approximately 20--30{\%} of INH resistant Mycobacterium tuberculosis isolates do not have mutations in any of the genes associated with INH resistance. This suggests that other mechanism(s) may be involved, namely efflux pump systems capable of extruding the drug to the exterior of the cell. In a previous work, we have induced clinical INH susceptible M. tuberculosis isolates and the H37Rv reference strain to high-level resistance to INH, by gradual exposure to increasing concentrations of this drug. In the present study, we have characterized these strains and Mycobacterium bovis BCG induced to INH resistance with respect to their efflux activity and its contribution to INH resistance using the following approach: determination of the susceptibility to INH in the presence and absence of the efflux inhibitors (EIs) chlorpromazine, thioridazine and verapamil; evaluation of efflux activity by a semi-automated fluorometric method; and quantification of the expression level of genes coding for efflux pumps by real-time RT-qPCR. The EIs decreased INH resistance in the INH induced strains, in particular verapamil promoted a reversal of resistance in some of the strains tested. The induced strains presented an increased efflux activity that was inhibited by the EIs and showed overexpression of the efflux pump genes efpA, mmpL7, mmr, p55 and the Tap-like gene Rv1258c. Altogether, these results correlate efflux activity with INH resistance and demonstrate that efflux pumps play an important role in acquired INH resistance in M. tuberculosis complex. The development of EIs that can restore the antimicrobial activity of the antibiotic subject to efflux is an approach that can be useful in order to prevent the emergence of this resistance and guide the development of new effective anti-TB therapeutical approaches.}
      \field{issn}{1567-1348}
      \field{journaltitle}{Infection, Genetics and Evolution}
      \field{month}{06}
      \field{number}{4}
      \field{title}{{Contribution of efflux activity to isoniazid resistance in the Mycobacterium tuberculosis complex}}
      \field{volume}{12}
      \field{year}{2012}
      \field{pages}{695\bibrangedash 700}
      \verb{doi}
      \verb http://dx.doi.org/10.1016/j.meegid.2011.08.009
      \endverb
      \verb{url}
      \verb http://www.sciencedirect.com/science/article/pii/S1567134811002887
      \endverb
    \endentry
    \entry{Manjunatha2015}{article}{}
      \name{labelname}{2}{}{%
        {{hash=be8674f6cc03382aa462597d2cc1bc1d}{Manjunatha}{M\bibinitperiod}{Ujjini\bibnamedelima H}{U\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=55cfd356590cd8481821d6ac32a0ce3f}{Smith}{S\bibinitperiod}{Paul\bibnamedelima W}{P\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=be8674f6cc03382aa462597d2cc1bc1d}{Manjunatha}{M\bibinitperiod}{Ujjini\bibnamedelima H}{U\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=55cfd356590cd8481821d6ac32a0ce3f}{Smith}{S\bibinitperiod}{Paul\bibnamedelima W}{P\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{538ab133a8bef52b6b8672fc40fe5585}
      \strng{fullhash}{538ab133a8bef52b6b8672fc40fe5585}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening}}
      \field{abstract}{Abstract Tuberculosis poses a major global health problem and multi-drug resistant strains are increasingly prevalent. Hence there is an urgent need to discover new TB drugs. Cell based phenotypic screening represents a powerful approach to identify anti-mycobacterial compounds and elucidate novel targets. Three high throughput phenotypic screens were performed at NITD against mycobacterium. Hits were identified and chemical series selected for optimisation. This produced compounds with good in vitro anti-mycobacterial activity and pharmacokinetic properties. Some compounds displayed oral activity in mouse efficacy models of TB. Herein, we review the TB discovery efforts at NITD and share experiences in optimisation of phenotypic hits, describing challenges encountered and lessons learned. We also offer perspectives to facilitate future selection and advancement of phenotypic hits.}
      \field{issn}{0968-0896}
      \field{journaltitle}{Bioorganic {\&} Medicinal Chemistry}
      \field{month}{08}
      \field{number}{16}
      \field{title}{{Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening}}
      \field{volume}{23}
      \field{year}{2015}
      \field{pages}{5087\bibrangedash 5097}
      \verb{doi}
      \verb http://dx.doi.org/10.1016/j.bmc.2014.12.031
      \endverb
      \verb{url}
      \verb http://www.sciencedirect.com/science/article/pii/S0968089614008797
      \endverb
    \endentry
    \entry{Ballell2013}{article}{}
      \name{labelname}{24}{}{%
        {{hash=92f9f1ebf3e833237d95513e96fb2683}{Ballell}{B\bibinitperiod}{Llu{\'{\i}}s}{L\bibinitperiod}{}{}{}{}}%
        {{hash=efe2cecb5400eed22762474ccee551df}{Bates}{B\bibinitperiod}{Robert\bibnamedelima H}{R\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=a6a697dfcfe00f4eed02d45342907903}{Young}{Y\bibinitperiod}{Rob\bibnamedelima J}{R\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=d624b2a0fb75d41ac6f14b4ebb6c414e}{Alvarez-Gomez}{A\bibinithyphendelim G\bibinitperiod}{Daniel}{D\bibinitperiod}{}{}{}{}}%
        {{hash=f961b135ebec0ec2ea7cd846a7f18a40}{Alvarez-Ruiz}{A\bibinithyphendelim R\bibinitperiod}{Emilio}{E\bibinitperiod}{}{}{}{}}%
        {{hash=eb94738be4b5124a107198c7e147ee7e}{Barroso}{B\bibinitperiod}{Vanessa}{V\bibinitperiod}{}{}{}{}}%
        {{hash=db388038e9f9f9a2a5173ca4e78d8361}{Blanco}{B\bibinitperiod}{Delia}{D\bibinitperiod}{}{}{}{}}%
        {{hash=153dba706e242d0c063dba7b00df65bd}{Crespo}{C\bibinitperiod}{Benigno}{B\bibinitperiod}{}{}{}{}}%
        {{hash=2e9a080216c809365c08d8c86327aede}{Escribano}{E\bibinitperiod}{Jaime}{J\bibinitperiod}{}{}{}{}}%
        {{hash=47c28321b0d9453b21d5e5e486ca866c}{Gonz{\'{a}}lez}{G\bibinitperiod}{Rub{\'{e}}n}{R\bibinitperiod}{}{}{}{}}%
        {{hash=83234e74f41ee378970e4d4ad091c96f}{Lozano}{L\bibinitperiod}{Sonia}{S\bibinitperiod}{}{}{}{}}%
        {{hash=83d3606d048952a7d15d7e34562b2652}{Huss}{H\bibinitperiod}{Sophie}{S\bibinitperiod}{}{}{}{}}%
        {{hash=17ac4c08a68a5fe3faa177272c88864a}{Santos-Villarejo}{S\bibinithyphendelim V\bibinitperiod}{Angel}{A\bibinitperiod}{}{}{}{}}%
        {{hash=f1be1b647b77a5e62805e06ca2ce245a}{Mart{\'{\i}}n-Plaza}{M\bibinithyphendelim P\bibinitperiod}{Jos{\'{e}}\bibnamedelima Julio}{J\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=3a464467a05b17272248c688ea08c332}{Mendoza}{M\bibinitperiod}{Alfonso}{A\bibinitperiod}{}{}{}{}}%
        {{hash=d79950ba2c762d4afc001ef32e65a506}{Rebollo-Lopez}{R\bibinithyphendelim L\bibinitperiod}{Mar{\'{\i}}a\bibnamedelima Jos{\'{e}}}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=ff636669f7099d0d93590b54dc39d7bf}{Remui{\~{n}}an-Blanco}{R\bibinitperiod}{Modesto}{M\bibinitperiod}{}{}{}{}}%
        {{hash=f9f586da9a74a597b8e62502929c27e4}{Lavandera}{L\bibinitperiod}{Jos{\'{e}}\bibnamedelima Luis}{J\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=28464e2b203f48dfbc59175b10b19697}{P{\'{e}}rez-Herran}{P\bibinithyphendelim H\bibinitperiod}{Esther}{E\bibinitperiod}{}{}{}{}}%
        {{hash=28fbc29383d067537b378baa24acafb6}{Gamo-Benito}{G\bibinithyphendelim B\bibinitperiod}{Francisco\bibnamedelima Javier}{F\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=e2e605566c9852d6ccc362bfe8c7e4c3}{Garc{\'{\i}}a-Bustos}{G\bibinithyphendelim B\bibinitperiod}{Jos{\'{e}}\bibnamedelima Francisco}{J\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{hash=2a40f7c9a32e3db6619f4de4b1a71fc4}{Barros}{B\bibinitperiod}{David}{D\bibinitperiod}{}{}{}{}}%
        {{hash=2af59264b17833d1b508913a539cb353}{Castro}{C\bibinitperiod}{Julia\bibnamedelima P}{J\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=42e7056dbae76aad662a45566123a6e5}{Cammack}{C\bibinitperiod}{Nicholas}{N\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{24}{}{%
        {{hash=92f9f1ebf3e833237d95513e96fb2683}{Ballell}{B\bibinitperiod}{Llu{\'{\i}}s}{L\bibinitperiod}{}{}{}{}}%
        {{hash=efe2cecb5400eed22762474ccee551df}{Bates}{B\bibinitperiod}{Robert\bibnamedelima H}{R\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=a6a697dfcfe00f4eed02d45342907903}{Young}{Y\bibinitperiod}{Rob\bibnamedelima J}{R\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=d624b2a0fb75d41ac6f14b4ebb6c414e}{Alvarez-Gomez}{A\bibinithyphendelim G\bibinitperiod}{Daniel}{D\bibinitperiod}{}{}{}{}}%
        {{hash=f961b135ebec0ec2ea7cd846a7f18a40}{Alvarez-Ruiz}{A\bibinithyphendelim R\bibinitperiod}{Emilio}{E\bibinitperiod}{}{}{}{}}%
        {{hash=eb94738be4b5124a107198c7e147ee7e}{Barroso}{B\bibinitperiod}{Vanessa}{V\bibinitperiod}{}{}{}{}}%
        {{hash=db388038e9f9f9a2a5173ca4e78d8361}{Blanco}{B\bibinitperiod}{Delia}{D\bibinitperiod}{}{}{}{}}%
        {{hash=153dba706e242d0c063dba7b00df65bd}{Crespo}{C\bibinitperiod}{Benigno}{B\bibinitperiod}{}{}{}{}}%
        {{hash=2e9a080216c809365c08d8c86327aede}{Escribano}{E\bibinitperiod}{Jaime}{J\bibinitperiod}{}{}{}{}}%
        {{hash=47c28321b0d9453b21d5e5e486ca866c}{Gonz{\'{a}}lez}{G\bibinitperiod}{Rub{\'{e}}n}{R\bibinitperiod}{}{}{}{}}%
        {{hash=83234e74f41ee378970e4d4ad091c96f}{Lozano}{L\bibinitperiod}{Sonia}{S\bibinitperiod}{}{}{}{}}%
        {{hash=83d3606d048952a7d15d7e34562b2652}{Huss}{H\bibinitperiod}{Sophie}{S\bibinitperiod}{}{}{}{}}%
        {{hash=17ac4c08a68a5fe3faa177272c88864a}{Santos-Villarejo}{S\bibinithyphendelim V\bibinitperiod}{Angel}{A\bibinitperiod}{}{}{}{}}%
        {{hash=f1be1b647b77a5e62805e06ca2ce245a}{Mart{\'{\i}}n-Plaza}{M\bibinithyphendelim P\bibinitperiod}{Jos{\'{e}}\bibnamedelima Julio}{J\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=3a464467a05b17272248c688ea08c332}{Mendoza}{M\bibinitperiod}{Alfonso}{A\bibinitperiod}{}{}{}{}}%
        {{hash=d79950ba2c762d4afc001ef32e65a506}{Rebollo-Lopez}{R\bibinithyphendelim L\bibinitperiod}{Mar{\'{\i}}a\bibnamedelima Jos{\'{e}}}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=ff636669f7099d0d93590b54dc39d7bf}{Remui{\~{n}}an-Blanco}{R\bibinitperiod}{Modesto}{M\bibinitperiod}{}{}{}{}}%
        {{hash=f9f586da9a74a597b8e62502929c27e4}{Lavandera}{L\bibinitperiod}{Jos{\'{e}}\bibnamedelima Luis}{J\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=28464e2b203f48dfbc59175b10b19697}{P{\'{e}}rez-Herran}{P\bibinithyphendelim H\bibinitperiod}{Esther}{E\bibinitperiod}{}{}{}{}}%
        {{hash=28fbc29383d067537b378baa24acafb6}{Gamo-Benito}{G\bibinithyphendelim B\bibinitperiod}{Francisco\bibnamedelima Javier}{F\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=e2e605566c9852d6ccc362bfe8c7e4c3}{Garc{\'{\i}}a-Bustos}{G\bibinithyphendelim B\bibinitperiod}{Jos{\'{e}}\bibnamedelima Francisco}{J\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{hash=2a40f7c9a32e3db6619f4de4b1a71fc4}{Barros}{B\bibinitperiod}{David}{D\bibinitperiod}{}{}{}{}}%
        {{hash=2af59264b17833d1b508913a539cb353}{Castro}{C\bibinitperiod}{Julia\bibnamedelima P}{J\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=42e7056dbae76aad662a45566123a6e5}{Cammack}{C\bibinitperiod}{Nicholas}{N\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{00395da62851ee7dc7452487fbf270db}
      \strng{fullhash}{432d7012e25884411c70a1fb3c39dd6c}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Fueling open-source drug discovery: 177 small-molecule leads against tuberculosis.}}
      \field{abstract}{With the aim of fuelling open-source, translational, early-stage drug discovery activities, the results of the recently completed antimycobacterial phenotypic screening campaign against Mycobacterium bovis BCG with hit confirmation in M. tuberculosis H37Rv were made publicly accessible. A set of 177 potent non-cytotoxic H37Rv hits was identified and will be made available to maximize the potential impact of the compounds toward a chemical genetics/proteomics exercise, while at the same time providing a plethora of potential starting points for new synthetic lead-generation activities. Two additional drug-discovery-relevant datasets are included: a) a drug-like property analysis reflecting the latest lead-like guidelines and b) an early lead-generation package of the most promising hits within the clusters identified.}
      \field{issn}{1860-7187}
      \field{journaltitle}{ChemMedChem}
      \field{month}{03}
      \field{number}{2}
      \field{title}{{Fueling open-source drug discovery: 177 small-molecule leads against tuberculosis.}}
      \field{volume}{8}
      \field{year}{2013}
      \field{pages}{313\bibrangedash 21}
      \verb{doi}
      \verb 10.1002/cmdc.201200428
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Ballell et al. - 2013 - Fueling open-source drug discovery 177 small-molecule leads against tuberculosis.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3743164%7B%5C&%7Dtool=pmcentrez%7B%5C&%7Drendertype=abstract
      \endverb
    \endentry
    \entry{Park2015}{article}{}
      \name{labelname}{12}{}{%
        {{hash=b89a4a24f6008ea325d03ba9fe4809f2}{Park}{P\bibinitperiod}{Sae\bibnamedelima Woong}{S\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=934a8ad50c4b2116fff3eba8de09e7a0}{Casalena}{C\bibinitperiod}{Dominick\bibnamedelima E.}{D\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=0aeca80896b1de8b52db244238491f8b}{Wilson}{W\bibinitperiod}{Daniel\bibnamedelima J.}{D\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=f60e70f11c521708f7d9fe2df92a4138}{Dai}{D\bibinitperiod}{Ran}{R\bibinitperiod}{}{}{}{}}%
        {{hash=df193b65675892822947ec0cefd68e0c}{Nag}{N\bibinitperiod}{Partha\bibnamedelima P.}{P\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=8cfebbe54197d0a6e7c196b6fe8cf3a3}{Liu}{L\bibinitperiod}{Feng}{F\bibinitperiod}{}{}{}{}}%
        {{hash=a1c348fb1951fd1fa0634ecf3503f50e}{Boyce}{B\bibinitperiod}{Jim\bibnamedelima P.}{J\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=808f38a5826d1cf980d29bd0b3e6179e}{Bittker}{B\bibinitperiod}{Joshua\bibnamedelima A.}{J\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=f392e7ee4276c992292e4abaf6fb6b10}{Schreiber}{S\bibinitperiod}{Stuart\bibnamedelima L.}{S\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=f7e058592d83a0b30cea2057bfddac71}{Finzel}{F\bibinitperiod}{Barry\bibnamedelima C.}{B\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=b66fe07f682d19c587e7a028cd4e4dbf}{Schnappinger}{S\bibinitperiod}{Dirk}{D\bibinitperiod}{}{}{}{}}%
        {{hash=46f8a492a751adb3f8133a39e65ee030}{Aldrich}{A\bibinitperiod}{Courtney\bibnamedelima C.}{C\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{12}{}{%
        {{hash=b89a4a24f6008ea325d03ba9fe4809f2}{Park}{P\bibinitperiod}{Sae\bibnamedelima Woong}{S\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=934a8ad50c4b2116fff3eba8de09e7a0}{Casalena}{C\bibinitperiod}{Dominick\bibnamedelima E.}{D\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=0aeca80896b1de8b52db244238491f8b}{Wilson}{W\bibinitperiod}{Daniel\bibnamedelima J.}{D\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=f60e70f11c521708f7d9fe2df92a4138}{Dai}{D\bibinitperiod}{Ran}{R\bibinitperiod}{}{}{}{}}%
        {{hash=df193b65675892822947ec0cefd68e0c}{Nag}{N\bibinitperiod}{Partha\bibnamedelima P.}{P\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=8cfebbe54197d0a6e7c196b6fe8cf3a3}{Liu}{L\bibinitperiod}{Feng}{F\bibinitperiod}{}{}{}{}}%
        {{hash=a1c348fb1951fd1fa0634ecf3503f50e}{Boyce}{B\bibinitperiod}{Jim\bibnamedelima P.}{J\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=808f38a5826d1cf980d29bd0b3e6179e}{Bittker}{B\bibinitperiod}{Joshua\bibnamedelima A.}{J\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=f392e7ee4276c992292e4abaf6fb6b10}{Schreiber}{S\bibinitperiod}{Stuart\bibnamedelima L.}{S\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=f7e058592d83a0b30cea2057bfddac71}{Finzel}{F\bibinitperiod}{Barry\bibnamedelima C.}{B\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=b66fe07f682d19c587e7a028cd4e4dbf}{Schnappinger}{S\bibinitperiod}{Dirk}{D\bibinitperiod}{}{}{}{}}%
        {{hash=46f8a492a751adb3f8133a39e65ee030}{Aldrich}{A\bibinitperiod}{Courtney\bibnamedelima C.}{C\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{9b5169cc60e951ff54ce30108fce7ec2}
      \strng{fullhash}{336bbd95b23644c7550c6aaf425d92f0}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Target-Based Identification of Whole-Cell Active Inhibitors of Biotin Biosynthesis in Mycobacterium tuberculosis}}
      \field{abstract}{Summary Biotin biosynthesis is essential for survival and persistence of Mycobacterium tuberculosis (Mtb) invivo. The aminotransferase BioA, which catalyzes the antepenultimate step in the biotin pathway, has been established as a promising target due to its vulnerability to chemical inhibition. We performed high-throughput screening (HTS) employing a fluorescence displacement assay and identified a diverse set of potent inhibitors including many diversity-oriented synthesis (DOS) scaffolds. To efficiently select only hits targeting biotin biosynthesis, we then deployed a whole-cell counterscreen in biotin-free and biotin-containing medium against wild-type Mtb and in parallel with isogenic bioA Mtb strains that possess differential levels of BioA expression. This counterscreen proved crucial to filter out compounds whose whole-cell activity was off target as well as identify hits with weak, but measurable whole-cell activity in BioA-depleted strains. Several of the most promising hits were cocrystallized with BioA to provide a framework for future structure-based drug design efforts.}
      \field{issn}{1074-5521}
      \field{journaltitle}{Chemistry {\&} Biology}
      \field{month}{01}
      \field{number}{1}
      \field{title}{{Target-Based Identification of Whole-Cell Active Inhibitors of Biotin Biosynthesis in Mycobacterium tuberculosis}}
      \field{volume}{22}
      \field{year}{2015}
      \field{pages}{76\bibrangedash 86}
      \verb{doi}
      \verb http://dx.doi.org/10.1016/j.chembiol.2014.11.012
      \endverb
      \verb{url}
      \verb http://www.sciencedirect.com/science/article/pii/S1074552114004219
      \endverb
    \endentry
    \entry{Arora2014}{article}{}
      \name{labelname}{7}{}{%
        {{hash=5f5722e01e5e7e19f4c3fcf8bb90f5cc}{Arora}{A\bibinitperiod}{Garima}{G\bibinitperiod}{}{}{}{}}%
        {{hash=1a4de17540d71b6ba10cfa95fd25657e}{Tiwari}{T\bibinitperiod}{Prabhakar}{P\bibinitperiod}{}{}{}{}}%
        {{hash=e0b6ed6a34f5e85b20ac4922ae86a00d}{Mandal}{M\bibinitperiod}{Rahul\bibnamedelima Shubhra}{R\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=00ec883074119e48a096ec3ec50cf00a}{Gupta}{G\bibinitperiod}{Arpit}{A\bibinitperiod}{}{}{}{}}%
        {{hash=e59885af95460776d2989573c763e72e}{Sharma}{S\bibinitperiod}{Deepak}{D\bibinitperiod}{}{}{}{}}%
        {{hash=8b7c3e755091774e225b4b13f18b4b3b}{Saha}{S\bibinitperiod}{Sudipto}{S\bibinitperiod}{}{}{}{}}%
        {{hash=4be4b5b53ba30c69beccb869b653b137}{Singh}{S\bibinitperiod}{Ramandeep}{R\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{7}{}{%
        {{hash=5f5722e01e5e7e19f4c3fcf8bb90f5cc}{Arora}{A\bibinitperiod}{Garima}{G\bibinitperiod}{}{}{}{}}%
        {{hash=1a4de17540d71b6ba10cfa95fd25657e}{Tiwari}{T\bibinitperiod}{Prabhakar}{P\bibinitperiod}{}{}{}{}}%
        {{hash=e0b6ed6a34f5e85b20ac4922ae86a00d}{Mandal}{M\bibinitperiod}{Rahul\bibnamedelima Shubhra}{R\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=00ec883074119e48a096ec3ec50cf00a}{Gupta}{G\bibinitperiod}{Arpit}{A\bibinitperiod}{}{}{}{}}%
        {{hash=e59885af95460776d2989573c763e72e}{Sharma}{S\bibinitperiod}{Deepak}{D\bibinitperiod}{}{}{}{}}%
        {{hash=8b7c3e755091774e225b4b13f18b4b3b}{Saha}{S\bibinitperiod}{Sudipto}{S\bibinitperiod}{}{}{}{}}%
        {{hash=4be4b5b53ba30c69beccb869b653b137}{Singh}{S\bibinitperiod}{Ramandeep}{R\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{bd83ba22dc67c0942620aaf990cabc5f}
      \strng{fullhash}{2298394e04e0682df9a05b6f48196be3}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{High Throughput Screen Identifies Small Molecule Inhibitors Specific for Mycobacterium tuberculosis Phosphoserine Phosphatase}}
      \field{abstract}{The emergence of drug resistant strains of Mycobacterium tuberculosis (M. tuberculosis) makes identification and validation of newer drug targets a global priority. Phosphoserine phosphatase (PSP), a key essential metabolic enzyme involved in conversion of O-phospho-L-serine to L-serine was characterized in this study. The M. tuberculosis genome harbors all enzymes involved in L-serine biosynthesis including 2 PSP homologs, Rv0505c (SerB1) and Rv3042c (SerB2). In the present study we have biochemically characterized SerB2 enzyme and developed malachite green based high throughput assay system (HTS) to identify SerB2 inhibitors. We have identified 10 compounds that were structurally different from known PSP inhibitors and few of these scaffolds were highly specific in their ability to inhibit SerB2 enzyme, non-cytotoxic against mammalian cell lines and inhibited M. tuberculosis growth in vitro. Surface plasma resonance experiments demonstrated the relative binding for these inhibitors. The two best hits identified in our screen, clorobiocin and rosaniline were bactericidal in activity and killed intracellular bacteria in a dose dependent manner. We have also identified amino acid residues critical for these SerB2-small molecule interactions. This is the first study where we validate that M. tuberculosis SerB2 is a druggable and suitable target to pursue for further HTS screening.}
      \field{annotation}{10.1074/jbc.M114.597682}
      \field{journaltitle}{Journal of Biological Chemistry}
      \field{month}{07}
      \field{title}{{High Throughput Screen Identifies Small Molecule Inhibitors Specific for Mycobacterium tuberculosis Phosphoserine Phosphatase}}
      \field{year}{2014}
      \verb{doi}
      \verb 10.1074/jbc.M114.597682
      \endverb
      \verb{url}
      \verb http://www.jbc.org/content/early/2014/07/18/jbc.M114.597682.abstract
      \endverb
    \endentry
    \entry{Ekins2013}{article}{}
      \name{labelname}{3}{}{%
        {{hash=5752f3a4325e2b3630c5d6a2fbf20203}{Ekins}{E\bibinitperiod}{Sean}{S\bibinitperiod}{}{}{}{}}%
        {{hash=b29e3d2397d9dfe5f7aa31eb83854009}{Clark}{C\bibinitperiod}{Alex\bibnamedelima M}{A\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=2ee17840ffa0764e1766671301082834}{Sarker}{S\bibinitperiod}{Malabika}{M\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=5752f3a4325e2b3630c5d6a2fbf20203}{Ekins}{E\bibinitperiod}{Sean}{S\bibinitperiod}{}{}{}{}}%
        {{hash=b29e3d2397d9dfe5f7aa31eb83854009}{Clark}{C\bibinitperiod}{Alex\bibnamedelima M}{A\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=2ee17840ffa0764e1766671301082834}{Sarker}{S\bibinitperiod}{Malabika}{M\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{0c1d5cb8a64cafcba65a66466b4105e9}
      \strng{fullhash}{0c1d5cb8a64cafcba65a66466b4105e9}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{TB Mobile: a mobile app for anti-tuberculosis molecules with known targets}}
      \field{abstract}{An increasing number of researchers are focused on strategies for developing inhibitors of Mycobacterium tuberculosis (Mtb) as tuberculosis (TB) drugs.}
      \field{issn}{1758-2946}
      \field{journaltitle}{Journal of Cheminformatics}
      \field{number}{1}
      \field{title}{{TB Mobile: a mobile app for anti-tuberculosis molecules with known targets}}
      \field{volume}{5}
      \field{year}{2013}
      \field{pages}{1\bibrangedash 14}
      \verb{doi}
      \verb 10.1186/1758-2946-5-13
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1186/1758-2946-5-13
      \endverb
    \endentry
    \entry{Crowther2010}{article}{}
      \name{labelname}{11}{}{%
        {{hash=1e7d02cf40b803f7e666ba3456522cda}{Crowther}{C\bibinitperiod}{Gregory\bibnamedelima J}{G\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=c530077ac76e5b88ee07fd4b2a12221b}{Shanmugam}{S\bibinitperiod}{Dhanasekaran}{D\bibinitperiod}{}{}{}{}}%
        {{hash=18a2c6408fa9f72cacf90d163b0a6168}{Carmona}{C\bibinitperiod}{Santiago\bibnamedelima J}{S\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=baa80a5be2aa40a51a6d75320eb6e906}{Doyle}{D\bibinitperiod}{Maria\bibnamedelima A}{M\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=cab27c24778bcfc63d1cc662fe4dc2d3}{Hertz-Fowler}{H\bibinithyphendelim F\bibinitperiod}{Christiane}{C\bibinitperiod}{}{}{}{}}%
        {{hash=2434c07ae5efa48a249b1894ed10c6c0}{Berriman}{B\bibinitperiod}{Matthew}{M\bibinitperiod}{}{}{}{}}%
        {{hash=5e5aca67350d87e82feb0c1b99bff907}{Nwaka}{N\bibinitperiod}{Solomon}{S\bibinitperiod}{}{}{}{}}%
        {{hash=03ae736dd714fa0199036669c996aae5}{Ralph}{R\bibinitperiod}{Stuart\bibnamedelima A}{S\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=e52eafe861d8f59e41cc13b5b4f96450}{Roos}{R\bibinitperiod}{David\bibnamedelima S}{D\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=e45aa1fa6f62eb50825183bf05f7a5d9}{{Van\bibnamedelimb Voorhis}}{V\bibinitperiod}{Wesley\bibnamedelima C}{W\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=af5876c5e761cc3e2a6cc1edcc6022a1}{Ag\x{fffd}ero}{A\bibinitperiod}{Fern\x{fffd}n}{F\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{11}{}{%
        {{hash=1e7d02cf40b803f7e666ba3456522cda}{Crowther}{C\bibinitperiod}{Gregory\bibnamedelima J}{G\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=c530077ac76e5b88ee07fd4b2a12221b}{Shanmugam}{S\bibinitperiod}{Dhanasekaran}{D\bibinitperiod}{}{}{}{}}%
        {{hash=18a2c6408fa9f72cacf90d163b0a6168}{Carmona}{C\bibinitperiod}{Santiago\bibnamedelima J}{S\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=baa80a5be2aa40a51a6d75320eb6e906}{Doyle}{D\bibinitperiod}{Maria\bibnamedelima A}{M\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=cab27c24778bcfc63d1cc662fe4dc2d3}{Hertz-Fowler}{H\bibinithyphendelim F\bibinitperiod}{Christiane}{C\bibinitperiod}{}{}{}{}}%
        {{hash=2434c07ae5efa48a249b1894ed10c6c0}{Berriman}{B\bibinitperiod}{Matthew}{M\bibinitperiod}{}{}{}{}}%
        {{hash=5e5aca67350d87e82feb0c1b99bff907}{Nwaka}{N\bibinitperiod}{Solomon}{S\bibinitperiod}{}{}{}{}}%
        {{hash=03ae736dd714fa0199036669c996aae5}{Ralph}{R\bibinitperiod}{Stuart\bibnamedelima A}{S\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=e52eafe861d8f59e41cc13b5b4f96450}{Roos}{R\bibinitperiod}{David\bibnamedelima S}{D\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=e45aa1fa6f62eb50825183bf05f7a5d9}{{Van\bibnamedelimb Voorhis}}{V\bibinitperiod}{Wesley\bibnamedelima C}{W\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=af5876c5e761cc3e2a6cc1edcc6022a1}{Ag\x{fffd}ero}{A\bibinitperiod}{Fern\x{fffd}n}{F\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Public Library of Science}%
      }
      \strng{namehash}{16bf0feaed87493db379fb7a5fdf300c}
      \strng{fullhash}{10395e71a9450134924aafc51f1e1874}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Identification of Attractive Drug Targets in Neglected-Disease Pathogens Using an In Silico Approach}}
      \field{abstract}{In cell-based drug development, researchers attempt to create drugs that kill a pathogen without necessarily understanding the details of how the drugs work. In contrast, target-based drug development entails the search for compounds that act on a specific intracellular target?often a protein known or suspected to be required for survival of the pathogen. The latter approach to drug development has been facilitated greatly by the sequencing of many pathogen genomes and the incorporation of genome data into user-friendly databases. The present paper shows how the database TDRtargets.org can identify proteins that might be considered good drug targets for diseases such as African sleeping sickness, Chagas disease, parasitic worm infections, tuberculosis, and malaria. These proteins may score highly in searches of the database because they are dissimilar to human proteins, are structurally similar to other ?druggable? proteins, have functions that are easy to measure, and/or fulfill other criteria. Researchers can use the lists of high-scoring proteins as a basis for deciding which potential drug targets to pursue experimentally.}
      \field{journaltitle}{PLoS Negl Trop Dis}
      \field{month}{08}
      \field{number}{8}
      \field{title}{{Identification of Attractive Drug Targets in Neglected-Disease Pathogens Using an In Silico Approach}}
      \field{volume}{4}
      \field{year}{2010}
      \field{pages}{e804}
      \verb{url}
      \verb http://dx.doi.org/10.1371%7B%%7D2Fjournal.pntd.0000804
      \endverb
    \endentry
    \entry{Ekins2010}{article}{}
      \name{labelname}{8}{}{%
        {{hash=5752f3a4325e2b3630c5d6a2fbf20203}{Ekins}{E\bibinitperiod}{Sean}{S\bibinitperiod}{}{}{}{}}%
        {{hash=575e765c403d077a0daef3dec4661dcb}{Bradford}{B\bibinitperiod}{Justin}{J\bibinitperiod}{}{}{}{}}%
        {{hash=32e361699323ea60524fa7569b11556a}{Dole}{D\bibinitperiod}{Krishna}{K\bibinitperiod}{}{}{}{}}%
        {{hash=89a11b08ffad8bb37917985aefc9982a}{Spektor}{S\bibinitperiod}{Anna}{A\bibinitperiod}{}{}{}{}}%
        {{hash=e5b089155938ceb370607b18d545339c}{Gregory}{G\bibinitperiod}{Kellan}{K\bibinitperiod}{}{}{}{}}%
        {{hash=95174b6fa5d6202d60176a8e5780c412}{Blondeau}{B\bibinitperiod}{David}{D\bibinitperiod}{}{}{}{}}%
        {{hash=45dcab353d8e4f32e3c73d0676fe5b00}{Hohman}{H\bibinitperiod}{Moses}{M\bibinitperiod}{}{}{}{}}%
        {{hash=85fb36f668a6af1185cb14be5b242b31}{Bunin}{B\bibinitperiod}{Barry\bibnamedelima a}{B\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{8}{}{%
        {{hash=5752f3a4325e2b3630c5d6a2fbf20203}{Ekins}{E\bibinitperiod}{Sean}{S\bibinitperiod}{}{}{}{}}%
        {{hash=575e765c403d077a0daef3dec4661dcb}{Bradford}{B\bibinitperiod}{Justin}{J\bibinitperiod}{}{}{}{}}%
        {{hash=32e361699323ea60524fa7569b11556a}{Dole}{D\bibinitperiod}{Krishna}{K\bibinitperiod}{}{}{}{}}%
        {{hash=89a11b08ffad8bb37917985aefc9982a}{Spektor}{S\bibinitperiod}{Anna}{A\bibinitperiod}{}{}{}{}}%
        {{hash=e5b089155938ceb370607b18d545339c}{Gregory}{G\bibinitperiod}{Kellan}{K\bibinitperiod}{}{}{}{}}%
        {{hash=95174b6fa5d6202d60176a8e5780c412}{Blondeau}{B\bibinitperiod}{David}{D\bibinitperiod}{}{}{}{}}%
        {{hash=45dcab353d8e4f32e3c73d0676fe5b00}{Hohman}{H\bibinitperiod}{Moses}{M\bibinitperiod}{}{}{}{}}%
        {{hash=85fb36f668a6af1185cb14be5b242b31}{Bunin}{B\bibinitperiod}{Barry\bibnamedelima a}{B\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{0f369f193e1ab7717e2185c2797e8a90}
      \strng{fullhash}{adf749eb224dfc0c25732ba07c6be8f4}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{A collaborative database and computational models for tuberculosis drug discovery.}}
      \field{abstract}{The search for molecules with activity against Mycobacterium tuberculosis (Mtb) is employing many approaches in parallel including high throughput screening and computational methods. We have developed a database (CDD TB) to capture public and private Mtb data while enabling data mining and collaborations with other researchers. We have used the public data along with several cheminformatics approaches to produce models that describe active and inactive compounds. We have compared these datasets to those for known FDA approved drugs and between Mtb active and inactive compounds. The distribution of polar surface area and pK(a) of active compounds was found to be a statistically significant determinant of activity against Mtb. Hydrophobicity was not always statistically significant. Bayesian classification models for 220, 463 molecules were generated and tested with external molecules, and enabled the discrimination of active or inactive substructures from other datasets in the CDD TB. Computational pharmacophores based on known Mtb drugs were able to map to and retrieve a small subset of some of the Mtb datasets, including a high percentage of Mtb actives. The combination of the database, dataset analysis, Bayesian and pharmacophore models provides new insights into molecular properties and features that are determinants of activity in whole cells. This study provides novel insights into the key 1D molecular descriptors, 2D chemical substructures and 3D pharmacophores which can be used to mine the chemistry space, prioritizing those molecules with a higher probability of activity against Mtb.}
      \field{isbn}{1742-2051 (Electronic)$\backslash$r1742-2051 (Linking)}
      \field{issn}{1742-206X}
      \field{journaltitle}{Molecular bioSystems}
      \field{number}{5}
      \field{title}{{A collaborative database and computational models for tuberculosis drug discovery.}}
      \field{volume}{6}
      \field{year}{2010}
      \field{pages}{840\bibrangedash 851}
      \verb{doi}
      \verb 10.1039/b917766c
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/B917766C.pdf:pdf
      \endverb
    \endentry
    \entry{Kinnings2009}{article}{}
      \name{labelname}{6}{}{%
        {{hash=ccf49e1eef79216484c626f6dcd672cb}{Kinnings}{K\bibinitperiod}{Sarah\bibnamedelima L}{S\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=65c7e91544e551a0ae7b503838594258}{Liu}{L\bibinitperiod}{Nina}{N\bibinitperiod}{}{}{}{}}%
        {{hash=83c8552c3d65bca87bc1e7b45486b2f5}{Buchmeier}{B\bibinitperiod}{Nancy}{N\bibinitperiod}{}{}{}{}}%
        {{hash=c02fffc4f95fe946af461def20320345}{Tonge}{T\bibinitperiod}{Peter\bibnamedelima J}{P\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=d9501bb096bed7e71af1f43d9ee08d98}{Xie}{X\bibinitperiod}{Lei}{L\bibinitperiod}{}{}{}{}}%
        {{hash=7c11f3af2e76014f9f3869e767aba8c4}{Bourne}{B\bibinitperiod}{Philip\bibnamedelima E}{P\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{6}{}{%
        {{hash=ccf49e1eef79216484c626f6dcd672cb}{Kinnings}{K\bibinitperiod}{Sarah\bibnamedelima L}{S\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=65c7e91544e551a0ae7b503838594258}{Liu}{L\bibinitperiod}{Nina}{N\bibinitperiod}{}{}{}{}}%
        {{hash=83c8552c3d65bca87bc1e7b45486b2f5}{Buchmeier}{B\bibinitperiod}{Nancy}{N\bibinitperiod}{}{}{}{}}%
        {{hash=c02fffc4f95fe946af461def20320345}{Tonge}{T\bibinitperiod}{Peter\bibnamedelima J}{P\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=d9501bb096bed7e71af1f43d9ee08d98}{Xie}{X\bibinitperiod}{Lei}{L\bibinitperiod}{}{}{}{}}%
        {{hash=7c11f3af2e76014f9f3869e767aba8c4}{Bourne}{B\bibinitperiod}{Philip\bibnamedelima E}{P\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Public Library of Science}%
      }
      \strng{namehash}{5bd598bf589fd8282cb1ddda1203a564}
      \strng{fullhash}{9c882be9547cc23bc0899619e28d1445}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Drug Discovery Using Chemical Systems Biology: Repositioning the Safe Medicine Comtan to Treat Multi-Drug and Extensively Drug Resistant Tuberculosis}}
      \field{abstract}{{<}title{>}Author Summary{<}/title{>} {<}p{>}The rise of multi-drug resistant (MDR) and extensively drug resistant (XDR) tuberculosis around the world, including in industrialized nations, poses a great threat to human health. This resistance highlights the need to develop new, effective and inexpensive anti-tubercular agents. Unfortunately, conventional approaches have yielded very few successes in the field of anti-infective drug discovery. It is a challenge to design drugs with both efficacy and safety. These challenges are reflected in the high costs involved in bringing new drugs to market. It has been estimated that the cost to launch a successful new drug is in excess of US{\$}800 million. We have developed a novel computational strategy to systematically identify cross-reactivity between different drug target families. In this paper we demonstrate the strength of this approach through the discovery that existing commercially available drugs prescribed for the treatment of Parkinson's disease have the potential to treat MDR and XDR tuberculosis. The protocol described herein can be included in a drug discovery pipeline in an effort to accelerate the development of new drugs with reduced side effects.{<}/p{>}}
      \field{journaltitle}{PLoS Comput Biol}
      \field{month}{07}
      \field{number}{7}
      \field{title}{{Drug Discovery Using Chemical Systems Biology: Repositioning the Safe Medicine Comtan to Treat Multi-Drug and Extensively Drug Resistant Tuberculosis}}
      \field{volume}{5}
      \field{year}{2009}
      \field{pages}{e1000423}
      \verb{url}
      \verb http://dx.doi.org/10.1371%7B%%7D2Fjournal.pcbi.1000423
      \endverb
    \endentry
    \entry{DeJonge2007}{article}{}
      \name{labelname}{5}{}{%
        {{hash=73caf1b80ea52fdae4df55d563fe67e7}{Jonge}{J\bibinitperiod}{Marc\bibnamedelima R}{M\bibinitperiod\bibinitdelim R\bibinitperiod}{de}{d\bibinitperiod}{}{}}%
        {{hash=80f20d1ff5b9337f9705ea450375e585}{Koymans}{K\bibinitperiod}{Luc\bibnamedelimb H\bibnamedelima M}{L\bibinitperiod\bibinitdelim H\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=88f613460682846d13080244f7055659}{Guillemont}{G\bibinitperiod}{J{\'{e}}r{\^{o}}me\bibnamedelimb E\bibnamedelima G}{J\bibinitperiod\bibinitdelim E\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=624c57206eaf07675ab40e09cab6819b}{Koul}{K\bibinitperiod}{Anil}{A\bibinitperiod}{}{}{}{}}%
        {{hash=f96b7db4e4195d4fdf4e1566196ce2a0}{Andries}{A\bibinitperiod}{Koen}{K\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{5}{}{%
        {{hash=73caf1b80ea52fdae4df55d563fe67e7}{Jonge}{J\bibinitperiod}{Marc\bibnamedelima R}{M\bibinitperiod\bibinitdelim R\bibinitperiod}{de}{d\bibinitperiod}{}{}}%
        {{hash=80f20d1ff5b9337f9705ea450375e585}{Koymans}{K\bibinitperiod}{Luc\bibnamedelimb H\bibnamedelima M}{L\bibinitperiod\bibinitdelim H\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=88f613460682846d13080244f7055659}{Guillemont}{G\bibinitperiod}{J{\'{e}}r{\^{o}}me\bibnamedelimb E\bibnamedelima G}{J\bibinitperiod\bibinitdelim E\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=624c57206eaf07675ab40e09cab6819b}{Koul}{K\bibinitperiod}{Anil}{A\bibinitperiod}{}{}{}{}}%
        {{hash=f96b7db4e4195d4fdf4e1566196ce2a0}{Andries}{A\bibinitperiod}{Koen}{K\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Wiley Subscription Services, Inc., A Wiley Company}%
      }
      \strng{namehash}{4f379376ceabea6ff249c7e6e94d42a1}
      \strng{fullhash}{7c20964b0584fadf5f9bb498a3ae9350}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910}}
      \field{issn}{1097-0134}
      \field{journaltitle}{Proteins: Structure, Function, and Bioinformatics}
      \field{month}{06}
      \field{number}{4}
      \field{title}{{A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910}}
      \field{volume}{67}
      \field{year}{2007}
      \field{pages}{971\bibrangedash 980}
      \verb{doi}
      \verb 10.1002/prot.21376
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1002/prot.21376
      \endverb
    \endentry
    \entry{Kumar2009}{article}{}
      \name{labelname}{2}{}{%
        {{hash=19f536f34203969fcb522aabafe24ea3}{Kumar}{K\bibinitperiod}{Ashutosh}{A\bibinitperiod}{}{}{}{}}%
        {{hash=0254373fd95c4e9d15993d2559e0f4df}{Siddiqi}{S\bibinitperiod}{Mohammad\bibnamedelima Imran}{M\bibinitperiod\bibinitdelim I\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=19f536f34203969fcb522aabafe24ea3}{Kumar}{K\bibinitperiod}{Ashutosh}{A\bibinitperiod}{}{}{}{}}%
        {{hash=0254373fd95c4e9d15993d2559e0f4df}{Siddiqi}{S\bibinitperiod}{Mohammad\bibnamedelima Imran}{M\bibinitperiod\bibinitdelim I\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{0ec14916d38c0ecbb6af3980b58f110a}
      \strng{fullhash}{0ec14916d38c0ecbb6af3980b58f110a}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Receptor based 3D-QSAR to identify putative binders of Mycobacterium tuberculosis Enoyl acyl carrier protein reductase}}
      \field{abstract}{In the current study, the applicability and scope of 3D-QSAR models (CoMFA and CoMSIA) to complement virtual screening using 3D pharmacophore and molecular docking is examined and applied to identify potential hits against Mycobacterium tuberculosis Enoyl acyl carrier protein reductase (MtENR). Initially CoMFA and CoMSIA models were developed using series of structurally related arylamides as MtENR inhibitors. Docking studies were employed to position the inhibitors into MtENR active site to derive receptor based 3D-QSAR models. Both CoMFA and CoMSIA yielded significant cross validated q2 values of 0.663 and 0.639 and r2 values of 0.989 and 0.963, respectively. The statistically significant models were validated by a test set of eight compounds with predictive r2 value of 0.882 and 0.875 for CoMFA and CoMSIA. The contour maps from 3D-QSAR models in combination with docked binding structures help to better interpret the structure activity relationship. Integrated with CoMFA and CoMSIA predictive models structure based (3D-pharmacophore and molecular docking) virtual screening have been employed to explore potential hits against MtENR. A representative set of 20 compounds with high predicted IC50 values were sorted out in the present study.}
      \field{issn}{0948-5023}
      \field{journaltitle}{Journal of Molecular Modeling}
      \field{number}{5}
      \field{title}{{Receptor based 3D-QSAR to identify putative binders of Mycobacterium tuberculosis Enoyl acyl carrier protein reductase}}
      \field{volume}{16}
      \field{year}{2009}
      \field{pages}{877\bibrangedash 893}
      \verb{doi}
      \verb 10.1007/s00894-009-0584-0
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1007/s00894-009-0584-0
      \endverb
    \endentry
    \entry{Lew2011}{article}{}
      \name{labelname}{4}{}{%
        {{hash=8845b7662cd3d4cbd59b622b6697b4d1}{Lew}{L\bibinitperiod}{Jocelyne\bibnamedelima M}{J\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=2eecc063e9164b475a87c913e8c57ce9}{Kapopoulou}{K\bibinitperiod}{Adamandia}{A\bibinitperiod}{}{}{}{}}%
        {{hash=6b467b9459a68dd3ca4c7a31ab59624d}{Jones}{J\bibinitperiod}{Louis\bibnamedelima M}{L\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=5caaa32aa1fbff7fb189b8042c605dea}{Cole}{C\bibinitperiod}{Stewart\bibnamedelima T}{S\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=8845b7662cd3d4cbd59b622b6697b4d1}{Lew}{L\bibinitperiod}{Jocelyne\bibnamedelima M}{J\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=2eecc063e9164b475a87c913e8c57ce9}{Kapopoulou}{K\bibinitperiod}{Adamandia}{A\bibinitperiod}{}{}{}{}}%
        {{hash=6b467b9459a68dd3ca4c7a31ab59624d}{Jones}{J\bibinitperiod}{Louis\bibnamedelima M}{L\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=5caaa32aa1fbff7fb189b8042c605dea}{Cole}{C\bibinitperiod}{Stewart\bibnamedelima T}{S\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{9708996f9e7dc5f9b76ab50070c82b77}
      \strng{fullhash}{124869b2fcdc7d55d5827232a0bb6f19}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{TubercuList -- 10 years after}}
      \field{abstract}{Summary TubercuList (http://tuberculist.epfl.ch/), the relational database that presents genome-derived information about H37Rv, the paradigm strain of Mycobacterium tuberculosis, has been active for ten years and now presents its twentieth release. Here, we describe some of the recent changes that have resulted from manual annotation with information from the scientific literature. Through manual curation, TubercuList strives to provide current gene-based information and is thus distinguished from other online sources of genome sequence data for M. tuberculosis. New, mostly small, genes have been discovered and the coordinates of some existing coding sequences have been changed when bioinformatics or experimental data suggest that this is required. Nucleotides that are polymorphic between different sources of H37Rv are annotated and gene essentiality data have been updated. A host of functional information has been gleaned from the literature and many new activities of proteins and RNAs have been included. To facilitate basic and translational research, TubercuList also provides links to other specialized databases that present diverse datasets such as 3D-structures, expression profiles, drug development criteria and drug resistance information, in addition to direct access to PubMed articles pertinent to particular genes. TubercuList has been and remains a highly valuable tool for the tuberculosis research community with {>}75,000 visitors per month.}
      \field{issn}{1472-9792}
      \field{journaltitle}{Tuberculosis}
      \field{month}{01}
      \field{number}{1}
      \field{title}{{TubercuList -- 10 years after}}
      \field{volume}{91}
      \field{year}{2011}
      \field{pages}{1\bibrangedash 7}
      \verb{doi}
      \verb http://dx.doi.org/10.1016/j.tube.2010.09.008
      \endverb
      \verb{url}
      \verb http://www.sciencedirect.com/science/article/pii/S1472979210001113
      \endverb
    \endentry
    \entry{Radusky2014}{article}{}
      \name{labelname}{7}{}{%
        {{hash=fe5bb5a12cbac077e3386095ab5d5563}{Radusky}{R\bibinitperiod}{Leandro}{L\bibinitperiod}{}{}{}{}}%
        {{hash=24bc5c794d795856ef8ded69bd8840a9}{Defelipe}{D\bibinitperiod}{Lucas\bibnamedelima A}{L\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=bc5549d9852fb4f4a9fd54a0b8176944}{Lanzarotti}{L\bibinitperiod}{Esteban}{E\bibinitperiod}{}{}{}{}}%
        {{hash=60c3a2ca50ab034b548e7585d978f287}{Luque}{L\bibinitperiod}{Javier}{J\bibinitperiod}{}{}{}{}}%
        {{hash=632125ec5c0252102e633bb321b1e16a}{Barril}{B\bibinitperiod}{Xavier}{X\bibinitperiod}{}{}{}{}}%
        {{hash=8ff85b0022daa3e701ff0783543845bf}{Marti}{M\bibinitperiod}{Marcelo\bibnamedelima A}{M\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=9585bb94b9f85420b6de2a3aa078e646}{Turjanski}{T\bibinitperiod}{Adri{\'{a}}n\bibnamedelima G}{A\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{7}{}{%
        {{hash=fe5bb5a12cbac077e3386095ab5d5563}{Radusky}{R\bibinitperiod}{Leandro}{L\bibinitperiod}{}{}{}{}}%
        {{hash=24bc5c794d795856ef8ded69bd8840a9}{Defelipe}{D\bibinitperiod}{Lucas\bibnamedelima A}{L\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=bc5549d9852fb4f4a9fd54a0b8176944}{Lanzarotti}{L\bibinitperiod}{Esteban}{E\bibinitperiod}{}{}{}{}}%
        {{hash=60c3a2ca50ab034b548e7585d978f287}{Luque}{L\bibinitperiod}{Javier}{J\bibinitperiod}{}{}{}{}}%
        {{hash=632125ec5c0252102e633bb321b1e16a}{Barril}{B\bibinitperiod}{Xavier}{X\bibinitperiod}{}{}{}{}}%
        {{hash=8ff85b0022daa3e701ff0783543845bf}{Marti}{M\bibinitperiod}{Marcelo\bibnamedelima A}{M\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=9585bb94b9f85420b6de2a3aa078e646}{Turjanski}{T\bibinitperiod}{Adri{\'{a}}n\bibnamedelima G}{A\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{46285b9fe17da8a8af2f09f590aac11a}
      \strng{fullhash}{1fe33895d8c7979e88ab5fe6b6fffe47}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{TuberQ: a Mycobacterium tuberculosis protein druggability database}}
      \field{abstract}{In 2012 an estimated 8.6 million people developed tuberculosis (TB) and 1.3 million died from the disease [including 320\x{2009}000 deaths among human immunodeficiency virus (HIV)-positive people]. There is an urgent need for new anti-TB drugs owing to the following: the fact that current treatments have severe side effects, the increasing emergence of multidrug-resistant strains of Mycobacterium tuberculosis (Mtb), the negative drug--drug interactions with certain HIV (or other disease) treatments and the ineffectiveness against dormant Mtb. In this context we present here the TuberQ database, a novel resource for all researchers working in the field of drug development in TB. The main feature of TuberQ is to provide a druggability analysis of Mtb proteins in a consistent and effective manner, contributing to a better selection of potential drug targets for screening campaigns and the analysis of targets for structure-based drug design projects. The structural druggability analysis is combined with features related to the characteristics of putative inhibitor binding pockets and with functional and biological data of proteins. The structural analysis is performed on all available unique Mtb structures and high-quality structural homology-based models. This information is shown in an interactive manner, depicting the protein structure, the pockets and the associated characteristics for each protein. TuberQ also provides information about gene essentiality information, as determined from whole cell--based knockout experiments, and expression information obtained from microarray experiments done in different stress-related conditions. We hope that TuberQ will be a powerful tool for researchers working in TB and eventually will lead to the identification of novel putative targets and progresses in therapeutic activities.Database URL: http://tuberq.proteinq.com.ar/}
      \field{annotation}{10.1093/database/bau035}
      \field{journaltitle}{Database}
      \field{month}{01}
      \field{title}{{TuberQ: a Mycobacterium tuberculosis protein druggability database}}
      \field{volume}{2014}
      \field{year}{2014}
      \verb{doi}
      \verb 10.1093/database/bau035
      \endverb
      \verb{url}
      \verb http://database.oxfordjournals.org/content/2014/bau035.abstract
      \endverb
    \endentry
    \entry{Clark2014}{article}{}
      \name{labelname}{3}{}{%
        {{hash=e53f75dcb71c9fd5c97d2051342de065}{Clark}{C\bibinitperiod}{Alex\bibnamedelima M.}{A\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=2ee17840ffa0764e1766671301082834}{Sarker}{S\bibinitperiod}{Malabika}{M\bibinitperiod}{}{}{}{}}%
        {{hash=5752f3a4325e2b3630c5d6a2fbf20203}{Ekins}{E\bibinitperiod}{Sean}{S\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=e53f75dcb71c9fd5c97d2051342de065}{Clark}{C\bibinitperiod}{Alex\bibnamedelima M.}{A\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=2ee17840ffa0764e1766671301082834}{Sarker}{S\bibinitperiod}{Malabika}{M\bibinitperiod}{}{}{}{}}%
        {{hash=5752f3a4325e2b3630c5d6a2fbf20203}{Ekins}{E\bibinitperiod}{Sean}{S\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{cec6d90cb4b35f16382906d8d623df6b}
      \strng{fullhash}{cec6d90cb4b35f16382906d8d623df6b}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{New target prediction and visualization tools incorporating open source molecular fingerprints for TB Mobile 2.0}}
      \field{abstract}{BackgroundWe recently developed a freely available mobile app (TB Mobile) for both iOS and Android platforms that displays Mycobacterium tuberculosis (Mtb) active molecule structures and their targets with links to associated data. The app was developed to make target information available to as large an audience as possible.ResultsWe now report a major update of the iOS version of the app. This includes enhancements that use an implementation of ECFP{\_}6 fingerprints that we have made open source. Using these fingerprints, the user can propose compounds with possible anti-TB activity, and view the compounds within a cluster landscape. Proposed compounds can also be compared to existing target data, using a n?ive Bayesian scoring system to rank probable targets. We have curated an additional 60 new compounds and their targets for Mtb and added these to the original set of 745 compounds. We have also curated 20 further compounds (many without targets in TB Mobile) to evaluate this version of the app with 805 compounds and associated targets.Conclusions TB Mobile can now manage a small collection of compounds that can be imported from external sources, or exported by various means such as email or app-to-app inter-process communication. This means that TB Mobile can be used as a node within a growing ecosystem of mobile apps for cheminformatics. It can also cluster compounds and use internal algorithms to help identify potential targets based on molecular similarity. TB Mobile represents a valuable dataset, data-visualization aid and target prediction tool.}
      \field{isbn}{1758-2946}
      \field{issn}{17582946}
      \field{journaltitle}{Journal of Cheminformatics}
      \field{number}{1}
      \field{title}{{New target prediction and visualization tools incorporating open source molecular fingerprints for TB Mobile 2.0}}
      \field{volume}{6}
      \field{year}{2014}
      \field{pages}{1\bibrangedash 17}
      \verb{doi}
      \verb 10.1186/s13321-014-0038-2
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/art{\%}3A10.1186{\%}2Fs13321-014-0038-2.pdf:pdf
      \endverb
    \endentry
    \entry{Rebollo-Lopez2015}{article}{}
      \name{labelname}{24}{}{%
        {{hash=1f1f118c0318d0070d18e4dc30a77626}{Rebollo-Lopez}{R\bibinithyphendelim L\bibinitperiod}{Mar{\'{\i}}a\bibnamedelima Jose}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=57dbebc061f4e8b1479160d3078c3799}{Leli{\`{e}}vre}{L\bibinitperiod}{Jo{\"{e}}l}{J\bibinitperiod}{}{}{}{}}%
        {{hash=d624b2a0fb75d41ac6f14b4ebb6c414e}{Alvarez-Gomez}{A\bibinithyphendelim G\bibinitperiod}{Daniel}{D\bibinitperiod}{}{}{}{}}%
        {{hash=b76d24156916dabb996a815e5b481f90}{Castro-Pichel}{C\bibinithyphendelim P\bibinitperiod}{Julia}{J\bibinitperiod}{}{}{}{}}%
        {{hash=9f1694dcbbd71d71a2b23228fee9da83}{Mart{\'{\i}}nez-Jim{\'{e}}nez}{M\bibinithyphendelim J\bibinitperiod}{Francisco}{F\bibinitperiod}{}{}{}{}}%
        {{hash=d0d9d6fafa34670d65fe13aa0977dbe6}{Papadatos}{P\bibinitperiod}{George}{G\bibinitperiod}{}{}{}{}}%
        {{hash=08a43e8ef8e3a2d464e9e8800f2ab3c9}{Kumar}{K\bibinitperiod}{Vinod}{V\bibinitperiod}{}{}{}{}}%
        {{hash=0c4aa186b62fc42cabaa30bb0046188c}{Colmenarejo}{C\bibinitperiod}{Gonzalo}{G\bibinitperiod}{}{}{}{}}%
        {{hash=2391162477fc4444870064ffe139c2a7}{Mugumbate}{M\bibinitperiod}{Grace}{G\bibinitperiod}{}{}{}{}}%
        {{hash=14a873e8089ad9892c55a43c2d204744}{Hurle}{H\bibinitperiod}{Mark}{M\bibinitperiod}{}{}{}{}}%
        {{hash=eb94738be4b5124a107198c7e147ee7e}{Barroso}{B\bibinitperiod}{Vanessa}{V\bibinitperiod}{}{}{}{}}%
        {{hash=a6a697dfcfe00f4eed02d45342907903}{Young}{Y\bibinitperiod}{Rob\bibnamedelima J}{R\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=af516c68c69249247d8a15ac5ce24cca}{Martinez-Hoyos}{M\bibinithyphendelim H\bibinitperiod}{Mar{\'{\i}}a}{M\bibinitperiod}{}{}{}{}}%
        {{hash=617bd17a1027a151e6f6425da2465227}{{Gonz{\'{a}}lez\bibnamedelimb Del\bibnamedelimb R{\'{\i}}o}}{G\bibinitperiod}{Rub{\'{e}}n}{R\bibinitperiod}{}{}{}{}}%
        {{hash=efe2cecb5400eed22762474ccee551df}{Bates}{B\bibinitperiod}{Robert\bibnamedelima H}{R\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=53f20b82555faedfb12fbcacc78a23a1}{Lopez-Roman}{L\bibinithyphendelim R\bibinitperiod}{Eva\bibnamedelima Maria}{E\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=4827ece82fa835310f281a0eb5872155}{Mendoza-Losana}{M\bibinithyphendelim L\bibinitperiod}{Alfonso}{A\bibinitperiod}{}{}{}{}}%
        {{hash=34171cc7063378bfb9cfc8390ada4490}{Brown}{B\bibinitperiod}{James\bibnamedelima R}{J\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=f961b135ebec0ec2ea7cd846a7f18a40}{Alvarez-Ruiz}{A\bibinithyphendelim R\bibinitperiod}{Emilio}{E\bibinitperiod}{}{}{}{}}%
        {{hash=24f88df3c6af6a41f2b4b5d26f2b5d94}{Marti-Renom}{M\bibinithyphendelim R\bibinitperiod}{Marc\bibnamedelima A}{M\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=53d44917db2ed8d5ebb266672e3d6189}{Overington}{O\bibinitperiod}{John\bibnamedelima P}{J\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=42e7056dbae76aad662a45566123a6e5}{Cammack}{C\bibinitperiod}{Nicholas}{N\bibinitperiod}{}{}{}{}}%
        {{hash=92f9f1ebf3e833237d95513e96fb2683}{Ballell}{B\bibinitperiod}{Llu{\'{\i}}s}{L\bibinitperiod}{}{}{}{}}%
        {{hash=539d4f4009dfac77f29948f95ca2be6d}{Barros-Aguire}{B\bibinithyphendelim A\bibinitperiod}{David}{D\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{24}{}{%
        {{hash=1f1f118c0318d0070d18e4dc30a77626}{Rebollo-Lopez}{R\bibinithyphendelim L\bibinitperiod}{Mar{\'{\i}}a\bibnamedelima Jose}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=57dbebc061f4e8b1479160d3078c3799}{Leli{\`{e}}vre}{L\bibinitperiod}{Jo{\"{e}}l}{J\bibinitperiod}{}{}{}{}}%
        {{hash=d624b2a0fb75d41ac6f14b4ebb6c414e}{Alvarez-Gomez}{A\bibinithyphendelim G\bibinitperiod}{Daniel}{D\bibinitperiod}{}{}{}{}}%
        {{hash=b76d24156916dabb996a815e5b481f90}{Castro-Pichel}{C\bibinithyphendelim P\bibinitperiod}{Julia}{J\bibinitperiod}{}{}{}{}}%
        {{hash=9f1694dcbbd71d71a2b23228fee9da83}{Mart{\'{\i}}nez-Jim{\'{e}}nez}{M\bibinithyphendelim J\bibinitperiod}{Francisco}{F\bibinitperiod}{}{}{}{}}%
        {{hash=d0d9d6fafa34670d65fe13aa0977dbe6}{Papadatos}{P\bibinitperiod}{George}{G\bibinitperiod}{}{}{}{}}%
        {{hash=08a43e8ef8e3a2d464e9e8800f2ab3c9}{Kumar}{K\bibinitperiod}{Vinod}{V\bibinitperiod}{}{}{}{}}%
        {{hash=0c4aa186b62fc42cabaa30bb0046188c}{Colmenarejo}{C\bibinitperiod}{Gonzalo}{G\bibinitperiod}{}{}{}{}}%
        {{hash=2391162477fc4444870064ffe139c2a7}{Mugumbate}{M\bibinitperiod}{Grace}{G\bibinitperiod}{}{}{}{}}%
        {{hash=14a873e8089ad9892c55a43c2d204744}{Hurle}{H\bibinitperiod}{Mark}{M\bibinitperiod}{}{}{}{}}%
        {{hash=eb94738be4b5124a107198c7e147ee7e}{Barroso}{B\bibinitperiod}{Vanessa}{V\bibinitperiod}{}{}{}{}}%
        {{hash=a6a697dfcfe00f4eed02d45342907903}{Young}{Y\bibinitperiod}{Rob\bibnamedelima J}{R\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=af516c68c69249247d8a15ac5ce24cca}{Martinez-Hoyos}{M\bibinithyphendelim H\bibinitperiod}{Mar{\'{\i}}a}{M\bibinitperiod}{}{}{}{}}%
        {{hash=617bd17a1027a151e6f6425da2465227}{{Gonz{\'{a}}lez\bibnamedelimb Del\bibnamedelimb R{\'{\i}}o}}{G\bibinitperiod}{Rub{\'{e}}n}{R\bibinitperiod}{}{}{}{}}%
        {{hash=efe2cecb5400eed22762474ccee551df}{Bates}{B\bibinitperiod}{Robert\bibnamedelima H}{R\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=53f20b82555faedfb12fbcacc78a23a1}{Lopez-Roman}{L\bibinithyphendelim R\bibinitperiod}{Eva\bibnamedelima Maria}{E\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=4827ece82fa835310f281a0eb5872155}{Mendoza-Losana}{M\bibinithyphendelim L\bibinitperiod}{Alfonso}{A\bibinitperiod}{}{}{}{}}%
        {{hash=34171cc7063378bfb9cfc8390ada4490}{Brown}{B\bibinitperiod}{James\bibnamedelima R}{J\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=f961b135ebec0ec2ea7cd846a7f18a40}{Alvarez-Ruiz}{A\bibinithyphendelim R\bibinitperiod}{Emilio}{E\bibinitperiod}{}{}{}{}}%
        {{hash=24f88df3c6af6a41f2b4b5d26f2b5d94}{Marti-Renom}{M\bibinithyphendelim R\bibinitperiod}{Marc\bibnamedelima A}{M\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=53d44917db2ed8d5ebb266672e3d6189}{Overington}{O\bibinitperiod}{John\bibnamedelima P}{J\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=42e7056dbae76aad662a45566123a6e5}{Cammack}{C\bibinitperiod}{Nicholas}{N\bibinitperiod}{}{}{}{}}%
        {{hash=92f9f1ebf3e833237d95513e96fb2683}{Ballell}{B\bibinitperiod}{Llu{\'{\i}}s}{L\bibinitperiod}{}{}{}{}}%
        {{hash=539d4f4009dfac77f29948f95ca2be6d}{Barros-Aguire}{B\bibinithyphendelim A\bibinitperiod}{David}{D\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{576c44671206422b040af987ba7d3184}
      \strng{fullhash}{a1364df07416c4afa144396e7417dd52}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Release of 50 new, drug-like compounds and their computational target predictions for open source anti-tubercular drug discovery.}}
      \field{abstract}{As a follow up to the antimycobacterial screening exercise and the release of GSK{$\textasciiacute$}s first Tres Cantos Antimycobacterial Set (TCAMS-TB), this paper presents the results of a second antitubercular screening effort of two hundred and fifty thousand compounds recently added to the GSK collection. The compounds were further prioritized based on not only antitubercular potency but also on physicochemical characteristics. The 50 most attractive compounds were then progressed for evaluation in three different predictive computational biology algorithms based on structural similarity or GSK historical biological assay data in order to determine their possible mechanisms of action. This effort has resulted in the identification of novel compounds and their hypothesized targets that will hopefully fuel future TB drug discovery and target validation programs alike.}
      \field{isbn}{1932-6203 (Electronic)1932-6203 (Linking)}
      \field{issn}{1932-6203}
      \field{journaltitle}{PloS one}
      \field{number}{12}
      \field{title}{{Release of 50 new, drug-like compounds and their computational target predictions for open source anti-tubercular drug discovery.}}
      \field{volume}{10}
      \field{year}{2015}
      \field{pages}{e0142293}
      \verb{doi}
      \verb 10.1371/journal.pone.0142293
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Rebollo-Lopez et al. - 2015 - Release of 50 new, drug-like compounds and their computational target predictions for open source anti-tub.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/26642067
      \endverb
    \endentry
    \entry{WHO_CANCER}{report}{}
      \name{labelname}{1}{}{%
        {{hash=d61df84a19b345b1669aaec7c0e26f43}{{International\bibnamedelimb Agency\bibnamedelimb for\bibnamedelimb Research\bibnamedelimb on\bibnamedelimb Cancer.}}{I\bibinitperiod}{}{}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=d61df84a19b345b1669aaec7c0e26f43}{{International\bibnamedelimb Agency\bibnamedelimb for\bibnamedelimb Research\bibnamedelimb on\bibnamedelimb Cancer.}}{I\bibinitperiod}{}{}{}{}{}{}}%
      }
      \strng{namehash}{d61df84a19b345b1669aaec7c0e26f43}
      \strng{fullhash}{d61df84a19b345b1669aaec7c0e26f43}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{World Cancer Report 2014}}
      \field{title}{{World Cancer Report 2014}}
      \field{type}{techreport}
      \field{year}{2014}
    \endentry
    \entry{Scott2012}{article}{}
      \name{labelname}{3}{}{%
        {{hash=c2879cb0c04460bef911a04663f2b529}{Scott}{S\bibinitperiod}{A\bibnamedelima M}{A\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=e5f24d4a7c9817c33e3df1a1bace176f}{Wolchok}{W\bibinitperiod}{J\bibnamedelima D}{J\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=e93f5f6ff7d06fbe30598414c6c66ce5}{Old}{O\bibinitperiod}{L\bibnamedelima J}{L\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=c2879cb0c04460bef911a04663f2b529}{Scott}{S\bibinitperiod}{A\bibnamedelima M}{A\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=e5f24d4a7c9817c33e3df1a1bace176f}{Wolchok}{W\bibinitperiod}{J\bibnamedelima D}{J\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=e93f5f6ff7d06fbe30598414c6c66ce5}{Old}{O\bibinitperiod}{L\bibnamedelima J}{L\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group}%
      }
      \strng{namehash}{9b3113f68a0bc2c18bc3f22d6acff6c0}
      \strng{fullhash}{9b3113f68a0bc2c18bc3f22d6acff6c0}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Antibody therapy of cancer}}
      \field{abstract}{The use of monoclonal antibodies (mAbs) for cancer therapy has achieved considerable success in recent years. Antibody-drug conjugates are powerful new treatment options for lymphomas and solid tumours, and immunomodulatory antibodies have also recently achieved remarkable clinical success. The development of therapeutic antibodies requires a deep understanding of cancer serology, protein-engineering techniques, mechanisms of action and resistance, and the interplay between the immune system and cancer cells. This Review outlines the fundamental strategies that are required to develop antibody therapies for cancer patients through iterative approaches to target and antibody selection, extending from preclinical studies to human trials.}
      \field{isbn}{1474-1768 (Electronic)$\backslash$r1474-175X (Linking)}
      \field{issn}{1474-1768}
      \field{journaltitle}{Nat Rev Cancer}
      \field{number}{4}
      \field{title}{{Antibody therapy of cancer}}
      \field{volume}{12}
      \field{year}{2012}
      \field{pages}{278\bibrangedash 287}
      \verb{doi}
      \verb 10.1038/nrc3236
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/nrc3236.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/22437872
      \endverb
    \endentry
    \entry{Jonker2007}{article}{}
      \name{labelname}{15}{}{%
        {{hash=c6e9b799fa77d0c4610b27ff9b6e3e3a}{Jonker}{J\bibinitperiod}{Derek\bibnamedelima J}{D\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=d9a5e453b03655da31387662d9cc3a78}{O'Callaghan}{O\bibinitperiod}{Chris\bibnamedelima J}{C\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=69bfd6ca4a0982e2e124068cfcac251f}{Karapetis}{K\bibinitperiod}{Christos\bibnamedelima S}{C\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=cf001a2eb6a5bbbf502832fd598d994f}{Zalcberg}{Z\bibinitperiod}{John\bibnamedelima R}{J\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=6e580e6c8f80947c6d4390f8a6a1b594}{Tu}{T\bibinitperiod}{Dongsheng}{D\bibinitperiod}{}{}{}{}}%
        {{hash=893af5b39bba1f1b9703e2ef81a71bc4}{Au}{A\bibinitperiod}{Heather-Jane}{H\bibinithyphendelim J\bibinitperiod}{}{}{}{}}%
        {{hash=699404d477533a7283397ce9c14cbd29}{Berry}{B\bibinitperiod}{Scott\bibnamedelima R}{S\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=d6101a2eeee9c721cb7959e4ed97bc7e}{Krahn}{K\bibinitperiod}{Marianne}{M\bibinitperiod}{}{}{}{}}%
        {{hash=ad1098e31f8438fd3daace7d33281ded}{Price}{P\bibinitperiod}{Timothy}{T\bibinitperiod}{}{}{}{}}%
        {{hash=733968338f24bdb2bde63e0c10e249c8}{Simes}{S\bibinitperiod}{R\bibnamedelima John}{R\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=5aa6cac075472f40d29514d5c87cd394}{Tebbutt}{T\bibinitperiod}{Niall\bibnamedelima C}{N\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=51238d89ced2bd90995287231ed9a61c}{Hazel}{H\bibinitperiod}{Guy}{G\bibinitperiod}{van}{v\bibinitperiod}{}{}}%
        {{hash=5d6972f2c86aff4a10f50fb986728d77}{Wierzbicki}{W\bibinitperiod}{Rafal}{R\bibinitperiod}{}{}{}{}}%
        {{hash=d72a7cf38af6e6da4fb72b0ccdebee61}{Langer}{L\bibinitperiod}{Christiane}{C\bibinitperiod}{}{}{}{}}%
        {{hash=b2dce0962f84cbac2095d2c9ea065d47}{Moore}{M\bibinitperiod}{Malcolm\bibnamedelima J}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{15}{}{%
        {{hash=c6e9b799fa77d0c4610b27ff9b6e3e3a}{Jonker}{J\bibinitperiod}{Derek\bibnamedelima J}{D\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=d9a5e453b03655da31387662d9cc3a78}{O'Callaghan}{O\bibinitperiod}{Chris\bibnamedelima J}{C\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=69bfd6ca4a0982e2e124068cfcac251f}{Karapetis}{K\bibinitperiod}{Christos\bibnamedelima S}{C\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=cf001a2eb6a5bbbf502832fd598d994f}{Zalcberg}{Z\bibinitperiod}{John\bibnamedelima R}{J\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=6e580e6c8f80947c6d4390f8a6a1b594}{Tu}{T\bibinitperiod}{Dongsheng}{D\bibinitperiod}{}{}{}{}}%
        {{hash=893af5b39bba1f1b9703e2ef81a71bc4}{Au}{A\bibinitperiod}{Heather-Jane}{H\bibinithyphendelim J\bibinitperiod}{}{}{}{}}%
        {{hash=699404d477533a7283397ce9c14cbd29}{Berry}{B\bibinitperiod}{Scott\bibnamedelima R}{S\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=d6101a2eeee9c721cb7959e4ed97bc7e}{Krahn}{K\bibinitperiod}{Marianne}{M\bibinitperiod}{}{}{}{}}%
        {{hash=ad1098e31f8438fd3daace7d33281ded}{Price}{P\bibinitperiod}{Timothy}{T\bibinitperiod}{}{}{}{}}%
        {{hash=733968338f24bdb2bde63e0c10e249c8}{Simes}{S\bibinitperiod}{R\bibnamedelima John}{R\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=5aa6cac075472f40d29514d5c87cd394}{Tebbutt}{T\bibinitperiod}{Niall\bibnamedelima C}{N\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=51238d89ced2bd90995287231ed9a61c}{Hazel}{H\bibinitperiod}{Guy}{G\bibinitperiod}{van}{v\bibinitperiod}{}{}}%
        {{hash=5d6972f2c86aff4a10f50fb986728d77}{Wierzbicki}{W\bibinitperiod}{Rafal}{R\bibinitperiod}{}{}{}{}}%
        {{hash=d72a7cf38af6e6da4fb72b0ccdebee61}{Langer}{L\bibinitperiod}{Christiane}{C\bibinitperiod}{}{}{}{}}%
        {{hash=b2dce0962f84cbac2095d2c9ea065d47}{Moore}{M\bibinitperiod}{Malcolm\bibnamedelima J}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Massachusetts Medical Society}%
      }
      \strng{namehash}{634a3f810118ce9e64eea4c27878da7b}
      \strng{fullhash}{96fa606caabe707d7a28a04587f138b1}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Cetuximab for the Treatment of Colorectal Cancer}}
      \field{annotation}{doi: 10.1056/NEJMoa071834}
      \field{issn}{0028-4793}
      \field{journaltitle}{New England Journal of Medicine}
      \field{month}{11}
      \field{number}{20}
      \field{title}{{Cetuximab for the Treatment of Colorectal Cancer}}
      \field{volume}{357}
      \field{year}{2007}
      \field{pages}{2040\bibrangedash 2048}
      \verb{doi}
      \verb 10.1056/NEJMoa071834
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1056/NEJMoa071834
      \endverb
    \endentry
    \entry{Tejani2010}{article}{}
      \name{labelname}{3}{}{%
        {{hash=a53cea8ee1778ee656221ba5f62b0d59}{Tejani}{T\bibinitperiod}{Mohamedtaki\bibnamedelima A}{M\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=8ba6359b60241bf39c9056f9b0b50861}{Cohen}{C\bibinitperiod}{Roger\bibnamedelima B}{R\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=1fbc9c450ea738693452edf63e581bb5}{Mehra}{M\bibinitperiod}{Ranee}{R\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=a53cea8ee1778ee656221ba5f62b0d59}{Tejani}{T\bibinitperiod}{Mohamedtaki\bibnamedelima A}{M\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=8ba6359b60241bf39c9056f9b0b50861}{Cohen}{C\bibinitperiod}{Roger\bibnamedelima B}{R\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=1fbc9c450ea738693452edf63e581bb5}{Mehra}{M\bibinitperiod}{Ranee}{R\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Dove Medical Press}%
      }
      \strng{namehash}{7ca53ee8af2e6d31324538c94d3ef19a}
      \strng{fullhash}{7ca53ee8af2e6d31324538c94d3ef19a}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer}}
      \field{abstract}{Recurrent and/or metastatic squamous cell carcinoma of the head and neck (HNSCC) continues to be a source of significant morbidity and mortality worldwide. Agents that target the epidermal growth factor receptor (EGFR) have demonstrated beneficial effects in this setting. Cetuximab, a monoclonal antibody against the EGFR, improves locoregional control and overall survival when used as a radiation sensitizer in patients with locoregionally advanced HNSCC undergoing definitive radiation therapy with curative intent. Cetuximab is also active as monotherapy in patients whose cancer has progressed on platinum-containing therapy. In the first-line setting for incurable HNSCC, cetuximab added to platinum-based chemotherapy significantly improves overall survival compared with standard chemotherapy alone. These positive results have had a significant impact on the standard of care for advanced HNSCC. In this review, we will discuss the mechanism of action, clinical data and common toxicities that pertain to the use of cetuximab in the treatment of advanced incurable HNSCC.}
      \field{issn}{1177-5475}
      \field{journaltitle}{Biologics : Targets {\&} Therapy}
      \field{month}{08}
      \field{title}{{The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer}}
      \field{volume}{4}
      \field{year}{2010}
      \field{pages}{173\bibrangedash 185}
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2921255/
      \endverb
    \endentry
    \entry{Postow2015}{article}{}
      \name{labelname}{3}{}{%
        {{hash=fd2930a953d64909361cbf0683108878}{Postow}{P\bibinitperiod}{Michael\bibnamedelima A}{M\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=85d150de8f80fd8b247ca39c2e18b97f}{Callahan}{C\bibinitperiod}{Margaret\bibnamedelima K}{M\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=a050b2ff75bda8e77c969fa33ce9bccf}{Wolchok}{W\bibinitperiod}{Jedd\bibnamedelima D}{J\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=fd2930a953d64909361cbf0683108878}{Postow}{P\bibinitperiod}{Michael\bibnamedelima A}{M\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=85d150de8f80fd8b247ca39c2e18b97f}{Callahan}{C\bibinitperiod}{Margaret\bibnamedelima K}{M\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=a050b2ff75bda8e77c969fa33ce9bccf}{Wolchok}{W\bibinitperiod}{Jedd\bibnamedelima D}{J\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{dfb1be449dd939369d90a8101230efb4}
      \strng{fullhash}{dfb1be449dd939369d90a8101230efb4}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Immune Checkpoint Blockade in Cancer Therapy}}
      \field{abstract}{Immunologic checkpoint blockade with antibodies that target cytotoxic T lymphocyte--associated antigen 4 (CTLA-4) and the programmed cell death protein 1 pathway (PD-1/PD-L1) have demonstrated promise in a variety of malignancies. Ipilimumab (CTLA-4) and pembrolizumab (PD-1) are approved by the US Food and Drug Administration for the treatment of advanced melanoma, and additional regulatory approvals are expected across the oncologic spectrum for a variety of other agents that target these pathways. Treatment with both CTLA-4 and PD-1/PD-L1 blockade is associated with a unique pattern of adverse events called immune-related adverse events, and occasionally, unusual kinetics of tumor response are seen. Combination approaches involving CTLA-4 and PD-1/PD-L1 blockade are being investigated to determine whether they enhance the efficacy of either approach alone. Principles learned during the development of CTLA-4 and PD-1/PD-L1 approaches will likely be used as new immunologic checkpoint blocking antibodies begin clinical investigation.}
      \field{annotation}{10.1200/JCO.2014.59.4358}
      \field{journaltitle}{Journal of Clinical Oncology}
      \field{month}{01}
      \field{title}{{Immune Checkpoint Blockade in Cancer Therapy}}
      \field{year}{2015}
      \verb{doi}
      \verb 10.1200/JCO.2014.59.4358
      \endverb
      \verb{url}
      \verb http://jco.ascopubs.org/content/early/2015/01/20/JCO.2014.59.4358.abstract
      \endverb
    \endentry
    \entry{Demko2008}{article}{}
      \name{labelname}{4}{}{%
        {{hash=72ccad56c5750313d6698db300a32086}{Demko}{D\bibinitperiod}{Suzanne}{S\bibinitperiod}{}{}{}{}}%
        {{hash=7a086a0862d6af9a7e0942f4e8aacab5}{Summers}{S\bibinitperiod}{Jeffrey}{J\bibinitperiod}{}{}{}{}}%
        {{hash=681df724680c3d0b0f010a44eed156c6}{Keegan}{K\bibinitperiod}{Patricia}{P\bibinitperiod}{}{}{}{}}%
        {{hash=1c83ded9b78682dc95ab5f6263482297}{Pazdur}{P\bibinitperiod}{Richard}{R\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=72ccad56c5750313d6698db300a32086}{Demko}{D\bibinitperiod}{Suzanne}{S\bibinitperiod}{}{}{}{}}%
        {{hash=7a086a0862d6af9a7e0942f4e8aacab5}{Summers}{S\bibinitperiod}{Jeffrey}{J\bibinitperiod}{}{}{}{}}%
        {{hash=681df724680c3d0b0f010a44eed156c6}{Keegan}{K\bibinitperiod}{Patricia}{P\bibinitperiod}{}{}{}{}}%
        {{hash=1c83ded9b78682dc95ab5f6263482297}{Pazdur}{P\bibinitperiod}{Richard}{R\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{11edace4cb15c235b727c528d0c9af55}
      \strng{fullhash}{6d979bc47b7844bae92c9fe65f4587db}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{FDA Drug Approval Summary: Alemtuzumab as Single-Agent Treatment for B-Cell Chronic Lymphocytic Leukemia}}
      \field{abstract}{On September 19, 2007, the U.S. Food and Drug Administration granted regular approval and expanded labeling for alemtuzumab (Campath{{$\textregistered$}}; Genzyme Corporation, Cambridge, MA) as single-agent treatment for B-cell chronic lymphocytic leukemia (B-CLL). Alemtuzumab was initially approved in 2001 under accelerated approval regulations. Conversion to regular approval was based on a single study submitted to verify clinical benefit. Efficacy and safety were demonstrated in an open-label, international, multicenter, randomized trial of 297 patients with previously untreated, Rai stage I--IV B-CLL experiencing progression of their disease. Patients were randomized to either alemtuzumab, 30 mg i.v. over 2 hours three times per week on alternate days for a maximum of 12 weeks, or chlorambucil, 40 mg/m2 orally every 28 days for a maximum of 12 months. The progression-free survival time, the primary study endpoint, was significantly longer in the alemtuzumab arm than in the chlorambucil arm. Both the overall and complete response rates were also significantly higher in the alemtuzumab arm. No differences in survival were observed. There were no new safety signals identified in patients receiving alemtuzumab. The most serious, and sometimes fatal, toxicities of alemtuzumab are cytopenias, infusion reactions, and infections.}
      \field{annotation}{10.1634/theoncologist.2007-0218}
      \field{journaltitle}{The Oncologist}
      \field{month}{02}
      \field{number}{2}
      \field{title}{{FDA Drug Approval Summary: Alemtuzumab as Single-Agent Treatment for B-Cell Chronic Lymphocytic Leukemia}}
      \field{volume}{13}
      \field{year}{2008}
      \field{pages}{167\bibrangedash 174}
      \verb{doi}
      \verb 10.1634/theoncologist.2007-0218
      \endverb
      \verb{url}
      \verb http://theoncologist.alphamedpress.org/content/13/2/167.abstract
      \endverb
    \endentry
    \entry{Ferrara2004}{article}{}
      \name{labelname}{4}{}{%
        {{hash=b2a522ffc1a8087f44ce47bce13aac2a}{Ferrara}{F\bibinitperiod}{Napoleone}{N\bibinitperiod}{}{}{}{}}%
        {{hash=df9e45131e1cb39a36f3d6e271e41885}{Hillan}{H\bibinitperiod}{Kenneth\bibnamedelima J}{K\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=6aa9a7a85062864c38e5c7ad11693c9c}{Gerber}{G\bibinitperiod}{Hans-Peter}{H\bibinithyphendelim P\bibinitperiod}{}{}{}{}}%
        {{hash=aa84810acd391c68618d3e96db5fd2ff}{Novotny}{N\bibinitperiod}{William}{W\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=b2a522ffc1a8087f44ce47bce13aac2a}{Ferrara}{F\bibinitperiod}{Napoleone}{N\bibinitperiod}{}{}{}{}}%
        {{hash=df9e45131e1cb39a36f3d6e271e41885}{Hillan}{H\bibinitperiod}{Kenneth\bibnamedelima J}{K\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=6aa9a7a85062864c38e5c7ad11693c9c}{Gerber}{G\bibinitperiod}{Hans-Peter}{H\bibinithyphendelim P\bibinitperiod}{}{}{}{}}%
        {{hash=aa84810acd391c68618d3e96db5fd2ff}{Novotny}{N\bibinitperiod}{William}{W\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{706247e205c1c091a5abaf9c11900637}
      \strng{fullhash}{116bddec72fd976d38e5c0a517938412}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer}}
      \field{annotation}{10.1038/nrd1381}
      \field{issn}{1474-1776}
      \field{journaltitle}{Nat Rev Drug Discov}
      \field{month}{05}
      \field{number}{5}
      \field{title}{{Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer}}
      \field{volume}{3}
      \field{year}{2004}
      \field{pages}{391\bibrangedash 400}
      \verb{url}
      \verb http://dx.doi.org/10.1038/nrd1381
      \endverb
    \endentry
    \entry{Keating2014}{article}{}
      \name{labelname}{1}{}{%
        {{hash=1212c1603bc2a7ff9ecc8ca9658bad9a}{Keating}{K\bibinitperiod}{Gillian\bibnamedelima M}{G\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=1212c1603bc2a7ff9ecc8ca9658bad9a}{Keating}{K\bibinitperiod}{Gillian\bibnamedelima M}{G\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{1212c1603bc2a7ff9ecc8ca9658bad9a}
      \strng{fullhash}{1212c1603bc2a7ff9ecc8ca9658bad9a}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Bevacizumab: A Review of Its Use in Advanced Cancer}}
      \field{abstract}{The humanized monoclonal antibody bevacizumab (Avastin{{$\textregistered$}}) has been available in the EU since 2005. Results of phase III trials demonstrate that adding intravenous bevacizumab to antineoplastic agents improves progression-free survival and/or overall survival in patients with advanced cancer, including when used as first- or second-line therapy in metastatic colorectal cancer, as first-line therapy in advanced nonsquamous non-small cell lung cancer, as first-line therapy in metastatic renal cell carcinoma, as first-line therapy in metastatic breast cancer, and as first-line therapy in epithelial ovarian, fallopian tube or primary peritoneal cancer or in recurrent, platinum-sensitive or platinum-resistant disease. Results of these studies are supported by the findings of routine oncology practice studies conducted in real-world settings. The tolerability profile of bevacizumab is well defined and adverse events associated with its use (e.g. hypertension, proteinuria, haemorrhage, wound healing complications, arterial thromboembolism, gastrointestinal perforation) are generally manageable. In conclusion, bevacizumab remains an important option for use in patients with advanced cancer.}
      \field{issn}{1179-1950}
      \field{journaltitle}{Drugs}
      \field{number}{16}
      \field{title}{{Bevacizumab: A Review of Its Use in Advanced Cancer}}
      \field{volume}{74}
      \field{year}{2014}
      \field{pages}{1891\bibrangedash 1925}
      \verb{doi}
      \verb 10.1007/s40265-014-0302-9
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1007/s40265-014-0302-9
      \endverb
    \endentry
    \entry{Witzig2002}{article}{}
      \name{labelname}{11}{}{%
        {{hash=a5501d45dea767217a8dc453214b05ab}{Witzig}{W\bibinitperiod}{Thomas\bibnamedelima E}{T\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=4e157da32ee3dd419dffa84c1174e575}{Flinn}{F\bibinitperiod}{Ian\bibnamedelima W}{I\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=042e5e17ad292ca3d82a324d6c7d8475}{Gordon}{G\bibinitperiod}{Leo\bibnamedelima I}{L\bibinitperiod\bibinitdelim I\bibinitperiod}{}{}{}{}}%
        {{hash=42b800df62abeff7f982ee046c543048}{Emmanouilides}{E\bibinitperiod}{Christos}{C\bibinitperiod}{}{}{}{}}%
        {{hash=073dea46926e033deb955e7e824a014c}{Czuczman}{C\bibinitperiod}{Myron\bibnamedelima S}{M\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=d6f70fbc2e302273fb0361ca86c63936}{Saleh}{S\bibinitperiod}{Mansoor\bibnamedelima N}{M\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
        {{hash=37c73f41a49c1176cb4dc8527762e484}{Cripe}{C\bibinitperiod}{Larry}{L\bibinitperiod}{}{}{}{}}%
        {{hash=2d6d76a0e7ea136010c720691b44044a}{Wiseman}{W\bibinitperiod}{Gregory}{G\bibinitperiod}{}{}{}{}}%
        {{hash=ac8e0fc3cf4f98fce55593b31f30a387}{Olejnik}{O\bibinitperiod}{Teresa}{T\bibinitperiod}{}{}{}{}}%
        {{hash=c0e0ba3c4a509656d57586010d59ba34}{Multani}{M\bibinitperiod}{Pratik\bibnamedelima S}{P\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=5641b1c1cd0cf4267ea19a2223dbc7f3}{White}{W\bibinitperiod}{Christine\bibnamedelima A}{C\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{11}{}{%
        {{hash=a5501d45dea767217a8dc453214b05ab}{Witzig}{W\bibinitperiod}{Thomas\bibnamedelima E}{T\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=4e157da32ee3dd419dffa84c1174e575}{Flinn}{F\bibinitperiod}{Ian\bibnamedelima W}{I\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=042e5e17ad292ca3d82a324d6c7d8475}{Gordon}{G\bibinitperiod}{Leo\bibnamedelima I}{L\bibinitperiod\bibinitdelim I\bibinitperiod}{}{}{}{}}%
        {{hash=42b800df62abeff7f982ee046c543048}{Emmanouilides}{E\bibinitperiod}{Christos}{C\bibinitperiod}{}{}{}{}}%
        {{hash=073dea46926e033deb955e7e824a014c}{Czuczman}{C\bibinitperiod}{Myron\bibnamedelima S}{M\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=d6f70fbc2e302273fb0361ca86c63936}{Saleh}{S\bibinitperiod}{Mansoor\bibnamedelima N}{M\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
        {{hash=37c73f41a49c1176cb4dc8527762e484}{Cripe}{C\bibinitperiod}{Larry}{L\bibinitperiod}{}{}{}{}}%
        {{hash=2d6d76a0e7ea136010c720691b44044a}{Wiseman}{W\bibinitperiod}{Gregory}{G\bibinitperiod}{}{}{}{}}%
        {{hash=ac8e0fc3cf4f98fce55593b31f30a387}{Olejnik}{O\bibinitperiod}{Teresa}{T\bibinitperiod}{}{}{}{}}%
        {{hash=c0e0ba3c4a509656d57586010d59ba34}{Multani}{M\bibinitperiod}{Pratik\bibnamedelima S}{P\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=5641b1c1cd0cf4267ea19a2223dbc7f3}{White}{W\bibinitperiod}{Christine\bibnamedelima A}{C\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{a14c42100cf6586b7f23c9f356136702}
      \strng{fullhash}{1ddf54d4357679b161f9e61866d77bdc}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin's Lymphoma}}
      \field{abstract}{PURPOSE: Rituximab is commonly used as a single agent or in combination therapy for non-Hodgkin's lymphoma (NHL). Ibritumomab tiuxetan radioimmunotherapy targets the same antigen as rituximab and has demonstrated efficacy in rituximab-na{\"{\i}}ve NHL. This study evaluated ibritumomab tiuxetan in the treatment of rituximab-refractory follicular NHL.PATIENTS AND METHODS: Eligible patients were refractory to rituximab; this was defined as no objective response to rituximab (375 mg/m2 weekly for 4 weeks) or time to progression (TTP) of \x{2264} 6 months. The ibritumomab tiuxetan treatment regimen consisted of pretreatment with rituximab (250 mg/m2 intravenously on days 1 and 8) to deplete peripheral blood B cells, then yttrium-90 ibritumomab tiuxetan (0.4 mCi/kg; maximum, 32 mCi) intravenously on day 8, administered on an outpatient basis. An imaging/dosimetry dose of indium-111 ibritumomab tiuxetan (5 mCi) was injected after rituximab (day 1) in 28 patients.RESULTS: Fifty-seven patients were treated. The median age was 54 years, 74{\%} had tumors \x{2265} 5 cm, and all were extensively pretreated (median, four prior therapies; range, one to nine). The estimated radiation-absorbed doses to healthy organs were below the study-defined limit in all patients studied with dosimetry. The overall response rate for the 54 patients with follicular NHL was 74{\%} (15{\%} complete responses and 59{\%} partial responses). The Kaplan-Meier--estimated TTP was 6.8 months (range, 1.1 to \x{2265} 25.9 months) for all patients and 8.7 months for responders. Adverse events were primarily hematologic; the incidence of grade 4 neutropenia, thrombocytopenia, and anemia was 35{\%}, 9{\%}, and 4{\%}, respectively.CONCLUSION: Ibritumomab tiuxetan radioimmunotherapy is effective in rituximab-refractory patients. The only significant toxicity is hematologic.}
      \field{annotation}{10.1200/JCO.2002.11.017}
      \field{journaltitle}{Journal of Clinical Oncology}
      \field{month}{08}
      \field{number}{15}
      \field{title}{{Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin's Lymphoma}}
      \field{volume}{20}
      \field{year}{2002}
      \field{pages}{3262\bibrangedash 3269}
      \verb{doi}
      \verb 10.1200/JCO.2002.11.017
      \endverb
      \verb{url}
      \verb http://jco.ascopubs.org/content/20/15/3262.abstract
      \endverb
    \endentry
    \entry{Zhang2009}{article}{}
      \name{labelname}{3}{}{%
        {{hash=ac94487142bcc73ec00646f41c277977}{Zhang}{Z\bibinitperiod}{Jianming}{J\bibinitperiod}{}{}{}{}}%
        {{hash=60061fbf1aecd520b9add74fdc4f61eb}{Yang}{Y\bibinitperiod}{Priscilla\bibnamedelima L}{P\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=fabe6c6461e55d2d47e6c8fb604e93f8}{Gray}{G\bibinitperiod}{Nathanael\bibnamedelima S}{N\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=ac94487142bcc73ec00646f41c277977}{Zhang}{Z\bibinitperiod}{Jianming}{J\bibinitperiod}{}{}{}{}}%
        {{hash=60061fbf1aecd520b9add74fdc4f61eb}{Yang}{Y\bibinitperiod}{Priscilla\bibnamedelima L}{P\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=fabe6c6461e55d2d47e6c8fb604e93f8}{Gray}{G\bibinitperiod}{Nathanael\bibnamedelima S}{N\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{4737b124b9a903e114646b7add908b56}
      \strng{fullhash}{4737b124b9a903e114646b7add908b56}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Targeting cancer with small molecule kinase inhibitors.}}
      \field{abstract}{Deregulation of kinase activity has emerged as a major mechanism by which cancer cells evade normal physiological constraints on growth and survival. To date, 11 kinase inhibitors have received US Food and Drug Administration approval as cancer treatments, and there are considerable efforts to develop selective small molecule inhibitors for a host of other kinases that are implicated in cancer and other diseases. Herein we discuss the current challenges in the field, such as designing selective inhibitors and developing strategies to overcome resistance mutations. This Review provides a broad overview of some of the approaches currently used to discover and characterize new kinase inhibitors.}
      \field{isbn}{1474-1768 (Electronic)$\backslash$r1474-175X (Linking)}
      \field{issn}{1474-175X}
      \field{journaltitle}{Nature reviews. Cancer}
      \field{number}{1}
      \field{title}{{Targeting cancer with small molecule kinase inhibitors.}}
      \field{volume}{9}
      \field{year}{2009}
      \field{pages}{28\bibrangedash 39}
      \verb{doi}
      \verb 10.1038/nrc2559
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Zhang, Yang, Gray - 2009 - Targeting cancer with small molecule kinase inhibitors.pdf:pdf
      \endverb
    \endentry
    \entry{Weinstein2006}{article}{}
      \name{labelname}{2}{}{%
        {{hash=74d62037270ddb2e03fd11225533f92f}{Weinstein}{W\bibinitperiod}{I\bibnamedelima Bernard}{I\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=93296d435079f596cc8fa9d0f324ebde}{Joe}{J\bibinitperiod}{Andrew\bibnamedelima K}{A\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=74d62037270ddb2e03fd11225533f92f}{Weinstein}{W\bibinitperiod}{I\bibnamedelima Bernard}{I\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=93296d435079f596cc8fa9d0f324ebde}{Joe}{J\bibinitperiod}{Andrew\bibnamedelima K}{A\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group}%
      }
      \strng{namehash}{d21d5aa8f242645786db752a18086eb9}
      \strng{fullhash}{d21d5aa8f242645786db752a18086eb9}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Mechanisms of Disease: oncogene addiction, a rationale for molecular targeting in cancer therapy}}
      \field{annotation}{10.1038/ncponc0558}
      \field{issn}{1743-4254}
      \field{journaltitle}{Nat Clin Prac Oncol}
      \field{month}{08}
      \field{number}{8}
      \field{title}{{Mechanisms of Disease: oncogene addiction, a rationale for molecular targeting in cancer therapy}}
      \field{volume}{3}
      \field{year}{2006}
      \field{pages}{448\bibrangedash 457}
      \verb{url}
      \verb http://dx.doi.org/10.1038/ncponc0558
      \endverb
    \endentry
    \entry{Ascierto2012}{article}{}
      \name{labelname}{10}{}{%
        {{hash=63c3b9ff59855459e565e6ae64dd2713}{Ascierto}{A\bibinitperiod}{Paolo\bibnamedelima A}{P\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=892d9643aee836f231303fa78c56aac6}{Kirkwood}{K\bibinitperiod}{John\bibnamedelima M}{J\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=614521d0b379184a21884e77ad486c01}{Grob}{G\bibinitperiod}{Jean-Jacques}{J\bibinithyphendelim J\bibinitperiod}{}{}{}{}}%
        {{hash=16d2ea111feffd7f496d76ade0635e37}{Simeone}{S\bibinitperiod}{Ester}{E\bibinitperiod}{}{}{}{}}%
        {{hash=113ae64f180f9fc5faeb1e02d978a869}{Grimaldi}{G\bibinitperiod}{Antonio\bibnamedelima M}{A\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=7ea227bd53fa458e9cfd6f3c8c43a57b}{Maio}{M\bibinitperiod}{Michele}{M\bibinitperiod}{}{}{}{}}%
        {{hash=f495a50af03456104e9ff153638c407e}{Palmieri}{P\bibinitperiod}{Giuseppe}{G\bibinitperiod}{}{}{}{}}%
        {{hash=5b2142b1987d2960913536de79a02db8}{Testori}{T\bibinitperiod}{Alessandro}{A\bibinitperiod}{}{}{}{}}%
        {{hash=8b609333a7ea38d53e768bb289bebf47}{Marincola}{M\bibinitperiod}{Francesco\bibnamedelima M}{F\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=8613f2ab157d054968edfbbf9e57a3d8}{Mozzillo}{M\bibinitperiod}{Nicola}{N\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{10}{}{%
        {{hash=63c3b9ff59855459e565e6ae64dd2713}{Ascierto}{A\bibinitperiod}{Paolo\bibnamedelima A}{P\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=892d9643aee836f231303fa78c56aac6}{Kirkwood}{K\bibinitperiod}{John\bibnamedelima M}{J\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=614521d0b379184a21884e77ad486c01}{Grob}{G\bibinitperiod}{Jean-Jacques}{J\bibinithyphendelim J\bibinitperiod}{}{}{}{}}%
        {{hash=16d2ea111feffd7f496d76ade0635e37}{Simeone}{S\bibinitperiod}{Ester}{E\bibinitperiod}{}{}{}{}}%
        {{hash=113ae64f180f9fc5faeb1e02d978a869}{Grimaldi}{G\bibinitperiod}{Antonio\bibnamedelima M}{A\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=7ea227bd53fa458e9cfd6f3c8c43a57b}{Maio}{M\bibinitperiod}{Michele}{M\bibinitperiod}{}{}{}{}}%
        {{hash=f495a50af03456104e9ff153638c407e}{Palmieri}{P\bibinitperiod}{Giuseppe}{G\bibinitperiod}{}{}{}{}}%
        {{hash=5b2142b1987d2960913536de79a02db8}{Testori}{T\bibinitperiod}{Alessandro}{A\bibinitperiod}{}{}{}{}}%
        {{hash=8b609333a7ea38d53e768bb289bebf47}{Marincola}{M\bibinitperiod}{Francesco\bibnamedelima M}{F\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=8613f2ab157d054968edfbbf9e57a3d8}{Mozzillo}{M\bibinitperiod}{Nicola}{N\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {BioMed Central}%
      }
      \strng{namehash}{a2b5491fe1708e43f737202e70ceeb59}
      \strng{fullhash}{745972ce4d2d17f63870b976e88c91f1}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{The role of BRAF V600 mutation in melanoma}}
      \field{abstract}{BRAF is a serine/threonine protein kinase activating the MAP kinase/ERK-signaling pathway. About 50 {\%} of melanomas harbors activating BRAF mutations (over 90 {\%} V600E). BRAFV600E has been implicated in different mechanisms underlying melanomagenesis, most of which due to the deregulated activation of the downstream MEK/ERK effectors. The first selective inhibitor of mutant BRAF, vemurafenib, after highly encouraging results of the phase I and II trial, was compared to dacarbazine in a phase III trial in treatment-na{\"{\i}}ve patients (BRIM-3). The study results showed a relative reduction of 63 {\%} in risk of death and 74 {\%} in risk of tumor progression. Considering all trials so far completed, median overall survival reached approximately 16 months for vemurafenib compared to less than 10 months for dacarbazine treatment. Vemurafenib has been extensively tested on melanoma patients expressing the BRAFV600E mutated form; it has been demonstrated to be also effective in inhibiting melanomas carrying the V600K mutation. In 2011, both FDA and EMA therefore approved vemurafenib for metastatic melanoma carrying BRAFV600 mutations. Some findings suggest that continuation of vemurafenib treatment is potentially beneficial after local therapy in a subset of patients with disease progression (PD). Among who continued vemurafenib {>}30 days after local therapy of PD lesion(s), a median overall survival was not reached, with a median follow-up of 15.5 months from initiation of BRAF inhibitor therapy. For patients who did not continue treatment, median overall survival from the time of disease progression was 1.4 months. A clinical phase I/II trial is evaluating the safety, tolerability and efficacy of vemurafenib in combination with the CTLA-4 inhibitor mAb ipilimumab. In the BRIM-7 trial vemurafenib is tested in association with GDC-0973, a potent and highly selective inhibitor of MEK1/2. Preliminary data seem to indicate that an additional inhibitor of mutated BRAF, GSK2118436, might be also active on a wider range of BRAF mutations (V600E-K-D-R); actually, treatment with such a compound is under evaluation in a phase III study among stage III-IV melanoma patients positive for BRAF mutations. Overall, BRAF inhibitors were well tolerated; common adverse events are arthralgia, rash, fatigue, alopecia, keratoacanthoma or cutaneous squamous-cell carcinoma, photosensitivity, nausea, and diarrhea, with some variants between different inhibitors.}
      \field{issn}{1479-5876}
      \field{journaltitle}{Journal of Translational Medicine}
      \field{month}{07}
      \field{title}{{The role of BRAF V600 mutation in melanoma}}
      \field{volume}{10}
      \field{year}{2012}
      \field{pages}{85}
      \verb{doi}
      \verb 10.1186/1479-5876-10-85
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3391993/
      \endverb
    \endentry
    \entry{Bollag2010}{article}{}
      \name{labelname}{40}{}{%
        {{hash=87eae7f85b8231ace019d2d72e0de572}{Bollag}{B\bibinitperiod}{Gideon}{G\bibinitperiod}{}{}{}{}}%
        {{hash=7b8a5131c72993678d77bff47cac20f7}{Hirth}{H\bibinitperiod}{Peter}{P\bibinitperiod}{}{}{}{}}%
        {{hash=7c20d5b1c508ad9a8914cea147bb2dd3}{Tsai}{T\bibinitperiod}{James}{J\bibinitperiod}{}{}{}{}}%
        {{hash=3b399366aacf073f8da5d3e0ee2f3eec}{Zhang}{Z\bibinitperiod}{Jiazhong}{J\bibinitperiod}{}{}{}{}}%
        {{hash=d2e2eb7087f42caf9a6c71606091d126}{Ibrahim}{I\bibinitperiod}{Prabha\bibnamedelima N}{P\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
        {{hash=252ffb1473d8b9544ba246cd5158e473}{Cho}{C\bibinitperiod}{Hanna}{H\bibinitperiod}{}{}{}{}}%
        {{hash=5dfc986f8c544739a8675d0afd5fdf2e}{Spevak}{S\bibinitperiod}{Wayne}{W\bibinitperiod}{}{}{}{}}%
        {{hash=03ae9f31823ca904e5b163319d310224}{Zhang}{Z\bibinitperiod}{Chao}{C\bibinitperiod}{}{}{}{}}%
        {{hash=f5acec98b29ee91fa6b08b85a6a0adad}{Zhang}{Z\bibinitperiod}{Ying}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=1eb0c9b82ced713062f080e066664d80}{Habets}{H\bibinitperiod}{Gaston}{G\bibinitperiod}{}{}{}{}}%
        {{hash=fc89e83c71cb09b7d8465d074ac5a0c8}{Burton}{B\bibinitperiod}{Elizabeth\bibnamedelima A}{E\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=ee6353759c3087ce67e2db2f277d880d}{Wong}{W\bibinitperiod}{Bernice}{B\bibinitperiod}{}{}{}{}}%
        {{hash=d27dd54b9d4e22255c8d2e410652d6db}{Tsang}{T\bibinitperiod}{Garson}{G\bibinitperiod}{}{}{}{}}%
        {{hash=3453c1cc34c23f9197cca7b0a842b07d}{West}{W\bibinitperiod}{Brian\bibnamedelima L}{B\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=e791e27bf19423d01f64f67c8ca48055}{Powell}{P\bibinitperiod}{Ben}{B\bibinitperiod}{}{}{}{}}%
        {{hash=01ab9069dda9284968bc0e4e7387b7d4}{Shellooe}{S\bibinitperiod}{Rafe}{R\bibinitperiod}{}{}{}{}}%
        {{hash=1dad856b6a34915b8962f014f056b779}{Marimuthu}{M\bibinitperiod}{Adhirai}{A\bibinitperiod}{}{}{}{}}%
        {{hash=b2e1a075761da2ef6e3e90f4b6089f4b}{Nguyen}{N\bibinitperiod}{Hoa}{H\bibinitperiod}{}{}{}{}}%
        {{hash=fcc41521f7aac873314a8181cd094cc7}{Zhang}{Z\bibinitperiod}{Kam\bibnamedelimb Y\bibnamedelima J}{K\bibinitperiod\bibinitdelim Y\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=8786af2d83e2d764078241301d271b80}{Artis}{A\bibinitperiod}{Dean\bibnamedelima R}{D\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=0cfd2c2d149c4888fd0e8bfc386e0690}{Schlessinger}{S\bibinitperiod}{Joseph}{J\bibinitperiod}{}{}{}{}}%
        {{hash=7dcf47b56fc2673e72f25bf5f3f56e49}{Su}{S\bibinitperiod}{Fei}{F\bibinitperiod}{}{}{}{}}%
        {{hash=fa6114daca2d94260c5b8d12c72bbcc6}{Higgins}{H\bibinitperiod}{Brian}{B\bibinitperiod}{}{}{}{}}%
        {{hash=e597cc895e641cab9871d7d4075423b3}{Iyer}{I\bibinitperiod}{Raman}{R\bibinitperiod}{}{}{}{}}%
        {{hash=07c64dd64dccc22c5e81bdac6c0f047b}{D'Andrea}{D\bibinitperiod}{Kurt}{K\bibinitperiod}{}{}{}{}}%
        {{hash=b26d3f12a23488979e72644f21343763}{Koehler}{K\bibinitperiod}{Astrid}{A\bibinitperiod}{}{}{}{}}%
        {{hash=0cc180f816815b76057e4e06ff75d112}{Stumm}{S\bibinitperiod}{Michael}{M\bibinitperiod}{}{}{}{}}%
        {{hash=4e997825e4ba42e49d653136daa9c089}{Lin}{L\bibinitperiod}{Paul\bibnamedelima S}{P\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=ff62272db4d7d4cb49af4e92b3e4f64b}{Lee}{L\bibinitperiod}{Richard\bibnamedelima J}{R\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=9a4a0fc898413a88767a8ba750288e42}{Grippo}{G\bibinitperiod}{Joseph}{J\bibinitperiod}{}{}{}{}}%
        {{hash=5011e502a27870c9c6da22c66ae7c483}{Puzanov}{P\bibinitperiod}{Igor}{I\bibinitperiod}{}{}{}{}}%
        {{hash=b4102cb8ed7fee1c17a48ccdd2df2543}{Kim}{K\bibinitperiod}{Kevin\bibnamedelima B}{K\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=a38abcd070caaf3de4ecf67b7ab25769}{Ribas}{R\bibinitperiod}{Antoni}{A\bibinitperiod}{}{}{}{}}%
        {{hash=0bd57bd44ee5f635fa6f5347f408b088}{McArthur}{M\bibinitperiod}{Grant\bibnamedelima A}{G\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=239aa76222543444ec96b99fc03ad569}{Sosman}{S\bibinitperiod}{Jeffrey\bibnamedelima A}{J\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=ee9fa088a1d65fc575397e291a8f5814}{Chapman}{C\bibinitperiod}{Paul\bibnamedelima B}{P\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=af37fea3d029b2697b1732328a84e4d6}{Flaherty}{F\bibinitperiod}{Keith\bibnamedelima T}{K\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=2dda16c0a5d50fc830d0d4a3787937fa}{Xu}{X\bibinitperiod}{Xiaowei}{X\bibinitperiod}{}{}{}{}}%
        {{hash=841b09a91eb4536aedd3e3a2155670dd}{Nathanson}{N\bibinitperiod}{Katherine\bibnamedelima L}{K\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=4b199badbcdf6b350af9fe5140c1c83e}{Nolop}{N\bibinitperiod}{Keith}{K\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{40}{}{%
        {{hash=87eae7f85b8231ace019d2d72e0de572}{Bollag}{B\bibinitperiod}{Gideon}{G\bibinitperiod}{}{}{}{}}%
        {{hash=7b8a5131c72993678d77bff47cac20f7}{Hirth}{H\bibinitperiod}{Peter}{P\bibinitperiod}{}{}{}{}}%
        {{hash=7c20d5b1c508ad9a8914cea147bb2dd3}{Tsai}{T\bibinitperiod}{James}{J\bibinitperiod}{}{}{}{}}%
        {{hash=3b399366aacf073f8da5d3e0ee2f3eec}{Zhang}{Z\bibinitperiod}{Jiazhong}{J\bibinitperiod}{}{}{}{}}%
        {{hash=d2e2eb7087f42caf9a6c71606091d126}{Ibrahim}{I\bibinitperiod}{Prabha\bibnamedelima N}{P\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
        {{hash=252ffb1473d8b9544ba246cd5158e473}{Cho}{C\bibinitperiod}{Hanna}{H\bibinitperiod}{}{}{}{}}%
        {{hash=5dfc986f8c544739a8675d0afd5fdf2e}{Spevak}{S\bibinitperiod}{Wayne}{W\bibinitperiod}{}{}{}{}}%
        {{hash=03ae9f31823ca904e5b163319d310224}{Zhang}{Z\bibinitperiod}{Chao}{C\bibinitperiod}{}{}{}{}}%
        {{hash=f5acec98b29ee91fa6b08b85a6a0adad}{Zhang}{Z\bibinitperiod}{Ying}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=1eb0c9b82ced713062f080e066664d80}{Habets}{H\bibinitperiod}{Gaston}{G\bibinitperiod}{}{}{}{}}%
        {{hash=fc89e83c71cb09b7d8465d074ac5a0c8}{Burton}{B\bibinitperiod}{Elizabeth\bibnamedelima A}{E\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=ee6353759c3087ce67e2db2f277d880d}{Wong}{W\bibinitperiod}{Bernice}{B\bibinitperiod}{}{}{}{}}%
        {{hash=d27dd54b9d4e22255c8d2e410652d6db}{Tsang}{T\bibinitperiod}{Garson}{G\bibinitperiod}{}{}{}{}}%
        {{hash=3453c1cc34c23f9197cca7b0a842b07d}{West}{W\bibinitperiod}{Brian\bibnamedelima L}{B\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=e791e27bf19423d01f64f67c8ca48055}{Powell}{P\bibinitperiod}{Ben}{B\bibinitperiod}{}{}{}{}}%
        {{hash=01ab9069dda9284968bc0e4e7387b7d4}{Shellooe}{S\bibinitperiod}{Rafe}{R\bibinitperiod}{}{}{}{}}%
        {{hash=1dad856b6a34915b8962f014f056b779}{Marimuthu}{M\bibinitperiod}{Adhirai}{A\bibinitperiod}{}{}{}{}}%
        {{hash=b2e1a075761da2ef6e3e90f4b6089f4b}{Nguyen}{N\bibinitperiod}{Hoa}{H\bibinitperiod}{}{}{}{}}%
        {{hash=fcc41521f7aac873314a8181cd094cc7}{Zhang}{Z\bibinitperiod}{Kam\bibnamedelimb Y\bibnamedelima J}{K\bibinitperiod\bibinitdelim Y\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=8786af2d83e2d764078241301d271b80}{Artis}{A\bibinitperiod}{Dean\bibnamedelima R}{D\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=0cfd2c2d149c4888fd0e8bfc386e0690}{Schlessinger}{S\bibinitperiod}{Joseph}{J\bibinitperiod}{}{}{}{}}%
        {{hash=7dcf47b56fc2673e72f25bf5f3f56e49}{Su}{S\bibinitperiod}{Fei}{F\bibinitperiod}{}{}{}{}}%
        {{hash=fa6114daca2d94260c5b8d12c72bbcc6}{Higgins}{H\bibinitperiod}{Brian}{B\bibinitperiod}{}{}{}{}}%
        {{hash=e597cc895e641cab9871d7d4075423b3}{Iyer}{I\bibinitperiod}{Raman}{R\bibinitperiod}{}{}{}{}}%
        {{hash=07c64dd64dccc22c5e81bdac6c0f047b}{D'Andrea}{D\bibinitperiod}{Kurt}{K\bibinitperiod}{}{}{}{}}%
        {{hash=b26d3f12a23488979e72644f21343763}{Koehler}{K\bibinitperiod}{Astrid}{A\bibinitperiod}{}{}{}{}}%
        {{hash=0cc180f816815b76057e4e06ff75d112}{Stumm}{S\bibinitperiod}{Michael}{M\bibinitperiod}{}{}{}{}}%
        {{hash=4e997825e4ba42e49d653136daa9c089}{Lin}{L\bibinitperiod}{Paul\bibnamedelima S}{P\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=ff62272db4d7d4cb49af4e92b3e4f64b}{Lee}{L\bibinitperiod}{Richard\bibnamedelima J}{R\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=9a4a0fc898413a88767a8ba750288e42}{Grippo}{G\bibinitperiod}{Joseph}{J\bibinitperiod}{}{}{}{}}%
        {{hash=5011e502a27870c9c6da22c66ae7c483}{Puzanov}{P\bibinitperiod}{Igor}{I\bibinitperiod}{}{}{}{}}%
        {{hash=b4102cb8ed7fee1c17a48ccdd2df2543}{Kim}{K\bibinitperiod}{Kevin\bibnamedelima B}{K\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=a38abcd070caaf3de4ecf67b7ab25769}{Ribas}{R\bibinitperiod}{Antoni}{A\bibinitperiod}{}{}{}{}}%
        {{hash=0bd57bd44ee5f635fa6f5347f408b088}{McArthur}{M\bibinitperiod}{Grant\bibnamedelima A}{G\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=239aa76222543444ec96b99fc03ad569}{Sosman}{S\bibinitperiod}{Jeffrey\bibnamedelima A}{J\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=ee9fa088a1d65fc575397e291a8f5814}{Chapman}{C\bibinitperiod}{Paul\bibnamedelima B}{P\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=af37fea3d029b2697b1732328a84e4d6}{Flaherty}{F\bibinitperiod}{Keith\bibnamedelima T}{K\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=2dda16c0a5d50fc830d0d4a3787937fa}{Xu}{X\bibinitperiod}{Xiaowei}{X\bibinitperiod}{}{}{}{}}%
        {{hash=841b09a91eb4536aedd3e3a2155670dd}{Nathanson}{N\bibinitperiod}{Katherine\bibnamedelima L}{K\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=4b199badbcdf6b350af9fe5140c1c83e}{Nolop}{N\bibinitperiod}{Keith}{K\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{29c059e4fe5ebceec1a3730b1318f182}
      \strng{fullhash}{de091a97b15ee257c49fd8533dc1c32a}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma}}
      \field{abstract}{B-RAF is the most frequently mutated protein kinase in human cancers. The finding that oncogenic mutations in BRAF are common in melanoma followed by the demonstration that these tumors are dependent on the RAF/MEK/ERK pathway offered hope that inhibition of B-RAF kinase activity could benefit melanoma patients. Herein, we describe the structure-guided discovery of PLX4032 (RG7204), a potent inhibitor of oncogenic B-RAF kinase activity. Preclinical experiments demonstrated that PLX4032 selectively blocked the RAF/MEK/ERK pathway in BRAF mutant cells and caused regression of BRAF mutant xenografts. Toxicology studies confirmed a wide safety margin consistent with the high degree of selectivity, enabling Phase 1 clinical trials using a crystalline formulation of PLX4032. In a subset of melanoma patients, pathway inhibition was monitored in paired biopsy specimens collected before treatment initiation and following two weeks of treatment. This analysis revealed substantial inhibition of ERK phosphorylation, yet clinical evaluation did not show tumor regressions. At higher drug exposures afforded by a new amorphous drug formulation,, greater than 80{\%} inhibition of ERK phosphorylation in the tumors of patients correlated with clinical response. Indeed, the Phase 1 clinical data revealed a remarkably high 81{\%} response rate in metastatic melanoma patients treated at an oral dose of 960 mg twice daily. These data demonstrate that BRAF-mutant melanomas are highly dependent on B-RAF kinase activity.}
      \field{issn}{0028-0836}
      \field{journaltitle}{Nature}
      \field{month}{09}
      \field{number}{7315}
      \field{title}{{Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma}}
      \field{volume}{467}
      \field{year}{2010}
      \field{pages}{596\bibrangedash 599}
      \verb{doi}
      \verb 10.1038/nature09454
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948082/
      \endverb
    \endentry
    \entry{Gibney2013}{article}{}
      \name{labelname}{2}{}{%
        {{hash=7b54a8db80fc338d05786f622efe1bba}{Gibney}{G\bibinitperiod}{Geoffrey\bibnamedelima T}{G\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=3b9b7b60dbad2eb3daca4f22e81fac72}{Zager}{Z\bibinitperiod}{Jonathan\bibnamedelima S}{J\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=7b54a8db80fc338d05786f622efe1bba}{Gibney}{G\bibinitperiod}{Geoffrey\bibnamedelima T}{G\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=3b9b7b60dbad2eb3daca4f22e81fac72}{Zager}{Z\bibinitperiod}{Jonathan\bibnamedelima S}{J\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Taylor {\&} Francis}%
      }
      \strng{namehash}{b806110a0cbffb720b229f1825b2f262}
      \strng{fullhash}{b806110a0cbffb720b229f1825b2f262}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies}}
      \field{annotation}{doi: 10.1517/17425255.2013.794220}
      \field{issn}{1742-5255}
      \field{journaltitle}{Expert Opinion on Drug Metabolism {\&} Toxicology}
      \field{month}{07}
      \field{number}{7}
      \field{title}{{Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies}}
      \field{volume}{9}
      \field{year}{2013}
      \field{pages}{893\bibrangedash 899}
      \verb{doi}
      \verb 10.1517/17425255.2013.794220
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1517/17425255.2013.794220
      \endverb
    \endentry
    \entry{Flaherty2012}{article}{}
      \name{labelname}{26}{}{%
        {{hash=af37fea3d029b2697b1732328a84e4d6}{Flaherty}{F\bibinitperiod}{Keith\bibnamedelima T}{K\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=52ce1ebef3d3dfe875b314a657d67295}{Infante}{I\bibinitperiod}{Jeffery\bibnamedelima R}{J\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=b22849b0a5fa30474512b60ce07648f2}{Daud}{D\bibinitperiod}{Adil}{A\bibinitperiod}{}{}{}{}}%
        {{hash=99987b2325ec91684774bf5f4d447734}{Gonzalez}{G\bibinitperiod}{Rene}{R\bibinitperiod}{}{}{}{}}%
        {{hash=7e70df0b44df925b4f8f55afec492926}{Kefford}{K\bibinitperiod}{Richard\bibnamedelima F}{R\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{hash=c567956836367b92cd5a339551d90919}{Sosman}{S\bibinitperiod}{Jeffrey}{J\bibinitperiod}{}{}{}{}}%
        {{hash=80ba73c10aaa3a3b7a6742c8b9ce0957}{Hamid}{H\bibinitperiod}{Omid}{O\bibinitperiod}{}{}{}{}}%
        {{hash=9cd4723000b245dacc02a068b13ba466}{Schuchter}{S\bibinitperiod}{Lynn}{L\bibinitperiod}{}{}{}{}}%
        {{hash=0b40cc242a02d571991f3aba8e599375}{Cebon}{C\bibinitperiod}{Jonathan}{J\bibinitperiod}{}{}{}{}}%
        {{hash=1f159fec78726fa0bc44ee55c12c54f4}{Ibrahim}{I\bibinitperiod}{Nageatte}{N\bibinitperiod}{}{}{}{}}%
        {{hash=a7727317564fd8147127616148117b4c}{Kudchadkar}{K\bibinitperiod}{Ragini}{R\bibinitperiod}{}{}{}{}}%
        {{hash=14fc1cdca15a21565e2e72ecba6dd5cd}{Burris}{B\bibinitperiod}{Howard\bibnamedelima A}{H\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=c7c055a5722849810974ee9f003120e4}{Falchook}{F\bibinitperiod}{Gerald}{G\bibinitperiod}{}{}{}{}}%
        {{hash=b8d42fe6cd1117a4a42da8e549370279}{Algazi}{A\bibinitperiod}{Alain}{A\bibinitperiod}{}{}{}{}}%
        {{hash=b393ee1bd789f6ba3a67296a6d2de9a8}{Lewis}{L\bibinitperiod}{Karl}{K\bibinitperiod}{}{}{}{}}%
        {{hash=b91c620a281b517b74ae2c5e57c5ce5b}{Long}{L\bibinitperiod}{Georgina\bibnamedelima V}{G\bibinitperiod\bibinitdelim V\bibinitperiod}{}{}{}{}}%
        {{hash=5011e502a27870c9c6da22c66ae7c483}{Puzanov}{P\bibinitperiod}{Igor}{I\bibinitperiod}{}{}{}{}}%
        {{hash=886b0558afc22aecd4e6a5f3b5f8bdbc}{Lebowitz}{L\bibinitperiod}{Peter}{P\bibinitperiod}{}{}{}{}}%
        {{hash=726bb18dd2359b015847fcab6a297b79}{Singh}{S\bibinitperiod}{Ajay}{A\bibinitperiod}{}{}{}{}}%
        {{hash=f183bcaf32e2020502a9927ab9ff3110}{Little}{L\bibinitperiod}{Shonda}{S\bibinitperiod}{}{}{}{}}%
        {{hash=5918631c2d1cdd4eaddbfc27a01281ae}{Sun}{S\bibinitperiod}{Peng}{P\bibinitperiod}{}{}{}{}}%
        {{hash=b72925f033118199e873febd35cf07e5}{Allred}{A\bibinitperiod}{Alicia}{A\bibinitperiod}{}{}{}{}}%
        {{hash=74db56ecd41a02faf3da785946ab1234}{Ouellet}{O\bibinitperiod}{Daniele}{D\bibinitperiod}{}{}{}{}}%
        {{hash=b4102cb8ed7fee1c17a48ccdd2df2543}{Kim}{K\bibinitperiod}{Kevin\bibnamedelima B}{K\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=f5ef2d048872d2df7bb27d3f4625ce97}{Patel}{P\bibinitperiod}{Kiran}{K\bibinitperiod}{}{}{}{}}%
        {{hash=d8713e0ea49876ae4b04a92bbb329cf4}{Weber}{W\bibinitperiod}{Jeffrey}{J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{26}{}{%
        {{hash=af37fea3d029b2697b1732328a84e4d6}{Flaherty}{F\bibinitperiod}{Keith\bibnamedelima T}{K\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=52ce1ebef3d3dfe875b314a657d67295}{Infante}{I\bibinitperiod}{Jeffery\bibnamedelima R}{J\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=b22849b0a5fa30474512b60ce07648f2}{Daud}{D\bibinitperiod}{Adil}{A\bibinitperiod}{}{}{}{}}%
        {{hash=99987b2325ec91684774bf5f4d447734}{Gonzalez}{G\bibinitperiod}{Rene}{R\bibinitperiod}{}{}{}{}}%
        {{hash=7e70df0b44df925b4f8f55afec492926}{Kefford}{K\bibinitperiod}{Richard\bibnamedelima F}{R\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{hash=c567956836367b92cd5a339551d90919}{Sosman}{S\bibinitperiod}{Jeffrey}{J\bibinitperiod}{}{}{}{}}%
        {{hash=80ba73c10aaa3a3b7a6742c8b9ce0957}{Hamid}{H\bibinitperiod}{Omid}{O\bibinitperiod}{}{}{}{}}%
        {{hash=9cd4723000b245dacc02a068b13ba466}{Schuchter}{S\bibinitperiod}{Lynn}{L\bibinitperiod}{}{}{}{}}%
        {{hash=0b40cc242a02d571991f3aba8e599375}{Cebon}{C\bibinitperiod}{Jonathan}{J\bibinitperiod}{}{}{}{}}%
        {{hash=1f159fec78726fa0bc44ee55c12c54f4}{Ibrahim}{I\bibinitperiod}{Nageatte}{N\bibinitperiod}{}{}{}{}}%
        {{hash=a7727317564fd8147127616148117b4c}{Kudchadkar}{K\bibinitperiod}{Ragini}{R\bibinitperiod}{}{}{}{}}%
        {{hash=14fc1cdca15a21565e2e72ecba6dd5cd}{Burris}{B\bibinitperiod}{Howard\bibnamedelima A}{H\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=c7c055a5722849810974ee9f003120e4}{Falchook}{F\bibinitperiod}{Gerald}{G\bibinitperiod}{}{}{}{}}%
        {{hash=b8d42fe6cd1117a4a42da8e549370279}{Algazi}{A\bibinitperiod}{Alain}{A\bibinitperiod}{}{}{}{}}%
        {{hash=b393ee1bd789f6ba3a67296a6d2de9a8}{Lewis}{L\bibinitperiod}{Karl}{K\bibinitperiod}{}{}{}{}}%
        {{hash=b91c620a281b517b74ae2c5e57c5ce5b}{Long}{L\bibinitperiod}{Georgina\bibnamedelima V}{G\bibinitperiod\bibinitdelim V\bibinitperiod}{}{}{}{}}%
        {{hash=5011e502a27870c9c6da22c66ae7c483}{Puzanov}{P\bibinitperiod}{Igor}{I\bibinitperiod}{}{}{}{}}%
        {{hash=886b0558afc22aecd4e6a5f3b5f8bdbc}{Lebowitz}{L\bibinitperiod}{Peter}{P\bibinitperiod}{}{}{}{}}%
        {{hash=726bb18dd2359b015847fcab6a297b79}{Singh}{S\bibinitperiod}{Ajay}{A\bibinitperiod}{}{}{}{}}%
        {{hash=f183bcaf32e2020502a9927ab9ff3110}{Little}{L\bibinitperiod}{Shonda}{S\bibinitperiod}{}{}{}{}}%
        {{hash=5918631c2d1cdd4eaddbfc27a01281ae}{Sun}{S\bibinitperiod}{Peng}{P\bibinitperiod}{}{}{}{}}%
        {{hash=b72925f033118199e873febd35cf07e5}{Allred}{A\bibinitperiod}{Alicia}{A\bibinitperiod}{}{}{}{}}%
        {{hash=74db56ecd41a02faf3da785946ab1234}{Ouellet}{O\bibinitperiod}{Daniele}{D\bibinitperiod}{}{}{}{}}%
        {{hash=b4102cb8ed7fee1c17a48ccdd2df2543}{Kim}{K\bibinitperiod}{Kevin\bibnamedelima B}{K\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=f5ef2d048872d2df7bb27d3f4625ce97}{Patel}{P\bibinitperiod}{Kiran}{K\bibinitperiod}{}{}{}{}}%
        {{hash=d8713e0ea49876ae4b04a92bbb329cf4}{Weber}{W\bibinitperiod}{Jeffrey}{J\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Massachusetts Medical Society}%
      }
      \strng{namehash}{de5f4506102799b49046b1e24aec33b3}
      \strng{fullhash}{d085e71d7943310e76fee48b4700f135}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations}}
      \field{annotation}{doi: 10.1056/NEJMoa1210093}
      \field{issn}{0028-4793}
      \field{journaltitle}{New England Journal of Medicine}
      \field{month}{09}
      \field{number}{18}
      \field{title}{{Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations}}
      \field{volume}{367}
      \field{year}{2012}
      \field{pages}{1694\bibrangedash 1703}
      \verb{doi}
      \verb 10.1056/NEJMoa1210093
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1056/NEJMoa1210093
      \endverb
    \endentry
    \entry{Flaherty2012a}{article}{}
      \name{labelname}{25}{}{%
        {{hash=af37fea3d029b2697b1732328a84e4d6}{Flaherty}{F\bibinitperiod}{Keith\bibnamedelima T}{K\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=7713bc0c5b89e037abeb39d6d303482b}{Robert}{R\bibinitperiod}{Caroline}{C\bibinitperiod}{}{}{}{}}%
        {{hash=66adce8551a64b2cea34f5c8d76cdad5}{Hersey}{H\bibinitperiod}{Peter}{P\bibinitperiod}{}{}{}{}}%
        {{hash=89213a9b2f28640560f2414ad900b3c4}{Nathan}{N\bibinitperiod}{Paul}{P\bibinitperiod}{}{}{}{}}%
        {{hash=19684712620f686dd11abed002950c03}{Garbe}{G\bibinitperiod}{Claus}{C\bibinitperiod}{}{}{}{}}%
        {{hash=6d0259a6f8f355cc8eca61e7354d3df3}{Milhem}{M\bibinitperiod}{Mohammed}{M\bibinitperiod}{}{}{}{}}%
        {{hash=576d898ca397edb675164a402470c5ec}{Demidov}{D\bibinitperiod}{Lev\bibnamedelima V}{L\bibinitperiod\bibinitdelim V\bibinitperiod}{}{}{}{}}%
        {{hash=5d2ceb6e694e971753e78b3a304117d5}{Hassel}{H\bibinitperiod}{Jessica\bibnamedelima C}{J\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=dac9da33dceeb2c2eb61b7edfbb4f1e6}{Rutkowski}{R\bibinitperiod}{Piotr}{P\bibinitperiod}{}{}{}{}}%
        {{hash=ffaf33656d90745819c47c7e51e580dd}{Mohr}{M\bibinitperiod}{Peter}{P\bibinitperiod}{}{}{}{}}%
        {{hash=5bde0fb868f205866180a581118fc0b3}{Dummer}{D\bibinitperiod}{Reinhard}{R\bibinitperiod}{}{}{}{}}%
        {{hash=ef4ed559b78b2bf6ccd85b7acc0593dd}{Trefzer}{T\bibinitperiod}{Uwe}{U\bibinitperiod}{}{}{}{}}%
        {{hash=286baa65f4ba0dc9ba05a224c3f1fc92}{Larkin}{L\bibinitperiod}{James\bibnamedelimb M\bibnamedelima G}{J\bibinitperiod\bibinitdelim M\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=f94e2a10c3baf41595717b6af5896762}{Utikal}{U\bibinitperiod}{Jochen}{J\bibinitperiod}{}{}{}{}}%
        {{hash=76603730dfd457b0a43777f9763656bd}{Dreno}{D\bibinitperiod}{Brigitte}{B\bibinitperiod}{}{}{}{}}%
        {{hash=7967c11172ff5b2ea46331d45ab08c50}{Nyakas}{N\bibinitperiod}{Marta}{M\bibinitperiod}{}{}{}{}}%
        {{hash=7ff9840f801885e50da45c4bc55453eb}{Middleton}{M\bibinitperiod}{Mark\bibnamedelima R}{M\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=a2edf979a0fd451b5baa1048aa990c28}{Becker}{B\bibinitperiod}{J{\"{u}}rgen\bibnamedelima C}{J\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=8e8bc7d820d798f9aadf3488114e9922}{Casey}{C\bibinitperiod}{Michelle}{M\bibinitperiod}{}{}{}{}}%
        {{hash=17b76e6b12dce07f97e73f114d44b708}{Sherman}{S\bibinitperiod}{Laurie\bibnamedelima J}{L\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=723b4057040e7c3e8d3735caf029a637}{Wu}{W\bibinitperiod}{Frank\bibnamedelima S}{F\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=74db56ecd41a02faf3da785946ab1234}{Ouellet}{O\bibinitperiod}{Daniele}{D\bibinitperiod}{}{}{}{}}%
        {{hash=13295c390ea48215c3bc5c7ccb5fef0a}{Martin}{M\bibinitperiod}{Anne-Marie}{A\bibinithyphendelim M\bibinitperiod}{}{}{}{}}%
        {{hash=f5ef2d048872d2df7bb27d3f4625ce97}{Patel}{P\bibinitperiod}{Kiran}{K\bibinitperiod}{}{}{}{}}%
        {{hash=5e2b115df41d17855e2edeb91f539d7f}{Schadendorf}{S\bibinitperiod}{Dirk}{D\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{25}{}{%
        {{hash=af37fea3d029b2697b1732328a84e4d6}{Flaherty}{F\bibinitperiod}{Keith\bibnamedelima T}{K\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=7713bc0c5b89e037abeb39d6d303482b}{Robert}{R\bibinitperiod}{Caroline}{C\bibinitperiod}{}{}{}{}}%
        {{hash=66adce8551a64b2cea34f5c8d76cdad5}{Hersey}{H\bibinitperiod}{Peter}{P\bibinitperiod}{}{}{}{}}%
        {{hash=89213a9b2f28640560f2414ad900b3c4}{Nathan}{N\bibinitperiod}{Paul}{P\bibinitperiod}{}{}{}{}}%
        {{hash=19684712620f686dd11abed002950c03}{Garbe}{G\bibinitperiod}{Claus}{C\bibinitperiod}{}{}{}{}}%
        {{hash=6d0259a6f8f355cc8eca61e7354d3df3}{Milhem}{M\bibinitperiod}{Mohammed}{M\bibinitperiod}{}{}{}{}}%
        {{hash=576d898ca397edb675164a402470c5ec}{Demidov}{D\bibinitperiod}{Lev\bibnamedelima V}{L\bibinitperiod\bibinitdelim V\bibinitperiod}{}{}{}{}}%
        {{hash=5d2ceb6e694e971753e78b3a304117d5}{Hassel}{H\bibinitperiod}{Jessica\bibnamedelima C}{J\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=dac9da33dceeb2c2eb61b7edfbb4f1e6}{Rutkowski}{R\bibinitperiod}{Piotr}{P\bibinitperiod}{}{}{}{}}%
        {{hash=ffaf33656d90745819c47c7e51e580dd}{Mohr}{M\bibinitperiod}{Peter}{P\bibinitperiod}{}{}{}{}}%
        {{hash=5bde0fb868f205866180a581118fc0b3}{Dummer}{D\bibinitperiod}{Reinhard}{R\bibinitperiod}{}{}{}{}}%
        {{hash=ef4ed559b78b2bf6ccd85b7acc0593dd}{Trefzer}{T\bibinitperiod}{Uwe}{U\bibinitperiod}{}{}{}{}}%
        {{hash=286baa65f4ba0dc9ba05a224c3f1fc92}{Larkin}{L\bibinitperiod}{James\bibnamedelimb M\bibnamedelima G}{J\bibinitperiod\bibinitdelim M\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=f94e2a10c3baf41595717b6af5896762}{Utikal}{U\bibinitperiod}{Jochen}{J\bibinitperiod}{}{}{}{}}%
        {{hash=76603730dfd457b0a43777f9763656bd}{Dreno}{D\bibinitperiod}{Brigitte}{B\bibinitperiod}{}{}{}{}}%
        {{hash=7967c11172ff5b2ea46331d45ab08c50}{Nyakas}{N\bibinitperiod}{Marta}{M\bibinitperiod}{}{}{}{}}%
        {{hash=7ff9840f801885e50da45c4bc55453eb}{Middleton}{M\bibinitperiod}{Mark\bibnamedelima R}{M\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=a2edf979a0fd451b5baa1048aa990c28}{Becker}{B\bibinitperiod}{J{\"{u}}rgen\bibnamedelima C}{J\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=8e8bc7d820d798f9aadf3488114e9922}{Casey}{C\bibinitperiod}{Michelle}{M\bibinitperiod}{}{}{}{}}%
        {{hash=17b76e6b12dce07f97e73f114d44b708}{Sherman}{S\bibinitperiod}{Laurie\bibnamedelima J}{L\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=723b4057040e7c3e8d3735caf029a637}{Wu}{W\bibinitperiod}{Frank\bibnamedelima S}{F\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=74db56ecd41a02faf3da785946ab1234}{Ouellet}{O\bibinitperiod}{Daniele}{D\bibinitperiod}{}{}{}{}}%
        {{hash=13295c390ea48215c3bc5c7ccb5fef0a}{Martin}{M\bibinitperiod}{Anne-Marie}{A\bibinithyphendelim M\bibinitperiod}{}{}{}{}}%
        {{hash=f5ef2d048872d2df7bb27d3f4625ce97}{Patel}{P\bibinitperiod}{Kiran}{K\bibinitperiod}{}{}{}{}}%
        {{hash=5e2b115df41d17855e2edeb91f539d7f}{Schadendorf}{S\bibinitperiod}{Dirk}{D\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Massachusetts Medical Society}%
      }
      \strng{namehash}{de5f4506102799b49046b1e24aec33b3}
      \strng{fullhash}{80d56b83a288c936ba83efad2fc849bf}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma}}
      \field{annotation}{doi: 10.1056/NEJMoa1203421}
      \field{issn}{0028-4793}
      \field{journaltitle}{New England Journal of Medicine}
      \field{month}{06}
      \field{number}{2}
      \field{title}{{Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma}}
      \field{volume}{367}
      \field{year}{2012}
      \field{pages}{107\bibrangedash 114}
      \verb{doi}
      \verb 10.1056/NEJMoa1203421
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1056/NEJMoa1203421
      \endverb
    \endentry
    \entry{Ivy2009}{article}{}
      \name{labelname}{3}{}{%
        {{hash=a9f4ded756f023166e401e18736f301d}{Ivy}{I\bibinitperiod}{S.\bibnamedelimi Percy}{S\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=f7d2dfc1fbfdfe6b67aeaf7b4430e35d}{Wick}{W\bibinitperiod}{Jeannette\bibnamedelima Y.}{J\bibinitperiod\bibinitdelim Y\bibinitperiod}{}{}{}{}}%
        {{hash=63484592afcecc6a692da3a110fec431}{Kaufman}{K\bibinitperiod}{Bennett\bibnamedelima M.}{B\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=a9f4ded756f023166e401e18736f301d}{Ivy}{I\bibinitperiod}{S.\bibnamedelimi Percy}{S\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=f7d2dfc1fbfdfe6b67aeaf7b4430e35d}{Wick}{W\bibinitperiod}{Jeannette\bibnamedelima Y.}{J\bibinitperiod\bibinitdelim Y\bibinitperiod}{}{}{}{}}%
        {{hash=63484592afcecc6a692da3a110fec431}{Kaufman}{K\bibinitperiod}{Bennett\bibnamedelima M.}{B\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group}%
      }
      \strng{namehash}{b87d42234e8230e0f3207c09f24f170f}
      \strng{fullhash}{b87d42234e8230e0f3207c09f24f170f}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{An overview of small-molecule inhibitors of VEGFR signaling.}}
      \field{abstract}{VEGFR inhibitors are in broad use for the treatment of metastatic renal-cell carcinoma, gastrointestinal stromal tumors and hepatocellular carcinoma and in development in a number of other oncology indications, including colorectal cancer, non-small-cell lung cancer, pancreatic cancer, thyroid malignancies, ovarian cancer, breast cancer and sarcomas. This Review outlines the structure-activity relationships of the 44 VEGFR inhibitors currently in development. An overview of the pharmacokinetic profile of each molecule and its stage in development is provided. Phase III clinical trials being conducted for licensing of these agents for specific indications and phase III developmental efficacy trials are described in detailed tables that include the disease studied, trial design including combination therapy, study end points, and projected or final accrual. The relative frequency of on-target and off-target adverse events observed in 3,060 patients is described for a subset of agents in development in clinical trials sponsored by the National Cancer Institute. No interagent comparisons were undertaken and no data from pharmaceutical pharmacovigilance databases were used. The on-target effects seem to be mechanistically based and predicted by VEGFR inhibition. Small-molecule inhibitors of angiogenesis are active in a wide variety of malignancies and fill a unique niche for cancer therapeutics.}
      \field{isbn}{1759-4774}
      \field{issn}{1759-4782}
      \field{journaltitle}{Nature reviews. Clinical oncology}
      \field{number}{10}
      \field{title}{{An overview of small-molecule inhibitors of VEGFR signaling.}}
      \field{volume}{6}
      \field{year}{2009}
      \field{pages}{569\bibrangedash 79}
      \verb{doi}
      \verb 10.1038/nrclinonc.2009.130
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Ivy, Wick, Kaufman - 2009 - An overview of small-molecule inhibitors of VEGFR signaling.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.nature.com/doifinder/10.1038/nrclinonc.2009.130$%5Cbackslash$nhttp://www.ncbi.nlm.nih.gov/pubmed/19736552
      \endverb
    \endentry
    \entry{Holohan2013}{article}{}
      \name{labelname}{4}{}{%
        {{hash=6c32e713d24904dc6b3391437c574eb0}{Holohan}{H\bibinitperiod}{Caitriona}{C\bibinitperiod}{}{}{}{}}%
        {{hash=d4eae07cc0a417267219fda8277cd464}{{Van\bibnamedelimb Schaeybroeck}}{V\bibinitperiod}{Sandra}{S\bibinitperiod}{}{}{}{}}%
        {{hash=c4ce53d2e84389c0aa7202ee39161a56}{Longley}{L\bibinitperiod}{Daniel\bibnamedelima B}{D\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=fe74a923e323074806e55c1056c6e0fc}{Johnston}{J\bibinitperiod}{Patrick\bibnamedelima G}{P\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=6c32e713d24904dc6b3391437c574eb0}{Holohan}{H\bibinitperiod}{Caitriona}{C\bibinitperiod}{}{}{}{}}%
        {{hash=d4eae07cc0a417267219fda8277cd464}{{Van\bibnamedelimb Schaeybroeck}}{V\bibinitperiod}{Sandra}{S\bibinitperiod}{}{}{}{}}%
        {{hash=c4ce53d2e84389c0aa7202ee39161a56}{Longley}{L\bibinitperiod}{Daniel\bibnamedelima B}{D\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=fe74a923e323074806e55c1056c6e0fc}{Johnston}{J\bibinitperiod}{Patrick\bibnamedelima G}{P\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group}%
      }
      \strng{namehash}{18a6fca3287344fac5ec4d7f788e4c11}
      \strng{fullhash}{0e76ca14fc6d946a0764d9d679ed3edb}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Cancer drug resistance: an evolving paradigm.}}
      \field{abstract}{Resistance to chemotherapy and molecularly targeted therapies is a major problem facing current cancer research. The mechanisms of resistance to 'classical' cytotoxic chemotherapeutics and to therapies that are designed to be selective for specific molecular targets share many features, such as alterations in the drug target, activation of prosurvival pathways and ineffective induction of cell death. With the increasing arsenal of anticancer agents, improving preclinical models and the advent of powerful high-throughput screening techniques, there are now unprecedented opportunities to understand and overcome drug resistance through the clinical assessment of rational therapeutic drug combinations and the use of predictive biomarkers to enable patient stratification.}
      \field{issn}{1474-1768}
      \field{journaltitle}{Nature reviews. Cancer}
      \field{month}{10}
      \field{number}{10}
      \field{title}{{Cancer drug resistance: an evolving paradigm.}}
      \field{volume}{13}
      \field{year}{2013}
      \field{pages}{714\bibrangedash 26}
      \verb{doi}
      \verb 10.1038/nrc3599
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/nrc3599.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/24060863
      \endverb
    \endentry
    \entry{Manning2002}{article}{}
      \name{labelname}{1}{}{%
        {{hash=879316ae059a5d96fd637d6016cd9646}{Manning}{M\bibinitperiod}{G}{G\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=879316ae059a5d96fd637d6016cd9646}{Manning}{M\bibinitperiod}{G}{G\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{879316ae059a5d96fd637d6016cd9646}
      \strng{fullhash}{879316ae059a5d96fd637d6016cd9646}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{The Protein Kinase Complement of the Human Genome}}
      \field{abstract}{We have catalogued the protein kinase complement of the human genome (the "kinome") using public and proprietary genomic, complementary DNA, and expressed sequence tag (EST) sequences. This provides a starting point for comprehensive analysis of protein phosphorylation in normal and disease states, as well as a detailed view of the current state of human genome analysis through a focus on one large gene family. We identify 518 putative protein kinase genes, of which 71 have not previously been reported or described as kinases, and we extend or correct the protein sequences of 56 more kinases. New genes include members of well-studied families as well as previously unidentified families, some of which are conserved in model organisms. Classification and comparison with model organism kinomes identified orthologous groups and highlighted expansions specific to human and other lineages. We also identified 106 protein kinase pseudogenes. Chromosomal mapping revealed several small clusters of kinase genes and revealed that 244 kinases map to disease loci or cancer amplicons.}
      \field{isbn}{0036-8075}
      \field{issn}{00368075}
      \field{journaltitle}{Science}
      \field{number}{5600}
      \field{title}{{The Protein Kinase Complement of the Human Genome}}
      \field{volume}{298}
      \field{year}{2002}
      \field{pages}{1912\bibrangedash 1934}
      \verb{doi}
      \verb 10.1126/science.1075762
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Manning - 2002 - The Protein Kinase Complement of the Human Genome.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.sciencemag.org/content/298/5600/1912.abstract$%5Cbackslash$nhttp://www.ncbi.nlm.nih.gov/pubmed/12471243$%5Cbackslash$nhttp://www.sciencemag.org/cgi/doi/10.1126/science.1075762
      \endverb
    \endentry
    \entry{Muller2015}{article}{}
      \name{labelname}{4}{}{%
        {{hash=15d8b389fefa4ef8bf5081c868b8da11}{M{\"{u}}ller}{M\bibinitperiod}{Susanne}{S\bibinitperiod}{}{}{}{}}%
        {{hash=295e2a3621160b5fb9b3a73ff90a7817}{Chaikuad}{C\bibinitperiod}{Apirat}{A\bibinitperiod}{}{}{}{}}%
        {{hash=fabe6c6461e55d2d47e6c8fb604e93f8}{Gray}{G\bibinitperiod}{Nathanael\bibnamedelima S}{N\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=1a281309c878486e0f24ba3197554e32}{Knapp}{K\bibinitperiod}{Stefan}{S\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=15d8b389fefa4ef8bf5081c868b8da11}{M{\"{u}}ller}{M\bibinitperiod}{Susanne}{S\bibinitperiod}{}{}{}{}}%
        {{hash=295e2a3621160b5fb9b3a73ff90a7817}{Chaikuad}{C\bibinitperiod}{Apirat}{A\bibinitperiod}{}{}{}{}}%
        {{hash=fabe6c6461e55d2d47e6c8fb604e93f8}{Gray}{G\bibinitperiod}{Nathanael\bibnamedelima S}{N\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=1a281309c878486e0f24ba3197554e32}{Knapp}{K\bibinitperiod}{Stefan}{S\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group}%
      }
      \strng{namehash}{4a02dbc2ae46f45edad5d3fb92a7cd18}
      \strng{fullhash}{a649b356f2c48bb5e2cb65d0ceed60aa}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{The ins and outs of selective kinase inhibitor development}}
      \field{abstract}{Protein kinases have emerged as one of the most successful families of drug targets. To date, most selective kinase inhibitors have been discovered serendipitously either through broad selectivity screening or through the discovery of unique binding modes. Here we discuss design strategies that could lead to a broader coverage of the kinome with selective inhibitors and to a more rational approach for developing them. A berrant kinase function has been linked to the development of a large diversity of diseases and in particular to cancer, where recent large-scale sequencing efforts have highlighted protein kinases as one of the most frequently mutated proteins. However, the long time span from the discovery of kinases as oncogenes and as key players in tumorigenesis to the clinical approval of the first kinase small-molecule inhibitor imatinib (STI-571, Gleevec) in 2001 provides evidence of the difficult and controversial path to success in this area. The first crystal structure of a protein kinase domain (PKA) was published in 1991 and provided an initial model for inhibitor design 1}
      \field{isbn}{1552-4450}
      \field{issn}{1552-4450}
      \field{journaltitle}{NATURE CHEMICAL BIOLOGY www.nature.com/naturechemicalbiology}
      \field{number}{11}
      \field{title}{{The ins and outs of selective kinase inhibitor development}}
      \field{volume}{11}
      \field{year}{2015}
      \field{pages}{818\bibrangedash 821}
      \verb{doi}
      \verb 10.1038/nchembio.1938
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/M{\"{u}}ller et al. - 2015 - The ins and outs of selective kinase inhibitor development.pdf:pdf
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1038/nchembio.1938
      \endverb
    \endentry
    \entry{Lui1998}{article}{}
      \name{labelname}{5}{}{%
        {{hash=29bdd03a757ee4168cad6d145c3f26ac}{Liu}{L\bibinitperiod}{Y.}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=e2f25fe642500b4d9e8ba451aedd6777}{Shah}{S\bibinitperiod}{K.}{K\bibinitperiod}{}{}{}{}}%
        {{hash=eb5d5ae09823dbd21f6e0bbbf8a1b5ba}{Yang}{Y\bibinitperiod}{F.}{F\bibinitperiod}{}{}{}{}}%
        {{hash=e728a881568b2aee5597fd2766bc080a}{Witucki}{W\bibinitperiod}{L.}{L\bibinitperiod}{}{}{}{}}%
        {{hash=807e90962327b642875d2a2f4269b372}{Shokat}{S\bibinitperiod}{K.M.}{K\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{5}{}{%
        {{hash=29bdd03a757ee4168cad6d145c3f26ac}{Liu}{L\bibinitperiod}{Y.}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=e2f25fe642500b4d9e8ba451aedd6777}{Shah}{S\bibinitperiod}{K.}{K\bibinitperiod}{}{}{}{}}%
        {{hash=eb5d5ae09823dbd21f6e0bbbf8a1b5ba}{Yang}{Y\bibinitperiod}{F.}{F\bibinitperiod}{}{}{}{}}%
        {{hash=e728a881568b2aee5597fd2766bc080a}{Witucki}{W\bibinitperiod}{L.}{L\bibinitperiod}{}{}{}{}}%
        {{hash=807e90962327b642875d2a2f4269b372}{Shokat}{S\bibinitperiod}{K.M.}{K\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{c2a0d9b722896b4bbe76a68a02897bba}
      \strng{fullhash}{53b63aa19a4154b58e458a5a7010a937}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src}}
      \field{abstract}{Engineered proteins with specificity for unnatural substrates or ligands are useful tools for studying or manipulating complex biological systems. We have engineered the prototypical tyrosine kinase v-Src to accept an unnatural ATP analogue N6-(benzyl) ATP in order to identify v-Src's direct cellular substrates. Here we have used molecular modeling to analyze the binding mode of N6-(benzyl) ATP. Based on this modeling we proposed that a new ATP analogue (N6-(2-phenethyl) ATP might be a better substrate than N6-(benzyl) ATP for the I338G mutant of v-Src. In fact the newly proposed analogue (N6-(2-phenethyl) ATP is a somewhat improved substrate for the engineered kinase (kcat=0.6min{$\textminus$}1, KM=8$\mu$M). We also synthesized and screened three analogues of N6-(benzyl) ATP: N6-(2-methylbenzyl), ATP N6-(3-methylbenzyl), and ATP N6-(4-methylbenzyl) ATP to further probe the dimensions and shape of the introduced pocket. Results from screening newly synthesized ATP analogues agreed well with our modeling predictions. We conclude that rather than engineering a {$\textquoteleft$}new' pocket by mutation of Ile 338 in v-Src to the smaller Ala or Gly residues, the I338G and I338A mutants possess a {$\textquoteleft$}path' for the N6 substituent on ATP to gain access to an existing pocket in the ATP binding site. We expect to be able to extend the engineering of v-Src's ATP specificity to other kinase families based on our understanding of the binding modes of ATP analogues to engineered kinases.}
      \field{issn}{09680896}
      \field{journaltitle}{Bioorganic {\&} Medicinal Chemistry}
      \field{number}{8}
      \field{title}{{A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src}}
      \field{volume}{6}
      \field{year}{1998}
      \field{pages}{1219\bibrangedash 1226}
      \verb{doi}
      \verb 10.1016/S0968-0896(98)00099-6
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Liu et al. - 1998 - A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src.pdf:pdf
      \endverb
    \endentry
    \entry{Noble2004}{article}{}
      \name{labelname}{3}{}{%
        {{hash=96dfdcf58a38dbb27b542d68455aff50}{Noble}{N\bibinitperiod}{Martin\bibnamedelimb E\bibnamedelima M}{M\bibinitperiod\bibinitdelim E\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=8430039fbed85ecd02a2af03beb95a13}{Endicott}{E\bibinitperiod}{Jane\bibnamedelima A}{J\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=1beea9567dc3b6071b3b0995afa98d10}{Johnson}{J\bibinitperiod}{Louise\bibnamedelima N}{L\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=96dfdcf58a38dbb27b542d68455aff50}{Noble}{N\bibinitperiod}{Martin\bibnamedelimb E\bibnamedelima M}{M\bibinitperiod\bibinitdelim E\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=8430039fbed85ecd02a2af03beb95a13}{Endicott}{E\bibinitperiod}{Jane\bibnamedelima A}{J\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=1beea9567dc3b6071b3b0995afa98d10}{Johnson}{J\bibinitperiod}{Louise\bibnamedelima N}{L\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{c3fcedf29230e4e46cdece2deaea9157}
      \strng{fullhash}{c3fcedf29230e4e46cdece2deaea9157}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Protein Kinase Inhibitors: Insights into Drug Design from Structure}}
      \field{abstract}{Protein kinases are targets for treatment of a number of diseases. This review focuses on kinase inhibitors that are in the clinic or in clinical trials and for which structural information is available. Structures have informed drug design and have illuminated the mechanism of inhibition. We review progress with the receptor tyrosine kinases (growth factor receptors EGFR, VEGFR, and FGFR) and nonreceptor tyrosine kinases (Bcr-Abl), where advances have been made with cancer therapeutic agents such as Herceptin and Gleevec. Among the serine-threonine kinases, p38, Rho-kinase, cyclin-dependent kinases, and Chk1 have been targeted with productive results for inflammation and cancer. Structures have provided insights into targeting the inactive or active form of the kinase, for targeting the global constellation of residues at the ATP site or less conserved additional pockets or single residues, and into targeting noncatalytic domains.}
      \field{journaltitle}{Science}
      \field{month}{03}
      \field{number}{5665}
      \field{title}{{Protein Kinase Inhibitors: Insights into Drug Design from Structure}}
      \field{volume}{303}
      \field{year}{2004}
      \field{pages}{1800\bibrangedash 1805}
      \verb{file}
      \verb :home/fran/Downloads/1800.full.pdf:pdf
      \endverb
      \verb{url}
      \verb http://science.sciencemag.org/content/303/5665/1800.abstract
      \endverb
    \endentry
    \entry{Inhibitor2016}{article}{}
      \name{labelname}{5}{}{%
        {{hash=3e30c45974e4a692ce8cd1aa4d471d60}{Inhibitor}{I\bibinitperiod}{Kinase}{K\bibinitperiod}{}{}{}{}}%
        {{hash=51ed6c7e8e02a94ac110951fbb71fe2a}{Drug}{D\bibinitperiod}{Focused}{F\bibinitperiod}{}{}{}{}}%
        {{hash=fabe6c6461e55d2d47e6c8fb604e93f8}{Gray}{G\bibinitperiod}{Nathanael\bibnamedelima S}{N\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=c4637409a493a6bedef1eeb9c6777c93}{Ii}{I\bibinitperiod}{Type}{T\bibinitperiod}{}{}{}{}}%
        {{hash=87a27f91fc95364eba97cd887805a21f}{Link}{L\bibinitperiod}{Citable}{C\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{5}{}{%
        {{hash=3e30c45974e4a692ce8cd1aa4d471d60}{Inhibitor}{I\bibinitperiod}{Kinase}{K\bibinitperiod}{}{}{}{}}%
        {{hash=51ed6c7e8e02a94ac110951fbb71fe2a}{Drug}{D\bibinitperiod}{Focused}{F\bibinitperiod}{}{}{}{}}%
        {{hash=fabe6c6461e55d2d47e6c8fb604e93f8}{Gray}{G\bibinitperiod}{Nathanael\bibnamedelima S}{N\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=c4637409a493a6bedef1eeb9c6777c93}{Ii}{I\bibinitperiod}{Type}{T\bibinitperiod}{}{}{}{}}%
        {{hash=87a27f91fc95364eba97cd887805a21f}{Link}{L\bibinitperiod}{Citable}{C\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{716b901500560227fff45a638836fac0}
      \strng{fullhash}{153b06fe0e36da40559592fcb5d06450}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Exploration of Type II Binding Mode : A Privileged Approach for}}
      \field{title}{{Exploration of Type II Binding Mode : A Privileged Approach for}}
      \field{year}{2016}
      \verb{doi}
      \verb 10.1021/cb500129t
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/cb500129t.pdf:pdf
      \endverb
    \endentry
    \entry{Guimaraes2011}{article}{}
      \name{labelname}{7}{}{%
        {{hash=6714b8a850eb66a35c7a0a569b3db536}{Guimar{\~{a}}es}{G\bibinitperiod}{Cristiano\bibnamedelimb R\bibnamedelima W}{C\bibinitperiod\bibinitdelim R\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=e4c9a2a4a77c1977692c1ee55872c7cf}{Rai}{R\bibinitperiod}{Brajesh\bibnamedelima K}{B\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=a4a2bec23418efdd345e0c0c02342ee1}{Munchhof}{M\bibinitperiod}{Michael\bibnamedelima J}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=46936d907cca7347747a9ebdb9fdef9e}{Liu}{L\bibinitperiod}{Shenping}{S\bibinitperiod}{}{}{}{}}%
        {{hash=c33641e67eeaefc87b7821dc9b51ff90}{Wang}{W\bibinitperiod}{Jian}{J\bibinitperiod}{}{}{}{}}%
        {{hash=47e449adfc7f6d00654fe9e0b03f03af}{Bhattacharya}{B\bibinitperiod}{Samit\bibnamedelima K}{S\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=9ac1d3573df4addbb243ee5b7e42ef1c}{Buckbinder}{B\bibinitperiod}{Leonard}{L\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{7}{}{%
        {{hash=6714b8a850eb66a35c7a0a569b3db536}{Guimar{\~{a}}es}{G\bibinitperiod}{Cristiano\bibnamedelimb R\bibnamedelima W}{C\bibinitperiod\bibinitdelim R\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=e4c9a2a4a77c1977692c1ee55872c7cf}{Rai}{R\bibinitperiod}{Brajesh\bibnamedelima K}{B\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=a4a2bec23418efdd345e0c0c02342ee1}{Munchhof}{M\bibinitperiod}{Michael\bibnamedelima J}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=46936d907cca7347747a9ebdb9fdef9e}{Liu}{L\bibinitperiod}{Shenping}{S\bibinitperiod}{}{}{}{}}%
        {{hash=c33641e67eeaefc87b7821dc9b51ff90}{Wang}{W\bibinitperiod}{Jian}{J\bibinitperiod}{}{}{}{}}%
        {{hash=47e449adfc7f6d00654fe9e0b03f03af}{Bhattacharya}{B\bibinitperiod}{Samit\bibnamedelima K}{S\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=9ac1d3573df4addbb243ee5b7e42ef1c}{Buckbinder}{B\bibinitperiod}{Leonard}{L\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {American Chemical Society}%
      }
      \strng{namehash}{1136064ccf0c344a4c65be5a3bd96c0a}
      \strng{fullhash}{f6b17d0b5618c4635179a6f6348771fc}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Understanding the Impact of the P-loop Conformation on Kinase Selectivity}}
      \field{annotation}{doi: 10.1021/ci200153c}
      \field{issn}{1549-9596}
      \field{journaltitle}{Journal of Chemical Information and Modeling}
      \field{month}{06}
      \field{number}{6}
      \field{title}{{Understanding the Impact of the P-loop Conformation on Kinase Selectivity}}
      \field{volume}{51}
      \field{year}{2011}
      \field{pages}{1199\bibrangedash 1204}
      \verb{doi}
      \verb 10.1021/ci200153c
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1021/ci200153c
      \endverb
    \endentry
    \entry{Morris2013}{article}{}
      \name{labelname}{43}{}{%
        {{hash=2fba706f8426c242e73671fcd8f1e049}{Morris}{M\bibinitperiod}{Erick\bibnamedelima J}{E\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=2bdc8e1befcdf7ecfaa33fd2bd821389}{Jha}{J\bibinitperiod}{Sharda}{S\bibinitperiod}{}{}{}{}}%
        {{hash=bfc3adf7e3338acfe82ecb8f14b87664}{Restaino}{R\bibinitperiod}{Clifford\bibnamedelima R}{C\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=92f3ca905fb5b9384efc9b92e1a18b87}{Dayananth}{D\bibinitperiod}{Priya}{P\bibinitperiod}{}{}{}{}}%
        {{hash=1a5e6778ef2dbdeb988ab6152f69b704}{Zhu}{Z\bibinitperiod}{Hugh}{H\bibinitperiod}{}{}{}{}}%
        {{hash=d78505b492960cdf2af17b725dcb25e2}{Cooper}{C\bibinitperiod}{Alan}{A\bibinitperiod}{}{}{}{}}%
        {{hash=41db064db55748de19b9d1922fcff979}{Carr}{C\bibinitperiod}{Donna}{D\bibinitperiod}{}{}{}{}}%
        {{hash=4b68b1d48cbc3fe39144f8c68715d039}{Deng}{D\bibinitperiod}{Yongi}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=5430f20f8efcf371575f326dafa33961}{Jin}{J\bibinitperiod}{Weihong}{W\bibinitperiod}{}{}{}{}}%
        {{hash=a36f25a9ce1f4eb3a78b6d483b791bdc}{Black}{B\bibinitperiod}{Stuart}{S\bibinitperiod}{}{}{}{}}%
        {{hash=9072939c45d81cbe40d50191564b1f6e}{Long}{L\bibinitperiod}{Brian}{B\bibinitperiod}{}{}{}{}}%
        {{hash=b5543792063b78426cd607839a35ba1f}{Liu}{L\bibinitperiod}{Jenny}{J\bibinitperiod}{}{}{}{}}%
        {{hash=981aff289f0bbca9bb03706f6c549f52}{DiNunzio}{D\bibinitperiod}{Edward}{E\bibinitperiod}{}{}{}{}}%
        {{hash=bae6f6ea811839ec5b1c27f32ac8e052}{Windsor}{W\bibinitperiod}{William}{W\bibinitperiod}{}{}{}{}}%
        {{hash=1fd12bc1239dbd0f08abcac60417ae75}{Zhang}{Z\bibinitperiod}{Rumin}{R\bibinitperiod}{}{}{}{}}%
        {{hash=69fb872997eab8c14159c4bd2d4f2866}{Zhao}{Z\bibinitperiod}{Shuxia}{S\bibinitperiod}{}{}{}{}}%
        {{hash=ef231831072194eb8f3c0ab1fe0093e5}{Angagaw}{A\bibinitperiod}{Minilik\bibnamedelima H}{M\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=d9a6ba6a13e2314c6e37ca32542aacf7}{Pinheiro}{P\bibinitperiod}{Elaine\bibnamedelima M}{E\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=6438254b8cc79db0baf0c36538d2ceea}{Desai}{D\bibinitperiod}{Jagdish}{J\bibinitperiod}{}{}{}{}}%
        {{hash=047c3f96dd534550e148d9947507b71b}{Xiao}{X\bibinitperiod}{Li}{L\bibinitperiod}{}{}{}{}}%
        {{hash=ea2b00bf8aa2e15025ef3bd6d0d23286}{Shipps}{S\bibinitperiod}{Gerald}{G\bibinitperiod}{}{}{}{}}%
        {{hash=7875d1210578b9ca4cf558699172deaa}{Hruza}{H\bibinitperiod}{Alan}{A\bibinitperiod}{}{}{}{}}%
        {{hash=7060e413e4e24e85bae3d8b6948249b0}{Wang}{W\bibinitperiod}{James}{J\bibinitperiod}{}{}{}{}}%
        {{hash=88014343448e464ea0ffffcb3ba5e0c5}{Kelly}{K\bibinitperiod}{Joe}{J\bibinitperiod}{}{}{}{}}%
        {{hash=49624ce43ea0a0245a9df688619e7c8a}{Paliwal}{P\bibinitperiod}{Sunil}{S\bibinitperiod}{}{}{}{}}%
        {{hash=a48bc43fa4615a28c9419cd87c7d4953}{Gao}{G\bibinitperiod}{Xiaolei}{X\bibinitperiod}{}{}{}{}}%
        {{hash=5c588596e5af240702a536414e4264af}{Babu}{B\bibinitperiod}{Boga\bibnamedelima Sobhana}{B\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=0c0518a95690dc3847d1c6cfb569a20f}{Zhu}{Z\bibinitperiod}{Liang}{L\bibinitperiod}{}{}{}{}}%
        {{hash=eaf3ced246b5f73d107564a79e8f2876}{Daublain}{D\bibinitperiod}{Pierre}{P\bibinitperiod}{}{}{}{}}%
        {{hash=880bd45fc914edafbb19fcf1b8e46840}{Zhang}{Z\bibinitperiod}{Ling}{L\bibinitperiod}{}{}{}{}}%
        {{hash=af88169a5e1951e795a28ae4c08d41c8}{Lutterbach}{L\bibinitperiod}{Bart\bibnamedelima A}{B\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=6c6e577f8d6a689d27f9ad6cb11c7882}{Pelletier}{P\bibinitperiod}{Marc\bibnamedelima R}{M\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=4b090ad37eee879f2b17e848659ecfe4}{Philippar}{P\bibinitperiod}{Ulrike}{U\bibinitperiod}{}{}{}{}}%
        {{hash=424d1d288d24fab118dd52bb874e1ca8}{Siliphaivanh}{S\bibinitperiod}{Phieng}{P\bibinitperiod}{}{}{}{}}%
        {{hash=eb5be0f649b866d608a5abfe4fc539bd}{Witter}{W\bibinitperiod}{David}{D\bibinitperiod}{}{}{}{}}%
        {{hash=2bb70f3818f5ee08a460be8f9725dcb1}{Kirschmeier}{K\bibinitperiod}{Paul}{P\bibinitperiod}{}{}{}{}}%
        {{hash=6bbaadd6b27a7807134edff258ed5126}{Bishop}{B\bibinitperiod}{W\bibnamedelima Robert}{W\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=1388cfdd5819b42a4dd075c7781df682}{Hicklin}{H\bibinitperiod}{Daniel}{D\bibinitperiod}{}{}{}{}}%
        {{hash=a5d6eb7335c14be5ecc46a69cd4e0e23}{Gilliland}{G\bibinitperiod}{D\bibnamedelima Gary}{D\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=b8e7322b3827f15442019fe4c1dbac19}{Jayaraman}{J\bibinitperiod}{Lata}{L\bibinitperiod}{}{}{}{}}%
        {{hash=42b775c68fb9dfc89d9ca4d08b87357f}{Zawel}{Z\bibinitperiod}{Leigh}{L\bibinitperiod}{}{}{}{}}%
        {{hash=8fea27d8cbb1e30526dc2cc23f8b987d}{Fawell}{F\bibinitperiod}{Stephen}{S\bibinitperiod}{}{}{}{}}%
        {{hash=087b00608829544429140957c69508e3}{Samatar}{S\bibinitperiod}{Ahmed\bibnamedelima A}{A\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{43}{}{%
        {{hash=2fba706f8426c242e73671fcd8f1e049}{Morris}{M\bibinitperiod}{Erick\bibnamedelima J}{E\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=2bdc8e1befcdf7ecfaa33fd2bd821389}{Jha}{J\bibinitperiod}{Sharda}{S\bibinitperiod}{}{}{}{}}%
        {{hash=bfc3adf7e3338acfe82ecb8f14b87664}{Restaino}{R\bibinitperiod}{Clifford\bibnamedelima R}{C\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=92f3ca905fb5b9384efc9b92e1a18b87}{Dayananth}{D\bibinitperiod}{Priya}{P\bibinitperiod}{}{}{}{}}%
        {{hash=1a5e6778ef2dbdeb988ab6152f69b704}{Zhu}{Z\bibinitperiod}{Hugh}{H\bibinitperiod}{}{}{}{}}%
        {{hash=d78505b492960cdf2af17b725dcb25e2}{Cooper}{C\bibinitperiod}{Alan}{A\bibinitperiod}{}{}{}{}}%
        {{hash=41db064db55748de19b9d1922fcff979}{Carr}{C\bibinitperiod}{Donna}{D\bibinitperiod}{}{}{}{}}%
        {{hash=4b68b1d48cbc3fe39144f8c68715d039}{Deng}{D\bibinitperiod}{Yongi}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=5430f20f8efcf371575f326dafa33961}{Jin}{J\bibinitperiod}{Weihong}{W\bibinitperiod}{}{}{}{}}%
        {{hash=a36f25a9ce1f4eb3a78b6d483b791bdc}{Black}{B\bibinitperiod}{Stuart}{S\bibinitperiod}{}{}{}{}}%
        {{hash=9072939c45d81cbe40d50191564b1f6e}{Long}{L\bibinitperiod}{Brian}{B\bibinitperiod}{}{}{}{}}%
        {{hash=b5543792063b78426cd607839a35ba1f}{Liu}{L\bibinitperiod}{Jenny}{J\bibinitperiod}{}{}{}{}}%
        {{hash=981aff289f0bbca9bb03706f6c549f52}{DiNunzio}{D\bibinitperiod}{Edward}{E\bibinitperiod}{}{}{}{}}%
        {{hash=bae6f6ea811839ec5b1c27f32ac8e052}{Windsor}{W\bibinitperiod}{William}{W\bibinitperiod}{}{}{}{}}%
        {{hash=1fd12bc1239dbd0f08abcac60417ae75}{Zhang}{Z\bibinitperiod}{Rumin}{R\bibinitperiod}{}{}{}{}}%
        {{hash=69fb872997eab8c14159c4bd2d4f2866}{Zhao}{Z\bibinitperiod}{Shuxia}{S\bibinitperiod}{}{}{}{}}%
        {{hash=ef231831072194eb8f3c0ab1fe0093e5}{Angagaw}{A\bibinitperiod}{Minilik\bibnamedelima H}{M\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=d9a6ba6a13e2314c6e37ca32542aacf7}{Pinheiro}{P\bibinitperiod}{Elaine\bibnamedelima M}{E\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=6438254b8cc79db0baf0c36538d2ceea}{Desai}{D\bibinitperiod}{Jagdish}{J\bibinitperiod}{}{}{}{}}%
        {{hash=047c3f96dd534550e148d9947507b71b}{Xiao}{X\bibinitperiod}{Li}{L\bibinitperiod}{}{}{}{}}%
        {{hash=ea2b00bf8aa2e15025ef3bd6d0d23286}{Shipps}{S\bibinitperiod}{Gerald}{G\bibinitperiod}{}{}{}{}}%
        {{hash=7875d1210578b9ca4cf558699172deaa}{Hruza}{H\bibinitperiod}{Alan}{A\bibinitperiod}{}{}{}{}}%
        {{hash=7060e413e4e24e85bae3d8b6948249b0}{Wang}{W\bibinitperiod}{James}{J\bibinitperiod}{}{}{}{}}%
        {{hash=88014343448e464ea0ffffcb3ba5e0c5}{Kelly}{K\bibinitperiod}{Joe}{J\bibinitperiod}{}{}{}{}}%
        {{hash=49624ce43ea0a0245a9df688619e7c8a}{Paliwal}{P\bibinitperiod}{Sunil}{S\bibinitperiod}{}{}{}{}}%
        {{hash=a48bc43fa4615a28c9419cd87c7d4953}{Gao}{G\bibinitperiod}{Xiaolei}{X\bibinitperiod}{}{}{}{}}%
        {{hash=5c588596e5af240702a536414e4264af}{Babu}{B\bibinitperiod}{Boga\bibnamedelima Sobhana}{B\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=0c0518a95690dc3847d1c6cfb569a20f}{Zhu}{Z\bibinitperiod}{Liang}{L\bibinitperiod}{}{}{}{}}%
        {{hash=eaf3ced246b5f73d107564a79e8f2876}{Daublain}{D\bibinitperiod}{Pierre}{P\bibinitperiod}{}{}{}{}}%
        {{hash=880bd45fc914edafbb19fcf1b8e46840}{Zhang}{Z\bibinitperiod}{Ling}{L\bibinitperiod}{}{}{}{}}%
        {{hash=af88169a5e1951e795a28ae4c08d41c8}{Lutterbach}{L\bibinitperiod}{Bart\bibnamedelima A}{B\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=6c6e577f8d6a689d27f9ad6cb11c7882}{Pelletier}{P\bibinitperiod}{Marc\bibnamedelima R}{M\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=4b090ad37eee879f2b17e848659ecfe4}{Philippar}{P\bibinitperiod}{Ulrike}{U\bibinitperiod}{}{}{}{}}%
        {{hash=424d1d288d24fab118dd52bb874e1ca8}{Siliphaivanh}{S\bibinitperiod}{Phieng}{P\bibinitperiod}{}{}{}{}}%
        {{hash=eb5be0f649b866d608a5abfe4fc539bd}{Witter}{W\bibinitperiod}{David}{D\bibinitperiod}{}{}{}{}}%
        {{hash=2bb70f3818f5ee08a460be8f9725dcb1}{Kirschmeier}{K\bibinitperiod}{Paul}{P\bibinitperiod}{}{}{}{}}%
        {{hash=6bbaadd6b27a7807134edff258ed5126}{Bishop}{B\bibinitperiod}{W\bibnamedelima Robert}{W\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=1388cfdd5819b42a4dd075c7781df682}{Hicklin}{H\bibinitperiod}{Daniel}{D\bibinitperiod}{}{}{}{}}%
        {{hash=a5d6eb7335c14be5ecc46a69cd4e0e23}{Gilliland}{G\bibinitperiod}{D\bibnamedelima Gary}{D\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=b8e7322b3827f15442019fe4c1dbac19}{Jayaraman}{J\bibinitperiod}{Lata}{L\bibinitperiod}{}{}{}{}}%
        {{hash=42b775c68fb9dfc89d9ca4d08b87357f}{Zawel}{Z\bibinitperiod}{Leigh}{L\bibinitperiod}{}{}{}{}}%
        {{hash=8fea27d8cbb1e30526dc2cc23f8b987d}{Fawell}{F\bibinitperiod}{Stephen}{S\bibinitperiod}{}{}{}{}}%
        {{hash=087b00608829544429140957c69508e3}{Samatar}{S\bibinitperiod}{Ahmed\bibnamedelima A}{A\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{ba13d875669672c3a845b81ca014329c}
      \strng{fullhash}{09c280ace8df5e46744b1b8987dbe3f4}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors}}
      \field{abstract}{The high frequency of activating RAS or BRAF mutations in cancer provides strong rationale for targeting the mitogen-activated protein kinase (MAPK) pathway. Selective BRAF and MAP-ERK kinase (MEK) inhibitors have shown clinical efficacy in patients with melanoma. However, the majority of responses are transient, and resistance is often associated with pathway reactivation of the extracellular signal-regulated kinase (ERK) signaling pathway. Here, we describe the identification and characterization of SCH772984, a novel and selective inhibitor of ERK1/2 that displays behaviors of both type I and type II kinase inhibitors. SCH772984 has nanomolar cellular potency in tumor cells with mutations in BRAF, NRAS, or KRAS and induces tumor regressions in xenograft models at tolerated doses. Importantly, SCH772984 effectively inhibited MAPK signaling and cell proliferation in BRAF or MEK inhibitor--resistant models as well as in tumor cells resistant to concurrent treatment with BRAF and MEK inhibitors. These data support the clinical development of ERK inhibitors for tumors refractory to MAPK inhibitors.Significance: BRAF and MEK inhibitors have activity in MAPK-dependent cancers with BRAF or RAS mutations. However, resistance is associated with pathway alterations resulting in phospho-ERK reactivation. Here, we describe a novel ERK1/2 kinase inhibitor that has antitumor activity in MAPK inhibitor-na{\"{\i}}ve and MAPK inhibitor-resistant cells containing BRAF or RAS mutations. Cancer Discov; 3(7); 742--50. {{$\copyright$}}2013 AACR.See related commentary by Nissan et al., p. 719This article is highlighted in the In This Issue feature, p. 705}
      \field{annotation}{10.1158/2159-8290.CD-13-0070}
      \field{journaltitle}{Cancer Discovery}
      \field{month}{07}
      \field{number}{7}
      \field{title}{{Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors}}
      \field{volume}{3}
      \field{year}{2013}
      \field{pages}{742\bibrangedash 750}
      \verb{doi}
      \verb 10.1158/2159-8290.CD-13-0070
      \endverb
      \verb{url}
      \verb http://cancerdiscovery.aacrjournals.org/content/3/7/742.abstract
      \endverb
    \endentry
    \entry{Cohen2005}{article}{}
      \name{labelname}{4}{}{%
        {{hash=ab236f548fa11d536a6e77fbd2c5f7f3}{Cohen}{C\bibinitperiod}{Michael\bibnamedelima S}{M\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=03ae9f31823ca904e5b163319d310224}{Zhang}{Z\bibinitperiod}{Chao}{C\bibinitperiod}{}{}{}{}}%
        {{hash=b628d8bb864ec9dccf1a8dc3f40b048f}{Shokat}{S\bibinitperiod}{Kevan\bibnamedelima M}{K\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=29c7f7c59f424247bd56ec0a91afa32c}{Taunton}{T\bibinitperiod}{Jack}{J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{4}{}{%
        {{hash=ab236f548fa11d536a6e77fbd2c5f7f3}{Cohen}{C\bibinitperiod}{Michael\bibnamedelima S}{M\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=03ae9f31823ca904e5b163319d310224}{Zhang}{Z\bibinitperiod}{Chao}{C\bibinitperiod}{}{}{}{}}%
        {{hash=b628d8bb864ec9dccf1a8dc3f40b048f}{Shokat}{S\bibinitperiod}{Kevan\bibnamedelima M}{K\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=29c7f7c59f424247bd56ec0a91afa32c}{Taunton}{T\bibinitperiod}{Jack}{J\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{3ccc923a5800e355aac8346c36b433dd}
      \strng{fullhash}{60029e827d0427391192108192debd5f}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors}}
      \field{abstract}{The active sites of 491 human protein kinase domains are highly conserved, which makes the design of selective inhibitors a formidable challenge. We used a structural bioinformatics approach to identify two selectivity filters, a threonine and a cysteine, at defined positions in the active site of p90 ribosomal protein S6 kinase (RSK). A fluoromethylketone inhibitor, designed to exploit both selectivity filters, potently and selectively inactivated RSK1 and RSK2 in mammalian cells. Kinases with only one selectivity filter were resistant to the inhibitor, yet they became sensitized after genetic introduction of the second selectivity filter. Thus, two amino acids that distinguish RSK from other protein kinases are sufficient to confer inhibitor sensitivity.}
      \field{journaltitle}{Science}
      \field{month}{05}
      \field{number}{5726}
      \field{title}{{Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors}}
      \field{volume}{308}
      \field{year}{2005}
      \field{pages}{1318\bibrangedash 1321}
      \verb{url}
      \verb http://science.sciencemag.org/content/308/5726/1318.abstract
      \endverb
    \endentry
    \entry{Potashman2009}{article}{}
      \name{labelname}{2}{}{%
        {{hash=ddeed5ccdc87520f813247afdb8457ca}{Potashman}{P\bibinitperiod}{Michele\bibnamedelima H}{M\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=6410f16304b86f5bd6428c314ac39114}{Duggan}{D\bibinitperiod}{Mark\bibnamedelima E}{M\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=ddeed5ccdc87520f813247afdb8457ca}{Potashman}{P\bibinitperiod}{Michele\bibnamedelima H}{M\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=6410f16304b86f5bd6428c314ac39114}{Duggan}{D\bibinitperiod}{Mark\bibnamedelima E}{M\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {American Chemical Society}%
      }
      \strng{namehash}{7f5cbfb2a750d1c11e330930f6ef47c3}
      \strng{fullhash}{7f5cbfb2a750d1c11e330930f6ef47c3}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Covalent Modifiers: An Orthogonal Approach to Drug Design}}
      \field{annotation}{doi: 10.1021/jm8008597}
      \field{issn}{0022-2623}
      \field{journaltitle}{Journal of Medicinal Chemistry}
      \field{month}{03}
      \field{number}{5}
      \field{title}{{Covalent Modifiers: An Orthogonal Approach to Drug Design}}
      \field{volume}{52}
      \field{year}{2009}
      \field{pages}{1231\bibrangedash 1246}
      \verb{doi}
      \verb 10.1021/jm8008597
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1021/jm8008597
      \endverb
    \endentry
    \entry{Liu2013a}{article}{}
      \name{labelname}{7}{}{%
        {{hash=a8f352e1725448281095f9e18d8cef49}{Liu}{L\bibinitperiod}{Qingsong}{Q\bibinitperiod}{}{}{}{}}%
        {{hash=e57a4ba10887c7f8b83e43af07be43d0}{Sabnis}{S\bibinitperiod}{Yogesh}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=31c53327fd1ea736e1e0863448529e06}{Zhao}{Z\bibinitperiod}{Zheng}{Z\bibinitperiod}{}{}{}{}}%
        {{hash=0042938c0c4b8a87b35f602200cc32c0}{Zhang}{Z\bibinitperiod}{Tinghu}{T\bibinitperiod}{}{}{}{}}%
        {{hash=2ab03a74c0063c98b0d1a0247040d79d}{Buhrlage}{B\bibinitperiod}{Sara\bibnamedelima J}{S\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=54f5f24da77b4658161f0a1df1d070e1}{Jones}{J\bibinitperiod}{Lyn\bibnamedelima H}{L\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=fabe6c6461e55d2d47e6c8fb604e93f8}{Gray}{G\bibinitperiod}{Nathanael\bibnamedelima S}{N\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{7}{}{%
        {{hash=a8f352e1725448281095f9e18d8cef49}{Liu}{L\bibinitperiod}{Qingsong}{Q\bibinitperiod}{}{}{}{}}%
        {{hash=e57a4ba10887c7f8b83e43af07be43d0}{Sabnis}{S\bibinitperiod}{Yogesh}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=31c53327fd1ea736e1e0863448529e06}{Zhao}{Z\bibinitperiod}{Zheng}{Z\bibinitperiod}{}{}{}{}}%
        {{hash=0042938c0c4b8a87b35f602200cc32c0}{Zhang}{Z\bibinitperiod}{Tinghu}{T\bibinitperiod}{}{}{}{}}%
        {{hash=2ab03a74c0063c98b0d1a0247040d79d}{Buhrlage}{B\bibinitperiod}{Sara\bibnamedelima J}{S\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=54f5f24da77b4658161f0a1df1d070e1}{Jones}{J\bibinitperiod}{Lyn\bibnamedelima H}{L\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=fabe6c6461e55d2d47e6c8fb604e93f8}{Gray}{G\bibinitperiod}{Nathanael\bibnamedelima S}{N\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{de4595f869ec02a67e3a3dc4684eb85f}
      \strng{fullhash}{1737dbb82507f654b8627473e7848aea}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Developing irreversible inhibitors of the protein kinase cysteinome}}
      \field{abstract}{Protein kinases are a large family of approximately 530 highly conserved enzymes that transfer a $\gamma$-phosphate group from ATP to a variety of amino acid residues such as tyrosine, serine and threonine which serves as a ubiquitous mechanism for cellular signal transduction. The clinical success of a number of kinase-directed drugs and the frequent observation of disease causing mutations in protein kinases suggest that a large number of kinases may represent therapeutically relevant targets. To-date the majority of clinical and preclinical kinase inhibitors are ATP-competitive, non-covalent inhibitors that achieve selectivity through recognition of unique features of particular protein kinases. Recently there has been renewed interest in the development of irreversible inhibitors that form covalent bonds with cysteine or other nucleophilic residues in the ATP-binding pocket. Irreversible kinase inhibitors have a number of potential advantages including prolonged pharmacodynamics, suitability for rational design, high potency and ability to validate pharmacological specificity through mutation of the reactive cysteine residue. Here we review recent efforts to develop cysteine-targeted irreversible protein kinase inhibitors and discuss their modes of recognizing the ATP-binding pocket and their biological activity profiles. In addition, we provided an informatics assessment of the potential {$\textquoteleft$}kinase-cysteinome' and discuss strategies for the efficient development of new covalent inhibitors.}
      \field{issn}{1074-5521}
      \field{journaltitle}{Chemistry {\&} biology}
      \field{month}{02}
      \field{number}{2}
      \field{title}{{Developing irreversible inhibitors of the protein kinase cysteinome}}
      \field{volume}{20}
      \field{year}{2013}
      \field{pages}{146\bibrangedash 159}
      \verb{doi}
      \verb 10.1016/j.chembiol.2012.12.006
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583020/
      \endverb
    \endentry
    \entry{Barf2012}{article}{}
      \name{labelname}{2}{}{%
        {{hash=51d3fa41f1c5bfdeaa4c3f806fccedd2}{Barf}{B\bibinitperiod}{Tjeerd}{T\bibinitperiod}{}{}{}{}}%
        {{hash=b05b95b4b1d470e8913951153975cf14}{Kaptein}{K\bibinitperiod}{Allard}{A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=51d3fa41f1c5bfdeaa4c3f806fccedd2}{Barf}{B\bibinitperiod}{Tjeerd}{T\bibinitperiod}{}{}{}{}}%
        {{hash=b05b95b4b1d470e8913951153975cf14}{Kaptein}{K\bibinitperiod}{Allard}{A\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{214122ddd9d7b2edd07cef70528d234f}
      \strng{fullhash}{214122ddd9d7b2edd07cef70528d234f}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Irreversible Protein Kinase Inhibitors: Balancing the Bene fi ts and Risks}}
      \field{journaltitle}{Journal of medicinal chemistry}
      \field{title}{{Irreversible Protein Kinase Inhibitors: Balancing the Bene fi ts and Risks}}
      \field{volume}{55}
      \field{year}{2012}
      \field{pages}{6243\bibrangedash 6262}
      \verb{doi}
      \verb 10.1021/jm3003203
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/barf2012.pdf:pdf
      \endverb
    \endentry
    \entry{Liebler2008}{article}{}
      \name{labelname}{1}{}{%
        {{hash=f65da1ad7ca8e22f4370d0a63fbeb3fe}{Liebler}{L\bibinitperiod}{Daniel\bibnamedelima C}{D\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=f65da1ad7ca8e22f4370d0a63fbeb3fe}{Liebler}{L\bibinitperiod}{Daniel\bibnamedelima C}{D\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {American Chemical Society}%
      }
      \strng{namehash}{f65da1ad7ca8e22f4370d0a63fbeb3fe}
      \strng{fullhash}{f65da1ad7ca8e22f4370d0a63fbeb3fe}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Protein Damage by Reactive Electrophiles: Targets and Consequences}}
      \field{annotation}{doi: 10.1021/tx700235t}
      \field{issn}{0893-228X}
      \field{journaltitle}{Chemical Research in Toxicology}
      \field{month}{01}
      \field{number}{1}
      \field{title}{{Protein Damage by Reactive Electrophiles: Targets and Consequences}}
      \field{volume}{21}
      \field{year}{2008}
      \field{pages}{117\bibrangedash 128}
      \verb{doi}
      \verb 10.1021/tx700235t
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1021/tx700235t
      \endverb
    \endentry
    \entry{Okamoto2015}{article}{}
      \name{labelname}{9}{}{%
        {{hash=847760bec6760f26981e737374bf5f2e}{Okamoto}{O\bibinitperiod}{Kiyoshi}{K\bibinitperiod}{}{}{}{}}%
        {{hash=2e62f64b5cfd1a844cfaae8ae4d8dbf6}{Ikemori-Kawada}{I\bibinithyphendelim K\bibinitperiod}{Megumi}{M\bibinitperiod}{}{}{}{}}%
        {{hash=d3bfdb3c8b4176ab67b0e9ee3f2eb853}{Jestel}{J\bibinitperiod}{Anja}{A\bibinitperiod}{}{}{}{}}%
        {{hash=10666611338f57b1c20bb1fbb3c4940c}{K{\"{o}}nig}{K\bibinitperiod}{Konstanze}{K\bibinitperiod}{von}{v\bibinitperiod}{}{}}%
        {{hash=fa27275fa2e95163f2da2b66e777d3f6}{Funahashi}{F\bibinitperiod}{Yasuhiro}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=7840fa6a87f4fe503cbbadd67ce6120d}{Matsushima}{M\bibinitperiod}{Tomohiro}{T\bibinitperiod}{}{}{}{}}%
        {{hash=47e6866c83f06074472fccc8ccc39c10}{Tsuruoka}{T\bibinitperiod}{Akihiko}{A\bibinitperiod}{}{}{}{}}%
        {{hash=59b33d139abbbde8a5474edc906bd604}{Inoue}{I\bibinitperiod}{Atsushi}{A\bibinitperiod}{}{}{}{}}%
        {{hash=2d43bf218e24c77f19192a5808786025}{Matsui}{M\bibinitperiod}{Junji}{J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{9}{}{%
        {{hash=847760bec6760f26981e737374bf5f2e}{Okamoto}{O\bibinitperiod}{Kiyoshi}{K\bibinitperiod}{}{}{}{}}%
        {{hash=2e62f64b5cfd1a844cfaae8ae4d8dbf6}{Ikemori-Kawada}{I\bibinithyphendelim K\bibinitperiod}{Megumi}{M\bibinitperiod}{}{}{}{}}%
        {{hash=d3bfdb3c8b4176ab67b0e9ee3f2eb853}{Jestel}{J\bibinitperiod}{Anja}{A\bibinitperiod}{}{}{}{}}%
        {{hash=10666611338f57b1c20bb1fbb3c4940c}{K{\"{o}}nig}{K\bibinitperiod}{Konstanze}{K\bibinitperiod}{von}{v\bibinitperiod}{}{}}%
        {{hash=fa27275fa2e95163f2da2b66e777d3f6}{Funahashi}{F\bibinitperiod}{Yasuhiro}{Y\bibinitperiod}{}{}{}{}}%
        {{hash=7840fa6a87f4fe503cbbadd67ce6120d}{Matsushima}{M\bibinitperiod}{Tomohiro}{T\bibinitperiod}{}{}{}{}}%
        {{hash=47e6866c83f06074472fccc8ccc39c10}{Tsuruoka}{T\bibinitperiod}{Akihiko}{A\bibinitperiod}{}{}{}{}}%
        {{hash=59b33d139abbbde8a5474edc906bd604}{Inoue}{I\bibinitperiod}{Atsushi}{A\bibinitperiod}{}{}{}{}}%
        {{hash=2d43bf218e24c77f19192a5808786025}{Matsui}{M\bibinitperiod}{Junji}{J\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {American Chemical Society}%
      }
      \strng{namehash}{32e03266160c0426ab52620c46b6e003}
      \strng{fullhash}{ab5257c53c2d416d82ea1d6afd34501a}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Distinct Binding Mode of Multikinase Inhibitor Lenvatinib Revealed by Biochemical Characterization}}
      \field{abstract}{Lenvatinib is an oral multikinase inhibitor that selectively inhibits vascular endothelial growth factor (VEGF) receptors 1 to 3 and other proangiogenic and oncogenic pathway-related receptor tyrosine kinases. To elucidate the origin of the potency of lenvatinib in VEGF receptor 2 (VEGFR2) inhibition, we conducted a kinetic interaction analysis of lenvatinib with VEGFR2 and X-ray analysis of the crystal structure of VEGFR2--lenvatinib complexes. Kinetic analysis revealed that lenvatinib had a rapid association rate constant and a relatively slow dissociation rate constant in complex with VEGFR2. Co-crystal structure analysis demonstrated that lenvatinib binds at its ATP mimetic quinoline moiety to the ATP binding site and to the neighboring region via a cyclopropane ring, adopting an Asp-Phe-Gly (DFG)-{$\textquotedblleft$}in{$\textquotedblright$} conformation. These results suggest that lenvatinib is very distinct in its binding mode of interaction compared to the several approved VEGFR2 kinase inhibitors.}
      \field{issn}{1948-5875}
      \field{journaltitle}{ACS Medicinal Chemistry Letters}
      \field{month}{01}
      \field{number}{1}
      \field{title}{{Distinct Binding Mode of Multikinase Inhibitor Lenvatinib Revealed by Biochemical Characterization}}
      \field{volume}{6}
      \field{year}{2015}
      \field{pages}{89\bibrangedash 94}
      \verb{doi}
      \verb 10.1021/ml500394m
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4291723/
      \endverb
    \endentry
    \entry{Davis2011}{article}{}
      \name{labelname}{9}{}{%
        {{hash=0873b559d19f44effc0698b297cf54b5}{Davis}{D\bibinitperiod}{Mindy\bibnamedelima I}{M\bibinitperiod\bibinitdelim I\bibinitperiod}{}{}{}{}}%
        {{hash=84beb3ef02821b31444b556e4f5aa501}{Hunt}{H\bibinitperiod}{Jeremy\bibnamedelima P}{J\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=c94d2bf13a5fe9e4dd5d6302f3021036}{Herrgard}{H\bibinitperiod}{Sanna}{S\bibinitperiod}{}{}{}{}}%
        {{hash=eedf61a524cf71c6b7e19c33d5d10354}{Ciceri}{C\bibinitperiod}{Pietro}{P\bibinitperiod}{}{}{}{}}%
        {{hash=019c61c35d671cb404d9fd81fc9a06bc}{Wodicka}{W\bibinitperiod}{Lisa\bibnamedelima M}{L\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=65406820b865b00f94176716ba9fc8ec}{Pallares}{P\bibinitperiod}{Gabriel}{G\bibinitperiod}{}{}{}{}}%
        {{hash=fe2f95a46f2668f90196c63d3bb91908}{Hocker}{H\bibinitperiod}{Michael}{M\bibinitperiod}{}{}{}{}}%
        {{hash=281ffed0bab47ea010245e901dd06ced}{Treiber}{T\bibinitperiod}{Daniel\bibnamedelima K}{D\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=80d27d9db3f3649cf2b1c2fa9e1ff230}{Zarrinkar}{Z\bibinitperiod}{Patrick\bibnamedelima P}{P\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{9}{}{%
        {{hash=0873b559d19f44effc0698b297cf54b5}{Davis}{D\bibinitperiod}{Mindy\bibnamedelima I}{M\bibinitperiod\bibinitdelim I\bibinitperiod}{}{}{}{}}%
        {{hash=84beb3ef02821b31444b556e4f5aa501}{Hunt}{H\bibinitperiod}{Jeremy\bibnamedelima P}{J\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=c94d2bf13a5fe9e4dd5d6302f3021036}{Herrgard}{H\bibinitperiod}{Sanna}{S\bibinitperiod}{}{}{}{}}%
        {{hash=eedf61a524cf71c6b7e19c33d5d10354}{Ciceri}{C\bibinitperiod}{Pietro}{P\bibinitperiod}{}{}{}{}}%
        {{hash=019c61c35d671cb404d9fd81fc9a06bc}{Wodicka}{W\bibinitperiod}{Lisa\bibnamedelima M}{L\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=65406820b865b00f94176716ba9fc8ec}{Pallares}{P\bibinitperiod}{Gabriel}{G\bibinitperiod}{}{}{}{}}%
        {{hash=fe2f95a46f2668f90196c63d3bb91908}{Hocker}{H\bibinitperiod}{Michael}{M\bibinitperiod}{}{}{}{}}%
        {{hash=281ffed0bab47ea010245e901dd06ced}{Treiber}{T\bibinitperiod}{Daniel\bibnamedelima K}{D\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=80d27d9db3f3649cf2b1c2fa9e1ff230}{Zarrinkar}{Z\bibinitperiod}{Patrick\bibnamedelima P}{P\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.}%
      }
      \strng{namehash}{20769f4908436a68d1aef9abbf11660a}
      \strng{fullhash}{b35e6d44af0304ba5eb289002615c422}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Comprehensive analysis of kinase inhibitor selectivity}}
      \field{annotation}{10.1038/nbt.1990}
      \field{issn}{1087-0156}
      \field{journaltitle}{Nat Biotech}
      \field{month}{11}
      \field{number}{11}
      \field{title}{{Comprehensive analysis of kinase inhibitor selectivity}}
      \field{volume}{29}
      \field{year}{2011}
      \field{pages}{1046\bibrangedash 1051}
      \verb{url}
      \verb http://dx.doi.org/10.1038/nbt.1990%20http://www.nature.com/nbt/journal/v29/n11/abs/nbt.1990.html%7B%5C#%7Dsupplementary-information
      \endverb
    \endentry
    \entry{Zhang2009a}{article}{}
      \name{labelname}{3}{}{%
        {{hash=ac94487142bcc73ec00646f41c277977}{Zhang}{Z\bibinitperiod}{Jianming}{J\bibinitperiod}{}{}{}{}}%
        {{hash=60061fbf1aecd520b9add74fdc4f61eb}{Yang}{Y\bibinitperiod}{Priscilla\bibnamedelima L}{P\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=fabe6c6461e55d2d47e6c8fb604e93f8}{Gray}{G\bibinitperiod}{Nathanael\bibnamedelima S}{N\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=ac94487142bcc73ec00646f41c277977}{Zhang}{Z\bibinitperiod}{Jianming}{J\bibinitperiod}{}{}{}{}}%
        {{hash=60061fbf1aecd520b9add74fdc4f61eb}{Yang}{Y\bibinitperiod}{Priscilla\bibnamedelima L}{P\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=fabe6c6461e55d2d47e6c8fb604e93f8}{Gray}{G\bibinitperiod}{Nathanael\bibnamedelima S}{N\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group}%
      }
      \strng{namehash}{4737b124b9a903e114646b7add908b56}
      \strng{fullhash}{4737b124b9a903e114646b7add908b56}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Targeting cancer with small molecule kinase inhibitors}}
      \field{annotation}{10.1038/nrc2559}
      \field{issn}{1474-175X}
      \field{journaltitle}{Nat Rev Cancer}
      \field{month}{01}
      \field{number}{1}
      \field{title}{{Targeting cancer with small molecule kinase inhibitors}}
      \field{volume}{9}
      \field{year}{2009}
      \field{pages}{28\bibrangedash 39}
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Zhang, Yang, Gray - 2009 - Targeting cancer with small molecule kinase inhibitors.pdf:pdf
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1038/nrc2559%20http://www.nature.com/nrc/journal/v9/n1/suppinfo/nrc2559%7B%5C_%7DS1.html
      \endverb
    \endentry
    \entry{Gottesman2002}{article}{}
      \name{labelname}{1}{}{%
        {{hash=a1354f1c1b5296ca8179b1c7ffaf1bd6}{Gottesman}{G\bibinitperiod}{Michael\bibnamedelima M}{M\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{1}{}{%
        {{hash=a1354f1c1b5296ca8179b1c7ffaf1bd6}{Gottesman}{G\bibinitperiod}{Michael\bibnamedelima M}{M\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Annual Reviews}%
      }
      \strng{namehash}{a1354f1c1b5296ca8179b1c7ffaf1bd6}
      \strng{fullhash}{a1354f1c1b5296ca8179b1c7ffaf1bd6}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Mechanisms of Cancer Drug Resistance}}
      \field{annotation}{doi: 10.1146/annurev.med.53.082901.103929}
      \field{issn}{0066-4219}
      \field{journaltitle}{Annual Review of Medicine}
      \field{month}{02}
      \field{number}{1}
      \field{title}{{Mechanisms of Cancer Drug Resistance}}
      \field{volume}{53}
      \field{year}{2002}
      \field{pages}{615\bibrangedash 627}
      \verb{doi}
      \verb 10.1146/annurev.med.53.082901.103929
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1146/annurev.med.53.082901.103929
      \endverb
    \endentry
    \entry{Lowe2004}{article}{}
      \name{labelname}{3}{}{%
        {{hash=8e267aad7e0431290c9a80dbe14198e5}{Lowe}{L\bibinitperiod}{Scott\bibnamedelima W}{S\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=15c91d0027dc4d881d0379c5e0894c4e}{Cepero}{C\bibinitperiod}{Enrique}{E\bibinitperiod}{}{}{}{}}%
        {{hash=f57536643371a452e08971b8ad5073da}{Evan}{E\bibinitperiod}{Gerard}{G\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=8e267aad7e0431290c9a80dbe14198e5}{Lowe}{L\bibinitperiod}{Scott\bibnamedelima W}{S\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=15c91d0027dc4d881d0379c5e0894c4e}{Cepero}{C\bibinitperiod}{Enrique}{E\bibinitperiod}{}{}{}{}}%
        {{hash=f57536643371a452e08971b8ad5073da}{Evan}{E\bibinitperiod}{Gerard}{G\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{591e6c4492d37ce584f753c14deebcb4}
      \strng{fullhash}{591e6c4492d37ce584f753c14deebcb4}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Intrinsic tumour suppression}}
      \field{annotation}{10.1038/nature03098}
      \field{issn}{0028-0836}
      \field{journaltitle}{Nature}
      \field{month}{11}
      \field{number}{7015}
      \field{title}{{Intrinsic tumour suppression}}
      \field{volume}{432}
      \field{year}{2004}
      \field{pages}{307\bibrangedash 315}
      \verb{url}
      \verb http://dx.doi.org/10.1038/nature03098
      \endverb
    \endentry
    \entry{Logue2012}{article}{}
      \name{labelname}{2}{}{%
        {{hash=f55da953001639a8f8362a83f5fd0fd4}{Logue}{L\bibinitperiod}{Jeremy\bibnamedelima S.}{J\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=10ea24437e630bf72ce6b5de74925beb}{Morrison}{M\bibinitperiod}{Deborah\bibnamedelima K.}{D\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=f55da953001639a8f8362a83f5fd0fd4}{Logue}{L\bibinitperiod}{Jeremy\bibnamedelima S.}{J\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=10ea24437e630bf72ce6b5de74925beb}{Morrison}{M\bibinitperiod}{Deborah\bibnamedelima K.}{D\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{ba59ee8f1d98fffbd59dcc5651d9b291}
      \strng{fullhash}{ba59ee8f1d98fffbd59dcc5651d9b291}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Complexity in the signaling network: Insights from the use of targeted inhibitors in cancer therapy}}
      \field{abstract}{Cancer often arises when normal cellular growth goes awry due to defects in critical signal transduction pathways. A growing number of inhibitors that target specific components of these pathways are in clinical use, but the success of these agents has been limited by the resistance to inhibitor therapy that ultimately develops. Studies have now shown that cancer cells respond to chronic drug treatment by adapting their signaling circuitry, taking advantage of pathway redundancy and routes of feedback and cross-talk to maintain their function. This review focuses on the compensatory signaling mechanisms highlighted by the use of targeted inhibitors in cancer therapy.}
      \field{isbn}{1549-5477 (Electronic)$\backslash$r0890-9369 (Linking)}
      \field{issn}{08909369}
      \field{journaltitle}{Genes and Development}
      \field{number}{7}
      \field{title}{{Complexity in the signaling network: Insights from the use of targeted inhibitors in cancer therapy}}
      \field{volume}{26}
      \field{year}{2012}
      \field{pages}{641\bibrangedash 650}
      \verb{doi}
      \verb 10.1101/gad.186965.112
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/Genes Dev.-2012-Logue-641-50.pdf:pdf
      \endverb
    \endentry
    \entry{McMillin2013}{article}{}
      \name{labelname}{3}{}{%
        {{hash=c30fb952510309c896ab0e40e4484cb6}{McMillin}{M\bibinitperiod}{Douglas\bibnamedelima W}{D\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=83b25172a11d5d9a84c82051d78c5cc1}{Negri}{N\bibinitperiod}{Joseph\bibnamedelima M}{J\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=3b6118fc53c59da93b95a8c510432bde}{Mitsiades}{M\bibinitperiod}{Constantine\bibnamedelima S}{C\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=c30fb952510309c896ab0e40e4484cb6}{McMillin}{M\bibinitperiod}{Douglas\bibnamedelima W}{D\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=83b25172a11d5d9a84c82051d78c5cc1}{Negri}{N\bibinitperiod}{Joseph\bibnamedelima M}{J\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
        {{hash=3b6118fc53c59da93b95a8c510432bde}{Mitsiades}{M\bibinitperiod}{Constantine\bibnamedelima S}{C\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.}%
      }
      \strng{namehash}{0b40abbb7f2bdc3045c07c6850a7343c}
      \strng{fullhash}{0b40abbb7f2bdc3045c07c6850a7343c}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{The role of tumour-stromal interactions in modifying drug response: challenges and opportunities}}
      \field{annotation}{10.1038/nrd3870}
      \field{issn}{1474-1776}
      \field{journaltitle}{Nat Rev Drug Discov}
      \field{month}{03}
      \field{number}{3}
      \field{title}{{The role of tumour-stromal interactions in modifying drug response: challenges and opportunities}}
      \field{volume}{12}
      \field{year}{2013}
      \field{pages}{217\bibrangedash 228}
      \verb{url}
      \verb http://dx.doi.org/10.1038/nrd3870
      \endverb
    \endentry
    \entry{Maier2005}{article}{}
      \name{labelname}{5}{}{%
        {{hash=e6332b3fbc053e818beb40d6b92306d1}{Maier}{M\bibinitperiod}{Sabine}{S\bibinitperiod}{}{}{}{}}%
        {{hash=1c9d9f1741c41277726c521dc7fbf4e1}{Dahlstroem}{D\bibinitperiod}{Christina}{C\bibinitperiod}{}{}{}{}}%
        {{hash=6ccd7e784b4fc236e90ebfc8cd3e0a62}{Haefliger}{H\bibinitperiod}{Carolina}{C\bibinitperiod}{}{}{}{}}%
        {{hash=27baf3e62a5cfa12c1e6f95b90b40284}{Plum}{P\bibinitperiod}{Achim}{A\bibinitperiod}{}{}{}{}}%
        {{hash=360e5b8f2e397dd0acdf2916097159f3}{Piepenbrock}{P\bibinitperiod}{Christian}{C\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{5}{}{%
        {{hash=e6332b3fbc053e818beb40d6b92306d1}{Maier}{M\bibinitperiod}{Sabine}{S\bibinitperiod}{}{}{}{}}%
        {{hash=1c9d9f1741c41277726c521dc7fbf4e1}{Dahlstroem}{D\bibinitperiod}{Christina}{C\bibinitperiod}{}{}{}{}}%
        {{hash=6ccd7e784b4fc236e90ebfc8cd3e0a62}{Haefliger}{H\bibinitperiod}{Carolina}{C\bibinitperiod}{}{}{}{}}%
        {{hash=27baf3e62a5cfa12c1e6f95b90b40284}{Plum}{P\bibinitperiod}{Achim}{A\bibinitperiod}{}{}{}{}}%
        {{hash=360e5b8f2e397dd0acdf2916097159f3}{Piepenbrock}{P\bibinitperiod}{Christian}{C\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{52dcbddef5b35796453038d1e1d55930}
      \strng{fullhash}{6a4b16c1e94efd70a593e8b47bc07817}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Identifying DNA Methylation Biomarkers of Cancer Drug Response}}
      \field{abstract}{In the last few years, DNA methylation has become one of the most studied gene regulation mechanisms in carcinogenesis as a result of the cumulative evidence produced by the scientific community. Moreover, advances in the technologies that allow detection of DNA methylation in a variety of analytes have opened the possibility of developing methylation-based tests. A number of studies have provided evidence that specific methylation changes can alter the response to different therapeutic agents in cancer and, therefore, be useful biomarkers. For example, the association of the methylation status of DNA repair genes such as MGMT and MLH1 illustrate the two main mechanisms of response to DNA damaging agents. Loss of methylation of MGMT, and the subsequent increase in gene expression, leads to a reduction in response to alkylating agents as a result of enhanced repair of drug-induced DNA damage. Conversely, the increase in methylation of MLH1 and its resulting loss of expression has been consistently observed in drug-resistant tumor cells. MLH1 encodes a mismatch repair enzyme activated in response to DNA damage; activation of MLH1 also induces apoptosis of tumor cells, and thus loss of its expression leads to resistance to DNA-damaging agents. Other methylation-regulated genes that could serve as biomarkers in cancer therapy include drug transporters, genes involved in microtubule formation and stability, and genes related to hormonal therapy response. These methylation markers have potential applications for disease prognosis, treatment response prediction, and the development of novel treatment strategies.}
      \field{issn}{1175-2203}
      \field{journaltitle}{American Journal of Pharmacogenomics}
      \field{number}{4}
      \field{title}{{Identifying DNA Methylation Biomarkers of Cancer Drug Response}}
      \field{volume}{5}
      \field{year}{2005}
      \field{pages}{223\bibrangedash 232}
      \verb{doi}
      \verb 10.2165/00129785-200505040-00003
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.2165/00129785-200505040-00003
      \endverb
    \endentry
    \entry{Koivisto1997}{article}{}
      \name{labelname}{11}{}{%
        {{hash=83021009def8842ea5ab4a483868842c}{Koivisto}{K\bibinitperiod}{Pasi}{P\bibinitperiod}{}{}{}{}}%
        {{hash=199a9152a2e6bb96b2beb4f09ed64b21}{Kononen}{K\bibinitperiod}{Juha}{J\bibinitperiod}{}{}{}{}}%
        {{hash=560d241e00d660bcd40521091c38c389}{Palmberg}{P\bibinitperiod}{Christian}{C\bibinitperiod}{}{}{}{}}%
        {{hash=3dad937f613791a00e74f7fe16642ba4}{Tammela}{T\bibinitperiod}{Teuvo}{T\bibinitperiod}{}{}{}{}}%
        {{hash=b932363a5f64dc893a8c8aa13826187c}{Hyytinen}{H\bibinitperiod}{Eija}{E\bibinitperiod}{}{}{}{}}%
        {{hash=69f651c5aa39ad29a55b83c4828d915e}{Isola}{I\bibinitperiod}{Jorma}{J\bibinitperiod}{}{}{}{}}%
        {{hash=c1fb4e38b6d63246deccbbf86d3b1575}{Trapman}{T\bibinitperiod}{Jan}{J\bibinitperiod}{}{}{}{}}%
        {{hash=56e94e52248ef6490dbd18cd2eaf7cce}{Cleutjens}{C\bibinitperiod}{Kitty}{K\bibinitperiod}{}{}{}{}}%
        {{hash=e63ad953054a2923b8a3c0b94fbb4df1}{Noordzij}{N\bibinitperiod}{Arjan}{A\bibinitperiod}{}{}{}{}}%
        {{hash=4fec5b3d1a4c9169a688d0827889c1fa}{Visakorpi}{V\bibinitperiod}{Tapio}{T\bibinitperiod}{}{}{}{}}%
        {{hash=f5dd63ebcc739e6edbd7ae920b10490d}{Kallioniemi}{K\bibinitperiod}{Olli-P.}{O\bibinithyphendelim P\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{11}{}{%
        {{hash=83021009def8842ea5ab4a483868842c}{Koivisto}{K\bibinitperiod}{Pasi}{P\bibinitperiod}{}{}{}{}}%
        {{hash=199a9152a2e6bb96b2beb4f09ed64b21}{Kononen}{K\bibinitperiod}{Juha}{J\bibinitperiod}{}{}{}{}}%
        {{hash=560d241e00d660bcd40521091c38c389}{Palmberg}{P\bibinitperiod}{Christian}{C\bibinitperiod}{}{}{}{}}%
        {{hash=3dad937f613791a00e74f7fe16642ba4}{Tammela}{T\bibinitperiod}{Teuvo}{T\bibinitperiod}{}{}{}{}}%
        {{hash=b932363a5f64dc893a8c8aa13826187c}{Hyytinen}{H\bibinitperiod}{Eija}{E\bibinitperiod}{}{}{}{}}%
        {{hash=69f651c5aa39ad29a55b83c4828d915e}{Isola}{I\bibinitperiod}{Jorma}{J\bibinitperiod}{}{}{}{}}%
        {{hash=c1fb4e38b6d63246deccbbf86d3b1575}{Trapman}{T\bibinitperiod}{Jan}{J\bibinitperiod}{}{}{}{}}%
        {{hash=56e94e52248ef6490dbd18cd2eaf7cce}{Cleutjens}{C\bibinitperiod}{Kitty}{K\bibinitperiod}{}{}{}{}}%
        {{hash=e63ad953054a2923b8a3c0b94fbb4df1}{Noordzij}{N\bibinitperiod}{Arjan}{A\bibinitperiod}{}{}{}{}}%
        {{hash=4fec5b3d1a4c9169a688d0827889c1fa}{Visakorpi}{V\bibinitperiod}{Tapio}{T\bibinitperiod}{}{}{}{}}%
        {{hash=f5dd63ebcc739e6edbd7ae920b10490d}{Kallioniemi}{K\bibinitperiod}{Olli-P.}{O\bibinithyphendelim P\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{f895be2a33ad75758813678735d6b15c}
      \strng{fullhash}{14ddaf44959bd07e3b2a7424581b777f}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Androgen Receptor Gene Amplification: A Possible Molecular Mechanism for Androgen Deprivation Therapy Failure in Prostate Cancer}}
      \field{abstract}{Progression of prostate cancer during endocrine therapy is a major clinical problem, the molecular mechanisms of which remain poorly understood. Amplification of the androgen receptor (AR) gene was recently described in recurrent prostate carcinomas from patients who had failed androgen deprivation therapy. To evaluate the hypothesis that amplification of the AR gene is a cause for the failure of androgen deprivation therapy in prostate cancer, we studied whether AR amplification leads to gene overexpression, whether the amplified AR gene is structurally intact, and whether tumors with AR amplification have distinct biological and clinical characteristics. Tumor specimens were collected from 54 prostate cancer patients at the time of a local recurrence following therapy failure. In 26 cases, paired primary tumor specimens from the same patients prior to therapy were also available. Fifteen (28{\%}) of the recurrent therapy-resistant tumors, but none of the untreated primary tumors, contained AR gene amplification as determined by fluorescence in situ hybridization. According to single-stranded conformation polymorphism analysis, the AR gene was wild type in all but one of the 13 AR amplified cases studied. In one tumor, a presumed mutation in the hormone-binding domain at codon 674 leading to a Gly \x{2192} Ala substitution was found, but functional studies indicated that this mutation did not change the transactivational properties of the receptor. AR amplification was associated with a substantially increased level of mRNA expression of the gene by in situ hybridization. Clinicopathological correlations indicated that AR amplification was most likely to occur in tumors that had initially responded well to endocrine therapy and whose response duration was more than 12 months. Tumors that recurred earlier or those that showed no initial therapy response did not contain AR amplification. The median survival time after recurrence was two times longer for patients with AR amplification in comparison to those with no amplification (P = 0.03, Willcoxon-Breslow test). In conclusion, failure of conventional androgen deprivation therapy in prostate cancer may be caused by a clonal expansion of tumor cells that are able to continue androgen-dependent growth despite of the low concentrations of serum androgens. Amplification and the increased expression of a wild-type AR gene may play a key role in this process. {{$\copyright$}}1997 American Association for Cancer Research.}
      \field{journaltitle}{Cancer Research}
      \field{month}{01}
      \field{number}{2}
      \field{title}{{Androgen Receptor Gene Amplification: A Possible Molecular Mechanism for Androgen Deprivation Therapy Failure in Prostate Cancer}}
      \field{volume}{57}
      \field{year}{1997}
      \field{pages}{314\bibrangedash 319}
      \verb{url}
      \verb http://cancerres.aacrjournals.org/content/57/2/314.abstract
      \endverb
    \endentry
    \entry{Schmitt2015}{article}{}
      \name{labelname}{3}{}{%
        {{hash=a36e66a0f1ebea79542937d112f33c2c}{Schmitt}{S\bibinitperiod}{Michael\bibnamedelima W.}{M\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=6e4eb2931bf50ae5d848b0b3f3dc1524}{Loeb}{L\bibinitperiod}{Lawrence\bibnamedelima A.}{L\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=47a3e5c261ea08656d36bccde039469f}{Salk}{S\bibinitperiod}{Jesse\bibnamedelima J.}{J\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=a36e66a0f1ebea79542937d112f33c2c}{Schmitt}{S\bibinitperiod}{Michael\bibnamedelima W.}{M\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=6e4eb2931bf50ae5d848b0b3f3dc1524}{Loeb}{L\bibinitperiod}{Lawrence\bibnamedelima A.}{L\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=47a3e5c261ea08656d36bccde039469f}{Salk}{S\bibinitperiod}{Jesse\bibnamedelima J.}{J\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group}%
      }
      \strng{namehash}{ebe5644efcdc41f0769afe7616e82668}
      \strng{fullhash}{ebe5644efcdc41f0769afe7616e82668}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{The influence of subclonal resistance mutations on targeted cancer therapy.}}
      \field{abstract}{Clinical oncology is being revolutionized by the increasing use of molecularly targeted therapies. This paradigm holds great promise for improving cancer treatment; however, allocating specific therapies to the patients who are most likely to derive a durable benefit continues to represent a considerable challenge. Evidence continues to emerge that cancers are characterized by extensive intratumour genetic heterogeneity, and that patients being considered for treatment with a targeted agent might, therefore, already possess resistance to the drug in a minority of cells. Indeed, multiple examples of pre-existing subclonal resistance mutations to various molecularly targeted agents have been described, which we review herein. Early detection of pre-existing or emerging drug resistance could enable more personalized use of targeted cancer therapy, as patients could be stratified to receive the therapies that are most likely to be effective. We consider how monitoring of drug resistance could be incorporated into clinical practice to optimize the use of targeted therapies in individual patients.}
      \field{issn}{1759-4782}
      \field{journaltitle}{Nature reviews. Clinical oncology}
      \field{title}{{The influence of subclonal resistance mutations on targeted cancer therapy.}}
      \field{year}{2015}
      \verb{doi}
      \verb 10.1038/nrclinonc.2015.175
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/schmitt2015.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.nature.com/doifinder/10.1038/nrclinonc.2015.175$%5Cbackslash$nhttp://www.ncbi.nlm.nih.gov/pubmed/26483300
      \endverb
    \endentry
    \entry{Chen2011}{article}{}
      \name{labelname}{2}{}{%
        {{hash=838eb8b79df802c3fc789123cb8868dd}{Chen}{C\bibinitperiod}{Yi-fan}{Y\bibinithyphendelim f\bibinitperiod}{}{}{}{}}%
        {{hash=346db2d2a87e22a9250e7bfe471beb3e}{Fu}{F\bibinitperiod}{Li-wu}{L\bibinithyphendelim w\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=838eb8b79df802c3fc789123cb8868dd}{Chen}{C\bibinitperiod}{Yi-fan}{Y\bibinithyphendelim f\bibinitperiod}{}{}{}{}}%
        {{hash=346db2d2a87e22a9250e7bfe471beb3e}{Fu}{F\bibinitperiod}{Li-wu}{L\bibinithyphendelim w\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{5cbefd25773cc49085ba67de0a1c5560}
      \strng{fullhash}{5cbefd25773cc49085ba67de0a1c5560}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Mechanisms of acquired resistance to tyrosine kinase inhibitors}}
      \field{issn}{2211-3835}
      \field{journaltitle}{Acta Pharmaceutica Sinica B}
      \field{month}{12}
      \field{number}{4}
      \field{title}{{Mechanisms of acquired resistance to tyrosine kinase inhibitors}}
      \field{volume}{1}
      \field{year}{2011}
      \field{pages}{197\bibrangedash 207}
      \verb{doi}
      \verb http://dx.doi.org/10.1016/j.apsb.2011.10.007
      \endverb
      \verb{url}
      \verb http://www.sciencedirect.com/science/article/pii/S2211383511000876
      \endverb
    \endentry
    \entry{Barouch-Bentov2011a}{article}{}
      \name{labelname}{2}{}{%
        {{hash=f1c3e5165a862ff0406acf074bc1a4ff}{Barouch-Bentov}{B\bibinithyphendelim B\bibinitperiod}{Rina}{R\bibinitperiod}{}{}{}{}}%
        {{hash=0f5bf5358f926234ff2094c55b885010}{Sauer}{S\bibinitperiod}{Karsten}{K\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=f1c3e5165a862ff0406acf074bc1a4ff}{Barouch-Bentov}{B\bibinithyphendelim B\bibinitperiod}{Rina}{R\bibinitperiod}{}{}{}{}}%
        {{hash=0f5bf5358f926234ff2094c55b885010}{Sauer}{S\bibinitperiod}{Karsten}{K\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{b996fa312837b24998517323bb416ace}
      \strng{fullhash}{b996fa312837b24998517323bb416ace}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Mechanisms of Drug-Resistance in Kinases}}
      \field{abstract}{INTRODUCTION: Because of their important roles in disease and excellent {$\textquotedblleft$}druggability{$\textquotedblright$}, kinases have become the second-largest drug target family. The great success of the BCR-ABL inhibitor imatinib in treating CML illustrates the high potential of kinase inhibitor (KI) therapeutics, but also unveiled a major limitation: the development of drug-resistance. This is a significant concern as KIs reach large patient populations for an expanding array of indications. AREAS COVERED: We provide an up-to-date understanding of the mechanisms through which KIs function, and through which cells can become KI-resistant. We review current and future approaches to overcome KI-resistance, focussing on currently approved KIs and KIs in clinical trials. We then discuss approaches to improve KI efficacy and overcome drug-resistance and novel approaches to develop less drug-resistance prone KI-therapeutics. EXPERT OPINION: Although drug-resistance is a concern for current KI-therapeutics, recent progress in our understanding of the underlying mechanisms and promising technological advances may overcome this limitation and provide powerful new therapeutics.}
      \field{issn}{1354-3784}
      \field{journaltitle}{Expert opinion on investigational drugs}
      \field{month}{02}
      \field{number}{2}
      \field{title}{{Mechanisms of Drug-Resistance in Kinases}}
      \field{volume}{20}
      \field{year}{2011}
      \field{pages}{153\bibrangedash 208}
      \verb{doi}
      \verb 10.1517/13543784.2011.546344
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3095104/
      \endverb
    \endentry
    \entry{Gorre2001}{article}{}
      \name{labelname}{7}{}{%
        {{hash=c8a9cbad8cfa2b5a8ad09452a9533cb9}{Gorre}{G\bibinitperiod}{Mercedes\bibnamedelima E}{M\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=c0b63a80cf33f0666a50c643d6e6c798}{Mohammed}{M\bibinitperiod}{Mansoor}{M\bibinitperiod}{}{}{}{}}%
        {{hash=71c6d88cef5acaa8bc18e9be42d8dde8}{Ellwood}{E\bibinitperiod}{Katharine}{K\bibinitperiod}{}{}{}{}}%
        {{hash=ac7a2252da43c90b85c4b1f6d31df7fc}{Hsu}{H\bibinitperiod}{Nicholas}{N\bibinitperiod}{}{}{}{}}%
        {{hash=cc11273b857b652546513e2e2f73129a}{Paquette}{P\bibinitperiod}{Ron}{R\bibinitperiod}{}{}{}{}}%
        {{hash=35aa2081393170f21bb85d865876677a}{Rao}{R\bibinitperiod}{P\bibnamedelima Nagesh}{P\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
        {{hash=f22edf6d53eef45e28e683b05a6365ea}{Sawyers}{S\bibinitperiod}{Charles\bibnamedelima L}{C\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{7}{}{%
        {{hash=c8a9cbad8cfa2b5a8ad09452a9533cb9}{Gorre}{G\bibinitperiod}{Mercedes\bibnamedelima E}{M\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=c0b63a80cf33f0666a50c643d6e6c798}{Mohammed}{M\bibinitperiod}{Mansoor}{M\bibinitperiod}{}{}{}{}}%
        {{hash=71c6d88cef5acaa8bc18e9be42d8dde8}{Ellwood}{E\bibinitperiod}{Katharine}{K\bibinitperiod}{}{}{}{}}%
        {{hash=ac7a2252da43c90b85c4b1f6d31df7fc}{Hsu}{H\bibinitperiod}{Nicholas}{N\bibinitperiod}{}{}{}{}}%
        {{hash=cc11273b857b652546513e2e2f73129a}{Paquette}{P\bibinitperiod}{Ron}{R\bibinitperiod}{}{}{}{}}%
        {{hash=35aa2081393170f21bb85d865876677a}{Rao}{R\bibinitperiod}{P\bibnamedelima Nagesh}{P\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
        {{hash=f22edf6d53eef45e28e683b05a6365ea}{Sawyers}{S\bibinitperiod}{Charles\bibnamedelima L}{C\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{a45409e6edc0726bd1b561df7fd2346a}
      \strng{fullhash}{6c01aee90bc8caab0fcc46be97b7b672}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification}}
      \field{abstract}{Clinical studies with the Abl tyrosine kinase inhibitor STI-571 in chronic myeloid leukemia demonstrate that many patients with advanced stage disease respond initially but then relapse. Through biochemical and molecular analysis of clinical material, we find that drug resistance is associated with the reactivation of BCR-ABL signal transduction in all cases examined. In six of nine patients, resistance was associated with a single amino acid substitution in a threonine residue of the Abl kinase domain known to form a critical hydrogen bond with the drug. This substitution of threonine with isoleucine was sufficient to confer STI-571 resistance in a reconstitution experiment. In three patients, resistance was associated with progressiveBCR-ABL gene amplification. These studies provide evidence that genetically complex cancers retain dependence on an initial oncogenic event and suggest a strategy for identifying inhibitors of STI-571 resistance.}
      \field{journaltitle}{Science}
      \field{month}{08}
      \field{number}{5531}
      \field{title}{{Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification}}
      \field{volume}{293}
      \field{year}{2001}
      \field{pages}{876\bibrangedash 880}
      \verb{url}
      \verb http://science.sciencemag.org/content/293/5531/876.abstract
      \endverb
    \endentry
    \entry{Soverini2016}{article}{}
      \name{labelname}{9}{}{%
        {{hash=0a9e9a02e71800c149bfaff090a05e47}{Soverini}{S\bibinitperiod}{Simona}{S\bibinitperiod}{}{}{}{}}%
        {{hash=42e17c34d483c3fb2aa376c78b8043f1}{Branford}{B\bibinitperiod}{Susan}{S\bibinitperiod}{}{}{}{}}%
        {{hash=0cde4574b87e87e5767dd9e024f4427a}{Nicolini}{N\bibinitperiod}{Franck\bibnamedelima E}{F\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=c35a3fbc1bf6528c77e1b61ae7f77709}{Talpaz}{T\bibinitperiod}{Moshe}{M\bibinitperiod}{}{}{}{}}%
        {{hash=249fe77ad183fc6795a8499b6863eb90}{Deininger}{D\bibinitperiod}{Michael\bibnamedelimb W\bibnamedelima N}{M\bibinitperiod\bibinitdelim W\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
        {{hash=032a8d086021b639c99eec77315a3f32}{Martinelli}{M\bibinitperiod}{Giovanni}{G\bibinitperiod}{}{}{}{}}%
        {{hash=ed21f2add1c5b9222c502609601b029b}{M{\"{u}}ller}{M\bibinitperiod}{Martin\bibnamedelima C}{M\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=494cfc6fb18817448568dbf4e911e819}{Radich}{R\bibinitperiod}{Jerald\bibnamedelima P}{J\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=09d68d1fdd85e495ccf25e270b1f2023}{Shah}{S\bibinitperiod}{Neil\bibnamedelima P}{N\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{9}{}{%
        {{hash=0a9e9a02e71800c149bfaff090a05e47}{Soverini}{S\bibinitperiod}{Simona}{S\bibinitperiod}{}{}{}{}}%
        {{hash=42e17c34d483c3fb2aa376c78b8043f1}{Branford}{B\bibinitperiod}{Susan}{S\bibinitperiod}{}{}{}{}}%
        {{hash=0cde4574b87e87e5767dd9e024f4427a}{Nicolini}{N\bibinitperiod}{Franck\bibnamedelima E}{F\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=c35a3fbc1bf6528c77e1b61ae7f77709}{Talpaz}{T\bibinitperiod}{Moshe}{M\bibinitperiod}{}{}{}{}}%
        {{hash=249fe77ad183fc6795a8499b6863eb90}{Deininger}{D\bibinitperiod}{Michael\bibnamedelimb W\bibnamedelima N}{M\bibinitperiod\bibinitdelim W\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
        {{hash=032a8d086021b639c99eec77315a3f32}{Martinelli}{M\bibinitperiod}{Giovanni}{G\bibinitperiod}{}{}{}{}}%
        {{hash=ed21f2add1c5b9222c502609601b029b}{M{\"{u}}ller}{M\bibinitperiod}{Martin\bibnamedelima C}{M\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=494cfc6fb18817448568dbf4e911e819}{Radich}{R\bibinitperiod}{Jerald\bibnamedelima P}{J\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=09d68d1fdd85e495ccf25e270b1f2023}{Shah}{S\bibinitperiod}{Neil\bibnamedelima P}{N\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Elsevier}%
      }
      \strng{namehash}{e652330e53b4fb86088418234ea76d68}
      \strng{fullhash}{e75f7f2ddf7f6afd77a7f16cf54902b1}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia}}
      \field{annotation}{doi: 10.1016/j.leukres.2013.09.011}
      \field{issn}{0145-2126}
      \field{journaltitle}{Leukemia Research}
      \field{month}{07}
      \field{number}{1}
      \field{title}{{Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia}}
      \field{volume}{38}
      \field{year}{2016}
      \field{pages}{10\bibrangedash 20}
      \verb{doi}
      \verb 10.1016/j.leukres.2013.09.011
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1016/j.leukres.2013.09.011
      \endverb
    \endentry
    \entry{Shih2005}{article}{}
      \name{labelname}{3}{}{%
        {{hash=097b13d55a363aeef488832a2555978e}{Shih}{S\bibinitperiod}{Jin-Yuan}{J\bibinithyphendelim Y\bibinitperiod}{}{}{}{}}%
        {{hash=26255e7a3c1ba4e8e0e0f5fa63a741d6}{Gow}{G\bibinitperiod}{Chien-Hung}{C\bibinithyphendelim H\bibinitperiod}{}{}{}{}}%
        {{hash=8c7b09ba94093e2119b6af7becca215a}{Yang}{Y\bibinitperiod}{Pan-Chyr}{P\bibinithyphendelim C\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=097b13d55a363aeef488832a2555978e}{Shih}{S\bibinitperiod}{Jin-Yuan}{J\bibinithyphendelim Y\bibinitperiod}{}{}{}{}}%
        {{hash=26255e7a3c1ba4e8e0e0f5fa63a741d6}{Gow}{G\bibinitperiod}{Chien-Hung}{C\bibinithyphendelim H\bibinitperiod}{}{}{}{}}%
        {{hash=8c7b09ba94093e2119b6af7becca215a}{Yang}{Y\bibinitperiod}{Pan-Chyr}{P\bibinithyphendelim C\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Massachusetts Medical Society}%
      }
      \strng{namehash}{d06c803369769e84025216ed5637b6a9}
      \strng{fullhash}{d06c803369769e84025216ed5637b6a9}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{EGFR Mutation Conferring Primary Resistance to Gefitinib in Non--Small-Cell Lung Cancer}}
      \field{annotation}{doi: 10.1056/NEJM200507143530217}
      \field{issn}{0028-4793}
      \field{journaltitle}{New England Journal of Medicine}
      \field{month}{07}
      \field{number}{2}
      \field{title}{{EGFR Mutation Conferring Primary Resistance to Gefitinib in Non--Small-Cell Lung Cancer}}
      \field{volume}{353}
      \field{year}{2005}
      \field{pages}{207\bibrangedash 208}
      \verb{doi}
      \verb 10.1056/NEJM200507143530217
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1056/NEJM200507143530217
      \endverb
    \endentry
    \entry{Walter2013}{article}{}
      \name{labelname}{30}{}{%
        {{hash=cca789921c494236ec14c7db5c2878fc}{Walter}{W\bibinitperiod}{Annette\bibnamedelima O}{A\bibinitperiod\bibinitdelim O\bibinitperiod}{}{}{}{}}%
        {{hash=cf677020cb59ee903228bd940483f261}{Sjin}{S\bibinitperiod}{Robert\bibnamedelimb Tjin\bibnamedelima Tham}{R\bibinitperiod\bibinitdelim T\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=6c5b4f554b577226a962e927ad4b196d}{Haringsma}{H\bibinitperiod}{Henry\bibnamedelima J}{H\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=bf7ffa68555d1660e1f6f0dcdf1a38e2}{Ohashi}{O\bibinitperiod}{Kadoaki}{K\bibinitperiod}{}{}{}{}}%
        {{hash=65ea74598909191bc1e0ad5a2d66e922}{Sun}{S\bibinitperiod}{Jing}{J\bibinitperiod}{}{}{}{}}%
        {{hash=bfe1058ef5492d64f1e0f193c736faa8}{Lee}{L\bibinitperiod}{Kwangho}{K\bibinitperiod}{}{}{}{}}%
        {{hash=f0e5e463196c34f4b907df07394a20df}{Dubrovskiy}{D\bibinitperiod}{Aleksandr}{A\bibinitperiod}{}{}{}{}}%
        {{hash=5cbdfca8ebe0f2869d00f9107338bcdc}{Labenski}{L\bibinitperiod}{Matthew}{M\bibinitperiod}{}{}{}{}}%
        {{hash=ba72e8d8a8abe30d9d20832861803a72}{Zhu}{Z\bibinitperiod}{Zhendong}{Z\bibinitperiod}{}{}{}{}}%
        {{hash=9f4446a6d583221d3d173f806ecf8627}{Wang}{W\bibinitperiod}{Zhigang}{Z\bibinitperiod}{}{}{}{}}%
        {{hash=317a92fa1f91c6949eb2bcdb302df34c}{Sheets}{S\bibinitperiod}{Michael}{M\bibinitperiod}{}{}{}{}}%
        {{hash=8fd09416626a0e5bd54a542296e3cc02}{{St\bibnamedelimb Martin}}{S\bibinitperiod}{Thia}{T\bibinitperiod}{}{}{}{}}%
        {{hash=d320eb9999cfa2b9ca9eada10017fc88}{Karp}{K\bibinitperiod}{Russell}{R\bibinitperiod}{}{}{}{}}%
        {{hash=32a6fa3fb0519b0f2ad00732902c571c}{Kalken}{K\bibinitperiod}{Dan}{D\bibinitperiod}{van}{v\bibinitperiod}{}{}}%
        {{hash=74e8771eabf644b9966df55877434537}{Chaturvedi}{C\bibinitperiod}{Prasoon}{P\bibinitperiod}{}{}{}{}}%
        {{hash=ab6c13a43e4a88eadf82c6c7aaf2976e}{Niu}{N\bibinitperiod}{Deqiang}{D\bibinitperiod}{}{}{}{}}%
        {{hash=230219635bc09a341b8b87210877a101}{Nacht}{N\bibinitperiod}{Mariana}{M\bibinitperiod}{}{}{}{}}%
        {{hash=f048e1809ed2d21d092a20d30987b9ab}{Petter}{P\bibinitperiod}{Russell\bibnamedelima C}{R\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=4e88a62d4f3a7f529b3c5a77a2c5a2d8}{Westlin}{W\bibinitperiod}{William}{W\bibinitperiod}{}{}{}{}}%
        {{hash=68434cdeb7a3c089fd99baba0e0a4a3b}{Lin}{L\bibinitperiod}{Kevin}{K\bibinitperiod}{}{}{}{}}%
        {{hash=4666719f28c34e4f94e852bc4fc18b8e}{Jaw-Tsai}{J\bibinithyphendelim T\bibinitperiod}{Sarah}{S\bibinitperiod}{}{}{}{}}%
        {{hash=67b202c72147e9c0a41f943ef7d2da50}{Raponi}{R\bibinitperiod}{Mitch}{M\bibinitperiod}{}{}{}{}}%
        {{hash=f5efe5ccfcb886b6e498c802a46ec7ec}{{Van\bibnamedelimb Dyke}}{V\bibinitperiod}{Terry}{T\bibinitperiod}{}{}{}{}}%
        {{hash=841fb4e62a9a5d592b9e89194f7b13aa}{Etter}{E\bibinitperiod}{Jeff}{J\bibinitperiod}{}{}{}{}}%
        {{hash=edc177d9163f251894097883fa6a592f}{Weaver}{W\bibinitperiod}{Zoe}{Z\bibinitperiod}{}{}{}{}}%
        {{hash=1f9445cbbdbb17a9eb7353afdab8a763}{Pao}{P\bibinitperiod}{William}{W\bibinitperiod}{}{}{}{}}%
        {{hash=ba7cc9c093b23938d671bf86afa5b3fd}{Singh}{S\bibinitperiod}{Juswinder}{J\bibinitperiod}{}{}{}{}}%
        {{hash=60be570203dbd7412e376dc3051fce5f}{Simmons}{S\bibinitperiod}{Andrew\bibnamedelima D}{A\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=5d71d3960f01caa4ecafb3fcf8986f1d}{Harding}{H\bibinitperiod}{Thomas\bibnamedelima C}{T\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=d2c136ce91bb9434800c7bbb5529e412}{Allen}{A\bibinitperiod}{Andrew}{A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{30}{}{%
        {{hash=cca789921c494236ec14c7db5c2878fc}{Walter}{W\bibinitperiod}{Annette\bibnamedelima O}{A\bibinitperiod\bibinitdelim O\bibinitperiod}{}{}{}{}}%
        {{hash=cf677020cb59ee903228bd940483f261}{Sjin}{S\bibinitperiod}{Robert\bibnamedelimb Tjin\bibnamedelima Tham}{R\bibinitperiod\bibinitdelim T\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=6c5b4f554b577226a962e927ad4b196d}{Haringsma}{H\bibinitperiod}{Henry\bibnamedelima J}{H\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=bf7ffa68555d1660e1f6f0dcdf1a38e2}{Ohashi}{O\bibinitperiod}{Kadoaki}{K\bibinitperiod}{}{}{}{}}%
        {{hash=65ea74598909191bc1e0ad5a2d66e922}{Sun}{S\bibinitperiod}{Jing}{J\bibinitperiod}{}{}{}{}}%
        {{hash=bfe1058ef5492d64f1e0f193c736faa8}{Lee}{L\bibinitperiod}{Kwangho}{K\bibinitperiod}{}{}{}{}}%
        {{hash=f0e5e463196c34f4b907df07394a20df}{Dubrovskiy}{D\bibinitperiod}{Aleksandr}{A\bibinitperiod}{}{}{}{}}%
        {{hash=5cbdfca8ebe0f2869d00f9107338bcdc}{Labenski}{L\bibinitperiod}{Matthew}{M\bibinitperiod}{}{}{}{}}%
        {{hash=ba72e8d8a8abe30d9d20832861803a72}{Zhu}{Z\bibinitperiod}{Zhendong}{Z\bibinitperiod}{}{}{}{}}%
        {{hash=9f4446a6d583221d3d173f806ecf8627}{Wang}{W\bibinitperiod}{Zhigang}{Z\bibinitperiod}{}{}{}{}}%
        {{hash=317a92fa1f91c6949eb2bcdb302df34c}{Sheets}{S\bibinitperiod}{Michael}{M\bibinitperiod}{}{}{}{}}%
        {{hash=8fd09416626a0e5bd54a542296e3cc02}{{St\bibnamedelimb Martin}}{S\bibinitperiod}{Thia}{T\bibinitperiod}{}{}{}{}}%
        {{hash=d320eb9999cfa2b9ca9eada10017fc88}{Karp}{K\bibinitperiod}{Russell}{R\bibinitperiod}{}{}{}{}}%
        {{hash=32a6fa3fb0519b0f2ad00732902c571c}{Kalken}{K\bibinitperiod}{Dan}{D\bibinitperiod}{van}{v\bibinitperiod}{}{}}%
        {{hash=74e8771eabf644b9966df55877434537}{Chaturvedi}{C\bibinitperiod}{Prasoon}{P\bibinitperiod}{}{}{}{}}%
        {{hash=ab6c13a43e4a88eadf82c6c7aaf2976e}{Niu}{N\bibinitperiod}{Deqiang}{D\bibinitperiod}{}{}{}{}}%
        {{hash=230219635bc09a341b8b87210877a101}{Nacht}{N\bibinitperiod}{Mariana}{M\bibinitperiod}{}{}{}{}}%
        {{hash=f048e1809ed2d21d092a20d30987b9ab}{Petter}{P\bibinitperiod}{Russell\bibnamedelima C}{R\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=4e88a62d4f3a7f529b3c5a77a2c5a2d8}{Westlin}{W\bibinitperiod}{William}{W\bibinitperiod}{}{}{}{}}%
        {{hash=68434cdeb7a3c089fd99baba0e0a4a3b}{Lin}{L\bibinitperiod}{Kevin}{K\bibinitperiod}{}{}{}{}}%
        {{hash=4666719f28c34e4f94e852bc4fc18b8e}{Jaw-Tsai}{J\bibinithyphendelim T\bibinitperiod}{Sarah}{S\bibinitperiod}{}{}{}{}}%
        {{hash=67b202c72147e9c0a41f943ef7d2da50}{Raponi}{R\bibinitperiod}{Mitch}{M\bibinitperiod}{}{}{}{}}%
        {{hash=f5efe5ccfcb886b6e498c802a46ec7ec}{{Van\bibnamedelimb Dyke}}{V\bibinitperiod}{Terry}{T\bibinitperiod}{}{}{}{}}%
        {{hash=841fb4e62a9a5d592b9e89194f7b13aa}{Etter}{E\bibinitperiod}{Jeff}{J\bibinitperiod}{}{}{}{}}%
        {{hash=edc177d9163f251894097883fa6a592f}{Weaver}{W\bibinitperiod}{Zoe}{Z\bibinitperiod}{}{}{}{}}%
        {{hash=1f9445cbbdbb17a9eb7353afdab8a763}{Pao}{P\bibinitperiod}{William}{W\bibinitperiod}{}{}{}{}}%
        {{hash=ba7cc9c093b23938d671bf86afa5b3fd}{Singh}{S\bibinitperiod}{Juswinder}{J\bibinitperiod}{}{}{}{}}%
        {{hash=60be570203dbd7412e376dc3051fce5f}{Simmons}{S\bibinitperiod}{Andrew\bibnamedelima D}{A\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=5d71d3960f01caa4ecafb3fcf8986f1d}{Harding}{H\bibinitperiod}{Thomas\bibnamedelima C}{T\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=d2c136ce91bb9434800c7bbb5529e412}{Allen}{A\bibinitperiod}{Andrew}{A\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{3d4581139d53d7d61cf2c68faa01469b}
      \strng{fullhash}{0f0805436004ca10cc2cb6cc18dd3b53}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC}}
      \field{abstract}{Patients with non--small cell lung cancer (NSCLC) with activating EGF receptor (EGFR) mutations initially respond to first-generation reversible EGFR tyrosine kinase inhibitors. However, clinical efficacy is limited by acquired resistance, frequently driven by the EGFRT790M mutation. CO-1686 is a novel, irreversible, and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR, including T790M, while exhibiting minimal activity toward the wild-type (WT) receptor. Oral administration of CO-1686 as single agent induces tumor regression in EGFR-mutated NSCLC tumor xenograft and transgenic models. Minimal activity of CO-1686 against the WT EGFR receptor was observed. In NSCLC cells with acquired resistance to CO-1686 in vitro, there was no evidence of additional mutations or amplification of the EGFR gene, but resistant cells exhibited signs of epithelial--mesenchymal transition and demonstrated increased sensitivity to AKT inhibitors. These results suggest that CO-1686 may offer a novel therapeutic option for patients with mutant EGFR NSCLC.Significance: We report the preclinical development of a novel covalent inhibitor, CO-1686, that irreversibly and selectively inhibits mutant EGFR, in particular the T790M drug-resistance mutation, in NSCLC models. CO-1686 is the first drug of its class in clinical development for the treatment of T790M-positive NSCLC, potentially offering potent inhibition of mutant EGFR while avoiding the on-target toxicity observed with inhibition of the WT EGFR. Cancer Discov; 3(12); 1404--15. {{$\copyright$}}2013 AACR.This article is highlighted in the In This Issue feature, p. 1317}
      \field{annotation}{10.1158/2159-8290.CD-13-0314}
      \field{journaltitle}{Cancer Discovery}
      \field{month}{12}
      \field{number}{12}
      \field{title}{{Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC}}
      \field{volume}{3}
      \field{year}{2013}
      \field{pages}{1404\bibrangedash 1415}
      \verb{doi}
      \verb 10.1158/2159-8290.CD-13-0314
      \endverb
      \verb{url}
      \verb http://cancerdiscovery.aacrjournals.org/content/3/12/1404.abstract
      \endverb
    \endentry
    \entry{Cross2014}{article}{}
      \name{labelname}{26}{}{%
        {{hash=730caf584e659bb8c7b2cdb21a2ff85d}{Cross}{C\bibinitperiod}{Darren\bibnamedelimb A\bibnamedelima E}{D\bibinitperiod\bibinitdelim A\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=e6f89ccdf09de3450bd4678c362348b7}{Ashton}{A\bibinitperiod}{Susan\bibnamedelima E}{S\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=bfb954977cc0afc320caed7d1cdd92ec}{Ghiorghiu}{G\bibinitperiod}{Serban}{S\bibinitperiod}{}{}{}{}}%
        {{hash=b7cd7e931130b100968ab68e7990179f}{Eberlein}{E\bibinitperiod}{Cath}{C\bibinitperiod}{}{}{}{}}%
        {{hash=b1f53e50947052b0dd53ab4c54700f39}{Nebhan}{N\bibinitperiod}{Caroline\bibnamedelima A}{C\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=07f181f03d9209e0bd608cb46864ed93}{Spitzler}{S\bibinitperiod}{Paula\bibnamedelima J}{P\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=4be7ed8315ea23f658c28349ee55a98a}{Orme}{O\bibinitperiod}{Jonathon\bibnamedelima P}{J\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=e47976f1fe8587c931d63fb1814246a6}{Finlay}{F\bibinitperiod}{M\bibnamedelima Raymond\bibnamedelima V}{M\bibinitperiod\bibinitdelim R\bibinitperiod\bibinitdelim V\bibinitperiod}{}{}{}{}}%
        {{hash=bbf0958ea69ace728ec58e0199b72027}{Ward}{W\bibinitperiod}{Richard\bibnamedelima A}{R\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=5314d8131e9a6633cb2ac83521f7ce03}{Mellor}{M\bibinitperiod}{Martine\bibnamedelima J}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=0c9e04c7b5619196867412acc6ee5817}{Hughes}{H\bibinitperiod}{Gareth}{G\bibinitperiod}{}{}{}{}}%
        {{hash=30e3b5e08e476aa6ede3ad8c7fb7caed}{Rahi}{R\bibinitperiod}{Amar}{A\bibinitperiod}{}{}{}{}}%
        {{hash=f2804395ed5443db24e7009f329c591f}{Jacobs}{J\bibinitperiod}{Vivien\bibnamedelima N}{V\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
        {{hash=1c2895c17d684dfbb5f680286e6481ab}{Brewer}{B\bibinitperiod}{Monica\bibnamedelima Red}{M\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=a5a098895ee1f55efcfcd84e6320b4fc}{Ichihara}{I\bibinitperiod}{Eiki}{E\bibinitperiod}{}{}{}{}}%
        {{hash=65ea74598909191bc1e0ad5a2d66e922}{Sun}{S\bibinitperiod}{Jing}{J\bibinitperiod}{}{}{}{}}%
        {{hash=46869c5054f2de0c51621d9b60bab602}{Jin}{J\bibinitperiod}{Hailing}{H\bibinitperiod}{}{}{}{}}%
        {{hash=c4395e579ca44aaced064425a258dbf3}{Ballard}{B\bibinitperiod}{Peter}{P\bibinitperiod}{}{}{}{}}%
        {{hash=f8e5d2280281be9b381647bab8a611e6}{Al-Kadhimi}{A\bibinithyphendelim K\bibinitperiod}{Katherine}{K\bibinitperiod}{}{}{}{}}%
        {{hash=baf2684715e4619413119a2f21224c2a}{Rowlinson}{R\bibinitperiod}{Rachel}{R\bibinitperiod}{}{}{}{}}%
        {{hash=bad48efd2b68f1a54ec4f11cded655bb}{Klinowska}{K\bibinitperiod}{Teresa}{T\bibinitperiod}{}{}{}{}}%
        {{hash=df2cf1b98d260362cf694cd3e6461184}{Richmond}{R\bibinitperiod}{Graham\bibnamedelimb H\bibnamedelima P}{G\bibinitperiod\bibinitdelim H\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=c2bfc744d84c6bd9ec7d9f83404255fd}{Cantarini}{C\bibinitperiod}{Mireille}{M\bibinitperiod}{}{}{}{}}%
        {{hash=d2229394934f5465cb16aa426b2fd68c}{Kim}{K\bibinitperiod}{Dong-Wan}{D\bibinithyphendelim W\bibinitperiod}{}{}{}{}}%
        {{hash=7cbad32221d61c4cd3aaded9d5222573}{Ranson}{R\bibinitperiod}{Malcolm\bibnamedelima R}{M\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=1f9445cbbdbb17a9eb7353afdab8a763}{Pao}{P\bibinitperiod}{William}{W\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{26}{}{%
        {{hash=730caf584e659bb8c7b2cdb21a2ff85d}{Cross}{C\bibinitperiod}{Darren\bibnamedelimb A\bibnamedelima E}{D\bibinitperiod\bibinitdelim A\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=e6f89ccdf09de3450bd4678c362348b7}{Ashton}{A\bibinitperiod}{Susan\bibnamedelima E}{S\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=bfb954977cc0afc320caed7d1cdd92ec}{Ghiorghiu}{G\bibinitperiod}{Serban}{S\bibinitperiod}{}{}{}{}}%
        {{hash=b7cd7e931130b100968ab68e7990179f}{Eberlein}{E\bibinitperiod}{Cath}{C\bibinitperiod}{}{}{}{}}%
        {{hash=b1f53e50947052b0dd53ab4c54700f39}{Nebhan}{N\bibinitperiod}{Caroline\bibnamedelima A}{C\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=07f181f03d9209e0bd608cb46864ed93}{Spitzler}{S\bibinitperiod}{Paula\bibnamedelima J}{P\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=4be7ed8315ea23f658c28349ee55a98a}{Orme}{O\bibinitperiod}{Jonathon\bibnamedelima P}{J\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=e47976f1fe8587c931d63fb1814246a6}{Finlay}{F\bibinitperiod}{M\bibnamedelima Raymond\bibnamedelima V}{M\bibinitperiod\bibinitdelim R\bibinitperiod\bibinitdelim V\bibinitperiod}{}{}{}{}}%
        {{hash=bbf0958ea69ace728ec58e0199b72027}{Ward}{W\bibinitperiod}{Richard\bibnamedelima A}{R\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=5314d8131e9a6633cb2ac83521f7ce03}{Mellor}{M\bibinitperiod}{Martine\bibnamedelima J}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=0c9e04c7b5619196867412acc6ee5817}{Hughes}{H\bibinitperiod}{Gareth}{G\bibinitperiod}{}{}{}{}}%
        {{hash=30e3b5e08e476aa6ede3ad8c7fb7caed}{Rahi}{R\bibinitperiod}{Amar}{A\bibinitperiod}{}{}{}{}}%
        {{hash=f2804395ed5443db24e7009f329c591f}{Jacobs}{J\bibinitperiod}{Vivien\bibnamedelima N}{V\bibinitperiod\bibinitdelim N\bibinitperiod}{}{}{}{}}%
        {{hash=1c2895c17d684dfbb5f680286e6481ab}{Brewer}{B\bibinitperiod}{Monica\bibnamedelima Red}{M\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=a5a098895ee1f55efcfcd84e6320b4fc}{Ichihara}{I\bibinitperiod}{Eiki}{E\bibinitperiod}{}{}{}{}}%
        {{hash=65ea74598909191bc1e0ad5a2d66e922}{Sun}{S\bibinitperiod}{Jing}{J\bibinitperiod}{}{}{}{}}%
        {{hash=46869c5054f2de0c51621d9b60bab602}{Jin}{J\bibinitperiod}{Hailing}{H\bibinitperiod}{}{}{}{}}%
        {{hash=c4395e579ca44aaced064425a258dbf3}{Ballard}{B\bibinitperiod}{Peter}{P\bibinitperiod}{}{}{}{}}%
        {{hash=f8e5d2280281be9b381647bab8a611e6}{Al-Kadhimi}{A\bibinithyphendelim K\bibinitperiod}{Katherine}{K\bibinitperiod}{}{}{}{}}%
        {{hash=baf2684715e4619413119a2f21224c2a}{Rowlinson}{R\bibinitperiod}{Rachel}{R\bibinitperiod}{}{}{}{}}%
        {{hash=bad48efd2b68f1a54ec4f11cded655bb}{Klinowska}{K\bibinitperiod}{Teresa}{T\bibinitperiod}{}{}{}{}}%
        {{hash=df2cf1b98d260362cf694cd3e6461184}{Richmond}{R\bibinitperiod}{Graham\bibnamedelimb H\bibnamedelima P}{G\bibinitperiod\bibinitdelim H\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=c2bfc744d84c6bd9ec7d9f83404255fd}{Cantarini}{C\bibinitperiod}{Mireille}{M\bibinitperiod}{}{}{}{}}%
        {{hash=d2229394934f5465cb16aa426b2fd68c}{Kim}{K\bibinitperiod}{Dong-Wan}{D\bibinithyphendelim W\bibinitperiod}{}{}{}{}}%
        {{hash=7cbad32221d61c4cd3aaded9d5222573}{Ranson}{R\bibinitperiod}{Malcolm\bibnamedelima R}{M\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=1f9445cbbdbb17a9eb7353afdab8a763}{Pao}{P\bibinitperiod}{William}{W\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{697190affcef5e8252710cdce4259277}
      \strng{fullhash}{177280f9b627870fec550c1f70fbce25}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer}}
      \field{abstract}{First generation EGF receptor tyrosine kinase inhibitors (EGFR TKIs) provide significant clinical benefit in patients with advanced EGFR mutant (EGFRm+) non-small cell lung cancer (NSCLC). Patients ultimately develop disease progression, often driven by acquisition of a second T790M EGFR TKI resistance mutation. AZD9291 is a novel oral, potent and selective third generation irreversible inhibitor of both EGFRm+ sensitizing and T790M resistance mutants that spares wild-type EGFR. This monoanilino-pyrimidine compound is structurally distinct from other third generation EGFR TKIs and offers a pharmacologically differentiated profile from earlier generation EGFR TKIs. Pre-clinically, the drug potently inhibits signaling pathways and cellular growth in both EGFRm+ and EGFRm+/T790M mutant cell lines in vitro, with lower activity against wild-type EGFR lines, translating into profound and sustained tumor regression in EGFR mutant tumor xenograft and transgenic models. The treatment of two patients with advanced EGFRm T790M+ NSCLC is described as proof of principle.}
      \field{issn}{2159-8274}
      \field{journaltitle}{Cancer discovery}
      \field{month}{09}
      \field{number}{9}
      \field{title}{{AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer}}
      \field{volume}{4}
      \field{year}{2014}
      \field{pages}{1046\bibrangedash 1061}
      \verb{doi}
      \verb 10.1158/2159-8290.CD-14-0337
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315625/
      \endverb
    \endentry
    \entry{Ercan2015}{article}{}
      \name{labelname}{8}{}{%
        {{hash=808dd167f023b8edc89c9fa87362ad69}{Ercan}{E\bibinitperiod}{Dalia}{D\bibinitperiod}{}{}{}{}}%
        {{hash=1ec3602d84fa696e9d0277bed04f6485}{Choi}{C\bibinitperiod}{Hwan\bibnamedelima Geun}{H\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=c6ba104fde2bb4aba691518a73c8ae34}{Yun}{Y\bibinitperiod}{Cai-Hong}{C\bibinithyphendelim H\bibinitperiod}{}{}{}{}}%
        {{hash=c09d676ff94346afdb4de7d73029253c}{Capelletti}{C\bibinitperiod}{Marzia}{M\bibinitperiod}{}{}{}{}}%
        {{hash=141eee66b6dff86df5d983d145e98b14}{Xie}{X\bibinitperiod}{Ting}{T\bibinitperiod}{}{}{}{}}%
        {{hash=17a71501a921f463a4ec3f0da1ce20b0}{Eck}{E\bibinitperiod}{Michael\bibnamedelima J}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=fabe6c6461e55d2d47e6c8fb604e93f8}{Gray}{G\bibinitperiod}{Nathanael\bibnamedelima S}{N\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=ad239ed98ae02c67ea857442596c2084}{J{\"{a}}nne}{J\bibinitperiod}{Pasi\bibnamedelima A}{P\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{8}{}{%
        {{hash=808dd167f023b8edc89c9fa87362ad69}{Ercan}{E\bibinitperiod}{Dalia}{D\bibinitperiod}{}{}{}{}}%
        {{hash=1ec3602d84fa696e9d0277bed04f6485}{Choi}{C\bibinitperiod}{Hwan\bibnamedelima Geun}{H\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=c6ba104fde2bb4aba691518a73c8ae34}{Yun}{Y\bibinitperiod}{Cai-Hong}{C\bibinithyphendelim H\bibinitperiod}{}{}{}{}}%
        {{hash=c09d676ff94346afdb4de7d73029253c}{Capelletti}{C\bibinitperiod}{Marzia}{M\bibinitperiod}{}{}{}{}}%
        {{hash=141eee66b6dff86df5d983d145e98b14}{Xie}{X\bibinitperiod}{Ting}{T\bibinitperiod}{}{}{}{}}%
        {{hash=17a71501a921f463a4ec3f0da1ce20b0}{Eck}{E\bibinitperiod}{Michael\bibnamedelima J}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=fabe6c6461e55d2d47e6c8fb604e93f8}{Gray}{G\bibinitperiod}{Nathanael\bibnamedelima S}{N\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=ad239ed98ae02c67ea857442596c2084}{J{\"{a}}nne}{J\bibinitperiod}{Pasi\bibnamedelima A}{P\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{6d089ab0a02f4ec52a6769af8e9be120}
      \strng{fullhash}{5ae70d9fb45ded5c9f2de36a991b8521}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors}}
      \field{abstract}{Purpose: Mutant selective irreversible pyrimidine-based EGFR kinase inhibitors, including WZ4002, CO-1686, and AZD9291, are effective in preclinical models and in lung cancer patients harboring the EGFR T790M gefitinib/erlotinib resistance mutation. However, little is known about how cancers develop acquired resistance to this class of EGFR inhibitors. We sought to identify and study EGFR mutations that confer resistance to this class of agents.Experimental Design: We performed an N-ethyl-N-nitrosourea (ENU) mutagenesis screen in EGFR-mutant (sensitizing alone or with concurrent EGFR T790M) Ba/F3 cells and selected drug-resistant clones. We evaluated the sensitivity of EGFR inhibitors in models harboring drug-resistant EGFR mutations.Results: We identified 3 major drug resistance mutations. EGFR L718Q, L844V, and C797S cause resistance to both WZ4002 and CO-1686 while, in contrast, only EGFR C797S leads to AZD9291 resistance. Cells containing an EGFR-sensitizing mutation, Del 19 or L858R, in conjunction with L718Q, L844V, or C797S retain sensitivity to quinazoline-based EGFR inhibitors, gefitinib and afatinib. The C797S mutation, in the presence of Del 19 or L858R and T790M, causes resistance to all current EGFR inhibitors, but L858R/T790M/C797S remains partially sensitive to cetuximab which leads to disruption of EGFR dimerization.Conclusions: Our findings provide insights into resistance mechanisms to irreversible pyrimidine-based EGFR inhibitors and identify specific genomic contexts in which sensitivity is retained to existing clinical EGFR inhibitors. These findings will guide the development of new strategies to inhibit EGFR. Clin Cancer Res; 21(17); 3913--23. {{$\copyright$}}2015 AACR.See related commentary by Ayeni et al., p. 3818}
      \field{journaltitle}{American Association for Cancer Research}
      \field{month}{08}
      \field{number}{17}
      \field{title}{{EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors}}
      \field{volume}{21}
      \field{year}{2015}
      \field{pages}{3913\bibrangedash 3923}
      \verb{url}
      \verb http://clincancerres.aacrjournals.org/content/21/17/3913.abstract
      \endverb
    \endentry
    \entry{Doebele2012}{article}{}
      \name{labelname}{12}{}{%
        {{hash=f892e20c7878cac4291dda2df8fbdef5}{Doebele}{D\bibinitperiod}{Robert\bibnamedelima C}{R\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=216659548df74f70e7a623d2446cb70d}{Pilling}{P\bibinitperiod}{Amanda\bibnamedelima B}{A\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=baf1d10fe98ea3a7760799186bf079de}{Aisner}{A\bibinitperiod}{Dara\bibnamedelima L}{D\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=dd1f8f0af2081da6eb220367e77eb810}{Kutateladze}{K\bibinitperiod}{Tatiana\bibnamedelima G}{T\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=bcf6cfac0921c31fa4fa843326ff1e53}{Le}{L\bibinitperiod}{Anh\bibnamedelima T}{A\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=e954de5d35aaa129ef458465cceb1e60}{Weickhardt}{W\bibinitperiod}{Andrew\bibnamedelima J}{A\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=38b6ded2c677b77673850a6ab04a0a74}{Kondo}{K\bibinitperiod}{Kimi\bibnamedelima L}{K\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=83c192b18189cdb1cf5950da79bd6e5c}{Linderman}{L\bibinitperiod}{Derek}{D\bibinitperiod}{}{}{}{}}%
        {{hash=c8cc87dc86b444764638b45566c27fde}{Heasley}{H\bibinitperiod}{Lynn\bibnamedelima E}{L\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=d11bb39ad713123dd66c6ed6e58e3631}{Franklin}{F\bibinitperiod}{Wilbur\bibnamedelima A}{W\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=3e77a7f396c134c410c592e1702ebe5f}{Varella-Garcia}{V\bibinithyphendelim G\bibinitperiod}{Marileila}{M\bibinitperiod}{}{}{}{}}%
        {{hash=84655618e0bd5c0cc9da2cfa927b74a2}{Camidge}{C\bibinitperiod}{D\bibnamedelima Ross}{D\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{12}{}{%
        {{hash=f892e20c7878cac4291dda2df8fbdef5}{Doebele}{D\bibinitperiod}{Robert\bibnamedelima C}{R\bibinitperiod\bibinitdelim C\bibinitperiod}{}{}{}{}}%
        {{hash=216659548df74f70e7a623d2446cb70d}{Pilling}{P\bibinitperiod}{Amanda\bibnamedelima B}{A\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=baf1d10fe98ea3a7760799186bf079de}{Aisner}{A\bibinitperiod}{Dara\bibnamedelima L}{D\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=dd1f8f0af2081da6eb220367e77eb810}{Kutateladze}{K\bibinitperiod}{Tatiana\bibnamedelima G}{T\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=bcf6cfac0921c31fa4fa843326ff1e53}{Le}{L\bibinitperiod}{Anh\bibnamedelima T}{A\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=e954de5d35aaa129ef458465cceb1e60}{Weickhardt}{W\bibinitperiod}{Andrew\bibnamedelima J}{A\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=38b6ded2c677b77673850a6ab04a0a74}{Kondo}{K\bibinitperiod}{Kimi\bibnamedelima L}{K\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=83c192b18189cdb1cf5950da79bd6e5c}{Linderman}{L\bibinitperiod}{Derek}{D\bibinitperiod}{}{}{}{}}%
        {{hash=c8cc87dc86b444764638b45566c27fde}{Heasley}{H\bibinitperiod}{Lynn\bibnamedelima E}{L\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=d11bb39ad713123dd66c6ed6e58e3631}{Franklin}{F\bibinitperiod}{Wilbur\bibnamedelima A}{W\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=3e77a7f396c134c410c592e1702ebe5f}{Varella-Garcia}{V\bibinithyphendelim G\bibinitperiod}{Marileila}{M\bibinitperiod}{}{}{}{}}%
        {{hash=84655618e0bd5c0cc9da2cfa927b74a2}{Camidge}{C\bibinitperiod}{D\bibnamedelima Ross}{D\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{120caf6315ae2e6d57408e32031cd129}
      \strng{fullhash}{7eae89ff4006f12ee9898e9a15623174}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer}}
      \field{abstract}{PURPOSE: Patients with anaplastic lymphoma kinase (ALK) gene rearrangements often manifest dramatic responses to crizotinib, a small molecule ALK inhibitor. Unfortunately, not every patient responds and acquired drug resistance inevitably develops in those that do respond. This study aimed to define molecular mechanisms of resistance to crizotinib in ALK+ non-small cell lung cancer (NSCLC) patients. EXPERIMENTAL DESIGN: We analyzed tissue obtained from 14 ALK+ NSCLC patients demonstrating evidence of radiologic progression while on crizotinib in order to define mechanisms of intrinsic and acquired resistance to crizotinib. RESULTS: Eleven patients had material evaluable for molecular analysis. Four patients (36{\%}) developed secondary mutations in the tyrosine kinase domain of ALK. A novel mutation in the ALK kinase domain, encoding a G1269A amino acid substitution that confers resistance to crizotinib in vitro, was identified in two of these cases. Two patients, one with a resistance mutation, exhibited new onset ALK copy number gain (CNG). One patient demonstrated outgrowth of EGFR mutant NSCLC without evidence of a persistent ALK gene rearrangement. Two patients exhibited a KRAS mutation, one of which occurred without evidence of a persisting ALK gene rearrangement. One patient demonstrated the emergence of an ALK gene fusion negative tumor compared to the baseline sample, but with no identifiable alternate driver. Two patients retained ALK positivity with no identifiable resistance mechanism. CONCLUSIONS: Crizotinib resistance in ALK+ NSCLC occurs through somatic kinase domain mutations, ALK gene fusion CNG, and emergence of separate oncogenic drivers.}
      \field{issn}{1078-0432}
      \field{journaltitle}{Clinical cancer research : an official journal of the American Association for Cancer Research}
      \field{month}{03}
      \field{number}{5}
      \field{title}{{Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer}}
      \field{volume}{18}
      \field{year}{2012}
      \field{pages}{1472\bibrangedash 1482}
      \verb{doi}
      \verb 10.1158/1078-0432.CCR-11-2906
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3311875/
      \endverb
    \endentry
    \entry{Shaw2015}{article}{}
      \name{labelname}{23}{}{%
        {{hash=26810537245ab20bf81e7bc8e77adffb}{Shaw}{S\bibinitperiod}{Alice\bibnamedelima T}{A\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=915aefadf29c81dc868d8a8eca13d1e7}{Friboulet}{F\bibinitperiod}{Luc}{L\bibinitperiod}{}{}{}{}}%
        {{hash=e163f9bc8578bee284cfa1f841c68524}{Leshchiner}{L\bibinitperiod}{Ignaty}{I\bibinitperiod}{}{}{}{}}%
        {{hash=2255d1786ea59311825c0de0a6981b20}{Gainor}{G\bibinitperiod}{Justin\bibnamedelima F}{J\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{hash=d2760dd5145b66f69ed28ac840afa8d7}{Bergqvist}{B\bibinitperiod}{Simon}{S\bibinitperiod}{}{}{}{}}%
        {{hash=7138cc2aaba25ecf23ed78f144293fa0}{Brooun}{B\bibinitperiod}{Alexei}{A\bibinitperiod}{}{}{}{}}%
        {{hash=046a9f5a5e167367d798dda9e8fde3b6}{Burke}{B\bibinitperiod}{Benjamin\bibnamedelima J}{B\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=7ac189797c74a23b96bfd1b112e2a193}{Deng}{D\bibinitperiod}{Ya-Li}{Y\bibinithyphendelim L\bibinitperiod}{}{}{}{}}%
        {{hash=c0e0d23e2d09e45e6f51cc2bcea6d9f9}{Liu}{L\bibinitperiod}{Wei}{W\bibinitperiod}{}{}{}{}}%
        {{hash=6afff24c6bc00877b2c2f81a2decd2bb}{Dardaei}{D\bibinitperiod}{Leila}{L\bibinitperiod}{}{}{}{}}%
        {{hash=4d183c60447231d5bf4e0f5037677953}{Frias}{F\bibinitperiod}{Rosa\bibnamedelima L}{R\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=d560c7653af3480f5acbd25c31689704}{Schultz}{S\bibinitperiod}{Kate\bibnamedelima R}{K\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=503503487c354e1aa8da3e34cfc8f81e}{Logan}{L\bibinitperiod}{Jennifer}{J\bibinitperiod}{}{}{}{}}%
        {{hash=c0019f9fcf669c64ce2bc05be2375ac4}{James}{J\bibinitperiod}{Leonard\bibnamedelima P}{L\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=046ffda9473dee948b6a769a271f034e}{Smeal}{S\bibinitperiod}{Tod}{T\bibinitperiod}{}{}{}{}}%
        {{hash=0e424fe6d9f257edfdf865c3eda64ba3}{Timofeevski}{T\bibinitperiod}{Sergei}{S\bibinitperiod}{}{}{}{}}%
        {{hash=01a8ed53b680160f06cf011f5b4afbdc}{Katayama}{K\bibinitperiod}{Ryohei}{R\bibinitperiod}{}{}{}{}}%
        {{hash=aa9ff97c722ae958e8b5ee11ffe17fe7}{Iafrate}{I\bibinitperiod}{A\bibnamedelima John}{A\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=7cbbab8bcab15c08539869f2516e3198}{Le}{L\bibinitperiod}{Long}{L\bibinitperiod}{}{}{}{}}%
        {{hash=12d296ee4a7efdab147aa264767917d2}{McTigue}{M\bibinitperiod}{Michele}{M\bibinitperiod}{}{}{}{}}%
        {{hash=6aa396b9c7916e3eec93b398e26b1bbf}{Getz}{G\bibinitperiod}{Gad}{G\bibinitperiod}{}{}{}{}}%
        {{hash=d71ca7bb52a670820a0fc3e9b3964fc6}{Johnson}{J\bibinitperiod}{Ted\bibnamedelima W}{T\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=f3074982fe5e4cd63eb33357cd7bfcd4}{Engelman}{E\bibinitperiod}{Jeffrey\bibnamedelima A}{J\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{23}{}{%
        {{hash=26810537245ab20bf81e7bc8e77adffb}{Shaw}{S\bibinitperiod}{Alice\bibnamedelima T}{A\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=915aefadf29c81dc868d8a8eca13d1e7}{Friboulet}{F\bibinitperiod}{Luc}{L\bibinitperiod}{}{}{}{}}%
        {{hash=e163f9bc8578bee284cfa1f841c68524}{Leshchiner}{L\bibinitperiod}{Ignaty}{I\bibinitperiod}{}{}{}{}}%
        {{hash=2255d1786ea59311825c0de0a6981b20}{Gainor}{G\bibinitperiod}{Justin\bibnamedelima F}{J\bibinitperiod\bibinitdelim F\bibinitperiod}{}{}{}{}}%
        {{hash=d2760dd5145b66f69ed28ac840afa8d7}{Bergqvist}{B\bibinitperiod}{Simon}{S\bibinitperiod}{}{}{}{}}%
        {{hash=7138cc2aaba25ecf23ed78f144293fa0}{Brooun}{B\bibinitperiod}{Alexei}{A\bibinitperiod}{}{}{}{}}%
        {{hash=046a9f5a5e167367d798dda9e8fde3b6}{Burke}{B\bibinitperiod}{Benjamin\bibnamedelima J}{B\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=7ac189797c74a23b96bfd1b112e2a193}{Deng}{D\bibinitperiod}{Ya-Li}{Y\bibinithyphendelim L\bibinitperiod}{}{}{}{}}%
        {{hash=c0e0d23e2d09e45e6f51cc2bcea6d9f9}{Liu}{L\bibinitperiod}{Wei}{W\bibinitperiod}{}{}{}{}}%
        {{hash=6afff24c6bc00877b2c2f81a2decd2bb}{Dardaei}{D\bibinitperiod}{Leila}{L\bibinitperiod}{}{}{}{}}%
        {{hash=4d183c60447231d5bf4e0f5037677953}{Frias}{F\bibinitperiod}{Rosa\bibnamedelima L}{R\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=d560c7653af3480f5acbd25c31689704}{Schultz}{S\bibinitperiod}{Kate\bibnamedelima R}{K\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=503503487c354e1aa8da3e34cfc8f81e}{Logan}{L\bibinitperiod}{Jennifer}{J\bibinitperiod}{}{}{}{}}%
        {{hash=c0019f9fcf669c64ce2bc05be2375ac4}{James}{J\bibinitperiod}{Leonard\bibnamedelima P}{L\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=046ffda9473dee948b6a769a271f034e}{Smeal}{S\bibinitperiod}{Tod}{T\bibinitperiod}{}{}{}{}}%
        {{hash=0e424fe6d9f257edfdf865c3eda64ba3}{Timofeevski}{T\bibinitperiod}{Sergei}{S\bibinitperiod}{}{}{}{}}%
        {{hash=01a8ed53b680160f06cf011f5b4afbdc}{Katayama}{K\bibinitperiod}{Ryohei}{R\bibinitperiod}{}{}{}{}}%
        {{hash=aa9ff97c722ae958e8b5ee11ffe17fe7}{Iafrate}{I\bibinitperiod}{A\bibnamedelima John}{A\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=7cbbab8bcab15c08539869f2516e3198}{Le}{L\bibinitperiod}{Long}{L\bibinitperiod}{}{}{}{}}%
        {{hash=12d296ee4a7efdab147aa264767917d2}{McTigue}{M\bibinitperiod}{Michele}{M\bibinitperiod}{}{}{}{}}%
        {{hash=6aa396b9c7916e3eec93b398e26b1bbf}{Getz}{G\bibinitperiod}{Gad}{G\bibinitperiod}{}{}{}{}}%
        {{hash=d71ca7bb52a670820a0fc3e9b3964fc6}{Johnson}{J\bibinitperiod}{Ted\bibnamedelima W}{T\bibinitperiod\bibinitdelim W\bibinitperiod}{}{}{}{}}%
        {{hash=f3074982fe5e4cd63eb33357cd7bfcd4}{Engelman}{E\bibinitperiod}{Jeffrey\bibnamedelima A}{J\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Massachusetts Medical Society}%
      }
      \strng{namehash}{6a05b6280e2339afbb0c4f5367b76a80}
      \strng{fullhash}{df9598c765f62fb003fd5ae6ada321c7}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F}}
      \field{annotation}{doi: 10.1056/NEJMoa1508887}
      \field{issn}{0028-4793}
      \field{journaltitle}{New England Journal of Medicine}
      \field{month}{12}
      \field{number}{1}
      \field{title}{{Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F}}
      \field{volume}{374}
      \field{year}{2015}
      \field{pages}{54\bibrangedash 61}
      \verb{doi}
      \verb 10.1056/NEJMoa1508887
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1056/NEJMoa1508887
      \endverb
    \endentry
    \entry{Wu2016}{article}{}
      \name{labelname}{3}{}{%
        {{hash=f16c2583d9abd02d089eb43170a7c6c3}{Wu}{W\bibinitperiod}{Jingjing}{J\bibinitperiod}{}{}{}{}}%
        {{hash=bcc5f6dee5c229c5ef57f91d6303ad98}{Savooji}{S\bibinitperiod}{John}{J\bibinitperiod}{}{}{}{}}%
        {{hash=60c6c6c68cab254f94d65859f51062e6}{Liu}{L\bibinitperiod}{Delong}{D\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=f16c2583d9abd02d089eb43170a7c6c3}{Wu}{W\bibinitperiod}{Jingjing}{J\bibinitperiod}{}{}{}{}}%
        {{hash=bcc5f6dee5c229c5ef57f91d6303ad98}{Savooji}{S\bibinitperiod}{John}{J\bibinitperiod}{}{}{}{}}%
        {{hash=60c6c6c68cab254f94d65859f51062e6}{Liu}{L\bibinitperiod}{Delong}{D\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{d2cb8568e7de25d94074687c187de256}
      \strng{fullhash}{d2cb8568e7de25d94074687c187de256}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Second- and third-generation ALK inhibitors for non-small cell lung cancer}}
      \field{abstract}{Crizotinib as the first-generation ALK inhibitor has shown significant activity in ALK-mutated non-small cell lung cancer (NSCLC). Second- and third-generation ALK inhibitors are entering clinical applications for ALK+ NSCLC. In addition, a third-generation ALK inhibitor, lorlatinib (PF-06463922), was reported to resensitize NSCLC to crizotinib. This review provided a summary of clinical development of alectinib, ceritinib, brigatinib (AP26113), and lorlatinib.}
      \field{issn}{1756-8722}
      \field{journaltitle}{Journal of Hematology {\{}{\&}{\}} Oncology}
      \field{number}{1}
      \field{title}{{Second- and third-generation ALK inhibitors for non-small cell lung cancer}}
      \field{volume}{9}
      \field{year}{2016}
      \field{pages}{1\bibrangedash 7}
      \verb{doi}
      \verb 10.1186/s13045-016-0251-8
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1186/s13045-016-0251-8
      \endverb
    \endentry
    \entry{Burrell2014}{article}{}
      \name{labelname}{2}{}{%
        {{hash=0f242162379eb537f3b68ff29dd5c3ee}{Burrell}{B\bibinitperiod}{Rebecca\bibnamedelima a.}{R\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
        {{hash=41ddb60dd242de6b2d07fa4624f293ee}{Swanton}{S\bibinitperiod}{Charles}{C\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=0f242162379eb537f3b68ff29dd5c3ee}{Burrell}{B\bibinitperiod}{Rebecca\bibnamedelima a.}{R\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
        {{hash=41ddb60dd242de6b2d07fa4624f293ee}{Swanton}{S\bibinitperiod}{Charles}{C\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Elsevier B.V}%
      }
      \strng{namehash}{3683470ab6043aa378f3628065fcaf57}
      \strng{fullhash}{3683470ab6043aa378f3628065fcaf57}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Tumour heterogeneity and the evolution of polyclonal drug resistance}}
      \field{abstract}{Cancer drug resistance is a major problem, with the majority of patients with metastatic disease ultimately developing multidrug resistance and succumbing to their disease. Our understanding of molecular events underpinning treatment failure has been enhanced by new genomic technologies and pre-clinical studies. Intratumour genetic heterogeneity (ITH) is a prominent contributor to therapeutic failure, and it is becoming increasingly apparent that individual tumours may achieve resistance via multiple routes simultaneously - termed polyclonal resistance. Efforts to target single resistance mechanisms to overcome therapeutic failure may therefore yield only limited success. Clinical studies with sequential analysis of tumour material are needed to enhance our understanding of inter-clonal functional relationships and tumour evolution during therapy, and to improve drug development strategies in cancer medicine. {{$\copyright$}} 2014 Federation of European Biochemical Societies.}
      \field{isbn}{1878-0261 (Electronic) 1574-7891 (Linking)}
      \field{issn}{15747891}
      \field{journaltitle}{Molecular Oncology}
      \field{number}{6}
      \field{title}{{Tumour heterogeneity and the evolution of polyclonal drug resistance}}
      \field{volume}{8}
      \field{year}{2014}
      \field{pages}{1095\bibrangedash 1111}
      \verb{doi}
      \verb 10.1016/j.molonc.2014.06.005
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/1-s2.0-S157478911400129X-main.pdf:pdf
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1016/j.molonc.2014.06.005
      \endverb
    \endentry
    \entry{Cortes2016}{article}{}
      \name{labelname}{2}{}{%
        {{hash=e6c0605ffc29f41e440d2bfa79a33019}{Cortes}{C\bibinitperiod}{Javier}{J\bibinitperiod}{}{}{}{}}%
        {{hash=694e773657fa47f470964c25a884a0b0}{Roch{\'{e}}}{R\bibinitperiod}{Henri}{H\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=e6c0605ffc29f41e440d2bfa79a33019}{Cortes}{C\bibinitperiod}{Javier}{J\bibinitperiod}{}{}{}{}}%
        {{hash=694e773657fa47f470964c25a884a0b0}{Roch{\'{e}}}{R\bibinitperiod}{Henri}{H\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Elsevier}%
      }
      \strng{namehash}{ff279e9ef02c0ba92429875e73b5402a}
      \strng{fullhash}{ff279e9ef02c0ba92429875e73b5402a}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Docetaxel combined with targeted therapies in metastatic breast cancer}}
      \field{annotation}{doi: 10.1016/j.ctrv.2011.08.001}
      \field{issn}{0305-7372}
      \field{journaltitle}{Cancer Treatment Reviews}
      \field{month}{07}
      \field{number}{5}
      \field{title}{{Docetaxel combined with targeted therapies in metastatic breast cancer}}
      \field{volume}{38}
      \field{year}{2016}
      \field{pages}{387\bibrangedash 396}
      \verb{doi}
      \verb 10.1016/j.ctrv.2011.08.001
      \endverb
      \verb{url}
      \verb http://dx.doi.org/10.1016/j.ctrv.2011.08.001
      \endverb
    \endentry
    \entry{Vanneman2012}{article}{}
      \name{labelname}{2}{}{%
        {{hash=46f8ff0cb7dd578f72e1e8927d67d160}{Vanneman}{V\bibinitperiod}{Matthew}{M\bibinitperiod}{}{}{}{}}%
        {{hash=080baedac5a0a38b397977f2e21dd992}{Dranoff}{D\bibinitperiod}{Glenn}{G\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{2}{}{%
        {{hash=46f8ff0cb7dd578f72e1e8927d67d160}{Vanneman}{V\bibinitperiod}{Matthew}{M\bibinitperiod}{}{}{}{}}%
        {{hash=080baedac5a0a38b397977f2e21dd992}{Dranoff}{D\bibinitperiod}{Glenn}{G\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.}%
      }
      \strng{namehash}{863ab2bf4acd5fca5370190f970254af}
      \strng{fullhash}{863ab2bf4acd5fca5370190f970254af}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Combining immunotherapy and targeted therapies in cancer treatment}}
      \field{annotation}{10.1038/nrc3237}
      \field{issn}{1474-175X}
      \field{journaltitle}{Nat Rev Cancer}
      \field{month}{04}
      \field{number}{4}
      \field{title}{{Combining immunotherapy and targeted therapies in cancer treatment}}
      \field{volume}{12}
      \field{year}{2012}
      \field{pages}{237\bibrangedash 251}
      \verb{url}
      \verb http://dx.doi.org/10.1038/nrc3237
      \endverb
    \endentry
    \entry{Al-Lazikani2012}{article}{}
      \name{labelname}{3}{}{%
        {{hash=6c2de189b3311c216fbbd5bfb9f79020}{Al-Lazikani}{A\bibinithyphendelim L\bibinitperiod}{Bissan}{B\bibinitperiod}{}{}{}{}}%
        {{hash=ec9ac9b8c704d8f7877d547d357f8519}{Banerji}{B\bibinitperiod}{Udai}{U\bibinitperiod}{}{}{}{}}%
        {{hash=82e2e3df21abbbdbbcb18fa631e52f4c}{Workman}{W\bibinitperiod}{Paul}{P\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=6c2de189b3311c216fbbd5bfb9f79020}{Al-Lazikani}{A\bibinithyphendelim L\bibinitperiod}{Bissan}{B\bibinitperiod}{}{}{}{}}%
        {{hash=ec9ac9b8c704d8f7877d547d357f8519}{Banerji}{B\bibinitperiod}{Udai}{U\bibinitperiod}{}{}{}{}}%
        {{hash=82e2e3df21abbbdbbcb18fa631e52f4c}{Workman}{W\bibinitperiod}{Paul}{P\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group}%
      }
      \strng{namehash}{1edc8eb6018e1b2d6c574787701a2abd}
      \strng{fullhash}{1edc8eb6018e1b2d6c574787701a2abd}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Combinatorial drug therapy for cancer in the post-genomic era.}}
      \field{abstract}{Over the past decade, whole genome sequencing and other 'omics' technologies have defined pathogenic driver mutations to which tumor cells are addicted. Such addictions, synthetic lethalities and other tumor vulnerabilities have yielded novel targets for a new generation of cancer drugs to treat discrete, genetically defined patient subgroups. This personalized cancer medicine strategy could eventually replace the conventional one-size-fits-all cytotoxic chemotherapy approach. However, the extraordinary intratumor genetic heterogeneity in cancers revealed by deep sequencing explains why de novo and acquired resistance arise with molecularly targeted drugs and cytotoxic chemotherapy, limiting their utility. One solution to the enduring challenge of polygenic cancer drug resistance is rational combinatorial targeted therapy.}
      \field{issn}{1546-1696}
      \field{journaltitle}{Nature biotechnology}
      \field{month}{07}
      \field{number}{7}
      \field{title}{{Combinatorial drug therapy for cancer in the post-genomic era.}}
      \field{volume}{30}
      \field{year}{2012}
      \field{pages}{679\bibrangedash 92}
      \verb{doi}
      \verb 10.1038/nbt.2284
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Al-Lazikani, Banerji, Workman - 2012 - Combinatorial drug therapy for cancer in the post-genomic era.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/22781697
      \endverb
    \endentry
    \entry{Bozic2013}{article}{}
      \name{labelname}{15}{}{%
        {{hash=68e6e98a8496a5e2b7a31ec49920b885}{Bozic}{B\bibinitperiod}{Ivana}{I\bibinitperiod}{}{}{}{}}%
        {{hash=df507dfaaa3258432a4e78ff9589492b}{Reiter}{R\bibinitperiod}{Johannes\bibnamedelima G}{J\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=1490d61b4eb7b6c927b241c8e711d29e}{Allen}{A\bibinitperiod}{Benjamin}{B\bibinitperiod}{}{}{}{}}%
        {{hash=7329ef74890275905474a437d24df996}{Antal}{A\bibinitperiod}{Tibor}{T\bibinitperiod}{}{}{}{}}%
        {{hash=1a126fe7ca5387e01e1bebcd84f3c49b}{Chatterjee}{C\bibinitperiod}{Krishnendu}{K\bibinitperiod}{}{}{}{}}%
        {{hash=dd4e818268f6b510c00a07613cf841ad}{Shah}{S\bibinitperiod}{Preya}{P\bibinitperiod}{}{}{}{}}%
        {{hash=4d9e1b11e4acc2813fcf000e6b76513c}{Moon}{M\bibinitperiod}{Yo\bibnamedelima Sup}{Y\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=ff91ee166610cd9392869f6fb00d40af}{Yaqubie}{Y\bibinitperiod}{Amin}{A\bibinitperiod}{}{}{}{}}%
        {{hash=d42507249ea0823ee5d1d3589b753606}{Kelly}{K\bibinitperiod}{Nicole}{N\bibinitperiod}{}{}{}{}}%
        {{hash=2e3dc5069a4f903531f63c3883d753cf}{Le}{L\bibinitperiod}{Dung\bibnamedelima T}{D\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=ffd284352533a71c8e201fef2aca5ea6}{Lipson}{L\bibinitperiod}{Evan\bibnamedelima J}{E\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=ee9fa088a1d65fc575397e291a8f5814}{Chapman}{C\bibinitperiod}{Paul\bibnamedelima B}{P\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=fdae98f5ebe82221cebdb75592836d1d}{Diaz}{D\bibinitperiod}{Luis\bibnamedelima a}{L\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
        {{hash=bbb27aa05dcd963d1c27727276613af6}{Vogelstein}{V\bibinitperiod}{Bert}{B\bibinitperiod}{}{}{}{}}%
        {{hash=13b6956393e41bce59dba670da9ce424}{Nowak}{N\bibinitperiod}{Martin\bibnamedelima a}{M\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{15}{}{%
        {{hash=68e6e98a8496a5e2b7a31ec49920b885}{Bozic}{B\bibinitperiod}{Ivana}{I\bibinitperiod}{}{}{}{}}%
        {{hash=df507dfaaa3258432a4e78ff9589492b}{Reiter}{R\bibinitperiod}{Johannes\bibnamedelima G}{J\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=1490d61b4eb7b6c927b241c8e711d29e}{Allen}{A\bibinitperiod}{Benjamin}{B\bibinitperiod}{}{}{}{}}%
        {{hash=7329ef74890275905474a437d24df996}{Antal}{A\bibinitperiod}{Tibor}{T\bibinitperiod}{}{}{}{}}%
        {{hash=1a126fe7ca5387e01e1bebcd84f3c49b}{Chatterjee}{C\bibinitperiod}{Krishnendu}{K\bibinitperiod}{}{}{}{}}%
        {{hash=dd4e818268f6b510c00a07613cf841ad}{Shah}{S\bibinitperiod}{Preya}{P\bibinitperiod}{}{}{}{}}%
        {{hash=4d9e1b11e4acc2813fcf000e6b76513c}{Moon}{M\bibinitperiod}{Yo\bibnamedelima Sup}{Y\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=ff91ee166610cd9392869f6fb00d40af}{Yaqubie}{Y\bibinitperiod}{Amin}{A\bibinitperiod}{}{}{}{}}%
        {{hash=d42507249ea0823ee5d1d3589b753606}{Kelly}{K\bibinitperiod}{Nicole}{N\bibinitperiod}{}{}{}{}}%
        {{hash=2e3dc5069a4f903531f63c3883d753cf}{Le}{L\bibinitperiod}{Dung\bibnamedelima T}{D\bibinitperiod\bibinitdelim T\bibinitperiod}{}{}{}{}}%
        {{hash=ffd284352533a71c8e201fef2aca5ea6}{Lipson}{L\bibinitperiod}{Evan\bibnamedelima J}{E\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=ee9fa088a1d65fc575397e291a8f5814}{Chapman}{C\bibinitperiod}{Paul\bibnamedelima B}{P\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=fdae98f5ebe82221cebdb75592836d1d}{Diaz}{D\bibinitperiod}{Luis\bibnamedelima a}{L\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
        {{hash=bbb27aa05dcd963d1c27727276613af6}{Vogelstein}{V\bibinitperiod}{Bert}{B\bibinitperiod}{}{}{}{}}%
        {{hash=13b6956393e41bce59dba670da9ce424}{Nowak}{N\bibinitperiod}{Martin\bibnamedelima a}{M\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{31b47cfc022ca05e5f642b4972129694}
      \strng{fullhash}{f4c2db33bb2e7bd5c2335b22f5c959bf}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Evolutionary dynamics of cancer in response to targeted combination therapy.}}
      \field{abstract}{In solid tumors, targeted treatments can lead to dramatic regressions, but responses are often short-lived because resistant cancer cells arise. The major strategy proposed for overcoming resistance is combination therapy. We present a mathematical model describing the evolutionary dynamics of lesions in response to treatment. We first studied 20 melanoma patients receiving vemurafenib. We then applied our model to an independent set of pancreatic, colorectal, and melanoma cancer patients with metastatic disease. We find that dual therapy results in long-term disease control for most patients, if there are no single mutations that cause cross-resistance to both drugs; in patients with large disease burden, triple therapy is needed. We also find that simultaneous therapy with two drugs is much more effective than sequential therapy. Our results provide realistic expectations for the efficacy of new drug combinations and inform the design of trials for new cancer therapeutics. DOI:http://dx.doi.org/10.7554/eLife.00747.001.}
      \field{issn}{2050-084X}
      \field{journaltitle}{eLife}
      \field{month}{01}
      \field{title}{{Evolutionary dynamics of cancer in response to targeted combination therapy.}}
      \field{volume}{2}
      \field{year}{2013}
      \field{pages}{e00747}
      \verb{doi}
      \verb 10.7554/eLife.00747
      \endverb
      \verb{file}
      \verb :home/fran/.local/share/data/Mendeley Ltd./Mendeley Desktop/Downloaded/Bozic et al. - 2013 - Evolutionary dynamics of cancer in response to targeted combination therapy.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3691570%7B%5C&%7Dtool=pmcentrez%7B%5C&%7Drendertype=abstract
      \endverb
    \endentry
    \entry{Komarova2014}{article}{}
      \name{labelname}{3}{}{%
        {{hash=d3fe554da5d742f167abeb0a3802c9f8}{Komarova}{K\bibinitperiod}{Natalia\bibnamedelima L}{N\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=fbdd48dd1614a394a021c262168379a9}{Burger}{B\bibinitperiod}{Jan\bibnamedelima a}{J\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
        {{hash=ad7577549d55738f7b64bb2bea284096}{Wodarz}{W\bibinitperiod}{Dominik}{D\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{3}{}{%
        {{hash=d3fe554da5d742f167abeb0a3802c9f8}{Komarova}{K\bibinitperiod}{Natalia\bibnamedelima L}{N\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=fbdd48dd1614a394a021c262168379a9}{Burger}{B\bibinitperiod}{Jan\bibnamedelima a}{J\bibinitperiod\bibinitdelim a\bibinitperiod}{}{}{}{}}%
        {{hash=ad7577549d55738f7b64bb2bea284096}{Wodarz}{W\bibinitperiod}{Dominik}{D\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{73f793b478302f6a80b1f1958bf3c2fa}
      \strng{fullhash}{73f793b478302f6a80b1f1958bf3c2fa}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL).}}
      \field{abstract}{The Bruton tyrosine kinase inhibitor (BTKi) ibrutinib is a new targeted therapy for patients with chronic lymphocytic leukemia (CLL). Ibrutinib is given orally on a continuous schedule and induces durable remissions in the majority of CLL patients. However, a small proportion of patients initially responds to the BTKi and then develops resistance. Estimating the frequency, timing, and individual risk of developing resistance to ibrutinib, therefore, would be valuable for long-term management of patients. Computational evolutionary models, based on measured kinetic parameters of patients, allow us to approach these questions and to develop a roadmap for personalized prognosis and treatment management. Our kinetic models predict that BTKi-resistant mutants exist before initiation of ibrutinib therapy, although they only comprise a minority of the overall tumor burden. Furthermore, we can estimate the time required for resistant cells to grow to detectable levels. We predict that this can be highly variable, depending mostly on growth and death rates of the individual CLL cell clone. For a specific patient, this time can be predicted with a high degree of certainty. Our model can thus be used to predict for how long ibrutinib can suppress the disease in individual patients. Furthermore, the model can suggest whether prior debulking of the tumor with chemo-immunotherapy can prolong progression-free survival under ibrutinib. Finally, by applying the models to data that document progression during ibrutinib therapy, we estimated that resistant mutants might have a small ({<}2{\%}) mean fitness advantage in the absence of treatment, compared with sensitive cells.}
      \field{isbn}{1091-6490 (Electronic)$\backslash$r0027-8424 (Linking)}
      \field{issn}{1091-6490}
      \field{journaltitle}{Proceedings of the National Academy of Sciences of the United States of America}
      \field{number}{38}
      \field{title}{{Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL).}}
      \field{volume}{111}
      \field{year}{2014}
      \field{pages}{13906\bibrangedash 11}
      \verb{doi}
      \verb 10.1073/pnas.1409362111
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/PNAS-2014-Komarova-13906-11.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.pnas.org/content/111/38/13906.full
      \endverb
    \endentry
    \entry{Williams2016}{article}{}
      \name{labelname}{5}{}{%
        {{hash=8139164a9c076731730b62026958123d}{Williams}{W\bibinitperiod}{Marc\bibnamedelima J}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=88c3eeda7ffbd7d3b63a22e2527e8c0d}{Werner}{W\bibinitperiod}{Benjamin}{B\bibinitperiod}{}{}{}{}}%
        {{hash=8341669a3d0db82e877ef918042cb0d0}{Barnes}{B\bibinitperiod}{Chris\bibnamedelima P}{C\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=d45c7a9db3287943efa6f23bc445ebe3}{Graham}{G\bibinitperiod}{Trevor\bibnamedelima A}{T\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=04d31891bb580b2c600eb251525541cc}{Sottoriva}{S\bibinitperiod}{Andrea}{A\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{5}{}{%
        {{hash=8139164a9c076731730b62026958123d}{Williams}{W\bibinitperiod}{Marc\bibnamedelima J}{M\bibinitperiod\bibinitdelim J\bibinitperiod}{}{}{}{}}%
        {{hash=88c3eeda7ffbd7d3b63a22e2527e8c0d}{Werner}{W\bibinitperiod}{Benjamin}{B\bibinitperiod}{}{}{}{}}%
        {{hash=8341669a3d0db82e877ef918042cb0d0}{Barnes}{B\bibinitperiod}{Chris\bibnamedelima P}{C\bibinitperiod\bibinitdelim P\bibinitperiod}{}{}{}{}}%
        {{hash=d45c7a9db3287943efa6f23bc445ebe3}{Graham}{G\bibinitperiod}{Trevor\bibnamedelima A}{T\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=04d31891bb580b2c600eb251525541cc}{Sottoriva}{S\bibinitperiod}{Andrea}{A\bibinitperiod}{}{}{}{}}%
      }
      \list{publisher}{1}{%
        {Nature Publishing Group}%
      }
      \strng{namehash}{a21d2b84a026855aabc92edef03d3c31}
      \strng{fullhash}{fc9cef6209e6caf27201949e93091af8}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Identification of neutral tumor evolution across cancer types}}
      \field{issn}{1061-4036}
      \field{journaltitle}{Nature Genetics}
      \field{number}{August 2015}
      \field{title}{{Identification of neutral tumor evolution across cancer types}}
      \field{year}{2016}
      \verb{doi}
      \verb 10.1038/ng.3489
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/ng.3489.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.nature.com/doifinder/10.1038/ng.3489
      \endverb
    \endentry
    \entry{Attolini2010}{article}{}
      \name{labelname}{8}{}{%
        {{hash=975800e80bf529794e733782f1f3cb3d}{Attolini}{A\bibinitperiod}{Camille\bibnamedelima Stephan-Otto}{C\bibinitperiod\bibinitdelim S\bibinithyphendelim O\bibinitperiod}{}{}{}{}}%
        {{hash=e6d5182250a998c6626c67d681de50cf}{Cheng}{C\bibinitperiod}{Yu-Kang}{Y\bibinithyphendelim K\bibinitperiod}{}{}{}{}}%
        {{hash=1e251929d54a7f11c024d2fa3b4d56fb}{Beroukhim}{B\bibinitperiod}{Rameen}{R\bibinitperiod}{}{}{}{}}%
        {{hash=6aa396b9c7916e3eec93b398e26b1bbf}{Getz}{G\bibinitperiod}{Gad}{G\bibinitperiod}{}{}{}{}}%
        {{hash=6789a07c9dab853530704b1c78787681}{Abdel-Wahab}{A\bibinithyphendelim W\bibinitperiod}{Omar}{O\bibinitperiod}{}{}{}{}}%
        {{hash=d1b60a109e1b35c0e933fedf71910788}{Levine}{L\bibinitperiod}{Ross\bibnamedelima L}{R\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=ee89127e205377bb0b3e577b649211de}{Mellinghoff}{M\bibinitperiod}{Ingo\bibnamedelima K}{I\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=9d9e35b29002d128ad9fe36ab6636cdb}{Michor}{M\bibinitperiod}{Franziska}{F\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{8}{}{%
        {{hash=975800e80bf529794e733782f1f3cb3d}{Attolini}{A\bibinitperiod}{Camille\bibnamedelima Stephan-Otto}{C\bibinitperiod\bibinitdelim S\bibinithyphendelim O\bibinitperiod}{}{}{}{}}%
        {{hash=e6d5182250a998c6626c67d681de50cf}{Cheng}{C\bibinitperiod}{Yu-Kang}{Y\bibinithyphendelim K\bibinitperiod}{}{}{}{}}%
        {{hash=1e251929d54a7f11c024d2fa3b4d56fb}{Beroukhim}{B\bibinitperiod}{Rameen}{R\bibinitperiod}{}{}{}{}}%
        {{hash=6aa396b9c7916e3eec93b398e26b1bbf}{Getz}{G\bibinitperiod}{Gad}{G\bibinitperiod}{}{}{}{}}%
        {{hash=6789a07c9dab853530704b1c78787681}{Abdel-Wahab}{A\bibinithyphendelim W\bibinitperiod}{Omar}{O\bibinitperiod}{}{}{}{}}%
        {{hash=d1b60a109e1b35c0e933fedf71910788}{Levine}{L\bibinitperiod}{Ross\bibnamedelima L}{R\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=ee89127e205377bb0b3e577b649211de}{Mellinghoff}{M\bibinitperiod}{Ingo\bibnamedelima K}{I\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=9d9e35b29002d128ad9fe36ab6636cdb}{Michor}{M\bibinitperiod}{Franziska}{F\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{13c6b9ef7a2638b9dc28c34f1286a85c}
      \strng{fullhash}{e8e38c47c28a5ea076a10ef28e2c9fb1}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{A mathematical framework to determine the temporal sequence of somatic genetic events in cancer.}}
      \field{abstract}{Human cancer is caused by the accumulation of genetic alterations in cells. Of special importance are changes that occur early during malignant transformation because they may result in oncogene addiction and represent promising targets for therapeutic intervention. Here we describe a computational approach, called Retracing the Evolutionary Steps in Cancer (RESIC), to deduce the temporal sequence of genetic events during tumorigenesis from cross-sectional genomic data of tumors at their fully transformed stage. When applied to a dataset of 70 advanced colorectal cancers, our algorithm accurately predicts the sequence of APC, KRAS, and TP53 mutations previously defined by analyzing tumors at different stages of colon cancer formation. We further validate the method with glioblastoma and leukemia sample data and then apply it to complex integrated genomics databases, finding that high-level EGFR amplification appears to be a late event in primary glioblastomas. RESIC represents the first evolutionary mathematical approach to identify the temporal sequence of mutations driving tumorigenesis and may be useful to guide the validation of candidate genes emerging from cancer genome surveys.}
      \field{isbn}{1091-6490 (Electronic)$\backslash$r0027-8424 (Linking)}
      \field{issn}{1091-6490}
      \field{journaltitle}{Proceedings of the National Academy of Sciences of the United States of America}
      \field{number}{41}
      \field{title}{{A mathematical framework to determine the temporal sequence of somatic genetic events in cancer.}}
      \field{volume}{107}
      \field{year}{2010}
      \field{pages}{17604\bibrangedash 9}
      \verb{doi}
      \verb 10.1073/pnas.1009117107
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/PNAS-2010-Attolini-17604-9.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.pnas.org/content/107/41/17604.short
      \endverb
    \endentry
    \entry{Chmielecki2011}{article}{}
      \name{labelname}{21}{}{%
        {{hash=9a086f1a7b8d9fb0825d4452a78f2b63}{Chmielecki}{C\bibinitperiod}{J}{J\bibinitperiod}{}{}{}{}}%
        {{hash=fd6a63d1461212912feb7c2302828083}{Foo}{F\bibinitperiod}{J}{J\bibinitperiod}{}{}{}{}}%
        {{hash=dfbb33f9fc881c14fe6d7535f53f3883}{Oxnard}{O\bibinitperiod}{G\bibnamedelima R}{G\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=0b5c884b29882d20c71a528dd92ecf7e}{Hutchinson}{H\bibinitperiod}{K}{K\bibinitperiod}{}{}{}{}}%
        {{hash=d8e0d15ee4f29113f38d60cec221e7c7}{Ohashi}{O\bibinitperiod}{K}{K\bibinitperiod}{}{}{}{}}%
        {{hash=a8affc3fc78b3f4e86493eb8d1906ba9}{Somwar}{S\bibinitperiod}{R}{R\bibinitperiod}{}{}{}{}}%
        {{hash=9a75ee293f2555f40976345739087998}{Wang}{W\bibinitperiod}{L}{L\bibinitperiod}{}{}{}{}}%
        {{hash=3d0aeaec88009b0fbfc640d0526f719c}{Amato}{A\bibinitperiod}{K\bibnamedelima R}{K\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=38863ca09bf5073bad14cb06549d4475}{Arcila}{A\bibinitperiod}{M}{M\bibinitperiod}{}{}{}{}}%
        {{hash=e8d9c38a8e6d44a078d2d5ed69ff571b}{Sos}{S\bibinitperiod}{M\bibnamedelima L}{M\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=81c253f629b2ee52336d2b48eea7988f}{Socci}{S\bibinitperiod}{N\bibnamedelima D}{N\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=57e5addee1980e87e6fcf6858471ef34}{Viale}{V\bibinitperiod}{A}{A\bibinitperiod}{}{}{}{}}%
        {{hash=6c10f60ead9a51403f62087cb53526ed}{Stanchina}{S\bibinitperiod}{E}{E\bibinitperiod}{de}{d\bibinitperiod}{}{}}%
        {{hash=99828276fde6a68a349bc9be059cfb99}{Ginsberg}{G\bibinitperiod}{M\bibnamedelima S}{M\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=0908cad7841cf466eba5ddb1b8d38f99}{Thomas}{T\bibinitperiod}{R\bibnamedelima K}{R\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=b790cf9fd0a0c3c87ae06a795e127291}{Kris}{K\bibinitperiod}{M\bibnamedelima G}{M\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=c7ebbcf27e16d8bfdb741fe3c6b64ad1}{Inoue}{I\bibinitperiod}{A}{A\bibinitperiod}{}{}{}{}}%
        {{hash=729b8ed4020054f201287dd9d18840ba}{Ladanyi}{L\bibinitperiod}{M}{M\bibinitperiod}{}{}{}{}}%
        {{hash=c3c4d58a922b273acb4efd15a2c2b87f}{Miller}{M\bibinitperiod}{V\bibnamedelima A}{V\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=b0c14ffcabc8dcf4ecbc94cfca60b7a2}{Michor}{M\bibinitperiod}{F}{F\bibinitperiod}{}{}{}{}}%
        {{hash=4b039dea98b86daf174454351be8e3b5}{Pao}{P\bibinitperiod}{W}{W\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{21}{}{%
        {{hash=9a086f1a7b8d9fb0825d4452a78f2b63}{Chmielecki}{C\bibinitperiod}{J}{J\bibinitperiod}{}{}{}{}}%
        {{hash=fd6a63d1461212912feb7c2302828083}{Foo}{F\bibinitperiod}{J}{J\bibinitperiod}{}{}{}{}}%
        {{hash=dfbb33f9fc881c14fe6d7535f53f3883}{Oxnard}{O\bibinitperiod}{G\bibnamedelima R}{G\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=0b5c884b29882d20c71a528dd92ecf7e}{Hutchinson}{H\bibinitperiod}{K}{K\bibinitperiod}{}{}{}{}}%
        {{hash=d8e0d15ee4f29113f38d60cec221e7c7}{Ohashi}{O\bibinitperiod}{K}{K\bibinitperiod}{}{}{}{}}%
        {{hash=a8affc3fc78b3f4e86493eb8d1906ba9}{Somwar}{S\bibinitperiod}{R}{R\bibinitperiod}{}{}{}{}}%
        {{hash=9a75ee293f2555f40976345739087998}{Wang}{W\bibinitperiod}{L}{L\bibinitperiod}{}{}{}{}}%
        {{hash=3d0aeaec88009b0fbfc640d0526f719c}{Amato}{A\bibinitperiod}{K\bibnamedelima R}{K\bibinitperiod\bibinitdelim R\bibinitperiod}{}{}{}{}}%
        {{hash=38863ca09bf5073bad14cb06549d4475}{Arcila}{A\bibinitperiod}{M}{M\bibinitperiod}{}{}{}{}}%
        {{hash=e8d9c38a8e6d44a078d2d5ed69ff571b}{Sos}{S\bibinitperiod}{M\bibnamedelima L}{M\bibinitperiod\bibinitdelim L\bibinitperiod}{}{}{}{}}%
        {{hash=81c253f629b2ee52336d2b48eea7988f}{Socci}{S\bibinitperiod}{N\bibnamedelima D}{N\bibinitperiod\bibinitdelim D\bibinitperiod}{}{}{}{}}%
        {{hash=57e5addee1980e87e6fcf6858471ef34}{Viale}{V\bibinitperiod}{A}{A\bibinitperiod}{}{}{}{}}%
        {{hash=6c10f60ead9a51403f62087cb53526ed}{Stanchina}{S\bibinitperiod}{E}{E\bibinitperiod}{de}{d\bibinitperiod}{}{}}%
        {{hash=99828276fde6a68a349bc9be059cfb99}{Ginsberg}{G\bibinitperiod}{M\bibnamedelima S}{M\bibinitperiod\bibinitdelim S\bibinitperiod}{}{}{}{}}%
        {{hash=0908cad7841cf466eba5ddb1b8d38f99}{Thomas}{T\bibinitperiod}{R\bibnamedelima K}{R\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=b790cf9fd0a0c3c87ae06a795e127291}{Kris}{K\bibinitperiod}{M\bibnamedelima G}{M\bibinitperiod\bibinitdelim G\bibinitperiod}{}{}{}{}}%
        {{hash=c7ebbcf27e16d8bfdb741fe3c6b64ad1}{Inoue}{I\bibinitperiod}{A}{A\bibinitperiod}{}{}{}{}}%
        {{hash=729b8ed4020054f201287dd9d18840ba}{Ladanyi}{L\bibinitperiod}{M}{M\bibinitperiod}{}{}{}{}}%
        {{hash=c3c4d58a922b273acb4efd15a2c2b87f}{Miller}{M\bibinitperiod}{V\bibnamedelima A}{V\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=b0c14ffcabc8dcf4ecbc94cfca60b7a2}{Michor}{M\bibinitperiod}{F}{F\bibinitperiod}{}{}{}{}}%
        {{hash=4b039dea98b86daf174454351be8e3b5}{Pao}{P\bibinitperiod}{W}{W\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{5659e3e73545fe2a5fd8b5b3de0d70e5}
      \strng{fullhash}{55e6e3060a1f9269aea72d91084a23e5}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling}}
      \field{abstract}{Non-small cell lung cancers (NSCLCs) that harbor mutations within the epidermal growth factor receptor (EGFR) gene are sensitive to the tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib. Unfortunately, all patients treated with these drugs will acquire resistance, most commonly as a result of a secondary mutation within EGFR (T790M). Because both drugs were developed to target wild-type EGFR, we hypothesized that current dosing schedules were not optimized for mutant EGFR or to prevent resistance. To investigate this further, we developed isogenic TKI-sensitive and TKI-resistant pairs of cell lines that mimic the behavior of human tumors. We determined that the drug-sensitive and drug-resistant EGFR-mutant cells exhibited differential growth kinetics, with the drug-resistant cells showing slower growth. We incorporated these data into evolutionary mathematical cancer models with constraints derived from clinical data sets. This modeling predicted alternative therapeutic strategies that could prolong the clinical benefit of TKIs against EGFR-mutant NSCLCs by delaying the development of resistance.}
      \field{isbn}{1946-6242 (Electronic)$\backslash$r1946-6234 (Linking)}
      \field{issn}{1946-6242}
      \field{journaltitle}{Sci Transl Med}
      \field{number}{90}
      \field{title}{{Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling}}
      \field{volume}{3}
      \field{year}{2011}
      \field{pages}{90ra59}
      \verb{doi}
      \verb 10.1126/scitranslmed.3002356
      \endverb
      \verb{file}
      \verb :home/fran/Downloads/10.1126@scitranslmed.3002356.pdf:pdf
      \endverb
      \verb{url}
      \verb http://www.ncbi.nlm.nih.gov/pubmed/21734175$%5Cbackslash$nhttp://stm.sciencemag.org/content/3/90/90ra59
      \endverb
    \endentry
    \entry{Huang2007}{article}{}
      \name{labelname}{8}{}{%
        {{hash=af617c9a6fae2c31fbb58a2ba5f8ba92}{Huang}{H\bibinitperiod}{Paul\bibnamedelima H}{P\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=f93291da17e39eab8f6eb3cfedaed924}{Mukasa}{M\bibinitperiod}{Akitake}{A\bibinitperiod}{}{}{}{}}%
        {{hash=47bd53e7f31eef9a1bdc631f03c59de3}{Bonavia}{B\bibinitperiod}{Rudy}{R\bibinitperiod}{}{}{}{}}%
        {{hash=68b461a1ba1fb05aeb9fc32692b74a1c}{Flynn}{F\bibinitperiod}{Ryan\bibnamedelima A}{R\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=242d4df9c693b242ef52791700453be8}{Brewer}{B\bibinitperiod}{Zachary\bibnamedelima E}{Z\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=0a8d39f7f39bff02e8a413dd3209b779}{Cavenee}{C\bibinitperiod}{Webster\bibnamedelima K}{W\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=5e60849b76da3aa3ddda17128e3ed1e9}{Furnari}{F\bibinitperiod}{Frank\bibnamedelima B}{F\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=71977f6db130f1938b761df4fbd091f9}{White}{W\bibinitperiod}{Forest\bibnamedelima M}{F\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \name{author}{8}{}{%
        {{hash=af617c9a6fae2c31fbb58a2ba5f8ba92}{Huang}{H\bibinitperiod}{Paul\bibnamedelima H}{P\bibinitperiod\bibinitdelim H\bibinitperiod}{}{}{}{}}%
        {{hash=f93291da17e39eab8f6eb3cfedaed924}{Mukasa}{M\bibinitperiod}{Akitake}{A\bibinitperiod}{}{}{}{}}%
        {{hash=47bd53e7f31eef9a1bdc631f03c59de3}{Bonavia}{B\bibinitperiod}{Rudy}{R\bibinitperiod}{}{}{}{}}%
        {{hash=68b461a1ba1fb05aeb9fc32692b74a1c}{Flynn}{F\bibinitperiod}{Ryan\bibnamedelima A}{R\bibinitperiod\bibinitdelim A\bibinitperiod}{}{}{}{}}%
        {{hash=242d4df9c693b242ef52791700453be8}{Brewer}{B\bibinitperiod}{Zachary\bibnamedelima E}{Z\bibinitperiod\bibinitdelim E\bibinitperiod}{}{}{}{}}%
        {{hash=0a8d39f7f39bff02e8a413dd3209b779}{Cavenee}{C\bibinitperiod}{Webster\bibnamedelima K}{W\bibinitperiod\bibinitdelim K\bibinitperiod}{}{}{}{}}%
        {{hash=5e60849b76da3aa3ddda17128e3ed1e9}{Furnari}{F\bibinitperiod}{Frank\bibnamedelima B}{F\bibinitperiod\bibinitdelim B\bibinitperiod}{}{}{}{}}%
        {{hash=71977f6db130f1938b761df4fbd091f9}{White}{W\bibinitperiod}{Forest\bibnamedelima M}{F\bibinitperiod\bibinitdelim M\bibinitperiod}{}{}{}{}}%
      }
      \strng{namehash}{81238470218aad60ccc8674ee84becf7}
      \strng{fullhash}{852d2abc47e7b223df408f562178279f}
      \field{sortinit}{0}
      \field{sortinithash}{09a46d48ed195f537673d934cf21f011}
      \field{labeltitle}{{Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma}}
      \field{abstract}{Glioblastoma multiforme (GBM) is the most aggressive brain tumor in adults and remains incurable despite multimodal intensive treatment regimens. EGFRvIII is a truncated extracellular mutant of the EGF receptor (EGFR) commonly found in GBMs that confers enhanced tumorigenic behavior. To gain a molecular understanding of the mechanisms by which EGFRvIII acts, we have performed a large-scale analysis of EGFRvIII-activated phosphotyrosine-mediated signaling pathways and thereby have identified and quantified 99 phosphorylation sites on 69 proteins. Distinct signaling responses were observed as a function of titrated EGFRvIII receptor levels with the phosphatidylinositol 3-kinase pathway being dominant over the MAPK and STAT3 pathways at a high level of EGFRvIII expression. Within this data set, the activating phosphorylation site on the c-Met receptor was found to be highly responsive to EGFRvIII levels, indicating cross-activation of the c-Met receptor tyrosine kinase by EGFRvIII. To determine the significance of this finding, we devised a combined treatment regimen that used a c-Met kinase inhibitor and either an EGFR kinase inhibitor or cisplatin. This regimen resulted in enhanced cytotoxicity of EGFRvIII-expressing cells compared with treatment with either compound alone. These results suggest that the clinical use of c-Met kinase inhibitors in combination with either EGFR inhibitors or standard chemotherapeutics might represent a previously undescribed therapeutic approach to overcome the observed chemoresistance in patients with GBMs expressing EGFRvIII.}
      \field{annotation}{10.1073/pnas.0705158104}
      \field{journaltitle}{Proceedings of the National Academy of Sciences}
      \field{month}{07}
      \field{number}{31}
      \field{title}{{Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma}}
      \field{volume}{104}
      \field{year}{2007}
      \field{pages}{12867\bibrangedash 12872}
      \verb{doi}
      \verb 10.1073/pnas.0705158104
      \endverb
      \verb{url}
      \verb http://www.pnas.org/content/104/31/12867.abstract
      \endverb
    \endentry
  \endsortlist
\endrefsection
\endinput

